Cover
Cover | 12 Months Ended |
Dec. 31, 2021shares | |
Entity Listings [Line Items] | |
Document Type | 20-F/A |
Document Registration Statement | false |
Document Annual Report | true |
Document Period End Date | Dec. 31, 2021 |
Current Fiscal Year End Date | --12-31 |
Document Transition Report | false |
Document Shell Company Report | false |
Entity File Number | 1-10257 |
Entity Registrant Name | BARCLAYS BANK PLC |
Entity Incorporation, State or Country Code | X0 |
Entity Address, Address Line One | 1 CHURCHILL PLACE |
Entity Address, City or Town | LONDON |
Entity Address, Postal Zip Code | E14 5HP |
Entity Address, Country | GB |
Entity Common Stock, Shares Outstanding | 2,342,558,515 |
Entity Well-known Seasoned Issuer | Yes |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Emerging Growth Company | false |
ICFR Auditor Attestation Flag | false |
Document Accounting Standard | International Financial Reporting Standards |
Entity Shell Company | false |
Amendment Description | Barclays Bank PLC (the Company) is filing this Amendment No. 1 on Form 20-F/A (Amendment No. 1) to amend its Annual Report on Form 20-F for the fiscal year ended 31 December 2021 (Original Filing) that was filed with the US Securities and Exchange Commission (SEC) on 23 February 2022 (Original Filing Date). The purpose of this Amendment No. 1 is to:•reflect the restatement of the Company’s financial statements and consolidated financial statements as at and for the year ended 31 December 2021, including the notes thereto (Restated Financial Statements), which are hereby refiled to reflect both a £220m litigation and conduct provision and associated income statement charge recognised in the year ended 31 December 2021 and a contingent liability disclosure in respect of the impact of the c.$15bn over-issuance of securities in excess of the maximum aggregate offering price registered under the Company’s Registration Statement on Form F-3, as declared effective by the SEC in August 2019 (2019 F-3) (the Over-issuance of Securities), and related potential claims and enforcement actions against the Company and its affiliates, as well as a small number of non-adjusting post-balance sheet events as described in further detail under Note 1a to the Restated Financial Statements;•amend related disclosures in the Original Filing to reflect the Restated Financial Statements;•amend the disclosure under the headings ‘Governance—Corporate Governance Statement—Audit, Risk and Internal Control,’ ‘Governance—Corporate Governance Statement—Changes in internal control over financial reporting’ and ‘Additional unaudited information—Disclosure controls and procedures’ and include disclosure under the heading ‘Governance—Corporate Governance Statement—Material Weakness,’ to reflect management’s conclusion that the Company’s internal control over financial reporting and disclosure controls and procedures were not effective under the applicable Committee of Sponsoring Organizations (COSO) Framework as at 31 December 2021 due to a material weakness in the Company’s internal control over financial reporting identified subsequent to the Original Filing Date as a result of the Over-issuance of Securities having occurred and not been immediately identified, as publicly disclosed by the Company in its announcement of 28 March 2022, and to disclose the remediation efforts undertaken by the Company’s management as at the date of this filing;•amend disclosure under the heading ‘Risk review—Material existing and emerging risks’ to include a risk factor on the material weakness in the Company’s internal control over financial reporting identified subsequent to the Original Filing Date and a risk factor on the Over-issuance of Securities;•include the revised Report of Independent Registered Public Accounting Firm of KPMG LLP (KPMG) on the Restated Financial Statements; •include currently-dated certifications from the Chief Executive and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, included in this Amendment No. 1 as Exhibits 12.1 and 13.1;•include a currently-dated consent letter from the Company’s independent registered public accounting firm, KPMG, as Exhibit 15.1;•include 'Articles of Association of Barclays Bank PLC' as Exhibit 1.1; and•amend Exhibit 99.1 to reflect the Restated Financial Statements.Other disclosure in this Amendment No. 1 is included for the convenience of the reader only and has not been updated from the Original Filing. Therefore, except for the changes expressly described above, this Amendment No. 1 continues to present information as at the Original Filing Date and does not amend, supplement or update any information contained in the Original Filing to give effect to any subsequent events. Accordingly, this Amendment No. 1 should be read in conjunction with the Company's reports filed with the SEC subsequent to the Original Filing Date. The filing of this Amendment No. 1, and the inclusion of newly executed certifications, should not be understood to mean that any other statements or disclosure contained in the Original Filing are true and complete as of any date subsequent to the Original Filing Date, except as expressly noted above.See Restatement of financial statements (Note 1a) on page 118 for further details on the Over-issuance of Securities. |
Amendment Flag | true |
Document Fiscal Year Focus | 2021 |
Document Fiscal Period Focus | FY |
Entity Central Index Key | 0000312070 |
Entity Filer Category | Non-accelerated Filer |
1.700% Fixed Rate Senior Notes due 2022 | |
Entity Listings [Line Items] | |
Title of 12(b) Security | 1.700% Fixed Rate Senior Notes due 2022 |
Trading Symbol | BCS22A |
Security Exchange Name | NYSE |
iPath® Bloomberg Commodity Index Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Bloomberg Commodity Index Total ReturnSM ETN |
Trading Symbol | DJP |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Agriculture Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Agriculture Subindex Total ReturnSM ETN |
Trading Symbol | JJA |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Aluminum Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Aluminum Subindex Total ReturnSM ETN |
Trading Symbol | JJU |
Security Exchange Name | NYSEArca |
iPath® Bloomberg Cocoa Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Bloomberg Cocoa Subindex Total ReturnSM ETN |
Trading Symbol | NIB |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Coffee Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Coffee Subindex Total ReturnSM ETN |
Trading Symbol | JO |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Copper Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Copper Subindex Total ReturnSM ETN |
Trading Symbol | JJC |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Cotton Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Cotton Subindex Total ReturnSM ETN |
Trading Symbol | BAL |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Energy Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Energy Subindex Total ReturnSM ETN |
Trading Symbol | JJE |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Grains Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Grains Subindex Total ReturnSM ETN |
Trading Symbol | JJG |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Industrial Metals Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Industrial Metals Subindex Total ReturnSM ETN |
Trading Symbol | JJM |
Security Exchange Name | NYSEArca |
iPath® Bloomberg Lead Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Bloomberg Lead Subindex Total ReturnSM ETN |
Trading Symbol | LD |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Livestock Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Livestock Subindex Total ReturnSM ETN |
Trading Symbol | COW |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Nickel Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Nickel Subindex Total ReturnSM ETN |
Trading Symbol | JJN |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Platinum Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Platinum Subindex Total ReturnSM ETN |
Trading Symbol | PGM |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Precious Metals Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Precious Metals Subindex Total ReturnSM ETN |
Trading Symbol | JJP |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Softs Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Softs Subindex Total ReturnSM ETN |
Trading Symbol | JJS |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Sugar Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Sugar Subindex Total ReturnSM ETN |
Trading Symbol | SGG |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Tin Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Tin Subindex Total ReturnSM ETN |
Trading Symbol | JJT |
Security Exchange Name | NYSEArca |
iPath® Series B Bloomberg Natural Gas Subindex Total ReturnSM ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Bloomberg Natural Gas Subindex Total ReturnSM ETN |
Trading Symbol | GAZ |
Security Exchange Name | NYSEArca |
iPath® S&P GSCI® Total Return Index ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® S&P GSCI® Total Return Index ETN |
Trading Symbol | GSP |
Security Exchange Name | NYSEArca |
iPath® Pure Beta Broad Commodity ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Pure Beta Broad Commodity ETN |
Trading Symbol | BCM |
Security Exchange Name | NYSEArca |
iPath® Pure Beta Crude Oil ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Pure Beta Crude Oil ETN |
Trading Symbol | OLEM |
Security Exchange Name | NYSEArca |
iPath® Series B Carbon ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B Carbon ETN |
Trading Symbol | GRN |
Security Exchange Name | NYSEArca |
Pacer® iPath® Gold ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | Pacer® iPath® Gold ETN |
Trading Symbol | GBUG |
Security Exchange Name | NYSEArca |
iPath® Silver ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Silver ETN |
Trading Symbol | SBUG |
Security Exchange Name | NYSEArca |
iPath® Shiller CAPETM ETNs | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Shiller CAPETM ETNs |
Trading Symbol | CAPE |
Security Exchange Name | NYSEArca |
Pacer® iPath® Gold Trendpilot ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | Pacer® iPath® Gold Trendpilot ETN |
Trading Symbol | PBUG |
Security Exchange Name | NYSEArca |
iPath® Series B S&P 500 VIX Short-Term FuturesTM ETNs | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B S&P 500 VIX Short-Term FuturesTM ETNs |
Trading Symbol | VXX |
iPath® Series B S&P 500 VIX Mid-Term FuturesTM ETNs | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Series B S&P 500 VIX Mid-Term FuturesTM ETNs |
Trading Symbol | VXZ |
iPath® S&P MLP ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® S&P MLP ETN |
Trading Symbol | IMLP |
iPath® Select MLP ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | iPath® Select MLP ETN |
Trading Symbol | ATMP |
Barclays Women in Leadership ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | Barclays Women in Leadership ETN |
Trading Symbol | WIL |
Barclays Return on Disability ETN | |
Entity Listings [Line Items] | |
Title of 12(b) Security | Barclays Return on Disability ETN |
Trading Symbol | RODI |
Business Contact | |
Entity Listings [Line Items] | |
Entity Address, Address Line One | 1 CHURCHILL PLACE |
Entity Address, City or Town | LONDON |
Entity Address, Postal Zip Code | E14 5HP |
Entity Address, Country | GB |
Contact Personnel Name | GARTH WRIGHT |
City Area Code | +44 |
Local Phone Number | (0)20 7116 3170 |
Contact Personnel Email Address | GARTH.WRIGHT@BARCLAYS.COM |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Audit Information [Abstract] | |
Auditor Location | London, United Kingdom |
Auditor Firm ID | 1118 |
Auditor Name | KPMG LLP |
Consolidated Income Statement
Consolidated Income Statement - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Profit (loss) [abstract] | ||||
Interest and similar income | £ 5,672 | [1] | £ 6,006 | £ 8,085 |
Interest and similar expense | (2,599) | [1] | (2,846) | (4,178) |
Net interest income | 3,073 | [1] | 3,160 | 3,907 |
Fee and commission income | 8,581 | [1] | 7,417 | 7,664 |
Fee and commission expense | (1,994) | [1] | (1,758) | (1,992) |
Net fee and commission income | 6,587 | [1] | 5,659 | 5,672 |
Net trading income | 5,788 | [1] | 7,076 | 4,073 |
Net investment (expense)/income | (80) | [1] | (121) | 420 |
Other income | 40 | [1] | 4 | 79 |
Total income | 15,408 | [1] | 15,778 | 14,151 |
Credit impairment releases/(charges) | 277 | [1] | (3,377) | (1,202) |
Net operating income | 15,685 | [1] | 12,401 | 12,949 |
Staff costs | (4,456) | [1] | (4,365) | (4,565) |
Infrastructure costs | (1,054) | [1] | (816) | (835) |
Administration and general expenses | (4,375) | [1] | (4,202) | (4,318) |
Litigation and conduct | (374) | [1] | (76) | (264) |
Total operating expenses | (10,259) | [1] | (9,459) | (9,982) |
Share of post-tax results of associates and joint ventures | 4 | [1] | 7 | 57 |
(Loss)/ profit on disposal of subsidiaries, associates and joint ventures | (12) | [1] | 126 | 88 |
Profit before tax | 5,418 | [2] | 3,075 | 3,112 |
Taxation | (830) | [1] | (624) | (332) |
Profit after tax | 4,588 | [1] | 2,451 | 2,780 |
Attributable to: | ||||
Equity holders of the parent | 3,957 | [1] | 1,774 | 2,120 |
Other equity instrument holders | 631 | [1] | 677 | 660 |
Total equity holders of the parent | 4,588 | [1] | 2,451 | 2,780 |
Profit after tax | £ 4,588 | [1] | £ 2,451 | £ 2,780 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Consolidated statement of compr
Consolidated statement of comprehensive income - GBP (£) £ in Millions | 12 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |||
Statement of comprehensive income [abstract] | |||||
Profit after tax | £ 4,588 | [1] | £ 2,451 | £ 2,780 | |
Currency translation reserve | |||||
Currency translation differences | [3] | (155) | [2] | (647) | (544) |
Fair value through other comprehensive income reserve movement relating to debt securities | |||||
Net (losses)/gains from changes in fair value | (1,383) | [4] | 2,402 | 2,465 | |
Net gains transferred to net profit on disposal | (248) | [4] | (251) | (454) | |
Net (gains)/losses related to (releases of) impairment | (6) | [4] | 1 | 1 | |
Net gains/(losses) due to fair value hedging | 1,105 | [4] | (1,640) | (1,782) | |
Other movements | 0 | [4] | 0 | (8) | |
Tax | 170 | [4] | (130) | (63) | |
Cash flow hedging reserve | |||||
Net (losses)/gains from changes in fair value | (2,212) | [4] | 1,366 | 823 | |
Net gains transferred to net profit | (327) | [4] | (282) | (141) | |
Tax | 740 | [4] | (291) | (171) | |
Other | 0 | [4] | 3 | 16 | |
Other comprehensive (loss)/income that may be recycled to profit or loss | (2,316) | [4] | 531 | 142 | |
Other comprehensive income/(loss) not recycled to profit or loss: | |||||
Retirement benefit remeasurements | 1,299 | [4] | (77) | (280) | |
Fair value through other comprehensive income reserve movements relating to equity instruments | 0 | [4] | 1 | 0 | |
Own credit | (105) | [4] | (810) | (316) | |
Tax | (563) | [4] | 198 | 150 | |
Other comprehensive income/(loss) not recycled to profit or loss | 631 | [4] | (688) | (446) | |
Other comprehensive loss for the year | (1,685) | [4] | (157) | (304) | |
Total comprehensive income for the year | 2,903 | [4] | 2,294 | 2,476 | |
Attributable to: | |||||
Equity holders of the parent | 2,903 | [4] | 2,294 | 2,476 | |
Total comprehensive income for the year | £ 2,903 | [4] | £ 2,294 | £ 2,476 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[3] | Includes £28m loss (2020: £8m loss; 2019: £15m profit) on recycling of currency translation differences. | ||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Consolidated statement of com_2
Consolidated statement of comprehensive income (Parenthetical) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of comprehensive income [abstract] | |||
(Loss) gain on recycling of currency translation differences | £ (28) | £ (8) | £ 15 |
Consolidated balance sheet
Consolidated balance sheet - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Assets | |||||
Cash and balances at central banks | £ 169,085 | [1] | £ 155,902 | £ 125,940 | |
Cash collateral and settlement balances | 88,085 | [2] | 97,616 | ||
Loans and advances at amortised cost | 145,259 | [2] | 134,267 | ||
Reverse repurchase agreements and other similar secured lending | 3,177 | [2] | 8,981 | ||
Trading portfolio assets | 146,871 | [2] | 127,664 | ||
Financial assets at fair value through the income statement | 188,226 | [2] | 171,761 | ||
Derivative financial instruments | 262,291 | [2] | 302,693 | ||
Financial assets at fair value through other comprehensive income | 45,908 | [2] | 51,902 | ||
Investments in associates and joint ventures | 24 | [2] | 24 | ||
Goodwill and intangible assets | 1,449 | [2] | 1,154 | ||
Property, plant and equipment | 1,248 | [2] | 1,537 | ||
Current tax assets | 589 | [2] | 424 | ||
Deferred tax assets | 2,981 | [2] | 2,552 | ||
Retirement benefit assets | 3,879 | [2] | 1,814 | ||
Other assets | 2,706 | [2] | 1,440 | ||
Total assets | 1,061,778 | [2] | 1,059,731 | 876,700 | |
Liabilities | |||||
Deposits at amortised cost | 262,828 | [2] | 244,696 | ||
Cash collateral and settlement balances | 79,047 | [2] | 85,549 | ||
Repurchase agreements and other similar secured borrowing | 12,769 | [2] | 10,443 | ||
Debt securities in issue | 48,388 | [2] | 29,423 | ||
Subordinated liabilities | 32,185 | [2] | 32,005 | 33,425 | |
Trading portfolio liabilities | 53,291 | [2] | 46,139 | ||
Financial liabilities designated at fair value | 251,131 | [2] | 249,626 | ||
Derivative financial instruments | 256,523 | [2] | 300,580 | ||
Current tax liabilities | 688 | [2] | 644 | ||
Deferred tax liabilities | 6 | [2] | 225 | ||
Retirement benefit liabilities | 246 | [2] | 232 | ||
Other liabilities | 7,249 | [2] | 5,251 | ||
Provisions | 1,110 | [2] | 1,208 | ||
Total liabilities | 1,005,461 | [2] | 1,006,021 | ||
Equity | |||||
Called up share capital and share premium | 2,348 | [2] | 2,348 | ||
Other equity instruments | 9,693 | [2] | 8,621 | ||
Other reserves | 861 | [2] | 3,183 | ||
Retained earnings | 43,415 | [2] | 39,558 | ||
Total equity | 56,317 | [3] | 53,710 | [3] | £ 50,615 |
Total liabilities and equity | £ 1,061,778 | [2] | £ 1,059,731 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Consolidated statement of chang
Consolidated statement of changes in equity - GBP (£) £ in Millions | Total | Called up share capital and share premium | [1] | Other equity instruments | [1] | Other reserves | [2] | Retained earnings | |||
Beginning balance, equity at Dec. 31, 2019 | £ 50,615 | £ 2,348 | £ 8,323 | £ 3,235 | £ 36,709 | ||||||
Profit after tax | 2,451 | 677 | 1,774 | ||||||||
Currency translation movements | (647) | [3] | (647) | ||||||||
Fair value through other comprehensive income reserve | 383 | 383 | |||||||||
Cash flow hedges | 793 | 793 | |||||||||
Retirement benefit remeasurement | (108) | (108) | |||||||||
Own credit reserve | (581) | (581) | |||||||||
Other | 3 | 3 | |||||||||
Total comprehensive income for the year | 2,294 | 677 | (52) | 1,669 | |||||||
Issue and redemption of other equity instruments | 245 | 298 | (53) | ||||||||
Other equity instruments coupons paid | (677) | (677) | |||||||||
Employee share schemes | 349 | 349 | |||||||||
Vesting of Barclays PLC shares under share-based payment schemes | (300) | (300) | |||||||||
Dividends on ordinary shares | (263) | (263) | |||||||||
Dividends on preference shares and other shareholders equity | (42) | (42) | |||||||||
Capital contribution from Barclays Plc | 1,500 | 1,500 | |||||||||
Other reserve movements | (11) | (11) | |||||||||
Ending balance, equity at Dec. 31, 2020 | 53,710 | [4] | 2,348 | 8,621 | 3,183 | 39,558 | [4] | ||||
Profit after tax | 4,588 | [5] | 631 | 3,957 | [4] | ||||||
Currency translation movements | (155) | [3],[4] | (155) | ||||||||
Fair value through other comprehensive income reserve | (362) | [4] | (362) | ||||||||
Cash flow hedges | (1,799) | [4] | (1,799) | ||||||||
Retirement benefit remeasurement | [4] | 644 | 644 | ||||||||
Own credit reserve | (13) | [4] | (13) | ||||||||
Other | [6] | 0 | |||||||||
Total comprehensive income for the year | 2,903 | [6] | 631 | (2,329) | 4,601 | [4] | |||||
Issue and redemption of other equity instruments | 1,075 | [4] | 1,072 | 3 | [4] | ||||||
Other equity instruments coupons paid | (631) | [4] | (631) | ||||||||
Employee share schemes | [4] | 436 | 436 | ||||||||
Vesting of Barclays PLC shares under share-based payment schemes | [4] | (356) | (356) | ||||||||
Dividends on ordinary shares | [4] | (794) | (794) | ||||||||
Dividends on preference shares and other shareholders equity | [4] | (27) | (27) | ||||||||
Capital contribution from Barclays Plc | [4] | 0 | |||||||||
Other reserve movements | 1 | [4] | 7 | (6) | [4] | ||||||
Ending balance, equity at Dec. 31, 2021 | £ 56,317 | [4] | £ 2,348 | £ 9,693 | £ 861 | £ 43,415 | [4] | ||||
[1] | For further details refer to Note 27. | ||||||||||
[2] | For further details refer to Note 28. | ||||||||||
[3] | Includes £28m loss (2020: £8m loss; 2019: £15m profit) on recycling of currency translation differences. | ||||||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||||
[6] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Consolidated cash flow statemen
Consolidated cash flow statement - GBP (£) £ in Millions | 12 Months Ended | ||||
Dec. 31, 2021 | [1] | Dec. 31, 2020 | Dec. 31, 2019 | ||
Reconciliation of profit before tax to net cash flows from operating activities: | |||||
Profit before tax | £ 5,418 | £ 3,075 | £ 3,112 | ||
Adjustment for non-cash items: | |||||
Credit impairment (releases)/charges | (277) | 3,377 | 1,202 | ||
Depreciation, amortisation and impairment of property, plant, equipment and intangibles | 683 | 441 | 459 | ||
Other provisions, including pensions | 85 | 634 | 417 | ||
Net loss/(profit) on disposal of investments and property, plant and equipment | 12 | (119) | (84) | ||
Other non-cash movements including exchange rate movements | 1,968 | (2,362) | (742) | ||
Changes in operating assets and liabilities | |||||
Net decrease/(increase) in cash collateral and settlement balances | 3,633 | 4,098 | (5,762) | ||
Net (increase)/decrease in loans and advances at amortised cost | (7,190) | 7,142 | 3,937 | ||
Net decrease/(increase) in reverse repurchase agreements and other similar secured lending | 5,804 | (7,250) | (118) | ||
Net increase in deposits at amortised cost | 18,132 | 31,148 | 14,544 | ||
Net increase/(decrease) in debt securities in issue | 18,965 | (4,113) | (5,762) | ||
Net increase/(decrease) in repurchase agreements and other similar secured borrowing | 2,326 | 8,411 | (5,346) | ||
Net (increase)/decrease in derivative financial instruments | (3,655) | (1,604) | 2,390 | ||
Net increase in trading portfolio assets | (19,207) | (14,327) | (9,299) | ||
Net increase/(decrease) in trading portfolio liabilities | 7,152 | 10,927 | (1,402) | ||
Net (increase)/decrease in financial assets and liabilities at fair value through the income statement | (14,960) | 2,889 | 2,485 | ||
Net increase in other assets | (2,235) | (93) | (44) | ||
Net increase/(decrease) in other liabilities | 2,082 | 13 | (991) | ||
Corporate income tax (paid)/received | (1,239) | (12) | 894 | ||
Net cash from operating activities | 17,497 | 42,275 | (110) | ||
Net cash from investing activities | |||||
Purchase of debt securities at amortised cost | (6,931) | (7,890) | (8,565) | ||
Proceeds from sale or redemption of debt securities at amortised cost | 2,424 | 3,527 | 1,305 | ||
Purchase of financial assets at fair value through other comprehensive income | (44,058) | (57,640) | (67,056) | ||
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 47,601 | 53,367 | 67,743 | ||
Purchase of property, plant and equipment and intangibles | (758) | (303) | (610) | ||
Disposal of subsidiaries and associates, net of cash disposed | 65 | 736 | 617 | ||
Other cash flows associated with investing activities | 4 | 11 | 95 | ||
Net cash from investing activities | (1,653) | (8,192) | (6,471) | ||
Net cash from financing activities | |||||
Dividends paid and other coupon payments on equity instruments | (1,452) | (982) | (934) | ||
Issuance of subordinated liabilities | 9,099 | 3,856 | 6,785 | ||
Redemption of subordinated liabilities | (7,241) | (4,746) | (6,574) | ||
Issue of shares and other equity instruments | 1,072 | 1,134 | 2,292 | ||
Repurchase of shares and other equity instruments | 0 | (903) | (1,970) | ||
Vesting of employee share schemes | (356) | (300) | (349) | ||
Net cash from financing activities | 1,122 | (1,941) | (750) | ||
Effect of exchange rates on cash and cash equivalents | (4,231) | 1,669 | (3,345) | ||
Net increase/(decrease) in cash and cash equivalents | 12,735 | 33,811 | (10,676) | ||
Cash and cash equivalents at beginning of year | 173,125 | 139,314 | 149,990 | ||
Cash and cash equivalents at end of year | 185,860 | 173,125 | [1] | 139,314 | |
Cash and cash equivalents comprise: | |||||
Cash and balances at central banks | 169,085 | 155,902 | 125,940 | ||
Loans and advances to banks with original maturity less than three months | 6,473 | 7,281 | 8,158 | ||
Cash collateral balances with central banks with original maturity less than three months | 9,690 | 9,086 | 4,736 | ||
Treasury and other eligible bills with original maturity less than three months | 612 | 856 | 480 | ||
Cash and cash equivalents | £ 185,860 | £ 173,125 | [1] | £ 139,314 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Consolidated cash flow statem_2
Consolidated cash flow statement (Parenthetical) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of cash flows [abstract] | ||
Interest received, classified as operating activities | £ 11,616 | £ 12,860 |
Interest paid, classified as operating activities | 7,493 | 8,653 |
Balances with banks and other regulatory authorities | £ 4,260 | £ 3,119 |
Parent company accounts - balan
Parent company accounts - balance sheet - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | ||
Assets | ||||
Cash and balances at central banks | £ 169,085 | [1] | £ 155,902 | |
Cash collateral and settlement balances | 88,085 | [2] | 97,616 | |
Loans and advances at amortised cost | 145,259 | [2] | 134,267 | |
Reverse repurchase agreements and other similar secured lending | 3,177 | [2] | 8,981 | |
Trading portfolio assets | 146,871 | [2] | 127,664 | |
Financial assets at fair value through the income statement | 188,226 | [2] | 171,761 | |
Derivative financial instruments | 262,291 | [2] | 302,693 | |
Financial assets at fair value through other comprehensive income | 45,908 | [2] | 51,902 | |
Investments in associates and joint ventures | 24 | [2] | 24 | |
Goodwill and intangible assets | 1,449 | [2] | 1,154 | |
Property, plant and equipment | 1,248 | [2] | 1,537 | |
Current tax assets | 589 | [2] | 424 | |
Deferred tax assets | 2,981 | [2] | 2,552 | |
Retirement benefit assets | 3,879 | [2] | 1,814 | |
Other assets | 2,706 | [2] | 1,440 | |
Total assets | 1,061,778 | [2] | 1,059,731 | |
Liabilities | ||||
Deposits at amortised cost | 262,828 | [2] | 244,696 | |
Cash collateral and settlement balances | 79,047 | [2] | 85,549 | |
Repurchase agreements and other similar secured borrowing | 12,769 | [2] | 10,443 | |
Debt securities in issue | 48,388 | [2] | 29,423 | |
Subordinated liabilities | 32,185 | [2] | 32,005 | |
Trading portfolio liabilities | 53,291 | [2] | 46,139 | |
Financial liabilities designated at fair value | 251,131 | [2] | 249,626 | |
Derivative financial instruments | 256,523 | [2] | 300,580 | |
Current tax liabilities | 688 | [2] | 644 | |
Deferred tax liabilities | 6 | [2] | 225 | |
Retirement benefit liabilities | 246 | [2] | 232 | |
Other liabilities | 7,249 | [2] | 5,251 | |
Provisions | 1,110 | [2] | 1,208 | |
Total liabilities | 1,005,461 | [2] | 1,006,021 | |
Equity | ||||
Called up share capital and share premium | 2,348 | [2] | 2,348 | |
Other equity instruments | 9,693 | [2] | 8,621 | |
Other reserves | 861 | [2] | 3,183 | |
Retained earnings | 43,415 | [2] | 39,558 | |
Total equity | [3] | 56,317 | 53,710 | |
Total liabilities and equity | 1,061,778 | [2] | 1,059,731 | |
Barclays Bank PLC | ||||
Assets | ||||
Cash and balances at central banks | 144,964 | [4] | 133,386 | |
Cash collateral and settlement balances | 75,571 | [5] | 87,723 | |
Loans and advances at amortised cost | 199,782 | [5] | 191,538 | |
Reverse repurchase agreements and other similar secured lending | 4,982 | [5] | 11,535 | |
Trading portfolio assets | 96,724 | [5] | 84,089 | |
Financial assets at fair value through the income statement | 236,577 | [5] | 203,073 | |
Derivative financial instruments | 234,409 | [5] | 297,129 | |
Financial assets at fair value through other comprehensive income | 44,163 | [5] | 50,308 | |
Investments in associates and joint ventures | 12 | [5] | 13 | |
Investment in subsidiaries | 19,134 | [5] | 17,780 | |
Goodwill and intangible assets | 109 | [5] | 112 | |
Property, plant and equipment | 128 | [5] | 425 | |
Current tax assets | 671 | [5] | 545 | |
Deferred tax assets | 1,679 | [5] | 1,171 | |
Retirement benefit assets | 3,825 | [5] | 1,812 | |
Other assets | 1,941 | [5] | 913 | |
Total assets | 1,064,671 | [5] | 1,081,552 | |
Liabilities | ||||
Deposits at amortised cost | 286,761 | [5] | 272,190 | |
Cash collateral and settlement balances | 56,419 | [5] | 68,862 | |
Repurchase agreements and other similar secured borrowing | 29,202 | [5] | 27,722 | |
Debt securities in issue | 32,585 | [5] | 17,221 | |
Subordinated liabilities | 31,875 | [5] | 31,852 | |
Trading portfolio liabilities | 50,116 | [5] | 48,093 | |
Financial liabilities designated at fair value | 291,062 | [5] | 267,137 | |
Derivative financial instruments | 227,991 | [5] | 292,538 | |
Current tax liabilities | 342 | [5] | 336 | |
Deferred tax liabilities | 6 | [5] | 225 | |
Retirement benefit liabilities | 104 | [5] | 104 | |
Other liabilities | 4,597 | [5] | 3,145 | |
Provisions | 919 | [5] | 984 | |
Total liabilities | 1,011,979 | [5] | 1,030,409 | |
Equity | ||||
Called up share capital and share premium | 2,348 | [5] | 2,348 | |
Other equity instruments | 14,400 | [5] | 13,328 | |
Other reserves | (1,236) | [5] | 776 | |
Retained earnings | 37,180 | [5] | 34,691 | |
Total equity | [6] | 52,692 | 51,143 | |
Total liabilities and equity | £ 1,064,671 | [5] | £ 1,081,552 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[6] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Parent company accounts - bal_2
Parent company accounts - balance sheet (Parenthetical) (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||
Profit after tax | £ 4,588 | [1] | £ 2,451 | £ 2,780 |
Barclays Bank PLC | ||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||
Profit after tax | £ 3,436 | [2],[3] | £ 2,134 | £ 2,409 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details.The Parent company financials on pages 111 to 114 form part of this note. |
Parent company accounts - State
Parent company accounts - Statement of changes in equity - GBP (£) £ in Millions | Total | Called up share capital and share premium | [1] | Other equity instruments | [1] | Other reserves | [2] | Retained earnings | Barclays Bank PLC | Barclays Bank PLCCalled up share capital and share premium | [3] | Barclays Bank PLCOther equity instruments | [3] | Barclays Bank PLCOther reserves | [4] | Barclays Bank PLCRetained earnings | |||||
Beginning balance, equity at Dec. 31, 2019 | £ 50,615 | £ 2,348 | £ 8,323 | £ 3,235 | £ 36,709 | £ 46,425 | £ 2,348 | £ 11,089 | £ 678 | £ 32,310 | |||||||||||
Profit after tax | 2,451 | 677 | 1,774 | 2,134 | 829 | 1,305 | |||||||||||||||
Currency translation movements | (647) | [5] | (647) | (519) | [6] | (519) | |||||||||||||||
Fair value through other comprehensive income reserve | 383 | 383 | 389 | 389 | |||||||||||||||||
Cash flow hedges | 793 | 793 | 788 | 788 | |||||||||||||||||
Retirement benefit remeasurement | (108) | (108) | (113) | (113) | |||||||||||||||||
Own credit reserve | (581) | (581) | (560) | (560) | |||||||||||||||||
Other | 3 | 3 | 2 | 2 | |||||||||||||||||
Total comprehensive income for the year | 2,294 | 677 | (52) | 1,669 | 2,121 | 829 | 98 | 1,194 | |||||||||||||
Issue and redemption of other equity instruments | 245 | 298 | (53) | 2,186 | 2,239 | (53) | |||||||||||||||
Other equity instruments coupons paid | (677) | (677) | (829) | (829) | |||||||||||||||||
Employee share schemes | 349 | 349 | 349 | 349 | |||||||||||||||||
Vesting of Barclays PLC shares under share-based payment schemes | (300) | (300) | (300) | (300) | |||||||||||||||||
Dividends paid on ordinary shares | (263) | (263) | (263) | (263) | |||||||||||||||||
Dividends paid on preference shares and other shareholders' equity | (42) | (42) | (42) | (42) | |||||||||||||||||
Capital contribution from Barclays Plc | 1,500 | 1,500 | 1,500 | 1,500 | |||||||||||||||||
Other reserve movements | (11) | (11) | (4) | (4) | |||||||||||||||||
Ending balance, equity at Dec. 31, 2020 | 53,710 | [7] | 2,348 | 8,621 | 3,183 | 39,558 | [7] | 51,143 | [8] | 2,348 | 13,328 | [9] | 776 | 34,691 | [8] | ||||||
Profit after tax | 4,588 | [10] | 631 | 3,957 | [7] | 3,436 | [11],[12] | 795 | [9] | 2,641 | [8] | ||||||||||
Currency translation movements | (155) | [5],[7] | (155) | 128 | [6],[8],[12] | 128 | |||||||||||||||
Fair value through other comprehensive income reserve | (362) | [7] | (362) | (363) | [8] | (363) | |||||||||||||||
Cash flow hedges | (1,799) | [7] | (1,799) | (1,815) | [8] | (1,815) | |||||||||||||||
Retirement benefit remeasurement | 644 | [7] | 644 | [7] | 612 | [8] | 612 | [8] | |||||||||||||
Own credit reserve | (13) | [7] | (13) | 31 | [8] | 31 | |||||||||||||||
Other | 0 | [13] | 0 | [12] | |||||||||||||||||
Total comprehensive income for the year | 2,903 | [13] | 631 | (2,329) | 4,601 | [7] | 2,029 | [8],[12] | 795 | [9] | (2,019) | 3,253 | [8] | ||||||||
Issue and redemption of other equity instruments | 1,075 | [7] | 1,072 | 3 | [7] | 1,075 | [8] | 1,072 | [9] | 3 | [8] | ||||||||||
Other equity instruments coupons paid | (631) | [7] | (631) | (795) | [8] | (795) | [9] | ||||||||||||||
Employee share schemes | 436 | [7] | 436 | [7] | 418 | [8] | 418 | [8] | |||||||||||||
Vesting of Barclays PLC shares under share-based payment schemes | (356) | [7] | (356) | [7] | (356) | [8] | (356) | [8] | |||||||||||||
Dividends paid on ordinary shares | (794) | [7] | (794) | [7] | (794) | [8] | (794) | [8] | |||||||||||||
Dividends paid on preference shares and other shareholders' equity | (27) | [7] | (27) | [7] | (27) | [8] | (27) | [8] | |||||||||||||
Capital contribution from Barclays Plc | [7] | 0 | |||||||||||||||||||
Other reserve movements | 1 | [7] | 7 | (6) | [7] | (1) | [8] | 7 | (8) | [8] | |||||||||||
Ending balance, equity at Dec. 31, 2021 | £ 56,317 | [7] | £ 2,348 | £ 9,693 | £ 861 | £ 43,415 | [7] | £ 52,692 | [8] | £ 2,348 | £ 14,400 | [9] | £ (1,236) | £ 37,180 | [8] | ||||||
[1] | For further details refer to Note 27. | ||||||||||||||||||||
[2] | For further details refer to Note 28. | ||||||||||||||||||||
[3] | For further details refer to Note 27 in the Barclays Bank PLC Annual Report 2021. | ||||||||||||||||||||
[4] | For further details refer to Note 28 in the Barclays Bank PLC Annual Report 2021. | ||||||||||||||||||||
[5] | Includes £28m loss (2020: £8m loss; 2019: £15m profit) on recycling of currency translation differences. | ||||||||||||||||||||
[6] | Includes £0m (2020:£0m; 2019: £45m profit) on recycling of currency translation differences. | ||||||||||||||||||||
[7] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||||||||||||||
[8] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||||||||||||||
[9] | Other equity instruments includes AT1 securities issued by Barclays Bank PLC and borrowings of $6bn from a wholly-owned, indirect subsidiary of Barclays Bank PLC. The borrowings have been recorded as equity since, under their terms, interest payments are non cumulative and discretionary whilst repayment of principal is perpetually deferrable by Barclays Bank PLC. Should Barclays Bank PLC make a discretionary dividend payment on its ordinary shares in the six months preceding the date of an interest payment, it will be obliged to make that interest payment. In 2021, interest paid on these borrowings was £164m. | ||||||||||||||||||||
[10] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||||||||||||||
[11] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||||||||||||||
[12] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details.The Parent company financials on pages 111 to 114 form part of this note. | ||||||||||||||||||||
[13] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Parent company accounts - Sta_2
Parent company accounts - Statement of changes in equity (Parenthetical) - GBP (£) £ in Millions | Apr. 29, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Capital contribution from Barclays Plc | £ 0 | [1] | £ 1,500 | |
Capital contribution from parent | ||||
Capital contribution from Barclays Plc | £ 750 | |||
Barclays Bank PLC | ||||
Amounts payable, related party transactions | 6,000 | 6,000 | ||
Interest paid, classified as financing activities | £ 164 | 152 | ||
Capital contribution from Barclays Plc | £ 1,500 | |||
Barclays Bank PLC | Capital contribution from parent | ||||
Capital contribution from Barclays Plc | £ 750 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Parent company accounts - Cash
Parent company accounts - Cash flow statement - GBP (£) £ in Millions | 12 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |||
Reconciliation of profit before tax to net cash flows from operating activities: | |||||
Profit/(loss) before tax | £ 5,418 | [1] | £ 3,075 | £ 3,112 | |
Adjustment for non-cash items: | |||||
Credit impairment (releases)/charges | (277) | [1] | 3,377 | 1,202 | |
Depreciation, amortisation and impairment of property, plant, equipment and intangibles | 683 | [1] | 441 | 459 | |
Other provisions, including pensions | 85 | [1] | 634 | 417 | |
Net profit on disposal of investments and property, plant and equipment | 12 | [1] | (119) | (84) | |
Other non-cash movements including exchange rate movements | 1,968 | [1] | (2,362) | (742) | |
Net decrease/(increase) in cash collateral and settlement balances | 3,633 | [1] | 4,098 | (5,762) | |
Net (increase)/decrease in loans and advances at amortised cost | (7,190) | [1] | 7,142 | 3,937 | |
Net decrease/(increase) in reverse repurchase agreements and other similar secured lending | 5,804 | [1] | (7,250) | (118) | |
Net increase in deposits at amortised cost | 18,132 | [1] | 31,148 | 14,544 | |
Net increase/(decrease) in debt securities in issue | 18,965 | [1] | (4,113) | (5,762) | |
Net increase/(decrease) in repurchase agreements and other similar secured borrowing | 2,326 | [1] | 8,411 | (5,346) | |
Net increase in derivative financial instruments | (3,655) | [1] | (1,604) | 2,390 | |
Net increase in trading portfolio assets | (19,207) | [1] | (14,327) | (9,299) | |
Net increase/(decrease) in trading portfolio liabilities | 7,152 | [1] | 10,927 | (1,402) | |
Net (increase)/decrease in financial assets and liabilities at fair value through the income statement | (14,960) | [1] | 2,889 | 2,485 | |
Net increase in other assets | (2,235) | [1] | (93) | (44) | |
Net increase/(decrease) in other liabilities | 2,082 | [1] | 13 | (991) | |
Corporate income tax (paid)/received | (1,239) | [1] | (12) | 894 | |
Net cash from operating activities | 17,497 | [1] | 42,275 | (110) | |
Net cash from investing activities | |||||
Purchase of debt securities at amortised cost | (6,931) | [1] | (7,890) | (8,565) | |
Proceeds from sale or redemption of debt securities at amortised cost | 2,424 | [1] | 3,527 | 1,305 | |
Purchase of financial assets at fair value through other comprehensive income | (44,058) | [1] | (57,640) | (67,056) | |
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 47,601 | [1] | 53,367 | 67,743 | |
Purchase of property, plant and equipment and intangibles | (758) | [1] | (303) | (610) | |
Disposal of subsidiaries and associates, net of cash disposed | 65 | [1] | 736 | 617 | |
Other cash flows associated with investing activities | 4 | [1] | 11 | 95 | |
Net cash from investing activities | (1,653) | [1] | (8,192) | (6,471) | |
Net cash from financing activities | |||||
Dividends paid and other coupon payments on equity instruments | (1,452) | [1] | (982) | (934) | |
Issuance of subordinated liabilities | 9,099 | [1] | 3,856 | 6,785 | |
Redemption of subordinated liabilities | (7,241) | [1] | (4,746) | (6,574) | |
Issue of shares and other equity instruments | 1,072 | [1] | 1,134 | 2,292 | |
Repurchase of shares and other equity instruments | 0 | [1] | (903) | (1,970) | |
Vesting of shares under employee share schemes | (356) | [1] | (300) | (349) | |
Net cash from financing activities | 1,122 | [1] | (1,941) | (750) | |
Effect of exchange rates on cash and cash equivalents | (4,231) | [1] | 1,669 | (3,345) | |
Net increase/(decrease) in cash and cash equivalents | 12,735 | [1] | 33,811 | (10,676) | |
Cash and cash equivalents at beginning of year | 173,125 | [1] | 139,314 | 149,990 | |
Cash and cash equivalents at end of year | 185,860 | [1] | 173,125 | [1] | 139,314 |
Cash and balances at central banks | 169,085 | [1] | 155,902 | 125,940 | |
Loans and advances to banks with original maturity less than three months | 6,473 | [1] | 7,281 | 8,158 | |
Cash collateral balances with central banks with original maturity less than three months | 9,690 | [1] | 9,086 | 4,736 | |
Short-term investments, classified as cash equivalents | 612 | [1] | 856 | 480 | |
Cash and cash equivalents | 185,860 | [1] | 173,125 | [1] | 139,314 |
Barclays Bank PLC | |||||
Reconciliation of profit before tax to net cash flows from operating activities: | |||||
Profit/(loss) before tax | 3,323 | [2] | 2,155 | 2,018 | |
Adjustment for non-cash items: | |||||
Credit impairment (releases)/charges | (414) | [3] | 1,577 | 235 | |
Depreciation, amortisation and impairment of property, plant, equipment and intangibles | 331 | [3] | 66 | 67 | |
Other provisions, including pensions | 75 | [3] | 505 | 268 | |
Net profit on disposal of investments and property, plant and equipment | (49) | [3] | (397) | (128) | |
Other non-cash movements including exchange rate movements | 1,109 | [3] | (2,045) | 1,203 | |
Net decrease/(increase) in cash collateral and settlement balances | 313 | [3] | 1,863 | (7,110) | |
Net (increase)/decrease in loans and advances at amortised cost | (10,255) | [3] | (29,049) | 5,483 | |
Net decrease/(increase) in reverse repurchase agreements and other similar secured lending | 6,553 | [3] | (6,596) | 1,551 | |
Net increase in deposits at amortised cost | 14,571 | [3] | 32,059 | 9,614 | |
Net increase/(decrease) in debt securities in issue | 15,364 | [3] | (2,662) | (12,454) | |
Net increase/(decrease) in repurchase agreements and other similar secured borrowing | 1,480 | [3] | 18,537 | 899 | |
Net increase in derivative financial instruments | (1,827) | [3] | (860) | (3,863) | |
Net increase in trading portfolio assets | (12,635) | [3] | (5,010) | (5,599) | |
Net increase/(decrease) in trading portfolio liabilities | 2,023 | [3] | 2,963 | (1,496) | |
Net (increase)/decrease in financial assets and liabilities at fair value through the income statement | (9,579) | [3] | 18,799 | 7,290 | |
Net increase in other assets | (1,989) | [3] | (83) | (349) | |
Net increase/(decrease) in other liabilities | 1,557 | [3] | 380 | (1,006) | |
Corporate income tax (paid)/received | (373) | [3] | 354 | 919 | |
Net cash from operating activities | 9,578 | [3] | 32,556 | (2,458) | |
Net cash from investing activities | |||||
Purchase of debt securities at amortised cost | (5,442) | [3] | (7,129) | (7,688) | |
Proceeds from sale or redemption of debt securities at amortised cost | 1,278 | [3] | 3,054 | 232 | |
Purchase of financial assets at fair value through other comprehensive income | (37,842) | [3] | (51,368) | (61,877) | |
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 41,544 | [3] | 47,254 | 62,915 | |
Purchase of property, plant and equipment and intangibles | (20) | [3] | (27) | (139) | |
Disposal of subsidiaries and associates, net of cash disposed | 65 | [3] | 736 | 587 | |
Increase in investment in subsidiaries | (1,473) | [3] | (1,907) | (1,494) | |
Other cash flows associated with investing activities | 0 | [3] | 8 | 0 | |
Net cash from investing activities | (1,890) | [3] | (9,379) | (7,464) | |
Net cash from financing activities | |||||
Dividends paid and other coupon payments on equity instruments | (1,616) | [3] | (1,134) | (1,113) | |
Issuance of subordinated liabilities | 8,788 | [3] | 3,700 | 6,627 | |
Redemption of subordinated liabilities | (7,095) | [3] | (4,580) | (6,402) | |
Issue of shares and other equity instruments | 1,072 | [3] | 3,075 | 2,292 | |
Repurchase of shares and other equity instruments | 0 | [3] | (903) | (1,970) | |
Vesting of shares under employee share schemes | (356) | [3] | (300) | (349) | |
Net cash from financing activities | 793 | [3] | (142) | (915) | |
Effect of exchange rates on cash and cash equivalents | (2,913) | [3] | 1,169 | (2,753) | |
Net increase/(decrease) in cash and cash equivalents | 5,568 | [3] | 24,204 | (13,590) | |
Cash and cash equivalents at beginning of year | 153,491 | [3] | 129,287 | 142,877 | |
Cash and cash equivalents at end of year | 159,059 | [3] | 153,491 | [3] | 129,287 |
Cash and balances at central banks | 144,964 | [3] | 133,386 | 112,287 | |
Loans and advances to banks with original maturity less than three months | 3,793 | [3] | 10,174 | 11,823 | |
Cash collateral balances with central banks with original maturity less than three months | 9,690 | [3] | 9,086 | 4,736 | |
Short-term investments, classified as cash equivalents | 612 | [3] | 845 | 441 | |
Cash and cash equivalents | £ 159,059 | [3] | £ 153,491 | [3] | £ 129,287 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Parent company accounts - Cas_2
Parent company accounts - Cash flow statement (Parenthetical) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Condensed Cash Flow Statements, Captions [Line Items] | ||
Interest received, classified as operating activities | £ 11,616 | £ 12,860 |
Interest paid, classified as operating activities | 7,493 | 8,653 |
Balances with banks and other regulatory authorities | 4,260 | 3,119 |
Barclays Bank PLC | ||
Condensed Cash Flow Statements, Captions [Line Items] | ||
Interest received, classified as operating activities | 7,284 | 7,921 |
Interest paid, classified as operating activities | 5,496 | 6,441 |
Dividends received | 1,174 | 610 |
Balances with banks and other regulatory authorities | £ 1,585 | £ 1,353 |
Parent company accounts - Incom
Parent company accounts - Income Statement - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Condensed Statement of Income Captions [Line Items] | ||||
Interest and similar income | £ 5,672 | [1] | £ 6,006 | £ 8,085 |
Interest and similar expense | (2,599) | [1] | (2,846) | (4,178) |
Net interest income | 3,073 | [1] | 3,160 | 3,907 |
Fee and commission income | 8,581 | [1] | 7,417 | 7,664 |
Fee and commission expense | (1,994) | [1] | (1,758) | (1,992) |
Net fee and commission income | 6,587 | [1] | 5,659 | 5,672 |
Net trading income | 5,788 | [1] | 7,076 | 4,073 |
Net investment income | (80) | [1] | (121) | 420 |
Other income | 40 | [1] | 4 | 79 |
Total income | 15,408 | [1] | 15,778 | 14,151 |
Credit impairment releases/(charges) | 277 | [1] | (3,377) | (1,202) |
Net operating income | 15,685 | [1] | 12,401 | 12,949 |
Staff costs | (4,456) | [1] | (4,365) | (4,565) |
Infrastructure costs | (1,054) | [1] | (816) | (835) |
Administration and general expenses | (4,375) | [1] | (4,202) | (4,318) |
Litigation and conduct | (374) | [1] | (76) | (264) |
Total operating expenses | (10,259) | [1] | (9,459) | (9,982) |
Share of post-tax results of associates and joint ventures | 4 | [1] | 7 | 57 |
(Loss)/ profit on disposal of subsidiaries, associates and joint ventures | (12) | [1] | 126 | 88 |
Profit before tax | 5,418 | [2] | 3,075 | 3,112 |
Taxation | (830) | [1] | (624) | (332) |
Profit after tax | 4,588 | [1] | 2,451 | 2,780 |
Attributable to: | ||||
Equity holders of the parent | 3,957 | [1] | 1,774 | 2,120 |
Other equity instrument holders | 631 | [1] | 677 | 660 |
Total equity holders of the parent | 4,588 | [1] | 2,451 | 2,780 |
Barclays Bank PLC | ||||
Condensed Statement of Income Captions [Line Items] | ||||
Interest and similar income | 4,190 | [3] | 4,016 | 5,866 |
Interest and similar expense | (3,096) | [3] | (3,059) | (4,729) |
Net interest income | 1,094 | [3] | 957 | 1,137 |
Fee and commission income | 4,272 | [3] | 3,770 | 4,226 |
Fee and commission expense | (2,728) | [3] | (3,177) | (3,045) |
Net fee and commission income | 1,544 | [3] | 593 | 1,181 |
Net trading income | 4,575 | [3] | 6,066 | 3,679 |
Net investment income | 1,123 | [3] | 574 | 1,225 |
Other income | 4 | [3] | 130 | 59 |
Total income | 8,340 | [3] | 8,320 | 7,281 |
Credit impairment releases/(charges) | 414 | [3] | (1,577) | (235) |
Net operating income | 8,754 | [3] | 6,743 | 7,046 |
Staff costs | (1,598) | [3] | (1,623) | (1,826) |
Infrastructure costs | (409) | [3] | (154) | (161) |
Administration and general expenses | (3,158) | [3] | (3,154) | (3,019) |
Litigation and conduct | (360) | [3] | (60) | (154) |
Total operating expenses | (5,525) | [3] | (4,991) | (5,160) |
Share of post-tax results of associates and joint ventures | 0 | [3] | 2 | 0 |
(Loss)/ profit on disposal of subsidiaries, associates and joint ventures | 94 | [3] | 401 | 132 |
Profit before tax | 3,323 | [3] | 2,155 | 2,018 |
Taxation | 113 | [3] | (21) | 391 |
Profit after tax | 3,436 | [3],[4] | 2,134 | 2,409 |
Attributable to: | ||||
Equity holders of the parent | 2,641 | [3] | 1,305 | 1,570 |
Other equity instrument holders | 795 | [3] | 829 | 839 |
Total equity holders of the parent | £ 3,436 | [3] | £ 2,134 | £ 2,409 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details.The Parent company financials on pages 111 to 114 form part of this note. |
Parent company accounts - Inc_2
Parent company accounts - Income Statement (Parenthetical) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Barclays Bank PLC | |||
Condensed Statement of Income Captions [Line Items] | |||
Dividends paid to equity holders of parent, classified as financing activities | £ 1,174 | £ 610 | £ 980 |
Parent company accounts - Sta_3
Parent company accounts - Statement of comprehensive income - GBP (£) £ in Millions | 12 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |||
Condensed Statement of Income Captions [Line Items] | |||||
Profit after tax | £ 4,588 | [1] | £ 2,451 | £ 2,780 | |
Currency translation reserve | |||||
Currency translation differences | [3] | (155) | [2] | (647) | (544) |
Fair value through other comprehensive income reserve movement relating to debt securities | |||||
Net (losses)/gains from changes in fair value | (1,383) | [4] | 2,402 | 2,465 | |
Net gains transferred to net profit on disposal | (248) | [4] | (251) | (454) | |
Net (gains)/losses related to (releases of) impairment | (6) | [4] | 1 | 1 | |
Net gains/(losses) due to fair value hedging | 1,105 | [4] | (1,640) | (1,782) | |
Other movements | 0 | [4] | 0 | (8) | |
Tax | 170 | [4] | (130) | (63) | |
Cash flow hedging reserve | |||||
Net (losses)/gains from changes in fair value | (2,212) | [4] | 1,366 | 823 | |
Net gains transferred to net profit | (327) | [4] | (282) | (141) | |
Tax | 740 | [4] | (291) | (171) | |
Other | 0 | [4] | 3 | 16 | |
Other comprehensive (loss)/income that may be recycled to profit or loss | (2,316) | [4] | 531 | 142 | |
Other comprehensive income/(loss) not recycled to profit or loss: | |||||
Retirement benefit remeasurements | 1,299 | [4] | (77) | (280) | |
Fair value through other comprehensive income reserve movements relating to equity instruments | 0 | [4] | 1 | 0 | |
Own credit | (105) | [4] | (810) | (316) | |
Tax | (563) | [4] | 198 | 150 | |
Other comprehensive income/(loss) not recycled to profit or loss | 631 | [4] | (688) | (446) | |
Other comprehensive loss for the year | (1,685) | [4] | (157) | (304) | |
Total comprehensive income for the year | 2,903 | [4] | 2,294 | 2,476 | |
Attributable to: | |||||
Equity holders of the parent | 2,903 | [4] | 2,294 | 2,476 | |
Total comprehensive income for the year | 2,903 | [4] | 2,294 | 2,476 | |
Barclays Bank PLC | |||||
Condensed Statement of Income Captions [Line Items] | |||||
Profit after tax | 3,436 | [5],[6] | 2,134 | 2,409 | |
Currency translation reserve | |||||
Currency translation differences | [8] | 128 | [6],[7] | (519) | (198) |
Fair value through other comprehensive income reserve movement relating to debt securities | |||||
Net (losses)/gains from changes in fair value | (1,382) | [6] | 2,405 | 2,463 | |
Net gains transferred to net profit on disposal | (248) | [6] | (252) | (454) | |
Net (gains)/losses related to (releases of) impairment | (6) | [6] | 1 | 1 | |
Net gains/(losses) due to fair value hedging | 1,103 | [6] | (1,634) | (1,780) | |
Other movements | 0 | [6] | 0 | (3) | |
Tax | 170 | [6] | (131) | (63) | |
Cash flow hedging reserve | |||||
Net (losses)/gains from changes in fair value | (2,230) | [6] | 1,375 | 850 | |
Net gains transferred to net profit | (333) | [6] | (296) | (149) | |
Tax | 748 | [6] | (291) | (175) | |
Other | 0 | [6] | 2 | 9 | |
Other comprehensive (loss)/income that may be recycled to profit or loss | (2,050) | [6] | 660 | 501 | |
Other comprehensive income/(loss) not recycled to profit or loss: | |||||
Retirement benefit remeasurements | 1,261 | [6] | (85) | (269) | |
Fair value through other comprehensive income reserve movements relating to equity instruments | 0 | [6] | 0 | (3) | |
Own credit | (55) | [6] | (778) | (277) | |
Tax | (563) | [6] | 190 | 149 | |
Other comprehensive income/(loss) not recycled to profit or loss | 643 | [6] | (673) | (400) | |
Other comprehensive loss for the year | (1,407) | [6] | (13) | 101 | |
Total comprehensive income for the year | 2,029 | [6],[7] | 2,121 | 2,510 | |
Attributable to: | |||||
Equity holders of the parent | 2,029 | [6] | 2,121 | 2,510 | |
Total comprehensive income for the year | £ 2,029 | [6],[7] | £ 2,121 | £ 2,510 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[3] | Includes £28m loss (2020: £8m loss; 2019: £15m profit) on recycling of currency translation differences. | ||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[6] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details.The Parent company financials on pages 111 to 114 form part of this note. | ||||
[7] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[8] | Includes £0m (2020:£0m; 2019: £45m profit) on recycling of currency translation differences. |
Ordinary shares, preference sha
Ordinary shares, preference shares and other equity | 12 Months Ended |
Dec. 31, 2021 | |
Equity [abstract] | |
Ordinary shares, preference shares and other equity | Ordinary shares, preference shares and other equity Called up share capital, allotted and fully paid and other equity instruments Barclays Bank Group Barclays Bank Group Ordinary share capital Preference share capital Total share capital Other equity instruments £m £m £m £m As at 1 January 2021 2,342 6 2,348 8,621 AT1 securities issuance — — — 1,072 As at 31 December 2021 2,342 6 2,348 9,693 As at 1 January 2020 2,342 6 2,348 8,323 AT1 securities issuance — — — 1,134 Increase in borrowings from subsidiary — — — — AT1 securities redemption — — — (836) As at 31 December 2020 2,342 6 2,348 8,621 Ordinary shares The issued ordinary share capital of Barclays Bank PLC, as at 31 December 2021, comprised 2,342m (2020: 2,342m) ordinary shares of £1 each. Preference shares The issued preference share capital of Barclays Bank PLC, as at 31 December 2021, comprised 1,000 Sterling Preference Shares of £1 each (2020: 1,000); 31,856 Euro Preference Shares of €100 each (2020: 31,856); and 58,133 US Dollar Preference Shares of $100 each (2020: 58,133). Ordinary share capital and preference share capital constitutes 100% (2020: 100%) of total share capital issued. Sterling £1 Preference Shares 1,000 Sterling cumulative callable preference shares of £1 each (the £1 Preference Shares) were issued on 31 December 2004 at nil premium. The £1 Preference Shares entitle the holders thereof to receive Sterling cumulative cash dividends out of distributable profits of Barclays Bank PLC, semi-annually at a rate reset semi-annually equal to the Sterling interbank offered rate for six-month sterling deposits. Barclays Bank PLC shall be obliged to pay such dividends if: (1) it has profits available for the purpose of distribution under the Companies Act 2006 as at each dividend payment date; and (2) it is solvent on the relevant dividend payment date, provided that a capital regulations condition is satisfied on such dividend payment date. The dividends shall not be due and payable on the relevant dividend payment date except to the extent that Barclays Bank PLC could make such payment and still be solvent immediately thereafter. Barclays Bank PLC shall be considered solvent on any date if: (1) it is able to pay its debts to senior creditors as they fall due; and (2) its auditors have reported within the previous six months that its assets exceed its liabilities. If Barclays Bank PLC shall not pay, or shall pay only in part, a dividend for a period of seven days or more after the due date for payment, the holders of the £1 Preference Shares may institute proceedings for the winding-up of Barclays Bank PLC. No remedy against Barclays Bank PLC shall be available to the holder of any £1 Preference Shares for the recovery of amounts owing in respect of £1 Preference Shares other than the institution of proceedings for the winding-up of Barclays Bank PLC and/or proving in such winding-up. On a winding-up or other return of capital (other than a redemption or purchase by Barclays Bank PLC of any of its issued shares, or a reduction of share capital, permitted by the Articles of Barclays Bank PLC and under applicable law), the assets of Barclays Bank PLC available to shareholders shall be applied in priority to any payment to the holders of ordinary shares and any other class of shares in the capital of Barclays Bank PLC then in issue ranking junior to the £1 Preference Shares on such a return of capital and pari passu on such a return of capital with the holders of any other class of shares in the capital of Barclays Bank PLC then in issue (other than any class of shares in the capital of Barclays Bank PLC then in issue ranking in priority to the £1 Preference Shares on a winding-up or other such return of capital), in payment to the holders of the £1 Preference Shares of a sum equal to the aggregate of: (1) an amount equal to the dividends accrued thereon for the then current dividend period (and any accumulated arrears thereof) to the date of the commencement of the winding-up or other such return of capital; and (2) an amount equal to £1 per £1 Preference Share. After payment of the full amount of the liquidating distributions to which they are entitled, the holders of the £1 Preference Shares will have no right or claim to any of the remaining assets of Barclays Bank PLC and will not be entitled to any further participation in such return of capital. The £1 Preference Shares are redeemable at the option of Barclays Bank PLC, in whole but not in part only, subject to the Companies Act 2006 and Barclays Bank PLC's Articles. Holders of the £1 Preference Shares are not entitled to receive notice of, or to attend, or vote at, any general meeting of Barclays Bank PLC. Euro Preference Shares 140,000 Euro non-cumulative callable preference shares of €100 each (the Euro Preference Shares) were issued on 15 March 2005 for a consideration of €1,383.3m (£966.7m), of which the nominal value was €14m and the balance was share premium. The Euro Preference Shares entitled the holders thereof to receive Euro non-cumulative cash dividends out of distributable profits of Barclays Bank PLC, annually at a fixed rate of 4.75% per annum on the amount of €10,000 per preference share until 15 March 2020, and since 15 March 2020 quarterly at a rate reset quarterly equal to 0.71% per annum above the Euro interbank offered rate for three-month Euro deposits. The board of directors of Barclays Bank PLC may resolve, in its absolute discretion, not to pay in full, or at all, the dividend on the Euro Preference Shares in respect of a particular dividend period. The Euro Preference Shares are redeemable at the option of Barclays Bank PLC, in whole but not in part only, on each dividend payment date at €10,000 per share plus any dividends accrued for the then current dividend period to the date fixed for redemption. US Dollar Preference Shares 100,000 US Dollar non-cumulative callable preference shares of $100 each (the US Dollar Preference Shares), represented by 100,000 American Depositary Shares, Series 1, were issued on 8 June 2005 for a consideration of $995.4m (£548.1m), of which the nominal value was $10m and the balance was share premium. The US Dollar Preference Shares entitle the holders thereof to receive US Dollar non-cumulative cash dividends out of distributable profits of Barclays Bank PLC, semi-annually at a fixed rate of 6.278% per annum on the amount of $10,000 per preference share until 15 December 2034, and thereafter quarterly at a rate reset quarterly equal to 1.55% per annum above the London interbank offered rate for three-month US Dollar deposits. The board of directors of Barclays Bank PLC may resolve, for any reason and in its absolute discretion, not to declare or pay in full or in part any dividends on the US Dollar Preference Shares in respect of a particular dividend period. The US Dollar Preference Shares are redeemable at the option of Barclays Bank PLC, in whole but not in part only, on 15 December 2034, and on each dividend payment date thereafter at $10,000 per share plus any dividends accrued for the then current dividend period to the date fixed for redemption. No redemption or purchase of any Euro Preference Shares and US Dollar Preference Shares (together, the Preference Shares) may be made by Barclays Bank PLC without the prior consent of the PRA and any such redemption will be subject to the Companies Act 2006 and the Articles of Barclays Bank PLC. On a winding-up of Barclays Bank PLC or other return of capital (other than a redemption or purchase of shares of Barclays Bank PLC, or a reduction of share capital), a holder of Preference Shares will rank in the application of assets of Barclays Bank PLC available to shareholders: (1) junior to the holder of any shares of Barclays Bank PLC in issue ranking in priority to the Preference Shares; (2) equally in all respects with holders of other preference shares and any other shares of Barclays Bank PLC in issue ranking pari passu with the Preference Shares; and (3) in priority to the holders of ordinary shares and any other shares of Barclays Bank PLC in issue ranking junior to the Preference Shares. The holders of the £13m 6% Callable Perpetual Core Tier One Notes and the $179m 6.86% Callable Perpetual Core Tier One Notes of Barclays Bank PLC (together, the TONs) and the holders of the £35m 5.3304% Step-up Callable Perpetual Reserve Capital Instruments of Barclays Bank PLC (the RCIs) would, for the purposes only of calculating the amounts payable in respect of such securities on a winding-up of Barclays Bank PLC, subject to limited exceptions and to the extent that the TONs and the RCIs are then in issue, rank pari passu with the holders of the most senior class or classes of preference shares then in issue in the capital of Barclays Bank PLC. Accordingly, the holders of the preference shares would rank equally with the holders of such TONs and RCIs on such a winding-up of Barclays Bank PLC (unless one or more classes of shares of Barclays Bank PLC ranking in priority to the preference shares are in issue at the time of such winding-up, in which event the holders of such TONs and RCIs would rank equally with the holders of such shares and in priority to the holders of the preference shares). Subject to such ranking, in such event, holders of the preference shares will be entitled to receive out of assets of Barclays Bank PLC available for distributions to shareholders, liquidating distributions in the amount of €10,000 per Euro Preference Share and $10,000 per US Dollar Preference Share, plus, in each case, an amount equal to the accrued dividend for the then current dividend period to the date of the commencement of the winding-up or other such return of capital. If a dividend is not paid in full on any preference shares on any dividend payment date, then a dividend restriction shall apply. This dividend restriction will mean that neither Barclays Bank PLC nor Barclays PLC may (a) declare or pay a dividend (other than payment by Barclays PLC of a final dividend declared by its shareholders prior to the relevant dividend payment date, or a dividend paid by Barclays Bank PLC to Barclays PLC) on any of their respective ordinary shares, other preference shares or other share capital or (b) redeem, purchase, reduce or otherwise acquire any of their respective share capital, other than shares of Barclays Bank PLC held by Barclays PLC or a wholly owned subsidiary, until the earlier of: (1)the date on which Barclays Bank PLC next declares and pays in full a preference share dividend; and (2)the date on or by which all the preference shares are redeemed in full or purchased by Barclays Bank PLC. Holders of the preference shares are not entitled to receive notice of, or to attend, or vote at, any general meeting of Barclays Bank PLC. Barclays Bank PLC is not permitted to create a class of shares ranking as regards participation in the profits or assets of Barclays Bank PLC in priority to the preference shares, save with the sanction of a special resolution of a separate general meeting of the holders of the preference shares (requiring a majority of not less than three-fourths of the holders of the preference shares voting at the separate general meeting) or with the consent in writing of the holders of three-fourths of the preference shares. Except as described above, the holders of the preference shares have no right to participate in the surplus assets of Barclays Bank PLC. Other equity instruments Other equity instruments issued by Barclays Bank PLC of £14,400m (2020: £13,328m) include AT1 securities issued to Barclays PLC and borrowings of $6bn from a wholly-owned, indirect subsidiary of Barclays Bank PLC. As a result, the other equity instruments balance recorded by Barclays Bank Group is £9,693m (2020: £8,621m). Barclays PLC uses funds from its own market issuance of AT1 securities to purchase AT1 securities from the Barclays Bank Group. The AT1 securities are perpetual securities with no fixed maturity and are structured to qualify as AT1 instruments under prevailing capital rules applicable as at the relevant issue date. In 2021, there was one issuance of AT1 instruments, in the form of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities for £1,072m (2020: one issuance for £1,134m). There were no redemptions in 2021 (2020: one redemption of £836m). AT1 equity instruments 2021 2020 Initial call date £m £m AT1 equity instruments - Barclays Bank Group 7.875% Perpetual Subordinated Contingent Convertible Securities 2022 1,000 1,000 7.875% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2022 1,136 1,136 7.25% Perpetual Subordinated Contingent Convertible Securities 2023 500 500 7.75% Perpetual Subordinated Contingent Convertible Securities (USD 2,500m) 2023 1,925 1,925 5.875% Perpetual Subordinated Contingent Convertible Securities 2024 623 623 8% Perpetual Subordinated Contingent Convertible Securities (USD 2,000m) 2024 1,509 1,509 7.125% Perpetual Subordinated Contingent Convertible Securities 2025 299 299 6.375% Perpetual Subordinated Contingent Convertible Securities 2025 495 495 6.125% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2025 1,134 1,134 4.375% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2028 1,072 — 9,693 8,621 |
Consolidated statement of cha_2
Consolidated statement of changes in equity - Parenthetical (Details) - GBP (£) £ in Millions | Apr. 29, 2022 | Dec. 31, 2021 | [1] | Dec. 31, 2020 |
Capital contribution from Barclays Plc | £ 0 | £ 1,500 | ||
Capital contribution from parent | ||||
Capital contribution from Barclays Plc | £ 750 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Parent company accounts - Sta_4
Parent company accounts - Statement of comprehensive income (Parenthetical) (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Condensed Statement of Income Captions [Line Items] | |||
Reclassification adjustments on exchange differences on translation, net of tax | £ (28) | £ (8) | £ 15 |
Barclays Bank PLC | |||
Condensed Statement of Income Captions [Line Items] | |||
Reclassification adjustments on exchange differences on translation, net of tax | £ 0 | £ 0 | £ (45) |
Other disclosures - Risk Manage
Other disclosures - Risk Management and Principal Risks (audited) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of credit risk exposure [abstract] | |
Other disclosures - Risk Management and Principal Risks (audited) | All disclosures in this section pages 48 Overview Credit risk represents a significant risk to the Barclays Bank Group and mainly arises from exposure to wholesale and retail loans and advances together with the counterparty credit risk arising from derivative contracts entered into with clients. The continued impact of the COVID-19 pandemic has meant that management was required to monitor economic uncertainty judgement over the course of 2021. Customer and client default rates have remained relatively stable despite the impact of the pandemic and volatile macroeconomic environment. In retail cards, credit profiles did not show material deterioration due to continued government support measures in some geographies and customer deleveraging. In wholesale, watch list balances continue to improve. However, the degree of economic uncertainty remains relatively high: credit deterioration may still occur when support measures are fully withdrawn; emerging supply chain disruption and inflationary pressures may challenge economic stability. Given this backdrop, management has maintained economic uncertainty adjustments to modelled outputs to address these sources of uncertainties and ensure that the potential impact of stress are provided for. This uncertainty continues to be captured in two distinct ways: firstly, the identification of customers and clients who may be more vulnerable to the withdrawal of support and emerging economic instability and secondly, model uncertainty which does not capture certain macroeconomic and risk parameter uncertainties which are applied at a portfolio level. Refer to the Management adjustment to models for impairment section on pages 57 Further detail can be found in the financial statements section in Note 7 Credit impairment charges. Descriptions of terminology can be found in the glossary, available at home.barclays/annualreport. Summary of performance in the period Credit impairment release of £277m (2020: £3,377m charge) was driven by an improved macro-economic outlook. CIB credit impairment release of £461m (2020: £1,565m charge) was also supported by net single name wholesale loan release and a benign credit environment and CC&P credit impairment charges of £185m (2020: £1,720m charge) was supported by lower delinquencies and higher customer repayments. As at 31 December 2021, 30 and 90 days arrears rates in US cards were 1.6% (2020: 2.5%) and 0.8% (2020: 1.4%) respectively. Key metrics Decrease of £1,837m impairment allowance Impairment allowances on loans and advances at amortised cost including off-balance sheet elements of the allowance in Barclays Bank Group decreased by £1,837m to £3,998m (2020: £5,835m) during the year. This is driven by a decrease in Wholesale Loans of £842m, Credit cards, unsecured loans and other retail lending of £677m and Home Loans £48m and further decrease in off-balance sheet provisions of £270m. Please refer to page 52 Please see risk management section on pages 41 Maximum exposure and effect of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure Barclays Bank Group As at 31 December 2021 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 169,085 — — — — 169,085 Cash collateral and settlement balances 88,085 — — — — 88,085 Loans and advances at amortised cost: Home loans 10,985 — (338) (10,483) (89) 75 Credit cards, unsecured loans and other retail lending 25,960 — (968) (4,229) (252) 20,511 Wholesale loans 108,314 (5,001) (118) (30,287) (5,080) 67,828 Total loans and advances at amortised cost 145,259 (5,001) (1,424) (44,999) (5,421) 88,414 Of which credit-impaired (Stage 3): Home loans 615 — (11) (604) — — Credit cards, unsecured loans and other retail lending 563 — (29) (217) (3) 314 Wholesale loans 486 — — (76) (22) 388 Total credit-impaired loans and advances at amortised cost 1,664 — (40) (897) (25) 702 Reverse repurchase agreements and other similar secured lending 3,177 — — (3,177) — — Trading portfolio assets: Debt securities 50,700 — — (461) — 50,239 Traded loans 12,525 — — (268) — 12,257 Total trading portfolio assets 63,225 — — (729) — 62,496 Financial assets at fair value through the income statement: Loans and advances 35,901 — — (29,485) — 6,416 Debt securities 2,256 — — (319) — 1,937 Reverse repurchase agreements 145,186 — (1,428) (143,229) — 529 Other financial assets 85 — — — — 85 Total financial assets at fair value through the income statement 183,428 — (1,428) (173,033) — 8,967 Derivative financial instruments 262,291 (202,347) (34,149) (5,804) (5,738) 14,253 Financial assets at fair value through other comprehensive income 45,907 — — (53) (931) 44,923 Other assets 994 — — — — 994 Total on-balance sheet 961,451 (207,348) (37,001) (227,795) (12,090) 477,217 Off-balance sheet: Contingent liabilities 23,746 — (906) (1,367) (256) 21,217 Loan commitments 284,451 — (99) (40,104) (1,627) 242,621 Total off-balance sheet 308,197 — (1,005) (41,471) (1,883) 263,838 Total 1,269,648 (207,348) (38,006) (269,266) (13,973) 741,055 Off-balance sheet exposures are shown gross of provisions of £499m (2020: £769m). See Note 24 for further details. In addition to the above, Barclays Bank Group holds forward starting reverse repos amounting to £39.3bn (2020: £30.8bn). The balances are fully collateralised. Wholesale loans and advances at amortised cost include £1.0bn (2020: £1.2bn) of CBILs and CLBILs supported by UK government guarantees of £0.8bn (2020: £0.9bn). Barclays Bank Group has issued £1.7bn (2020: £2.6bn) of guarantees that have been provided to subsidiaries of Barclays PLC outside the Barclays Bank Group. These guarantees have not been reported in the prior periods and the comparatives have not been restated. For further information on credit risk mitigation techniques, refer to the Credit risk management section. Maximum exposure and effects of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure Barclays Bank Group As at 31 December 2020 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 155,902 — — — — 155,902 Cash collateral and settlement balances 97,616 — — — — 97,616 Loans and advances at amortised cost: Home loans 11,193 — (283) (10,782) (85) 43 Credit cards, unsecured loans and other retail lending 23,368 — (827) (3,459) (195) 18,887 Wholesale loans 99,706 (6,988) (50) (24,328) (4,419) 63,921 Total loans and advances at amortised cost 134,267 (6,988) (1,160) (38,569) (4,699) 82,851 Of which credit-impaired (Stage 3): Home loans 723 — (13) (708) — 2 Credit cards, unsecured loans and other retail lending 600 — (10) (218) (2) 370 Wholesale loans 1,327 — (4) (167) (85) 1,071 Total credit-impaired loans and advances at amortised cost 2,650 — (27) (1,093) (87) 1,443 Reverse repurchase agreements and other similar secured lending 8,981 — — (8,981) — — Trading portfolio assets: Debt securities 56,196 — — (391) — 55,805 Traded loans 8,348 — — (374) — 7,974 Total trading portfolio assets 64,544 — — (765) — 63,779 Financial assets at fair value through the income statement: Loans and advances 27,449 — (9) (21,819) — 5,621 Debt securities 1,697 — — (292) — 1,405 Reverse repurchase agreements 138,558 — (685) (137,466) — 407 Other financial assets 315 — — — — 315 Total financial assets at fair value through the income statement 168,019 — (694) (159,577) — 7,748 Derivative financial instruments 302,693 (233,088) (43,164) (4,656) (6,409) 15,376 Financial assets at fair value through other comprehensive income 51,901 — — (106) (1,065) 50,730 Other assets 614 — — — — 614 Total on-balance sheet 984,537 (240,076) (45,018) (212,654) (12,173) 474,616 Off-balance sheet: Contingent liabilities 20,932 — (1,095) (2,135) (282) 17,420 Loan commitments 265,022 — (56) (35,970) (1,479) 227,517 Total off-balance sheet 285,954 — (1,151) (38,105) (1,761) 244,937 Total 1,270,491 (240,076) (46,169) (250,759) (13,934) 719,553 Loans and advances at amortised cost by product The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure as ECL is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Barclays Bank Group (audited) Stage 2 As at 31 December 2021 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total a Gross exposure £m £m £m £m £m £m £m Home loans 9,760 548 22 83 653 958 11,371 Credit cards, unsecured loans and other retail lending 24,011 2,402 198 182 2,782 1,469 28,262 Wholesale loans 95,242 12,275 301 386 12,962 921 109,125 Total 129,013 15,225 521 651 16,397 3,348 148,758 Impairment allowance Home loans 8 33 1 1 35 343 386 Credit cards, unsecured loans and other retail lending 605 677 39 75 791 906 2,302 Wholesale loans 183 188 3 2 193 435 811 Total 796 898 43 78 1,019 1,684 3,499 Net exposure Home loans 9,752 515 21 82 618 615 10,985 Credit cards, unsecured loans and other retail lending 23,406 1,725 159 107 1,991 563 25,960 Wholesale loans 95,059 12,087 298 384 12,769 486 108,314 Total 128,217 14,327 478 573 15,378 1,664 145,259 Coverage ratio % % % % % % % Home loans 0.1 6.0 4.5 1.2 5.4 35.8 3.4 Credit cards, unsecured loans and other retail lending 2.5 28.2 19.7 41.2 28.4 61.7 8.1 Wholesale loans 0.2 1.5 1.0 0.5 1.5 47.2 0.7 Total 0.6 5.9 8.3 12.0 6.2 50.3 2.4 As at 31 December 2020 Gross exposure £m £m £m £m £m £m £m Home loans 9,627 761 53 87 901 1,099 11,627 Credit cards, unsecured loans and other retail lending 18,923 4,987 393 191 5,571 1,853 26,347 Wholesale loans 83,254 14,184 1,066 688 15,938 2,167 101,359 Total 111,804 19,932 1,512 966 22,410 5,119 139,333 Impairment allowance Home loans 6 40 6 6 52 376 434 Credit cards, unsecured loans and other retail lending 399 1,092 111 124 1,327 1,253 2,979 Wholesale loans 280 475 49 9 533 840 1,653 Total 685 1,607 166 139 1,912 2,469 5,066 Net exposure Home loans 9,621 721 47 81 849 723 11,193 Credit cards, unsecured loans and other retail lending 18,524 3,895 282 67 4,244 600 23,368 Wholesale loans 82,974 13,709 1,017 679 15,405 1,327 99,706 Total 111,119 18,325 1,346 827 20,498 2,650 134,267 Coverage ratio % % % % % % % Home loans 0.1 5.3 11.3 6.9 5.8 34.2 3.7 Credit cards, unsecured loans and other retail lending 2.1 21.9 28.2 64.9 23.8 67.6 11.3 Wholesale loans 0.3 3.3 4.6 1.3 3.3 38.8 1.6 Total 0.6 8.1 11.0 14.4 8.5 48.2 3.6 Note a. Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £135.5bn (2020: £150.3bn) and impairment allowance of £104m (2020: £145m). This comprises £4m (2020: £7m) ECL on £135.3bn (2020: £146.3bn) Stage 1 assets, £0m (2020: £6m) on £65m (2020: £3.8bn) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets and £100m (2020: £132m) on £100m (2020: £132m) Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £499m (2020: £769m). Movement in gross exposures and impairment allowance including provisions for loan commitments and financial guarantees The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in page 126 Loans and advances at amortised cost (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2021 9,627 6 901 52 1,099 376 11,627 434 Transfers from Stage 1 to Stage 2 (253) — 253 — — — — — Transfers from Stage 2 to Stage 1 331 22 (331) (22) — — — — Transfers to Stage 3 (80) — (52) (5) 132 5 — — Transfers from Stage 3 22 — 49 4 (71) (4) — — Business activity in the year a 1,745 2 — — — — 1,745 2 Refinements to models used for calculation b — — — (4) — 38 — 34 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (742) (22) (25) 11 (70) (50) (837) (61) Final repayments (890) — (142) (1) (114) (4) (1,146) (5) Disposals — — — — — — — — Write-offs c — — — — (18) (18) (18) (18) As at 31 December 2021 d 9,760 8 653 35 958 343 11,371 386 Credit cards, unsecured loans and other retail lending As at 1 January 2021 18,923 399 5,571 1,327 1,853 1,253 26,347 2,979 Transfers from Stage 1 to Stage 2 (897) (41) 897 41 — — — — Transfers from Stage 2 to Stage 1 2,520 548 (2,520) (548) — — — — Transfers to Stage 3 (307) (13) (362) (165) 669 178 — — Transfers from Stage 3 21 5 13 9 (34) (14) — — Business activity in the year a 4,731 84 106 23 16 5 4,853 112 Refinements to models used for calculation b — (3) — (27) — — — (30) Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 509 (360) (514) 147 (96) 337 (101) 124 Final repayments (1,489) (14) (409) (16) (76) (5) (1,974) (35) Disposals e — — — — (37) (22) (37) (22) Write-offs c — — — — (826) (826) (826) (826) As at 31 December 2021 d 24,011 605 2,782 791 1,469 906 28,262 2,302 Wholesale loans As at 1 January 2021 83,254 280 15,938 533 2,167 840 101,359 1,653 Transfers from Stage 1 to Stage 2 (4,122) (14) 4,122 14 — — — — Transfers from Stage 2 to Stage 1 5,454 179 (5,454) (179) — — — — Transfers to Stage 3 (32) (1) (164) (12) 196 13 — — Transfers from Stage 3 363 3 145 5 (508) (8) — — Business activity in the year a 27,946 74 1,674 15 37 23 29,657 112 Refinements to models used for calculation b — — — 3 — — — 3 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 2,448 (301) 1,072 (14) (82) 47 3,438 (268) Final repayments (19,481) (29) (4,322) (168) (504) (125) (24,307) (322) Disposals e (588) (8) (49) (4) (71) (41) (708) (53) Write-offs c — — — — (314) (314) (314) (314) As at 31 December 2021 d 95,242 183 12,962 193 921 435 109,125 811 Notes a. Business activity in the year does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. b. Refinements to models used for calculation include a £34m movement in Home loans, £30m in Credit cards, unsecured loans and other retail lending and £3m in Wholesale loans. These reflect methodology changes made during the year. Barclays Bank Group continually reviews the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. c. In 2021, gross write-offs amounted to £1,158m (2020: £1,337m) and post write-off recoveries amounted to £31m (2020: £4m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £1,127m (2020: £1,333m). d. Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £135.5bn (2020: £150.3bn) and impairment allowance of £104m (2020: £145m). This comprises £4m (2020: £7m) ECL on £135.3bn (2020: £146.3bn) Stage 1 assets, £0m (2020: £6m) on £65m (2020: £3.8bn) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets and £100m (2020: £132m) on £100m (2020: £132m) Stage 3 other assets. e. The £37m of disposals reported within Credit cards, unsecured loans and other retail lending portfolio relate to debt sales undertaken during the year. The £708m of disposals reported within Wholesale loans include debt sales and sale of Barclays Asset Finance. Reconciliation of ECL movement to credit impairment (release)/charge for the period £m Home loans (30) Credit cards, unsecured loans and other retail lending 171 Wholesale loans (475) ECL movement excluding assets derecognised due to disposals and write-offs (334) Recoveries and reimbursements a 259 Exchange and other adjustments b 70 Credit impairment release on loan commitments and financial guarantees (257) Credit impairment release on other financial assets c (15) Credit impairment release for the year (277) Notes a Recoveries and reimbursements includes a net reduction in amounts recoverable from financial guarantee contracts held with third parties of £290m and cash recoveries of previously written off amounts of £31m. b Includes foreign exchange and interest and fees in suspense. c Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £135.5bn (2020: £150.3bn) and impairment allowance of £104m (2020: £145m). This comprises £4m (2020: £7m) ECL on £135.3bn (2020: £146.3bn) Stage 1 assets, £0m (2020: £6m) on £65m (2020: £3.8bn) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets and £100m (2020: £132m) on £100m (2020: £132m) Stage 3 other assets. Loan commitments and financial guarantees (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2021 125 — 2 — 4 — 131 — Net transfers between stages — — — — — — — — Business activity in the year 19 — — — — — 19 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (4) — — — — — (4) — Limit management and final repayments (87) — (2) — (3) — (92) — As at 31 December 2021 53 — — — 1 — 54 — Credit cards, unsecured loans and other retail lending As at 1 January 2021 68,211 34 6,244 33 30 23 74,485 90 Net transfers between stages 2,992 (4) (3,431) (2) 439 6 — — Business activity in the year 10,628 — 410 — 2 — 11,040 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 3,712 6 585 2 (437) (9) 3,860 (1) Limit management and final repayments (6,888) — (594) — (2) — (7,484) — As at 31 December 2021 78,655 36 3,214 33 32 20 81,901 89 Wholesale loans d As at 1 January 2021 160,404 205 39,426 446 2,031 28 201,861 679 Net transfers between stages 7,801 220 (6,730) (214) (1,071) (6) — — Business activity in the year 45,395 14 4,658 102 9 — 50,062 116 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 10,551 (232) 2 12 539 (13) 11,092 (233) Limit management and final repayments (46,145) (40) (8,939) (105) (491) (7) (55,575) (152) As at 31 December 2021 178,006 167 28,417 241 1,017 2 207,440 410 d Barclays Bank Group has issued £1.7bn (2020: £2.6bn) of guarantees that have been provided to subsidiaries of Barclays PLC outside the Barclays Bank Group. These guarantees have not been reported in the prior periods and the comparatives have not been restated. Loans and advances at amortised cost (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2020 9,604 16 674 40 1,056 292 11,334 348 Transfers from Stage 1 to Stage 2 (537) (1) 537 1 — — — — Transfers from Stage 2 to Stage 1 204 7 (204) (7) — — — — Transfers to Stage 3 (157) — (52) (7) 209 7 — — Transfers from Stage 3 29 — 55 1 (84) (1) — — Business activity in the year a 1,193 1 — — 1 — 1,194 1 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 133 (17) (62) 25 32 96 103 104 Final repayments (842) — (47) (1) (98) (1) (987) (2) Write-offs b — — — — (17) (17) (17) (17) As at 31 December 2020 c 9,627 6 901 52 1,099 376 11,627 434 Credit cards, unsecured loans and other retail lending As at 1 January 2020 29,541 362 4,450 784 2,129 1,471 36,120 2,617 Transfers from Stage 1 to Stage 2 (4,116) (92) 4,116 92 — — — — Transfers from Stage 2 to Stage 1 994 139 (994) (139) — — — — Transfers to Stage 3 (464) (19) (516) (188) 980 207 — — Transfers from Stage 3 21 12 59 8 (80) (20) — — Business activity in the year a 3,467 35 130 32 29 7 3,626 74 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (4,613) 15 (1,231) 806 38 731 (5,806) 1,552 Final repayments (2,232) (29) (168) (23) (68) (8) (2,468) (60) Transfers to Barclays Group d (2,182) (16) (92) (25) (47) (41) (2,321) (82) Disposals e (1,493) (8) (183) (20) (92) (58) (1,768) (86) Write-offs b — — — — (1,036) (1,036) (1,036) (1,036) As at 31 December 2020 c 18,923 399 5,571 1,327 1,853 1,253 26,347 2,979 Wholesale loans As at 1 January 2020 89,200 114 7,515 234 1,163 383 97,878 731 Transfers from Stage 1 to Stage 2 (10,213) (31) 10,213 31 — — — — Transfers from Stage 2 to Stage 1 2,651 25 (2,651) (25) — — — — Transfers to Stage 3 (772) (3) (642) (50) 1,414 53 — — Transfers from Stage 3 189 — 34 1 (223) (1) — — Business activity in the year a 19,773 44 1,954 144 393 67 22,120 255 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 7,033 154 2,969 248 5 687 10,007 1,089 Final repayments (24,098) (22) (2,844) (28) (283) (59) (27,225) (109) Transfers to Barclays Group d (509) (1) (600) (22) (18) (6) (1,127) (29) Disposals e — — (10) — — — (10) — Write-offs b — — — — (284) (284) (284) (284) As at 31 December 2020 c 83,254 280 15,938 533 2,167 840 101,359 1,653 Notes a. Business activity during the year does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. b. In 2020, gross write-offs amounted to £1,337m (2019: £1,293m) and post write-off recoveries amounted to £4m (2019: £73m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £1,333m (2019: £1,220m). c. Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £150.3bn (2019: £125.5bn) and impairment allowance of £145m (2019: £22m). This comprises £7m ECL (2019 £10m) on £146.3bn stage 1 assets (2019: £124.7bn), £6m (2019: £2m) on £3.8bn stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (2019: £0.8bn) and £132m (2019: £10m) on £132m Stage 3 other assets (2019: £10m). d. Transfers to Barclays Group include a £2.3bn transfer of the Barclays Partner Finance retail portfolio reported within Credit cards, unsecured loans and other retail lending and £1.1bn transfer of the Barclays Mercantile Business Finance Limited reported within loans to Barclays Principal Investments Limited. e. The £1.8bn disposals reported within Credit cards, unsecured loans and other retail lending portfolio include sale of motor financing business within Barclays Partner Finance business. Disposal within Wholesale loans include sale of debt securities as part of Group Treasury Operations. Reconciliation of ECL movement to credit impairment (release)/charge for the period £m Home loans 103 Credit cards, unsecured loans and other retail lending 1,484 Wholesale loans 1,206 ECL movement excluding assets derecognised due to disposals and write-offs 2,793 Recoveries and reimbursements a (368) Exchange and other adjustments b 267 Credit impairment charge on loan commitments and financial guarantees 547 Credit impairment charge on other financial assets c 138 Credit impairment charge for the year 3,377 Notes a Recoveries and reimbursements includes £364m for reimbursements expected to be received under the arrangement where Group has entered into financial guarantee contracts which provide credit protection over certain loan assets with third parties. Cash recoveries of previously written off amounts to £4m. b Includes foreign exchange and interest and fees in suspense. c Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £150.3bn (2019: £125.5bn) and impairment allowance of £145m (2019: £22m). This comprises £7m ECL (2019: £10m) on £146.3bn stage 1 assets (2019: £124.7bn), £6m (2019: £2m) on £3.8bn stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (2019: £0.8bn) and £132m (2019: £10m) on £132m Stage 3 other assets (2019: £10m). Loan commitments and financial guarantees (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2020 34 — — — — — 34 — Net transfers between stages (4) — 4 — — — — — Business activity in the year 113 — — — — — 113 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1 — — — 4 — 5 — Limit management and final repayments (19) — (2) — — — (21) — As at 31 December 2020 125 — 2 — 4 — 131 — Credit cards, unsecured loans and other retail lending As at 1 January 2020 78,257 22 2,053 15 67 14 80,377 51 Net transfers between stages (4,124) 6 3,603 (2) 521 (4) — — Business activity in the year 4,591 2 128 1 1 1 4,720 4 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1,471 5 1,076 20 (553) 15 1,994 40 Limit management and final repayments (11,984) (1) (616) (1) (6) (3) (12,606) (5) As at 31 December 2020 68,211 34 6,244 33 30 23 74,485 90 Wholesale loans a As at 1 January 2020 183,001 63 12,053 97 636 41 195,690 201 Net transfers between stages (28,048) 67 27,052 (72) 996 5 — — Business activity in the year 42,904 32 4,705 102 774 2 48,383 136 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 12,755 50 (219) 334 (79) (19) 12,457 365 Limit management and final repayments (50,208) (7) (4,165) (15) (296) (1) (54,669) (23) As at 31 December 2020 160,404 205 39,426 446 2,031 28 201,861 679 Note a Barclays Bank Group has issued £1.7bn (2020: £2.6bn) of guarantees that have been provided to subsidiaries of Barclays PLC outside the Barclays Bank Group. These guarantees have not been reported in the prior periods and the comparatives have not been restated. Management adjustments to models for impairment (audited) Management adjustments to impairment models are applied in order to factor in certain conditions or changes in policy that are not fully incorporated into the impairment models, or to reflect additional facts and circumstances at the period end. Management adjustments are reviewed and incorporated into future model development where applicable. Total management adjustments to impairment allowance are presented by product below: Overview of management adjustments to models for impairment (audited) a 2021 2020 Management adjustments to impairment allowances Proportion of total impairment allowances Management adjustments to impairment allowances Proportion of total impairment allowances As at 31 December £m % £m % Home loans 34 8.8 54 12.4 Credit cards, unsecured loans and other retail lending 966 40.4 960 31.3 Wholesale loans 142 11.6 (78) (3.3) Total 1,142 28.6 936 16.0 Management adjustments to models are presented by product below: (audited) a Impairment allowance pre management adjustments b Economic uncertainty adjustments (a) Other adjustments (b) Total adjustments (a+b) Total impairment allowance c As at 31 December, 2021 £m £m £m £m £m Home loans 352 34 — 34 386 Credit cards, unsecured loans and other retail lending 1,425 771 195 966 2,391 Wholesale loans 1,079 244 (102) 142 1,221 Total 2,856 1,049 93 1,142 3,998 As at 31 December, 2020 £m £m £m £m £m Home loans 380 21 33 54 434 Credit cards, unsecured loans and other retail lending 2,109 986 (26) 960 3,069 Wholesale loans 2,410 379 (457) (78) 2,332 Total 4,899 1,386 (450) 936 5,835 Notes: a. Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance . b. Includes £2.2bn (2020: £3.9bn) of modelled ECL, £0.5bn (2020: £0.8bn) of individually assessed impairments and £0.2bn (2020: £0.2bn) ECL from non-modelled exposures. c. Total impairment allowance consists of ECL stock on drawn and undrawn exposures. Economic uncertainty adjustments Throughout the COVID-19 pandemic in 2020 and 2021, macroeconomic forecasts anticipated lasting impacts to unemployment levels and customer and client stress. More recent macroeconomic forecasts indicated that the outlook has improved, with measures of government and bank support starting to taper down and no material deterioration in customer delinquencies observed to date. However, the degree of economic uncertainty remains relatively high: credit deterioration may still occur when support measures are fully withdrawn across geographies; emerging supply chain disruption and inflationary pressures may challenge economic stability; and economic consensus may not capture the range of economic uncertainty associated with fast moving new COVID-19 variants such as Omicron. Given this backdrop, management has recognised economic uncertainty adjustments to modelled outputs to address these sources of uncertainties and ensure that the potential impacts of stress are provided for. This uncertainty continues to be captured in two distinct ways. Firstly, customer uncertainty: the identification of customers and clients who may be more vulnerable to the withdrawal of support schemes and emerging economic instability; and secondly, model uncertainty: to capture the impact from model limitations and sensitivities to specific macroeconomic parameters which are applied at a portfolio level. The economic uncertainty adjustments of £1.0bn (2020 £1.4bn) include customer and client uncertainty provisions of £0.9bn (2020 £1.1bn) and model uncertainty provisions of £0.1bn (2020 £0.3bn). Customer uncertainty provisions comprise: a. An adjustment of £0.1bn (2020: £0.1bn) to adjust the probability of default (PDs) to pre-COVID-19 levels to offset the temporary improvement to PDs in light of reduced customer spend behaviour and support measures. b. A vulnerable customer adjustment of £0.8bn (2020: £1.0bn) has been applied to customers and clients considered potentially vulnerable to the withdrawal of support schemes and emerging economic instability against which lifetime coverage is applied. This has marginally reduced considering the improved macro-economic and low customer delinquencies observed in 2021. This is split between credit cards, unsecured loans and other retail lending of £0.6bn (2020: £0.8bn) and wholesale loans of £0.2bn (2020: £0.2bn). Model uncertainty provisions reduced by £0.2bn reflecting an update in adjustment in response to the modelled provisions following the update in the Q421 scenarios. Other adjustments Other adjustments are operational in nature and are expected to remain in place until they can be corrected in the underlying models. These adjustments result from data limitations and model performance related issues identified through established governance processes. The quantum of adjustments reduced in response to the Q421 scenarios as well as model enhancements made during the year. Material adjustments consist of the following: Credit cards, unsecured loans and other retail lending : Includes an adjustment for model inaccuracies informed by model monitoring. Wholesale loans : Represents the net adjustments for model inaccuracies informed by model monitoring. Further, it includes an adjustment to offset modelled E |
Significant accounting policies
Significant accounting policies | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of objectives, policies and processes for managing capital [abstract] | |
Significant accounting policies | Significant accounting policies 1. Reporting entity Barclays Bank PLC is a public company limited by shares registered in England under company number 1026167, having its registered office at 1 Churchill Place, London, E14 5HP. These financial statements are prepared for Barclays Bank PLC and its subsidiaries (the Barclays Bank Group) under Section 399 of the Companies Act 2006. The Barclays Bank Group is a major global financial services provider engaged in credit cards, wholesale banking, investment banking, wealth management and investment management services. In addition, separate financial statements have been presented for the holding company. 2. Compliance with International Financial Reporting Standards The consolidated financial statements of the Barclays Bank Group, and the separate financial statements of Barclays Bank PLC, have been prepared in accordance with UK-adopted international accounting standards. The consolidated financial statements of the Barclays Bank Group, and the separate financial statements of Barclays Bank PLC, have also been prepared in accordance with (1) International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), including interpretations issued by the IFRS Interpretations Committee, as there are no applicable differences from IFRS as issued by the IASB for the periods presented; and (2) IFRS adopted pursuant to Regulation (EC) No. 1606/2002 as it applies in the European Union (“IFRS as adopted by the EU”). There are currently no differences between UK-adopted international accounting standards and IFRS as adopted by the EU and therefore no reconciliation of variances is provided. The principal accounting policies applied in the preparation of the consolidated and separate financial statements are set out below, and in the relevant notes to the financial statements. These policies have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. 3. Basis of preparation The consolidated and separate financial statements have been prepared under the historical cost convention modified to include the fair valuation of investment property, and particular financial instruments, to the extent required or permitted under IFRS as set out in the relevant accounting policies. The financial statements are stated in millions of pounds Sterling (£m), the functional currency of Barclays Bank PLC. The financial statements have been prepared on a going concern basis, in accordance with the Companies Act 2006 as applicable to companies using IFRS. The financial statements are prepared on a going concern basis as the Board is satisfied that the Barclays Bank Group and parent company have the resources to continue in business for a period of at least 12 months from approval of the financial statements. In making this assessment, the Board has considered a wide range of information relating to present and future conditions and includes a review of a working capital report (WCR). The WCR is used by the Board to assess the future performance of the Barclays Bank Group and whether it has the resources in place that are required to meet its ongoing regulatory requirements. The assessment is based upon business plans which contain future forecasts of profitability taken from the Barclays Bank Group’s medium term plan as well as projections of regulatory capital requirements and business funding needs. The WCR also includes an assessment the impact of internally generated stress testing scenarios on the liquidity and capital requirement forecasts. The stress tests used were based upon an assessment of reasonably possible downside economic scenarios that the Barclays Bank Group could experience. The WCR showed that the Barclays Bank Group had sufficient capital and liquidity in place to support its future business requirements and remained above its regulatory minimum requirements in the stress scenarios. Accordingly, the Board concluded that there was a reasonable expectation that the Barclays Bank Group has adequate resources to continue as a going concern for a period of at least 12 months from the date of approval of the financial statements. 4. Accounting policies The Barclays Bank Group prepares financial statements in accordance with IFRS. The Barclays Bank Group’s significant accounting policies relating to specific financial statement items, together with a description of the accounting estimates and judgements that were critical to preparing those items, are set out under the relevant notes. Accounting policies that affect the financial statements as a whole are set out below. (i) Consolidation The Barclays Bank Group applies IFRS 10 Consolidated financial statements . The consolidated financial statements combine the financial statements of Barclays Bank PLC and all its subsidiaries. Subsidiaries are entities over which Barclays Bank PLC has control. The Barclays Bank Group has control over another entity when the Barclays Bank Group has all of the following: 1) power over the relevant activities of the investee, for example through voting or other rights 2) exposure to, or rights to, variable returns from its involvement with the investee and 3) the ability to affect those returns through its power over the investee. The assessment of control is based on the consideration of all facts and circumstances. The Barclays Bank Group reassesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Intra-group transactions and balances are eliminated on consolidation. Consistent accounting policies are used throughout the Barclays Bank Group for the purposes of the consolidation. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has already been obtained and they do not result in loss of control. As the consolidated financial statements include partnerships where the Barclays Bank Group member is a partner, advantage has been taken of the exemption under Regulation 7 of the Partnership (Accounts) Regulations 2008 with regard to preparing and filing of individual partnership financial statements. Details of the principal subsidiaries are given in Note 32. (ii) Foreign currency translation The Barclays Bank Group applies IAS 21 The Effects of Changes in Foreign Exchange Rates . Transactions in foreign currencies are translated into Sterling at the rate ruling on the date of the transaction. Foreign currency monetary balances are translated into Sterling at the period end exchange rates. Exchange gains and losses on such balances are taken to the income statement. Non-monetary foreign currency balances in relation to items measured in terms of historical cost are carried at historical transaction date exchange rates. Non-monetary foreign currency balances in relation to items measured at fair value are translated using the exchange rate at the date when the fair value was measured. The Barclays Bank Group’s foreign operations (including subsidiaries, joint ventures, associates and branches) based mainly outside the UK may have different functional currencies. The functional currency of an operation is the currency of the main economy to which it is exposed. Prior to consolidation (or equity accounting) the assets and liabilities of non-Sterling operations are translated at the period end exchange rate and items of income, expense and other comprehensive income are translated into Sterling at the rate on the date of the transactions. Exchange differences arising on the translation of foreign operations are included in currency translation reserves within equity. These are transferred to the income statement when the Barclays Bank Group disposes of the entire interest in a foreign operation, when partial disposal results in the loss of control of an interest in a subsidiary, when an investment previously accounted for using the equity method is accounted for as a financial asset, or on the disposal of a foreign operation within a branch. (iii) Financial assets and liabilities The Barclays Bank Group applies IFRS 9 Financial Instruments to the recognition, classification and measurement, and derecognition of financial assets and financial liabilities and the impairment of financial assets. The Barclays Bank Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. Recognition The Barclays Bank Group recognises financial assets and liabilities when it becomes a party to the terms of the contract. Trade date or settlement date accounting is applied depending on the classification of the financial asset. Classification and measurement Financial assets are classified on the basis of two criteria: i) the business model within which financial assets are managed; and ii) their contractual cash flow characteristics (whether the cash flows represent ‘solely payments of principal and interest’ (SPPI)). The Barclays Bank Group assesses the business model criteria at a portfolio level. Information that is considered in determining the applicable business model includes (i) policies and objectives for the relevant portfolio, (ii) how the performance and risks of the portfolio are managed, evaluated and reported to management, and (iii) the frequency, volume and timing of sales in prior periods, sales expectation for future periods, and the reasons for such sales. The contractual cash flow characteristics of financial assets are assessed with reference to whether the cash flows represent SPPI. In assessing whether contractual cash flows are SPPI compliant, interest is defined as consideration primarily for the time value of money and the credit risk of the principal outstanding. The time value of money is defined as the element of interest that provides consideration only for the passage of time and not consideration for other risks or costs associated with holding the financial asset. Terms that could change the contractual cash flows so that it would not meet the condition for SPPI are considered, including: (i) contingent and leverage features, (ii) non-recourse arrangements and (iii) features that could modify the time value of money. Financial assets are measured at amortised cost if they are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, and their contractual cash flows represent SPPI. Financial assets are measured at fair value through other comprehensive income if they are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and their contractual cash flows represent SPPI. Other financial assets are measured at fair value through profit and loss. There is an option to make an irrevocable election on initial recognition for non traded equity investments to be measured at fair value through other comprehensive income, in which case dividends are recognised in profit or loss, but gains or losses are not reclassified to profit or loss upon derecognition, and the impairment requirements of IFRS 9 do not apply. The accounting policy for each type of financial asset or liability is included within the relevant note for the item. The Barclays Bank Group’s policies for determining the fair values of the assets and liabilities are set out in Note 16. Derecognition The Barclays Bank Group derecognises a financial asset, or a portion of a financial asset, from its balance sheet where (i) the contractual rights to cash flows from the asset have expired, or (ii) the contractual rights to the cash flows from the asset have been transferred (usually by sale) and with them either (a) substantially all the risks and rewards of the asset have been transferred, or (b) where neither substantially all the risks and rewards have been transferred or retained, where control over the asset has been lost. Financial liabilities are de-recognised when the liability has been settled, has expired or has been extinguished. An exchange of an existing financial liability for a new liability with the same lender on substantially different terms – generally a difference of 10% or more in the present value of the cash flows or a substantive qualitative amendment – is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Transactions in which the Barclays Bank Group transfers assets and liabilities, portions of them, or financial risks associated with them can be complex and it may not be obvious whether substantially all of the risks and rewards have been transferred. It is often necessary to perform a quantitative analysis. Such an analysis compares the Barclays Bank Group’s exposure to variability in asset cash flows before the transfer with its retained exposure after the transfer. A cash flow analysis of this nature may require judgement. In particular, it is necessary to estimate the asset’s expected future cash flows as well as potential variability around this expectation. The method of estimating expected future cash flows depends on the nature of the asset, with market and market-implied data used to the greatest extent possible. The potential variability around this expectation is typically determined by stressing underlying parameters to create reasonable alternative upside and downside scenarios. Probabilities are then assigned to each scenario. Stressed parameters may include default rates, loss severity, or prepayment rates. Accounting for reverse repurchase and repurchase agreements including other similar lending and borrowing Reverse repurchase agreements (and stock borrowing or similar transactions) are a form of secured lending whereby the Barclays Bank Group provides a loan or cash collateral in exchange for the transfer of collateral, generally in the form of marketable securities subject to an agreement to transfer the securities back at a fixed price in the future. Repurchase agreements are where the Barclays Bank Group obtains such loans or cash collateral, in exchange for the transfer of collateral. The Barclays Bank Group purchases (a reverse repurchase agreement) or borrows securities subject to a commitment to resell or return them. The securities are not included in the balance sheet as the Barclays Bank Group does not acquire the risks and rewards of ownership. Consideration paid (or cash collateral provided) is accounted for as a loan asset at amortised cost, unless it is designated or mandatorily at fair value through profit and loss. The Barclays Bank Group may also sell (a repurchase agreement) or lend securities subject to a commitment to repurchase or redeem them. The securities are retained on the balance sheet as the Barclays Bank Group retains substantially all the risks and rewards of ownership. Consideration received (or cash collateral provided) is accounted for as a financial liability at amortised cost, unless it is designated at fair value through profit and loss. (iv) Issued debt and equity instruments The Barclays Bank Group applies IAS 32, Financial Instruments: Presentation , to determine whether funding is either a financial liability (debt) or equity. Issued financial instruments or their components are classified as liabilities if the contractual arrangement results in the Barclays Bank Group having an obligation to either deliver cash or another financial asset, or a variable number of equity shares, to the holder of the instrument. If this is not the case, the instrument is generally an equity instrument and the proceeds included in equity, net of transaction costs. Dividends and other returns to equity holders are recognised when paid or declared by the members at the Annual General Meeting and treated as a deduction from equity. Where issued financial instruments contain both liability and equity components, these are accounted for separately. The fair value of the debt is estimated first and the balance of the proceeds is included within equity. (v) Changes in the basis for determining contractual cash flows resulting from interest rate benchmark reform A change in the basis for determining the contractual cash flows of a financial instrument that is required by interest rate benchmark reform is accounted for by updating the effective interest rate, without the recognition of an immediate gain or loss. This practical expedient is only applied where (1) the change to the contractual cash flows is necessary as a direct consequence of the reform and (2) the new basis for determining the contractual cash flows is economically equivalent to the previous basis. For changes made in addition to those required by the interest rate benchmark reform, the practical expedient is applied first, after which the normal IFRS 9 requirements for modifications of financial instruments is applied. Refer to Note 13 for further details regarding hedge accounting policies in respect of interest rate benchmark reform. Refer to Note 40 for further disclosure related to interest rate benchmark reform. (vi) Cash flow statement Cash comprises cash on hand and balances at central banks. Cash equivalents comprise loans and advances to banks, cash collateral balances with central banks related to payment schemes and treasury and other eligible bills, all with original maturities of three months or less. Repurchase and reverse repurchase agreements are not considered to be part of cash equivalents. Investments in debt securities at amortised cost, presented within loans and advances on the balance sheet, are deemed to be investing activities for the purposes of the cash flow statement, except those instruments considered to be cash equivalents. 5. New and amended standards and interpretations The accounting policies adopted have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. Future accounting developments The following accounting standards have been issued by the IASB but are not yet effective: IFRS 17 – Insurance contracts In May 2017, the IASB issued IFRS 17 Insurance Contracts , a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. Once effective, IFRS 17 will replace IFRS 4 Insurance Contracts that was issued in 2005. IFRS 17 applies to all types of insurance contracts (i.e. life, non-life, direct insurance and re-insurance), regardless of the type of entities that issue them, as well as to certain guarantees and financial instruments with discretionary participation features. A few scope exceptions will apply. In June 2020, the IASB published amendments to IFRS 17. The amendments that are relevant to the Barclays Bank Group are the scope exclusion for credit card contracts and similar contracts that provide insurance coverage, the optional scope exclusion for loan contracts that transfer significant insurance risk, and clarification that only financial guarantees issued are in scope of IFRS 9. The amendments also defer the effective date of IFRS 17, including the above amendments, to annual reporting periods beginning on or after 1 January 2023. IFRS 17, including the 2020 amendments to IFRS 17, has been endorsed by the EU. Following the UK’s withdrawal from the EU on 31 December 2020, the UK-adopted international accounting standards will be applicable. IFRS 17, including the amendments to IFRS 17, has not yet been endorsed by the UK. The Barclays Bank Group does not expect the impact of IFRS 17 to be material. Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 In February 2021 the IASB issued amendments to IAS 1 that require entities to disclose their material accounting policies rather than their significant accounting policies. The amendments to IFRS Practice Statement 2 provide guidance on the concept of materiality and its application to accounting policy information. Under the amendments, accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The amendments are effective for annual periods beginning on or after 1 January 2023, and will be applied from that date. Definition of Accounting Estimate - Amendments to IAS 8 In February 2021 the IASB issued amendments to IAS 8 that replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are clarified as monetary amounts in financial statements that are subject to measurement uncertainty. Where an entity's accounting policy requires an item to be measured at monetary amounts that cannot be observed directly, it should develop an accounting estimate to achieve this objective. The amendments are effective for annual periods beginning on or after 1 January 2023, and will be applied from that date. 6. Critical accounting estimates and judgements The preparation of financial statements in accordance with IFRS requires the use of estimates. It also requires management to exercise judgement in applying the accounting policies. The key areas involving a higher degree of judgement or complexity or areas where assumptions are significant to the consolidated and individual financial statements are highlighted under the relevant note. Critical accounting estimates and judgements are disclosed in: ▪ Credit impairment charges on pages 126 ▪ Tax on pages 130 ▪ Fair value of financial instruments on pages 145 ▪ Provisions including conduct and legal, competition and regulatory matters on pages 163 ▪ Pensions and post-retirement benefits – obligations on pages 178 7. Other disclosures To improve transparency and ease of reference, by concentrating related information in one place, certain disclosures required under IFRS have been included within the Risk review section as follows: ▪ Credit risk on pages 41 ▪ Market risk on page 42 ▪ Treasury and capital risk – capital on page 42 and on page 85 ▪ Treasury and capital risk – liquidity on page 42 and on page 80 These disclosures are covered by the Audit opinion (included on pages 102 to 104) where referenced as audited. 1a Restatement of financial statements Barclays Bank PLC has restated these financial statements to reflect both a provision and a contingent liability disclosure in respect of the impact of an over-issuance of securities in excess of the maximum aggregate offering price registered under Barclays Bank PLC’s registration statement on Form F-3, as declared effective by the SEC in August 2019 (2019 F-3). Due to an historic SEC settlement order, at the time the 2019 F-3 was filed, Barclays Bank PLC had ceased to be a “well-known seasoned issuer” (or WKSI) and had become an “ineligible issuer,” as defined in Rule 405 under the Securities Act of 1933, as amended (Securities Act), thus being required to register upfront a certain amount of securities with the SEC. In March 2022, Barclays Bank PLC became aware that it had issued securities in the US in excess of the amount it had registered with the SEC under the 2019 F-3. It has been estimated that the maximum offering price set forth in the 2019 F-3 was exceeded in February 2021, with issuances through to March 2022 exceeding the $20.8bn limit by approximately $15bn. The securities that were issued in this period comprise structured notes and exchange traded notes (ETNs). As such, certain offers and sales of these securities were not made in compliance with the Securities Act, giving rise to rights of rescission for certain purchasers of the securities. Under Section 12(a)(1) of the Securities Act, certain purchasers of unregistered securities have a right to recover, upon the tender of such security, the consideration paid for such security with interest, less the amount of any income received, or damages if the purchaser no longer owns the security (the Rescission Price). As a result, Barclays Bank PLC has elected to make a rescission offer to eligible purchasers of the relevant affected securities at the Rescission Price. A proportion of the expected costs associated with the rights of rescission of certain investors are attributable to Barclays Bank PLC’s financial statements for the year ended 31 December 2021. Accordingly, Barclays Bank PLC’s financial statements have been restated. The restatement impacts the consolidated income statement, the parent company income statement, the consolidated statement of comprehensive income, the parent company statement of comprehensive income, the consolidated balance sheet, the parent company balance sheet, the consolidated statement of changes in equity, the parent company statement of changes in equity, the consolidated cash flow statement, and the parent company cash flow statement for the year ended 31 December 2021. There was no effect on Barclays Bank PLC’s previously reported financial statements for the years ended 31 December 2020 and 2019. The impacts of the restatement are as follows: • Litigation and conduct charges in the consolidated income statement for the year ended 31 December 2021 were under-reported by £220m, increasing total operating expenses from a reported £10,039m to £10,259m. • Litigation and conduct charges in the parent income statement for the year ended 31 December 2021 were under-reported by £220m, increasing total operating expenses from a reported £5,305m to £5,525m. • Provisions on the consolidated balance sheet have increased from a reported £890m to £1,110m. • Provisions on the parent balance sheet have increased from a reported £699m to £919m . • The taxation charge in the consolidated income statement has reduced by £50m from a reported £880m to £830m with a corresponding decrease in current tax liabilities on the consolidated balance sheet from £738m to £688m. • The taxation credit in the parent income statement has increased by £50m from a reported £63m to £113m with a corresponding decrease in current tax liabilities on the parent balance sheet from £392m to £342m. • The overall impact of the restatement has been to reduce reported Barclays Bank Group profit after tax from £4,758m to £4,588m. • The overall impact of the restatement has been to reduce reported Barclays Bank PLC profit after tax from £3,606m to £3,436m. • The consolidated financial statements and parent company financial statements have been restated for the increased provision of £220m and lower tax charge of £50m. • The contractual maturity profile of financial liabilities designated at fair value has been restated to reflect the over-issuance of securities. The table below reflects each of the consolidated financial statement line items that were affected by the restatement: For the year ended 31 December 2021 As reported £m Restatement £m As restated £m Impact on the consolidated income statement Litigation and conduct (154) (220) (374) Operating expenses (10,039) (220) (10,259) Profit before tax 5,638 (220) 5,418 Taxation (880) 50 (830) Profit after tax 4,758 (170) 4,588 Impact on the consolidated statement of comprehensive income Profit after tax 4,758 (170) 4,588 Total comprehensive income for the year 3,073 (170) 2,903 Impact on the consolidated balance sheet Liabilities Current tax liabilities 738 (50) 688 Provisions 890 220 1,110 Total liabilities 1,005,291 170 1,005,461 Equity Retained earnings 43,585 (170) 43,415 Total equity 56,487 (170) 56,317 Impact on the consolidated cash flow statement Profit before tax 5,638 (220) 5,418 Adjustment for non-cash items Other provisions, including pensions (135) 220 85 The table below reflects each of the line items of the parent company financial statement that were affected by the restatement: For the year ended 31 December 2021 As reported £m Restatement £m As restated £m Impact on the parent company income statement Litigation and conduct (140) (220) (360) Operating expenses (5,305) (220) (5,525) Profit before tax 3,543 (220) 3,323 Taxation 63 50 113 Profit after tax 3,606 (170) 3,436 Attributable to: Equity holders to the parent 2,811 (170) 2,641 Total equity holders of the parent 3,606 (170) 3,436 Impact on the parent company statement of comprehensive income Profit after tax 3,606 (170) 3,436 Total comprehensive income for the year 2,199 (170) 2,029 Impact on the parent company balance sheet Liabilities Current tax liabilities 392 (50) 342 Provisions 699 220 919 Total liabilities 1,011,809 170 1,011,979 Equity Retained earnings 37,350 (170) 37,180 Total equity 52,862 (170) 52,692 Impact on the parent company cash flow statement Profit before tax 3,543 (220) 3,323 Adjustment for non-cash items Other provisions, including pensions (145) 220 75 The financial impact of the restatement has been reflected in Notes 2, 8, 9, 10, 23 and 41. Further, Note 25 (Legal, competition and regulatory matters) has also been amended to reflect matters relating to the over-issuance of securities by Barclays Bank PLC. Finally, other non-adjusting post-balance sheet events which have no impact on the restated amounts but have been disclosed include: • Legacy Loan Portfolio: Further to a decision by Clydesdale Financial Services Limited (CFS) in March 2022 to extend the proactive remediation of Azure Services Limited (ASL) loans beyond those brokered between April 2014 to April 2016 to include the full portfolio of ASL Loans brokered between 2006 and 2018, as at 31 March 2022, a customer remediation provision of £181m has been recognised in relation to the remediation of the ASL Loans originated outside of the April 2014 to April 2016 period. The provision represents the best estimate as at 31 March 2022. CFS continues to review complaints regarding other legacy partner finance loans, however, it is not currently possible to predict the outcome of this review or the financial impact on the Barclays Bank Group. This update has been reflected in Note 25. • Pensions: during 2019 and 2020, the UK Retirement Fund (UKRF), the Barclays Bank Group’s main pension scheme, subscribed for non-transferable listed senior fixed rate notes for £1.25bn. As a result of these transactions, the CET1 impact of the UKRF was deferred until 2023, 2024 and 2025 upon maturity of the notes. Following the PRA’s statement on 13 April 2022, Barclays Bank PLC is planning to unwind these transactions and to agree the terms and timing of this unwind with the UKRF Trustee as part of the next triennial actuarial valuation as at 30 September 2022. Upon unwind, this would result in a c .65bps reduction to the CET1 ratio potentially being accelerated to the fourth quarter of 2022 from 2023, 2024 and 2025. As at 31 March 2022, the UKRF was in an accounting surplus of £4.4bn on an IAS 19 basis and, as at 30 September 2021, it was in a funding surplus of £0.6bn. There may also be a pension related reduction in Pillar 2A requirements in 2022 which could partially mitigate the impact of the unwind on the Barclays Bank Group surplus capital position. Note 31 has been updated accordingly. |
Segmental reporting
Segmental reporting | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of operating segments [abstract] | |
Segmental reporting | Segmental reporting Presentation of segmental reporting The Barclays Bank Group’s segmental reporting is in accordance with IFRS 8 Operating Segments . Operating segments are reported in a manner consistent with the internal reporting provided to the Executive Committee, which is responsible for allocating resources and assessing performance of the operating segments, and has been identified as the chief operating decision maker. All transactions between business segments are conducted on an arm’s-length basis, with intra-segment revenue and costs being eliminated in Head Office. Income and expenses directly associated with each segment are included in determining business segment performance. The Barclays Bank Group divisions have been for segmental reporting purposes defined as Corporate and Investment Bank and Consumer, Cards and Payments. ▪ Corporate and Investment Bank which includes the Global Markets, Investment Banking and Corporate Banking businesses. ▪ Consumer, Cards and Payments which includes the International Cards and Consumer Bank, Private Bank and Unified Payments businesses. The below table also includes Head Office which comprises head office and certain central support functions including the Barclays Bank Group service company full time equivalent employees. Analysis of results by business Restated b Restated b Corporate and Consumer, Cards Head Barclays Bank £m £m £m £m For the year ended 31 December 2021 Total income 12,481 3,337 (410) 15,408 Credit impairment releases/(charges) 461 (185) 1 277 Net operating income/(expenses) 12,942 3,152 (409) 15,685 Operating expenses (7,169) (2,316) (400) (9,885) Litigation and conduct (237) (108) (29) (374) Total operating expenses (7,406) (2,424) (429) (10,259) Other net (expenses)/income a (8) 1 (1) (8) Profit/(loss) before tax 5,528 729 (839) 5,418 Total assets (£bn) 986.2 64.4 11.2 1,061.8 Number of employees (full time equivalent) 7,800 2,600 9,800 20,200 Average number of employees (full time equivalent) 20,300 Corporate and Investment Bank Consumer, Cards Head Barclays Bank £m £m £m £m For the year ended 31 December 2020 Total income 12,607 3,490 (319) 15,778 Credit impairment charges (1,565) (1,720) (92) (3,377) Net operating income/(expenses) 11,042 1,770 (411) 12,401 Operating expenses (7,125) (2,132) (126) (9,383) Litigation and conduct (4) (44) (28) (76) Total operating expenses (7,129) (2,176) (154) (9,459) Other net income a 16 114 3 133 Profit/(loss) before tax 3,929 (292) (562) 3,075 Total assets (£bn) 990.9 57.8 11.0 1,059.7 Number of employees (full time equivalent) 7,800 3,000 10,100 20,900 Average number of employees (full time equivalent) 20,145 Note a Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. b 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. Corporate and Consumer, Cards Head Barclays Bank Group £m £m £m £m For the year ended 31 December 2019 Total income 10,009 4,462 (320) 14,151 Credit impairment charges (157) (1,016) (29) (1,202) Net operating income/(expenses) 9,852 3,446 (349) 12,949 Operating expenses (7,267) (2,359) (92) (9,718) Litigation and conduct (108) (7) (149) (264) Total operating expenses (7,375) (2,366) (241) (9,982) Other net income/(expenses) a 113 40 (8) 145 Profit/(loss) before tax 2,590 1,120 (598) 3,112 Total assets (£bn) 799.6 65.7 11.4 876.7 Number of employees (full time equivalent) 8,100 3,100 9,300 20,500 Average number of employees (full time equivalent) 21,700 Note a Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. Income by geographic region a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 4,585 4,954 4,084 Europe 2,358 2,119 1,752 Americas 7,326 7,590 7,251 Africa and Middle East 45 37 62 Asia 1,094 1,078 1,002 Total 15,408 15,778 14,151 Income from individual countries which represent more than 5% of total income a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 4,585 4,954 4,084 United States 7,162 7,471 7,121 Note a The geographical analysis is based on the location of the office where the transactions are recorded. |
Net interest income
Net interest income | 12 Months Ended |
Dec. 31, 2021 | |
Analysis of income and expense [abstract] | |
Net interest income | Net interest income Accounting for interest income and expenses Interest income on loans and advances at amortised cost and financial assets at fair value through other comprehensive income, and interest expense on financial liabilities held at amortised cost, are calculated using the effective interest method which allocates interest, and direct and incremental fees and costs, over the expected lives of the assets and liabilities. The effective interest method requires the Barclays Bank Group to estimate future cash flows, in some cases based on its experience of customers’ behaviour, considering all contractual terms of the financial instrument, as well as the expected lives of the assets and liabilities. The Barclays Bank Group incurs certain costs to originate credit card balances with the most significant being co-brand partner fees. To the extent these costs are attributed to customers that continuously carry an outstanding balance (revolvers) and incremental to the origination of credit card balances, they are capitalised and subsequently included within the calculation of the effective interest rate. They are amortised to interest income over the period of expected repayment of the originated balance. Costs attributed to customers that settle their outstanding balances each period (transactors) are deferred on the balance sheet as a cost of obtaining a contract and amortised to fee and commission expense over the life of the customer relationship (refer to Note 4). There are no other individual estimates involved in the calculation of effective interest rates that are material to the results or financial position. 2021 2020 2019 £m £m £m Cash and balances at central banks 128 226 919 Loans and advances at amortised cost 4,265 4,510 5,514 Fair value through other comprehensive income 380 604 831 Negative interest on liabilities 248 68 13 Other 651 598 808 Interest and similar income 5,672 6,006 8,085 Deposits at amortised cost (331) (644) (1,778) Debt securities in issue a (413) (424) (873) Subordinated liabilities (934) (1,112) (1,096) Negative interest on assets (374) (325) (250) Other (547) (341) (181) Interest and similar expense (2,599) (2,846) (4,178) Net interest income 3,073 3,160 3,907 Notes a Barclays Bank Group has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest and similar expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparative of £25m in 2019 has not been restated. Interest and similar income presented above represents interest revenue calculated using the effective interest method. Costs to originate credit card balances of £623m (2020: £687m; 2019: £684m) have been amortised to interest and similar income during the period. Interest and similar income includes £7m (2020: £9m; 2019: £9m) accrued on impaired loans. Other interest expense includes £20m (2020: £23m, 2019: £25m) relating to IFRS 16 lease interest expenses. |
Net fee and commission income
Net fee and commission income | 12 Months Ended |
Dec. 31, 2021 | |
Fee and commission income (expense) [abstract] | |
Net fee and commission income | Net fee and commission income Accounting for net fee and commission income The Barclays Bank Group applies IFRS 15 Revenue from Contracts with Customers. IFRS 15 establishes a five-step model governing revenue recognition. The five-step model requires the Barclays Bank Group to (i) identify the contract with the customer, (ii) identify each of the performance obligations included in the contract, (iii) determine the amount of consideration in the contract, (iv) allocate the consideration to each of the identified performance obligations and (v) recognise revenue as each performance obligation is satisfied. The Barclays Bank Group recognises fee and commission income charged for services provided by the Barclays Bank Group as the services are provided, for example, on completion of the underlying transaction. Where the contractual arrangements also result in the Barclays Bank Group recognising financial instruments in scope of IFRS 9, such financial instruments are initially recognised at fair value in accordance with IFRS 9 before applying the provisions of IFRS 15. Fee and commission income is disaggregated below by fee types that reflect the nature of the services offered across the Barclays Bank Group and operating segments, in accordance with IFRS 15. The below table includes a total for fees in scope of IFRS 15. Refer to Note 2 for more detailed information about operating segments. 2021 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total £m £m £m £m Fee type Transactional 390 2,158 — 2,548 Advisory 968 128 — 1,096 Brokerage and execution 1,082 53 — 1,135 Underwriting and syndication 3,425 — — 3,425 Other 80 155 21 256 Total revenue from contracts with customers 5,945 2,494 21 8,460 Other non-contract fee income 116 5 — 121 Fee and commission income 6,061 2,499 21 8,581 Fee and commission expense (781) (1,207) (6) (1,994) Net fee and commission income 5,280 1,292 15 6,587 2020 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total £m £m £m £m Fee type Transactional 357 1,973 — 2,330 Advisory 593 100 — 693 Brokerage and execution 1,116 57 — 1,173 Underwriting and syndication 2,867 — — 2,867 Other 54 152 29 235 Total revenue from contracts with customers 4,987 2,282 29 7,298 Other non-contract fee income 114 5 — 119 Fee and commission income 5,101 2,287 29 7,417 Fee and commission expense (768) (988) (2) (1,758) Net fee and commission income 4,333 1,299 27 5,659 2019 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total £m £m £m £m Fee type Transactional 391 2,418 — 2,809 Advisory 821 83 — 904 Brokerage and execution 1,082 49 — 1,131 Underwriting and syndication 2,358 — — 2,358 Other 90 227 30 347 Total revenue from contracts with customers 4,742 2,777 30 7,549 Other non-contract fee income 110 5 — 115 Fee and commission income 4,852 2,782 30 7,664 Fee and commission expense (743) (1,249) — (1,992) Net fee and commission income 4,109 1,533 30 5,672 Fee types Transactional Transactional fees are service charges on deposit accounts, cash management services and transactional processing fees. These include interchange and merchant fee income generated from credit and bank card usage. Transaction and processing fees are recognised at the point in time the transaction occurs or service is performed. Interchange and merchant fees are recognised upon settlement of the card transaction payment. The Barclays Bank Group incurs certain card related costs including those related to cardholder reward programmes and payments to co-brand partners. Cardholder reward programmes costs related to customers that settle their outstanding balance each period (transactors) are expensed when incurred and presented in fee and commission expense while costs related to customers that continuously carry an outstanding balance (revolvers) are included in the effective interest rate of the receivable (refer to Note 3). Payments to partners for new cardholder account originations related to transactor accounts are deferred as costs to obtain a contract under IFRS 15, while costs related to revolver accounts are included in the effective interest rate of the receivable (refer to Note 3). Those costs deferred under IFRS 15 are capitalised and amortised over the estimated life of the customer relationship. Payments to co-brand partners based on revenue sharing are presented as a reduction of fee and commission income while payments based on profitability are presented in fee and commission expense. Advisory Advisory fees are generated from wealth management services and investment banking advisory services related to mergers, acquisitions and financial restructurings. Wealth management advisory fees are earned over the period the services are provided and are generally recognised quarterly when the market value of client assets is determined. Investment banking advisory fees are recognised at the point in time when the services related to the transaction have been completed under the terms of the engagement. Investment banking advisory costs are recognised as incurred in fee and commission expense if direct and incremental to the advisory services or are otherwise recognised in operating expenses. Brokerage and execution Brokerage and execution fees are earned for executing client transactions with various exchanges and over-the-counter markets and assisting clients in clearing transactions. Brokerage and execution fees are recognised at the point in time the associated service has been completed which is generally the trade date of the transaction. Underwriting and syndication Underwriting and syndication fees are earned for the distribution of client equity or debt securities and the arrangement and administration of a loan syndication. This includes commitment fees to provide loan financing. Underwriting fees are generally recognised on trade date if there is no remaining contingency, such as the transaction being conditional on the closing of an acquisition or another transaction. Underwriting costs are deferred and recognised in fee and commission expense when the associated underwriting fees are recorded. Syndication fees are earned for arranging and administering a loan syndication; however, the associated fee may be subject to variability until the loan has been syndicated to other syndicate members or until other contingencies have been resolved and therefore the fee revenue is deferred until the uncertainty is resolved. Included in underwriting and syndication fees are loan commitment fees which are not presented as part of the carrying value of the loan in accordance with IFRS 9. Such commitment fees are recognised over time through to the contractual maturity of the commitment. Contract assets and contract liabilities The Barclays Bank Group had no material contract assets or contract liabilities as at 31 December 2021 (2020: £nil; 2019: nil). Impairment of fee receivables and contract assets During 2021, there have been no material impairments recognised in relation to fees receivable and contract assets (2020: £nil; 2019: £nil). Fees in relation to transactional business can be added to outstanding customer balances. These amounts may be subsequently impaired as part of the overall loans and advances balance. Remaining performance obligations The Barclays Bank Group applies the practical expedient of IFRS 15 and does not disclose information about remaining performance obligations that have original expected durations of one year or less or because the Barclays Bank Group has a right to consideration that corresponds directly with the value of the service provided to the client or customer. Costs incurred in obtaining or fulfilling a contract The Barclays Bank Group expects that incremental costs of obtaining a contract such as success fee and commission fees paid are recoverable and therefore capitalised such contract costs. Capitalised contract costs net of amortisation as at 31 December 2021 is £148m (2020: £135m; 2019: £153m). Capitalised contract costs are amortised based on the transfer of services to which the asset relates which typically ranges over the expected life of the relationship. In 2021, the amount of amortisation was £35m (2020: £35m; 2019: £29m) and there was no impairment loss recognised in connection with the capitalised contract costs (2020: £nil; 2019: £nil). |
Net trading income
Net trading income | 12 Months Ended |
Dec. 31, 2021 | |
Trading income (expense) [abstract] | |
Net trading income | Net trading income Accounting for net trading income In accordance with IFRS 9, trading positions are held at fair value, and the resulting gains and losses are included in the income statement, together with interest and dividends arising from long and short positions and funding costs relating to trading activities. Income arises from both the sale and purchase of trading positions, margins which are achieved through market making and customer business and from changes in fair value caused by movements in interest and exchange rates, equity prices and other market variables. Gains or losses on non-trading financial instruments designated or mandatorily at fair value with changes in fair value recognised in the income statement are included in net trading income where the business model is to manage assets and liabilities on a fair value basis which includes use of derivatives or where an instrument is designated at fair value to eliminate an accounting mismatch and the related instrument's gain and losses are reported in trading income. 2021 2020 2019 £m £m £m Net gains on financial instruments held for trading 3,999 5,392 2,795 Net gains on financial instruments designated at fair value 682 695 240 Net gains on financial instruments mandatorily at fair value 1,107 989 1,038 Net trading income 5,788 7,076 4,073 |
Net investment (expense) income
Net investment (expense) income | 12 Months Ended |
Dec. 31, 2021 | |
Gains (losses) on financial instruments [abstract] | |
Net investment (expense)/income | Net investment (expense)/income Accounting for net investment income Dividends are recognised when the right to receive the dividend has been established. Other accounting policies relating to net investment income are set out in Note 12 and Note 14. 2021 2020 2019 £m £m £m Net (losses)/gains from financial assets mandatorily at fair value (116) (39) 218 Net gains from disposal of debt instruments at fair value through other comprehensive income 248 251 454 Net gains/(losses) from disposal of financial assets and liabilities measured at amortised cost a 22 (128) (38) Dividend income — — — Net losses on other investments b (234) (205) (214) Net investment (expense)/income (80) (121) 420 Notes a Included within the 2021 balance are gains of £25m relating to the sale of municipal bonds . Included within the 2020 balance are losses of £115m relating to partial redemption of contingent capital note. b Barclays has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparative of £25m in 2019 has not been restated. |
Credit impairment (release)_cha
Credit impairment (release)/charge | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of impairment loss and reversal of impairment loss [abstract] | |
Credit impairment (release)/charge | Credit impairment (release)/charge Accounting for the impairment of financial assets Impairment In accordance with IFRS 9, the Barclays Bank Group is required to recognise expected credit losses (ECLs) based on unbiased forward-looking information for all financial assets at amortised cost, lease receivables, debt financial assets at fair value through other comprehensive income, loan commitments and financial guarantee contracts. Intercompany exposures in the individual financial statements, including loan commitments and financial guarantee contracts, are also in scope of IFRS 9 for ECL purposes. At the reporting date, an allowance (or provision for loan commitments and financial guarantees) is required for the 12 month (Stage 1) ECLs. If the credit risk has significantly increased since initial recognition (Stage 2), or if the financial instrument is credit impaired (Stage 3), an allowance (or provision) should be recognised for the lifetime ECLs. The measurement of ECL is calculated using three main components: (i) probability of default (PD) (ii) loss given default (LGD) and (iii) the exposure at default (EAD). The 12 month and lifetime ECLs are calculated by multiplying the respective PD, LGD and the EAD. The 12 month and lifetime PDs represent the PD occurring over the next 12 months and the remaining maturity of the instrument respectively. The EAD represents the expected balance at default, taking into account the repayment of principal and interest from the balance sheet date to the default event together with any expected drawdowns of committed facilities. The LGD represents expected losses on the EAD given the event of default, taking into account, among other attributes, the mitigating effect of collateral value at the time it is expected to be realised and the time value of money. Determining a significant increase in credit risk since initial recognition: The Barclays Bank Group assesses when a significant increase in credit risk has occurred based on quantitative and qualitative assessments. The credit risk of an exposure is considered to have significantly increased when: i) Quantitative test The annualised lifetime PD has increased by more than an agreed threshold relative to the equivalent at origination. PD deterioration thresholds are defined as percentage increases, and are set at an origination score band and segment level to ensure the test appropriately captures significant increases in credit risk at all risk levels. Generally, thresholds are inversely correlated to the origination PD, i.e. as the origination PD increases, the threshold value reduces. The assessment of the point at which a PD increase is deemed ‘significant’, is based upon analysis of the portfolio’s risk profile against a common set of principles and performance metrics (consistent across both retail and wholesale businesses), incorporating expert credit judgement where appropriate. Application of quantitative PD floors does not represent the use of the low credit risk exemption as exposures can separately move into stage 2 via the qualitative route described below. Wholesale assets apply a 100% increase in PD and 0.2% PD floor to determine a significant increase in credit risk. Retail assets apply bespoke relative increase and absolute PD thresholds based on product type and origination PD. Thresholds are subject to maximums defined by Barclays Bank Group policy and typically apply minimum relative thresholds of 50%-100% and a maximum relative threshold of 400%. For existing/historical exposures where origination point scores or data are no longer available or do not represent a comparable estimate of lifetime PD, a proxy origination score is defined, based upon: ▪ back-population of the approved lifetime PD score either to origination date or, where this is not feasible, as far back as possible (subject to a data start point no later than 1 January 2015); or ▪ use of available historical account performance data and other customer information, to derive a comparable ‘proxy’ estimation of origination PD. ii) Qualitative test This is relevant for accounts that meet the portfolio’s ‘high risk’ criteria and are subject to closer credit monitoring. High risk customers may not be in arrears but either through an event or an observed behaviour exhibit credit distress. The definition and assessment of high risk includes as wide a range of information as reasonably available, such as industry and Barclays Bank Group-wide customer level data, including but not limited to bureau scores and high consumer indebtedness index, wherever possible or relevant. Whilst the high risk populations applied for IFRS 9 impairment purposes are aligned with risk management processes, they are also regularly reviewed and validated to ensure that they capture any incremental segments where there is evidence of credit deterioration. iii) Backstop criteria This is relevant for accounts that are more than 30 calendar days past due. The 30 days past due criteria is a backstop rather than a primary driver of moving exposures into Stage 2. The criteria for determining a significant increase in credit risk for assets with bullet repayments follows the same principle as all other assets, i.e. quantitative, qualitative and backstop tests are all applied. Exposures will move back to Stage 1 once they no longer meet the criteria for a significant increase in credit risk. This means that, at a minimum all payments must be up-to-date, the PD deterioration test is no longer met, the account is no longer classified as high risk, and the customer has evidenced an ability to maintain future payments. Exposures are only removed from Stage 3 and re-assigned to Stage 2 once the original default trigger event no longer applies. Exposures being removed from Stage 3 must no longer qualify as credit impaired, and: a) the obligor will also have demonstrated consistently good payment behaviour over a 12-month period, by making all consecutive contractual payments due and, for forborne exposures, the relevant EBA defined probationary period has also been successfully completed or; b) (for non-forborne exposures) the performance conditions are defined and approved within an appropriately sanctioned restructure plan, including 12 months’ payment history have been met. Management overlays and other exceptions to model outputs are applied only if consistent with the objective of identifying significant increases in credit risk. Forward-looking information The measurement of ECL involves complexity and judgement, including estimation of PD, LGD, a range of unbiased future economic scenarios, estimation of expected lives (where contractual life is not appropriate), and estimation of EAD and assessing significant increases in credit risk. Credit losses are the expected cash shortfalls from what is contractually due over the expected life of the financial instrument, discounted at the original effective interest rate (EIR). ECLs are the unbiased probability-weighted credit losses determined by evaluating a range of possible outcomes and considering future economic conditions. The Barclays Bank Group uses a five -scenario model to calculate ECL. An external consensus forecast is assembled from key sources, including HM Treasury (short and medium term forecasts), Bloomberg (based on median of economic forecasters) and the Urban Land Institute (for US House Prices), which forms the baseline scenario. In addition, two adverse scenarios (Downside 1 and Downside 2) and 2 favourable scenarios (Upside 1 and Upside 2) are derived, with associated probability weightings. The adverse scenarios are calibrated to a similar severity to internal stress tests, whilst also considering IFRS 9 specific sensitivities and non-linearity. Downside 2 is benchmarked to the Bank of England’s annual cyclical scenarios and to the most severe scenario from Moody’s inventory, but is not designed to be the same. The favourable scenarios are calibrated to be symmetric to the adverse scenarios, subject to a ceiling calibrated to relevant recent favourable benchmark scenarios. The scenarios include eight economic variables (GDP, unemployment, House Price Index (HPI) and base rates in both the UK and US markets) and expanded variables using statistical models based on historical correlations. The upside and downside shocks are designed to evolve over a five -year stress horizon, with all five scenarios converging to a steady state after approximately eight- years. The methodology for estimating probability weights for each of the scenarios involves a comparison of the distribution of key historical UK and US macroeconomic variables against the forecast paths of the 5 scenarios. The methodology works such that the baseline (reflecting current consensus outlook) has the highest weight and the weights of adverse and favourable scenarios depend on the deviation from the baseline; the further from the baseline, the smaller the weight. A single set of five scenarios is used across all portfolios and all five weights are normalised to equate to 100%. The same scenarios and weights that are used in the estimation of expected credit losses are also used for the Barclays Bank Group’s internal planning purposes. The impacts across the portfolios are different because of the sensitivities of each of the portfolios to specific macroeconomic variables, for example, mortgages are highly sensitive to house prices, and credit cards and unsecured consumer loans are highly sensitive to unemployment. Definition of default, credit impaired assets, write-offs, and interest income recognition The definition of default for the purpose of determining ECLs, and for internal credit risk management purposes, has been aligned to the Regulatory Capital CRR Article 178 definition of default, to maintain a consistent approach with IFRS 9 and associated regulatory guidance. The Regulatory Capital CRR Article 178 definition of default considers indicators that the debtor is unlikely to pay, includes exposures in forbearance and is no later than when the exposure is more than 90 days past due or 180 days past due in the case of UK mortgages. When exposures are identified as credit impaired at the time when they are purchased or originated interest income is calculated on the carrying value net of the impairment allowance. An asset is considered credit impaired when one or more events occur that have a detrimental impact on the estimated future cash flows of the financial asset. This comprises assets defined as defaulted and other individually assessed exposures where imminent default or actual loss is identified. Uncollectible loans are written off against the related allowance for loan impairment on completion of the Barclays Bank Group’s internal processes and when all reasonably expected recoverable amounts have been collected. Subsequent recoveries of amounts previously written off are credited to the income statement. The timing and extent of write-offs may involve some element of subjective judgement. Nevertheless, a write-off will often be prompted by a specific event, such as the inception of insolvency proceedings or other formal recovery action, which makes it possible to establish that some or the entire advance is beyond realistic prospect of recovery. Accounting for purchased financial guarantee contracts The Barclays Bank Group may enter into a financial guarantee contract which requires the issuer of such contract to reimburse the Barclays Bank Group for a loss it incurs because a specified debtor fails to make payment when due in accordance with the terms of a debt instrument. For these separate financial guarantee contracts, the Barclays Bank Group recognises a reimbursement asset aligned with the recognition of the underlying ECLs, if it is considered virtually certain that a reimbursement would be received if the specified debtor fails to make payment when due in accordance with the terms of the debt instrument. Loan modifications and renegotiations that are not credit-impaired When modification of a loan agreement occurs as a result of commercial restructuring activity rather than due to the credit risk of the borrower, an assessment must be performed to determine whether the terms of the new agreement are substantially different from the terms of the existing agreement. This assessment considers both the change in cash flows arising from the modified terms as well as the change in overall instrument risk profile. In respect of payment holidays granted to borrowers which are not due to forbearance, if the revised cash flows on a present value basis (based on the original EIR) are not substantially different from the original cash flows, the loan is not considered to be substantially modified. Where terms are substantially different, the existing loan will be derecognised and a new loan will be recognised at fair value, with any difference in valuation recognised immediately within the income statement, subject to observability criteria. Where terms are not substantially different, the loan carrying value will be adjusted to reflect the present value of modified cash flows discounted at the original EIR, with any resulting gain or loss recognised immediately within the income statement as a modification gain or loss. Note 1 sets out details for changes in the basis of determining the contractual cash flows of a financial instrument that are required by interest rate benchmark reform. Expected life Lifetime ECLs must be measured over the expected life. This is restricted to the maximum contractual life and takes into account expected prepayment, extension, call and similar options. The exceptions are certain revolver financial instruments, such as credit cards and bank overdrafts, that include both a drawn and an undrawn component where the entity’s contractual ability to demand repayment and cancel the undrawn commitment does not limit the entity’s exposure to credit losses to the contractual notice period. For revolving facilities, expected life is analytically derived to reflect behavioural life of the asset, i.e. the full period over which the business expects to be exposed to credit risk. Behavioural life is typically based upon historical analysis of the average time to default, closure or withdrawal of facility. Where data is insufficient or analysis inconclusive, an additional ‘maturity factor’ may be incorporated to reflect the full estimated life of the exposures, based upon experienced judgement and/or peer analysis. Potential future modifications of contracts are not taken into account when determining the expected life or EAD until they occur. Discounting ECLs are discounted at the EIR at initial recognition or an approximation thereof and consistent with income recognition. For loan commitments the EIR is the rate that is expected to apply when the loan is drawn down and a financial asset is recognised. Issued financial guarantee contracts are discounted at the risk free rate. Lease receivables are discounted at the rate implicit in the lease. For variable/floating rate financial assets, the spot rate at the reporting date is used and projections of changes in the variable rate over the expected life are not made to estimate future interest cash flows or for discounting. Modelling techniques The regulatory Basel Committee of Banking Supervisors (BCBS) ECL calculations are leveraged for IFRS 9 modelling but adjusted for key differences which include: ▪ BCBS requires 12 month through the economic cycle losses whereas IFRS 9 requires 12 months or lifetime point in time losses based on conditions at the reporting date and multiple forecasts of the future economic conditions over the expected lives; ▪ IFRS 9 models do not include certain conservative BCBS model floors and downturn assessments and require discounting to the reporting date at the original EIR rather than using the cost of capital to the date of default; ▪ management adjustments are made to modelled output to account for situations where known or expected risk factors and information have not been considered in the modelling process, for example forecast economic scenarios for uncertain political events; and ▪ ECL is measured at the individual financial instrument level, however a collective approach where financial instruments with similar risk characteristics are grouped together, with apportionment to individual financial instruments, is used where effects can only be seen at a collective level, for example for forward-looking information. For the IFRS 9 impairment assessment, the Barclays Bank Group’s risk models are used to determine the PD, LGD and EAD. For Stage 2 and 3, the Barclays Bank Group applies lifetime PDs but uses 12 month PDs for Stage 1. The ECL drivers of PD, EAD and LGD are modelled at an account level which considers vintage, among other credit factors. Also, the assessment of significant increase in credit risk is based on the initial lifetime PD curve, which accounts for the different credit risk underwritten over time. Forbearance A financial asset is subject to forbearance when it is modified due to the credit distress of the borrower. A modification made to the terms of an asset due to forbearance will typically be assessed as a non-substantial modification that does not result in derecognition of the original loan, except in circumstances where debt is exchanged for equity. Both performing and non-performing forbearance assets are classified as Stage 3 except where it is established that the concession granted has not resulted in diminished financial obligation and that no other regulatory definitions of default criteria have been triggered, in which case the asset is classified as Stage 2. The minimum probationary period for non-performing forbearance is 12 months and for performing forbearance, 24 months. Hence, a minimum of 36 months is required for non-performing forbearance to move out of a forborne state. No financial instrument in forbearance can transfer back to Stage 1 until all of the Stage 2 thresholds are no longer met and can only move out of Stage 3 when no longer credit impaired. Critical accounting estimates and judgements IFRS 9 impairment involves several important areas of judgement, including estimating forward looking modelled parameters (PD, LGD and EAD), developing a range of unbiased future economic scenarios, estimating expected lives and assessing significant increases in credit risk, based on the Barclays Bank Group’s experience of managing credit risk. The determination of expected life is most material for Barclays credit card portfolios which is obtained via behavioural life analysis to materially capture the risk of these facilities. Within the retail and small businesses portfolios, which comprise large numbers of small homogenous assets with similar risk characteristics where credit scoring techniques are generally used, the impairment allowance is calculated using forward looking modelled parameters which are typically run at account level. There are many models in use, each tailored to a product, line of business or customer category. Judgement and knowledge is needed in selecting the statistical methods to use when the models are developed or revised. Management adjustments to impairment models, which contain an element of subjectivity, are applied in order to factor in certain conditions or changes in policy that are not fully incorporated into the impairment models, or to reflect additional facts and circumstances at the period end. Management adjustments are reviewed and incorporated into future model development where appropriate. For individually significant assets in Stage 3, impairment allowances are calculated on an individual basis and all relevant considerations that have a bearing on the expected future cash flows across a range of economic scenarios are taken into account. These considerations can be particularly subjective and can include the business prospects for the customer, the realisable value of collateral, the Barclays Bank Group’s position relative to other claimants, the reliability of customer information and the likely cost and duration of the work-out process. The level of the impairment allowance is the difference between the value of the discounted expected future cash flows (discounted at the loan’s original effective interest rate), and its carrying amount. Furthermore, judgements change with time as new information becomes available or as work-out strategies evolve, resulting in frequent revisions to the impairment allowance as individual decisions are taken. Changes in these estimates would result in a change in the allowances and have a direct impact on the impairment charge. Temporary adjustments to calculated IFRS9 impairment allowances may be applied in limited circumstances to account for situations where known or expected risk factors or information have not been considered in the ECL assessment or modelling process. For further information please see page 57 2021 2020 2019 Impairment Charges Recoveries and Reimbursements a Total Impairment Charges Recoveries and Reimbursements Total Impairment Charges Recoveries and Reimbursements Total £m £m £m £m £m £m £m £m £m Loans and advances (264) 259 (5) 3,060 (368) 2,692 1,214 (73) 1,141 Provision for undrawn contractually committed facilities and guarantees provided (257) — (257) 547 — 547 55 — 55 Loans impairment (521) 259 (262) 3,607 (368) 3,239 1,269 (73) 1,196 Cash collateral and settlement balances (4) — (4) 2 — 2 1 — 1 Financial instruments at fair value through OCI (6) — (6) — — — — — — Other financial assets measured at cost (5) — (5) 136 — 136 5 — 5 Credit impairment (release)/charge (536) 259 (277) 3,745 (368) 3,377 1,275 (73) 1,202 Notes a. Recoveries and reimbursements include a net reduction in amounts recoverable from financial guarantee contracts held with third parties of £290m (2020: £364m) and cash recoveries of previously written off amounts of £31m (2020: £4m). Write-offs that can be subjected to enforcement activity The contractual amount outstanding on financial assets that were written off during the year and that can still be subjected to enforcement activity is £752m (2020: £816m). This is lower than the write-offs presented in the movement in gross exposures and impairment allowance table due to assets sold during the year post write-offs and post write-off recoveries. Modification of financial assets Financial assets of £3,260m (2020: £3,781m) were subject to non-substantial modification during the year, with a resulting loss of £2m (2020: £21m). The gross carrying amount at 31 December 2021 of financial assets subject to non-substantial modification for which the loss allowance has changed to a 12 month ECL during the year amounts to £419m (2020: £1,194m). |
Operating expenses
Operating expenses | 12 Months Ended |
Dec. 31, 2021 | |
Expenses by nature [abstract] | |
Operating expenses | Operating expenses Restated c 2021 2020 2019 £m £m £m Infrastructure costs Property and equipment 367 373 368 Depreciation and amortisation 403 421 457 Lease payments 4 1 7 Impairment of property, equipment and intangible assets a 280 21 3 Total infrastructure costs 1,054 816 835 Administration and general expenses Consultancy, legal and professional fees 390 345 362 Marketing and advertising 235 176 258 UK bank levy 134 249 185 Other administration and general expenses 3,616 3,432 3,513 Total administration and general expenses 4,375 4,202 4,318 Staff costs b 4,456 4,365 4,565 Litigation and conduct 374 76 264 Operating expenses 10,259 9,459 9,982 Note a Impairment of property, equipment and intangible assets includes £266m relating to structural cost actions taken as part of the real estate review conducted in 2021 (see Note 19). b For further details on staff costs including accounting policies, refer to Note 29. |
Tax
Tax | 12 Months Ended |
Dec. 31, 2021 | |
Major components of tax expense (income) [abstract] | |
Tax | Tax Accounting for income taxes The Barclays Bank Group applies IAS 12 Income Taxes in accounting for taxes on income. Income tax payable on taxable profits (current tax) is recognised as an expense in the periods in which the profits arise. Withholding taxes are also treated as income taxes. Income tax recoverable on tax allowable losses is recognised as a current tax asset only to the extent that it is regarded as recoverable by offsetting against taxable profits arising in the current or prior periods. Current tax is measured using tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised. Deferred tax liabilities are recognised for all taxable temporary differences except from the initial recognition of goodwill. Deferred tax is not recognised where the temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss. Deferred tax is determined using tax rates and legislation enacted or substantively enacted by the balance sheet date which are expected to apply when the deferred tax asset is realised or the deferred tax liability is settled. Deferred tax assets and liabilities are only offset when there is both a legal right to set-off and an intention to settle on a net basis. The Barclays Bank Group considers an uncertain tax position to exist when it considers that ultimately, in the future, the amount of profit subject to tax may be greater than the amount initially reflected in the Barclays Bank Group’s tax returns. The Barclays Bank Group accounts for provisions in respect of uncertain tax positions in two different ways. A current tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will alter the amount of cash tax due to, or from, a tax authority in the future. From recognition, the current tax provision is then measured at the amount the Barclays Bank Group ultimately expects to pay the tax authority to resolve the position. The accrual of interest and penalty amounts in respect of uncertain income tax positions is recognised as an expense within profit before tax. Deferred tax provisions are adjustments made to the carrying value of deferred tax assets in respect of uncertain tax positions. A deferred tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will result in a reduction in the carrying value of the deferred tax asset. From recognition of a provision, measurement of the underlying deferred tax asset is adjusted to take into account the expected impact of resolving the uncertain tax position on the loss or temporary difference giving rise to the deferred tax asset. The approach taken to measurement takes account of whether the uncertain tax position is a discrete position that will be reviewed by the tax authority in isolation from any other position, or one of a number of issues which are expected to be reviewed together concurrently and resolved simultaneously with a tax authority. The Barclays Bank Group’s measurement of provisions is based upon its best estimate of the additional profit that will become subject to tax. For a discrete position, consideration is given only to the merits of that position. Where a number of issues are expected to be reviewed and resolved together, the Barclays Bank Group will take into account not only the merits of its position in respect of each particular issue but also the overall level of provision relative to the aggregate of the uncertain tax positions across all the issues that are expected to be resolved at the same time. In addition, in assessing provision levels, it is assumed that tax authorities will review uncertain tax positions and that all facts will be fully and transparently disclosed. Critical accounting estimates and judgements There are two key areas of judgement that impact the reported tax position. Firstly, the level of provisioning for uncertain tax positions; and secondly, the recognition and measurement of deferred tax assets. The Barclays Bank Group does not consider there to be a significant risk of a material adjustment to the carrying amount of current and deferred tax balances, including provisions for uncertain tax positions in the next financial year. The provisions for uncertain tax positions cover a diverse range of issues and reflect advice from external counsel where relevant. It should be noted that only a proportion of the total uncertain tax positions will be under audit at any point in time, and could therefore be subject to challenge by a tax authority over the next year. Deferred tax assets have been recognised based on business profit forecasts. Details on the recognition of deferred tax assets are provided in this note. Restated a 2021 2020 2019 £m £m £m Current tax charge/(credit) Current year 904 993 327 Adjustments in respect of prior years 393 3 (50) 1,297 996 277 Deferred tax (credit)/charge Current year (179) (563) 157 Adjustments in respect of prior years (288) 191 (102) (467) (372) 55 Tax charge 830 624 332 a. 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. The table below shows the reconciliation between the actual tax charge and the tax charge that would result from applying the standard UK corporation tax rate to the Barclays Bank Group’s profit before tax. Restated a Restated a 2021 2021 2020 2020 2019 2019 £m % £m % £m % Profit before tax from continuing operations 5,418 3,075 3,112 Tax charge based on the standard UK corporation tax rate of 19% (2020: 19%, 2019: 19%) 1,029 19.0 % 584 19.0 % 593 19.0 % Impact of profits/losses earned in territories with different statutory rates to the UK (weighted average tax rate is 24.0% (2020: 25.0% , 2019: 26.0%)) 273 5.0 % 183 6.0 % 217 7.0 % Recurring items: Non-creditable taxes including withholding taxes 124 2.3 % 107 3.4 % 146 4.7 % Adjustments in respect of prior years 105 1.9 % 194 6.3 % (152) (4.9 %) Non-deductible expenses 61 1.1 % 28 0.9 % 34 1.1 % Impact of UK bank levy being non-deductible 25 0.5 % 48 1.6 % 35 1.1 % Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK 25 0.5 % 25 0.8 % 15 0.5 % Tax adjustments in respect of share-based payments (5) (0.1 %) 14 0.5 % (7) (0.2 %) Banking surcharge and other items (48) (0.9 %) (70) (2.3 %) (103) (3.3 %) Tax relief on payments made under AT1 instruments (113) (2.1 %) (124) (4.0 %) (121) (3.9 %) Changes in recognition of deferred tax and effect of unrecognised tax losses (140) (2.6 %) (123) (4.0 %) (85) (2.7 %) Non-taxable gains and income (309) (5.7 %) (200) (6.5 %) (240) (7.7 %) Non-recurring items: Remeasurement of UK deferred tax assets due to tax rate changes (218) (4.0 %) (43) (1.4 %) — — Non-deductible provisions for UK customer redress 21 0.4 % 7 0.2 % — — Non-deductible provisions for investigations and litigation — — (6) (0.2 %) — — Total tax charge 830 15.3 % 624 20.3 % 332 10.7 % a. 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. Factors driving the effective tax rate The effective tax rate of 15.3% is lower than the UK corporation tax rate of 19% primarily due to the impact of non-taxable gains and income, adjustments for the remeasurement of UK deferred tax assets as a result of the enactment in 2021 of an increase in the UK corporation tax rate to 25% from 1 April 2023, the use of unrecognised tax losses in the period and tax relief on payments made under AT1 instruments. These factors, which have each decreased the effective tax rate, are partially offset by profits earned outside the UK being taxed at local statutory tax rates that are higher than the UK tax rate and non-creditable taxes. The Barclays Bank Group’s future tax charge will be sensitive to the geographic mix of profits earned, the tax rates in force and changes to the tax rules in the jurisdictions that the Barclays Bank Group operates in. In its Budget held in October 2021, the UK Government announced that the banking surcharge rate will be reduced from 8% to 3% from 1 April 2023. This reduction in the banking surcharge rate was substantively enacted on 2 February 2022 and is a non-adjusting post balance sheet event. If the reduction in the banking surcharge rate had been substantively enacted at the balance sheet date then this would have resulted in the Barclays Bank Group’s UK deferred tax assets being remeasured and decreasing with a tax charge in the income statement of £183m and tax credit within other comprehensive income of £122m. In October 2021, the OECD and G20 Inclusive Framework on Base Erosion and Profit Shifting announced plans to introduce a global minimum tax rate of 15% from 2023. The model rules, which set out the scope of and the mechanism for calculating the global minimum tax, were released by the OECD on 20 December 2021. The Barclays Bank Group is reviewing the model rules and awaiting the OECD’s anticipated publication of further guidance, as well as new legislation expected to be released by governments implementing this new tax regime, and will assess the potential impact of new legislation during 2022. In the USA, a proposed Build Back Better Act has been passed by the House of Representatives but has not been passed by the Senate and at this time it is uncertain whether the Act will progress further. The proposed Act passed by the House of Representatives included proposals to implement material changes to international tax provisions, including amendments to the Base Erosion and Anti-Abuse Tax and the imposition of an alternative minimum tax based on accounting profits. It is unclear at this time whether any of these proposals could have a significant impact on the Barclays Bank Group if enacted. The Barclays Bank Group will continue to monitor developments and assess the potential impact of any future legislative changes ultimately enacted. Tax in the consolidated statement of comprehensive income Tax relating to each component of other comprehensive income can be found in the consolidated statement of comprehensive income which includes within Other a tax credit of £nil (2020: £3m). The total amount recognised in relation to the remeasurement of UK deferred tax through other comprehensive income was a £148m charge (2020: £49m). Tax included directly in equity Tax included directly in equity comprises a £38m credit (2020: £14m) relating to share-based payments and deductible costs on issuing other equity instruments. Deferred tax assets and liabilities The deferred tax amounts on the balance sheet were as follows: Barclays Bank Group 2021 2020 £m £m US Intermediate Holding Company Tax Group ("IHC Tax Group") 1,004 1,001 US Branch Tax Group 1,002 1,048 UK Tax Group 576 — Other (outside the UK and US tax groups) 399 503 Deferred tax asset 2,981 2,552 Deferred tax liability (6) (225) Net deferred tax 2,975 2,327 US deferred tax assets in the IHC and the US Branch Tax Groups The deferred tax asset in the IHC Tax Group of £1,004m (2020: £1,001m) includes £1m (2020: £nil) relating to tax losses, with the balance relating to temporary differences. The deferred tax asset in Barclays Bank PLC’s US Branch Tax Group of £1,002m (2020: £1,048m) relates entirely to temporary differences. In relation to the IHC Tax Group, these temporary differences include £301m (2020: £330m) arising from New York State and City prior net operating loss conversion which can be carried forward and will expire in 2034. Business profit forecasts indicate these amounts will be fully recovered before expiry. UK Tax Group deferred tax assets and liabilities The net deferred tax asset in the UK Tax Group of £576m (2020: £225m liability) includes a deferred tax asset of £1,074m (2020: £541m) relating to tax losses which is offset by a deferred tax liability of £498m (2020: £766m) relating to temporary differences. There is no time limit on utilisation of UK tax losses and business profit forecasts indicate these losses will be fully recovered. Other deferred tax assets (outside the UK and US tax groups) The deferred tax asset of £399m (2020: £503m) in other entities within the Barclays Bank Group includes £121m (2020: £170m) relating to tax losses. These deferred tax assets relate to a number of different territories and their recognition is based on profit forecasts or local country law which indicate that it is probable that those deferred tax assets will be fully recovered. Of the deferred tax asset of £399m (2020: £503m), an amount of £9m (2020: £8m) relates to entities which have suffered a loss in either the current or prior year and the utilisation of which is dependent upon future taxable profits. This has been taken into account in reaching the above conclusion that these deferred tax assets will be fully recovered in the future. The table below shows movements on deferred tax assets and liabilities during the year. The amounts are different from those disclosed on the balance sheet and in the preceding table as they are presented before offsetting asset and liability balances where there is a legal right to set-off and an intention to settle on a net basis. Barclays Bank Group Fixed asset timing differences Fair value through other comprehensive income Cash flow hedges Retirement benefit obligations Loan impairment allowance Other provisions Share based payments and deferred compensation Other temporary differences Tax losses carried forward Total £m £m £m £m £m £m £m £m £m £m Assets 659 — — 30 455 139 317 1,377 711 3,688 Liabilities (33) (21) (441) (826) — — — (40) — (1,361) As at 1 January 2021 626 (21) (441) (796) 455 139 317 1,337 711 2,327 Income statement 14 (6) — 1 38 3 (13) (55) 485 467 Other comprehensive income and reserves — 170 750 (855) — — 20 97 — 182 Other movements 8 1 — — (12) — 3 (1) — (1) 648 144 309 (1,650) 481 142 327 1,378 1,196 2,975 Assets 678 144 309 24 481 142 327 1,418 1,196 4,719 Liabilities (30) — — (1,674) — — — (40) — (1,744) As at 31 December 2021 648 144 309 (1,650) 481 142 327 1,378 1,196 2,975 Assets 719 110 — 31 284 127 305 1,329 523 3,428 Liabilities (29) (18) (139) (640) — — — (222) — (1,048) As at 1 January 2020 690 92 (139) (609) 284 127 305 1,107 523 2,380 Income statement (39) — — — 164 18 15 23 191 372 Other comprehensive income and reserves — (112) (291) (191) — — 3 238 — (353) Other movements (25) (1) (11) 4 7 (6) (6) (31) (3) (72) 626 (21) (441) (796) 455 139 317 1,337 711 2,327 Assets 659 — — 30 455 139 317 1,377 711 3,688 Liabilities (33) (21) (441) (826) — — — (40) — (1,361) As at 31 December 2020 626 (21) (441) (796) 455 139 317 1,337 711 2,327 The amount of deferred tax asset expected to be recovered after more than 12 months for the Barclays Bank Group is £4,328m (2020: £3,356m). The amount of deferred tax liability expected to be settled after more than 12 months for the Barclays Bank Group is £1,740m (2020: £1,359m). These amounts are before offsetting asset and liability balances where there is a legal right to set-off and an intention to settle on a net basis. Unrecognised deferred tax Tax losses and temporary differences The Barclays Bank Group has deferred tax assets not recognised in respect of gross deductible temporary differences of £110m (2020: £123m), unused tax credits of £283m (2020: £236m), and gross tax losses of £22,496m (2020: £19,953m). The tax losses include capital losses of £3,642m (2020: £2,987m). Of these tax losses, £63m (2020: £139m) expire within five years, £370m (2020: £236m) expire within six to ten years, £10,529m (2020: £7,271m) expire within 11 to 20 years and £11,534m (2020: £12,307m) can be carried forward indefinitely. Deferred tax assets have not been recognised in respect of these items because it is not probable that future taxable profits and gains will be available against which they can be utilised. Barclays Bank Group investments in subsidiaries, branches and associates Deferred tax is not recognised in respect of the value of Barclays Bank Group's investments in subsidiaries, branches and associates where the Barclays Bank Group is able to control the timing of the reversal of the temporary differences and it is probable that such differences will not reverse in the foreseeable future. The aggregate amount of these temporary differences for which deferred tax liabilities have not been recognised was £0.9bn (2020: £0.8bn). |
Dividends on ordinary shares an
Dividends on ordinary shares and preference shares | 12 Months Ended |
Dec. 31, 2021 | |
Dividends on ordinary shares | |
Dividends on ordinary shares and preference shares | Dividends on ordinary shares and preference shares The 2021 financial statements include £794m (2020: £263m) of dividends paid on ordinary shares. This comprises one interim dividend declared in relation to the prior year of £174m (2020: £263m) and two interim dividends in relation to 2021 of £520m, declared in February 2021, and £100m, declared in July 2021 (2020: nil ). This results in a total dividend for the year of £0.34 (2020: £0.11) per ordinary share. Dividends paid on preference shares amounted to £27m (2020: £42m). Dividends paid on the Euro preference shares amounted to £14.37 per share (2020: £439.21). Dividends paid on the 6.278% US$100 preference shares amounted to £459.69 per share (2020: £485.75). The Directors approved a third interim dividend in respect of 2021 of £200m, which was paid on 24 March 2022. |
Trading portfolio
Trading portfolio | 12 Months Ended |
Dec. 31, 2021 | |
Net assets (liabilities) [abstract] | |
Trading portfolio | Trading portfolio Accounting for trading portfolio assets and liabilities In accordance with IFRS 9, all assets and liabilities held for trading purposes are held at fair value with gains and losses in the changes in fair value taken to the income statement in net trading income (Note 5). Barclays Bank Group 2021 2020 £m £m Debt securities and other eligible bills 50,700 56,196 Equity securities 83,113 62,192 Traded loans 12,525 8,348 Commodities 533 928 Trading Portfolio Assets 146,871 127,664 Debt securities and other eligible bills (34,079) (28,836) Equity securities (19,212) (17,303) Trading Portfolio Liabilities (53,291) (46,139) |
Financial assets at fair value
Financial assets at fair value through the income statement | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through profit or loss [abstract] | |
Financial assets at fair value through the income statement | Financial assets at fair value through the income statemen t Accounting for financial assets mandatorily at fair value Financial assets that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Accounting for financial assets designated at fair value Financial assets, other than those held for trading, are classified in this category if they are so irrevocably designated at inception and the use of the designation removes or significantly reduces an accounting mismatch. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. The details on how the fair value amounts are derived for financial assets at fair value are described in Note 16. Barclays Bank Group 2021 2020 £m £m Loans and advances 2,813 2,170 Debt securities 318 291 Reverse repurchase agreements and other similar secured lending — 19 Financial assets designated at fair value 3,131 2,480 Loans and advances 33,089 25,279 Debt securities 1,937 1,406 Equity securities 4,798 3,742 Reverse repurchase agreements and other similar secured lending 145,186 138,539 Other financial assets 85 315 Financial assets mandatorily at fair value 185,095 169,281 Total 188,226 171,761 Credit risk of financial assets designated at fair value and related credit derivatives The following table shows the maximum exposure to credit risk, the changes in fair value attributable to changes in credit risk, and the cumulative changes in fair value since initial recognition for loans and advances. The table does not include debt securities and reverse repurchase agreements and other similar secured lending designated at fair value as they have minimal exposure to credit risk. Reverse repurchase agreements are collateralised and debt securities are primarily relating to high quality sovereigns. Barclays Bank Group Maximum exposure as at 31 December Changes in fair value during the year ended Cumulative changes in fair value from inception 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Loans and advances designated at fair value, attributable to credit risk 2,813 2,170 1 (46) (3) (51) Value mitigated by related credit derivatives 1,617 795 (3) 3 (3) 3 |
Derivative financial instrument
Derivative financial instruments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of nature and extent of risks arising from financial instruments [abstract] | |
Derivative financial instruments | Derivative financial instruments Accounting for derivatives Derivative instruments are contracts whose value is derived from one or more underlying financial instruments or indices defined in the contract. They include swaps, forward-rate agreements, futures, options and combinations of these instruments and primarily affect the Barclays Bank Group’s net interest income, net trading income and derivative assets and liabilities. Notional amounts of the contracts are not recorded on the balance sheet. Derivatives are used to hedge interest rate, credit risk, inflation risk, exchange rate, commodity, equity exposures and exposures to certain indices such as house price indices and retail price indices related to non-trading positions. All derivative instruments are held at fair value through profit or loss, except for derivatives that are in a designated cash flow or net investment hedge accounting relationship. Derivatives are classified as assets when their fair value is positive or as liabilities when their fair value is negative. This includes terms included in a contract or financial liability (the host) which, had they been a standalone contract, would have met the definition of a derivative. If these are separated from the host, i.e. when the economic characteristics of the embedded derivative are not closely related with those of the host contract and the combined instrument is not measured at fair value through profit or loss, then they are accounted for in the same way as derivatives. For financial assets, the requirements are whether the financial assets contain contractual terms that give rise on specified dates to cash flows that are SPPI, and consequently the requirements for accounting for embedded derivatives are not applicable to financial assets. Hedge accounting The Barclays Bank Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. The Barclays Bank Group applies hedge accounting to represent the economic effects of its interest rate, currency and contractually linked inflation risk management strategies. Where derivatives are held for risk management purposes, and when transactions meet the required criteria for documentation and hedge effectiveness, the Barclays Bank Group applies fair value hedge accounting, cash flow hedge accounting, or hedging of a net investment in a foreign operation, as appropriate to the risks being hedged. The Barclays Bank Group applies the ‘Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform’ issued in September 2019 (the Phase 1 amendments). The amendments provide temporary relief from applying specific hedge accounting requirements to hedging relationships directly affected by IBOR (‘Interbank Offered Rates’) reform. The reliefs have the effect that IBOR reform should not generally cause hedge accounting to terminate. However, any hedge ineffectiveness continues to be recorded in the income statement. Furthermore, the amendments set out triggers for when the reliefs will end, which include the uncertainty arising from interest rate benchmark reform no longer being present. In summary, the reliefs provided by the Phase 1 amendments are: ▪ When considering the ‘highly probable’ requirement, the Barclays Bank Group has assumed that the IBOR interest rates upon which our hedged items are based do not change as a result of IBOR Reform. ▪ In assessing whether the hedge is expected to be highly effective on a forward-looking basis the Barclays Bank Group has assumed that the IBOR interest rates upon which the cash flows of the hedged items and the interest rate swaps that hedge them are based are not altered by IBOR reform. ▪ The Barclays Bank Group will not discontinue hedge accounting during the period of IBOR-related uncertainty solely because the retrospective effectiveness falls outside the required 80% –125% range. ▪ The Barclays Bank Group has not recycled the cash flow hedge reserve relating to the period after the reforms are expected to take effect. ▪ The Barclays Bank Group has assessed whether the hedged IBOR risk component is a separately identifiable risk only when it first designates a hedged item in a fair value hedge and not on an ongoing basis. The Barclays Bank Group also applies the ‘Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2’ issued in August 2020. The Phase 2 amendments provide relief when changes are made to hedge relationships as a result of the interest rate benchmark reform. In summary, the reliefs provided by the Phase 2 amendments are: ▪ Under a temporary exception, the Barclays Bank Group has considered that changes to the hedge designation and hedge documentation due to the interest rate benchmark reform would not constitute the discontinuation of the hedge relationship nor the designation of a new hedging relationship. ▪ In respect of the retrospective hedge effectiveness assessment, the Barclays Bank Group may elect, on a hedge-by-hedge basis, to reset the cumulative fair value changes to zero when the exception to the retrospective assessment ends (Phase 1 relief). Any hedge ineffectiveness will continue to be measured and recognised in full in profit or loss. ▪ The Barclays Bank Group has deemed the amounts accumulated in the cash flow hedge reserve to be based on the alternative benchmark rate (on which the hedge future cash flows are determined) when there is a change in basis for determining the contractual cash flows. ▪ For hedges of groups of items (such as those forming part of a macro cash flow hedging strategy), the amendments provide relief for items within a designated group of items that are amended for changes directly required by the reform. ▪ In respect of whether a risk component of a hedged item is separately identifiable, the amendments provide temporary relief to entities to meet this requirement when an alternative risk free rate (RFR) financial instrument is designated as a risk component. These amendments allow the Barclays Bank Group upon designation of the hedge to assume that the separately identifiable requirement is met if the Barclays Bank Group reasonably expects the RFR risk will become separately identifiable within the next 24 months. The Barclays Bank Group applies this relief to each RFR on a rate-by-rate basis and starts when the Barclays Bank Group first designates the RFR as a non-contractually specified risk component. Fair value hedge accounting Changes in fair value of derivatives that qualify and are designated as fair value hedges are recorded in the income statement, together with changes in the fair value of the hedged asset or liability that are attributable to the hedged risk. The fair value changes adjust the carrying value of the hedged asset or liability held at amortised cost. If hedge relationships no longer meet the criteria for hedge accounting, hedge accounting is discontinued. For fair value hedges of interest rate risk, the fair value adjustment to the hedged item is amortised to the income statement over the period to maturity of the previously designated hedge relationship using the effective interest method. If the hedged item is sold or repaid, the unamortised fair value adjustment is recognised immediately in the income statement. For items classified as fair value through other comprehensive income, the hedge accounting adjustment is included in other comprehensive income. Cash flow hedge accounting For qualifying cash flow hedges, the fair value gain or loss associated with the effective portion of the cash flow hedge is recognised initially in other comprehensive income, and then recycled to the income statement in the periods when the hedged item will affect profit or loss. Any ineffective portion of the gain or loss on the hedging instrument is recognised in the income statement immediately. When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative gain or loss existing in equity at that time remains in equity and is recognised when the hedged item is ultimately recognised in the income statement. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was recognised in equity is immediately transferred to the income statement. Hedges of net investments The Barclays Bank Group’s net investments in foreign operations, including monetary items accounted for as part of the net investment, are hedged for foreign currency risks using both derivatives and foreign currency borrowings. Hedges of net investments are accounted for similarly to cash flow hedges; the effective portion of the gain or loss on the hedging instrument is being recognised directly in other comprehensive income and the ineffective portion being recognised immediately in the income statement. The cumulative gain or loss recognised in other comprehensive income is recognised in the income statement on the disposal or partial disposal of the foreign operation, or other reductions in the Barclays Bank Group’s investment in the operation. Barclays Bank Group 2021 2020 Notional contract amount Fair value Notional contract amount Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Total derivative assets/(liabilities) held for trading 47,286,623 262,046 (255,471) 42,515,577 302,429 (299,637) Total derivative assets/(liabilities) held for risk management 126,292 245 (1,052) 110,028 264 (943) Derivative assets/(liabilities) 47,412,915 262,291 (256,523) 42,625,605 302,693 (300,580) The fair values and notional amounts of derivatives held for trading are set out in the following table: Derivatives held for trading and risk management 2021 2020 Barclays Bank Group Notional contract amount Fair value Notional contract amount Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Derivatives held for trading Foreign exchange derivatives OTC derivatives 5,700,055 76,055 (74,014) 5,463,632 84,518 (83,912) Derivatives cleared by central counterparty 99,664 171 (208) 78,946 335 (335) Exchange traded derivatives 20,084 10 (3) 14,034 3 (3) Foreign exchange derivatives 5,819,803 76,236 (74,225) 5,556,612 84,856 (84,250) Interest rate derivatives OTC derivatives 14,229,139 124,187 (113,098) 13,551,506 171,244 (161,223) Derivatives cleared by central counterparty 18,865,670 1,055 (762) 18,330,003 965 (795) Exchange traded derivatives 5,200,838 905 (907) 2,971,966 371 (360) Interest rate derivatives 38,295,647 126,147 (114,767) 34,853,475 172,580 (162,378) Credit derivatives OTC derivatives 606,504 4,007 (4,752) 384,900 3,674 (3,909) Derivatives cleared by central counterparty 665,600 1,675 (1,809) 462,945 931 (1,095) Credit derivatives 1,272,104 5,682 (6,561) 847,845 4,605 (5,004) Equity and stock index derivatives OTC derivatives 278,370 18,793 (24,440) 213,078 18,803 (26,091) Exchange traded derivatives 1,469,078 32,901 (33,174) 927,114 20,165 (20,521) Equity and stock index derivatives 1,747,448 51,694 (57,614) 1,140,192 38,968 (46,612) Commodity derivatives OTC derivatives 4,670 56 (107) 4,244 89 (110) Exchange traded derivatives 146,951 2,231 (2,197) 113,209 1,331 (1,283) Commodity derivatives 151,621 2,287 (2,304) 117,453 1,420 (1,393) Derivative assets/(liabilities) held for trading 47,286,623 262,046 (255,471) 42,515,577 302,429 (299,637) Total OTC derivatives 20,818,738 223,098 (216,411) 19,617,360 278,328 (275,245) Total derivatives cleared by central counterparty 19,630,934 2,901 (2,779) 18,871,894 2,231 (2,225) Total exchange traded derivatives 6,836,951 36,047 (36,281) 4,026,323 21,870 (22,167) Derivative assets/(liabilities) held for trading 47,286,623 262,046 (255,471) 42,515,577 302,429 (299,637) Derivatives held for risk management Derivatives designated as cash flow hedges Currency Swaps 1,000 155 — 1,000 67 — Interest rate swaps 465 — (3) 1,819 49 — Interest rate derivatives cleared by central counterparty 63,584 — — 43,499 — — Derivatives designated as cash flow hedges 65,049 155 (3) 46,318 116 — Derivatives designated as fair value hedges Interest rate swaps 5,856 53 (1,045) 7,986 123 (943) Forward foreign exchange — — — — — — Interest rate derivatives cleared by central counterparty 52,964 — — 54,933 — — Derivatives designated as fair value hedges 58,820 53 (1,045) 62,919 123 (943) Derivatives designated as hedges of net investments Forward foreign exchange 2,423 37 (4) 791 25 — Derivatives designated as hedges of net investments 2,423 37 (4) 791 25 — Derivative assets/(liabilities) held for risk management 126,292 245 (1,052) 110,028 264 (943) Total OTC derivatives 9,744 245 (1,052) 11,596 264 (943) Total derivatives cleared by central counterparty 116,548 — — 98,432 — — Derivative assets/(liabilities) held for risk management 126,292 245 (1,052) 110,028 264 (943) Hedge accounting Hedge accounting is applied predominantly for the following risks: ▪ Interest rate risk – arises due to a mismatch between fixed interest rates and floating interest rates. Interest rate risk also includes exposure to inflation risk for certain types of investments. ▪ Currency risk – arises due to assets or liabilities being denominated in different currencies than the functional currency of the relevant entity. At a consolidated level, currency risk also arises when the functional currency of subsidiaries are different from the parent. ▪ Contractually linked inflation risk – arises from financial instruments within contractually specified inflation risk. The Barclays Bank Group does not hedge inflation risk that arises from other activities. In order to hedge these risks, the Barclays Bank Group uses the following hedging instruments: ▪ Interest rate derivatives to swap interest rate exposure into either fixed or variable rates. ▪ Currency derivatives to swap foreign currency exposures into the entity’s functional currency, and net investment exposure to local currency. ▪ Inflation derivatives to swap inflation exposure into either fixed or variable interest rates. In some cases, certain items which are economically hedged may be ineligible hedged items for the purposes of IAS 39, such as core deposits and equity. In these instances, a proxy hedging solution can be utilised whereby portfolios of floating rate assets are designated as eligible hedged items in cash flow hedges. In some hedging relationships, the Barclays Bank Group designates risk components of hedged items as follows: ▪ Benchmark interest rate risk as a component of interest rate risk, such as the LIBOR or Risk Free Rate (RFR) component. ▪ Inflation risk as a contractually specified component of a debt instrument. ▪ Spot exchange rate risk for foreign currency financial assets or financial liabilities. ▪ Components of cash flows of hedged items, for example certain interest payments for part of the life of an instrument. Using the benchmark interest rate risk results in other risks, such as credit risk and liquidity risk, being excluded from the hedge accounting relationship. Following market-wide interest rate benchmark reform, sensitivity to risk-free rates is considered to be the predominant interest rate risk and therefore the hedged items (which often reference risk-free or similar 'overnight' rates) change in fair value on a proportionate basis with reference to this risk. In respect of many of the Barclays Bank Group’s hedge accounting relationships, the hedged item and hedging instrument change frequently due to the dynamic nature of the risk management and hedge accounting strategy. The Barclays Bank Group applies hedge accounting to dynamic scenarios, predominantly in relation to interest rate risk, with a combination of hedged items in order for its financial statements to reflect as closely as possible the economic risk management undertaken. In some cases, if the hedge accounting objective changes, the relevant hedge accounting relationship is de-designated and is replaced with a different hedge accounting relationship. Changes in the GBP value of net investments due to foreign currency movements are captured in the currency translation reserve, resulting in a movement in CET1 capital. The Barclays Bank Group mitigates this by matching the CET1 capital movements to the revaluation of the foreign currency RWA exposures. Net investment hedges are designated where necessary to reduce the exposure to movement in a particular exchange rate to within limits mandated by Risk. As far as possible, existing external currency liabilities are designated as the hedging instruments. The hedging instruments share the same risk exposures as the hedged items. Hedge effectiveness is determined with reference to quantitative tests, predominantly regression testing, but to the extent hedging instruments are exposed to different risks than the hedged items, this could result in hedge ineffectiveness or hedge accounting failures. Sources of ineffectiveness include the following: ▪ Mismatches between the contractual terms of the hedged item and hedging instrument, including basis differences. ▪ Changes in credit risk of the hedging instruments. ▪ If a hedging relationship becomes over-hedged, for example in hedges of net investments if the net asset value designated at the start of the period falls below the amount of the hedging instrument. ▪ Cash flow hedges using external swaps with non-zero fair values. ▪ The effects of the reforms to IBOR, because these might take effect at a different time and have a different impact on hedged items and hedging instruments. The Barclays Bank Group's risk exposure continues, in part, to be affected by interest rate benchmark reform. In most cases, hedged items and hedging instruments are expected to transition to relevant risk-free rates at the end of their current cash flow period. For GBP LIBOR contracts, where uncertainty around the timing and effects of LIBOR reform continues beyond the end of the current cash flow period, financial instruments are generally expected to utilise 'synthetic LIBOR' (as permitted by the FCA on a temporary basis until their contracts are fully remediated). USD LIBOR linked hedge accounting relationships are still exposed to uncertainty regarding the precise timing and effects of benchmark reform. USD LIBOR benchmarks will cease to be published from 30 June 2023, but certain hedged items and hedging instruments continue to contractually reference these benchmarks beyond the cessation date. The following table summarises the significant hedge accounting exposures impacted by the IBOR reform as at 31 December 2021: Barclays Bank Group Nominal amount of hedged items directly impacted by IBOR reform Nominal amount of hedging instruments directly impacted by IBOR reform Current benchmark rate Expected convergence to RFR £m £m GBP London Interbank Offered rate (LIBOR) Reformed Sterling Overnight Index Average (SONIA) 9,718 200 USD LIBOR Secured Overnight Financing Rate (SOFR) 19,945 20,013 JPY LIBOR Tokyo Overnight Average (TONA) — 52 Singapore Swap Offered Rate (SOR) Singapore Overnight Rate Average (SORA) 110 110 Total IBOR Notionals 29,773 20,375 Hedged items in fair value hedges Barclays Bank Group Accumulated fair value adjustment included in carrying amount Carrying amount Total Of which: Accumulated fair value adjustment on items no longer in a hedge relationship Change in fair value used as a basis to determine ineffectiveness Hedge ineffectiveness recognised in the income statement a Hedged item statement of financial position classification and risk category £m £m £m £m £m 2021 Assets Loans and advances at amortised cost - Interest rate risk 1,257 24 6 (77) (1) - Inflation risk 556 354 — 9 — Debt securities classified as amortised cost - Interest rate risk 1,378 (39) — (75) (18) - Inflation risk 4,087 400 — (16) (1) Financial assets at fair value through other comprehensive income b - Interest rate risk 22,895 (293) 28 (1,122) 35 - Inflation risk 6,271 386 (32) 81 10 Total Assets 36,444 832 2 (1,200) 25 Liabilities Debt securities in issue - Interest rate risk (26,691) (622) (320) 769 6 Total Liabilities (26,691) (622) (320) 769 6 Total Hedged Items 9,753 210 (318) (431) 31 2020 Assets Loans and advances at amortised cost - Interest rate risk 835 99 2 55 — - Inflation risk 545 345 — 25 3 Debt securities classified as amortised cost - Interest rate risk 1,440 23 — 17 (7) - Inflation risk 4,071 (43) — 453 3 Financial assets at fair value through other comprehensive income b - Interest rate risk 27,959 964 322 864 (33) - Inflation risk 7,782 319 (9) 249 (9) Total Assets 42,632 1,707 315 1,663 (43) Liabilities Debt securities in issue - Interest rate risk (26,978) (1,477) (414) (797) (6) Total Liabilities (26,978) (1,477) (414) (797) (6) Total Hedged Items 15,654 230 (99) 866 (49) Note a Hedge ineffectiveness is recognised in net interest income. b For items classified as fair value through other comprehensive income, the hedge accounting adjustment is not included in the carrying amount, but rather adjusts other comprehensive income. Amount, timing and uncertainty of future cash flows The following table shows the fair value hedging instruments which are carried on the Barclays Bank Group’s balance sheet: Barclays Bank Group Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Fair value Interest rate risk 53 — — 51,219 527 8,855 Inflation risk — (1,045) — 7,601 (65) 1,624 Total 53 (1,045) — 58,820 462 10,479 As at 31 December 2020 Fair value Interest rate risk 117 (164) — 55,093 (185) 17,697 Inflation risk 6 (779) — 7,826 (730) 1,487 Total 123 (943) — 62,919 (915) 19,184 The following table profiles the expected notional values of current hedging instruments for fair value hedging in future years: 2021 2022 2023 2024 2025 2026 2027 and later As at 31 December 2021 £m £m £m £m £m £m £m Barclays Bank Group Fair value hedges of: Interest rate risk (outstanding notional amount) 51,219 49,156 43,857 37,590 31,635 27,011 22,555 Inflation risk (outstanding notional amount) 7,601 7,435 6,603 5,341 4,283 3,131 818 For Barclays Bank Group, there are 618 (2020: 586) interest rate risk fair value hedges with an average fixed rate of 1.1% (2020: 1.2%) across the relationships and 60 (2020: 70) inflation risk fair value hedges with an average rate of 0.59% (2020: 0.52%) across the relationships. Hedged items in cash flow hedges and hedges of net investments in foreign operations Barclays Bank Group Change in value of hedged item used as the basis for recognising ineffectiveness Balance in cash flow hedging reserve for continuing hedges Balance in currency translation reserve for continuing hedges Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied Balances remaining in currency translation reserve for which hedge accounting is no longer applied Hedging gains or losses recognised in other comprehensive income Hedge ineffectiveness recognised in the income statement a Description of hedge relationship and hedged risk £m £m £m £m £m £m £m 2021 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost 2,042 935 — (192) — 2,042 (211) Foreign exchange risk Loans and advances at amortised cost (88) (16) — — — (88) 1 Inflation risk Debt securities classified at amortised cost 252 204 — (12) — 252 (22) Total cash flow hedges 2,206 1,123 — (204) — 2,206 (232) Hedge of net investment in foreign operations USD foreign operations 143 — 1,184 — — 143 — EUR foreign operations (49) — (39) — — (49) — Other foreign operations (3) — 44 — 186 (3) — Total foreign operations 91 — 1,189 — 186 91 — 2020 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost (1,260) (758) — (780) — (1,260) 40 Foreign exchange risk Loans and advances at amortised cost (70) (15) — — — (70) — Inflation risk Debt securities classified at amortised cost (41) (65) — — — (41) 1 Total cash flow hedges (1,371) (838) — (780) — (1,371) 41 Hedge of net investment in foreign operations USD foreign operations (83) — 1,097 — — (83) — EUR foreign operations (2) — 16 — — (2) — Other foreign operations (9) — 55 — 162 (9) — Total foreign operations (94) — 1,168 — 162 (94) — Note a Hedge ineffectiveness is recognised in net interest income The following table shows the cash flow and net investment hedging instruments which are carried on the Barclays Bank Group’s balance sheet: Barclays Bank Group Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Cash flow Interest rate risk — — — 59,957 (2,253) 9,896 Foreign exchange risk 155 — — 1,000 89 — Inflation risk — (3) — 4,092 (274) — Total 155 (3) — 65,049 (2,438) 9,896 Net investment Foreign exchange risk 37 (4) (6,933) 9,356 (91) — As at 31 December 2020 Cash flow Interest rate risk 47 — — 42,520 1,300 27,160 Foreign exchange risk 67 — — 1,000 70 — Inflation risk 2 — — 2,798 42 0 Total 116 — — 46,318 1,412 27,160 Net investment Foreign exchange risk 25 — (4,832) 5,623 94 — For Barclays Bank Group, there is 1 (2020: 1) foreign exchange risk cash flow hedge with an average foreign exchange rate of JPY133.03: GBP 1 (2020: JPY133.03: GBP 1). The effect on the income statement and other comprehensive income of recycling amounts in respect of cash flow hedges and net investment hedges of foreign operations is set out in the following table: Barclays Bank Group 2021 2020 Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Description of hedge relationship and hedged risk £m £m £m £m Cash flow hedge of interest rate risk Recycled to net interest income 228 13 239 37 Cash flow hedge of foreign exchange risk Recycled to net interest income 87 — 55 — Hedge of net investment in foreign operations Recycled to other income — (28) — (4) A detailed reconciliation of the movements of the cash flow hedging reserve and the currency translation reserve is as follows: Barclays Bank Group 2021 2020 Cash flow hedging reserve Currency translation reserve Cash flow hedging reserve Currency translation reserve £m £m £m £m Balance on 1 January 1,181 2,736 388 3,383 Currency translation movements (6) (92) 50 (745) Hedging (losses)/gains for the year (2,206) (91) 1,316 94 Amounts reclassified in relation to cash flows affecting profit or loss (327) 28 (282) 4 Tax 740 — (291) — Balance on 31 December (618) 2,581 1,181 2,736 In 2020, amounts recycled from other comprehensive income £55m in respect of cash flow hedges of foreign exchange risk were presented within 'Hedging gains/(losses) for the year'. For 2021, the corresponding current year amounts of £87m were presented within 'Amounts reclassified in relation to cash flows affecting profit or loss'. |
Financial assets at fair valu_2
Financial assets at fair value through other comprehensive income | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through other comprehensive income [abstract] | |
Financial assets at fair value through other comprehensive income | Financial assets at fair value through other comprehensive income Accounting for financial assets at fair value through other comprehensive income (FVOCI) Financial assets that are debt instruments held in a business model that is achieved by both collecting contractual cash flows and selling and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at FVOCI. They are subsequently re-measured at fair value and changes therein (except for those relating to impairment, interest income and foreign currency exchange gains and losses) are recognised in other comprehensive income until the assets are sold. Interest (calculated using the effective interest method) is recognised in the income statement in net interest income (Note 3). Upon disposal, the cumulative gain or loss recognised in other comprehensive income is included in net investment income (Note 6). In determining whether the business model is achieved by both collecting contractual cash flows and selling financial assets, it is determined that both collecting contractual cash flows and selling financial assets are integral to achieving the objective of the business model. The Barclays Bank Group will consider past sales and expectations about future sales to establish if the business model is achieved. For equity securities that are not held for trading, the Barclays Bank Group may make an irrevocable election on initial recognition to present subsequent changes in the fair value of the instrument in other comprehensive income (except for dividend income which is recognised in profit or loss). Gains or losses on the de-recognition of these equity securities are not transferred to profit or loss. These assets are also not subject to the impairment requirements and therefore no amounts are recycled to the income statement. Where the Barclays Bank Group has not made the irrevocable election to present subsequent changes in the fair value of the instrument in other comprehensive income, equity securities are measured at fair value through profit or loss. Barclays Bank Group 2021 2020 £m £m Debt securities and other eligible bills 45,854 51,710 Equity securities 1 1 Loans and advances 53 191 Financial assets at fair value through other comprehensive income 45,908 51,902 Loans and advances and deposits at amortised cost Barclays Bank Group 2021 2020 As at 31 December £m £m Loans and advances at amortised cost to banks 8,750 9,003 Loans and advances at amortised cost to customers 117,014 110,101 Debt securities at amortised cost 19,495 15,163 Total loans and advances at amortised cost 145,259 134,267 Deposits at amortised cost from banks 17,911 17,348 Deposits at amortised cost from customers 244,917 227,348 Total deposits at amortised cost 262,828 244,696 |
Financial liabilities designate
Financial liabilities designated at fair value | 12 Months Ended |
Dec. 31, 2021 | |
Designated financial liabilities at fair value through profit or loss [abstract] | |
Financial liabilities designated at fair value | Financial liabilities designated at fair value Accounting for liabilities designated at fair value through profit and loss In accordance with IFRS 9, financial liabilities may be designated at fair value, with gains and losses taken to the income statement within net trading income (Note 5) and net investment income (Note 6). Movements in own credit are reported through other comprehensive income, unless the effects of changes in the liability's credit risk would create or enlarge an accounting mismatch in profit and loss. In these scenarios, all gains and losses on that liability (including the effects of changes in the credit risk of the liability) are presented in profit and loss. On derecognition of the financial liability no amount relating to own credit risk are recycled to the income statement. The Barclays Bank Group has the ability to make the fair value designation when holding the instruments at fair value reduces an accounting mismatch (caused by an offsetting liability or asset being held at fair value), or is managed by the Barclays Bank Group on the basis of its fair value, or includes terms that have substantive derivative characteristics (Note 13). The details on how the fair value amounts are arrived at for financial liabilities designated at fair value are described in Note 16. Barclays Bank Group 2021 2020 Fair value Contractual Fair value Contractual £m £m £m £m Debt securities 53,164 61,333 50,216 57,650 Deposits 29,409 29,836 21,718 22,120 Repurchase agreements and other similar secured borrowing 168,075 168,144 177,455 177,513 Subordinated debt a 483 613 — — Other financial liabilities — — 237 237 Financial liabilities designated at fair value 251,131 259,926 249,626 257,520 The cumulative own credit net loss recognised for Barclays Bank Group is £960m (2020: £954m). Note a. Subordinated debt measured at fair value (2020: £221m) was previously disclosed in Note 26 Subordinated Liabilities. For the current year, it is disclosed within Financial Liabilities designated at fair value to better reflect that it is accounted for at fair value. Loans and advances and deposits at amortised cost Barclays Bank Group 2021 2020 As at 31 December £m £m Loans and advances at amortised cost to banks 8,750 9,003 Loans and advances at amortised cost to customers 117,014 110,101 Debt securities at amortised cost 19,495 15,163 Total loans and advances at amortised cost 145,259 134,267 Deposits at amortised cost from banks 17,911 17,348 Deposits at amortised cost from customers 244,917 227,348 Total deposits at amortised cost 262,828 244,696 |
Fair value of financial instrum
Fair value of financial instruments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [abstract] | |
Fair value of financial instruments | Fair value of financial instruments Accounting for financial assets and liabilities – fair values Financial instruments that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. All financial instruments are initially recognised at fair value on the date of initial recognition (including transaction costs, other than financial instruments held at fair value through profit or loss) and depending on the subsequent classification of the financial asset or liability, may continue to be held at fair value either through profit or loss or other comprehensive income. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Wherever possible, fair value is determined by reference to a quoted market price for that instrument. For many of the Barclays Bank Group’s financial assets and liabilities, especially derivatives, quoted prices are not available and valuation models are used to estimate fair value. The models calculate the expected cash flows under the terms of each specific contract and then discount these values back to a present value. These models use as their basis independently sourced market inputs including, for example, interest rate yield curves, equities and commodities prices, option volatilities and currency rates. For financial liabilities measured at fair value, the carrying amount reflects the effect on fair value of changes in own credit spreads derived from observable market data such as in primary issuance and redemption activity for structured notes. On initial recognition, it is presumed that the transaction price is the fair value unless there is observable information available in an active market to the contrary. The best evidence of an instrument’s fair value on initial recognition is typically the transaction price. However, if fair value can be evidenced by comparison with other observable current market transactions in the same instrument, or is based on a valuation technique whose inputs include only data from observable markets, then the instrument should be recognised at the fair value derived from such observable market data. For valuations that have made use of unobservable inputs, the difference between the model valuation and the initial transaction price (Day One profit) is recognised in profit or loss either: on a straight-line basis over the term of the transaction; or over the period until all model inputs will become observable where appropriate; or released in full when previously unobservable inputs become observable. Various factors influence the availability of observable inputs and these may vary from product to product and change over time. Factors include the depth of activity in the relevant market, the type of product, whether the product is new and not widely traded in the marketplace, the maturity of market modelling and the nature of the transaction (bespoke or generic). To the extent that valuation is based on models or inputs that are not observable in the market, the determination of fair value can be more subjective, dependent on the significance of the unobservable input to the overall valuation. Unobservable inputs are determined based on the best information available, for example by reference to similar assets, similar maturities or other analytical techniques. The sensitivity of valuations used in the financial statements to possible changes in significant unobservable inputs is shown on page 153. Critical accounting estimates and judgements The valuation of financial instruments often involves a significant degree of judgement and complexity, in particular where valuation models make use of unobservable inputs (‘Level 3’ assets and liabilities). This note provides information on these instruments, including the related unrealised gains and losses recognised in the period, a description of significant valuation techniques and unobservable inputs, and a sensitivity analysis. Valuation IFRS 13 Fair value measurement requires an entity to classify its assets and liabilities according to a hierarchy that reflects the observability of significant market inputs. The three levels of the fair value hierarchy are defined below. Quoted market prices – Level 1 Assets and liabilities are classified as Level 1 if their value is observable in an active market. Such instruments are valued by reference to unadjusted quoted prices for identical assets or liabilities in active markets where the quoted price is readily available, and the price represents actual and regularly occurring market transactions. An active market is one in which transactions occur with sufficient volume and frequency to provide pricing information on an ongoing basis. Valuation technique using observable inputs – Level 2 Assets and liabilities classified as Level 2 have been valued using models whose inputs are observable either directly or indirectly. Valuations based on observable inputs include assets and liabilities such as swaps and forwards which are valued using market standard pricing techniques, and options that are commonly traded in markets where all the inputs to the market standard pricing models are observable. Valuation technique using significant unobservable inputs – Level 3 Assets and liabilities are classified as Level 3 if their valuation incorporates significant inputs that are not based on observable market data (unobservable inputs). A valuation input is considered observable if it can be directly observed from transactions in an active market, or if there is compelling external evidence demonstrating an executable exit price. Unobservable input levels are generally determined via reference to observable inputs, historical observations or using other analytical techniques. The following table shows Barclays Bank Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Assets and liabilities held at fair value 2021 2020 Valuation technique using Valuation technique using Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Barclays Bank Group £m £m £m £m £m £m £m £m Trading portfolio assets 80,836 63,754 2,281 146,871 60,619 65,182 1,863 127,664 Financial assets at fair value through the income statement 4,953 177,194 6,079 188,226 4,439 162,930 4,392 171,761 Derivative financial assets 6,150 252,131 4,010 262,291 9,154 289,071 4,468 302,693 Financial assets at fair value through other comprehensive income 16,070 29,800 38 45,908 12,150 39,599 153 51,902 Investment property — — 7 7 — — 10 10 Total assets 108,009 522,879 12,415 643,303 86,362 556,782 10,886 654,030 Trading portfolio liabilities (26,701) (26,563) (27) (53,291) (23,331) (22,780) (28) (46,139) Financial liabilities designated at fair value (174) (250,553) (404) (251,131) (159) (249,126) (341) (249,626) Derivative financial liabilities (6,571) (243,893) (6,059) (256,523) (8,762) (285,579) (6,239) (300,580) Total liabilities (33,446) (521,009) (6,490) (560,945) (32,252) (557,485) (6,608) (596,345) The following table shows Barclays Bank Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: Level 3 Assets and liabilities held at fair value by product type 2021 2020 Assets Liabilities Assets Liabilities Barclays Bank Group £m £m £m £m Interest rate derivatives 1,091 (1,351) 1,613 (1,615) Foreign exchange derivatives 376 (374) 144 (143) Credit derivatives 323 (709) 196 (351) Equity derivatives 2,220 (3,625) 2,497 (4,112) Corporate debt 1,205 (21) 698 (3) Reverse repurchase and repurchase agreements 13 (172) — (174) Non-asset backed loans 3,743 — 3,093 — Asset backed securities 558 — 767 (24) Equity cash products 393 — 542 — Private equity investments 148 — 84 — Other a 2,345 (238) 1,252 (186) Total 12,415 (6,490) 10,886 (6,608) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. Valuation techniques and sensitivity analysis Sensitivity analysis is performed on products with significant unobservable inputs (Level 3) to generate a range of reasonably possible alternative valuations. The sensitivity methodologies applied take account of nature of the valuation techniques used, as well as availability and reliability of observable proxy and historical data and impact of using alternative models. Sensitivities are dynamically calculated on a monthly basis. The calculation is based on range or spread data of a reliable reference source or a scenario based on relevant market analysis alongside the impact of using alternative models. Sensitivities are calculated without reflecting the impact of any diversification in the portfolio. The valuation techniques used, observability and sensitivity analysis for material products within Level 3, are described below. Interest rate derivatives Description: Derivatives linked to interest rates or inflation indices. The category includes futures, interest rate and inflation swaps, swaptions, caps, floors, inflation options, balance guaranteed swaps and other exotic interest rate derivatives. Valuation: Interest rate and inflation derivatives are generally valued using curves of forward rates constructed from market data to project and discount the expected future cash flows of trades. Instruments with optionality are valued using volatilities implied from market inputs, and use industry standard or bespoke models depending on the product type. Observability: In general, inputs are considered observable up to liquid maturities which are determined separately for each input and underlying. Unobservable inputs are generally set by referencing liquid market instruments and applying extrapolation techniques or inferred via another reasonable method. Foreign exchange derivatives Description: Derivatives linked to the foreign exchange (FX) market. The category includes FX forward contracts, FX swaps and FX options. The majority are traded as over the counter (OTC) derivatives. Valuation: FX derivatives are valued using industry standard and bespoke models depending on the product type. Valuation inputs include FX rates, interest rates, FX volatilities, interest rate volatilities, FX interest rate correlations and others as appropriate. Observability: FX correlations, forwards and volatilities are generally observable up to liquid maturities which are determined separately for each input and underlying. Unobservable inputs are set by referencing liquid market instruments and applying extrapolation techniques, or inferred via another reasonable method. Credit derivatives Description: Derivatives linked to the credit spread of a referenced entity, index or basket of referenced entities or a pool of referenced assets (e.g. a securitised product). The category includes single name and index credit default swaps (CDS) and total return swaps (TRS). Valuation: CDS are valued on industry standard models using curves of credit spreads as the principal input. Credit spreads are observed directly from broker data, third party vendors or priced to proxies. Observability: CDS contracts referencing entities that are actively traded are generally considered observable. Other valuation inputs are considered observable if products with significant sensitivity to the inputs are actively traded in a liquid market. Unobservable valuation inputs are generally determined with reference to recent transactions or inferred from observable trades of the same issuer or similar entities. Equity derivatives Description: Exchange traded or OTC derivatives linked to equity indices and single names. The category includes vanilla and exotic equity products. Valuation: Equity derivatives are valued using industry standard models. Valuation inputs include stock prices, dividends, volatilities, interest rates, equity repurchase curves and, for multi-asset products, correlations. Observability: In general, valuation inputs are observable up to liquid maturities which are determined separately for each input and underlying. Unobservable inputs are set by referencing liquid market instruments and applying extrapolation techniques, or inferred via another reasonable method. Corporate debt Description: Primarily corporate bonds. Valuation: Corporate bonds are valued using observable market prices sourced from broker quotes, inter-dealer prices or other reliable pricing sources. Observability: Prices for actively traded bonds are considered observable. Unobservable bonds prices are generally determined by reference to bond yields or CDS spreads for actively traded instruments issued by or referencing the same (or a similar) issuer. Reverse repurchase and repurchase agreements Description: Includes securities purchased under resale agreements, securities sold under repurchase agreements, and other similar secured lending agreements. The agreements are primarily short-term in nature. Valuation: Repurchase and reverse repurchase agreements are generally valued by discounting the expected future cash flows using industry standard models that incorporate market interest rates and repurchase rates, based on the specific details of the transaction. Observability: Inputs are deemed observable up to liquid maturities, and are determined based on the specific features of the transaction. Unobservable inputs are generally set by referencing liquid market instruments and applying extrapolation techniques, or inferred via another reasonable method. Non-asset backed loans Description: Largely made up of fixed rate loans. Valuation: Fixed rate loans are valued using models that discount expected future cash flows based on interest rates and loan spreads. Observability: Within this loan population, the loan spread is generally unobservable. Unobservable loan spreads are determined by incorporating funding costs, the level of comparable assets such as gilts, issuer credit quality and other factors. Asset backed securities Description: Securities that are linked to the cash flows of a pool of referenced assets via securitisation. The category includes residential mortgage backed securities, commercial mortgage backed securities, CDOs, collateralised loan obligations (CLOs) and other asset backed securities. Valuation: Where available, valuations are based on observable market prices sourced from broker quotes and inter-dealer prices. Otherwise, valuations are determined using industry standard discounted cash flow analysis that calculates the fair value based on valuation inputs such as constant default rate, conditional prepayment rate, loss given default and yield. These inputs are determined by reference to a number of sources including proxying to observed transactions, market indices or market research, and by assessing underlying collateral performance. Proxying to observed transactions, indices or research requires an assessment and comparison of the relevant securities’ underlying attributes including collateral, tranche, vintage, underlying asset composition (historical losses, borrower characteristics and loan attributes such as loan to value ratio and geographic concentration) and credit ratings (original and current). Observability: Where an asset backed product does not have an observable market price and the valuation is determined using a discounted cash flow analysis, the instrument is considered unobservable. Equity cash products Description: Includes listed equities, Exchange Traded Funds (ETF) and preference shares. Valuation: Valuation of equity cash products is primarily determined through market observable prices. Observability: Prices for actively traded equity cash products are considered observable. Unobservable equity prices are generally determined by reference to actively traded instruments that are similar in nature, or inferred via another reasonable method. Private equity investments Description: Includes investments in equity holdings in operating companies not quoted on a public exchange. Valuation: Private equity investments are valued in accordance with the ‘International Private Equity and Venture Capital Valuation Guidelines’ which require the use of a number of individual pricing benchmarks such as the prices of recent transactions in the same or similar entities, discounted cash flow analysis and comparison with the earnings multiples of listed companies. While the valuation of unquoted equity instruments is subjective by nature, the relevant methodologies are commonly applied by other market participants and have been consistently applied over time. Observability: Inputs are considered observable if there is active trading in a liquid market of products with significant sensitivity to the inputs. Unobservable inputs include earnings estimates, multiples of comparative companies, marketability discounts and discount rates. Other Description: Other includes commercial real estate loans, funds and fund-linked products, asset backed loans, issued debt, Government sponsored debt, commodity derivatives and investment property. Assets and liabilities reclassified between Level 1 and Level 2 During the year, there were no material transfers between Level 1 to Level 2 (2020: there were no material transfers between Level 1 and Level 2). Level 3 movement analysis The following table summarises the movements in the Level 3 balances during the year. Transfers have been reflected as if they had taken place at the beginning of the year. Assets and liabilities included in disposal groups classified as held for sale and measured at fair value less cost to sell are not included as these are measured at fair value on a non-recurring basis. Asset and liability transfers between Level 2 and Level 3 are primarily due to 1) an increase or decrease in observable market activity related to an input or 2) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Analysis of movements in Level 3 assets and liabilities As at 1 January 2021 Total gains and (losses) in the period recognised in the income statement Total gains or losses recognised in OCI Transfers As at 31 December 2021 Purchases Sales Issues Settlements Trading income Other income In Out Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 310 (123) — (12) 38 — — 41 (16) 389 Non-asset backed loans 709 1,580 (1,409) — (85) (1) — — 45 (81) 758 Asset backed securities 686 209 (370) — — (69) — — 114 (116) 454 Equity cash products 214 45 (53) — 4 23 — — 80 (10) 303 Other 103 117 (2) — (61) (3) — — 248 (25) 377 Trading portfolio assets 1,863 2,261 (1,957) — (154) (12) — — 528 (248) 2,281 Non-asset backed loans 2,280 1,379 (306) — (248) (59) (174) — 113 — 2,985 Equity cash products 320 3 (247) — — — 7 — 1 — 84 Private equity investments 88 68 (7) — (8) — 10 — 35 (38) 148 Other 1,704 11,253 (9,981) — (184) 2 21 — 48 (1) 2,862 Financial assets at fair value through the income statement 4,392 12,703 (10,541) — (440) (57) (136) — 197 (39) 6,079 Non-asset backed loans 106 — — — — — — — — (106) — Asset backed securities 47 — — — (7) — — (2) — — 38 Financial assets at fair value through other comprehensive income 153 — — — (7) — — (2) — (106) 38 Investment property 10 — (2) — — — (1) — — — 7 Trading portfolio liabilities (28) (5) 23 — — (6) — — (12) 1 (27) Financial liabilities designated at fair value (341) (4) — (101) 66 21 — — (68) 23 (404) Interest rate derivatives (2) 20 — — 105 (255) — — 90 (218) (260) Foreign exchange derivatives 1 — — — 40 (2) — — 10 (47) 2 Credit derivatives (155) (239) 9 — (45) 34 — — 10 — (386) Equity derivatives (1,615) 90 (1) — (15) (3) — — (3) 142 (1,405) Net derivative financial instruments a (1,771) (129) 8 — 85 (226) — — 107 (123) (2,049) Total 4,278 14,826 (12,469) (101) (450) (280) (137) (2) 752 (492) 5,925 Analysis of movements in Level 3 assets and liabilities As at 1 January 2020 Total gains and losses in the period recognised in the income statement Total gains or losses recognised in OCI Transfers As at 31 December 2020 Purchases Sales Issues Settlements Trading income Other income In Out Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m Corporate debt 120 77 (6) — — (35) — — 12 (17) 151 Non-asset backed loans 974 1,955 (2,182) — (12) (10) — — 39 (55) 709 Asset backed securities 656 458 (428) — (40) (25) — — 99 (34) 686 Equity cash products 392 5 (149) — — (41) — — 11 (4) 214 Other 122 — — — — (21) — — 2 — 103 Trading portfolio assets 2,264 2,495 (2,765) — (52) (132) — — 163 (110) 1,863 Non-asset backed loans 1,964 1,102 (283) — (293) 142 — — — (352) 2,280 Equity cash products 835 9 (404) — — (93) (36) — 9 — 320 Private equity investments 113 2 (20) — (1) — (9) — 15 (12) 88 Other 1,250 3,716 (3,606) — (26) 32 (48) — 386 — 1,704 Financial assets at fair value through the income statement 4,162 4,829 (4,313) — (320) 81 (93) — 410 (364) 4,392 Non-asset backed loans 343 — — — (237) — — — — — 106 Asset backed securities 86 — (35) — — — — (4) — — 47 Financial assets at fair value through other comprehensive income 429 — (35) — (237) — — (4) — — 153 Investment property 13 — (2) — — — (1) — — — 10 Trading portfolio liabilities — (27) — — — (1) — — — — (28) Financial liabilities designated at fair value (343) — 1 (21) 1 21 — — (38) 38 (341) Interest rate derivatives (206) 17 (12) — 85 109 — — (18) 23 (2) Foreign exchange derivatives (7) — — — 21 (16) — — (19) 22 1 Credit derivatives 198 (125) 24 — (371) 24 — — (21) 116 (155) Equity derivatives (820) (699) (43) — 105 (101) — — (13) (44) (1,615) Net derivative financial instruments a (835) (807) (31) — (160) 16 — — (71) 117 (1,771) Total 5,690 6,490 (7,145) (21) (768) (15) (94) (4) 464 (319) 4,278 Note a The derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets are £4,010m (2020: £4,468m) and derivative financial liabilities are £6,059m (2020: £6,239m). The following tables disclose the unrealised gains and losses recognised in the year arising on Level 3 financial assets and liabilities held at year end. Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at year end 2021 2020 Income statement Other compre- Income statement Other Barclays Bank Group Trading income Other income Total Trading income Other income Total As at 31 December £m £m £m £m £m £m £m £m Trading portfolio assets (67) — — (67) (114) — — (114) Financial assets at fair value through the income statement (53) 22 — (31) 115 (89) — 26 Fair value through other comprehensive income — — — — — — (1) (1) Investment property — — — — — (1) — (1) Trading portfolio liabilities (5) — — (5) — — — — Financial liabilities designated at fair value 16 (1) — 15 20 (1) — 19 Net derivative financial instruments (196) — — (196) (91) — — (91) Total (305) 21 — (284) (70) (91) (1) (162) Significant unobservable inputs The following table discloses the valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 along with the range of values used for those significant unobservable inputs: Valuation technique(s) a Significant unobservable inputs 2021 2020 Range Range Barclays Bank Group Min Max Min Max Units b Derivative financial instruments c Interest rate derivatives Discounted cash flows Inflation forwards — 3 1 3 % Credit spread 9 1,848 17 1,831 bps Correlation Model Inflation forwards (20) (13) (20) (13) % Comparable pricing Price — 38 — 84 points Option model Inflation volatility 31 130 31 227 bps vol Interest rate volatility 5 600 6 489 bps vol FX - IR correlation (20) 78 (30) 78 % IR - IR correlation (100) 99 (20) 99 % Credit derivatives Discounted cash flows Credit spread 2 2,925 5 480 bps Comparable pricing Price — — — 100 points Equity derivatives Option model Equity volatility 2 108 1 110 % Equity - equity correlation 10 100 (45) 100 % Discounted cash flow Discounted margin (129) 93 (225) 3,000 bps Foreign exchange derivatives Option Model Option Volatility — 100 — 30 points Non-derivative financial instruments Non-asset backed loans Discounted cash flows Loan spread 31 811 32 477 bps Credit spread 200 300 200 300 bps Price — 112 — 104 points Yield 3 10 5 8 % Comparable pricing Price — 145 — 137 points Asset backed securities Comparable pricing Price — 120 — 112 points Corporate debt Comparable pricing Price — 284 — 127 points Discounted cash flows Loan spread 229 854 — — bps Price — 100 — 104 points Commercial Real Estate loans Discounted cash flows Credit spread 68 543 146 483 bps Equity cash products Discounted cash flows Discount margin 26 34 49 49 bps Notes a A range has not been provided for Net Asset Value as there would be a wide range reflecting the diverse nature of the positions. b The units used to disclose ranges for significant unobservable inputs are percentages, points and basis points. Points are a percentage of par; for example, 100 points equals 100% of par. A basis point equals 1/100th of 1%; for example, 150 basis points equals 1.5%. c Certain derivative instruments are classified as Level 3 due to a significant unobservable credit spread input into the calculation of the Credit Valuation Adjustment for the instruments. The range of significant unobservable credit spreads is between 32bps- 1,848bps (2020: 17bps-1,831bps). The following section describes the significant unobservable inputs identified in the table above, and the sensitivity of fair value measurement of the instruments categorised as Level 3 assets or liabilities to increases in significant unobservable inputs. Where sensitivities are described, the inverse relationship will also generally apply. Where reliable interrelationships can be identified between significant unobservable inputs used in fair value measurement, a description of those interrelationships is included below. Forwards A price or rate that is applicable to a financial transaction that will take place in the future. In general, a significant increase in a forward in isolation will result in a fair value increase for the contracted receiver of the underlying (currency, bond, commodity, etc.), but the sensitivity is dependent on the specific terms of the instrument. Credit spread Credit spreads typically represent the difference in yield between an instrument and a benchmark security or reference rate. Credit spreads reflect the additional yield that a market participant demands for taking on exposure to the credit risk of an instrument and form part of the yield used in a discounted cash flow calculation. In general, a significant increase in credit spread in isolation will result in a movement in a fair value decrease for a cash asset. For a derivative instrument, a significant increase in credit spread in isolation can result in a fair value increase or decrease depending on the specific terms of the instrument. Volatility Volatility is a measure of the variability or uncertainty in return for a given derivative underlying. It is an estimate of how much a particular underlying instrument input or index will change in value over time. In general, volatilities are implied from observed option prices. For unobservable options the implied volatility may reflect additional assumptions about the nature of the underlying risk, and the strike/maturity profile of a specific contract. In general a significant increase in volatility in isolation will result in a fair value increase for the holder of a simple option, but the sensitivity is dependent on the specific terms of the instrument. There may be interrelationships between unobservable volatilities and other unobservable inputs (e.g. when equity prices fall, implied equity volatilities generally rise) but these are generally specific to individual markets and may vary over time. Correlation Correlation is a measure of the relationship between the movements of two variables. Correlation can be a significant input into valuation of derivative contracts with more than one underlying instrument. Credit correlation generally refers to the correlation between default processes for the separate names that make up the reference pool of a CDO structure. A significant increase in correlation in isolation can result in a fair value increase or decrease depending on the specific terms of the instrument. Comparable price Comparable instrument prices are used in valuation by calculating an implied yield (or spread over a liquid benchmark) from the price of a comparable observable instrument, then adjusting that yield (or spread) to account for relevant differences such as maturity or credit quality. Alternatively, a price-to-price basis can be assumed between the comparable and unobservable instruments in order to establish a value. In general, a significant increase in comparable price in isolation will result in an increase in the price of the unobservable instrument. For derivatives, a change in the comparable price in isolation can result in a fair value increase or decrease depending on the specific terms of the instrument. Loan spread Loan spreads typically represent the difference in yield between an instrument and a benchmark security or reference rate. Loan spreads typically reflect credit quality, the level of comparable assets such as gilts and other factors, and form part of the yield used in a discounted cash flow calculation. The ESHLA portfolio primarily consists of long-dated fixed rate loans extended to counterparties in the UK Education, Social Housing and Local Authority sectors. The loans are categorised as Level 3 in the fair value hierarchy due to their illiquid nature and the significance of unobservable loan spreads to the valuation. Valuation uncertainty arises from the long-dated nature of the portfolio, the lack of secondary market in the loans and the lack of observable loan spreads. The majority of ESHLA loans are to borrowers in heavily regulated sectors that are considered extremely low credit risk, and have a history of near zero defaults since inception. While the overall loan spread range is from 31bps to 601bps (2020: 32bps to 477bps), the vast majority of spreads are concentrated towards the bottom end of this range, with 99% (2020: 98%) of the loan notional being valued with spreads less than 200bps consistently for both years. In general, a significant increase in loan spreads in isolation will result in a fair value decrease for a loan. Sensitivity analysis of valuations using unobservable inputs 2021 2020 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity Barclays Bank Group £m £m £m £m £m £m £m £m Interest rate derivatives 51 — (79) — 82 — (123) — Foreign exchange derivatives 20 — (28) — 6 — (11) — Credit derivatives 112 — (103) — 55 — (44) — Equity derivatives 181 — (190) — 174 — (179) — Corporate debt 38 — (28) — 16 — (14) — Non asset backed loans 99 — (150) — 104 3 (190) (3) Equity cash products 25 — (42) — 158 — (141) — Private equity investments 10 — (11) — 15 — (15) — Other a 19 — (20) — 23 — (23) — Total 555 — (651) — 633 3 (740) (3) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. The effect of stressing unobservable inputs to a range of reasonably possible alternatives, alongside considering the impact of using alternative models, would be to increase fair values by up to £555m (2020: £636m) or to decrease fair values by up to £651m (2020: £743m) with substantially all the potential effect impacting profit and loss rather than reserves. Fair value adjustments Key balance sheet valuation adjustments are quantified below: 2021 2020 Barclays Bank Group £m £m Ex |
Offsetting financial assets and
Offsetting financial assets and financial liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Offsetting financial assets and financial liabilities | |
Offsetting of financial assets and financial liabilities | Offsetting financial assets and financial liabilities In accordance with IAS 32 Financial Instruments: Presentation , the Barclays Bank Group reports financial assets and financial liabilities on a net basis on the balance sheet only if there is a legally enforceable right to set-off the recognised amounts and there is intention to settle on a net basis, or to realise the asset and settle the liability simultaneously. The following table shows the impact of netting arrangements on: ▪ All financial assets and liabilities that are reported net on the balance sheet. ▪ All derivative financial instruments and reverse repurchase and repurchase agreements and other similar secured lending and borrowing agreements that are subject to enforceable master netting arrangements or similar agreements, but do not qualify for balance sheet netting. The ‘Net amounts’ presented in the table below are not intended to represent the Barclays Bank Group’s actual exposure to credit risk, as a variety of credit mitigation strategies are employed in addition to netting and collateral arrangements. Barclays Bank Group Amounts subject to enforceable netting arrangements Amounts not subject to enforceable netting arrangements c Balance sheet total d Effects of offsetting on-balance sheet Related amounts not offset Gross amounts Amounts offset a Net amounts reported on the balance sheet Financial instruments Financial collateral b Net amount As at 31 December 2021 £m £m £m £m £m £m £m £m Derivative financial assets 279,286 (24,137) 255,149 (202,347) (39,953) 12,849 7,142 262,291 Reverse repurchase agreements and other similar secured lending e 519,855 (375,376) 144,479 — (143,976) 503 3,884 148,363 Total assets 799,141 (399,513) 399,628 (202,347) (183,929) 13,352 11,026 410,654 Derivative financial liabilities (273,996) 23,606 (250,390) 202,347 34,151 (13,892) (6,133) (256,523) Repurchase agreements and other similar secured borrowing e (540,462) 375,376 (165,086) — 165,086 — (15,758) (180,844) Total liabilities (814,458) 398,982 (415,476) 202,347 199,237 (13,892) (21,891) (437,367) As at 31 December 2020 Derivative financial assets 342,896 (44,305) 298,591 (233,088) (47,820) 17,683 4,102 302,693 Reverse repurchase agreements and other similar secured lending e 448,377 (305,749) 142,628 — (142,244) 384 4,911 147,539 Total assets 791,273 (350,054) 441,219 (233,088) (190,064) 18,067 9,013 450,232 Derivative financial liabilities (333,748) 41,982 (291,766) 233,088 46,592 (12,086) (8,814) (300,580) Repurchase agreements and other similar secured borrowing e (475,616) 305,749 (169,867) — 169,867 — (18,031) (187,898) Total liabilities (809,364) 347,731 (461,633) 233,088 216,459 (12,086) (26,845) (488,478) Notes a Amounts offset for derivative financial assets additionally includes cash collateral netted of £3,815m (2020: £4,990m). Amounts offset for derivative financial liabilities additionally includes cash collateral netted of £4,346m (2020: £7,313m). Settlements assets and liabilities have been offset amounting to £22,837m (2020: £18,143m). b Financial collateral of £39,953m (2020: £47,820m) was received in respect of derivative assets, including £34,149m (2020: £43,164m) of cash collateral and £5,804m (2020: £4,656m) of non-cash collateral. Financial collateral of £34,151m (2020: £46,592m) was placed in respect of derivative liabilities, including £31,861m (2020: £42,518m) of cash collateral and £2,290m (2020: £4,074m) of non-cash collateral. The collateral amounts are limited to net balance sheet exposure so as to not include over-collateralisation. c This column includes contractual rights of set-off that are subject to uncertainty under the laws of the relevant jurisdiction. d The balance sheet total is the sum of ‘Net amounts reported on the balance sheet’ that are subject to enforceable netting arrangements and ‘Amounts not subject to enforceable netting arrangements’. e Reverse Repurchase agreements and other similar secured lending of £148,363m (2020: £147,539m) is split by fair value £145,186m (2020: £138,558m) and amortised cost £3,177m (2020: £8,981m). Repurchase agreements and other similar secured borrowing of £180,844m (2020: £187,898m) is split by fair value £168,075m (2020: £177,455m) and amortised cost £12,769m (2020: £10,443m). Derivative assets and liabilities The ‘Financial instruments’ column identifies financial assets and liabilities that are subject to set off under netting agreements, such as the ISDA Master Agreement or derivative exchange or clearing counterparty agreements, whereby all outstanding transactions with the same counterparty can be offset and close-out netting applied across all outstanding transactions covered by the agreements if an event of default or other predetermined events occur. Financial collateral refers to cash and non-cash collateral obtained, typically daily or weekly, to cover the net exposure between counterparties by enabling the collateral to be realised in an event of default or if other predetermined events occur. Reverse repurchase and repurchase agreements and other similar secured lending and borrowing The ‘Financial instruments’ column identifies financial assets and liabilities that are subject to set off under netting agreements, such as Global Master Repurchase Agreements and Global Master Securities Lending Agreements, whereby all outstanding transactions with the same counterparty can be offset and close-out netting applied across all outstanding transactions covered by the agreements if an event of default or other predetermined events occur. Financial collateral typically comprises highly liquid securities which are legally transferred and can be liquidated in the event of counterparty default. These offsetting collateral arrangements and other credit risk mitigation strategies used by the Barclays Bank Group are further explained in the Credit risk mitigation section on pages 41 and 42. |
Loans and advances and deposits
Loans and advances and deposits at amortised cost | 12 Months Ended |
Dec. 31, 2021 | |
Loans and advances and deposits at amortised cost | |
Loans and advances and deposits at amortised cost | 18 Loans and advances and deposits at amortised cost Accounting for loans and advances and deposits held at amortised cost Loans and advances to customers and banks, customer accounts, debt securities and most financial liabilities, are held at amortised cost. That is, the initial fair value (which is normally the amount advanced or borrowed) is adjusted for repayments and the amortisation of coupon, fees and expenses to represent the effective interest rate of the asset or liability. Balances deferred on-balance sheet as effective interest rate adjustments are amortised to interest income over the life of the financial instrument to which they relate. Financial assets that are held in a business model to collect the contractual cash flows and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at amortised cost. The carrying value of these financial assets at initial recognition includes any directly attributable transaction costs. Refer to Note 1 for details of ‘solely payments of principal and interest’. In determining whether the business model is a ‘hold to collect’ model, the objective of the business model must be to hold the financial asset to collect contractual cash flows rather than holding the financial asset for trading or short-term profit taking purposes. While the objective of the business model must be to hold the financial asset to collect contractual cash flows this does not mean the Barclays Bank Group is required to hold the financial assets until maturity. When determining if the business model objective is to collect contractual cash flows the Barclays Bank Group will consider past sales and expectations about future sales. Loans and advances and deposits at amortised cost Barclays Bank Group 2021 2020 As at 31 December £m £m Loans and advances at amortised cost to banks 8,750 9,003 Loans and advances at amortised cost to customers 117,014 110,101 Debt securities at amortised cost 19,495 15,163 Total loans and advances at amortised cost 145,259 134,267 Deposits at amortised cost from banks 17,911 17,348 Deposits at amortised cost from customers 244,917 227,348 Total deposits at amortised cost 262,828 244,696 |
Property, plant and equipment
Property, plant and equipment | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about property, plant and equipment [abstract] | |
Property, plant and equipment | Property, plant and equipment Accounting for property, plant and equipment The Barclays Bank Group applies IAS 16 Property Plant and Equipment and IAS 40 Investment Properties. Property, plant and equipment is stated at cost, which includes direct and incremental acquisition costs less accumulated depreciation and provisions for impairment, if required. Subsequent costs are capitalised if these result in enhancement of the asset. Depreciation is provided on the depreciable amount of items of property, plant and equipment on a straight-line basis over their estimated useful economic lives. Depreciation rates, methods and the residual values underlying the calculation of depreciation of items of property, plant and equipment are kept under review to take account of any change in circumstances. The Barclays Bank Group uses the following annual rates in calculating depreciation: Annual rates in calculating depreciation Depreciation rate Freehold land Not depreciated Freehold buildings and long-leasehold property (more than 50 years to run) 2%-3.3% Leasehold property over the remaining life of the lease (less than 50 years to run) Over the remaining life of the lease Costs of adaptation of freehold and leasehold property 6%-10% Equipment installed in freehold and leasehold property 6%-10% Computers and similar equipment 17%-33% Fixtures and fittings and other equipment 9%-20% Costs of adaptation and installed equipment are depreciated over the shorter of the life of the lease or the depreciation rates noted in the table above. Investment property The Barclays Bank Group initially recognises investment property at cost, and subsequently at fair value at each balance sheet date, reflecting market conditions at the reporting date. Gains and losses on remeasurement are included in the income statement. Barclays Bank Group Investment property Property Equipment Right of use assets a Total £m £m £m £m £m Cost As at 1 January 2021 10 1,619 987 688 3,304 Additions — 85 70 27 182 Disposals (2) (32) (12) (58) (104) Exchange and other movements (1) 30 13 58 100 As at 31 December 2021 7 1,702 1,058 715 3,482 Accumulated depreciation and impairment As at 1 January 2021 — (730) (821) (216) (1,767) Depreciation charge — (70) (55) (68) (193) Impairment charge b — (108) — (160) (268) Disposals — 27 10 9 46 Exchange and other movements — (39) (11) (2) (52) As at 31 December 2021 — (920) (877) (437) (2,234) Net book value 7 782 181 278 1,248 Cost As at 1 January 2020 13 1,635 1,080 621 3,349 Additions — 39 35 28 102 Disposals (1) (25) (97) (6) (129) Exchange and other movements (2) (30) (31) 45 (18) As at 31 December 2020 10 1,619 987 688 3,304 Accumulated depreciation and impairment As at 1 January 2020 — (697) (875) (146) (1,718) Depreciation charge — (72) (61) (77) (210) Impairment charge — — — (2) (2) Disposals — 22 93 1 116 Exchange and other movements — 17 22 8 47 As at 31 December 2020 — (730) (821) (216) (1,767) Net book value 10 889 166 472 1,537 Notes a Right of use (ROU) asset balances relate to Property Leases under IFRS 16. Refer to Note 20 for further details. b Impairment charge includes £266m related to structural cost action in relation to the real estate review. Property rentals of £6m (2020: £8m) have been included in other income within The Barclays Bank Group. The fair value of investment property is determined by reference to current market prices for similar properties, adjusted as necessary for condition and location, or by reference to recent transactions updated to reflect current economic conditions. Discounted cash flow techniques may be employed to calculate fair value where there have been no recent transactions, using current external market inputs such as market rents and interest rates. Valuations are carried out by management with the support of appropriately qualified independent valuers. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2021 | |
Leases | |
Leases | Leases Accounting for leases IFRS 16 applies to all leases with the exception of licenses of intellectual property, rights held by licensing agreement within the scope of IAS 38 Intangible Assets, service concession arrangements, leases of biological assets within the scope of IAS 41 Agriculture and leases of minerals, oil, natural gas and similar non-regenerative resources. IFRS 16 includes an accounting policy choice for a lessee to elect not to apply IFRS 16 to remaining assets within the scope of IAS 38 Intangible Assets which the Barclays Bank Group has decided to apply. When the Barclays Bank Group is the lessee, it is required to recognise both: ▪ a lease liability, measured at the present value of remaining cash flows on the lease; and ▪ a right of use (ROU) asset, measured at the amount of the initial measurement of the lease liability, plus any lease payments made prior to commencement date, initial direct costs, and estimated costs of restoring the underlying asset to the condition required by the lease, less any lease incentives received. Subsequently the lease liability will increase for the accrual of interest, resulting in a constant rate of return throughout the life of the lease, and reduce when payments are made. The right of use asset will amortise to the income statement over the life of the lease. The lease liability is remeasured when there is a change in the one of the following: ▪ future lease payments arising from a change in an index or rate; ▪ the Barclays Bank Group’s estimate of the amount expected to be payable under a residual value guarantee; or ▪ the Barclays Bank Group’s assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured a corresponding adjustment is made to the carrying amount of the ROU asset, or is recorded in the income statement if the carrying amount of the ROU asset has been reduced to nil. On the balance sheet, the ROU assets are included within property, plant and equipment and the lease liabilities are included within other liabilities. The Barclays Bank Group applies the recognition exemption in IFRS 16 for leases with a term not exceeding 12 months. For these leases the lease payments are recognised as an expense on a straight line basis over the lease term unless another systematic basis is more appropriate. When the Barclays Bank Group is the lessor, the lease must be classified as either a finance lease or an operating lease. A finance lease is a lease which confers substantially all the risks and rewards of the leased assets on the lessee. An operating lease is a lease where substantially all of the risks and rewards of the leased asset remain with the lessor. When the lease is deemed a finance lease, the leased asset is not held on the balance sheet; instead a finance lease receivable is recognised representing the minimum lease payments receivable under the terms of the lease, discounted at the rate of interest implicit in the lease. When the lease is deemed an operating lease, the lease income is recognised on a straight-line basis over the period of the lease unless another systematic basis is more appropriate. The Barclays Bank Group holds the leased assets on-balance sheet within property, plant and equipment. As a Lessor Finance lease receivables are included within loans and advances at amortised cost. During the previous year, Barclays Partner Finance sold the majority of its motor point of sale finance portfolio and the remaining balance was transferred to the Barclays Group. The Barclays Bank Group does not have any material operating leases as a lessor. Finance lease income Finance lease income is included within interest income. The following table shows amounts recognised in the income statement during the year. Barclays Bank Group 2021 2020 £m £m Finance income from net investment in lease — 10 Loss on sales — (27) As a Lessee The Barclays Bank Group leases various offices, branches and other premises under non-cancellable lease arrangements to meet its operational business requirements. In some instances, the Barclays Bank Group will sublease property to third parties when it is no longer needed to meet business requirements. Currently, the Barclays Bank Group does not have any material subleasing arrangements. ROU asset balances relate to property leases only. Refer to Note 19 for a breakdown of the carrying amount of ROU assets. The Barclays Bank Group has not recognised any expense related to short term leases during the current and previous year. The portfolio of short term leases to which the Barclays Bank Group is exposed at the end of the year is not dissimilar to the expenses recognised in the year. Lease liabilities Barclays Bank Group 2021 2020 £m £m As at 1 January 515 529 Interest expense 20 23 New leases 38 27 Disposals (45) (5) Cash payments (92) (114) Exchange and other movements 59 55 As at 31 December (see Note 22) 495 515 The below table sets out a maturity analysis of undiscounted lease liabilities, showing the lease payments to be paid after the reporting date. Undiscounted lease liabilities maturity analysis Barclays Bank Group 2021 2020 £m £m Not more than one year 81 91 One to two years 77 70 Two to three years 74 60 Three to four years 66 58 Four to five years 60 55 Five to ten years 210 227 Greater than ten years 30 68 Total undiscounted lease liabilities as at 31 December 598 629 In addition to the cash flows identified above, the Barclays Bank Group is exposed to: • Variable lease payments: This variability will typically arise from either inflation index instruments or market based pricing adjustments. Currently, the Barclays Bank Group has 47 leases (2020: 59 leases) out of the total 110 leases (2020: 121 leases) which have variable lease payment terms based on market based pricing adjustments. Of the gross cash flows identified above, £362m (2020: £121m) is attributable to leases with some degree of variability predominately linked to market based pricing adjustments. In 2021, the Barclays Bank Group recorded a gain on sale relating to a sale and leaseback transaction of the Monaco branch premises of £33m. The Barclays Bank Group does not have any restrictions or covenants imposed by the lessor on its property leases which restrict its businesses. |
Goodwill and intangible assets
Goodwill and intangible assets | 12 Months Ended |
Dec. 31, 2021 | |
Intangible assets and goodwill [abstract] | |
Goodwill and intangible assets | Goodwill and intangible assets Accounting for goodwill and intangible assets Goodwill The carrying value of goodwill is determined in accordance with IFRS 3 B usiness Combinations and IAS 36 Impairment of Assets. Goodwill arising on the acquisition of subsidiaries represents the excess of the fair value of the purchase consideration over the fair value of the Barclays Bank Group’s share of the assets acquired and the liabilities and contingent liabilities assumed on the date of the acquisition. Goodwill is reviewed annually for impairment, or more frequently when there are indications that impairment may have occurred. The test involves comparing the carrying value of the cash generating unit (CGU) including goodwill with the present value of the pre-tax cash flows, discounted at a rate of interest that reflects the inherent risks, of the CGU to which the goodwill relates, or the CGU's fair value if this is higher. Intangible assets Intangible assets other than goodwill are accounted for in accordance with IFRS 3 Business Combinations and IAS 38 Intangible Assets. Intangible assets are initially recognised when they are separable or arise from contractual or other legal rights, the cost can be measured reliably and, in the case of intangible assets not acquired in a business combination, where it is probable that future economic benefits attributable to the assets will flow from their use. For internally generated intangible assets, only costs incurred during the development phase are capitalised. Expenditure in the research phase is expensed when it is incurred. Intangible assets are stated at cost (which is, in the case of assets acquired in a business combination, the acquisition date fair value) less accumulated amortisation and provisions for impairment, if any, and are amortised over their useful lives in a manner that reflects the pattern to which they contribute to future cash flows, generally using the amortisation periods set out below: Annual rates in calculating amortisation Amortisation period Goodwill Not amortised Internally generated software a 12 months to 6 years Other software 12 months to 6 years Customer lists 12 months to 25 years Licences and other 12 months to 25 years Note a Exceptions to the above period relate to useful lives of certain core banking platforms that are assessed individually and, if appropriate, amortised over longer periods ranging from 10 years to 15 years. Intangible assets are reviewed for impairment when there are indications that impairment may have occurred. Intangible assets not yet available for use are reviewed annually for impairment. Intangible assets Goodwill Internally generated software Other software Customer lists Licences and other Total £m £m £m £m £m £m Barclays Bank Group Cost As at 1 January 2021 324 1,539 106 1,325 457 3,751 Additions a — 195 1 — 405 601 Disposals — (148) (12) (5) (2) (167) Exchange and other movements 2 (78) — 19 16 (41) As at 31 December 2021 326 1,508 95 1,339 876 4,144 Accumulated amortisation and impairment As at 1 January 2021 (68) (964) (55) (1,158) (352) (2,597) Disposals — 148 12 5 2 167 Amortisation charge — (126) (6) (36) (42) (210) Impairment charge — (12) — — — (12) Exchange and other movements — (12) (3) (18) (10) (43) As at 31 December 2021 (68) (966) (52) (1,207) (402) (2,695) Net book value 258 542 43 132 474 1,449 Note a. Additions in 'Licences and others' primarily relate to new and renewed long-term partnership agreements. Goodwill Internally generated software Other software Customer lists Licences and other Total £m £m £m £m £m £m Barclays Bank Group Cost As at 1 January 2020 406 1,430 81 1,371 458 3,746 Additions and disposals (77) 169 21 — 20 133 Exchange and other movements (5) (60) 4 (46) (21) (128) As at 31 December 2020 324 1,539 106 1,325 457 3,751 Accumulated amortisation and impairment As at 1 January 2020 (111) (870) (54) (1,159) (340) (2,534) Disposals 43 22 9 — 4 78 Amortisation charge — (132) (8) (40) (31) (211) Impairment charge — (18) — — — (18) Exchange and other movements — 34 (2) 41 15 88 As at 31 December 2020 (68) (964) (55) (1,158) (352) (2,597) Net book value 256 575 51 167 105 1,154 Goodwill Goodwill is allocated to business operations according to business segments as follows: Barclays Bank Group 2021 2020 £m £m Consumer, Cards and Payments 258 256 Total net book value of goodwill 258 256 2021 impairment review The 2021 impairment review was performed during Q4 2021. A detailed assessment has been performed, with the approach and results of this analysis set out below. Determining the carrying value of CGUs The carrying value for each CGU is the sum of the tangible equity, goodwill and intangible asset balances associated with that CGU. The Barclays Bank Group manages the assets and liabilities of its CGUs with reference to the tangible equity of the respective businesses. That tangible equity is derived from the level of risk weighted assets (RWAs) and capital required to be deployed in the CGU and therefore reflects its relative risk, as well as the level of capital that management considers a market participant would be required to hold and retain to support business growth. The goodwill held across the Barclays Bank Group has been allocated to the CGU where it originated, based upon historical records. The intangible asset balances are allocated to the CGUs based upon their expected usage of these assets. Cash flows The 5-year cash flows used in the calculation of value in use are based on the formally agreed medium term plans approved by the Board. These are prepared using macroeconomic assumptions which management considers reasonable and supportable, and reflect business agreed initiatives for the forecast period. Discount rates IAS 36 requires that the discount rate used in a value in use calculation reflects the pre-tax rate an investor would require if they were to choose an investment that would generate similar cash flows to those that the entity expects to generate from the asset. In determining the discount rate, management has identified the cost of equity associated with market participants that closely resemble the Barclays Bank Group's CGUs and adjusted them for tax to arrive at the pre-tax equivalent rate. A range of discount rates have been used across the CGUs ranging from 12.5% to 14.7% (2020: 12.0% to 16.3%). Terminal growth rate The terminal growth rate is used to estimate the effect of projecting cash flows to the end of an asset’s useful economic life. It is management’s judgement that the cash flows associated with the CGUs will grow in line with the major economies in which the Barclays Bank Group operate. The UK inflation rate is used as an approximation for the future growth rates. The terminal growth rate used is 2.0% (2020: 2.0%). Outcome of goodwill and intangibles review Based on management’s plans and assumptions the value in use exceeds the carrying value of the CGUs and no impairment has been indicated by the 2021 impairment review. Other intangible assets Determining the estimated useful lives of intangible assets (such as those arising from contractual relationships) requires an analysis of circumstances. The assessment of whether an asset is exhibiting indicators of impairment as well as the calculation of impairment, which requires the estimate of future cash flows and fair values less costs to sell, also requires the preparation of cash flow forecasts and fair values for assets that may not be regularly bought and sold. |
Other liabilities
Other liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Accruals and deferred income including contract liabilities [abstract] | |
Other liabilities | Other liabilities Barclays Bank Group 2021 2020 £m £m Accruals and deferred income 2,657 2,428 Other creditors 4,030 2,250 Items in the course of collection due to other banks 67 58 Lease liabilities (refer to Note 20) 495 515 Other liabilities 7,249 5,251 |
Provisions
Provisions | 12 Months Ended |
Dec. 31, 2021 | |
Provisions [abstract] | |
Provisions | Provisions Accounting for provisions The Barclays Bank Group applies IAS 37 Provisions, Contingent Liabilities and Contingent Assets in accounting for non-financial liabilities. Provisions are recognised for present obligations arising as consequences of past events where it is more likely than not that a transfer of economic benefit will be necessary to settle the obligation, which can be reliably estimated. Provision is made for the anticipated cost of restructuring, including redundancy costs, when an obligation exists; for example, when the Barclays Bank Group has a detailed formal plan for restructuring a business and has raised valid expectations in those affected by the restructuring by announcing its main features or starting to implement the plan. Critical accounting estimates and judgements The financial reporting of provisions involves a significant degree of judgement and is complex. Identifying whether a present obligation exists and estimating the probability, timing, nature and quantum of the outflows that may arise from past events requires judgements to be made based on the specific facts and circumstances relating to individual events and often requires specialist professional advice. When matters are at an early stage, accounting judgements and estimates can be difficult because of the high degree of uncertainty involved. Management continues to monitor matters as they develop to re-evaluate on an ongoing basis whether provisions should be recognised, however there can remain a wide range of possible outcomes and uncertainties, particularly in relation to legal, competition and regulatory matters, and as a result it is often not practicable to make meaningful estimates even when matters are at a more advanced stage. The complexity of such matters often requires the input of specialist professional advice in making assessments to produce estimates. Customer redress and legal, competition and regulatory matters are areas where a higher degree of professional judgement is required. The amount that is recognised as a provision can also be very sensitive to the assumptions made in calculating it. This gives rise to a large range of potential outcomes which require judgement in determining an appropriate provision level. See Note 25 for more detail of legal, competition and regulatory matters. Restated b Restated b Onerous contracts Redundancy and restructuring Undrawn contractually committed facilities and guarantees provided a Customer redress Legal, competition and regulatory matters Sundry provisions Total £m £m £m £m £m £m £m Barclays Bank Group As at 1 January 2021 6 44 769 44 222 123 1,208 Additions 1 55 129 235 54 28 502 Amounts utilised (2) (39) — (4) (45) (29) (119) Unused amounts reversed (3) (11) (386) (7) (18) (26) (451) Exchange and other movements — (3) (13) (2) (2) (10) (30) As at 31 December 2021 2 46 499 266 211 86 1,110 Note a Undrawn contractually committed facilities and guarantees provisions are accounted for under IFRS 9 Onerous contracts Onerous contract provisions comprise an estimate of the costs involved with fulfilling the terms and conditions of contracts net of any expected benefits to be received. Redundancy and restructuring These provisions comprise the estimated cost of restructuring, including redundancy costs where an obligation exists. Additions made during the year relate to formal restructuring plans and have either been utilised, or reversed where total costs are now expected to be lower than the original provision amount. Undrawn contractually committed facilities and guarantees Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure as ECL is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. For further information, refer to the Credit Risk section for loan commitments and financial guarantees on pages 54 to 56. Customer redress Customer redress provisions comprise the estimated cost of making redress payments to customers, clients and counterparties for losses or damages associated with inappropriate judgement in the execution of the Barclays Bank Group’s business activities. Provisions for other customer redress include £220m (2020: nil) in respect of the c.US$13bn over-issuance of structured notes by Barclays Bank PLC, which represents the best estimate as at 31 December 2021 of the rescission right investors had for these securities, see Restatement of financial statements (Note 1a) on page 118 for further details and Legal, competition and commitments (Note 25) for further details on provision dependencies and sensitivity. Legal, competition and regulatory matters The Barclays Bank Group is engaged in various legal proceedings, both in the UK and a number of other overseas jurisdictions, including the US. For further information in relation to legal proceedings and discussion of the associated uncertainties, please refer to Note 25. Sundry provisions This category includes provisions that do not fit into any of the other categories, such as fraud losses and dilapidation provisions. |
Contingent liabilities and comm
Contingent liabilities and commitments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | Contingent liabilities and commitments Accounting for contingent liabilities Contingent liabilities are possible obligations whose existence will be confirmed only by uncertain future events and present obligations where the transfer of economic resources is uncertain or cannot be reliably measured. Contingent liabilities are not recognised on the balance sheet but are disclosed unless the likelihood of an outflow of economic resources is remote. The following table summarises the nominal principal amount of contingent liabilities and commitments which are not recorded on-balance sheet: Barclays Bank Group 2021 2020 £m £m Guarantees and letters of credit pledged as collateral security 15,759 15,138 Performance guarantees, acceptances and endorsements 7,987 5,794 Total contingent liabilities and financial guarantees a 23,746 20,932 Of which: Financial guarantees carried at fair value 231 229 Documentary credits and other short-term trade related transactions 1,584 1,086 Standby facilities, credit lines and other commitments 282,867 263,936 Total commitments 284,451 265,022 Of which: Loan commitments carried at fair value 18,571 9,248 Note a. Barclays Bank Group has issued £1.7bn (2020: £2.6bn) of guarantees that have been provided to subsidiaries of Barclays PLC outside the Barclays Bank Group. These guarantees have not been reported in the prior periods and the comparatives have not been restated. Expected credit losses held against contingent liabilities and commitments equal £499m (2020: £769m) for Barclays Bank Group and are reported in Note 23. Further details on contingent liabilities relating to legal and competition and regulatory matters can be found in Note 25. |
Legal, competition and regulato
Legal, competition and regulatory matters | 12 Months Ended |
Dec. 31, 2021 | |
Legal proceedings provision [abstract] | |
Legal, competition and regulatory matters | Legal, competition and regulatory matters The Barclays Bank Group faces legal, competition and regulatory challenges, many of which are beyond our control. The extent of the impact of these matters cannot always be predicted but may materially impact our operations, financial results, condition and prospects. Matters arising from a set of similar circumstances can give rise to either a contingent liability or a provision, or both, depending on the relevant facts and circumstances. The recognition of provisions in relation to such matters involves critical accounting estimates and judgments in accordance with the relevant accounting policies applicable to Note 23, Provisions. We have not disclosed an estimate of the potential financial impact or effect on the Barclays Bank Group of contingent liabilities where it is not currently practicable to do so. Various matters detailed in this note seek damages of an unspecified amount. While certain matters specify the damages claimed, such claimed amounts do not necessarily reflect the Barclays Bank Group’s potential financial exposure in respect of those matters. Investigations into certain advisory services agreements FCA proceedings In 2008, Barclays Bank PLC and Qatar Holdings LLC entered into two advisory service agreements (the Agreements). The Financial Conduct Authority (FCA) conducted an investigation into whether the Agreements may have related to Barclays PLC’s capital raisings in June and November 2008 (the Capital Raisings) and therefore should have been disclosed in the announcements or public documents relating to the Capital Raisings. In 2013, the FCA issued warning notices (the Notices) finding that Barclays PLC and Barclays Bank PLC acted recklessly and in breach of certain disclosure-related listing rules, and that Barclays PLC was also in breach of Listing Principle 3. The financial penalty provided in the Notices is £50m. Barclays PLC and Barclays Bank PLC continue to contest the findings. Following the conclusion of the Serious Fraud Office (SFO) proceedings against certain former Barclays executives resulting in their acquittals, the FCA proceedings, which were stayed, have resumed and a hearing before the Regulatory Decisions Committee is scheduled for the first quarter of 2022. Investigations into LIBOR and other benchmarks and related civil actions Regulators and law enforcement agencies, including certain competition authorities, from a number of governments have conducted investigations relating to Barclays Bank PLC’s involvement in allegedly manipulating certain financial benchmarks, such as LIBOR. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Barclays Bank Group and other banks in relation to the alleged manipulation of LIBOR and/or other benchmarks. USD LIBOR civil actions The majority of the USD LIBOR cases, which have been filed in various US jurisdictions, have been consolidated for pre-trial purposes in the US District Court in the Southern District of New York (SDNY). The complaints are substantially similar and allege, among other things, that Barclays PLC, Barclays Bank PLC, Barclays Capital Inc. (BCI) and other financial institutions individually and collectively violated provisions of the US Sherman Antitrust Act (Antitrust Act), the US Commodity Exchange Act (CEA), the US Racketeer Influenced and Corrupt Organizations Act (RICO), the Securities Exchange Act of 1934 and various state laws by manipulating USD LIBOR rates. Putative class actions and individual actions seek unspecified damages with the exception of three lawsuits, in which the plaintiffs are seeking a combined total of approximately $100m in actual damages and additional punitive damages against all defendants, including Barclays Bank PLC. Some of the lawsuits also seek trebling of damages under the Antitrust Act and RICO. Barclays Bank PLC has previously settled certain claims. Two class action settlements where Barclays Bank PLC has respectively paid $7.1m and $20m have received final court approval. Barclays Bank PLC also settled a further matter for $7.5m. Sterling LIBOR civil actions In 2016, two putative class actions filed in the SDNY against Barclays Bank PLC, BCI and other Sterling LIBOR panel banks alleging, among other things, that the defendants manipulated the Sterling LIBOR rate in violation of the Antitrust Act, CEA and RICO, were consolidated. The defendants’ motion to dismiss the claims was granted in 2018. The plaintiffs have appealed the dismissal. Japanese Yen LIBOR civil actions In 2012, a putative class action was filed in the SDNY against Barclays Bank PLC and other Japanese Yen LIBOR panel banks by a lead plaintiff involved in exchange-traded derivatives and members of the Japanese Bankers Association’s Euroyen Tokyo Interbank Offered Rate (Euroyen TIBOR) panel. The complaint alleges, among other things, manipulation of the Euroyen TIBOR and Yen LIBOR rates and breaches of the CEA and the Antitrust Act. In 2014, the court dismissed the plaintiff’s antitrust claims, and, in 2020, the court dismissed the plaintiff’s remaining CEA claims. The plaintiff has appealed the lower court’s dismissal of such claims. In 2015, a second putative class action, making similar allegations to the above class action, was filed in the SDNY against Barclays PLC, Barclays Bank PLC and BCI. The plaintiffs filed an amended complaint in 2020. In 2021, the case was dismissed as against most defendants, including the Barclays entities. The plaintiffs and remaining defendants are seeking reconsideration of the decision. SIBOR/SOR civil action In 2016, a putative class action was filed in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants, alleging manipulation of the Singapore Interbank Offered Rate (SIBOR) and Singapore Swap Offer Rate (SOR). In 2018, the court dismissed all claims against Barclays PLC, Barclays Bank PLC and BCI. The plaintiffs’ appeal of the dismissal of their claims was granted in March 2021 and the matter has been remanded to the lower court for further proceedings. Defendants’ petition for US Supreme Court review was denied. Additionally, plaintiffs have filed an amended complaint, which defendants have moved to dismiss. ICE LIBOR civil actions In 2019, several putative class actions were filed in the SDNY against a panel of banks, including Barclays PLC, Barclays Bank PLC, BCI, other financial institution defendants and Intercontinental Exchange Inc. and certain of its affiliates (ICE), asserting antitrust claims that defendants manipulated USD LIBOR through defendants’ submissions to ICE. These actions have been consolidated. The defendants’ motion to dismiss was granted in 2020 and the plaintiffs appealed. In February 2022, the dismissal was affirmed on appeal. In August 2020, an ICE LIBOR-related action was filed by a group of individual plaintiffs in the US District Court for the Northern District of California on behalf of individual borrowers and consumers of loans and credit cards with variable interest rates linked to USD ICE LIBOR. Plaintiffs’ motions seeking, among other things, preliminary and permanent injunctions to enjoin the defendants from continuing to set LIBOR or enforce any financial instrument that relies in whole or in part on USD LIBOR were denied. The defendants have moved to dismiss the case. Non-US benchmarks civil actions Legal proceedings (which include the claims referred to below in ‘Local authority civil actions concerning LIBOR’) have been brought or threatened against Barclays Bank PLC (and, in certain cases, Barclays Bank UK PLC) and other banks in the UK in connection with alleged manipulation of LIBOR, EURIBOR and other benchmarks. Proceedings have also been brought in a number of other jurisdictions in Europe and Israel. Additional proceedings in other jurisdictions may be brought in the future. Credit Default Swap civil action A putative antitrust class action is pending in New Mexico federal court against Barclays Bank PLC, BCI, and various other financial institutions. The plaintiffs, the New Mexico State Investment Council and certain New Mexico pension funds, allege that the defendants conspired to manipulate the benchmark price used to value Credit Default Swap (CDS) contracts at settlement (i.e. the CDS final auction price). The plaintiffs allege violations of US antitrust laws and the CEA, and unjust enrichment under state law. Foreign Exchange investigations and related civil actions In 2015, the Barclays Bank Group reached settlements totalling approximately $2.38bn with various US federal and state authorities and the FCA in relation to investigations into certain sales and trading practices in the Foreign Exchange market. The European Commission announced two settlements in May 2019 and the Barclays Bank Group paid penalties totalling approximately €210m. In June 2019, the Swiss Competition Commission announced two settlements and the Barclays Bank Group paid penalties totalling approximately CHF27m. In December 2021, the European Commission announced a final settlement which required the Barclays Bank Group to pay penalties totalling approximately €54m, which amount has been provided for in previous periods. The financial impact of any ongoing matters is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Barclays Bank Group and other banks in relation to alleged manipulation of Foreign Exchange markets. FX opt out civil action In 2018, Barclays Bank PLC and BCI settled a consolidated action filed in the SDNY, alleging manipulation of Foreign Exchange markets (Consolidated FX Action), for a total amount of $384m. Also in 2018, a group of plaintiffs who opted out of the Consolidated FX Action filed a complaint in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants. Some of the plaintiff’s claims were dismissed in 2020. Retail basis civil action In 2015, a putative class action was filed against several international banks, including Barclays PLC and BCI, on behalf of a proposed class of individuals who exchanged currencies on a retail basis at bank branches (Retail Basis Claims). The SDNY has ruled that the Retail Basis Claims are not covered by the settlement agreement in the Consolidated FX Action. The Court subsequently dismissed all Retail Basis Claims against the Barclays Bank Group and all other defendants. The plaintiffs have filed an amended complaint. Non-US FX civil actions Legal proceedings have been brought or are threatened against Barclays PLC, Barclays Bank PLC, BCI and Barclays Execution Services Limited (BX) in connection with alleged manipulation of Foreign Exchange in the UK, a number of other jurisdictions in Europe, Israel, Brazil and Australia and additional proceedings may be brought in the future. These include two purported class actions filed against Barclays PLC, Barclays Bank PLC, BX, BCI and other financial institutions in the UK Competition Appeal Tribunal in 2019 following the settlements with the European Commission described above. Also in 2019, a separate claim was filed in the UK in the High Court of Justice (High Court), and subsequently transferred to the UK Competition Appeal Tribunal, by various banks and asset management firms against Barclays Bank PLC and other financial institutions alleging breaches of European and UK competition laws related to FX trading. Metals related civil actions A number of US civil complaints, each on behalf of a proposed class of plaintiffs, have been consolidated and transferred to the SDNY. The complaints allege that Barclays Bank PLC and other members of The London Gold Market Fixing Ltd. manipulated the prices of gold and gold derivative contracts in violation of the Antitrust Act and other federal laws. The parties have reached a joint settlement to resolve this matter for $50m, which is subject to court approval. The financial impact of Barclays’ share of the joint settlement is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. A separate US civil complaint by a proposed class of plaintiffs against a number of banks, including Barclays Bank PLC, BCI and BX, alleging manipulation of the price of silver in violation of the CEA, the Antitrust Act and state antitrust and consumer protection laws, has been dismissed as against the Barclays entities. The plaintiffs have the option to seek the court’s permission to appeal. Civil actions have also been filed in Canadian courts against Barclays PLC, Barclays Bank PLC, Barclays Capital Canada Inc. and BCI on behalf of proposed classes of plaintiffs alleging manipulation of gold and silver prices. US residential mortgage related civil actions There are various pending civil actions relating to US Residential Mortgage-Backed Securities (RMBS), including four actions arising from unresolved repurchase requests submitted by Trustees for certain RMBS, alleging breaches of various loan-level representations and warranties (R&Ws) made by Barclays Bank PLC and/or a subsidiary acquired in 2007. The unresolved repurchase requests had an original principal balance of approximately $2.1bn. The Trustees have also alleged that the relevant R&Ws may have been breached with respect to a greater (but unspecified) amount of loans than previously stated in the unresolved repurchase requests. These repurchase actions are ongoing. In one repurchase action, the New York Court of Appeals held that claims related to certain R&Ws are time-barred. Barclays Bank PLC has reached settlements to resolve two of the repurchase actions, subject to final court approval. Final court approval has been granted in relation to one of those matters and payment will be completed in the first quarter of 2022. The other matter is scheduled for a hearing in 2022 to seek approval of the settlement. The financial impact of the settlement is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. The remaining two repurchase actions are pending. In 2020, a civil litigation claim was filed in the New Mexico First Judicial District Court by the State of New Mexico against six banks, including BCI, on behalf of two New Mexico state pension funds and the New Mexico State Investment Council relating to legacy RMBS purchases. As to BCI, the complaint alleges that the funds purchased approximately $22m in RMBS underwritten by BCI. The parties have reached a joint settlement to resolve this matter for $32.5m. The financial impact of BCI’s share of the joint settlement is not material to the Barclays Bank Group’s operating results, cash flows or financial position. Government and agency securities civil actions Treasury auction securities civil actions Consolidated putative class action complaints filed in US federal court against Barclays Bank PLC, BCI and other financial institutions under the Antitrust Act and state common law allege that the defendants (i) conspired to manipulate the US Treasury securities market and/or (ii) conspired to prevent the creation of certain platforms by boycotting or threatening to boycott such trading platforms. The court dismissed the consolidated action in March 2021. The plaintiffs have filed an amended complaint, which the defendants have moved to dismiss. In addition, certain plaintiffs have filed a related, direct action against BCI and certain other financial institutions, alleging that defendants conspired to fix and manipulate the US Treasury securities market in violation of the Antitrust Act, the CEA and state common law. Supranational, Sovereign and Agency bonds civil actions Civil antitrust actions have been filed in the SDNY and Federal Court of Canada in Toronto against Barclays Bank PLC, BCI, BX, Barclays Capital Securities Limited and, with respect to the civil action filed in Canada only, Barclays Capital Canada Inc. and other financial institutions alleging that the defendants conspired to fix prices and restrain competition in the market for US dollar-denominated Supranational, Sovereign and Agency bonds. In one of the actions filed in the SDNY, the court granted the defendants’ motions to dismiss the plaintiffs’ complaint. The dismissal was affirmed on appeal and this matter is now concluded. The plaintiffs have voluntarily dismissed the other SDNY action. In the Federal Court of Canada action, the plaintiffs reached settlements with a small number of banks in 2020 (not including Barclays Capital Canada Inc.), but the plaintiffs have not commenced the class certification process and the action remains at an early stage. Variable Rate Demand Obligations civil actions Civil actions have been filed against Barclays Bank PLC and BCI and other financial institutions alleging the defendants conspired or colluded to artificially inflate interest rates set for Variable Rate Demand Obligations (VRDOs). VRDOs are municipal bonds with interest rates that reset on a periodic basis, most commonly weekly. Two actions in state court have been filed by private plaintiffs on behalf of the states of Illinois and California. Three putative class action complaints have been consolidated in the SDNY. In the consolidated SDNY class action, certain of the plaintiff’s claims were dismissed in November 2020 and defendants’ motion for partial dismissal of the amended consolidated complaint is pending. In the California action, the plaintiffs’ claims were dismissed in June 2021. The plaintiffs have appealed the dismissal. Government bond civil actions In a putative class action filed in the SDNY in 2019, plaintiffs alleged that BCI and certain other bond dealers conspired to fix the prices of US Government sponsored entity bonds in violation of US antitrust law. BCI agreed to a settlement of $87m, which received final court approval in 2020. Separately, various entities in Louisiana, including the Louisiana Attorney General and the City of Baton Rouge, commenced litigation against Barclays Bank PLC and other financial institutions making similar allegations as the SDNY class action plaintiffs. The parties have reached a settlement to resolve these matters. The financial impact of the settlement is not material to the Barclays Bank Group’s operating results, cash flows or financial position. In 2018, a separate putative class action against various financial institutions including Barclays PLC, Barclays Bank PLC, BCI, Barclays Bank Mexico, S.A., and certain other subsidiaries of the Barclays Bank Group was consolidated in the SDNY. The plaintiffs asserted antitrust and state law claims arising out of an alleged conspiracy to fix the prices of Mexican Government bonds. The Barclays entities have settled the claim for $5.7m, and the settlement has received final court approval. Odd-lot corporate bonds antitrust class action In 2020, BCI, together with other financial institutions, were named as defendants in a putative class action. The complaint alleges a conspiracy to boycott developing electronic trading platforms for odd-lots and price fixing. Plaintiffs demand unspecified money damages. The defendants’ motion to dismiss was granted in 2021. Plaintiffs have appealed the dismissal. Interest rate swap and credit default swap US civil actions Barclays PLC, Barclays Bank PLC and BCI, together with other financial institutions that act as market makers for interest rate swaps (IRS) are named as defendants in several antitrust class actions which were consolidated in the SDNY in 2016. The complaints allege the defendants conspired to prevent the development of exchanges for IRS and demand unspecified money damages. In 2018, trueEX LLC filed an antitrust class action in the SDNY against a number of financial institutions including Barclays PLC, Barclays Bank PLC and BCI based on similar allegations with respect to trueEX LLC’s development of an IRS platform. In 2017, Tera Group Inc. filed a separate civil antitrust action in the SDNY claiming that certain conduct alleged in the IRS cases also caused the plaintiff to suffer harm with respect to the Credit Default Swaps market. In 2018 and 2019, respectively, the court dismissed certain claims in both cases for unjust enrichment and tortious interference but denied motions to dismiss the federal and state antitrust claims, which remain pending. BDC Finance L.L.C. In 2008, BDC Finance L.L.C. (BDC) filed a complaint in the Supreme Court of the State of New York (NY Supreme Court), demanding damages of $298m, alleging that Barclays Bank PLC had breached a contract in connection with a portfolio of total return swaps governed by an ISDA Master Agreement (the Agreement). Following a trial, the court ruled in 2018 that Barclays Bank PLC was not a defaulting party, which was affirmed on appeal. In April 2021, the trial court entered judgement in favour of Barclays Bank PLC for $3.3m and as yet to be determined legal fees and costs. BDC appealed. In January 2022, the appellate court reversed the trial court’s summary judgment decision in favour of Barclays Bank PLC and remanded the case to the lower court for further proceedings. In 2011, BDC’s investment advisor, BDCM Fund Adviser, L.L.C. and its parent company, Black Diamond Capital Holdings, L.L.C. also sued Barclays Bank PLC and BCI in Connecticut State Court for unspecified damages allegedly resulting from Barclays Bank PLC’s conduct relating to the Agreement, asserting claims for violation of the Connecticut Unfair Trade Practices Act and tortious interference with business and prospective business relations. This case is currently stayed. Civil actions in respect of the US Anti-Terrorism Act There are a number of civil actions, on behalf of more than 4,000 plaintiffs, filed in US federal courts, in the US District Court in the Eastern District of New York (EDNY) and SDNY against Barclays Bank PLC and a number of other banks. The complaints generally allege that Barclays Bank PLC and those banks engaged in a conspiracy to facilitate US dollar-denominated transactions for the Iranian Government and various Iranian banks, which in turn funded acts of terrorism that injured or killed plaintiffs or plaintiffs’ family members. The plaintiffs seek to recover damages for pain, suffering and mental anguish under the provisions of the US Anti-Terrorism Act, which allow for the trebling of any proven damages. The court granted the defendants’ motions to dismiss three out of the six actions in the EDNY. Plaintiffs have appealed in one action. The remaining actions are stayed pending a decision on the appeal. Out of the two actions in the SDNY, the court also granted the defendants’ motion to dismiss the first action, which is stayed pending a decision on the EDNY appeal. The second SDNY action is stayed, pending any appeal on the dismissal of the first. Shareholder derivative action In November 2020, a purported Barclays shareholder filed a putative derivative action in New York state court against BCI and a number of current and former members of the Board of Directors of Barclays PLC and senior executives or employees of the Barclays Bank Group. The shareholder filed the claim on behalf of nominal defendant Barclays PLC, alleging that the individual defendants harmed the company through breaches of their duties, including under the Companies Act 2006. The plaintiff seeks damages on behalf of Barclays PLC for the losses that Barclays PLC allegedly suffered as a result of these alleged breaches. An amended complaint was filed in April 2021, which BCI and certain other defendants have moved to dismiss. Derivative transactions civil action In 2021, Vestia (a Dutch housing association) brought a claim against Barclays Bank PLC in the UK in the High Court in relation to a series of derivative transactions entered into with Barclays Bank PLC between 2008 and 2011, seeking damages of £329m. Barclays Bank PLC is defending the claim and has made a counterclaim. Timeshare loans, skilled person review and associated matters In August 2020, the FCA granted an application by Clydesdale Financial Services Limited (CFS), which trades as Barclays Partner Finance and houses Barclays’ point-of-sale finance business, for a validation order with respect to certain loans to customers brokered between April 2014 and April 2016 by Azure Services Limited (ASL), a timeshare operator, which did not, at the point of sale, hold the necessary broker licence. As a condition to the validation order, the FCA required CFS to undertake a skilled person review of the assessment of affordability processes for the loans brokered by ASL (ASL Loans) as well as CFS’ policies and procedures for assessing affordability and oversight of brokers more generally, and dictated a remediation methodology in the event that ASL Loans did not pass the affordability test. CFS has voluntarily agreed to remediate the ASL Loans, which is expected to amount to £37m, in accordance with the FCA’s methodology and the remediation exercise is at an advanced stage. The remaining scope of the skilled person review is complete. The skilled person made a number of observations, some of which were adverse, about both current and historic affordability practices as well as current oversight practices. CFS is not required to conduct a full back book review but, following a review of certain cohorts of loans to determine historic affordability and/or broker oversight practices that may have caused customer harm, where harm is identified, CFS’ intention is to remediate. Separately, and notwithstanding this, CFS decided in March 2022 to extend the proactive remediation of ASL Loans beyond those brokered between April 2014 to April 2016 to include the full portfolio of ASL Loans brokered between 2006 and 2018. As at 31 March 2022, a customer remediation provision of £181m has been recognised in relation to the remediation of the ASL Loans originated outside the April 2014 to April 2016 period. CFS continues to review complaints about other legacy partner finance loans, however, it is not currently possible to predict the outcome of this review or the financial impact on the Barclays Bank Group. Over-issuance of securities in the US Barclays Bank PLC maintains a US shelf registration statement with the Securities and Exchange Commission (SEC) in order to issue securities to US investors. The current shelf registration statement was declared effective by the SEC and was valid for three years from 1 August 2019. At the time this shelf registration statement was filed, Barclays Bank PLC was not eligible to be a “well-known seasoned issuer” (or WKSI) due to an historic SEC settlement order and was required to pre-register a set amount of securities to be issued under the US shelf with the SEC. On 10 March 2022, executive management became aware that Barclays Bank PLC had issued securities in excess of the set amount. It has been estimated that the Barclays Bank PLC US shelf limit was exceeded in February 2021, with issuances through to 10 March 2022 exceeding the $20.8bn limit by c.$15bn. The securities that have been over issued in this period comprise structured notes and exchange traded notes (ETNs). Securities issued in excess of the limit are considered to be “unregistered securities” for the purposes of US securities law with certain purchasers of those securities having the right to require Barclays Bank PLC to repurchase those securities at their original purchase price with compensatory interest and the potential for certain purchasers to bring civil claims and the SEC and other regulators to take enforcement actions against Barclays Bank PLC. Barclays Bank PLC has recognised a provision of £220m as at 31 December 2021 in relation to the c.$13bn over-issuance of structured notes which represents the best estimate of the rescission right investors have for these securities. The potential amount of the provision ultimately required is determined by (among other things) the market value of the structured notes subject to any rescission offer, participation rates in the rescission offer, prevailing interest rates and movements in foreign exchange rates. The majority of the structured notes subject to rescission provides an equity linked return to investors. As such, the value of these notes is highly sensitive to movements in the price of individual securities and range of indices. As at 31 March 2022, the estimated provision had increased to £540m, with the incremental £320m to be recognised in the 2022 financial statements. The increase in provision post year-end predominantly reflected a reduction in the market value of structured notes. For example, using the S&P 500 index as a benchmark proxy for how the portfolio of securities subject to rescission respond to equity market price movements implies a sensitivity of a c.£300m increase in the provision for a 5% reduction in the index. The provision calculation is non-linear and the sensitivity to a 5% change in the S&P 500 index is an indicative impact using information available as at 31 March 2022. The US equity markets have been volatile during H1 2022 with significant reductions in the value of US equity indices such as the S&P 500 from the year end 2021 levels. The sensitivity to a 5% change in the S&P index does not include the impact of market hedges that have been entered into subsequent to the year-end and were initiated from the end of Q1 2022, to reduce the net volatility to the income statement. When determining these market hedges, consideration was given to changes in the rescission costs which would arise from volatility in the market along with the positioning of the Markets business. The hedging arrangements may be modified, may not hedge all of the risks associated in the structured note population (in existing or modified form), may expire prior to the end of the Rescission Offer and do not cover any other losses arising out of potential private civil claims or enforcement actions. Any of the foregoing could result in material additional losses for the Barclays Bank Group. A contingent liability exists in relation to the c.$2bn over-issuance of ETNs due to evidentiary challenges and the high level of trading in the securities. A contingent liability also exists in relation to any potential civil claims or enforcement actions taken against Barclays Bank PLC, but Barclays Bank PLC is unable to assess the likelihood of liabilities that may arise out of such claims or actions, there is currently no indication of the timetable for resolution and it is not practicable to provide an estimate of the financial effects. Any liabilities, claims or actions in connection with the over-issuance of securities under the US shelf could have an adverse effect on Barclays Bank PLC’s and the Barclays Bank Group’s business, financial condition, results of operations and reputation as a frequent issuer in the securities markets. Investigation into UK cards’ affordability The FCA has been investigating certain aspects of the affordability assessment processes used by Barclays Bank UK PLC and Barclays Bank PLC for credit card applications made to Barclays’ UK credit card business. In October 2021, the FCA confirmed that this investigation was closed with no further action. HM Revenue & Customs (HMRC) assessments concerning UK Value Added Tax In 2018, HMRC issued notices that have the effect of removing certain overseas subsidiaries that have operations in the UK from Barclays’ UK VAT group, in which group supplies between members are generally free from VAT. The notices have retrospective effect and correspond to assessments of £181m (inclusive of interest), of which Barclays would expect to attribute an amount of approximately £128m to Barclays Bank UK PLC and £53m to Barclays Bank PLC. HMRC’s decision has been appealed to the First Tier Tribunal (Tax Chamber). Local authority civil actions concerning LIBOR Following settlement by Barclays Bank PLC of various governmental investigations concerning certain benchmark interest rate submissions referred to above in ‘Investigations into LIBOR and other benchmarks and related civil actions’, in the UK, certain local authorities brought claims in 2018 against Barclays Bank PLC and Barclays Bank UK PLC asserting that they entered into loans between 2006 and 2008 in reliance on misrepresentations made by Barclays Bank PLC in respect of its conduct in relation to LIBOR. Barclays Bank PLC and Barclays Bank UK PLC were successful in their a |
Subordinated liabilities
Subordinated liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Subordinated liabilities Accounting for subordinated liabilities Subordinated liabilities are measured at amortised cost using the effective interest method under IFRS 9, unless they are irrevocably designated at fair value through profit or loss at initial recognition because such designation eliminates or significantly reduces an accounting mismatch. Refer to Note 15 for details about accounting for liabilities designated at fair value through profit or loss. Barclays Bank Group 2021 2020 £m £m At amortised cost As at 1 January 32,005 33,425 Issuances 9,099 3,856 Redemptions (7,241) (5,954) Other (1,678) 678 As at 31 December 32,185 32,005 Designated at fair value (Note 15) 483 — Total subordinated liabilities 32,668 32,005 Issuances of £9,099m comprise £8,788m intra-group loans from Barclays PLC and £229m USD Floating Rate Notes and £82m ZAR Floating Rate Notes issued externally by Barclays Bank PLC subsidiaries. Redemptions of £7,241m comprise £4,736m notes issued externally by Barclays Bank PLC, £2,359m intra-group loans from Barclays PLC and £146m USD Floating Rate Notes issued externally by a Barclays Bank PLC subsidiary. £4,736m notes issued externally by Barclays Bank PLC comprise £1,961m GBP 10% Fixed Rate Subordinated Notes, £1,339m EUR 6% Fixed Rate Subordinated Notes, £1,075m USD 10.179% Fixed Rate Subordinated Notes, £200m GBP 9.5% Subordinated Bonds, £86m EUR Subordinated Floating Rate Notes and £75m GBP 9.25% Perpetual Subordinated Bonds. Other movements predominantly comprise fair value hedge adjustments, foreign exchange movements and reclassification of dated intra-group loans from Barclays PLC of £221m, and measured at fair value, from Subordinated liabilities to Financial liabilities designated at fair value (Note 15). Subordinated liabilities include accrued interest and comprise undated and dated subordinated liabilities as follows: Barclays Bank Group 2021 2020 £m £m Undated subordinated liabilities 795 905 Dated subordinated liabilities 31,873 31,100 Total subordinated liabilities 32,668 32,005 Undated subordinated liabilities a Barclays Bank Group 2021 2020 Initial call date £m £m Barclays Bank PLC externally issued subordinated liabilities Tier One Notes (TONs) 6% Callable Perpetual Core Tier One Notes 2032 15 17 6.86% Callable Perpetual Core Tier One Notes (USD 179m) 2032 194 205 Reserve Capital Instruments (RCIs) 5.3304% Step-up Callable Perpetual Reserve Capital Instruments 2036 51 56 Undated Notes 6.125% Undated Subordinated Notes 2027 39 43 Junior Undated Floating Rate Notes (USD 38m) Any interest payment date 28 28 Undated Floating Rate Primary Capital Notes Series 1 (USD 167m) Any interest payment date 90 89 Undated Floating Rate Primary Capital Notes Series 2 (USD 295m) Any interest payment date 189 186 Undated Floating Rate Primary Capital Notes Series 3 Any interest payment date 21 21 Bonds 9.25% Perpetual Subordinated Bonds (ex-Woolwich Plc) 2021 — 78 9% Permanent Interest Bearing Capital Bonds (GBP 40m) At any time 42 44 Loans 5.03% Reverse Dual Currency Undated Subordinated Loan (JPY 8,000m) 2028 51 57 5% Reverse Dual Currency Undated Subordinated Loan (JPY 12,000m) 2028 75 83 Total undated subordinated liabilities 795 905 Note a Instrument values are disclosed to the nearest million. Undated subordinated liabilities Undated subordinated liabilities are issued by Barclays Bank PLC and its subsidiaries for the development and expansion of their businesses and to strengthen their capital bases. The principal terms of the undated subordinated liabilities are described below: Subordination All undated subordinated liabilities rank behind the claims against the bank of depositors and other unsecured unsubordinated creditors and holders of dated subordinated liabilities in the following order: Junior Undated Floating Rate Notes; other issues of Undated Notes, Bonds and Loans ranking pari passu with each other; followed by TONs and RCIs ranking pari passu with each other. Interest All undated subordinated liabilities bear a fixed rate of interest until the initial call date, with the exception of the 9% Bonds which are fixed for the life of the issue, and the Junior and Series 1, Series 2 and Series 3 Undated Notes which are floating rate at rates fixed periodically in advance based on the related market rate. After the initial call date, in the event that they are not redeemed, the 6.125% Undated Notes will bear interest at rates fixed periodically in advance for five-year periods based on market rates. All other undated subordinated liabilities will bear interest at rates fixed periodically in advance based on market rates. Payment of interest Apart from the Junior Undated Floating Rate Notes, Barclays Bank PLC is not obliged to make a payment of interest on its Undated Notes, Bonds and Loans if, in the preceding six months, a dividend has not been declared or paid on any class of shares of Barclays PLC or, in certain cases, any class of preference shares of Barclays Bank PLC. Interest not paid becomes payable in each case if such a dividend is subsequently paid or in certain other circumstances. During the year, Barclays Bank PLC paid interest on each of its Undated Notes, Bonds and Loans. No payment of principal or any interest may be made unless Barclays Bank PLC satisfies a specified solvency test. Barclays Bank PLC may elect to defer any payment of interest on the RCIs. Any such deferred payment of interest must be paid on the earlier of: (i) the date of redemption of the RCIs; and (ii) the coupon payment date falling on or nearest to the tenth anniversary of the date of deferral of such payment. Whilst such deferral is continuing, (i) neither Barclays Bank PLC nor Barclays PLC may declare or pay a dividend, subject to certain exceptions, on any of its ordinary shares or preference shares and (ii) certain restrictions on the redemption, purchase or reduction of their respective share capital and certain other securities also apply. Barclays Bank PLC may elect to defer any payment of interest on the TONs if it determines that it is, or such payment would result in it being, in non-compliance with capital adequacy requirements and policies of the PRA. Any such deferred payment of interest will only be payable on a redemption of the TONs. Until such time as Barclays Bank PLC next makes a payment of interest on the TONs, (i) neither Barclays Bank PLC nor Barclays PLC may declare or pay a dividend, subject to certain exceptions, on any of their respective ordinary shares or preference shares, or make payments of interest in respect of Barclays Bank PLC’s Reserve Capital Instruments and (ii) certain restrictions on the redemption, purchase or reduction of their respective share capital and certain other securities also apply. Repayment All undated subordinated liabilities are repayable at the option of Barclays Bank PLC generally in whole at the initial call date and on any subsequent coupon or interest payment date or in the case of the 6.125% Undated Notes on any fifth anniversary after the initial call date. In addition, each issue of undated subordinated liabilities is repayable, at the option of Barclays Bank PLC, in whole for certain tax reasons, either at any time, or on an interest payment date. There are no events of default except non-payment of principal or mandatory interest. Any repayments require the prior consent of the PRA. Other All issues of undated subordinated liabilities are non-convertible. Dated subordinated liabilities a Barclays Bank Group 2021 2020 Initial call date Maturity date £m £m Barclays Bank PLC externally issued subordinated liabilities 10% Fixed Rate Subordinated Notes 2021 — 2,108 6% Fixed Rate Subordinated Notes (EUR 1,500m) 2021 — 1,427 10.179% Fixed Rate Subordinated Notes (USD 1,521m) 2021 — 1,101 9.5% Subordinated Bonds (ex-Woolwich Plc) 2021 — 221 Subordinated Floating Rate Notes (EUR 100m) 2021 — 90 7.625% Contingent Capital Notes (USD 3,000m) 2022 1,159 1,189 6.625% Fixed Rate Subordinated Notes (EUR 1,000m) 2022 889 982 Subordinated Floating Rate Notes (EUR 50m) 2022 42 45 Subordinated Floating Rate Notes (EUR 50m) 2023 42 45 5.75% Fixed Rate Subordinated Notes 2026 322 351 5.4% Reverse Dual Currency Subordinated Loan (JPY 15,000m) 2027 97 108 6.33% Subordinated Notes (GBP 50m) 2032 59 64 Subordinated Floating Rate Notes (EUR 68m) 2040 57 61 External issuances by other subsidiaries 2026 311 146 Barclays Bank PLC notes issued intra-group to Barclays PLC 2% Fixed Rate Subordinated Callable Notes (EUR 1,500) 2023 2028 1,288 1,388 3.75% Fixed Rate Resetting Subordinated Callable Notes (SGD 200m) 2025 2030 113 119 5.20% Fixed Rate Subordinated Notes (USD 1,367m) 2026 1,037 1,069 1.125% Fixed Rate Resetting Subordinated Callable Notes (EUR 1,000m) 2026 2031 831 — 4.836% Fixed Rate Subordinated Callable Notes (USD 1,200m) 2027 2028 937 973 5.088% Fixed-to-Floating Rate Subordinated Callable Notes (USD 1,300m) 2029 2030 1,005 1,049 3.811% Fixed Rate Resetting Subordinated Callable Notes (USD 1,000m) 2041 2042 778 — 5.25% Fixed Rate Subordinated Notes (USD 827m) 2045 618 660 4.95% Fixed Rate Subordinated Notes (USD 1,250m) 2047 896 960 Floating Rate Subordinated Notes (USD 456m) 2047 341 337 Barclays Bank PLC intra-group loans from Barclays PLC Various Fixed Rate Subordinated Loans 7,184 9,563 Various Subordinated Floating Rate Loans 646 489 Various Fixed Rate Subordinated Callable Loans 11,016 5,838 Various Subordinated Floating Rate Callable Loans 1,725 500 Zero Coupon Callable Loans 2051 483 221 Total dated subordinated liabilities 31,873 31,100 Notes a Instrument values are disclosed to the nearest million Dated subordinated liabilities Dated subordinated liabilities are issued by Barclays Bank PLC and its subsidiaries for the development and expansion of their businesses and to strengthen their respective capital bases. The principal terms of the dated subordinated liabilities are described below: Currency and maturity In addition to the individual dated subordinated liabilities listed in the table, the £21,052m (2020: £16,607m) of intra-group loans is made up of various fixed, fixed to floating rate, floating and zero coupon loans from Barclays PLC with notional amounts denominated in USD 14,809m, EUR 5,937m, GBP 1,250m, JPY 252,600m, AUD 2,315m, SEK 500m, NOK 970m, CAD 450m and CHF 435m, with maturities ranging from 2023 to 2051. Certain intra-group loans have a call date one year prior to their maturity. Subordination All dated subordinated liabilities, both externally issued and issued intra-group to Barclays PLC, rank behind the claims against Barclays Bank PLC of depositors and other unsecured unsubordinated creditors but before the claims of the undated subordinated liabilities and the holders of Barclays Bank PLC equity. The Barclays Bank PLC intra-group loans from Barclays PLC rank pari passu amongst themselves but ahead of the Barclays Bank PLC notes issued intra-group to Barclays PLC and the Barclays Bank PLC externally issued subordinated liabilities. The external dated subordinated liabilities issued by subsidiaries are similarly subordinated as the external subordinated liabilities issued by Barclays Bank PLC. Interest Interest on floating rate notes and loans is set by reference to market rates at the time of issuance and fixed periodically in advance, based on the related market rates. Interest on fixed rate notes and loans is set by reference to market rates at the time of issuance and fixed until maturity. Interest on fixed rate callable notes and loans is set by reference to market rates at the time of issuance and fixed until the call date or maturity as applicable. After the call date (where relevant), in the event that the notes or loans are not redeemed, the interest rate will be re-set to either a fixed or floating rate until maturity based on market rates. No interest is paid on zero coupon notes. Repayment Those subordinated liabilities with a call date are repayable at the option of Barclays Bank PLC on such call date in accordance with the conditions governing the respective debt obligations, some in whole or in part, and some only in whole, or otherwise on maturity. The remaining dated subordinated liabilities outstanding at 31 December 2021 are redeemable only on maturity, subject, in particular cases, to provisions allowing an early redemption in the event of certain changes in tax law or to certain changes in legislation or regulations. Any repayments prior to maturity may require, in the case of Barclays Bank PLC, the prior consent of the PRA or BoE or, in the case of the overseas issues, the consent of the local regulator for that jurisdiction and of the PRA in certain circumstances. There are no committed facilities in existence at the balance sheet date which permit the refinancing of debt beyond the date of maturity. Other The 7.625% Contingent Capital Notes will be automatically transferred from investors to Barclays PLC (or another entity within the Barclays Group) for nil consideration in the event the Barclays PLC transitional CET1 ratio falls below 7% |
Reserves
Reserves | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of reserves within equity [abstract] | |
Reserves | Reserves Currency translation reserve The currency translation reserve represents the cumulative gains and losses on the retranslation of the Barclays Bank Group's net investments in foreign operations, net of the effects of hedging. Fair value through other comprehensive income reserve The fair value through other comprehensive income reserve represents the changes in the fair value of fair value through other comprehensive income investments since initial recognition. Cash flow hedging reserve The cash flow hedging reserve represents the cumulative gains and losses on effective cash flow hedging instruments that will be recycled to the income statement when the hedged transactions affect profit or loss. Own credit reserve The own credit reserve reflects the cumulative own credit gains and losses on financial liabilities at fair value. Amounts in the own credit reserve are not recycled to profit or loss in future periods. Other reserves Other reserves includes redeemed ordinary and preference shares issued by the Barclays Bank Group. Barclays Bank Group 2021 2020 £m £m Currency translation reserve 2,581 2,736 Fair value through other comprehensive income reserve (118) 244 Cash flow hedging reserve (618) 1,181 Own credit reserve (960) (954) Other reserves (24) (24) Total 861 3,183 |
Staff costs
Staff costs | 12 Months Ended |
Dec. 31, 2021 | |
Classes of employee benefits expense [abstract] | |
Staff costs | Staff costs Accounting for staff costs The Barclays Bank Group applies IAS 19 Employee benefits in its accounting for most of the components of staff costs. Short-term employee benefits – salaries, accrued performance costs and social security are recognised over the period in which the employees provide the services to which the payments relate. Performance costs – recognised to the extent that the Barclays Bank Group has a present obligation to its employees that can be measured reliably and are recognised over the period of service that employees are required to work to qualify for the payments. Deferred cash and share awards are made to employees to incentivise performance over the period employees provide services. To receive payment under an award, employees must provide service over the vesting period. The period over which the expense for deferred cash and share awards is recognised is based upon the period employees consider their services contribute to the awards. For past awards, the Barclays Bank Group considers that it is appropriate to recognise the awards over the period from the date of grant to the date that the awards vest. In relation to awards granted from 2017, the Barclays Bank Group, taking into account the changing employee understanding surrounding those awards, considered it appropriate for expense to be recognised over four years including the financial year prior to the grant date. The accounting policies for share-based payments, and pensions and other post-retirement benefits, are included in Note 30 and Note 31 respectively. 2021 2020 2019 £m £m £m Performance costs 1,308 1,145 1,104 Salaries a 2,245 2,285 2,373 Social security costs 297 295 269 Post-retirement benefits b 181 176 184 Other compensation costs 172 208 237 Total compensation costs 4,203 4,109 4,167 Other resourcing costs Outsourcing 136 142 211 Redundancy and restructuring 49 47 69 Temporary staff costs 17 14 48 Other 51 53 70 Total other resourcing costs 253 256 398 Total staff costs 4,456 4,365 4,565 Notes a £152m (2020: £156m; 2019: £123m) of compensation was capitalised as internally generated software. b Post-retirement benefits charge includes £121m (2020: £127m; 2019: £126m) in respect of defined contribution schemes and £60m (2020: £49m; 2019: £58m) in respect of defined benefit schemes. |
Share-based payments
Share-based payments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Share-based payments | Share-based payments Accounting for share-based payments The Barclays Bank Group applies IFRS 2 Share-based Payments in accounting for employee remuneration in the form of shares. Employee incentives include awards in the form of shares and share options, as well as offering employees the opportunity to purchase shares on favourable terms. The cost of the employee services received in respect of the shares or share options granted is recognised in the income statement over the period that employees provide services. The overall cost of the award is calculated using the number of shares and options expected to vest and the fair value of the shares or options at the date of grant. The number of shares and options expected to vest takes into account the likelihood that performance and service conditions included in the terms of the awards will be met. Failure to meet the non-vesting condition is treated as a cancellation, resulting in an acceleration of recognition of the cost of the employee services. The fair value of shares is the market price ruling on the grant date, in some cases adjusted to reflect restrictions on transferability. The fair value of options granted is determined using option pricing models to estimate the numbers of shares likely to vest. These take into account the exercise price of the option, the current share price, the risk-free interest rate, the expected volatility of the share price over the life of the option and other relevant factors. Market conditions that must be met in order for the award to vest are also reflected in the fair value of the award, as are any other non-vesting conditions – such as continuing to make payments into a share-based savings scheme. The charge for the year arising from share based payment schemes was as follows: Charge for the year 2021 2020 2019 £m £m £m Deferred Share Value Plan / Share Value Plan 235 220 244 Others 159 129 148 Total equity settled 394 349 392 Cash settled 4 2 3 Total share based payments 398 351 395 The terms of the main current plans are as follows: Share Value Plan (SVP) The SVP was introduced in March 2010. SVP awards have been granted to participants in the form of a conditional right to receive Barclays PLC shares or provisional allocations of Barclays PLC shares which vest or are considered for release over a period of three, five or seven years. Participants do not pay to receive an award or to receive a release of shares. For awards granted before December 2017, the grantor may also make a dividend equivalent payment to participants on release of a SVP award. SVP awards are also made to eligible employees for recruitment purposes. All awards are subject to potential forfeiture in certain leaver scenarios. Deferred Share Value Plan (DSVP) The DSVP was introduced in February 2017. The terms of the DSVP are materially the same as the terms of the SVP as described above, save that Executive Directors are not eligible to participate in the DSVP and the DSVP operates over market purchase shares only. Other schemes In addition to the SVP and DSVP, the Barclays Group operates a number of other schemes settled in Barclays PLC Shares including Sharesave (both UK and Ireland), Sharepurchase (both UK and overseas), and the Barclays Group Long Term Incentive Plan. A delivery of upfront shares to ‘Material Risk Takers’ can be made as a Share Incentive Award (Holding Period). Share option and award plans The weighted average fair value per award granted, weighted average share price at the date of exercise/release of shares during the year, weighted average contractual remaining life and number of options and awards outstanding (including those exercisable) at the balance sheet date were as follows: 2021 2020 Weighted average fair value per award granted in year Weighted average share price at exercise/ release during year Weighted Number of Weighted average fair value per award granted in year Weighted average share price at exercise/ release during year Weighted Number of £ £ £ £ DSVP / SVP a.b 1.63 1.76 1.15 370,505 1.04 1.24 1 370,006 Others a 0.64-1.81 1.76-1.92 0-3 47,480 0.24-1.24 1.19-1.67 0-4 53,767 SVP and DSVP are nil cost awards on which the performance conditions are substantially completed at the date of grant. Consequently, the fair value of these awards is based on the market value at that date. Movements in options and awards The movement in the number of options and awards for the major schemes and the weighted average exercise price of options was: DSVP / SVP a,b Others a,c Number (000s) Number (000s) Weighted average 2021 2020 2021 2020 2021 2020 Outstanding at beginning of year/acquisition date 370,006 297,149 53,767 37,481 0.95 1.27 Transfers in the year d (2,214) 953 (2,697) 140 — — Granted in the year 174,338 203,157 79,050 136,227 1.43 0.84 Exercised/released in the year (144,943) (117,355) (78,273) (99,465) 1.36 1.21 Less: forfeited in the year (26,682) (13,898) (3,395) (18,285) 0.95 1.23 Less: expired in the year — — (972) (2,331) 1.69 1.33 Outstanding at end of year 370,505 370,006 47,480 53,767 0.95 0.95 Of which exercisable: — — 4,428 4,746 1.16 1.64 Notes a Options/award granted over Barclays PLC shares. b Weighted average exercise price is not applicable for SVP and DSVP awards as these are not share option schemes. c The number of awards within Others at the end of the year principally relates to Sharesave (number of awards exercisable at end of year was 1,499,920). The weighted average exercise price relates to Sharesave. d Awards of employees transferred between the Barclays Bank Group and the rest of the Barclays PLC Group. Awards and options granted to employees and former employees of the Barclays Bank Group under the Barclays PLC Group share plans may be satisfied using new issue shares, treasury shares and market purchase shares of Barclays PLC. Awards granted to employees and former employees of the Barclays Bank Group under DSVP may only be satisfied using market purchase shares of Barclays PLC. There were no significant modifications to the share based payments arrangements in 2021 and 2020. As at 31 December 2021, the total liability arising from cash-settled share based payments transactions was £4m (2020: £2m). |
Pensions and post-retirement be
Pensions and post-retirement benefits | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of defined benefit plans [abstract] | |
Pension and post-retirement benefits | Pensions and post-retirement benefits Accounting for pensions and post-retirement benefits The Barclays Bank Group operates a number of pension schemes and post-employment benefit schemes. Defined contribution schemes – the Barclays Bank Group recognises contributions due in respect of the accounting period in the income statement. Any contributions unpaid at the balance sheet date are included as a liability. Defined benefit schemes – the Barclays Bank Group recognises its obligations to members of each scheme at the period end, less the fair value of the scheme assets after applying the asset ceiling test. Each scheme’s obligations are calculated using the projected unit credit method. Scheme assets are stated at fair value as at the period end. Changes in pension scheme liabilities or assets (remeasurements) that do not arise from regular pension cost, net interest on net defined benefit liabilities or assets, past service costs, settlements or contributions to the scheme, are recognised in other comprehensive income. Remeasurements comprise experience adjustments (differences between previous actuarial assumptions and what has actually occurred), the effects of changes in actuarial assumptions, return on scheme assets (excluding amounts included in the interest on the assets) and any changes in the effect of the asset ceiling restriction (excluding amounts included in the interest on the restriction). Post-employment benefit schemes – the cost of providing healthcare benefits to retired employees is accrued as a liability in the financial statements over the period that the employees provide services to the Barclays Bank Group, using a methodology similar to that for defined benefit pension schemes. Pension schemes UK Retirement Fund (UKRF) The UKRF is the Barclays Bank Group’s main scheme, representing 97% of the Barclays Bank Group’s total retirement benefit obligations. Barclays Bank PLC is the principal employer of the UKRF. The UKRF was closed to new entrants on 1 October 2012, and comprises 10 sections, the two most significant of which are: ▪ Afterwork, which comprises a contributory cash balance defined benefit element, and a voluntary defined contribution element. The cash balance element is accrued each year and revalued until Normal Retirement Age in line with the increase in Retail Price Index (RPI) (up to a maximum of 5% p.a.). An increase of up to 2% a year may also be added at Barclays Bank PLC’s discretion. The costs of ill-health retirements and death in service benefits for Afterwork members are borne by the UKRF. The main risks that the Barclays Bank Group runs in relation to Afterwork are limited although additional contributions are required if pre-retirement investment returns are not sufficient to provide for the benefits. ▪ The 1964 Pension Scheme. Most employees recruited before July 1997 built up benefits in this non-contributory defined benefit scheme in respect of service up to 31 March 2010. Pensions were calculated by reference to service and pensionable salary. From 1 April 2010, members became eligible to accrue future service benefits in either Afterwork or the Pension Investment Plan (PIP), a historic defined contribution section which is now closed to future contributions. The risks that the Barclays Bank Group runs in relation to the 1964 section are typical of final salary pension schemes, principally that investment returns fall short of expectations, that inflation exceeds expectations, and that retirees live longer than expected. Barclays Pension Savings Plan (BPSP) The BPSP is a defined contribution scheme providing benefits for all new UK hires from 1 October 2012. BPSP is not subject to the same investment return, inflation or life expectancy risks for the Barclays Bank Group that defined benefit schemes are. Members’ benefits reflect contributions paid and the level of investment returns achieved. Other Apart from the UKRF and the BPSP, the Barclays Bank Group operates a number of smaller pension and long-term employee benefits and post-retirement health care plans globally, the largest of which are the US defined benefit and defined contribution schemes. Many of the schemes are funded, with assets backing the obligations held in separate legal vehicles such as trusts. Others are operated on an unfunded basis. The benefits provided, the approach to funding, and the legal basis of the schemes, reflect local environments. Governance The UKRF operates under trust law and is managed and administered on behalf of the members in accordance with the terms of the Trust Deed and Rules and all relevant legislation. The Corporate Trustee is Barclays Pension Funds Trustees Limited, a private limited company and a wholly owned subsidiary of Barclays Bank PLC. The Trustee is the legal owner of the assets of the UKRF which are held separately from the assets of the Barclays Bank Group. The Trustee Board comprises six Management Directors selected by Barclays Bank PLC, of whom three are independent Directors with no relationship with the Barclays Bank Group (and who are not members of the UKRF), plus three Member Nominated Directors selected from eligible active members of the UKRF, deferred members or pensioner members who apply for the role. The BPSP is a Group Personal Pension arrangement which operates as a collection of personal pension plans. Each personal pension plan is a direct contract between the employee and the BPSP provider (Legal & General Assurance Society Limited), and is regulated by the FCA. Similar principles of pension governance apply to the Barclays Bank Group’s other pension schemes, depending on local legislation. Amounts recognised The following tables include amounts recognised in the income statement and an analysis of benefit obligations and scheme assets for all Barclays Bank Group defined benefit schemes. The net position is reconciled to the assets and liabilities recognised on the balance sheet. The tables include funded and unfunded post-retirement benefits. Income statement charge 2021 2020 £m £m Current service cost 58 53 Net finance cost (26) (40) Past service cost — (4) Other movements 2 — Total 34 9 The Barclays Bank PLC is the principal employer of the UKRF and hence Scheme Assets and Defined Benefit Obligations relating to the UKRF are recognised within the Barclays Bank Group. Barclays Bank UK PLC and Barclays Execution Services Limited are participating employers in the UKRF and their share of the UKRF service cost is borne by them. Of the £240m current service cost in the table on the next page, £90m relates to Barclays Bank UK PLC and £92m relates to Barclays Execution Services Limited. While the entire current service cost is accounted for in the Barclays Bank Group on balance sheet, the income statement charge is accounted for across all the participating employers. Balance sheet reconciliation 2021 2020 Barclays Bank Group Total Of which relates to UKRF Barclays Bank Group Total Of which relates to UKRF £m £m £m £m Benefit obligation at beginning of the year (33,131) (32,108) (30,298) (29,304) Current service cost (240) (225) (232) (217) Interest costs on scheme liabilities (422) (405) (573) (549) Past service cost — — 4 — Remeasurement gain/(loss) - financial 849 820 (3,439) (3,358) Remeasurement gain/(loss) - demographic 53 50 (281) (286) Remeasurement gain/(loss) - experience (249) (259) 243 237 Employee contributions (4) — (5) (1) Benefits paid 1,309 1,268 1,406 1,370 Exchange and other movements 1 — 44 — Benefit obligation at end of the year (31,834) (30,859) (33,131) (32,108) Fair value of scheme assets at beginning of the year 34,713 33,915 32,093 31,362 Interest income on scheme assets 448 434 613 595 Employer contribution 971 955 265 248 Settlements — — — — Remeasurement - return on plan assets greater than discount rate 653 642 3,411 3,328 Employee contributions 4 — 5 1 Benefits paid (1,309) (1,268) (1,406) (1,370) Exchange and other movements (13) — (268) (249) Fair value of scheme assets at the end of the year 35,467 34,678 34,713 33,915 Net surplus 3,633 3,819 1,582 1,807 Retirement benefit assets 3,879 3,819 1,814 1,807 Retirement benefit liabilities (246) — (232) — Net retirement benefit assets 3,633 3,819 1,582 1,807 Included within the Barclays Bank Group’s benefit obligation is £821m (2020: £866m) relating to overseas pensions and £154m (2020: £157m) relating to other post-employment benefits. As at 31 December 2021, the UKRF’s scheme assets were in surplus versus IAS 19 obligations by £3,819m (2020: £1,807m). The movement for the UKRF during the year is driven by £700m of deficit reduction contributions, higher corporate bond yields and favourable asset returns, partially offset by higher expected long term price inflation. The weighted average duration of the benefit payments reflected in the defined benefit obligation for the UKRF is 16 years (2020: 17 years). The UKRF expected benefits are projected to be paid out for in excess of 50 years, although 25% of the total benefits are expected to be paid in the next 10 years; 30% in years 11 to 20 and 25% in years 20 to 30. The remainder of the benefits are expected to be paid beyond 30 years. Of the £1,268m (2020: £1,370m) UKRF benefits paid out, £419m (2020: £520m) related to transfers out of the fund. Where a scheme’s assets exceed its obligations, an asset is recognised to the extent that it does not exceed the present value of future contribution holidays or refunds of contributions (the asset ceiling). In the case of the UKRF the asset ceiling is not applied as, in certain specified circumstances such as wind-up, the Barclays Bank Group expects to be able to recover any surplus. Similarly, a liability in respect of future minimum funding requirements is not recognised. The UKRF Trustee does not have a substantive right to augment benefits, nor does it have the right to wind up the plan except in the dissolution of Barclays Bank PLC or termination of contributions by Barclays Bank PLC. The application of the asset ceiling to other plans and recognition of additional liabilities in respect of future minimum funding requirements is considered on an individual plan basis. Critical accounting estimates and judgements Actuarial valuation of the schemes’ obligations is dependent upon a series of assumptions. Below is a summary of the main financial and demographic assumptions adopted for the UKRF. Key UKRF financial assumptions 2021 2020 % p.a. % p.a. Discount rate 1.84 1.29 Inflation rate (RPI) 3.56 2.99 The UKRF discount rate assumption for 2021 was based on a standard Willis Towers Watson RATE Link model. The RPI inflation assumption for 2021 was set by reference to the Bank of England’s implied inflation curve. The inflation assumption incorporates a deduction of 20 basis points as an allowance for an inflation risk premium. The methodology used to derive the discount rate and inflation assumptions is consistent with that used at the prior year end. The UKRF’s post-retirement mortality assumptions are based on a best estimate assumption derived from an analysis in 2019 of the UKRF’s own post-retirement mortality experience and taking account of recent evidence from published mortality surveys. An allowance has been made for future mortality improvements based on the 2020 core projection model published by the Continuous Mortality Investigation Bureau subject to a long-term trend of 1.5% per annum in future improvements. The methodology used is consistent with the prior year ends, except that the 2019 core projection model was used at 2020. The table below shows how the assumed life expectancy at 60, for members of the UKRF, has varied over the past three years. Assumed life expectancy 2021 2020 2019 Life expectancy at 60 for current pensioners (years) – Males 27.3 27.2 27.1 – Females 29.6 29.4 29.3 Life expectancy at 60 for future pensioners currently aged 40 (years) – Males 29.1 29.0 28.9 – Females 31.4 31.2 31.1 The UKRF entered into a £5bn longevity swap in 2020 covering around a quarter of the pensioner liabilities. The swap is part of the UKRF’s investment portfolio and provides income in the event that pensions are paid out for longer than expected. The swap is not included directly within the balance sheet of Barclays PLC as it is an asset of the UKRF. At 31 December 2021, the swap is valued at nil (2020: nil) as experience since the swap was effected has been neutral. Sensitivity analysis on actuarial assumptions The sensitivity analysis has been calculated by valuing the UKRF liabilities using the amended assumptions shown in the table below and keeping the remaining assumptions the same as disclosed in the table above, except in the case of the inflation sensitivity where other assumptions that depend on assumed inflation have also been amended correspondingly. The difference between the recalculated liability figure and that stated in the balance sheet reconciliation table above is the figure shown. The selection of these movements to illustrate the sensitivity of the defined benefit obligation to key assumptions should not be interpreted as Barclays Bank Group expressing any specific view of the probability of such movements happening. Change in key assumptions 2021 2020 (Decrease)/Increase in UKRF defined benefit obligation (Decrease)/Increase in UKRF defined benefit obligation £bn £bn Discount rate 0.50% p.a. increase (2.3) (2.5) 0.25% p.a. increase (1.2) (1.3) 0.25% p.a. decrease 1.3 1.4 0.50% p.a. decrease 2.6 2.9 Assumed RPI 0.50% p.a. increase 1.6 1.8 0.25% p.a. increase 0.8 0.9 0.25% p.a. decrease (0.8) (0.9) 0.50% p.a. decrease (1.6) (1.8) Life expectancy at 60 One year increase 1.2 1.2 One year decrease (1.2) (1.2) Assets A long-term investment strategy has been set for the UKRF, with its asset allocation comprising a mixture of equities, bonds, property and other appropriate assets. This recognises that different asset classes are likely to produce different long-term returns and some asset classes may be more volatile than others. The long-term investment strategy ensures, among other aims, that investments are adequately diversified. The UKRF also employs derivative instruments, where appropriate, to achieve a desired exposure or return, or to match assets more closely to liabilities. The value of assets shown reflects the assets held by the schemes, with any derivative holdings reflected on a fair value basis. The value of the assets of the schemes and their percentage in relation to total scheme assets were as follows: Analysis of scheme assets Barclays Bank Group Total Of which relates to UKRF Quoted Unquoted a Value % of total Quoted Unquoted a Value % of total £m £m £m % £m £m £m % As at 31 December 2021 Equities 214 1,377 1,591 4.5 86 1,377 1,463 4.2 Private equities — 2,991 2,991 8.4 0 2,991 2,991 8.6 Bonds - fixed government 2,387 95 2,482 7.0 2,083 95 2,178 6.3 Bonds - index-linked government 13,478 679 14,157 39.9 13,455 679 14,134 40.8 Bonds - corporate and other 6,223 2,854 9,077 25.6 5,986 2,854 8,840 25.5 Property 14 1,490 1,504 4.3 0 1,490 1,490 4.3 Infrastructure — 1,815 1,815 5.1 0 1,815 1,815 5.2 Cash and liquid assets 189 1,577 1,766 5.0 176 1,577 1,753 5.1 Mixed investment funds 9 — 9 — — — — — Other 19 56 75 0.2 — 14 14 — Fair value of scheme assets 22,533 12,934 35,467 100.0 21,786 12,892 34,678 100.0 As at 31 December 2020 Equities 567 1,498 2,065 5.9 378 1,498 1,876 5.5 Private equities — 2,233 2,233 6.4 — 2,233 2,233 6.6 Bonds - fixed government 4,205 110 4,315 12.4 3,932 110 4,042 11.9 Bonds - index-linked government 10,706 1,014 11,720 33.8 10,697 1,014 11,711 34.5 Bonds - corporate and other 7,439 1,678 9,117 26.3 7,214 1,678 8,892 26.2 Property 10 1,416 1,426 4.1 — 1,416 1,416 4.2 Infrastructure — 1,812 1,812 5.2 — 1,812 1,812 5.3 Cash and liquid assets 64 1,830 1,894 5.5 46 1,830 1,876 5.5 Mixed Investment funds 9 — 9 — — — — — Other 14 108 122 0.4 — 57 57 0.2 Fair value of scheme assets 23,014 11,699 34,713 100.0 22,267 11,648 33,915 100.0 Notes a Valuations of unquoted assets are provided by the underlying managers or qualified independent valuers. Valuations of complex instruments are based on UKRF custodian valuations. All valuations are determined in accordance with relevant industry guidance. Included within the fair value of scheme assets were nil (2020: nil) relating to shares in Barclays PLC and nil (2020: nil) relating to bonds issued by Barclays PLC or Barclays Bank PLC. The UKRF invests in pooled investment vehicles which may hold shares or debt issued by Barclays PLC. The UKRF assets above do not include the Senior Notes asset referred to in the section below on Triennial Valuation, as these are non-transferable instruments and not recognised under IAS19. Approximately 45% of the UKRF assets are invested in liability-driven investment strategies; primarily UK gilts as well as interest rate and inflation swaps. These swaps are used to better match the assets to its liabilities. The swaps are used to reduce the scheme’s inflation and duration risks against its liabilities. Triennial Valuation The latest annual update as at 30 September 2021 showed the funding position had improved to a surplus of £0.6bn from a deficit of £0.9bn shown at 30 September 2020. The improvement was mainly due to £0.7bn of deficit reduction contributions and favourable asset returns, partially offset by higher expected long term price inflation. The main differences between the funding and accounting assumptions are a different approach to setting the discount rate and a more conservative longevity assumption for funding. The deficit reduction contributions agreed with the UKRF Trustee as part of the 30 September 2019 triennial valuation recovery plan are shown in the table below. Deficit reduction contributions under the 30 September 2019 valuation Year £m Cash paid: 2019 500 2020 500 2021 700 Future commitments: 2022 294 2023 286 2024 and beyond — During 2019 and 2020 the UKRF subscribed for non-transferable listed senior fixed rate notes for £1,250m, backed by UK gilts (the Senior Notes) entitling the UKRF to semi-annual coupon payments for five years, and full repayment in cash in three tranches: £250m in 2023, £750m in 2024, and £250m in 2025. As a result of these transactions, the CET1 impact of the UKRF was deferred until 2023, 2024 and 2025 upon maturity of the notes. Following the PRA’s statement on 13 April 2022, Barclays Bank PLC is planning to unwind these transactions and to agree the terms and timing of this unwind with the UKRF Trustee as part of the next triennial actuarial valuation as at 30 September 2022. Upon unwind, this would result in a c.65bps reduction to the CET1 ratio potentially being accelerated to Q422 from 2023, 2024 and 2025. As at 31 March 2022, the UKRF was in an accounting surplus of £4.4bn on an IAS 19 basis and as at 30 September 2021 was in a funding surplus of £0.6bn. There may also be a pension related reduction in Pillar 2A requirements in 2022 which could partially mitigate the impact of the unwind on the Barclays Bank Group surplus capital position. As the UKRF's investment in these Senior Notes does not qualify as a plan asset under IAS 19, the £1,250m does not appear in the IAS 19 plan assets. The Senior Notes were issued by Heron Issuer Limited (Heron) for £500m and Heron Issuer Number 2 Limited (Heron 2) for £750m, entities consolidated within the Barclays Bank Group under IFRS 10. Heron and Heron 2 acquired a total of £1,250m of gilts from Barclays Bank PLC for cash to support payments on the Senior Notes. There were no further transactions of this type in 2021 . The deficit reduction contributions are in addition to the regular contributions to meet the Barclays Bank Group’s share of the cost of benefits accruing over each year. The next funding valuation of the UKRF is due to be completed in 2023 with an effective date of 30 September 2022. Other support measures agreed which remain in place Collateral – The UKRF Trustee and Barclays Bank PLC have entered into an arrangement whereby a collateral pool has been put in place to provide security for the UKRF funding deficit as it increases or decreases over time. The collateral pool is currently made up of government securities, and agreement was made with the Trustee to cover at least 100% of the funding deficit with an overall cap of £9bn. The arrangement provides the UKRF Trustee with dedicated access to the pool of assets in the event of Barclays Bank PLC not paying a deficit reduction contribution to the UKRF or in the event of Barclays Bank PLC’s insolvency. These assets are included within Note 36 Assets pledged, collateral received and assets transferred. Support from Barclays PLC – In the event of Barclays Bank PLC not paying a deficit reduction contribution payment required by a specified pre-payment date, Barclays PLC has entered into an arrangement whereby it will be required to use, in first priority, dividends received from Barclays Bank UK PLC (if any) to invest the proceeds in Barclays Bank PLC (up to the maximum amount of the deficit reduction contribution unpaid by Barclays Bank PLC). The proceeds of the investment will be used to discharge Barclays Bank PLC’s unpaid deficit reduction contribution. Participation – As permitted under the Financial Services and Markets Act 2000 (Banking Reform) (Pensions) Regulations 2015, Barclays Bank UK PLC is a participating employer in the UKRF and will remain so during a transitional phase until September 2025 as set out in a deed of participation. Barclays Bank UK PLC will make contributions for the future service of its employees who are currently Afterwork members and, in the event of Barclays Bank PLC’s insolvency during this period, provision has been made to require Barclays Bank UK PLC to become the principal employer of the UKRF. Barclays Bank PLC’s Section 75 debt would be triggered by the insolvency (the debt would be calculated after allowing for the payment to the UKRF of the collateral above). Defined benefit contributions paid with respect to the UKRF were as follows: Contributions paid £m 2021 955 2020 748 2019 1,231 There were nil (2020: nil) Section 75 contributions included within the Barclays Bank Group’s contributions paid as no participating employers left the UKRF in 2021. The Barclays Bank Group’s expected contribution to the UKRF in respect of defined benefits in 2022 is £352m (2021: £783m). In addition, the expected contributions to UK defined contribution schemes in 2022 is £6m (2021: £9m) to the UKRF and £42m (2021: £47m) to the BPSP. |
Principal subsidiaries
Principal subsidiaries | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of subsidiaries [abstract] | |
Principal subsidiaries | Principal subsidiaries Barclays Bank Group applies IFRS 10 Consolidated Financial Statements. The consolidated financial statements combine the financial statements of Barclays Bank PLC and all of its subsidiaries. Subsidiaries are entities over which Barclays Bank Group has control. Under IFRS 10, this is when Barclays Bank Group is exposed to or has rights to variable returns from its involvement in an entity and has the ability to affect those returns through its power over an entity. Barclays Bank Group reassesses whether it controls an entity if facts and circumstances indicate that there have been changes to its power, its rights to variable returns or its ability to use its power to affect the amount of its returns. Intra-group transactions and balances are eliminated on consolidation and consistent accounting policies are used throughout the Barclays Bank Group for the purposes of the consolidation. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has been obtained and they do not result in loss of control. The significant judgements used in applying this policy are set out below. Principal subsidiaries of the Barclays Bank Group are set out below. This includes those subsidiaries that are most significant in the context of the Barclays Bank Group’s business, results or financial position. Company Name Principal place of business or incorporation Nature of business Percentage of voting rights held Non-controlling interests - proportion of ownership interests Non-controlling interests - proportion of voting interests % % % Barclays Bank Ireland PLC Ireland Banking 100 — — Barclays Capital Inc. United States Securities dealing 100 — — Barclays Capital Securities Limited United Kingdom Securities dealing 100 — — Barclays Securities Japan Limited Japan Securities dealing 100 — — Barclays US LLC United States Holding company 100 — — Barclays Bank Delaware United States Credit card issuer 100 — — The country of registration or incorporation is also the principal area of operation of each of the above subsidiaries. Ownership interests are in some cases different to voting interests due to the existence of non-voting equity interests, such as preference shares. Significant judgements and assumptions used to determine the scope of the consolidation Determining whether the Barclays Bank Group has control of an entity is generally straightforward based on ownership of the majority of the voting capital. However, in certain instances, this determination will involve significant judgement, particularly in the case of structured entities where voting rights are often not the determining factor in decisions over the relevant activities. This judgement will involve assessing the purpose and design of the entity. It will also often be necessary to consider whether the Barclays Bank Group, or another involved party with power over the relevant activities, is acting as a principal in its own right or as an agent on behalf of others. There is also often considerable judgement involved in the ongoing assessment of control over structured entities. In this regard, where market conditions have deteriorated such that the other investors’ exposures to the structure’s variable returns have been substantively eliminated, the Barclays Bank Group may conclude that the managers of the structured entity are acting as its agent and therefore will consolidate the structured entity. An interest in equity voting rights exceeding 50% would typically indicate that the Barclays Bank Group has control of an entity. However, the entity set out below is excluded from consolidation because the Barclays Bank Group does not have exposure to its variable returns. Company name Country of registration or incorporation Percentage of voting rights held (%) Equity shareholders' funds (£m) Retained profit for the year (£m) Palomino Limited Cayman Islands 100 — — This entity is managed by an external counterparty and consequently is not controlled by the Barclays Bank Group. Interests relating to this entity are included in Note 33. Significant restrictions As is typical for a group of its size and international scope, there are restrictions on the ability of the Barclays Bank Group to obtain distributions of capital, access the assets or repay the liabilities of members of the Barclays Bank Group due to the statutory, regulatory and contractual requirements of its subsidiaries and due to the protective rights of non-controlling interests. These are considered below. Regulatory requirements The Barclays Bank Group’s principal subsidiary companies have assets and liabilities before intercompany eliminations of £439bn (2020: £417bn) and £414bn (2020: £393bn) respectively. Certain classes of these assets and liabilities are subject to prudential regulation and regulatory capital requirements in the countries in which the subsidiaries are regulated. These prudential and regulatory capital requirements require entities to maintain minimum capital levels which cannot be returned to the parent company, Barclays Bank PLC, on a going concern basis. In order to meet capital requirements, subsidiaries may issue certain equity accounted and debt accounted financial instruments such as Tier 1 and Tier 2 capital instruments and other forms of subordinated liabilities. Refer to Note 26 and Note 27 for particulars of these instruments. These instruments may be subject to cancellation clauses or preference share restrictions that would limit the ability of the entity to repatriate the capital on a timely basis. Liquidity requirements Regulated subsidiaries of the Barclays Bank Group are required to meet PRA or local regulatory requirements pertaining to liquidity. Some of the regulated subsidiaries include Barclays Capital Securities Limited (which is regulated for liquidity matters on a combined basis with Barclays Bank PLC under a Domestic Liquidity Sub-Group (DoLSub) arrangement), Barclays Bank Ireland PLC, Barclays Capital Inc. and Barclays Bank Delaware Inc. See page 80 for further details of liquidity requirements, including those of the Barclays Bank Group’s significant subsidiaries. Statutory requirements The Barclays Bank Group’s subsidiaries are subject to statutory requirements not to make distributions of capital and unrealised profits and generally to maintain solvency. These requirements restrict the ability of subsidiaries to make remittances of dividends to Barclays Bank PLC, the parent, except in the event of a legal capital reduction or liquidation. In most cases the regulatory restrictions referred to above exceed the statutory restrictions. Asset encumbrance The Barclays Bank Group uses its financial assets to raise finance in the form of securitisations and through the liquidity schemes of central banks, as well as to provide security to the UK Retirement Fund. Once encumbered, the assets are not available for transfer around the Barclays Bank Group. The assets typically affected are disclosed in Note 36. Other restrictions The Barclays Bank Group is required to maintain balances with central banks and other regulatory authorities and these amounted to £4,260m (2020: £3,119m). |
Structured entities
Structured entities | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of information about consolidated structured entities [abstract] | |
Structured entities | Structured entities A structured entity is an entity in which voting or similar rights are not the dominant factor in deciding who controls the entity. An example is when voting rights relate to administrate tasks only and the relevant activities are directed by means of contractual arrangements. Structured entities are generally created to achieve a narrow and well-defined objective with restrictions around their ongoing activities. Depending on the Barclays Bank Group’s power over the activities of the entity and its exposure to and ability to influence its own returns, it may consolidate the entity. In other cases, it may sponsor or have exposure to such an entity but not consolidate it. Consolidated structured entities The Barclays Bank Group has contractual arrangements which may require it to provide financial support to the following types of consolidated structured entities: ▪ Securitisation: The Barclays Bank Group uses securitisation as a source of financing and a means of risk transfer. Where entities are controlled by the Barclays Bank Group, they are consolidated. Refer to Note 35 for further detail. ▪ Commercial paper (CP) conduits: These entities issue CP and use the proceeds to lend to clients as part of the Barclays Bank Group's multi-seller conduit programme. The Barclays Bank Group has provided £17.2bn (2020: £16.9bn) in contractual liquidity facilities to the CP conduits that the Barclays Bank Group consolidates. These amounts represent the maximum the conduits can lend externally. The amounts of CP conduit lending (drawn and undrawn) to unconsolidated structured entities can be seen in Other interests in unconsolidated structured entities under multi-seller conduit programme in the Summary of interests in unconsolidated structured entities table. ▪ Tender Option Bond (TOB) trusts: During 2021, the Barclays Bank Group provided undrawn liquidity facilities of £3.3bn (2020: £2.9bn) to consolidated TOB trusts. These trusts invest in fixed income instruments issued by state, local or other municipalities in the United States, funded by long-term senior floating-rate notes and junior residual securities. Unconsolidated structured entities The term ‘unconsolidated structured entities’ refers to structured entities not controlled by the Barclays Bank Group, and are established either by Barclays Bank Group or a third party. An interest in a structured entity is any form of contractual or non-contractual involvement which creates variability in returns arising from the performance of the entity for the Barclays Bank Group. Such interests include holdings of debt or equity securities, derivatives that transfer financial risks from the entity to the Barclays Bank Group, lending, loan commitments, financial guarantees and investment management agreements. Barclays Bank Group enters into transactions with unconsolidated structured entities in the normal course of business to facilitate customer transactions, to provide risk management services and for specific investment opportunities. This is predominantly within the CIB business. Structured entities may take the form of funds, trusts, securitisation vehicles, and private investment companies. The largest transactions include loans and derivatives with hedge fund structures and special purpose entities, multi-seller conduit lending, holding notes issued by securitisation vehicles and facilitating customer requirements through funds. The nature and extent of the Barclays Bank Group’s interests in structured entities is summarised below: Summary of interests in unconsolidated structured entities Secured financing Short-term traded interests Traded derivatives Other interests Total £m £m £m £m £m As at 31 December 2021 Assets Trading portfolio assets — 7,170 — — 7,170 Financial assets at fair value through the income statement 61,816 — — 3,417 65,233 Derivative financial instruments — — 5,160 — 5,160 Financial assets at fair value through other comprehensive income — — — 91 91 Loans and advances at amortised cost — — — 22,741 22,741 Reverse repurchase agreements and other similar secured lending 104 — — — 104 Other assets — — — 12 12 Total assets 61,920 7,170 5,160 26,261 100,511 Liabilities Derivative financial instruments — — 9,543 — 9,543 As at 31 December 2020 Assets Trading portfolio assets — 11,361 — — 11,361 Financial assets at fair value through the income statement 56,265 — — 2,780 59,045 Derivative financial instruments — — 2,968 — 2,968 Financial assets at fair value through other comprehensive income — — — 153 153 Loans and advances at amortised cost — — — 18,418 18,418 Reverse repurchase agreements and other similar secured lending 10 — — — 10 Other assets — — — 11 11 Total assets 56,275 11,361 2,968 21,362 91,966 Liabilities Derivative financial instruments — — 7,075 — 7,075 Secured financing arrangements, short-term traded interests and traded derivatives are typically managed under market risk management policies described in the Market risk management section which includes an indication of the change of risk measures compared to last year. For this reason, the total assets of these entities are not considered meaningful for the purposes of understanding the related risks and so have not been presented. Other interests include conduits and lending where the interest is driven by normal customer demand. As at 31 December 2021, there were 5,696 (2020: 3,162) structured entities that the Barclays Bank Group entered into transactions with. Secured financing The Barclays Bank Group routinely enters into reverse repurchase contracts, margin lending, stock borrowing and similar arrangements on normal commercial terms where the counterparty to the arrangement is a structured entity. Due to the nature of these arrangements, especially the transfer of collateral and ongoing margining, the Barclays Bank Group is able to manage its variable exposure to the performance of the structured entity counterparty . The counterparties included in secured financing mainly include hedge fund limited structures, investment companies and special purpose entities. Short-term traded interests As part of its market making activities, the Barclays Bank Group buys and sells interests in structured vehicles, which are predominantly debt securities issued by asset securitisation vehicles. Such interests are typically held individually or as part of a larger portfolio for no more than 90 days. In such cases, the Barclays Bank Group typically has no other involvement with the structured entity other than the securities it holds as part of trading activities and its maximum exposure to loss is restricted to the carrying value of the asset. Traded derivatives The Barclays Bank Group enters into a variety of derivative contracts with structured entities which reference market risk variables such as interest rates, foreign exchange rates and credit indices among other things. The main derivative types which are considered interests in structured entities include index-based and entity specific credit default swaps, balance guaranteed swaps, total return swaps, commodities swaps, and equity swaps. Interest rate swaps, foreign exchange derivatives that are not complex and which expose the Barclays Bank Group to insignificant credit risk by being senior in the payment waterfall of a securitisation and derivatives that are determined to introduce risk or variability to a structured entity are not considered to be an interest in an entity and have been excluded from the disclosures. A description of the types of derivatives and the risk management practices are detailed in Note 13. The risk of loss may be mitigated through ongoing margining requirements as well as a right to cash flows from the structured entity which are senior in the payment waterfall. Such margining requirements are consistent with market practice for many derivative arrangements and in line with the Barclays Bank Group’s normal credit policies. Derivative transactions require the counterparty to provide cash or other collateral under margining agreements to mitigate counterparty credit risk. The Barclays Bank Group is mainly exposed to settlement risk on these derivatives which is mitigated through daily margining. Total notional contract amounts were £217,055m (2020: £153,894m). Except for credit default swaps where the maximum exposure to loss is the swap notional amount, it is not possible to estimate the maximum exposure to loss in respect of derivative positions as the fair value of derivatives is subject to changes in market rates of interest, exchange rates and credit indices which by their nature are uncertain. In addition, the Barclays Bank Group’s losses would be subject to mitigating action under its traded market risk and credit risk policies that require the counterparty to provide collateral in cash or other assets in most cases. Other interests in unconsolidated structured entities The Barclays Bank Group’s interests in structured entities not held for the purposes of short-term trading activities are set out below, summarised by the nature of the interest and limited to significant categories, based on maximum exposure to loss. Nature of interest Multi-seller conduit programme Lending Other Total Of which: Barclays Bank Group owned, not consolidated entities 1 £m £m £m £m £m As at 31 December 2021 Financial assets at fair value through the income statement — 2 3,415 3,417 3,335 Financial assets at fair value through other comprehensive income — 53 38 91 — Loans and advances at amortised cost 5,184 14,294 3,263 22,741 — Other assets 8 4 — 12 — Total on-balance sheet exposures 5,192 14,353 6,716 26,261 3,335 Total off-balance sheet notional amounts 11,015 9,394 — 20,409 — Maximum exposure to loss 16,207 23,747 6,716 46,670 3,335 Total assets of the entity 65,441 160,611 28,582 254,634 11,513 As at 31 December 2020 Financial assets at fair value through the income statement — 15 2,765 2,780 2,698 Financial assets at fair value through other comprehensive income — 106 47 153 — Loans and advances at amortised cost 5,146 12,475 797 18,418 — Other assets 8 3 — 11 — Total on-balance sheet exposures 5,154 12,599 3,609 21,362 2,698 Total off-balance sheet notional amounts 11,750 7,531 — 19,281 — Maximum exposure to loss 16,904 20,130 3,609 40,643 2,698 Total assets of the entity 87,004 153,990 22,389 263,383 11,008 Maximum exposure to loss Unless specified otherwise below, the Barclays Bank Group’s maximum exposure to loss is the total of its on-balance sheet positions and its off-balance sheet arrangements, being loan commitments and financial guarantees. Exposure to loss is mitigated through collateral, financial guarantees, the availability of netting and credit protection held. Multi-seller conduit programme The Barclays Bank Group's multi-seller conduit programme engages in providing financing to various clients and holds whole or partial interests in pools of receivables or similar obligations. These instruments are protected from loss through over-collateralisation, seller guarantees, or other credit enhancements provided to the conduit entity. The Barclays Bank Group’s off-balance sheet exposure included in the table above represents liquidity facilities that are provided to the conduit for the benefit of the holders of the commercial paper issued by the conduit and will only be drawn where the conduit is unable to access the commercial paper market. If these liquidity facilities are drawn, the Barclays Bank Group is protected from loss through over-collateralisation, seller guarantees, or other credit enhancements provided to the conduit. 1 Comprises of Barclays Bank Group owned, not consolidated structured entities per IFRS 10 Consolidated Financial Statements, and Barclays Bank Group sponsored entities. Refer to Note 32 Principal subsidiaries for more details on consolidation. Lending The portfolio includes lending provided by the Barclays Bank Group to unconsolidated structured entities in the normal course of its lending business to earn income in the form of interest and lending fees and includes loans to structured entities that are generally collateralised by property, equipment or other assets. All loans are subject to the Barclays Bank Group’s credit sanctioning process. Collateral arrangements are specific to the circumstances of each loan with additional guarantees and collateral sought from the sponsor of the structured entity for certain arrangements. During the year the Barclays Bank Group incurred an impairment charge of £25m (2020: £22m) against such facilities. Other This includes fair value loans with structured entities where the market risk is materially hedged with corresponding derivative contracts, interests in debt securities issued by securitisation vehicles and drawn and undrawn loan facilities to these entities. In addition, other includes investment funds with interests restricted to management fees based on the performance of the fund and trusts held on behalf of beneficiaries with interests restricted to unpaid fees. Assets transferred to sponsored unconsolidated structured entities The Barclays Bank Group is considered to sponsor another entity if, it had a key role in establishing that entity, it transferred assets to the entity, the Barclays name appears in the name of the entity or it provides guarantees on the entity’s performance. As at 31 December 2021, assets transferred to sponsored unconsolidated structured entities were £1,662m (2020: £730m). |
Investments in associates and j
Investments in associates and joint ventures | 12 Months Ended |
Dec. 31, 2021 | |
Investments in subsidiaries, joint ventures and associates reported in separate financial statements [abstract] | |
Investments in associates and joint ventures | Investments in associates and joint ventures Accounting for associates and joint ventures The Barclays Bank Group applies IAS 28 Investments in Associates and IFRS 11 Joint Arrangements . Associates are entities in which the Barclays Bank Group has significant influence, but not control, over the operating and financial policies. Generally the Barclays Bank Group holds more than 20%, but less than 50%, of their voting shares. Joint ventures are arrangements where the Barclays Bank Group has joint control and rights to the net assets of the entity. The Barclays Bank Group’s investments in associates and joint ventures are initially recorded at cost and increased (or decreased) each year by the Barclays Bank Group’s share of the post acquisition profit/(loss). The Barclays Bank Group ceases to recognise its share of the losses of equity accounted associates when its share of the net assets and amounts due from the entity have been written off in full, unless it has a contractual or constructive obligation to make good its share of the losses. In some cases, investments in these entities may be held at fair value through profit or loss, for example, those held by private equity businesses. There are no individually significant investments in joint ventures or associates held by Barclays Bank Group. 2021 2020 Associates Joint ventures Total Associates Joint ventures Total £m £m £m £m £m £m Equity accounted (Group) 24 — 24 24 — 24 Summarised financial information for the Barclays Bank Group’s equity accounted associates and joint ventures is set out below. The amounts shown are the Barclays Bank Group’s share of the comprehensive income of the investees for the year ended 31 December 2021, with the exception of certain undertakings for which the amounts are based on accounts made up to dates not earlier than three months before the balance sheet date. Associates Joint ventures 2021 2020 2021 2020 £m £m £m £m (Loss)/profit from continuing operations — (1) — 2 Other comprehensive income / (loss) 1 (3) — — Total comprehensive income/(loss) from continuing operations 1 (4) — 2 |
Securitisations
Securitisations | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transferred financial assets that are not derecognised in their entirety [abstract] | |
Securitisations | Securitisations Accounting for securitisations The Barclays Bank Group uses securitisations as a source of finance and a means of risk transfer. Such transactions generally result in the transfer of contractual cash flows from portfolios of financial assets to holders of issued debt securities. Securitisations may, depending on the individual arrangement, result in continued recognition of the securitised assets and the recognition of the debt securities issued in the transaction; lead to partial continued recognition of the assets to the extent of the Barclays Bank Group’s continuing involvement in those assets or lead to derecognition of the assets and the separate recognition, as assets or liabilities, of any rights and obligations created or retained in the transfer. Full derecognition only occurs when the Barclays Bank Group transfers both its contractual right to receive cash flows from the financial assets, or retains the contractual rights to receive the cash flows, but assumes a contractual obligation to pay the cash flows to another party without material delay or reinvestment, and also transfers substantially all the risks and rewards of ownership, including credit risk, prepayment risk and interest rate risk. In the course of its normal banking activities, the Barclays Bank Group makes transfers of financial assets, either where legal rights to the cash flows from the asset are passed to the counterparty or beneficially, where the Barclays Bank Group retains the rights to the cash flows but assumes a responsibility to transfer them to the counterparty. Depending on the nature of the transaction, this may result in derecognition of the assets in their entirety, partial derecognition or no derecognition of the assets subject to the transfer. A summary of the main transactions, and the assets and liabilities and the financial risks arising from these transactions, is set out below: Transfers of financial assets that do not result in derecognition Securitisations The Barclays Bank Group is party to securitisation transactions involving its credit card balances. In these transactions, the assets, interests in the assets, or beneficial interests in the cash flows arising from the assets, are transferred to a special purpose entity, which then issues interest bearing debt securities to third party investors. Securitisations may, depending on the individual arrangement, result in continued recognition of the securitised assets and the recognition of the debt securities issued in the transaction. Partial continued recognition of the assets to the extent of the Barclays Bank Group’s continuing involvement in those assets can also occur or derecognition of the assets and the separate recognition, as assets or liabilities, of any rights and obligations created or retained in the transfer. The following table shows the carrying amount of securitised assets that have not resulted in full derecognition, together with the associated liabilities, for each category of asset on the balance sheet: 2021 2020 Assets Liabilities Assets Liabilities Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value £m £m £m £m £m £m £m £m Barclays Bank Group Loans and advances at amortised cost Credit cards, unsecured loans and other retail lending 1,303 1,423 (1,225) (1,219) 963 1,051 (952) (966) Balances included within loans and advances at amortised cost represent securitisations where substantially all the risks and rewards of the assets have been retained by Barclays Bank Group. The relationship between the transferred assets and the associated liabilities is that holders of notes may only look to cash flows from the securitised assets for payments of principal and interest due to them under the terms of their notes, although the contractual terms of their notes may be different to the maturity and interest of the transferred assets. If the Barclays Bank Group transfers a financial asset but does not transfer or retain substantially all the risk and rewards of the asset and retains control over it, the transferred assets are recognised to the extent of Barclays Bank Group's continuing involvement. In 2021, financial assets of £249m (2020: £nil) were transferred in this manner and the carrying value of the assets representing continued involvement is included in the table above. For transfers of assets in relation to repurchase agreements, see Note 36. Continuing involvement in financial assets that have been derecognised In some cases, the Barclays Bank Group may have transferred a financial asset in its entirety but may have continuing involvement in it. This arises in asset securitisations where loans and asset backed securities were derecognised as a result of the Barclays Bank Group’s involvement with asset backed securities, residential mortgage backed securities and commercial mortgage securities. Continuing involvement largely arises from providing financing into these structures in the form of retained notes, which do not bear first losses. The table below shows the potential financial implications of such continuing involvement: Continuing involvement a Gain/(loss) from continuing involvement Carrying amount Fair value Maximum exposure to loss For the year ended Cumulative to 31 December Type of transfer £m £m £m £m £m 2021 Asset backed securities 25 25 25 1 2 Residential mortgage backed securities 78 78 78 3 4 Commercial mortgage backed securities 311 307 311 5 11 Total 414 410 414 9 17 2020 Asset backed securities 56 56 56 1 1 Residential mortgage backed securities 49 49 49 1 1 Commercial mortgage backed securities 243 237 243 2 6 Total 348 342 348 4 8 Note a Assets which represent the Barclays Bank Group’s continuing involvement in derecognised assets are recorded in Loans and advances at amortised cost and Debt Securities at FVTP&L. |
Assets pledged, collateral rece
Assets pledged, collateral received and assets transferred | 12 Months Ended |
Dec. 31, 2021 | |
Assets pledged, collateral received and assets transferred | |
Assets pledged, collateral received and assets transferred | Assets pledged, collateral received and assets transferred Assets are pledged or transferred as collateral to secure liabilities under repurchase agreements, securitisations and stock lending agreements or as security deposits relating to derivatives. Assets transferred are non-cash assets transferred to a third party that do not qualify for derecognition from the Barclays Bank Group’s balance sheet, for example because the Barclays Bank Group retains substantially all the exposure to those assets under an agreement to repurchase them in the future for a fixed price. Where non-cash assets are pledged or transferred as collateral for cash received, the asset continues to be recognised in full, and a related liability is also recognised on the balance sheet. Where non-cash assets are pledged or transferred as collateral in an exchange for non-cash assets, the transferred asset continues to be recognised in full, and there is no associated liability as the non-cash collateral received is not recognised on the balance sheet. The Barclays Bank Group is unable to use, sell or pledge the transferred assets for the duration of the transaction and remains exposed to interest rate risk and credit risk on these pledged assets. Unless stated, the counterparty's recourse is not limited to the transferred assets. The following table summarises the nature and carrying amount of the assets pledged as security against these liabilities: Barclays Bank Group 2021 2020 £m £m Cash collateral and settlement balances 63,080 69,271 Loans and advances at amortised cost 29,962 25,437 Trading portfolio assets 71,201 76,750 Financial assets at fair value through the income statement 5,595 5,584 Financial assets at fair value through other comprehensive income 14,699 15,303 Assets pledged 184,537 192,345 The following table summarises the transferred financial assets and the associated liabilities: Barclays Bank Group Transferred assets Associated liabilities £m £m At 31 December 2021 Derivatives 64,826 (64,826) Repurchase agreements 48,504 (28,494) Securities lending arrangements 66,703 — Other 4,504 (4,174) 184,537 (97,494) At 31 December 2020 Derivatives 72,732 (72,732) Repurchase agreements 58,398 (39,044) Securities lending arrangements 59,824 — Other 1,391 (1,134) 192,345 (112,910) Included within Other are agreements where a counterparty's recourse is limited to the transferred assets. The relationship between the transferred assets and the associated liabilities is that holders of notes may only look to cash flows from the securitised assets for payments of principal and interest due to them under the terms of their notes. Carrying value Fair value Transferred assets Associated liabilities Transferred assets Associated liabilities Net position £m £m £m £m £m Barclays Bank Group 2021 Recourse to transferred assets only 1,303 (1,225) 1,423 (1,219) 204 2020 Recourse to transferred assets only 963 (952) 1,051 (966) 85 The Barclays Bank Group has an additional £3.5bn (2020: £3.1bn) of loans and advances within its asset backed funding programmes that can readily be used to raise additional secured funding and are available to support future issuances. Total assets pledged includes a collateral pool put in place to provide security for the UKRF funding deficit, as referred to in Note 31. Collateral held as security for assets Under certain transactions, including reverse repurchase agreements and stock borrowing transactions, the Barclays Bank Group is allowed to resell or re-pledge the collateral held. The fair value at the balance sheet date of collateral accepted and re-pledged to others was as follows: Barclays Bank Group 2021 2020 £m £m Fair value of securities accepted as collateral 934,363 792,317 Of which fair value of securities re-pledged/transferred to others 819,169 684,389 49 |
Related party transactions and
Related party transactions and Directors' remuneration | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transactions between related parties [abstract] | |
Related party transactions and Directors remuneration | Related party transactions and Directors’ remuneration Related party transactions Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions, or one other party controls both. Parent company The parent company, which is also the ultimate parent company, is Barclays PLC, which holds 100% of the issued ordinary shares of Barclays Bank PLC. Subsidiaries Transactions between Barclays Bank PLC and its subsidiaries also meet the definition of related party transactions. Where these are eliminated on consolidation, they are not disclosed in the Barclays Bank Group’s financial statements. A list of the Barclays Bank Group’s principal subsidiaries is shown in Note 32. Fellow subsidiaries Transactions between the Barclays Bank Group and other subsidiaries of the parent company also meet the definition of related party transactions. Associates and other entities The Barclays Bank Group provides banking services to its associates and the Barclays Bank Group pension funds (principally the UK Retirement Fund), providing loans, overdrafts, interest and non-interest bearing deposits and current accounts to these entities as well as other services. Barclays Bank Group companies also provide investment management and custodian services to the Barclays Bank Group pension schemes. All of these transactions are conducted on the same terms as third party transactions. Summarised financial information for the Barclays Bank Group’s investments in associates and joint ventures is set out in Note 34. Amounts included in the Barclays Bank Group’s financial statements, in aggregate, by category of related party entity are as follows: Parent Fellow subsidiaries Associates Pension funds £m £m £m £m For the year ended and as at 31 December 2021 Total income (611) 20 — 3 Operating expenses (64) (3,195) — (1) Total assets 6,491 909 — 3 Total liabilities 32,141 3,962 177 81 For the year ended and as at 31 December 2020 Total income (606) 41 — 3 Operating expenses (62) (2,937) — (1) Total assets 6,803 1,917 — 4 Total liabilities 25,819 3,954 66 69 Total liabilities include derivatives transacted on behalf of the pensions funds of £18m (2020: £13m). Key Management Personnel Key Management Personnel are defined as those persons having authority and responsibility for planning, directing and controlling the activities of Barclays Bank PLC (directly or indirectly) and comprise the Directors and Officers of Barclays Bank PLC, certain direct reports of the Chief Executive and the heads of major business units and functions. The Barclays Bank Group provides banking services to Key Management Personnel and persons connected to them. Transactions during the year and the balances outstanding were as follows: Loans outstanding 2021 2020 £m £m As at 1 January — — Loans issued during the year a — — Loan repayments during the year b — — As at 31 December — — Notes a Includes loans issued to existing Key Management Personnel and new or existing loans issued to newly appointed Key Management Personnel. b Includes loan repayments by existing Key Management Personnel and loans to former Key Management Personnel. No allowances for impairment were recognised in respect of loans to Key Management Personnel (or any connected person). Deposits outstanding 2021 2020 £m £m As at 1 January 3.4 4.2 Deposits received during the year a 9.0 13.3 Deposits repaid during the year b (10.3) (14.1) As at 31 December 2.1 3.4 Notes a Includes deposits received from existing Key Management Personnel and new or existing deposits received from newly appointed Key Management Personnel. b Includes deposits repaid by existing Key Management Personnel and deposits of former Key Management Personnel. Total commitments outstanding Total commitments outstanding refer to the total of any undrawn amounts on credit card and/or overdraft facilities provided to Key Management Personnel. Total commitments outstanding as at 31 December 2021 were £0.1m (2020: £0.2m). All loans to Key Management Personnel (and persons connected to them) were made in the ordinary course of business; were made on substantially the same terms, including interest rates and collateral, as those prevailing at the same time for comparable transactions with other persons; and did not involve more than a normal risk of collectability or present other unfavourable features. Remuneration of Key Management Personnel Total remuneration awarded to Key Management Personnel below represents the awards made to individuals that have been approved by the Board Remuneration Committee as part of the latest remuneration decisions. Costs recognised in the income statement reflect the accounting charge for the year included within operating expenses. The difference between the values awarded and the recognised income statement charge principally relates to the recognition of deferred costs for prior year awards. Figures are provided for the period that individuals met the definition of Key Management Personnel. 2021 2020 £m £m Salaries and other short-term benefits 35.2 37.5 Pension costs 0.2 0.1 Other long-term benefits 8.5 7.2 Share-based payments 13.2 12.4 Employer social security charges on emoluments 6.0 6.0 Costs recognised for accounting purposes 63.1 63.2 Employer social security charges on emoluments (6.0) (6.0) Other long-term benefits – difference between awards granted and costs recognised 3.3 0.4 Share-based payments – difference between awards granted and costs recognised 6.1 1.3 Total remuneration awarded 66.5 58.9 Disclosure required by the Companies Act 2006 The following information regarding the Barclays Bank PLC Board of Directors is presented in accordance with the Companies Act 2006: 2021 2020 £m £m Aggregate emoluments a 6.3 6.4 Amounts paid under LTIPs b 1.2 — 7.5 6.4 Notes a The aggregate emoluments include amounts paid for the 2021 year. In addition, deferred share awards for 2021 with a total value at grant of £1.4m (2020: £0.6m) will be made to Directors which will only vest subject to meeting certain conditions. b The figure above for "Amounts paid under LTIPs" for 2021 relates to LTIP awards that were released to Directors in 2021. This includes the first tranche of the 2017 LTIP, the release of which was delayed from June 2020 to March 2021. Dividend shares released on the awards are excluded (where applicable). There were no pension contributions paid to defined contribution schemes on behalf of Directors (2020: £nil). There were no notional pension contributions to defined contribution schemes. As at 31 December 2021, there were no Directors accruing benefits under a defined benefit scheme (2020: nil). The aggregate amount of compensation payable to departing officers in respect of loss of office was £426,139 (2020: £1,850,713). Of the figures in the table above, the amounts attributable to the highest paid Director in respect of qualifying services are as follows: 2021 2020 £m £m Aggregate emoluments a 2.1 3.0 Amounts paid under LTIPs 0.7 — 2.8 3.0 Note a The aggregate emoluments include amounts paid for the 2021 year. There were no actual pension contributions paid to defined contribution schemes on behalf of the highest paid Director (2020: £nil). There were no notional pension contributions to defined contribution schemes (2020: £nil). Advances and credit to Directors and guarantees on behalf of Directors In accordance with Section 413 of the Companies Act 2006, the total amount of advances and credits made available in 2021 to persons who served as Directors during the year was £nil (2020: £nil). The total value of guarantees entered into on behalf of Directors during 2021 was £nil (2020: £nil). |
Disposal of business
Disposal of business | 12 Months Ended |
Dec. 31, 2021 | |
Non-current assets or disposal groups classified as held for sale or as held for distribution to owners [abstract] | |
Disposal of business | Disposal of businessDuring the year, Barclays Bank PLC sold its investment in Barclays Insurance Guernsey PCC to Barclays Principal Investments Limited, a fellow Barclays PLC Group company, at its fair value of £65m. The Barclays Bank Group recorded a loss on disposal of £10m. |
Auditor's remuneration
Auditor's remuneration | 12 Months Ended |
Dec. 31, 2021 | |
Auditor's remuneration [abstract] | |
Auditor's remuneration | Auditor’s remuneration Auditor’s remuneration is included within consultancy, legal and professional fees in administration and general expenses and comprises: 2021 2020 2019 £m £m £m Audit of the Barclays Bank Group's annual accounts 19 17 16 Other services: Audit of the Barclays Bank PLC subsidiaries a 14 13 12 Other audit related fees b 7 7 6 Other services 1 1 1 Total Auditor's remuneration 41 38 35 Notes a Comprises the fees for the statutory audit of the subsidiaries both inside and outside UK and fees for the work performed by associates of KPMG in respect of the consolidated financial statements of the Company. b Comprises services in relation to statutory and regulatory filings. These include audit services for the review of the interim financial information under the Listing Rules of the UK listing authority. |
Interest rate benchmark reform
Interest rate benchmark reform | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial instruments by type of interest rate [abstract] | |
Interest rate benchmark reform | Interest rate benchmark reform Following the financial crisis, the reform and replacement of benchmark interest rates such as LIBOR has been a priority for global regulators. As a result, the UK’s Financial Conduct Authority (FCA) and other global regulators instructed market participants to prepare for the cessation of most LIBOR rates after the end of 2021 and to adopt “near Risk-Free Rates” (RFRs). Pursuant to FCA announcements during 2021, panel bank submissions for all GBP, JPY and CHF LIBOR and Euro Overnight Index Average (EONIA) tenors ceased, and representative LIBOR rates also ceased after 31 December 2021. For USD, certain actively used tenors will continue to be provided until June 2023; however, in line with the US banking regulators’ joint statement, Barclays ceased issuing or entering into new contracts that use USD LIBOR as a reference rate from 31 December 2021, other than in relation to those allowable use cases set out under the FCA's prohibition notice (ref 21A). These include market making in support of client activity; or transactions that reduce or hedge Barclays’ or any client of Barclays’ US dollar LIBOR exposure on contracts entered into before 1 January 2022. The Barclays Bank Group’s exposure to rates subject to benchmark interest rate reform has been predominantly to GBP, USD, JPY and CHF LIBOR and EONIA with the vast majority concentrated in derivatives within the Corporate and Investment Bank. Some additional exposure resides on floating rate loans and advances, repurchase agreements and debt securities held and issued within the Corporate and Investment Bank. Following transition activity in late 2021 and early 2022, GBP, USD (one week and two month tenors), JPY and CHF LIBOR and EONIA positions (“2021 scope”) have transitioned onto RFRs, and while there are a number of IBORs yet to cease, Barclays Bank Group’s exposure is now mainly to USD LIBOR. There are key differences between IBORs and RFRs. IBORs are ‘term rates’, which means that they are published for a borrowing period (for example three months), and they are ‘forward-looking’, because they are published at the beginning of a borrowing period, based upon an estimated inter-bank borrowing cost for the period. RFRs are based upon overnight rates from actual transactions, and are therefore published after the end of the overnight borrowing period. Furthermore, IBORs include a credit spread over the RFRs. Therefore, to transition existing contracts and agreements to RFRs, adjustments for term and credit differences may need to be applied to RFR-linked rates. The methodologies for these adjustments have been determined through in-depth consultations by industry working groups, on behalf of the respective global regulators and related market participants. How the Barclays Group is managing the transition to alternative benchmark rates Barclays has established a Group-wide LIBOR Transition Programme, with oversight from the Barclays Group Finance Director. The Transition Programme spans all business lines and has cross-functional governance which includes Legal, Compliance, Conduct Risk, Client Engagement and Communications, Risk, and Finance. The Transition Programme aims to drive strategic execution, and identify, manage and resolve key risks and issues as they arise. Barclays’ transition plans primarily focus on G5 currencies while providing quarterly updates on progress and exposures to the PRA/FCA and other regulators as required. The Transition Programme follows a risk based approach, using recognised ‘change delivery’ control standards. Accountable Executives are in place within key working groups and workstreams, with overall Board oversight delegated to the Board Risk Committee and the Barclays Group Finance Director. Barclays performs a prominent stewardship role to drive orderly transition via our representation on official sector and industry working groups across all major jurisdictions and product classes. Additionally, the Barclays Group Finance Director is Chair of the UK’s ‘Working Group on Sterling Risk-Free Reference Rates’ (UK £RFRWG), whose mandate is to catalyse a broad-based transition to using SONIA (‘Sterling Overnight Index Average’), as the primary sterling interest rate benchmark in bond, loan and derivatives markets. Approaches to transition exposure expiring post the expected end dates for LIBOR vary by product and nature of counterparty. The Barclays Group has actively engaged with the counterparties to transition or include appropriate fallback provisions and transition mechanisms in its floating rate assets and liabilities with maturities after 2021, when relevant IBORs excluding USD LIBOR ceased to be published. The fallback will provide the relevant replacement rate. In the case of the ISDA Protocol it is the RFR plus a credit adjusted spread that should be used post cessation or pre-cessation of the relevant IBOR. For the derivative population, adherence to the ISDA IBOR Fallbacks Protocol has provided Barclays with an efficient mechanism to amend outstanding trades to incorporate fallbacks. Beyond the ISDA IBOR Fallbacks Protocol, other options have included terminating or bilaterally agreeing new terms with counterparties. Derivative contracts facing central clearing counterparties have followed a market-wide, standardised approach to reform through a series of CCP-led conversions. The FCA has authorised broad usage of synthetic LIBOR as a temporary solution for the ‘tough legacy’ population of unremediated contracts for GBP and JPY. Given cleared derivatives for the 2021 scope transitioned via CCP driven conversions, synthetic LIBOR does not apply in this context. In line with regulatory expectations, Barclays’ strategy remains to actively transition LIBOR exposure where viable, and/or to implement and utilise robust contractual fallbacks where possible. Where contracts remain unremediated, they may be able to utilise synthetic LIBOR on a temporary basis. Barclays will continue to monitor, assess and limit the reliance on synthetic LIBOR. As announced by the FCA on 5 March 2021, USD LIBOR tenors (except 1 week and 2 month tenors) will cease to be representative from 30 June 2023. As detailed above, the key area of focus for transition prior to 2022 was on the other non-USD IBOR currency-tenors that ceased to be published at the end of 2021. Cessation of new USD LIBOR trading and transition of USD LIBOR exposures is the priority for the Barclays LIBOR Transition Programme in 2022/23. Clients and colleagues have been notified that we have prohibited entering into new USD LIBOR transactions (with narrow permitted exceptions) from 1 January 2022 in line with regulatory expectations. Whilst synthetic LIBOR will be published on a temporary basis for 1, 3 and 6 month tenors of GBP and JPY LIBOR to assist the transition of certain exposures, no synthetic rate has been announced for USD LIBOR. New York State legislation has been enacted (with US Federal legislation to follow) which provides a solution for contracts governed under New York law for USD LIBOR to the Secured Overnight Financing Rate (SOFR) transition with the additional benefit of statutory contract continuity and safe harbour protection. This contrasts with the legislation implemented in the UK which provides for statutory contract continuity with safe harbour protection only for the administrator, and could expose market participants to additional litigation risk. Clients have been engaged on the transition of their legacy USD LIBOR exposures through active transition or the implementation of fallbacks, and have been issued with communications on key regulatory developments in the transition away from USD LIBOR. Progress made during 2021 During 2021, the Barclays Bank Group delivered RFR product capabilities and alternatives to LIBOR across loans, bonds, securities financing transactions and derivatives required for LIBOR cessation to support transition of legacy contracts. Barclays Bank Group has transitioned over 99% (by gross notional exposure) of legacy positions in those rates within the 2021 scope, onto new RFRs in line with official sector expectations and milestones. This has been achieved through bilateral negotiation of contracts with clients, including the use of appropriate fallback provisions (which became effective post 31 December 2021, however, note that the switch onto the RFR may not take place until next reset post 31 December 2021 and so exposures may still be reported as LIBOR) and taking part in large scale transition events at a number of Central Counterparty Clearing Houses (London Clearing House (LCH), Chicago Mercantile Exchange (CME), EUREX and Japan Securities Clearing Corporation (JSCC) for OTC derivatives and Intercontinental Exchange (ICE) EU and LCH CurveGlobal for exchange traded derivatives). In relation to those contracts yet to be transitioned, we remain in active dialogue with clients. Barclays Bank Group transitioned the EONIA / LIBOR language in all active Credit Support Annexes (CSAs) via a number of mechanisms, primarily through bilateral CSA amendments but also by means of adherence to the ISDA 2021 EONIA Collateral Agreement Fallbacks Protocol. Barclays Bank Group delivered technology and business process changes required to ensure operational readiness in preparation for LIBOR cessation and transitions to RFRs for those benchmark rates ceasing at the end of 2021. Any incremental Technology or Business Process changes required to support USD LIBOR cessation will be delivered ahead of 30 June 2023. Whilst the majority of IBOR exposures have moved to RFRs, where appropriate other rates such as fixed rates or Bank of England base rates have also been used. Risks to which the Barclays Bank Group is exposed as a result of the transition Global regulators and central banks in the UK, US and EU have been driving international efforts to reform key benchmark interest rates and indices, such as LIBOR, which are used to determine the amounts payable under a wide range of transactions and make them more reliable and robust. These benchmark reforms have resulted in significant changes to the methodology and operation of certain benchmarks and indices, the adoption of RFRs, the discontinuation of certain reference rates (including LIBOR), and the introduction of implementing legislation and regulations. Specifically, regulators in the UK, US and EU have directed that certain non-US dollar LIBOR tenors cease at the end of 2021. Certain US dollar LIBOR tenors are to cease by the end of June 2023, and restrictions have been imposed on new use of USD LIBOR. Notwithstanding these developments, given the unpredictable consequences of benchmark reform, any of these developments could have an adverse impact on market participants, including the Group, in respect of any financial instruments linked to, or referencing, any of these benchmark interest rates. Uncertainty associated with such potential changes, including the availability and/or suitability of alternative RFRs, the participation of customers and third-party market participants in the transition process; challenges with respect to required documentation changes; and impact of legislation to deal with ‘certain legacy’ contracts that cannot convert into or add fall-back RFRs before cessation of the benchmark they reference, may adversely affect a broad range of transactions (including any securities, loans and derivatives which use LIBOR or any other affected benchmark to determine the amount of interest payable that are included in the Barclays Bank Group’s financial assets and liabilities) that use these reference rates and indices, and present a number of risks for the Barclays Bank Group, including, but not limited to: • Conduct risk: in undertaking actions to transition away from using certain reference rates (such as LIBOR) to new alternative RFRs, the Barclays Bank Group faces conduct risks. These may lead to customer complaints, regulatory sanctions or reputational impact if the Barclays Bank Group is considered to be (among other things) (i) undertaking market activities that are manipulative or create a false or misleading impression, (ii) misusing sensitive information or not identifying or appropriately managing or mitigating conflicts of interest, (iii) providing customers with inadequate advice, misleading information, unsuitable products or unacceptable service, (iv) not taking a consistent approach to remediation for customers in similar circumstances, (v) unduly delaying the communication and migration activities in relation to client exposure, leaving them insufficient time to prepare, or (vi) colluding or inappropriately sharing information with competitors. • Litigation risk : members of the Barclays Bank Group may face legal proceedings, regulatory investigations and/or other actions or proceedings regarding (among other things) (i) the conduct risks identified above, (ii) the interpretation and enforceability of provisions in LIBOR-based contracts, and (iii) the Barclays Bank Group’s preparation and readiness for the replacement of LIBOR with alternative RFRs. • Financial risk: the valuation of certain of the Barclays Bank Group’s financial assets and liabilities may change. Moreover, transitioning to alternative RFRs may impact the ability of members of the Barclays Bank Group to calculate and model amounts receivable by them on certain financial assets and determine the amounts payable on certain financial liabilities (such as debt securities issued by them) because certain alternative RFRs (such as the SONIA and SOFR) are look-back rates whereas term rates (such as LIBOR) allow borrowers to calculate at the start of any interest period exactly how much is payable at the end of such interest period. This may have a material adverse effect on the Barclays Bank Group’s cash flows. • Pricing risk: changes to existing reference rates and indices, discontinuation of any reference rate or indices and transition to alternative RFRs may impact the pricing mechanisms used by the Barclays Bank Group on certain transactions. • Operational risk: changes to existing reference rates and indices, discontinuation of any reference rate or index and transition to alternative RFRs may require changes to the Barclays Bank Group’s IT systems, trade reporting infrastructure, operational processes, and controls. In addition, if any reference rate or index (such as LIBOR) is no longer available to calculate amounts payable, the Barclays Bank Group may incur additional expenses in amending documentation for new and existing transactions and/or effecting the transition from the original reference rate or index to a new reference rate or index. • Accounting risk: an inability to apply hedge accounting in accordance with IAS 39 could lead to increased volatility in the Barclays Bank Group’s financial results and performance. Any of these factors may have a material adverse effect on the Barclays Bank Group’s business, results of operations, financial condition, prospects and reputation. While a number of the above risks in relation to transition of legacy 2021 scope onto RFRs have been substantially mitigated, they remain relevant in relation to USD and related LIBOR rate transitions. The Barclays Bank Group does not expect material changes to its risk management approach and strategy as a result of interest rate benchmark reform. The following table summarises the significant exposures impacted by interest rate benchmark reform: As at 31 December 2021 GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 11,761 15,801 24 222 442 28,250 Reverse repurchase agreements and other similar secured lending — 186 — — — 186 Financial assets at fair value through the income statement 101 8,538 5 327 194 9,165 Financial assets at fair value through other comprehensive income — — — — — — Non-derivative financial assets 11,862 24,525 29 549 636 37,601 Non-derivative financial liabilities Debt securities in issue — — — — — — Subordinated liabilities (36) (3,774) (1,213) — (113) (5,136) Financial liabilities designated at fair value (708) (212) — — — (920) Non-derivative financial liabilities (744) (3,986) (1,213) — (113) (6,056) Equity Other equity instruments — (3,062) — — — (3,062) Standby facilities, credit lines and other commitments a 58,094 42,767 1,284 375 12,973 115,493 As at 31 December 2020 GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 19,317 17,990 173 11 1,725 39,216 Reverse repurchase agreements and other similar secured lending — 334 — — — 334 Financial assets at fair value through the income statement 1,190 6,373 — 283 209 8,055 Financial assets at fair value through other comprehensive income 186 106 — — 8 300 Non-derivative financial assets 20,693 24,803 173 294 1,942 47,905 Non-derivative financial liabilities Debt securities in issue — (1,430) (22) — — (1,452) Subordinated liabilities (21) (876) — — — (897) Financial liabilities designated at fair value (149) (1,273) (759) — (139) (2,320) Non-derivative financial liabilities (170) (3,579) (781) — (139) (4,669) Equity Other equity instruments (2,122) (3,062) — — — (5,184) Standby facilities, credit lines and other commitments a 18,169 74,008 — 74 15,951 108,202 Notes a There has been a change on how exposures for multi currency loan facilities are reported in 2021, from base currency to the currency which needs to be remediated first. This has resulted in an increase in GBP LIBOR and a corresponding reduction in USD LIBOR exposure of £34bn. 2020 comparatives have not been restated to reflect this change. b Includes EUR LIBOR and SOR The table above represents the exposures to interest rate benchmark reform by balance sheet account, which have yet to transition. The exposure disclosed is for positions with contractual maturities after 31 December 2021 (apart from USD, which is for maturities after 30 June 2023). Trades with exposures to other IBORs whose respective cessation dates is in the future and mature before that date have been excluded (2020: exposures are disclosed for maturities after 31 December 2021 for all rates). Balances reported at amortised cost are disclosed at their gross carrying value and do not include any expected credit losses that may be held against them. The following table represents the derivative exposures to interest rate benchmark reform, which have yet to transition: As at 31 December 2021 GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 245,604 2,283,077 7,811 140,357 4,396 61,937 2,743,182 OTC interest rate derivatives - cleared by central counterparty — 2,211,729 — — — 168,649 2,380,378 Exchange traded interest rate derivatives — 466,339 — — — — 466,339 OTC foreign exchange derivatives 183,477 461,680 — 122,823 32,900 1,419 802,299 OTC equity and stock index derivatives — 9,949 — — — — 9,949 Derivative notional contract amount 429,081 5,432,774 7,811 263,180 37,296 232,005 6,402,147 As at 31 December 2020 GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 596,564 2,832,339 457,844 754,206 25,681 41,782 4,708,416 OTC interest rate derivatives - cleared by central counterparty 1,552,637 2,872,962 623,802 1,091,479 119,382 198,113 6,458,375 Exchange traded interest rate derivatives 300,182 333,705 — — 2,494 — 636,381 OTC foreign exchange derivatives 155,285 589,332 — 93,108 31,257 1,921 870,903 OTC equity and stock index derivatives 1,845 7,946 544 1,929 491 2,141 14,896 Derivative notional contract amount 2,606,513 6,636,284 1,082,190 1,940,722 179,305 243,957 12,688,971 Note a Includes EUR LIBOR, SOR and STIBOR The exposure disclosed is for positions with contractual maturities after 31 December 2021 (apart from USD, which is for maturities after 30 June 2023). Trades with exposures to other IBORs whose respective cessation dates is in the future and mature before that date have been excluded (2020: exposures are disclosed for maturities after 31 December 2021 for all rates). Derivatives are reported by using the notional contract amount and where derivatives have both pay and receive legs with exposure to benchmark reform, such as cross currency swaps, the notional contract amount is disclosed for both legs. As at 31 December 2021, there were £256bn (2020: £264bn) of cross currency swaps where both the pay and receive legs are impacted by interest rate benchmark reform. The Barclays Bank Group also had £9bn (2020: £23bn) of Barclays issued debt retained by the Barclays Bank Group, impacted by the interest rate benchmark reform, in USD LIBOR (2020: predominately in GBP and USD LIBOR.) Fallback clauses The 31 December 2021 exposure has been broken up into those with robust fallbacks and those without. Fallbacks here are defined as any mechanism involving a ‘switch’ or ‘hardwire’ or a contractual agreement to transition to an automatically selected rate. One of the most commonly used is the ISDA 2020 IBOR Protocol published in October 2020 which enabled market participants to incorporate fallback provisions into legacy non-cleared derivatives and certain non-derivatives transactions. Market participants who have adhered to the ISDA 2020 IBOR Protocol agree, between adhering parties, that their legacy contracts will be amended to include the relevant fallback provisions. In addition to this, ISDA developed bilateral Swap Rate Fallbacks templates for GBP and JPY Swap Rate bilateral derivative trades with the GBP ICE Swap Rate fallback provisions being published in August 2021 and the JPY ISDA Swap Rate fallback provisions being published in November 2021. Whilst the fallback provisions have been applied to the majority of trades, with some limited exceptions being worked through, the switch to the replacement rate as a result of fallback provision inclusion may not take place until the next rate reset post the cessation or pre-cessation event. The following tables present a breakdown of the exposures to IBOR reform (excluding USD LIBOR and other IBORs whose respective cessation dates is in the future) with fallbacks in place and those without. With appropriate fallback clause Without appropriate fallback clause GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 7,389 — 210 413 8,012 4,372 24 12 29 4,437 Financial assets at fair value through the income statement 84 5 327 8 424 17 — — 186 203 Non-derivative financial assets 7,473 5 537 421 8,436 4,389 24 12 215 4,640 Non-derivative financial liabilities Subordinated liabilities (36) (1,213) — — (1,249) — — — — — Financial liabilities designated at fair value (708) — — — (708) — — — — — Non-derivative financial liabilities (744) (1,213) — — (1,957) — — — — — Standby facilities, credit lines and other commitments 36,087 657 375 9,436 46,555 22,007 627 — 3,538 26,172 The majority of the remaining exposures without fallbacks in place are either undrawn facilities or syndicated facilities where the transition is led by a third party agent. Work is ongoing with clients and agents to transition facilities or insert fallbacks prior to the next rate reset. There may be some scenarios where synthetic LIBOR is temporarily used whilst Barclays continues to work with the client to remediate their exposures, with little expectation of longer term usage. With appropriate fallback clause Without appropriate fallback clause GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 234,813 7,568 135,720 4,362 3,626 386,089 10,791 244 4,638 35 403 16,111 OTC foreign exchange derivatives 183,203 — 122,822 32,900 — 338,925 274 — 1 — — 275 Derivative notional contract amount 418,016 7,568 258,542 37,262 3,626 725,014 11,065 244 4,639 35 403 16,386 Exposures that have not actively transitioned and do not have robust fallbacks in place will not necessarily need to apply the FCA’s approach to ‘tough legacy’ contracts and utilise synthetic LIBOR rates. In many cases, work is ongoing to transition trades or insert fallbacks prior to the next rate reset. There may be some scenarios where synthetic LIBOR is temporarily used whilst Barclays continues to work with the client to remediate their exposures, with little expectation of longer term usage. It is also key to note that not all remaining exposures can leverage synthetic LIBOR. CHF LIBOR, EUR LIBOR and EONIA do not have any synthetic LIBOR available and only the more commonly used, 1M, 3M and 6M GBP LIBOR and JPY LIBOR tenors have a synthetic rate being published. The volume of these residual exposures is very low and work is focused on transitioning these prior to next reset. The majority of remaining exposures where no synthetic rate is available are bilateral derivatives using GBP/JPY Swap Rates within the Markets businesses. The focus for these is agreeing the bilateral swap rate fallbacks that were published by ISDA in August (for GBP) and November (for JPY) 2021. Continued uptake of these bilateral fallbacks has been seen in early 2022 . |
Significant accounting polici_2
Significant accounting policies (Policy) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of objectives, policies and processes for managing capital [abstract] | |
Compliance with International Financial Reporting Standards | The principal accounting policies applied in the preparation of the consolidated and separate financial statements are set out below, and in the relevant notes to the financial statements. These policies have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. |
Basis of preparation | The consolidated and separate financial statements have been prepared under the historical cost convention modified to include the fair valuation of investment property, and particular financial instruments, to the extent required or permitted under IFRS as set out in the relevant accounting policies. The financial statements are stated in millions of pounds Sterling (£m), the functional currency of Barclays Bank PLC. The financial statements have been prepared on a going concern basis, in accordance with the Companies Act 2006 as applicable to companies using IFRS. The financial statements are prepared on a going concern basis as the Board is satisfied that the Barclays Bank Group and parent company have the resources to continue in business for a period of at least 12 months from approval of the financial statements. In making this assessment, the Board has considered a wide range of information relating to present and future conditions and includes a review of a working capital report (WCR). The WCR is used by the Board to assess the future performance of the Barclays Bank Group and whether it has the resources in place that are required to meet its ongoing regulatory requirements. The assessment is based upon business plans which contain future forecasts of profitability taken from the Barclays Bank Group’s medium term plan as well as projections of regulatory capital requirements and business funding needs. The WCR also includes an assessment the impact of internally generated stress testing scenarios on the liquidity and capital requirement forecasts. The stress tests used were based upon an assessment of reasonably possible downside economic scenarios that the Barclays Bank Group could experience. The WCR showed that the Barclays Bank Group had sufficient capital and liquidity in place to support its future business requirements and remained above its regulatory minimum requirements in the stress scenarios. Accordingly, the Board concluded that there was a reasonable expectation that the Barclays Bank Group has adequate resources to continue as a going concern for a period of at least 12 months from the date of approval of the financial statements. |
Consolidation | Consolidation The Barclays Bank Group applies IFRS 10 Consolidated financial statements . The consolidated financial statements combine the financial statements of Barclays Bank PLC and all its subsidiaries. Subsidiaries are entities over which Barclays Bank PLC has control. The Barclays Bank Group has control over another entity when the Barclays Bank Group has all of the following: 1) power over the relevant activities of the investee, for example through voting or other rights 2) exposure to, or rights to, variable returns from its involvement with the investee and 3) the ability to affect those returns through its power over the investee. The assessment of control is based on the consideration of all facts and circumstances. The Barclays Bank Group reassesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Intra-group transactions and balances are eliminated on consolidation. Consistent accounting policies are used throughout the Barclays Bank Group for the purposes of the consolidation. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has already been obtained and they do not result in loss of control. As the consolidated financial statements include partnerships where the Barclays Bank Group member is a partner, advantage has been taken of the exemption under Regulation 7 of the Partnership (Accounts) Regulations 2008 with regard to preparing and filing of individual partnership financial statements. |
Foreign currency translation | Foreign currency translation The Barclays Bank Group applies IAS 21 The Effects of Changes in Foreign Exchange Rates . Transactions in foreign currencies are translated into Sterling at the rate ruling on the date of the transaction. Foreign currency monetary balances are translated into Sterling at the period end exchange rates. Exchange gains and losses on such balances are taken to the income statement. Non-monetary foreign currency balances in relation to items measured in terms of historical cost are carried at historical transaction date exchange rates. Non-monetary foreign currency balances in relation to items measured at fair value are translated using the exchange rate at the date when the fair value was measured. The Barclays Bank Group’s foreign operations (including subsidiaries, joint ventures, associates and branches) based mainly outside the UK may have different functional currencies. The functional currency of an operation is the currency of the main economy to which it is exposed. Prior to consolidation (or equity accounting) the assets and liabilities of non-Sterling operations are translated at the period end exchange rate and items of income, expense and other comprehensive income are translated into Sterling at the rate on the date of the transactions. Exchange differences arising on the translation of foreign operations are included in currency translation reserves within equity. These are transferred to the income statement when the Barclays Bank Group disposes of the entire interest in a foreign operation, when partial disposal results in the loss of control of an interest in a subsidiary, when an investment previously accounted for using the equity method is accounted for as a financial asset, or on the disposal of a foreign operation within a branch. |
Financial assets and liabilities | Financial assets and liabilities The Barclays Bank Group applies IFRS 9 Financial Instruments to the recognition, classification and measurement, and derecognition of financial assets and financial liabilities and the impairment of financial assets. The Barclays Bank Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. Recognition The Barclays Bank Group recognises financial assets and liabilities when it becomes a party to the terms of the contract. Trade date or settlement date accounting is applied depending on the classification of the financial asset. Classification and measurement Financial assets are classified on the basis of two criteria: i) the business model within which financial assets are managed; and ii) their contractual cash flow characteristics (whether the cash flows represent ‘solely payments of principal and interest’ (SPPI)). The Barclays Bank Group assesses the business model criteria at a portfolio level. Information that is considered in determining the applicable business model includes (i) policies and objectives for the relevant portfolio, (ii) how the performance and risks of the portfolio are managed, evaluated and reported to management, and (iii) the frequency, volume and timing of sales in prior periods, sales expectation for future periods, and the reasons for such sales. The contractual cash flow characteristics of financial assets are assessed with reference to whether the cash flows represent SPPI. In assessing whether contractual cash flows are SPPI compliant, interest is defined as consideration primarily for the time value of money and the credit risk of the principal outstanding. The time value of money is defined as the element of interest that provides consideration only for the passage of time and not consideration for other risks or costs associated with holding the financial asset. Terms that could change the contractual cash flows so that it would not meet the condition for SPPI are considered, including: (i) contingent and leverage features, (ii) non-recourse arrangements and (iii) features that could modify the time value of money. Financial assets are measured at amortised cost if they are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, and their contractual cash flows represent SPPI. Financial assets are measured at fair value through other comprehensive income if they are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and their contractual cash flows represent SPPI. Other financial assets are measured at fair value through profit and loss. There is an option to make an irrevocable election on initial recognition for non traded equity investments to be measured at fair value through other comprehensive income, in which case dividends are recognised in profit or loss, but gains or losses are not reclassified to profit or loss upon derecognition, and the impairment requirements of IFRS 9 do not apply. The accounting policy for each type of financial asset or liability is included within the relevant note for the item. The Barclays Bank Group’s policies for determining the fair values of the assets and liabilities are set out in Note 16. Derecognition The Barclays Bank Group derecognises a financial asset, or a portion of a financial asset, from its balance sheet where (i) the contractual rights to cash flows from the asset have expired, or (ii) the contractual rights to the cash flows from the asset have been transferred (usually by sale) and with them either (a) substantially all the risks and rewards of the asset have been transferred, or (b) where neither substantially all the risks and rewards have been transferred or retained, where control over the asset has been lost. Financial liabilities are de-recognised when the liability has been settled, has expired or has been extinguished. An exchange of an existing financial liability for a new liability with the same lender on substantially different terms – generally a difference of 10% or more in the present value of the cash flows or a substantive qualitative amendment – is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Transactions in which the Barclays Bank Group transfers assets and liabilities, portions of them, or financial risks associated with them can be complex and it may not be obvious whether substantially all of the risks and rewards have been transferred. It is often necessary to perform a quantitative analysis. Such an analysis compares the Barclays Bank Group’s exposure to variability in asset cash flows before the transfer with its retained exposure after the transfer. A cash flow analysis of this nature may require judgement. In particular, it is necessary to estimate the asset’s expected future cash flows as well as potential variability around this expectation. The method of estimating expected future cash flows depends on the nature of the asset, with market and market-implied data used to the greatest extent possible. The potential variability around this expectation is typically determined by stressing underlying parameters to create reasonable alternative upside and downside scenarios. Probabilities are then assigned to each scenario. Stressed parameters may include default rates, loss severity, or prepayment rates. |
Accounting for reverse repurchase and repurchase agreements including other similar lending and borrowing | Accounting for reverse repurchase and repurchase agreements including other similar lending and borrowing Reverse repurchase agreements (and stock borrowing or similar transactions) are a form of secured lending whereby the Barclays Bank Group provides a loan or cash collateral in exchange for the transfer of collateral, generally in the form of marketable securities subject to an agreement to transfer the securities back at a fixed price in the future. Repurchase agreements are where the Barclays Bank Group obtains such loans or cash collateral, in exchange for the transfer of collateral. The Barclays Bank Group purchases (a reverse repurchase agreement) or borrows securities subject to a commitment to resell or return them. The securities are not included in the balance sheet as the Barclays Bank Group does not acquire the risks and rewards of ownership. Consideration paid (or cash collateral provided) is accounted for as a loan asset at amortised cost, unless it is designated or mandatorily at fair value through profit and loss. The Barclays Bank Group may also sell (a repurchase agreement) or lend securities subject to a commitment to repurchase or redeem them. The securities are retained on the balance sheet as the Barclays Bank Group retains substantially all the risks and rewards of ownership. Consideration received (or cash collateral provided) is accounted for as a financial liability at amortised cost, unless it is designated at fair value through profit and loss. |
Issued debt and equity instruments | Issued debt and equity instruments The Barclays Bank Group applies IAS 32, Financial Instruments: Presentation , to determine whether funding is either a financial liability (debt) or equity. Issued financial instruments or their components are classified as liabilities if the contractual arrangement results in the Barclays Bank Group having an obligation to either deliver cash or another financial asset, or a variable number of equity shares, to the holder of the instrument. If this is not the case, the instrument is generally an equity instrument and the proceeds included in equity, net of transaction costs. Dividends and other returns to equity holders are recognised when paid or declared by the members at the Annual General Meeting and treated as a deduction from equity. Where issued financial instruments contain both liability and equity components, these are accounted for separately. The fair value of the debt is estimated first and the balance of the proceeds is included within equity. |
Changes in the basis for determining contractual cash flows resulting from interest rate benchmark reform | Changes in the basis for determining contractual cash flows resulting from interest rate benchmark reform A change in the basis for determining the contractual cash flows of a financial instrument that is required by interest rate benchmark reform is accounted for by updating the effective interest rate, without the recognition of an immediate gain or loss. This practical expedient is only applied where (1) the change to the contractual cash flows is necessary as a direct consequence of the reform and (2) the new basis for determining the contractual cash flows is economically equivalent to the previous basis. For changes made in addition to those required by the interest rate benchmark reform, the practical expedient is applied first, after which the normal IFRS 9 requirements for modifications of financial instruments is applied. Refer to Note 13 for further details regarding hedge accounting policies in respect of interest rate benchmark reform. Refer to Note 40 for further disclosure related to interest rate benchmark reform. |
Cash flow statement | Cash flow statementCash comprises cash on hand and balances at central banks. Cash equivalents comprise loans and advances to banks, cash collateral balances with central banks related to payment schemes and treasury and other eligible bills, all with original maturities of three months or less. Repurchase and reverse repurchase agreements are not considered to be part of cash equivalents.Investments in debt securities at amortised cost, presented within loans and advances on the balance sheet, are deemed to be investing activities for the purposes of the cash flow statement, except those instruments considered to be cash equivalents. |
New and amended standards and interpretations | New and amended standards and interpretations The accounting policies adopted have been consistently applied, with the exception of the Interest Rate Benchmark Reform Phase 2 amendments (amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16) which were applied from 1 January 2020. Future accounting developments The following accounting standards have been issued by the IASB but are not yet effective: IFRS 17 – Insurance contracts In May 2017, the IASB issued IFRS 17 Insurance Contracts , a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. Once effective, IFRS 17 will replace IFRS 4 Insurance Contracts that was issued in 2005. IFRS 17 applies to all types of insurance contracts (i.e. life, non-life, direct insurance and re-insurance), regardless of the type of entities that issue them, as well as to certain guarantees and financial instruments with discretionary participation features. A few scope exceptions will apply. In June 2020, the IASB published amendments to IFRS 17. The amendments that are relevant to the Barclays Bank Group are the scope exclusion for credit card contracts and similar contracts that provide insurance coverage, the optional scope exclusion for loan contracts that transfer significant insurance risk, and clarification that only financial guarantees issued are in scope of IFRS 9. The amendments also defer the effective date of IFRS 17, including the above amendments, to annual reporting periods beginning on or after 1 January 2023. IFRS 17, including the 2020 amendments to IFRS 17, has been endorsed by the EU. Following the UK’s withdrawal from the EU on 31 December 2020, the UK-adopted international accounting standards will be applicable. IFRS 17, including the amendments to IFRS 17, has not yet been endorsed by the UK. The Barclays Bank Group does not expect the impact of IFRS 17 to be material. Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 In February 2021 the IASB issued amendments to IAS 1 that require entities to disclose their material accounting policies rather than their significant accounting policies. The amendments to IFRS Practice Statement 2 provide guidance on the concept of materiality and its application to accounting policy information. Under the amendments, accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The amendments are effective for annual periods beginning on or after 1 January 2023, and will be applied from that date. Definition of Accounting Estimate - Amendments to IAS 8 In February 2021 the IASB issued amendments to IAS 8 that replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are clarified as monetary amounts in financial statements that are subject to measurement uncertainty. Where an entity's accounting policy requires an item to be measured at monetary amounts that cannot be observed directly, it should develop an accounting estimate to achieve this objective. The amendments are effective for annual periods beginning on or after 1 January 2023, and will be applied from that date. |
Critical accounting estimates and judgements | The preparation of financial statements in accordance with IFRS requires the use of estimates. It also requires management to exercise judgement in applying the accounting policies. The key areas involving a higher degree of judgement or complexity or areas where assumptions are significant to the consolidated and individual financial statements are highlighted under the relevant note. Critical accounting estimates and judgements are disclosed in: ▪ Credit impairment charges on pages 126 ▪ Tax on pages 130 ▪ Fair value of financial instruments on pages 145 ▪ Provisions including conduct and legal, competition and regulatory matters on pages 163 ▪ Pensions and post-retirement benefits – obligations on pages 178 |
Presentation of segmental reporting | Presentation of segmental reporting The Barclays Bank Group’s segmental reporting is in accordance with IFRS 8 Operating Segments . Operating segments are reported in a manner consistent with the internal reporting provided to the Executive Committee, which is responsible for allocating resources and assessing performance of the operating segments, and has been identified as the chief operating decision maker. All transactions between business segments are conducted on an arm’s-length basis, with intra-segment revenue and costs being eliminated in Head Office. Income and expenses directly associated with each segment are included in determining business segment performance. |
Accounting for interest income and expense | Accounting for interest income and expenses Interest income on loans and advances at amortised cost and financial assets at fair value through other comprehensive income, and interest expense on financial liabilities held at amortised cost, are calculated using the effective interest method which allocates interest, and direct and incremental fees and costs, over the expected lives of the assets and liabilities. The effective interest method requires the Barclays Bank Group to estimate future cash flows, in some cases based on its experience of customers’ behaviour, considering all contractual terms of the financial instrument, as well as the expected lives of the assets and liabilities. The Barclays Bank Group incurs certain costs to originate credit card balances with the most significant being co-brand partner fees. To the extent these costs are attributed to customers that continuously carry an outstanding balance (revolvers) and incremental to the origination of credit card balances, they are capitalised and subsequently included within the calculation of the effective interest rate. They are amortised to interest income over the period of expected repayment of the originated balance. Costs attributed to customers that settle their outstanding balances each period (transactors) are deferred on the balance sheet as a cost of obtaining a contract and amortised to fee and commission expense over the life of the customer relationship (refer to Note 4). There are no other individual estimates involved in the calculation of effective interest rates that are material to the results or financial position. |
Accounting for net fee and commission income | Accounting for net fee and commission income The Barclays Bank Group applies IFRS 15 Revenue from Contracts with Customers. IFRS 15 establishes a five-step model governing revenue recognition. The five-step model requires the Barclays Bank Group to (i) identify the contract with the customer, (ii) identify each of the performance obligations included in the contract, (iii) determine the amount of consideration in the contract, (iv) allocate the consideration to each of the identified performance obligations and (v) recognise revenue as each performance obligation is satisfied. The Barclays Bank Group recognises fee and commission income charged for services provided by the Barclays Bank Group as the services are provided, for example, on completion of the underlying transaction. Where the contractual arrangements also result in the Barclays Bank Group recognising financial instruments in scope of IFRS 9, such financial instruments are initially recognised at fair value in accordance with IFRS 9 before applying the provisions of IFRS 15. |
Accounting for net trading income | Accounting for net trading income In accordance with IFRS 9, trading positions are held at fair value, and the resulting gains and losses are included in the income statement, together with interest and dividends arising from long and short positions and funding costs relating to trading activities. Income arises from both the sale and purchase of trading positions, margins which are achieved through market making and customer business and from changes in fair value caused by movements in interest and exchange rates, equity prices and other market variables. Gains or losses on non-trading financial instruments designated or mandatorily at fair value with changes in fair value recognised in the income statement are included in net trading income where the business model is to manage assets and liabilities on a fair value basis which includes use of derivatives or where an instrument is designated at fair value to eliminate an accounting mismatch and the related instrument's gain and losses are reported in trading income. |
Accounting for net investment income | Accounting for net investment income Dividends are recognised when the right to receive the dividend has been established. Other accounting policies relating to net investment income are set out in Note 12 and Note 14. |
Accounting for the impairment of financial assets | Accounting for the impairment of financial assets Impairment In accordance with IFRS 9, the Barclays Bank Group is required to recognise expected credit losses (ECLs) based on unbiased forward-looking information for all financial assets at amortised cost, lease receivables, debt financial assets at fair value through other comprehensive income, loan commitments and financial guarantee contracts. Intercompany exposures in the individual financial statements, including loan commitments and financial guarantee contracts, are also in scope of IFRS 9 for ECL purposes. At the reporting date, an allowance (or provision for loan commitments and financial guarantees) is required for the 12 month (Stage 1) ECLs. If the credit risk has significantly increased since initial recognition (Stage 2), or if the financial instrument is credit impaired (Stage 3), an allowance (or provision) should be recognised for the lifetime ECLs. The measurement of ECL is calculated using three main components: (i) probability of default (PD) (ii) loss given default (LGD) and (iii) the exposure at default (EAD). The 12 month and lifetime ECLs are calculated by multiplying the respective PD, LGD and the EAD. The 12 month and lifetime PDs represent the PD occurring over the next 12 months and the remaining maturity of the instrument respectively. The EAD represents the expected balance at default, taking into account the repayment of principal and interest from the balance sheet date to the default event together with any expected drawdowns of committed facilities. The LGD represents expected losses on the EAD given the event of default, taking into account, among other attributes, the mitigating effect of collateral value at the time it is expected to be realised and the time value of money. Determining a significant increase in credit risk since initial recognition: The Barclays Bank Group assesses when a significant increase in credit risk has occurred based on quantitative and qualitative assessments. The credit risk of an exposure is considered to have significantly increased when: i) Quantitative test The annualised lifetime PD has increased by more than an agreed threshold relative to the equivalent at origination. PD deterioration thresholds are defined as percentage increases, and are set at an origination score band and segment level to ensure the test appropriately captures significant increases in credit risk at all risk levels. Generally, thresholds are inversely correlated to the origination PD, i.e. as the origination PD increases, the threshold value reduces. The assessment of the point at which a PD increase is deemed ‘significant’, is based upon analysis of the portfolio’s risk profile against a common set of principles and performance metrics (consistent across both retail and wholesale businesses), incorporating expert credit judgement where appropriate. Application of quantitative PD floors does not represent the use of the low credit risk exemption as exposures can separately move into stage 2 via the qualitative route described below. Wholesale assets apply a 100% increase in PD and 0.2% PD floor to determine a significant increase in credit risk. Retail assets apply bespoke relative increase and absolute PD thresholds based on product type and origination PD. Thresholds are subject to maximums defined by Barclays Bank Group policy and typically apply minimum relative thresholds of 50%-100% and a maximum relative threshold of 400%. For existing/historical exposures where origination point scores or data are no longer available or do not represent a comparable estimate of lifetime PD, a proxy origination score is defined, based upon: ▪ back-population of the approved lifetime PD score either to origination date or, where this is not feasible, as far back as possible (subject to a data start point no later than 1 January 2015); or ▪ use of available historical account performance data and other customer information, to derive a comparable ‘proxy’ estimation of origination PD. ii) Qualitative test This is relevant for accounts that meet the portfolio’s ‘high risk’ criteria and are subject to closer credit monitoring. High risk customers may not be in arrears but either through an event or an observed behaviour exhibit credit distress. The definition and assessment of high risk includes as wide a range of information as reasonably available, such as industry and Barclays Bank Group-wide customer level data, including but not limited to bureau scores and high consumer indebtedness index, wherever possible or relevant. Whilst the high risk populations applied for IFRS 9 impairment purposes are aligned with risk management processes, they are also regularly reviewed and validated to ensure that they capture any incremental segments where there is evidence of credit deterioration. iii) Backstop criteria This is relevant for accounts that are more than 30 calendar days past due. The 30 days past due criteria is a backstop rather than a primary driver of moving exposures into Stage 2. The criteria for determining a significant increase in credit risk for assets with bullet repayments follows the same principle as all other assets, i.e. quantitative, qualitative and backstop tests are all applied. Exposures will move back to Stage 1 once they no longer meet the criteria for a significant increase in credit risk. This means that, at a minimum all payments must be up-to-date, the PD deterioration test is no longer met, the account is no longer classified as high risk, and the customer has evidenced an ability to maintain future payments. Exposures are only removed from Stage 3 and re-assigned to Stage 2 once the original default trigger event no longer applies. Exposures being removed from Stage 3 must no longer qualify as credit impaired, and: a) the obligor will also have demonstrated consistently good payment behaviour over a 12-month period, by making all consecutive contractual payments due and, for forborne exposures, the relevant EBA defined probationary period has also been successfully completed or; b) (for non-forborne exposures) the performance conditions are defined and approved within an appropriately sanctioned restructure plan, including 12 months’ payment history have been met. Management overlays and other exceptions to model outputs are applied only if consistent with the objective of identifying significant increases in credit risk. Forward-looking information The measurement of ECL involves complexity and judgement, including estimation of PD, LGD, a range of unbiased future economic scenarios, estimation of expected lives (where contractual life is not appropriate), and estimation of EAD and assessing significant increases in credit risk. Credit losses are the expected cash shortfalls from what is contractually due over the expected life of the financial instrument, discounted at the original effective interest rate (EIR). ECLs are the unbiased probability-weighted credit losses determined by evaluating a range of possible outcomes and considering future economic conditions. The Barclays Bank Group uses a five -scenario model to calculate ECL. An external consensus forecast is assembled from key sources, including HM Treasury (short and medium term forecasts), Bloomberg (based on median of economic forecasters) and the Urban Land Institute (for US House Prices), which forms the baseline scenario. In addition, two adverse scenarios (Downside 1 and Downside 2) and 2 favourable scenarios (Upside 1 and Upside 2) are derived, with associated probability weightings. The adverse scenarios are calibrated to a similar severity to internal stress tests, whilst also considering IFRS 9 specific sensitivities and non-linearity. Downside 2 is benchmarked to the Bank of England’s annual cyclical scenarios and to the most severe scenario from Moody’s inventory, but is not designed to be the same. The favourable scenarios are calibrated to be symmetric to the adverse scenarios, subject to a ceiling calibrated to relevant recent favourable benchmark scenarios. The scenarios include eight economic variables (GDP, unemployment, House Price Index (HPI) and base rates in both the UK and US markets) and expanded variables using statistical models based on historical correlations. The upside and downside shocks are designed to evolve over a five -year stress horizon, with all five scenarios converging to a steady state after approximately eight- years. The methodology for estimating probability weights for each of the scenarios involves a comparison of the distribution of key historical UK and US macroeconomic variables against the forecast paths of the 5 scenarios. The methodology works such that the baseline (reflecting current consensus outlook) has the highest weight and the weights of adverse and favourable scenarios depend on the deviation from the baseline; the further from the baseline, the smaller the weight. A single set of five scenarios is used across all portfolios and all five weights are normalised to equate to 100%. The same scenarios and weights that are used in the estimation of expected credit losses are also used for the Barclays Bank Group’s internal planning purposes. The impacts across the portfolios are different because of the sensitivities of each of the portfolios to specific macroeconomic variables, for example, mortgages are highly sensitive to house prices, and credit cards and unsecured consumer loans are highly sensitive to unemployment. Definition of default, credit impaired assets, write-offs, and interest income recognition The definition of default for the purpose of determining ECLs, and for internal credit risk management purposes, has been aligned to the Regulatory Capital CRR Article 178 definition of default, to maintain a consistent approach with IFRS 9 and associated regulatory guidance. The Regulatory Capital CRR Article 178 definition of default considers indicators that the debtor is unlikely to pay, includes exposures in forbearance and is no later than when the exposure is more than 90 days past due or 180 days past due in the case of UK mortgages. When exposures are identified as credit impaired at the time when they are purchased or originated interest income is calculated on the carrying value net of the impairment allowance. An asset is considered credit impaired when one or more events occur that have a detrimental impact on the estimated future cash flows of the financial asset. This comprises assets defined as defaulted and other individually assessed exposures where imminent default or actual loss is identified. Uncollectible loans are written off against the related allowance for loan impairment on completion of the Barclays Bank Group’s internal processes and when all reasonably expected recoverable amounts have been collected. Subsequent recoveries of amounts previously written off are credited to the income statement. The timing and extent of write-offs may involve some element of subjective judgement. Nevertheless, a write-off will often be prompted by a specific event, such as the inception of insolvency proceedings or other formal recovery action, which makes it possible to establish that some or the entire advance is beyond realistic prospect of recovery. Accounting for purchased financial guarantee contracts The Barclays Bank Group may enter into a financial guarantee contract which requires the issuer of such contract to reimburse the Barclays Bank Group for a loss it incurs because a specified debtor fails to make payment when due in accordance with the terms of a debt instrument. For these separate financial guarantee contracts, the Barclays Bank Group recognises a reimbursement asset aligned with the recognition of the underlying ECLs, if it is considered virtually certain that a reimbursement would be received if the specified debtor fails to make payment when due in accordance with the terms of the debt instrument. Loan modifications and renegotiations that are not credit-impaired When modification of a loan agreement occurs as a result of commercial restructuring activity rather than due to the credit risk of the borrower, an assessment must be performed to determine whether the terms of the new agreement are substantially different from the terms of the existing agreement. This assessment considers both the change in cash flows arising from the modified terms as well as the change in overall instrument risk profile. In respect of payment holidays granted to borrowers which are not due to forbearance, if the revised cash flows on a present value basis (based on the original EIR) are not substantially different from the original cash flows, the loan is not considered to be substantially modified. Where terms are substantially different, the existing loan will be derecognised and a new loan will be recognised at fair value, with any difference in valuation recognised immediately within the income statement, subject to observability criteria. Where terms are not substantially different, the loan carrying value will be adjusted to reflect the present value of modified cash flows discounted at the original EIR, with any resulting gain or loss recognised immediately within the income statement as a modification gain or loss. Note 1 sets out details for changes in the basis of determining the contractual cash flows of a financial instrument that are required by interest rate benchmark reform. Expected life Lifetime ECLs must be measured over the expected life. This is restricted to the maximum contractual life and takes into account expected prepayment, extension, call and similar options. The exceptions are certain revolver financial instruments, such as credit cards and bank overdrafts, that include both a drawn and an undrawn component where the entity’s contractual ability to demand repayment and cancel the undrawn commitment does not limit the entity’s exposure to credit losses to the contractual notice period. For revolving facilities, expected life is analytically derived to reflect behavioural life of the asset, i.e. the full period over which the business expects to be exposed to credit risk. Behavioural life is typically based upon historical analysis of the average time to default, closure or withdrawal of facility. Where data is insufficient or analysis inconclusive, an additional ‘maturity factor’ may be incorporated to reflect the full estimated life of the exposures, based upon experienced judgement and/or peer analysis. Potential future modifications of contracts are not taken into account when determining the expected life or EAD until they occur. Discounting ECLs are discounted at the EIR at initial recognition or an approximation thereof and consistent with income recognition. For loan commitments the EIR is the rate that is expected to apply when the loan is drawn down and a financial asset is recognised. Issued financial guarantee contracts are discounted at the risk free rate. Lease receivables are discounted at the rate implicit in the lease. For variable/floating rate financial assets, the spot rate at the reporting date is used and projections of changes in the variable rate over the expected life are not made to estimate future interest cash flows or for discounting. Modelling techniques The regulatory Basel Committee of Banking Supervisors (BCBS) ECL calculations are leveraged for IFRS 9 modelling but adjusted for key differences which include: ▪ BCBS requires 12 month through the economic cycle losses whereas IFRS 9 requires 12 months or lifetime point in time losses based on conditions at the reporting date and multiple forecasts of the future economic conditions over the expected lives; ▪ IFRS 9 models do not include certain conservative BCBS model floors and downturn assessments and require discounting to the reporting date at the original EIR rather than using the cost of capital to the date of default; ▪ management adjustments are made to modelled output to account for situations where known or expected risk factors and information have not been considered in the modelling process, for example forecast economic scenarios for uncertain political events; and ▪ ECL is measured at the individual financial instrument level, however a collective approach where financial instruments with similar risk characteristics are grouped together, with apportionment to individual financial instruments, is used where effects can only be seen at a collective level, for example for forward-looking information. For the IFRS 9 impairment assessment, the Barclays Bank Group’s risk models are used to determine the PD, LGD and EAD. For Stage 2 and 3, the Barclays Bank Group applies lifetime PDs but uses 12 month PDs for Stage 1. The ECL drivers of PD, EAD and LGD are modelled at an account level which considers vintage, among other credit factors. Also, the assessment of significant increase in credit risk is based on the initial lifetime PD curve, which accounts for the different credit risk underwritten over time. Forbearance A financial asset is subject to forbearance when it is modified due to the credit distress of the borrower. A modification made to the terms of an asset due to forbearance will typically be assessed as a non-substantial modification that does not result in derecognition of the original loan, except in circumstances where debt is exchanged for equity. Both performing and non-performing forbearance assets are classified as Stage 3 except where it is established that the concession granted has not resulted in diminished financial obligation and that no other regulatory definitions of default criteria have been triggered, in which case the asset is classified as Stage 2. The minimum probationary period for non-performing forbearance is 12 months and for performing forbearance, 24 months. Hence, a minimum of 36 months is required for non-performing forbearance to move out of a forborne state. No financial instrument in forbearance can transfer back to Stage 1 until all of the Stage 2 thresholds are no longer met and can only move out of Stage 3 when no longer credit impaired. Critical accounting estimates and judgements IFRS 9 impairment involves several important areas of judgement, including estimating forward looking modelled parameters (PD, LGD and EAD), developing a range of unbiased future economic scenarios, estimating expected lives and assessing significant increases in credit risk, based on the Barclays Bank Group’s experience of managing credit risk. The determination of expected life is most material for Barclays credit card portfolios which is obtained via behavioural life analysis to materially capture the risk of these facilities. Within the retail and small businesses portfolios, which comprise large numbers of small homogenous assets with similar risk characteristics where credit scoring techniques are generally used, the impairment allowance is calculated using forward looking modelled parameters which are typically run at account level. There are many models in use, each tailored to a product, line of business or customer category. Judgement and knowledge is needed in selecting the statistical methods to use when the models are developed or revised. Management adjustments to impairment models, which contain an element of subjectivity, are applied in order to factor in certain conditions or changes in policy that are not fully incorporated into the impairment models, or to reflect additional facts and circumstances at the period end. Management adjustments are reviewed and incorporated into future model development where appropriate. For individually significant assets in Stage 3, impairment allowances are calculated on an individual basis and all relevant considerations that have a bearing on the expected future cash flows across a range of economic scenarios are taken into account. These considerations can be particularly subjective and can include the business prospects for the customer, the realisable value of collateral, the Barclays Bank Group’s position relative to other claimants, the reliability of customer information and the likely cost and duration of the work-out process. The level of the impairment allowance is the difference between the value of the discounted expected future cash flows (discounted at the loan’s original effective interest rate), and its carrying amount. Furthermore, judgements change with time as new information becomes available or as work-out strategies evolve, resulting in frequent revisions to the impairment allowance as individual decisions are taken. Changes in these estimates would result in a change in the allowances and have a direct impact on the impairment charge. Temporary adjustments to calculated IFRS9 impairment allowances may be applied in limited circumstances to account for situations where known or expected risk factors or information have not been considered in the ECL assessment or modelling process. For further information please see page 57 |
Accounting for purchased financial guarantee contracts | The Barclays Bank Group may enter into a financial guarantee contract which requires the issuer of such contract to reimburse the Barclays Bank Group for a loss it incurs because a specified debtor fails to make payment when due in accordance with the terms of a debt instrument. For these separate financial guarantee contracts, the Barclays Bank Group recognises a reimbursement asset aligned with the recognition of the underlying ECLs, if it is considered virtually certain that a reimbursement would be received if the specified debtor fails to make payment when due in accordance with the terms of the debt instrument. |
Accounting for income taxes | Accounting for income taxes The Barclays Bank Group applies IAS 12 Income Taxes in accounting for taxes on income. Income tax payable on taxable profits (current tax) is recognised as an expense in the periods in which the profits arise. Withholding taxes are also treated as income taxes. Income tax recoverable on tax allowable losses is recognised as a current tax asset only to the extent that it is regarded as recoverable by offsetting against taxable profits arising in the current or prior periods. Current tax is measured using tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised. Deferred tax liabilities are recognised for all taxable temporary differences except from the initial recognition of goodwill. Deferred tax is not recognised where the temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss. Deferred tax is determined using tax rates and legislation enacted or substantively enacted by the balance sheet date which are expected to apply when the deferred tax asset is realised or the deferred tax liability is settled. Deferred tax assets and liabilities are only offset when there is both a legal right to set-off and an intention to settle on a net basis. The Barclays Bank Group considers an uncertain tax position to exist when it considers that ultimately, in the future, the amount of profit subject to tax may be greater than the amount initially reflected in the Barclays Bank Group’s tax returns. The Barclays Bank Group accounts for provisions in respect of uncertain tax positions in two different ways. A current tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will alter the amount of cash tax due to, or from, a tax authority in the future. From recognition, the current tax provision is then measured at the amount the Barclays Bank Group ultimately expects to pay the tax authority to resolve the position. The accrual of interest and penalty amounts in respect of uncertain income tax positions is recognised as an expense within profit before tax. Deferred tax provisions are adjustments made to the carrying value of deferred tax assets in respect of uncertain tax positions. A deferred tax provision is recognised when it is considered probable that the outcome of a review by a tax authority of an uncertain tax position will result in a reduction in the carrying value of the deferred tax asset. From recognition of a provision, measurement of the underlying deferred tax asset is adjusted to take into account the expected impact of resolving the uncertain tax position on the loss or temporary difference giving rise to the deferred tax asset. The approach taken to measurement takes account of whether the uncertain tax position is a discrete position that will be reviewed by the tax authority in isolation from any other position, or one of a number of issues which are expected to be reviewed together concurrently and resolved simultaneously with a tax authority. The Barclays Bank Group’s measurement of provisions is based upon its best estimate of the additional profit that will become subject to tax. For a discrete position, consideration is given only to the merits of that position. Where a number of issues are expected to be reviewed and resolved together, the Barclays Bank Group will take into account not only the merits of its position in respect of each particular issue but also the overall level of provision relative to the aggregate of the uncertain tax positions across all the issues that are expected to be resolved at the same time. In addition, in assessing provision levels, it is assumed that tax authorities will review uncertain tax positions and that all facts will be fully and transparently disclosed. Critical accounting estimates and judgements There are two key areas of judgement that impact the reported tax position. Firstly, the level of provisioning for uncertain tax positions; and secondly, the recognition and measurement of deferred tax assets. The Barclays Bank Group does not consider there to be a significant risk of a material adjustment to the carrying amount of current and deferred tax balances, including provisions for uncertain tax positions in the next financial year. The provisions for uncertain tax positions cover a diverse range of issues and reflect advice from external counsel where relevant. It should be noted that only a proportion of the total uncertain tax positions will be under audit at any point in time, and could therefore be subject to challenge by a tax authority over the next year. Deferred tax assets have been recognised based on business profit forecasts. Details on the recognition of deferred tax assets are provided in this note. |
Accounting for trading portfolio assets and liabilities | Accounting for trading portfolio assets and liabilities In accordance with IFRS 9, all assets and liabilities held for trading purposes are held at fair value with gains and losses in the changes in fair value taken to the income statement in net trading income (Note 5). |
Accounting for financial instruments at fair value through the income statement | Accounting for financial assets mandatorily at fair value Financial assets that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Accounting for financial assets designated at fair value Financial assets, other than those held for trading, are classified in this category if they are so irrevocably designated at inception and the use of the designation removes or significantly reduces an accounting mismatch. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. The details on how the fair value amounts are derived for financial assets at fair value are described in Note 16. |
Accounting for derivatives | Accounting for derivatives Derivative instruments are contracts whose value is derived from one or more underlying financial instruments or indices defined in the contract. They include swaps, forward-rate agreements, futures, options and combinations of these instruments and primarily affect the Barclays Bank Group’s net interest income, net trading income and derivative assets and liabilities. Notional amounts of the contracts are not recorded on the balance sheet. Derivatives are used to hedge interest rate, credit risk, inflation risk, exchange rate, commodity, equity exposures and exposures to certain indices such as house price indices and retail price indices related to non-trading positions. All derivative instruments are held at fair value through profit or loss, except for derivatives that are in a designated cash flow or net investment hedge accounting relationship. Derivatives are classified as assets when their fair value is positive or as liabilities when their fair value is negative. This includes terms included in a contract or financial liability (the host) which, had they been a standalone contract, would have met the definition of a derivative. If these are separated from the host, i.e. when the economic characteristics of the embedded derivative are not closely related with those of the host contract and the combined instrument is not measured at fair value through profit or loss, then they are accounted for in the same way as derivatives. For financial assets, the requirements are whether the financial assets contain contractual terms that give rise on specified dates to cash flows that are SPPI, and consequently the requirements for accounting for embedded derivatives are not applicable to financial assets. |
Hedge accounting | Hedge accounting The Barclays Bank Group applies the requirements of IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes. The Barclays Bank Group applies hedge accounting to represent the economic effects of its interest rate, currency and contractually linked inflation risk management strategies. Where derivatives are held for risk management purposes, and when transactions meet the required criteria for documentation and hedge effectiveness, the Barclays Bank Group applies fair value hedge accounting, cash flow hedge accounting, or hedging of a net investment in a foreign operation, as appropriate to the risks being hedged. The Barclays Bank Group applies the ‘Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform’ issued in September 2019 (the Phase 1 amendments). The amendments provide temporary relief from applying specific hedge accounting requirements to hedging relationships directly affected by IBOR (‘Interbank Offered Rates’) reform. The reliefs have the effect that IBOR reform should not generally cause hedge accounting to terminate. However, any hedge ineffectiveness continues to be recorded in the income statement. Furthermore, the amendments set out triggers for when the reliefs will end, which include the uncertainty arising from interest rate benchmark reform no longer being present. In summary, the reliefs provided by the Phase 1 amendments are: ▪ When considering the ‘highly probable’ requirement, the Barclays Bank Group has assumed that the IBOR interest rates upon which our hedged items are based do not change as a result of IBOR Reform. ▪ In assessing whether the hedge is expected to be highly effective on a forward-looking basis the Barclays Bank Group has assumed that the IBOR interest rates upon which the cash flows of the hedged items and the interest rate swaps that hedge them are based are not altered by IBOR reform. ▪ The Barclays Bank Group will not discontinue hedge accounting during the period of IBOR-related uncertainty solely because the retrospective effectiveness falls outside the required 80% –125% range. ▪ The Barclays Bank Group has not recycled the cash flow hedge reserve relating to the period after the reforms are expected to take effect. ▪ The Barclays Bank Group has assessed whether the hedged IBOR risk component is a separately identifiable risk only when it first designates a hedged item in a fair value hedge and not on an ongoing basis. The Barclays Bank Group also applies the ‘Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2’ issued in August 2020. The Phase 2 amendments provide relief when changes are made to hedge relationships as a result of the interest rate benchmark reform. In summary, the reliefs provided by the Phase 2 amendments are: ▪ Under a temporary exception, the Barclays Bank Group has considered that changes to the hedge designation and hedge documentation due to the interest rate benchmark reform would not constitute the discontinuation of the hedge relationship nor the designation of a new hedging relationship. ▪ In respect of the retrospective hedge effectiveness assessment, the Barclays Bank Group may elect, on a hedge-by-hedge basis, to reset the cumulative fair value changes to zero when the exception to the retrospective assessment ends (Phase 1 relief). Any hedge ineffectiveness will continue to be measured and recognised in full in profit or loss. ▪ The Barclays Bank Group has deemed the amounts accumulated in the cash flow hedge reserve to be based on the alternative benchmark rate (on which the hedge future cash flows are determined) when there is a change in basis for determining the contractual cash flows. ▪ For hedges of groups of items (such as those forming part of a macro cash flow hedging strategy), the amendments provide relief for items within a designated group of items that are amended for changes directly required by the reform. ▪ In respect of whether a risk component of a hedged item is separately identifiable, the amendments provide temporary relief to entities to meet this requirement when an alternative risk free rate (RFR) financial instrument is designated as a risk component. These amendments allow the Barclays Bank Group upon designation of the hedge to assume that the separately identifiable requirement is met if the Barclays Bank Group reasonably expects the RFR risk will become separately identifiable within the next 24 months. The Barclays Bank Group applies this relief to each RFR on a rate-by-rate basis and starts when the Barclays Bank Group first designates the RFR as a non-contractually specified risk component. Fair value hedge accounting Changes in fair value of derivatives that qualify and are designated as fair value hedges are recorded in the income statement, together with changes in the fair value of the hedged asset or liability that are attributable to the hedged risk. The fair value changes adjust the carrying value of the hedged asset or liability held at amortised cost. If hedge relationships no longer meet the criteria for hedge accounting, hedge accounting is discontinued. For fair value hedges of interest rate risk, the fair value adjustment to the hedged item is amortised to the income statement over the period to maturity of the previously designated hedge relationship using the effective interest method. If the hedged item is sold or repaid, the unamortised fair value adjustment is recognised immediately in the income statement. For items classified as fair value through other comprehensive income, the hedge accounting adjustment is included in other comprehensive income. Cash flow hedge accounting For qualifying cash flow hedges, the fair value gain or loss associated with the effective portion of the cash flow hedge is recognised initially in other comprehensive income, and then recycled to the income statement in the periods when the hedged item will affect profit or loss. Any ineffective portion of the gain or loss on the hedging instrument is recognised in the income statement immediately. When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative gain or loss existing in equity at that time remains in equity and is recognised when the hedged item is ultimately recognised in the income statement. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was recognised in equity is immediately transferred to the income statement. Hedges of net investments The Barclays Bank Group’s net investments in foreign operations, including monetary items accounted for as part of the net investment, are hedged for foreign currency risks using both derivatives and foreign currency borrowings. Hedges of net investments are accounted for similarly to cash flow hedges; the effective portion of the gain or loss on the hedging instrument is being recognised directly in other comprehensive income and the ineffective portion being recognised immediately in the income statement. The cumulative gain or loss recognised in other comprehensive income is recognised in the income statement on the disposal or partial disposal of the foreign operation, or other reductions in the Barclays Bank Group’s investment in the operation. |
Accounting for financial assets at fair value through other comprehensive income | Accounting for financial assets at fair value through other comprehensive income (FVOCI) Financial assets that are debt instruments held in a business model that is achieved by both collecting contractual cash flows and selling and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at FVOCI. They are subsequently re-measured at fair value and changes therein (except for those relating to impairment, interest income and foreign currency exchange gains and losses) are recognised in other comprehensive income until the assets are sold. Interest (calculated using the effective interest method) is recognised in the income statement in net interest income (Note 3). Upon disposal, the cumulative gain or loss recognised in other comprehensive income is included in net investment income (Note 6). In determining whether the business model is achieved by both collecting contractual cash flows and selling financial assets, it is determined that both collecting contractual cash flows and selling financial assets are integral to achieving the objective of the business model. The Barclays Bank Group will consider past sales and expectations about future sales to establish if the business model is achieved. For equity securities that are not held for trading, the Barclays Bank Group may make an irrevocable election on initial recognition to present subsequent changes in the fair value of the instrument in other comprehensive income (except for dividend income which is recognised in profit or loss). Gains or losses on the de-recognition of these equity securities are not transferred to profit or loss. These assets are also not subject to the impairment requirements and therefore no amounts are recycled to the income statement. Where the Barclays Bank Group has not made the irrevocable election to present subsequent changes in the fair value of the instrument in other comprehensive income, equity securities are measured at fair value through profit or loss. |
Accounting for financial liabilities designated at fair value | Accounting for liabilities designated at fair value through profit and loss In accordance with IFRS 9, financial liabilities may be designated at fair value, with gains and losses taken to the income statement within net trading income (Note 5) and net investment income (Note 6). Movements in own credit are reported through other comprehensive income, unless the effects of changes in the liability's credit risk would create or enlarge an accounting mismatch in profit and loss. In these scenarios, all gains and losses on that liability (including the effects of changes in the credit risk of the liability) are presented in profit and loss. On derecognition of the financial liability no amount relating to own credit risk are recycled to the income statement. The Barclays Bank Group has the ability to make the fair value designation when holding the instruments at fair value reduces an accounting mismatch (caused by an offsetting liability or asset being held at fair value), or is managed by the Barclays Bank Group on the basis of its fair value, or includes terms that have substantive derivative characteristics (Note 13). The details on how the fair value amounts are arrived at for financial liabilities designated at fair value are described in Note 16. Accounting for loans and advances and deposits held at amortised cost Loans and advances to customers and banks, customer accounts, debt securities and most financial liabilities, are held at amortised cost. That is, the initial fair value (which is normally the amount advanced or borrowed) is adjusted for repayments and the amortisation of coupon, fees and expenses to represent the effective interest rate of the asset or liability. Balances deferred on-balance sheet as effective interest rate adjustments are amortised to interest income over the life of the financial instrument to which they relate. Financial assets that are held in a business model to collect the contractual cash flows and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at amortised cost. The carrying value of these financial assets at initial recognition includes any directly attributable transaction costs. Refer to Note 1 for details of ‘solely payments of principal and interest’. In determining whether the business model is a ‘hold to collect’ model, the objective of the business model must be to hold the financial asset to collect contractual cash flows rather than holding the financial asset for trading or short-term profit taking purposes. While the objective of the business model must be to hold the financial asset to collect contractual cash flows this does not mean the Barclays Bank Group is required to hold the financial assets until maturity. When determining if the business model objective is to collect contractual cash flows the Barclays Bank Group will consider past sales and expectations about future sales. |
Accounting for fair value of financial instruments | Accounting for financial assets and liabilities – fair values Financial instruments that are held for trading are recognised at fair value through profit or loss. In addition, financial assets are held at fair value through profit or loss if they do not contain contractual terms that give rise on specified dates to cash flows that are SPPI, or if the financial asset is not held in a business model that is either (i) a business model to collect the contractual cash flows or (ii) a business model that is achieved by both collecting contractual cash flows and selling. Subsequent changes in fair value for these instruments are recognised in the income statement in net investment income, except if reporting it in trading income reduces an accounting mismatch. All financial instruments are initially recognised at fair value on the date of initial recognition (including transaction costs, other than financial instruments held at fair value through profit or loss) and depending on the subsequent classification of the financial asset or liability, may continue to be held at fair value either through profit or loss or other comprehensive income. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Wherever possible, fair value is determined by reference to a quoted market price for that instrument. For many of the Barclays Bank Group’s financial assets and liabilities, especially derivatives, quoted prices are not available and valuation models are used to estimate fair value. The models calculate the expected cash flows under the terms of each specific contract and then discount these values back to a present value. These models use as their basis independently sourced market inputs including, for example, interest rate yield curves, equities and commodities prices, option volatilities and currency rates. For financial liabilities measured at fair value, the carrying amount reflects the effect on fair value of changes in own credit spreads derived from observable market data such as in primary issuance and redemption activity for structured notes. On initial recognition, it is presumed that the transaction price is the fair value unless there is observable information available in an active market to the contrary. The best evidence of an instrument’s fair value on initial recognition is typically the transaction price. However, if fair value can be evidenced by comparison with other observable current market transactions in the same instrument, or is based on a valuation technique whose inputs include only data from observable markets, then the instrument should be recognised at the fair value derived from such observable market data. For valuations that have made use of unobservable inputs, the difference between the model valuation and the initial transaction price (Day One profit) is recognised in profit or loss either: on a straight-line basis over the term of the transaction; or over the period until all model inputs will become observable where appropriate; or released in full when previously unobservable inputs become observable. Various factors influence the availability of observable inputs and these may vary from product to product and change over time. Factors include the depth of activity in the relevant market, the type of product, whether the product is new and not widely traded in the marketplace, the maturity of market modelling and the nature of the transaction (bespoke or generic). To the extent that valuation is based on models or inputs that are not observable in the market, the determination of fair value can be more subjective, dependent on the significance of the unobservable input to the overall valuation. Unobservable inputs are determined based on the best information available, for example by reference to similar assets, similar maturities or other analytical techniques. The sensitivity of valuations used in the financial statements to possible changes in significant unobservable inputs is shown on page 153. Critical accounting estimates and judgements The valuation of financial instruments often involves a significant degree of judgement and complexity, in particular where valuation models make use of unobservable inputs (‘Level 3’ assets and liabilities). This note provides information on these instruments, including the related unrealised gains and losses recognised in the period, a description of significant valuation techniques and unobservable inputs, and a sensitivity analysis. |
Accounting for offsetting financial assets and financial liabilities | In accordance with IAS 32 Financial Instruments: Presentation , the Barclays Bank Group reports financial assets and financial liabilities on a net basis on the balance sheet only if there is a legally enforceable right to set-off the recognised amounts and there is intention to settle on a net basis, or to realise the asset and settle the liability simultaneously. The following table shows the impact of netting arrangements on: ▪ All financial assets and liabilities that are reported net on the balance sheet. ▪ All derivative financial instruments and reverse repurchase and repurchase agreements and other similar secured lending and borrowing agreements that are subject to enforceable master netting arrangements or similar agreements, but do not qualify for balance sheet netting. |
Accounting for loans and advances and deposits at amortised cost | Accounting for loans and advances and deposits held at amortised cost Loans and advances to customers and banks, customer accounts, debt securities and most financial liabilities, are held at amortised cost. That is, the initial fair value (which is normally the amount advanced or borrowed) is adjusted for repayments and the amortisation of coupon, fees and expenses to represent the effective interest rate of the asset or liability. Balances deferred on-balance sheet as effective interest rate adjustments are amortised to interest income over the life of the financial instrument to which they relate. Financial assets that are held in a business model to collect the contractual cash flows and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at amortised cost. The carrying value of these financial assets at initial recognition includes any directly attributable transaction costs. Refer to Note 1 for details of ‘solely payments of principal and interest’. In determining whether the business model is a ‘hold to collect’ model, the objective of the business model must be to hold the financial asset to collect contractual cash flows rather than holding the financial asset for trading or short-term profit taking purposes. While the objective of the business model must be to hold the financial asset to collect contractual cash flows this does not mean the Barclays Bank Group is required to hold the financial assets until maturity. When determining if the business model objective is to collect contractual cash flows the Barclays Bank Group will consider past sales and expectations about future sales. |
Accounting for property, plant and equipment | Accounting for property, plant and equipment The Barclays Bank Group applies IAS 16 Property Plant and Equipment and IAS 40 Investment Properties. Property, plant and equipment is stated at cost, which includes direct and incremental acquisition costs less accumulated depreciation and provisions for impairment, if required. Subsequent costs are capitalised if these result in enhancement of the asset. Depreciation is provided on the depreciable amount of items of property, plant and equipment on a straight-line basis over their estimated useful economic lives. Depreciation rates, methods and the residual values underlying the calculation of depreciation of items of property, plant and equipment are kept under review to take account of any change in circumstances. The Barclays Bank Group uses the following annual rates in calculating depreciation: Annual rates in calculating depreciation Depreciation rate Freehold land Not depreciated Freehold buildings and long-leasehold property (more than 50 years to run) 2%-3.3% Leasehold property over the remaining life of the lease (less than 50 years to run) Over the remaining life of the lease Costs of adaptation of freehold and leasehold property 6%-10% Equipment installed in freehold and leasehold property 6%-10% Computers and similar equipment 17%-33% Fixtures and fittings and other equipment 9%-20% Costs of adaptation and installed equipment are depreciated over the shorter of the life of the lease or the depreciation rates noted in the table above. Investment property The Barclays Bank Group initially recognises investment property at cost, and subsequently at fair value at each balance sheet date, reflecting market conditions at the reporting date. Gains and losses on remeasurement are included in the income statement. |
Accounting for leases under IFRS 16 effective from 1 January 2019 | Accounting for leases IFRS 16 applies to all leases with the exception of licenses of intellectual property, rights held by licensing agreement within the scope of IAS 38 Intangible Assets, service concession arrangements, leases of biological assets within the scope of IAS 41 Agriculture and leases of minerals, oil, natural gas and similar non-regenerative resources. IFRS 16 includes an accounting policy choice for a lessee to elect not to apply IFRS 16 to remaining assets within the scope of IAS 38 Intangible Assets which the Barclays Bank Group has decided to apply. When the Barclays Bank Group is the lessee, it is required to recognise both: ▪ a lease liability, measured at the present value of remaining cash flows on the lease; and ▪ a right of use (ROU) asset, measured at the amount of the initial measurement of the lease liability, plus any lease payments made prior to commencement date, initial direct costs, and estimated costs of restoring the underlying asset to the condition required by the lease, less any lease incentives received. Subsequently the lease liability will increase for the accrual of interest, resulting in a constant rate of return throughout the life of the lease, and reduce when payments are made. The right of use asset will amortise to the income statement over the life of the lease. The lease liability is remeasured when there is a change in the one of the following: ▪ future lease payments arising from a change in an index or rate; ▪ the Barclays Bank Group’s estimate of the amount expected to be payable under a residual value guarantee; or ▪ the Barclays Bank Group’s assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured a corresponding adjustment is made to the carrying amount of the ROU asset, or is recorded in the income statement if the carrying amount of the ROU asset has been reduced to nil. On the balance sheet, the ROU assets are included within property, plant and equipment and the lease liabilities are included within other liabilities. The Barclays Bank Group applies the recognition exemption in IFRS 16 for leases with a term not exceeding 12 months. For these leases the lease payments are recognised as an expense on a straight line basis over the lease term unless another systematic basis is more appropriate. When the Barclays Bank Group is the lessor, the lease must be classified as either a finance lease or an operating lease. A finance lease is a lease which confers substantially all the risks and rewards of the leased assets on the lessee. An operating lease is a lease where substantially all of the risks and rewards of the leased asset remain with the lessor. When the lease is deemed a finance lease, the leased asset is not held on the balance sheet; instead a finance lease receivable is recognised representing the minimum lease payments receivable under the terms of the lease, discounted at the rate of interest implicit in the lease. When the lease is deemed an operating lease, the lease income is recognised on a straight-line basis over the period of the lease unless another systematic basis is more appropriate. The Barclays Bank Group holds the leased assets on-balance sheet within property, plant and equipment. |
Accounting for goodwill and intangible assets | Accounting for goodwill and intangible assets Goodwill The carrying value of goodwill is determined in accordance with IFRS 3 B usiness Combinations and IAS 36 Impairment of Assets. Goodwill arising on the acquisition of subsidiaries represents the excess of the fair value of the purchase consideration over the fair value of the Barclays Bank Group’s share of the assets acquired and the liabilities and contingent liabilities assumed on the date of the acquisition. Goodwill is reviewed annually for impairment, or more frequently when there are indications that impairment may have occurred. The test involves comparing the carrying value of the cash generating unit (CGU) including goodwill with the present value of the pre-tax cash flows, discounted at a rate of interest that reflects the inherent risks, of the CGU to which the goodwill relates, or the CGU's fair value if this is higher. Intangible assets Intangible assets other than goodwill are accounted for in accordance with IFRS 3 Business Combinations and IAS 38 Intangible Assets. Intangible assets are initially recognised when they are separable or arise from contractual or other legal rights, the cost can be measured reliably and, in the case of intangible assets not acquired in a business combination, where it is probable that future economic benefits attributable to the assets will flow from their use. For internally generated intangible assets, only costs incurred during the development phase are capitalised. Expenditure in the research phase is expensed when it is incurred. Intangible assets are stated at cost (which is, in the case of assets acquired in a business combination, the acquisition date fair value) less accumulated amortisation and provisions for impairment, if any, and are amortised over their useful lives in a manner that reflects the pattern to which they contribute to future cash flows, generally using the amortisation periods set out below: Annual rates in calculating amortisation Amortisation period Goodwill Not amortised Internally generated software a 12 months to 6 years Other software 12 months to 6 years Customer lists 12 months to 25 years Licences and other 12 months to 25 years Note a Exceptions to the above period relate to useful lives of certain core banking platforms that are assessed individually and, if appropriate, amortised over longer periods ranging from 10 years to 15 years. Intangible assets are reviewed for impairment when there are indications that impairment may have occurred. Intangible assets not yet available for use are reviewed annually for impairment. |
Accounting for provisions | Accounting for provisions The Barclays Bank Group applies IAS 37 Provisions, Contingent Liabilities and Contingent Assets in accounting for non-financial liabilities. Provisions are recognised for present obligations arising as consequences of past events where it is more likely than not that a transfer of economic benefit will be necessary to settle the obligation, which can be reliably estimated. Provision is made for the anticipated cost of restructuring, including redundancy costs, when an obligation exists; for example, when the Barclays Bank Group has a detailed formal plan for restructuring a business and has raised valid expectations in those affected by the restructuring by announcing its main features or starting to implement the plan. Critical accounting estimates and judgements The financial reporting of provisions involves a significant degree of judgement and is complex. Identifying whether a present obligation exists and estimating the probability, timing, nature and quantum of the outflows that may arise from past events requires judgements to be made based on the specific facts and circumstances relating to individual events and often requires specialist professional advice. When matters are at an early stage, accounting judgements and estimates can be difficult because of the high degree of uncertainty involved. Management continues to monitor matters as they develop to re-evaluate on an ongoing basis whether provisions should be recognised, however there can remain a wide range of possible outcomes and uncertainties, particularly in relation to legal, competition and regulatory matters, and as a result it is often not practicable to make meaningful estimates even when matters are at a more advanced stage. The complexity of such matters often requires the input of specialist professional advice in making assessments to produce estimates. Customer redress and legal, competition and regulatory matters are areas where a higher degree of professional judgement is required. The amount that is recognised as a provision can also be very sensitive to the assumptions made in calculating it. This gives rise to a large range of potential outcomes which require judgement in determining an appropriate provision level. See Note 25 for more detail of legal, competition and regulatory matters. |
Accounting for contingent liabilities | Accounting for contingent liabilities Contingent liabilities are possible obligations whose existence will be confirmed only by uncertain future events and present obligations where the transfer of economic resources is uncertain or cannot be reliably measured. Contingent liabilities are not recognised on the balance sheet but are disclosed unless the likelihood of an outflow of economic resources is remote. |
Accounting for subordinated liabilities | Accounting for subordinated liabilities Subordinated liabilities are measured at amortised cost using the effective interest method under IFRS 9, unless they are irrevocably designated at fair value through profit or loss at initial recognition because such designation eliminates or significantly reduces an accounting mismatch. Refer to Note 15 for details about accounting for liabilities designated at fair value through profit or loss. |
Accounting for staff costs, pensions and post-retirement benefits | Accounting for staff costs The Barclays Bank Group applies IAS 19 Employee benefits in its accounting for most of the components of staff costs. Short-term employee benefits – salaries, accrued performance costs and social security are recognised over the period in which the employees provide the services to which the payments relate. Performance costs – recognised to the extent that the Barclays Bank Group has a present obligation to its employees that can be measured reliably and are recognised over the period of service that employees are required to work to qualify for the payments. Deferred cash and share awards are made to employees to incentivise performance over the period employees provide services. To receive payment under an award, employees must provide service over the vesting period. The period over which the expense for deferred cash and share awards is recognised is based upon the period employees consider their services contribute to the awards. For past awards, the Barclays Bank Group considers that it is appropriate to recognise the awards over the period from the date of grant to the date that the awards vest. In relation to awards granted from 2017, the Barclays Bank Group, taking into account the changing employee understanding surrounding those awards, considered it appropriate for expense to be recognised over four years including the financial year prior to the grant date. The accounting policies for share-based payments, and pensions and other post-retirement benefits, are included in Note 30 and Note 31 respectively. Accounting for pensions and post-retirement benefits The Barclays Bank Group operates a number of pension schemes and post-employment benefit schemes. Defined contribution schemes – the Barclays Bank Group recognises contributions due in respect of the accounting period in the income statement. Any contributions unpaid at the balance sheet date are included as a liability. Defined benefit schemes – the Barclays Bank Group recognises its obligations to members of each scheme at the period end, less the fair value of the scheme assets after applying the asset ceiling test. Each scheme’s obligations are calculated using the projected unit credit method. Scheme assets are stated at fair value as at the period end. Changes in pension scheme liabilities or assets (remeasurements) that do not arise from regular pension cost, net interest on net defined benefit liabilities or assets, past service costs, settlements or contributions to the scheme, are recognised in other comprehensive income. Remeasurements comprise experience adjustments (differences between previous actuarial assumptions and what has actually occurred), the effects of changes in actuarial assumptions, return on scheme assets (excluding amounts included in the interest on the assets) and any changes in the effect of the asset ceiling restriction (excluding amounts included in the interest on the restriction). Post-employment benefit schemes – the cost of providing healthcare benefits to retired employees is accrued as a liability in the financial statements over the period that the employees provide services to the Barclays Bank Group, using a methodology similar to that for defined benefit pension schemes. |
Accounting for share-based payments | Accounting for share-based payments The Barclays Bank Group applies IFRS 2 Share-based Payments in accounting for employee remuneration in the form of shares. Employee incentives include awards in the form of shares and share options, as well as offering employees the opportunity to purchase shares on favourable terms. The cost of the employee services received in respect of the shares or share options granted is recognised in the income statement over the period that employees provide services. The overall cost of the award is calculated using the number of shares and options expected to vest and the fair value of the shares or options at the date of grant. The number of shares and options expected to vest takes into account the likelihood that performance and service conditions included in the terms of the awards will be met. Failure to meet the non-vesting condition is treated as a cancellation, resulting in an acceleration of recognition of the cost of the employee services. The fair value of shares is the market price ruling on the grant date, in some cases adjusted to reflect restrictions on transferability. The fair value of options granted is determined using option pricing models to estimate the numbers of shares likely to vest. These take into account the exercise price of the option, the current share price, the risk-free interest rate, the expected volatility of the share price over the life of the option and other relevant factors. Market conditions that must be met in order for the award to vest are also reflected in the fair value of the award, as are any other non-vesting conditions – such as continuing to make payments into a share-based savings scheme. |
Accounting for associates and joint ventures | Accounting for associates and joint ventures The Barclays Bank Group applies IAS 28 Investments in Associates and IFRS 11 Joint Arrangements . Associates are entities in which the Barclays Bank Group has significant influence, but not control, over the operating and financial policies. Generally the Barclays Bank Group holds more than 20%, but less than 50%, of their voting shares. Joint ventures are arrangements where the Barclays Bank Group has joint control and rights to the net assets of the entity. The Barclays Bank Group’s investments in associates and joint ventures are initially recorded at cost and increased (or decreased) each year by the Barclays Bank Group’s share of the post acquisition profit/(loss). The Barclays Bank Group ceases to recognise its share of the losses of equity accounted associates when its share of the net assets and amounts due from the entity have been written off in full, unless it has a contractual or constructive obligation to make good its share of the losses. In some cases, investments in these entities may be held at fair value through profit or loss, for example, those held by private equity businesses. |
Accounting for securitisations | Accounting for securitisations The Barclays Bank Group uses securitisations as a source of finance and a means of risk transfer. Such transactions generally result in the transfer of contractual cash flows from portfolios of financial assets to holders of issued debt securities. Securitisations may, depending on the individual arrangement, result in continued recognition of the securitised assets and the recognition of the debt securities issued in the transaction; lead to partial continued recognition of the assets to the extent of the Barclays Bank Group’s continuing involvement in those assets or lead to derecognition of the assets and the separate recognition, as assets or liabilities, of any rights and obligations created or retained in the transfer. Full derecognition only occurs when the Barclays Bank Group transfers both its contractual right to receive cash flows from the financial assets, or retains the contractual rights to receive the cash flows, but assumes a contractual obligation to pay the cash flows to another party without material delay or reinvestment, and also transfers substantially all the risks and rewards of ownership, including credit risk, prepayment risk and interest rate risk. |
Accounting for assets pledged, collateral received and assets transferred | Assets are pledged or transferred as collateral to secure liabilities under repurchase agreements, securitisations and stock lending agreements or as security deposits relating to derivatives. Assets transferred are non-cash assets transferred to a third party that do not qualify for derecognition from the Barclays Bank Group’s balance sheet, for example because the Barclays Bank Group retains substantially all the exposure to those assets under an agreement to repurchase them in the future for a fixed price. Where non-cash assets are pledged or transferred as collateral for cash received, the asset continues to be recognised in full, and a related liability is also recognised on the balance sheet. Where non-cash assets are pledged or transferred as collateral in an exchange for non-cash assets, the transferred asset continues to be recognised in full, and there is no associated liability as the non-cash collateral received is not recognised on the balance sheet. The Barclays Bank Group is unable to use, sell or pledge the transferred assets for the duration of the transaction and remains exposed to interest rate risk and credit risk on these pledged assets. Unless stated, the counterparty's recourse is not limited to the transferred assets. |
Other disclosures - Risk Mana_2
Other disclosures - Risk Management and Principal Risks Other disclosures - Risk Management and Principal Risks (audited) (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of credit risk exposure [abstract] | |
Maximum exposure and effects of collateral and other credit enhancements (audited) | Maximum exposure and effect of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure Barclays Bank Group As at 31 December 2021 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 169,085 — — — — 169,085 Cash collateral and settlement balances 88,085 — — — — 88,085 Loans and advances at amortised cost: Home loans 10,985 — (338) (10,483) (89) 75 Credit cards, unsecured loans and other retail lending 25,960 — (968) (4,229) (252) 20,511 Wholesale loans 108,314 (5,001) (118) (30,287) (5,080) 67,828 Total loans and advances at amortised cost 145,259 (5,001) (1,424) (44,999) (5,421) 88,414 Of which credit-impaired (Stage 3): Home loans 615 — (11) (604) — — Credit cards, unsecured loans and other retail lending 563 — (29) (217) (3) 314 Wholesale loans 486 — — (76) (22) 388 Total credit-impaired loans and advances at amortised cost 1,664 — (40) (897) (25) 702 Reverse repurchase agreements and other similar secured lending 3,177 — — (3,177) — — Trading portfolio assets: Debt securities 50,700 — — (461) — 50,239 Traded loans 12,525 — — (268) — 12,257 Total trading portfolio assets 63,225 — — (729) — 62,496 Financial assets at fair value through the income statement: Loans and advances 35,901 — — (29,485) — 6,416 Debt securities 2,256 — — (319) — 1,937 Reverse repurchase agreements 145,186 — (1,428) (143,229) — 529 Other financial assets 85 — — — — 85 Total financial assets at fair value through the income statement 183,428 — (1,428) (173,033) — 8,967 Derivative financial instruments 262,291 (202,347) (34,149) (5,804) (5,738) 14,253 Financial assets at fair value through other comprehensive income 45,907 — — (53) (931) 44,923 Other assets 994 — — — — 994 Total on-balance sheet 961,451 (207,348) (37,001) (227,795) (12,090) 477,217 Off-balance sheet: Contingent liabilities 23,746 — (906) (1,367) (256) 21,217 Loan commitments 284,451 — (99) (40,104) (1,627) 242,621 Total off-balance sheet 308,197 — (1,005) (41,471) (1,883) 263,838 Total 1,269,648 (207,348) (38,006) (269,266) (13,973) 741,055 Maximum exposure and effects of netting, collateral and risk transfer (audited) Maximum exposure Netting and set-off Cash collateral Non-cash collateral Risk transfer Net exposure Barclays Bank Group As at 31 December 2020 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 155,902 — — — — 155,902 Cash collateral and settlement balances 97,616 — — — — 97,616 Loans and advances at amortised cost: Home loans 11,193 — (283) (10,782) (85) 43 Credit cards, unsecured loans and other retail lending 23,368 — (827) (3,459) (195) 18,887 Wholesale loans 99,706 (6,988) (50) (24,328) (4,419) 63,921 Total loans and advances at amortised cost 134,267 (6,988) (1,160) (38,569) (4,699) 82,851 Of which credit-impaired (Stage 3): Home loans 723 — (13) (708) — 2 Credit cards, unsecured loans and other retail lending 600 — (10) (218) (2) 370 Wholesale loans 1,327 — (4) (167) (85) 1,071 Total credit-impaired loans and advances at amortised cost 2,650 — (27) (1,093) (87) 1,443 Reverse repurchase agreements and other similar secured lending 8,981 — — (8,981) — — Trading portfolio assets: Debt securities 56,196 — — (391) — 55,805 Traded loans 8,348 — — (374) — 7,974 Total trading portfolio assets 64,544 — — (765) — 63,779 Financial assets at fair value through the income statement: Loans and advances 27,449 — (9) (21,819) — 5,621 Debt securities 1,697 — — (292) — 1,405 Reverse repurchase agreements 138,558 — (685) (137,466) — 407 Other financial assets 315 — — — — 315 Total financial assets at fair value through the income statement 168,019 — (694) (159,577) — 7,748 Derivative financial instruments 302,693 (233,088) (43,164) (4,656) (6,409) 15,376 Financial assets at fair value through other comprehensive income 51,901 — — (106) (1,065) 50,730 Other assets 614 — — — — 614 Total on-balance sheet 984,537 (240,076) (45,018) (212,654) (12,173) 474,616 Off-balance sheet: Contingent liabilities 20,932 — (1,095) (2,135) (282) 17,420 Loan commitments 265,022 — (56) (35,970) (1,479) 227,517 Total off-balance sheet 285,954 — (1,151) (38,105) (1,761) 244,937 Total 1,270,491 (240,076) (46,169) (250,759) (13,934) 719,553 |
Loans and advances at amortised cost by product (audited) | The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure as ECL is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Barclays Bank Group (audited) Stage 2 As at 31 December 2021 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total a Gross exposure £m £m £m £m £m £m £m Home loans 9,760 548 22 83 653 958 11,371 Credit cards, unsecured loans and other retail lending 24,011 2,402 198 182 2,782 1,469 28,262 Wholesale loans 95,242 12,275 301 386 12,962 921 109,125 Total 129,013 15,225 521 651 16,397 3,348 148,758 Impairment allowance Home loans 8 33 1 1 35 343 386 Credit cards, unsecured loans and other retail lending 605 677 39 75 791 906 2,302 Wholesale loans 183 188 3 2 193 435 811 Total 796 898 43 78 1,019 1,684 3,499 Net exposure Home loans 9,752 515 21 82 618 615 10,985 Credit cards, unsecured loans and other retail lending 23,406 1,725 159 107 1,991 563 25,960 Wholesale loans 95,059 12,087 298 384 12,769 486 108,314 Total 128,217 14,327 478 573 15,378 1,664 145,259 Coverage ratio % % % % % % % Home loans 0.1 6.0 4.5 1.2 5.4 35.8 3.4 Credit cards, unsecured loans and other retail lending 2.5 28.2 19.7 41.2 28.4 61.7 8.1 Wholesale loans 0.2 1.5 1.0 0.5 1.5 47.2 0.7 Total 0.6 5.9 8.3 12.0 6.2 50.3 2.4 As at 31 December 2020 Gross exposure £m £m £m £m £m £m £m Home loans 9,627 761 53 87 901 1,099 11,627 Credit cards, unsecured loans and other retail lending 18,923 4,987 393 191 5,571 1,853 26,347 Wholesale loans 83,254 14,184 1,066 688 15,938 2,167 101,359 Total 111,804 19,932 1,512 966 22,410 5,119 139,333 Impairment allowance Home loans 6 40 6 6 52 376 434 Credit cards, unsecured loans and other retail lending 399 1,092 111 124 1,327 1,253 2,979 Wholesale loans 280 475 49 9 533 840 1,653 Total 685 1,607 166 139 1,912 2,469 5,066 Net exposure Home loans 9,621 721 47 81 849 723 11,193 Credit cards, unsecured loans and other retail lending 18,524 3,895 282 67 4,244 600 23,368 Wholesale loans 82,974 13,709 1,017 679 15,405 1,327 99,706 Total 111,119 18,325 1,346 827 20,498 2,650 134,267 Coverage ratio % % % % % % % Home loans 0.1 5.3 11.3 6.9 5.8 34.2 3.7 Credit cards, unsecured loans and other retail lending 2.1 21.9 28.2 64.9 23.8 67.6 11.3 Wholesale loans 0.3 3.3 4.6 1.3 3.3 38.8 1.6 Total 0.6 8.1 11.0 14.4 8.5 48.2 3.6 Note a. Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £135.5bn (2020: £150.3bn) and impairment allowance of £104m (2020: £145m). This comprises £4m (2020: £7m) ECL on £135.3bn (2020: £146.3bn) Stage 1 assets, £0m (2020: £6m) on £65m (2020: £3.8bn) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets and £100m (2020: £132m) on £100m (2020: £132m) Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £499m (2020: £769m). |
Movement in gross exposures and impairment allowance (audited) | The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in page 126 Loans and advances at amortised cost (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2021 9,627 6 901 52 1,099 376 11,627 434 Transfers from Stage 1 to Stage 2 (253) — 253 — — — — — Transfers from Stage 2 to Stage 1 331 22 (331) (22) — — — — Transfers to Stage 3 (80) — (52) (5) 132 5 — — Transfers from Stage 3 22 — 49 4 (71) (4) — — Business activity in the year a 1,745 2 — — — — 1,745 2 Refinements to models used for calculation b — — — (4) — 38 — 34 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (742) (22) (25) 11 (70) (50) (837) (61) Final repayments (890) — (142) (1) (114) (4) (1,146) (5) Disposals — — — — — — — — Write-offs c — — — — (18) (18) (18) (18) As at 31 December 2021 d 9,760 8 653 35 958 343 11,371 386 Credit cards, unsecured loans and other retail lending As at 1 January 2021 18,923 399 5,571 1,327 1,853 1,253 26,347 2,979 Transfers from Stage 1 to Stage 2 (897) (41) 897 41 — — — — Transfers from Stage 2 to Stage 1 2,520 548 (2,520) (548) — — — — Transfers to Stage 3 (307) (13) (362) (165) 669 178 — — Transfers from Stage 3 21 5 13 9 (34) (14) — — Business activity in the year a 4,731 84 106 23 16 5 4,853 112 Refinements to models used for calculation b — (3) — (27) — — — (30) Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 509 (360) (514) 147 (96) 337 (101) 124 Final repayments (1,489) (14) (409) (16) (76) (5) (1,974) (35) Disposals e — — — — (37) (22) (37) (22) Write-offs c — — — — (826) (826) (826) (826) As at 31 December 2021 d 24,011 605 2,782 791 1,469 906 28,262 2,302 Wholesale loans As at 1 January 2021 83,254 280 15,938 533 2,167 840 101,359 1,653 Transfers from Stage 1 to Stage 2 (4,122) (14) 4,122 14 — — — — Transfers from Stage 2 to Stage 1 5,454 179 (5,454) (179) — — — — Transfers to Stage 3 (32) (1) (164) (12) 196 13 — — Transfers from Stage 3 363 3 145 5 (508) (8) — — Business activity in the year a 27,946 74 1,674 15 37 23 29,657 112 Refinements to models used for calculation b — — — 3 — — — 3 Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 2,448 (301) 1,072 (14) (82) 47 3,438 (268) Final repayments (19,481) (29) (4,322) (168) (504) (125) (24,307) (322) Disposals e (588) (8) (49) (4) (71) (41) (708) (53) Write-offs c — — — — (314) (314) (314) (314) As at 31 December 2021 d 95,242 183 12,962 193 921 435 109,125 811 Notes a. Business activity in the year does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. b. Refinements to models used for calculation include a £34m movement in Home loans, £30m in Credit cards, unsecured loans and other retail lending and £3m in Wholesale loans. These reflect methodology changes made during the year. Barclays Bank Group continually reviews the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. c. In 2021, gross write-offs amounted to £1,158m (2020: £1,337m) and post write-off recoveries amounted to £31m (2020: £4m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £1,127m (2020: £1,333m). d. Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £135.5bn (2020: £150.3bn) and impairment allowance of £104m (2020: £145m). This comprises £4m (2020: £7m) ECL on £135.3bn (2020: £146.3bn) Stage 1 assets, £0m (2020: £6m) on £65m (2020: £3.8bn) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets and £100m (2020: £132m) on £100m (2020: £132m) Stage 3 other assets. e. The £37m of disposals reported within Credit cards, unsecured loans and other retail lending portfolio relate to debt sales undertaken during the year. The £708m of disposals reported within Wholesale loans include debt sales and sale of Barclays Asset Finance. Reconciliation of ECL movement to credit impairment (release)/charge for the period £m Home loans (30) Credit cards, unsecured loans and other retail lending 171 Wholesale loans (475) ECL movement excluding assets derecognised due to disposals and write-offs (334) Recoveries and reimbursements a 259 Exchange and other adjustments b 70 Credit impairment release on loan commitments and financial guarantees (257) Credit impairment release on other financial assets c (15) Credit impairment release for the year (277) Notes a Recoveries and reimbursements includes a net reduction in amounts recoverable from financial guarantee contracts held with third parties of £290m and cash recoveries of previously written off amounts of £31m. b Includes foreign exchange and interest and fees in suspense. c Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £135.5bn (2020: £150.3bn) and impairment allowance of £104m (2020: £145m). This comprises £4m (2020: £7m) ECL on £135.3bn (2020: £146.3bn) Stage 1 assets, £0m (2020: £6m) on £65m (2020: £3.8bn) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets and £100m (2020: £132m) on £100m (2020: £132m) Stage 3 other assets. Loan commitments and financial guarantees (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2021 125 — 2 — 4 — 131 — Net transfers between stages — — — — — — — — Business activity in the year 19 — — — — — 19 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (4) — — — — — (4) — Limit management and final repayments (87) — (2) — (3) — (92) — As at 31 December 2021 53 — — — 1 — 54 — Credit cards, unsecured loans and other retail lending As at 1 January 2021 68,211 34 6,244 33 30 23 74,485 90 Net transfers between stages 2,992 (4) (3,431) (2) 439 6 — — Business activity in the year 10,628 — 410 — 2 — 11,040 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 3,712 6 585 2 (437) (9) 3,860 (1) Limit management and final repayments (6,888) — (594) — (2) — (7,484) — As at 31 December 2021 78,655 36 3,214 33 32 20 81,901 89 Wholesale loans d As at 1 January 2021 160,404 205 39,426 446 2,031 28 201,861 679 Net transfers between stages 7,801 220 (6,730) (214) (1,071) (6) — — Business activity in the year 45,395 14 4,658 102 9 — 50,062 116 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 10,551 (232) 2 12 539 (13) 11,092 (233) Limit management and final repayments (46,145) (40) (8,939) (105) (491) (7) (55,575) (152) As at 31 December 2021 178,006 167 28,417 241 1,017 2 207,440 410 d Barclays Bank Group has issued £1.7bn (2020: £2.6bn) of guarantees that have been provided to subsidiaries of Barclays PLC outside the Barclays Bank Group. These guarantees have not been reported in the prior periods and the comparatives have not been restated. Loans and advances at amortised cost (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2020 9,604 16 674 40 1,056 292 11,334 348 Transfers from Stage 1 to Stage 2 (537) (1) 537 1 — — — — Transfers from Stage 2 to Stage 1 204 7 (204) (7) — — — — Transfers to Stage 3 (157) — (52) (7) 209 7 — — Transfers from Stage 3 29 — 55 1 (84) (1) — — Business activity in the year a 1,193 1 — — 1 — 1,194 1 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 133 (17) (62) 25 32 96 103 104 Final repayments (842) — (47) (1) (98) (1) (987) (2) Write-offs b — — — — (17) (17) (17) (17) As at 31 December 2020 c 9,627 6 901 52 1,099 376 11,627 434 Credit cards, unsecured loans and other retail lending As at 1 January 2020 29,541 362 4,450 784 2,129 1,471 36,120 2,617 Transfers from Stage 1 to Stage 2 (4,116) (92) 4,116 92 — — — — Transfers from Stage 2 to Stage 1 994 139 (994) (139) — — — — Transfers to Stage 3 (464) (19) (516) (188) 980 207 — — Transfers from Stage 3 21 12 59 8 (80) (20) — — Business activity in the year a 3,467 35 130 32 29 7 3,626 74 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes (4,613) 15 (1,231) 806 38 731 (5,806) 1,552 Final repayments (2,232) (29) (168) (23) (68) (8) (2,468) (60) Transfers to Barclays Group d (2,182) (16) (92) (25) (47) (41) (2,321) (82) Disposals e (1,493) (8) (183) (20) (92) (58) (1,768) (86) Write-offs b — — — — (1,036) (1,036) (1,036) (1,036) As at 31 December 2020 c 18,923 399 5,571 1,327 1,853 1,253 26,347 2,979 Wholesale loans As at 1 January 2020 89,200 114 7,515 234 1,163 383 97,878 731 Transfers from Stage 1 to Stage 2 (10,213) (31) 10,213 31 — — — — Transfers from Stage 2 to Stage 1 2,651 25 (2,651) (25) — — — — Transfers to Stage 3 (772) (3) (642) (50) 1,414 53 — — Transfers from Stage 3 189 — 34 1 (223) (1) — — Business activity in the year a 19,773 44 1,954 144 393 67 22,120 255 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes 7,033 154 2,969 248 5 687 10,007 1,089 Final repayments (24,098) (22) (2,844) (28) (283) (59) (27,225) (109) Transfers to Barclays Group d (509) (1) (600) (22) (18) (6) (1,127) (29) Disposals e — — (10) — — — (10) — Write-offs b — — — — (284) (284) (284) (284) As at 31 December 2020 c 83,254 280 15,938 533 2,167 840 101,359 1,653 Notes a. Business activity during the year does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. b. In 2020, gross write-offs amounted to £1,337m (2019: £1,293m) and post write-off recoveries amounted to £4m (2019: £73m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £1,333m (2019: £1,220m). c. Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £150.3bn (2019: £125.5bn) and impairment allowance of £145m (2019: £22m). This comprises £7m ECL (2019 £10m) on £146.3bn stage 1 assets (2019: £124.7bn), £6m (2019: £2m) on £3.8bn stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (2019: £0.8bn) and £132m (2019: £10m) on £132m Stage 3 other assets (2019: £10m). d. Transfers to Barclays Group include a £2.3bn transfer of the Barclays Partner Finance retail portfolio reported within Credit cards, unsecured loans and other retail lending and £1.1bn transfer of the Barclays Mercantile Business Finance Limited reported within loans to Barclays Principal Investments Limited. e. The £1.8bn disposals reported within Credit cards, unsecured loans and other retail lending portfolio include sale of motor financing business within Barclays Partner Finance business. Disposal within Wholesale loans include sale of debt securities as part of Group Treasury Operations. Reconciliation of ECL movement to credit impairment (release)/charge for the period £m Home loans 103 Credit cards, unsecured loans and other retail lending 1,484 Wholesale loans 1,206 ECL movement excluding assets derecognised due to disposals and write-offs 2,793 Recoveries and reimbursements a (368) Exchange and other adjustments b 267 Credit impairment charge on loan commitments and financial guarantees 547 Credit impairment charge on other financial assets c 138 Credit impairment charge for the year 3,377 Notes a Recoveries and reimbursements includes £364m for reimbursements expected to be received under the arrangement where Group has entered into financial guarantee contracts which provide credit protection over certain loan assets with third parties. Cash recoveries of previously written off amounts to £4m. b Includes foreign exchange and interest and fees in suspense. c Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £150.3bn (2019: £125.5bn) and impairment allowance of £145m (2019: £22m). This comprises £7m ECL (2019: £10m) on £146.3bn stage 1 assets (2019: £124.7bn), £6m (2019: £2m) on £3.8bn stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (2019: £0.8bn) and £132m (2019: £10m) on £132m Stage 3 other assets (2019: £10m). Loan commitments and financial guarantees (audited) Stage 1 Stage 2 Stage 3 Total Barclays Bank Group Gross ECL Gross ECL Gross ECL Gross ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2020 34 — — — — — 34 — Net transfers between stages (4) — 4 — — — — — Business activity in the year 113 — — — — — 113 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1 — — — 4 — 5 — Limit management and final repayments (19) — (2) — — — (21) — As at 31 December 2020 125 — 2 — 4 — 131 — Credit cards, unsecured loans and other retail lending As at 1 January 2020 78,257 22 2,053 15 67 14 80,377 51 Net transfers between stages (4,124) 6 3,603 (2) 521 (4) — — Business activity in the year 4,591 2 128 1 1 1 4,720 4 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1,471 5 1,076 20 (553) 15 1,994 40 Limit management and final repayments (11,984) (1) (616) (1) (6) (3) (12,606) (5) As at 31 December 2020 68,211 34 6,244 33 30 23 74,485 90 Wholesale loans a As at 1 January 2020 183,001 63 12,053 97 636 41 195,690 201 Net transfers between stages (28,048) 67 27,052 (72) 996 5 — — Business activity in the year 42,904 32 4,705 102 774 2 48,383 136 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 12,755 50 (219) 334 (79) (19) 12,457 365 Limit management and final repayments (50,208) (7) (4,165) (15) (296) (1) (54,669) (23) As at 31 December 2020 160,404 205 39,426 446 2,031 28 201,861 679 Note a Barclays Bank Group has issued £1.7bn (2020: £2.6bn) of guarantees that have been provided to subsidiaries of Barclays PLC outside the Barclays Bank Group. These guarantees have not been reported in the prior periods and the comparatives have not been restated. |
Management adjustments to models for impairment and Economic uncertainty management adjustments to models for impairment (audited) | Total management adjustments to impairment allowance are presented by product below: Overview of management adjustments to models for impairment (audited) a 2021 2020 Management adjustments to impairment allowances Proportion of total impairment allowances Management adjustments to impairment allowances Proportion of total impairment allowances As at 31 December £m % £m % Home loans 34 8.8 54 12.4 Credit cards, unsecured loans and other retail lending 966 40.4 960 31.3 Wholesale loans 142 11.6 (78) (3.3) Total 1,142 28.6 936 16.0 Management adjustments to models are presented by product below: (audited) a Impairment allowance pre management adjustments b Economic uncertainty adjustments (a) Other adjustments (b) Total adjustments (a+b) Total impairment allowance c As at 31 December, 2021 £m £m £m £m £m Home loans 352 34 — 34 386 Credit cards, unsecured loans and other retail lending 1,425 771 195 966 2,391 Wholesale loans 1,079 244 (102) 142 1,221 Total 2,856 1,049 93 1,142 3,998 As at 31 December, 2020 £m £m £m £m £m Home loans 380 21 33 54 434 Credit cards, unsecured loans and other retail lending 2,109 986 (26) 960 3,069 Wholesale loans 2,410 379 (457) (78) 2,332 Total 4,899 1,386 (450) 936 5,835 Notes: a. Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance . b. Includes £2.2bn (2020: £3.9bn) of modelled ECL, £0.5bn (2020: £0.8bn) of individually assessed impairments and £0.2bn (2020: £0.2bn) ECL from non-modelled exposures. c. Total impairment allowance consists of ECL stock on drawn and undrawn exposures. |
Core macroeconomic variables for each scenario and the respective scenario weights | Baseline average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 4.9 2.3 1.9 1.7 UK unemployment b 4.8 4.7 4.5 4.3 4.2 UK HPI c 4.7 1.0 1.9 1.9 2.3 UK bank rate 0.1 0.8 1.0 1.0 0.8 US GDP a 5.5 3.9 2.6 2.4 2.4 US unemployment d 5.5 4.2 3.6 3.6 3.6 US HPI e 11.8 4.5 5.2 4.9 5.0 US federal funds rate 0.2 0.3 0.9 1.2 1.3 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) 6.3 3.3 2.6 2.0 UK unemployment b 4.5 6.7 6.4 5.8 5.1 UK HPI c 6.1 2.4 2.3 5.0 2.4 UK bank rate 0.2 — (0.1) — 0.1 US GDP a (4.4) 3.9 3.1 2.9 2.9 US unemployment d 8.4 6.9 5.7 5.6 5.6 US HPI e 2.3 2.8 4.7 4.7 4.7 US federal funds rate 0.5 0.3 0.3 0.3 0.4 Downside 2 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 0.2 (4.0) 2.8 4.3 UK unemployment b 4.8 7.2 9.0 7.6 6.3 UK HPI c 4.7 (14.3) (21.8) 11.9 15.2 UK bank rate 0.1 2.2 3.9 3.1 2.2 US GDP a 5.5 (0.8) (3.5) 2.5 3.2 US unemployment d 5.5 6.4 9.1 8.1 6.4 US HPI e 11.8 (6.6) (9.0) 5.9 6.7 US federal funds rate 0.2 2.1 3.4 2.6 2.0 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) (3.9) 6.5 2.6 1.4 UK unemployment b 4.5 8.0 9.3 7.8 6.3 UK HPI c 6.1 (13.6) (10.8) 0.5 1.5 UK bank rate 0.2 (0.2) (0.2) (0.1) (0.1) US GDP a (4.4) (2.4) 3.6 2.1 2.0 US unemployment d 8.4 13.4 11.9 10.1 8.2 US HPI e 2.3 (17.2) (0.7) 0.6 1.3 US federal funds rate 0.5 0.3 0.3 0.3 0.3 Downside 1 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 2.8 (0.7) 2.3 2.9 UK unemployment b 4.8 6.2 6.8 6.0 5.3 UK HPI c 4.7 (6.8) (10.5) 6.9 8.6 UK bank rate 0.1 1.6 2.7 2.3 1.6 US GDP a 5.5 1.6 (0.4) 2.4 2.7 US unemployment d 5.5 5.4 6.6 6.1 5.2 US HPI e 11.8 (1.2) (2.1) 4.8 5.2 US federal funds rate 0.2 1.3 2.3 2.1 1.8 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) (3.9) 6.5 2.6 1.4 UK unemployment b 4.5 8.0 9.3 7.8 6.3 UK HPI c 6.1 (13.6) (10.8) 0.5 1.5 UK bank rate 0.2 (0.2) (0.2) (0.1) (0.1) US GDP a (4.4) (2.4) 3.6 2.1 2.0 US unemployment d 8.4 13.4 11.9 10.1 8.2 US HPI e 2.3 (17.2) (0.7) 0.6 1.3 US federal funds rate 0.5 0.3 0.3 0.3 0.3 Upside 2 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 7.2 4.0 2.7 2.1 UK unemployment b 4.8 4.5 4.1 4.0 4.0 UK HPI c 4.7 8.5 9.0 5.2 4.2 UK bank rate 0.1 0.2 0.5 0.5 0.3 US GDP a 5.5 5.3 4.1 3.5 3.4 US unemployment d 5.5 3.9 3.4 3.3 3.3 US HPI e 11.8 10.6 8.5 7.2 6.6 US federal funds rate 0.2 0.3 0.4 0.7 1.0 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) 12.2 5.3 3.9 2.9 UK unemployment b 4.5 6.2 5.5 4.8 4.4 UK HPI c 6.1 6.6 10.4 10.8 7.3 UK bank rate 0.2 0.1 0.3 0.3 0.5 US GDP a (4.4) 7.1 4.6 4.0 3.5 US unemployment d 8.4 5.5 4.3 4.1 4.1 US HPI e 2.3 8.8 9.1 8.9 7.5 US federal funds rate 0.5 0.3 0.4 0.6 0.9 Upside 1 average macroeconomic variables used in the calculation of ECL 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP a 6.2 6.0 3.1 2.3 1.9 UK unemployment b 4.8 4.6 4.3 4.2 4.1 UK HPI c 4.7 5.0 5.0 3.9 3.3 UK bank rate 0.1 0.6 0.8 0.8 0.5 US GDP a 5.5 4.6 3.4 2.9 2.9 US unemployment d 5.5 4.0 3.5 3.5 3.5 US HPI e 11.8 8.3 7.0 6.0 5.7 US federal funds rate 0.2 0.3 0.6 1.0 1.1 2020 2021 2022 2023 2024 As at 31 December 2020 % % % % % UK GDP a (10.1) 9.3 3.9 3.4 2.5 UK unemployment b 4.5 6.4 6.0 5.2 4.7 UK HPI c 6.1 4.6 6.1 6.1 4.7 UK bank rate 0.2 0.1 0.1 0.3 0.3 US GDP a (4.4) 5.5 4.0 3.7 3.3 US unemployment d 8.4 6.0 4.8 4.6 4.6 US HPI e 2.3 6.8 6.7 6.3 5.6 US federal funds rate 0.5 0.3 0.3 0.5 0.8 Notes a Average Real GDP seasonally adjusted change in year. b Average UK unemployment rate 16-year+. c Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. d Average US civilian unemployment rate 16-year+. e Change in year end US HPI = FHFA house price index, relative to prior year end. Scenario probability weighting (audited) Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 31 December 2021 Scenario probability weighting 20.9 27.2 30.1 14.8 7.0 As at 31 December 2020 Scenario probability weighting 20.2 24.2 24.7 15.5 15.4 Specific bases show the most extreme position of each variable in the context of the scenario, for example, the highest unemployment for downside scenarios, average unemployment for baseline scenarios and lowest unemployment for upside scenarios. GDP and HPI downside and upside scenario data represents the lowest and highest points relative to the start point in the 20 quarter period. Macroeconomic variables used in the calculation of ECL (specific bases) (audited) a Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 31 December 2021 UK GDP b 21.4 18.3 3.4 (1.6) (1.6) UK unemployment c 4.0 4.1 4.5 7.0 9.2 UK HPI d 35.7 23.8 2.4 (12.7) (29.9) UK bank rate c 0.1 0.1 0.7 2.8 4.0 US GDP b 22.8 19.6 3.4 1.5 (1.3) US unemployment c 3.3 3.5 4.1 6.8 9.5 US HPI d 53.3 45.2 6.2 2.2 (5.0) US federal funds rate c 0.1 0.1 0.8 2.3 3.5 As at 31 December 2020 UK GDP b 14.2 8.8 0.7 (22.1) (22.1) UK unemployment c 4.0 4.0 5.7 8.4 10.1 UK HPI d 48.2 30.8 3.6 (4.5) (18.3) UK bank rate c 0.1 0.1 — 0.6 0.6 US GDP b 15.7 12.8 1.6 (10.6) (10.6) US unemployment c 3.8 3.8 6.4 13.0 13.7 US HPI d 42.2 30.9 3.8 (3.7) (15.9) US federal funds rate c 0.1 0.1 0.3 1.3 1.3 Average basis represents the average quarterly value of variables in the 20 quarter period with GDP and HPI based on yearly average and quarterly CAGRs respectively. Macroeconomic variables used in the calculation of ECL (5 year averages) (audited) a Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 31 December 2021 UK GDP e 4.4 3.9 3.4 2.7 1.8 UK unemployment f 4.3 4.4 4.5 5.8 7.0 UK HPI g 6.3 4.4 2.4 0.3 (2.0) UK bank rate f 0.3 0.5 0.7 1.7 2.3 US GDP e 4.4 3.9 3.4 2.4 1.3 US unemployment f 3.9 4.0 4.1 5.7 7.1 US HPI g 8.9 7.7 6.2 3.6 1.4 US federal funds rate f 0.5 0.6 0.8 1.5 2.1 As at 31 December 2020 UK GDP e 2.5 1.6 0.7 0.1 (0.9) UK unemployment f 5.0 5.3 5.7 6.5 7.2 UK HPI g 8.2 5.5 3.6 (0.2) (3.6) UK bank rate f 0.3 0.2 — — (0.1) US GDP e 2.9 2.4 1.6 0.8 0.1 US unemployment f 5.3 5.7 6.4 8.3 10.4 US HPI g 7.3 5.5 3.8 0.8 (3.0) US federal funds rate f 0.5 0.5 0.3 0.3 0.3 Notes a UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HPI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA house price index. 20 quarter period starts from Q121 (2020: Q120). b Maximum growth relative to Q420 (2020: Q419), based on 20 quarter period in Upside scenarios; 5-year yearly average CAGR in Baseline; minimum growth relative to Q420 (2020: Q419), based on 20 quarter period in Downside scenarios. c Lowest quarter in Upside scenarios; 5-year average in Baseline; highest quarter in Downside scenarios. Period based on 20 quarters from Q121 (2020: Q120). d Maximum growth relative to Q420 (2020: Q419), based on 20 quarter period in Upside scenarios; 5-year quarter end CAGR in Baseline; minimum growth relative to Q420 (2020: Q419), based on 20 quarter period in Downside scenarios. e 5-year yearly average CAGR, starting 2020 (2020: 2019) f 5-year average. Period based on 20 quarters from Q121 (2020: Q120) g 5-year quarter end CAGR, starting Q420 (2020: Q419) |
ECL under 100% weighted scenarios for key principal portfolios | Scenarios As at 31 December 2021 Weighted Upside 2 Upside 1 Baseline Downside 1 Downside 2 Stage 1 Model exposure (£m) Home loans 3,905 3,915 3,911 3,906 3,885 3,868 Credit cards, unsecured loans and other retail lending 19,001 19,357 19,284 19,201 17,445 13,785 Wholesale loans 142,804 145,097 144,688 143,967 140,402 135,764 Stage 1 Model ECL (£m) Home loans 2 2 2 2 3 3 Credit cards, unsecured loans and other retail lending 221 157 164 173 254 332 Wholesale loans 219 189 200 216 250 282 Stage 1 Coverage (%) Home loans 0.1 0.1 0.1 0.1 0.1 0.1 Credit cards, unsecured loans and other retail lending 1.2 0.8 0.9 0.9 1.5 2.4 Wholesale loans 0.2 0.1 0.1 0.2 0.2 0.2 Stage 2 Model exposure (£m) Home loans 228 219 222 227 249 266 Credit cards, unsecured loans and other retail lending 1,991 1,584 1,683 1,793 3,605 7,331 Wholesale loans 29,124 26,831 27,240 27,961 31,525 36,163 Stage 2 Model ECL (£m) Home loans 12 10 10 11 18 24 Credit cards, unsecured loans and other retail lending 365 264 295 333 599 2,278 Wholesale loans 506 395 420 462 712 1,229 Stage 2 Coverage (%) Home loans 5.3 4.6 4.5 4.8 7.2 9.0 Credit cards, unsecured loans and other retail lending 18.3 16.7 17.5 18.6 16.6 31.1 Wholesale loans 1.7 1.5 1.5 1.7 2.3 3.4 Stage 3 Model exposure (£m) Home loans 610 610 610 610 610 610 Credit cards, unsecured loans and other retail lending 1,028 1,028 1,028 1,028 1,028 1,028 Wholesale loans a — — — — — — Stage 3 Model ECL (£m) Home loans 297 290 292 296 310 320 Credit cards, unsecured loans and other retail lending 696 685 690 696 710 722 Wholesale loans a — — — — — — Stage 3 Coverage (%) Home loans 48.7 47.5 47.9 48.5 50.8 52.5 Credit cards, unsecured loans and other retail lending 67.7 66.6 67.1 67.7 69.1 70.2 Wholesale loans a — — — — — — Total Model ECL (£m) Home loans 311 302 304 309 331 347 Credit cards, unsecured loans and other retail lending 1,282 1,106 1,149 1,202 1,563 3,332 Wholesale loans a 725 584 620 678 962 1,511 Total ECL 2,318 1,992 2,073 2,189 2,856 5,190 Note a Material wholesale loan defaults are individually assessed across different recovery strategies. As a result, ECL of £463m is reported as individually assessed impairments in the table below. Reconciliation to total ECL £m Total model ECL 2,318 ECL from individually assessed impairments 463 ECL from non-modelled and other management adjustments a 1,217 Total ECL 3,998 Note a Includes £1.1bn of post model adjustments of which £0.1bn is included as part of the total model ECL and £0.2bn ECL from non-modelled exposures. Scenarios As at 31 December 2020 Weighted Upside 2 Upside 1 Baseline Downside 1 Downside 2 Stage 1 Model exposure (£m) Home loans 4,404 4,422 4,416 4,407 4,387 4,365 Credit cards, unsecured loans and other retail lending 24,980 24,929 25,097 24,820 24,411 24,247 Wholesale loans 115,949 121,769 120,741 118,930 113,027 101,759 Stage 1 Model ECL (£m) Home loans 4 4 4 4 5 5 Credit cards, unsecured loans and other retail lending 236 187 204 230 258 263 Wholesale loans 219 239 231 205 218 221 Stage 1 Coverage (%) Home loans 0.1 0.1 0.1 0.1 0.1 0.1 Credit cards, unsecured loans and other retail lending 0.9 0.8 0.8 0.9 1.1 1.1 Wholesale loans 0.2 0.2 0.2 0.2 0.2 0.2 Stage 2 Model exposure (£m) Home loans 557 539 545 554 575 597 Credit cards, unsecured loans and other retail lending 3,171 2,111 2,462 3,215 4,721 5,796 Wholesale loans 29,834 24,015 25,043 26,853 32,757 44,024 Stage 2 Model ECL (£m) Home loans 33 31 31 32 36 40 Credit cards, unsecured loans and other retail lending 512 327 382 481 796 1,045 Wholesale loans 1,358 922 1,010 1,174 1,683 2,751 Stage 2 Coverage (%) Home loans 5.9 5.8 5.7 5.8 6.3 6.7 Credit cards, unsecured loans and other retail lending 16.1 15.5 15.5 15.0 16.9 18.0 Wholesale loans 4.6 3.8 4.0 4.4 5.1 6.2 Stage 3 Model exposure (£m) Home loans 728 728 728 728 728 728 Credit cards, unsecured loans and other retail lending 1,279 1,279 1,279 1,279 1,279 1,279 Wholesale loans a 863 863 863 863 863 863 Stage 3 Model ECL (£m) Home loans 298 278 281 284 306 363 Credit cards, unsecured loans and other retail lending 1,190 1,170 1,180 1,191 1,211 1,210 Wholesale loans a 25 20 21 23 29 40 Stage 3 Coverage (%) Home loans 40.9 38.2 38.6 39.0 42.0 49.9 Credit cards, unsecured loans and other retail lending 93.0 91.5 92.3 93.1 94.7 94.6 Wholesale loans a 2.9 2.3 2.4 2.7 3.4 4.6 Total Model ECL (£m) Home loans 335 313 316 320 347 408 Credit cards, unsecured loans and other retail lending 1,938 1,684 1,766 1,902 2,265 2,518 Wholesale loans a 1,602 1,181 1,262 1,402 1,930 3,012 Total ECL 3,875 3,178 3,344 3,624 4,542 5,938 Note a Material wholesale loan defaults are individually assessed across different recovery strategies. As a result, ECL of £835m is reported as individually assessed impairments in the table below. Reconciliation to total ECL a £m Total model ECL 3,875 ECL from individually assessed impairments 835 ECL from non-modelled and other management adjustments 1,125 Total ECL 5,835 Note a Includes £0.9bn of post model adjustment and £0.2bn ECL from non-model exposures. |
Concentrations of Credit Risk by geography and industry (audited) | Credit risk concentrations by geography (audited) Barclays Bank Group United Americas Europe Asia Africa and Middle East Total As at 31 December 2021 £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 45,470 38,735 76,846 7,789 245 169,085 Cash collateral and settlement balances 30,107 28,272 21,754 7,210 742 88,085 Loans and advances at amortised cost 62,269 50,718 23,576 4,775 3,921 145,259 Reverse repurchase agreements and other similar secured lending 9 123 351 2,508 186 3,177 Trading portfolio assets 12,852 29,478 15,062 4,943 890 63,225 Financial assets at fair value through the income statement 26,096 95,456 30,080 21,798 9,998 183,428 Derivative financial instruments 78,449 91,992 75,245 14,709 1,896 262,291 Financial assets at fair value through other comprehensive income 4,525 20,750 15,603 4,666 363 45,907 Other assets 747 224 17 6 — 994 Total on-balance sheet 260,524 355,748 258,534 68,404 18,241 961,451 Off-balance sheet: Contingent liabilities 7,926 10,329 3,957 1,131 403 23,746 Loan commitments 46,616 192,270 38,567 5,079 1,919 284,451 Total off-balance sheet 54,542 202,599 42,524 6,210 2,322 308,197 Total 315,066 558,347 301,058 74,614 20,563 1,269,648 As at 31 December 2020 On-balance sheet: Cash and balances at central banks 31,235 36,063 69,962 17,987 655 155,902 Cash collateral and settlement balances 30,261 27,255 30,105 9,487 508 97,616 Loans and advances at amortised cost 61,754 40,403 23,931 4,859 3,320 134,267 Reverse repurchase agreements and other similar secured lending 10 152 323 8,285 211 8,981 Trading portfolio assets 9,787 31,003 16,861 5,947 946 64,544 Financial assets at fair value through the income statement 31,745 88,302 25,706 14,742 7,524 168,019 Derivative financial instruments 93,685 90,796 101,099 14,532 2,581 302,693 Financial assets at fair value through other comprehensive income 6,921 19,451 22,138 3,276 115 51,901 Other assets 392 185 37 — — 614 Total on-balance sheet 265,790 333,610 290,162 79,115 15,860 984,537 Off-balance sheet: Contingent liabilities 5,200 10,121 3,809 1,222 580 20,932 Loan commitments 46,746 175,893 36,713 4,132 1,538 265,022 Total off-balance sheet 51,946 186,014 40,522 5,354 2,118 285,954 Total 317,736 519,624 330,684 84,469 17,978 1,270,491 Credit risk concentrations by industry (audited) Barclays Bank Group Banks Other financial Manu- Const- Govern- Energy Wholesale Business Home Cards, Other Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m £m £m On-balance sheet: Cash and balances at central banks 28 — — — 169,057 — — — — — — 169,085 Cash collateral and settlement balances 14,605 61,252 320 79 10,684 390 60 354 — — 341 88,085 Loans and advances at amortised cost 7,955 33,563 5,821 13,714 15,462 4,244 7,266 13,881 10,985 26,477 5,891 145,259 Reverse repurchase agreements and other similar secured lending 595 2,049 — — 533 — — — — — — 3,177 Trading portfolio assets 2,560 8,818 4,881 1,048 32,483 4,043 1,734 4,716 — — 2,942 63,225 Financial assets at fair value through the income statement 26,239 131,232 763 5,444 13,935 76 181 3,547 1,595 — 416 183,428 Derivative financial instruments 120,607 117,050 4,168 1,898 7,233 3,544 1,172 2,825 — — 3,794 262,291 Financial assets at fair value through other comprehensive income 9,942 2,972 — 514 31,975 — — 444 — — 60 45,907 Other assets 401 474 1 — 8 — — 105 — — 5 994 Total on-balance sheet 182,932 357,410 15,954 22,697 281,370 12,297 10,413 25,872 12,580 26,477 13,449 961,451 Off-balance sheet: Contingent liabilities 1,005 7,772 3,080 1,342 1,092 3,284 1,182 3,118 — 73 1,798 23,746 Loan commitments 1,340 53,212 42,434 15,752 1,360 26,447 15,811 25,201 341 76,759 25,794 284,451 Total off-balance sheet 2,345 60,984 45,514 17,094 2,452 29,731 16,993 28,319 341 76,832 27,592 308,197 Total 185,277 418,394 61,468 39,791 283,822 42,028 27,406 54,191 12,921 103,309 41,041 1,269,648 As at 31 December 2020 On-balance sheet: Cash and balances at central banks 3 — — — 155,899 — — — — — — 155,902 Cash collateral and settlement balances 17,961 66,696 375 35 10,828 871 30 576 — — 244 97,616 Loans and advances at amortised cost 8,649 24,766 7,122 12,889 13,759 4,554 7,814 13,528 11,193 23,955 6,038 134,267 Reverse repurchase agreements and other similar secured lending 656 7,964 — — 361 — — — — — — 8,981 Trading portfolio assets 2,752 11,464 4,104 516 35,607 3,052 1,883 2,625 — — 2,541 64,544 Financial assets at fair value through the income statement 22,766 131,929 603 2,481 5,519 13 64 3,479 971 — 194 168,019 Derivative financial instruments 155,986 116,421 4,126 2,725 11,649 3,288 1,235 2,496 — — 4,767 302,693 Financial assets at fair value through other comprehensive income 13,003 4,258 1 333 33,774 — — 527 — — 5 51,901 Other assets 303 193 5 3 1 10 1 95 — — 3 614 Total on-balance sheet 222,079 363,691 16,336 18,982 267,397 11,788 11,027 23,326 12,164 23,955 13,792 984,537 Off-balance sheet: Contingent liabilities 1,150 5,501 3,187 1,260 1,028 3,223 978 2,283 — 155 2,167 20,932 Loan commitments 1,773 51,900 39,447 12,843 1,398 25,766 16,626 24,001 134 69,646 21,488 265,022 Total off-balance sheet 2,923 57,401 42,634 14,103 2,426 28,989 17,604 26,284 134 69,801 23,655 285,954 Total 225,002 421,092 58,970 33,085 269,823 40,777 28,631 49,610 12,298 93,756 37,447 1,270,491 |
Balance Sheet credit quality (audited) | Balance sheet credit quality (audited) Barclays Bank Group PD Range 0.0 to <0.60% 0.60 to <11.35% 11.35% to 100% Total 0.0 to <0.60% 0.60 to <11.35% 11.35% to 100% Total As at 31 December 2021 £m £m £m £m % % % % Cash and balances at central banks 169,085 — — 169,085 100 — — 100 Cash collateral and settlement balances 78,881 9,194 10 88,085 90 10 — 100 Loans and advances at amortised cost Home loans 9,519 809 657 10,985 87 7 6 100 Credit cards, unsecured loans and other retail lending 18,460 6,178 1,322 25,960 71 24 5 100 Wholesale loans 78,239 26,992 3,083 108,314 72 25 3 100 Total loans and advances at amortised cost 106,218 33,979 5,062 145,259 73 23 4 100 Reverse repurchase agreements and other similar secured lending 3,091 86 — 3,177 97 3 — 100 Trading portfolio assets: Debt securities 44,488 5,735 477 50,700 88 11 1 100 Traded loans 2,172 10,144 209 12,525 17 81 2 100 Total trading portfolio assets 46,660 15,879 686 63,225 74 25 1 100 Financial assets at fair value through the income statement: Loans and advances 16,977 18,896 28 35,901 47 53 — 100 Debt securities 1346 858 52 2,256 60 38 2 100 Reverse repurchase agreements 108,609 36,047 530 145,186 75 25 — 100 Other financial assets 67 18 — 85 79 21 — 100 Total financial assets at fair value through the income statement 126,999 55,819 610 183,428 70 30 — 100 Derivative financial instruments 246,347 15,678 266 262,291 94 6 — 100 Financial assets at fair value through other comprehensive income 45,901 6 — 45,907 100 — — 100 Other assets 948 46 — 994 95 5 — 100 Total on-balance sheet 824,130 130,687 6,634 961,451 86 13 1 100 As at 31 December 2020 Cash and balances at central banks 155,902 — — 155,902 100 — — 100 Cash collateral and settlement balances 86,882 10,725 9 97,616 89 11 — 100 Loans and advances at amortised cost Home loans 7,582 2,840 771 11,193 68 25 7 100 Credit cards, unsecured loans and other retail lending 10,742 11,259 1,367 23,368 46 48 6 100 Wholesale loans 75,672 20,828 3,206 99,706 76 21 3 100 Total loans and advances at amortised cost 93,996 34,927 5,344 134,267 70 26 4 100 Reverse repurchase agreements and other similar secured lending 8,969 12 — 8,981 100 — — 100 Trading portfolio assets: Debt securities 51,109 4,871 216 56,196 91 9 — 100 Traded loans 704 5,107 2,537 8,348 9 61 30 100 Total trading portfolio assets 51,813 9,978 2,753 64,544 80 16 4 100 Financial assets at fair value through the income statement: Loans and advances 13,174 14,232 43 27,449 48 52 — 100 Debt securities 1,136 515 46 1,697 67 30 3 100 Reverse repurchase agreements 96,318 41,566 674 138,558 70 30 — 100 Other financial assets 302 13 — 315 96 4 — 100 Total financial assets at fair value through the income statement 110,930 56,326 763 168,019 66 34 — 100 Derivative financial instruments 282,864 19,352 477 302,693 94 6 — 100 Financial assets at fair value through other comprehensive income 51,893 8 — 51,901 100 — — 100 Other assets 572 42 — 614 93 7 — 100 Total on-balance sheet 843,821 131,370 9,346 984,537 86 13 1 100 |
Credit risk profile by internal PD band for loans and advances at amortised cost, contingent liabilities and loan commitments (audited) | The below tables represents credit risk profile by PD grade for loans and advances at amortised cost, contingent liabilities and loan commitments. Stage 1 higher risk assets, presented gross of associated collateral held, are of weaker credit quality but have not significantly deteriorated since origination. IFRS 9 Stage 1 and Stage 2 classification is not dependent solely on the absolute probability of default but on elements that determine a Significant Increase in Credit Risk (see Note 7 to the financial statements on page 126 Barclays Bank Group As at 31 December 2021 Credit risk profile by internal PD grade for loans and advances at amortised cost (audited) Gross carrying amount Allowance for ECL Net exposure Coverage ratio PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total Grading % £m £m £m £m £m £m £m £m £m % 1-3 0.0 to < 0.05% Strong 52,756 855 — 53,611 280 6 — 286 53,325 0.5 4-5 0.05 to < 0.15% Strong 17,797 211 — 18,008 6 2 — 8 18,000 — 6-8 0.15 to < 0.30% Strong 10,764 1,220 — 11,984 15 7 — 22 11,962 0.2 9-11 0.30 to < 0.60% Strong 21,865 1,136 — 23,001 55 15 — 70 22,931 0.3 12-14 0.60 to < 2.15% Satisfactory 16,429 3,508 — 19,937 160 116 — 276 19,661 1.4 15-19 2.15 to < 10% Satisfactory 6,653 4,995 — 11,648 169 302 — 471 11,177 4.0 19 10 to < 11.35% Satisfactory 2,156 1,276 — 3,432 39 252 — 291 3,141 8.5 20-21 11.35 to < 100% Higher Risk 593 3,196 — 3,789 72 319 — 391 3,398 10.3 22 100 % Credit Impaired — — 3,348 3,348 — — 1,684 1,684 1,664 50.3 Total 129,013 16,397 3,348 148,758 796 1,019 1,684 3,499 145,259 2.4 As at 31 December 2020 Credit risk profile by internal PD grade for loans and advances at amortised cost (audited) Gross carrying amount Allowance for ECL Net exposure Coverage ratio PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total Grading % £m £m £m £m £m £m £m £m £m % 1-3 0.0 to < 0.05% Strong 36,388 689 — 37,077 2 3 — 5 37,072 — 4-5 0.05 to < 0.15% Strong 17,008 627 — 17,635 17 4 — 21 17,614 0.1 6-8 0.15 to < 0.30% Strong 13,667 2,463 — 16,130 34 52 — 86 16,044 0.5 9-11 0.30 to < 0.60% Strong 21,049 2,432 — 23,481 88 127 — 215 23,266 0.9 12-14 0.60 to < 2.15% Satisfactory 16,951 4,913 — 21,864 293 351 — 644 21,220 2.9 15-19 2.15 to < 10% Satisfactory 5,264 6,661 — 11,925 183 651 — 834 11,091 7.0 19 10 to < 11.35% Satisfactory 1,042 1,698 — 2,740 25 99 — 124 2,616 4.5 20-21 11.35 to < 100% Higher Risk 435 2,927 — 3,362 43 625 — 668 2,694 19.9 22 100 % Credit Impaired — — 5,119 5,119 — — 2,469 2,469 2,650 48.2 Total 111,804 22,410 5,119 139,333 685 1,912 2,469 5,066 134,267 3.6 As at 31 December 2021 Credit risk profile by internal PD grade for contingent liabilities a (audited) Gross carrying amount Allowance for ECL Net exposure Coverage ratio PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total Grading % £m £m £m £m £m £m £m £m £m % 1-3 0.0 to < 0.05% Strong 8,240 172 — 8,412 2 1 — 3 8,409 — 4-5 0.05 to < 0.15% Strong 3,479 503 — 3,982 2 2 — 4 3,978 0.1 6-8 0.15 to < 0.30% Strong 1,996 199 — 2,195 2 2 — 4 2,191 0.2 9-11 0.30 to < 0.60% Strong 2,794 216 — 3,010 4 1 — 5 3,005 0.2 12-14 0.60 to < 2.15% Satisfactory 1,990 286 — 2,276 19 8 — 27 2,249 1.2 15-19 2.15 to < 10% Satisfactory 817 479 — 1,296 5 10 — 15 1,281 1.2 19 10 to < 11.35% Satisfactory 607 254 — 861 21 42 — 63 798 7.3 20-21 11.35 to < 100% Higher Risk 141 1,162 — 1,303 3 77 — 80 1,223 6.1 22 100 % Credit Impaired — — 180 180 — — 1 1 179 0.6 Total 20,064 3,271 180 23,515 58 143 1 202 23,313 0.9 As at 31 December 2020 Credit risk profile by internal PD grade for contingent liabilities a (audited) Gross carrying amount Allowance for ECL Net exposure Coverage ratio PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total Grading % £m £m £m £m £m £m £m £m £m % 1-3 0.0 to < 0.05% Strong 5,502 188 — 5,690 1 — — 1 5,689 — 4-5 0.05 to < 0.15% Strong 2,765 428 — 3,193 3 2 — 5 3,188 0.2 6-8 0.15 to < 0.30% Strong 1,468 165 — 1,633 3 4 — 7 1,626 0.4 9-11 0.30 to < 0.60% Strong 3,524 552 — 4,076 5 33 — 38 4,038 0.9 12-14 0.60 to < 2.15% Satisfactory 2,712 546 — 3,258 8 25 — 33 3,225 1.0 15-19 2.15 to < 10% Satisfactory 305 398 — 703 7 21 — 28 675 4.0 19 10 to < 11.35% Satisfactory 264 423 — 687 17 83 — 100 587 14.6 20-21 11.35 to < 100% Higher Risk 40 769 — 809 — 61 — 61 748 7.5 22 100 % Credit Impaired — — 654 654 — — 10 10 644 1.5 Total 16,580 3,469 654 20,703 44 229 10 283 20,420 1.4 As at 31 December 2021 Credit risk profile by internal PD grade for loan commitments a (audited) Gross carrying amount Allowance for ECL Net exposure Coverage ratio PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total Grading % £m £m £m £m £m £m £m £m £m % 1-3 0.0 to < 0.05% Strong 92,864 3,002 — 95,866 5 3 — 8 95,858 — 4-5 0.05 to < 0.15% Strong 55,979 5,345 — 61,324 10 5 — 15 61,309 — 6-8 0.15 to < 0.30% Strong 22,345 2,079 — 24,424 7 6 — 13 24,411 0.1 9-11 0.30 to < 0.60% Strong 23,445 2,312 — 25,757 5 5 — 10 25,747 — 12-14 0.60 to < 2.15% Satisfactory 23,189 3,240 — 26,429 79 23 — 102 26,327 0.4 15-19 2.15 to < 10% Satisfactory 6,362 2,749 — 9,111 20 21 — 41 9,070 0.5 19 10 to < 11.35% Satisfactory 10,270 2,964 — 13,234 8 13 — 21 13,213 0.2 20-21 11.35 to < 100% Higher Risk 2,196 6,669 — 8,865 11 55 — 66 8,799 0.7 22 100 % Credit Impaired — — 870 870 — — 21 21 849 2.4 Total 236,650 28,360 870 265,880 145 131 21 297 265,583 0.1 As at 31 December 2020 Credit risk profile by internal PD grade for loan commitments a (audited) Gross carrying amount Allowance for ECL Net exposure Coverage ratio PD range Credit quality description Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total Grading % £m £m £m £m £m £m £m £m £m % 1-3 0.0 to < 0.05% Strong 52,522 5,311 — 57,833 3 1 — 4 57,829 — 4-5 0.05 to < 0.15% Strong 62,677 5,730 — 68,407 11 8 — 19 68,388 — 6-8 0.15 to < 0.30% Strong 41,621 6,260 — 47,881 15 20 — 35 47,846 0.1 9-11 0.30 to < 0.60% Strong 25,461 6,187 — 31,648 14 19 — 33 31,615 0.1 12-14 0.60 to < 2.15% Satisfactory 20,730 6,978 — 27,708 113 18 — 131 27,577 0.5 15-19 2.15 to < 10% Satisfactory 3,621 2,991 — 6,612 23 44 — 67 6,545 1.0 19 10 to < 11.35% Satisfactory 4,778 4,971 — 9,749 11 25 — 36 9,713 0.4 20-21 11.35 to < 100% Higher Risk 750 3,775 — 4,525 5 115 — 120 4,405 2.7 22 100 % Credit Impaired — — 1,411 1,411 — — 41 41 1,370 2.9 Total 212,160 42,203 1,411 255,774 195 250 41 486 255,288 0.2 Notes a Excludes loan commitments and financial guarantees carried at fair value of £18.8bn (2020: £9.5bn) for Barclays Bank Group. b Barclays Bank Group has issued £1.7bn (2020: £2.6bn) of guarantees that have been provided to subsidiaries of Barclays PLC outside the Barclays Bank Group. These guarantees have not been reported in the prior periods and the comparatives have not been restated. |
Management Value at Risk (audited) | The daily average, maximum and minimum values of management VaR Management VaR (95%, one day) (audited) 2021 2020 Average High Low Average High Low For the year ended 31 December £m £m £m £m £m £m Credit risk 14 30 7 20 38 10 Interest rate risk 7 14 4 10 17 6 Equity risk 9 29 4 13 35 6 Basis risk 5 10 3 9 14 7 Spread risk 4 6 3 5 9 3 Foreign exchange risk 4 16 1 4 7 2 Commodity risk — 1 — 1 1 — Inflation risk 3 5 2 2 3 1 Diversification effect a (27) n/a n/a (33) n/a n/a Total management VaR 19 36 6 31 57 17 Note a Diversification effects recognise that forecast losses from different assets or businesses are unlikely to occur concurrently, hence the expected aggregate loss is lower than the sum of the expected losses from each area. Historical correlations between losses are taken into account in making these assessments. The high and low VaR figures reported for each category did not necessarily occur on the same day as the high and low VaR reported as a whole. Consequently, a diversification effect balance for the high and low VaR figures would not be meaningful and is therefore omitted from the above table. |
Contractual maturity of financial assets and liabilities (audited) | Contractual maturity of financial assets and liabilities (audited) Restated a Barclays Bank Group On Not more Over three Over six Over nine Over one Over two Over three Over five Over ten Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m £m Assets Cash and balances at central banks 168,881 204 — — — — — — — — 169,085 Cash collateral and settlement balances 2,743 85,342 — — — — — — — — 88,085 Loans and advances at amortised cost 17,470 7,855 6,745 4,238 9,611 19,162 20,813 27,416 14,420 17,529 145,259 Reverse repurchase agreements and other similar secured lending 58 2,934 — — — 184 — — — 1 3,177 Trading portfolio assets 146,871 — — — — — — — — — 146,871 Financial assets at fair value through the income statement 24,174 127,244 9,280 7,036 3,336 5,351 5,376 2,062 1,996 2,371 188,226 Derivative financial instruments 262,046 36 1 — — — — 184 15 9 262,291 Financial assets at fair value through other comprehensive income — 3,194 1,080 449 547 2,656 5,389 10,093 13,823 8,677 45,908 Other financial assets 607 255 130 2 — — — — — — 994 Total financial assets 622,850 227,064 17,236 11,725 13,494 27,353 31,578 39,755 30,254 28,587 1,049,896 Other assets 11,882 Total assets 1,061,778 Liabilities Deposits at amortised cost 201,501 41,632 12,380 1,920 2,898 558 435 242 1,031 231 262,828 Cash collateral and settlement balances 2,951 76,096 — — — — — — — — 79,047 Repurchase agreements and other similar secured borrowing 20 5,022 — — — 3,216 4,424 — — 87 12,769 Debt securities in issue — 18,274 12,150 5,845 3,254 463 3,319 1,792 2,654 637 48,388 Subordinated liabilities — 1,005 — 74 1,243 7,030 2,251 5,714 8,490 6,378 32,185 Trading portfolio liabilities 53,291 — — — — — — — — — 53,291 Financial liabilities designated at fair value 21,339 158,078 16,857 10,267 3,588 6,534 6,114 7,734 7,366 13,254 251,131 Derivative financial instruments 255,471 4 22 — 2 121 151 279 111 362 256,523 Other financial liabilities 87 3,656 15 15 12 443 52 102 183 27 4,592 Total financial liabilities 534,660 303,767 41,424 18,121 10,997 18,365 16,746 15,863 19,835 20,976 1,000,754 Other liabilities 4,707 Total liabilities 1,005,461 Cumulative liquidity gap 88,190 11,487 (12,701) (19,097) (16,600) (7,612) 7,220 31,112 41,531 49,142 56,317 a. 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. The contractual maturity profile of financial liabilities designated at fair value has been restated to reflect the impact of the over-issuance of securities. Securities issued by the Company in excess of the maximum aggregate offering price registered under the Company’s 2019 F-3 with a value of £6,997m have been classified as "on demand". Contractual maturity of financial assets and liabilities (audited) Barclays Bank Group On Not more Over three Over six Over nine Over one Over two Over three Over five Over ten Total As at 31 December 2020 £m £m £m £m £m £m £m £m £m £m £m Assets Cash and balances at central banks 155,122 182 598 — — — — — — — 155,902 Cash collateral and settlement balances 1,281 96,335 — — — — — — — — 97,616 Loans and advances at amortised cost 12,854 11,149 6,291 3,770 4,314 21,271 16,663 22,387 14,127 21,441 134,267 Reverse repurchase agreements and other similar secured lending 150 8,648 — — — — 183 — — — 8,981 Trading portfolio assets 127,664 — — — — — — — — — 127,664 Financial assets at fair value through the income statement 17,377 123,948 7,547 6,959 4,027 4,294 1,216 2,284 1,853 2,256 171,761 Derivative financial instruments 302,429 24 — — — 15 15 112 77 21 302,693 Financial assets at fair value through other comprehensive income — 3,086 1,627 151 95 3,059 3,770 12,741 19,236 8,137 51,902 Other financial assets 213 286 107 5 — 3 — — — — 614 Total financial assets 617,090 243,658 16,170 10,885 8,436 28,642 21,847 37,524 35,293 31,855 1,051,400 Other assets 8,331 Total assets 1,059,731 Liabilities Deposits at amortised cost 181,455 39,409 13,975 3,665 2,283 1,144 532 602 1,252 379 244,696 Cash collateral and settlement balances 1,944 83,605 — — — — — — — — 85,549 Repurchase agreements and other similar secured borrowing 4 2,545 — — — 1,400 2,329 4,073 — 92 10,443 Debt securities in issue — 12,207 3,808 3,833 1,791 2,124 640 2,815 1,995 210 29,423 Subordinated liabilities — 3,708 3,222 459 143 3,545 4,811 6,241 5,629 4,247 32,005 Trading portfolio liabilities 46,139 — — — — — — — — — 46,139 Financial liabilities designated at fair value 15,555 172,250 8,677 5,067 2,928 8,593 6,939 8,576 8,344 12,697 249,626 Derivative financial instruments 299,637 — 50 — — 66 67 174 183 403 300,580 Other financial liabilities 70 2,072 15 15 16 233 50 90 187 62 2,810 Total financial liabilities 544,804 315,796 29,747 13,039 7,161 17,105 15,368 22,571 17,590 18,090 1,001,271 Other liabilities 4,750 Total liabilities 1,006,021 Cumulative liquidity gap 72,286 148 (13,429) (15,583) (14,308) (2,771) 3,708 18,661 36,364 50,129 53,710 |
Contractual maturity of financial liabilities - undiscounted (audited) | Contractual maturity of financial liabilities - undiscounted (audited) Restated a Barclays Bank Group On Not more Over three Over six Over one Over three Over five Over ten Total £m £m £m £m £m £m £m £m £m As at 31 December 2021 Deposits at amortised cost 201,501 41,632 12,380 4,818 996 240 1,048 261 262,876 Cash collateral and settlement balances 2,951 76,096 — — — — — — 79,047 Repurchase agreements and other similar secured borrowing 20 5,022 — — 7,798 — — 146 12,986 Debt securities in issue — 18,293 12,168 9,075 3,879 1,832 2,938 744 48,929 Subordinated liabilities — 1,061 — 1,404 9,328 5,917 8,918 8,752 35,380 Trading portfolio liabilities 53,291 — — — — — — — 53,291 Financial liabilities designated at fair value 21,339 158,249 16,887 13,945 12,939 8,043 7,544 21,098 260,044 Derivative financial instruments 255,471 4 22 2 276 291 122 449 256,637 Other financial liabilities 87 3,658 19 38 526 122 208 29 4,687 Total financial liabilities 534,660 304,015 41,476 29,282 35,742 16,445 20,778 31,479 1,013,877 As at 31 December 2020 Deposits at amortised cost 181,455 39,409 13,975 5,949 1,686 600 1,258 385 244,717 Cash collateral and settlement balances 1,944 83,605 — — — — — — 85,549 Repurchase agreements and other similar secured borrowing 4 2,545 — — 3,729 4,087 — 154 10,519 Debt securities in issue — 12,226 3,818 5,629 2,799 2,923 2,098 277 29,770 Subordinated liabilities — 3,716 3,342 703 8,845 6,555 6,922 6,500 36,583 Trading portfolio liabilities 46,139 — — — — — — — 46,139 Financial liabilities designated at fair value 15,555 172,282 8,684 7,998 15,599 8,586 8,369 20,398 257,471 Derivative financial instruments 299,637 4 50 — 133 175 190 442 300,631 Other financial liabilities 70 2,076 19 39 313 113 227 86 2,943 Total financial liabilities 544,804 315,863 29,888 20,318 33,104 23,039 19,064 28,242 1,014,322 a. 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. The contractual maturity profile of financial liabilities designated at fair value has been restated to reflect the impact of the over-issuance of securities. Securities issued by the Company in excess of the maximum aggregate offering price registered under the Company’s 2019 F-3 with a value of £6,997m have been classified as "on demand". |
Maturity analysis of off-balance sheet commitments received (audited) | Maturity of off-balance sheet commitments received and given The table below presents the maturity split of the Barclays Bank Group’s off-balance sheet commitments received and given at the balance sheet date. The amounts disclosed in the table are the undiscounted cash flows (i.e. nominal values) on the basis of earliest opportunity at which they are available. Maturity analysis of off-balance sheet commitments received (audited) On Not more than three months Over three months but not more than six months Over six months but not more than nine months Over nine months but not more than one year Over one year but not more than two years Over two years but not more than three years Over three years but not more than five years Over five years but not more than ten years Over ten years Total Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m As at 31 December 2021 Guarantees, letters of credit and credit insurance 7,258 31 21 10 12 4 12 83 65 19 7,515 Other commitments received 455 — — — — — — — — — 455 Total off-balance sheet commitments received 7,713 31 21 10 12 4 12 83 65 19 7,970 As at 31 December 2020 Guarantees, letters of credit and credit insurance 6,462 86 37 68 8 18 14 47 40 25 6,805 Other commitments received 92 — — — — — — — — — 92 Total off-balance sheet commitments received 6,554 86 37 68 8 18 14 47 40 25 6,897 Maturity analysis of off-balance sheet commitments given (audited) On Not more than three months Over three months but not more than six months Over six months but not more than nine months Over nine months but not more than one year Over one year but not more than two years Over two years but not more than three years Over three years but not more than five years Over five years but not more than ten years Over ten years Total Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m As at 31 December 2021 Contingent liabilities 23,607 135 4 — — — — — — — 23,746 Documentary credits and other short-term trade related transactions 1,582 2 — — — — — — — — 1,584 Standby facilities, credit lines and other commitments 282,867 — — — — — — — — — 282,867 Total off-balance sheet commitments given 308,056 137 4 — — — — — — — 308,197 As at 31 December 2020 Contingent liabilities 20,630 213 57 6 1 25 — — — — 20,932 Documentary credits and other short-term trade related transactions 1,084 1 1 — — — — — — — 1,086 Standby facilities, credit lines and other commitments 262,586 564 93 123 95 49 196 202 21 7 263,936 Total off-balance sheet commitments given 284,300 778 151 129 96 74 196 202 21 7 285,954 |
Maturity analysis of off-balance sheet commitments given (audited) | Maturity of off-balance sheet commitments received and given The table below presents the maturity split of the Barclays Bank Group’s off-balance sheet commitments received and given at the balance sheet date. The amounts disclosed in the table are the undiscounted cash flows (i.e. nominal values) on the basis of earliest opportunity at which they are available. Maturity analysis of off-balance sheet commitments received (audited) On Not more than three months Over three months but not more than six months Over six months but not more than nine months Over nine months but not more than one year Over one year but not more than two years Over two years but not more than three years Over three years but not more than five years Over five years but not more than ten years Over ten years Total Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m As at 31 December 2021 Guarantees, letters of credit and credit insurance 7,258 31 21 10 12 4 12 83 65 19 7,515 Other commitments received 455 — — — — — — — — — 455 Total off-balance sheet commitments received 7,713 31 21 10 12 4 12 83 65 19 7,970 As at 31 December 2020 Guarantees, letters of credit and credit insurance 6,462 86 37 68 8 18 14 47 40 25 6,805 Other commitments received 92 — — — — — — — — — 92 Total off-balance sheet commitments received 6,554 86 37 68 8 18 14 47 40 25 6,897 Maturity analysis of off-balance sheet commitments given (audited) On Not more than three months Over three months but not more than six months Over six months but not more than nine months Over nine months but not more than one year Over one year but not more than two years Over two years but not more than three years Over three years but not more than five years Over five years but not more than ten years Over ten years Total Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m As at 31 December 2021 Contingent liabilities 23,607 135 4 — — — — — — — 23,746 Documentary credits and other short-term trade related transactions 1,582 2 — — — — — — — — 1,584 Standby facilities, credit lines and other commitments 282,867 — — — — — — — — — 282,867 Total off-balance sheet commitments given 308,056 137 4 — — — — — — — 308,197 As at 31 December 2020 Contingent liabilities 20,630 213 57 6 1 25 — — — — 20,932 Documentary credits and other short-term trade related transactions 1,084 1 1 — — — — — — — 1,086 Standby facilities, credit lines and other commitments 262,586 564 93 123 95 49 196 202 21 7 263,936 Total off-balance sheet commitments given 284,300 778 151 129 96 74 196 202 21 7 285,954 |
Capital resources (audited) | Capital resources (audited) Restated d 2021 2020 As at 31 December £m £m CET1 capital 23,928 25,227 T1 capital 32,395 32,172 Total regulatory capital 37,954 37,493 Total risk weighted assets (RWAs) (unaudited) 185,467 178,156 |
Functional currency of the operation (audited) | Functional currency of operations (audited) Foreign currency net investments Borrowings which hedge the net investments Derivatives which hedge the net investments Structural currency exposures pre- economic hedges Economic hedges Remaining structural currency exposures £m £m £m £m £m £m As at 31 December 2021 USD 26,023 (5,512) (2,356) 18,155 (7,111) 11,044 EUR 8,342 (1,324) (3) 7,015 (267) 6,748 JPY 614 (97) — 517 — 517 Other 2,085 — (64) 2,021 — 2,021 Total 37,064 (6,933) (2,423) 27,708 (7,378) 20,330 As at 31 December 2020 USD 24,262 (4,512) (764) 18,986 (5,918) 13,068 EUR 5,174 (278) (3) 4,893 (286) 4,607 JPY 582 — — 582 — 582 Other 1,596 (42) (24) 1,530 — 1,530 Total 31,614 (4,832) (791) 25,991 (6,204) 19,787 |
Sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 | The table below shows a sensitivity analysis on pre-tax net interest income for non-traded financial assets and liabilities, including the effect of any hedging. This analysis is not a forward guidance on NII and is intended as a quantification of risk exposure utilising the AEaR metric as described on page 200 of the Barclays PLC Pillar 3 Report 2021 (unaudited). Note that this metric assumes an instantaneous parallel change to forward interest rate curves. The model does not apply floors to shocked market rates, but does recognise contractual product specific interest rate floors where relevant. The main model assumptions are: (i) one-year ahead time horizon; (ii) balance sheet is held constant; (iii) balances are adjusted for customer behaviour (i.e. considers that customers may prepay before the contractual maturity or withdraw their deposits) and (iv) behavioural assumptions are kept unchanged in all rate scenarios. Net Interest Income sensitivity (AEaR) by currency (audited) 2021 2020 +25 basis -25 basis +25 basis -25 basis Barclays Bank Group £m £m £m £m GBP 21 (37) 32 (169) USD 55 (59) 47 (61) EUR (5) (4) 9 (32) Other currencies (3) 1 (2) (1) Total 68 (99) 86 (263) Note +25bps AEaR reflects refined modelling of pricing assumptions for 2021. Based on these assumptions, the 2020 scenario would have shown a GBP AEaR of £67m. Analysis of equity sensitivity (audited) 31 December 2021 31 December 2020 Restated a +25 basis -25 basis +25 basis -25 basis Barclays Bank Group £m £m £m £m Net interest income 68 (99) 86 (263) Taxation effects on the above (12) 18 (21) 63 Effect on profit for the year 56 (81) 65 (200) As percentage of net profit after tax 1.2% (1.8%) 2.7% (8.2%) Effect on profit for the year (per above) 56 (81) 65 (200) Fair value through other comprehensive income reserve (449) 380 (417) 433 Cash flow hedge reserve (626) 626 (554) 554 Taxation effects on the above 290 (272) 262 (266) Effect on equity (729) 653 (644) 521 As percentage of equity (1.3%) 1.2% (1.2%) 1.0% Note +25bps AEaR reflects refined modelling of pricing assumptions for 2021. Based on these assumptions, the 2020 scenario would have shown an effect on equity of £(617)m. a. 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Significant accounting polici_3
Significant accounting policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of objectives, policies and processes for managing capital [abstract] | |
Financial statement line items affected by the restatement | The table below reflects each of the consolidated financial statement line items that were affected by the restatement: For the year ended 31 December 2021 As reported £m Restatement £m As restated £m Impact on the consolidated income statement Litigation and conduct (154) (220) (374) Operating expenses (10,039) (220) (10,259) Profit before tax 5,638 (220) 5,418 Taxation (880) 50 (830) Profit after tax 4,758 (170) 4,588 Impact on the consolidated statement of comprehensive income Profit after tax 4,758 (170) 4,588 Total comprehensive income for the year 3,073 (170) 2,903 Impact on the consolidated balance sheet Liabilities Current tax liabilities 738 (50) 688 Provisions 890 220 1,110 Total liabilities 1,005,291 170 1,005,461 Equity Retained earnings 43,585 (170) 43,415 Total equity 56,487 (170) 56,317 Impact on the consolidated cash flow statement Profit before tax 5,638 (220) 5,418 Adjustment for non-cash items Other provisions, including pensions (135) 220 85 The table below reflects each of the line items of the parent company financial statement that were affected by the restatement: For the year ended 31 December 2021 As reported £m Restatement £m As restated £m Impact on the parent company income statement Litigation and conduct (140) (220) (360) Operating expenses (5,305) (220) (5,525) Profit before tax 3,543 (220) 3,323 Taxation 63 50 113 Profit after tax 3,606 (170) 3,436 Attributable to: Equity holders to the parent 2,811 (170) 2,641 Total equity holders of the parent 3,606 (170) 3,436 Impact on the parent company statement of comprehensive income Profit after tax 3,606 (170) 3,436 Total comprehensive income for the year 2,199 (170) 2,029 Impact on the parent company balance sheet Liabilities Current tax liabilities 392 (50) 342 Provisions 699 220 919 Total liabilities 1,011,809 170 1,011,979 Equity Retained earnings 37,350 (170) 37,180 Total equity 52,862 (170) 52,692 Impact on the parent company cash flow statement Profit before tax 3,543 (220) 3,323 Adjustment for non-cash items Other provisions, including pensions (145) 220 75 |
Segmental reporting (Tables)
Segmental reporting (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of operating segments [abstract] | |
Analysis of results by business | Analysis of results by business Restated b Restated b Corporate and Consumer, Cards Head Barclays Bank £m £m £m £m For the year ended 31 December 2021 Total income 12,481 3,337 (410) 15,408 Credit impairment releases/(charges) 461 (185) 1 277 Net operating income/(expenses) 12,942 3,152 (409) 15,685 Operating expenses (7,169) (2,316) (400) (9,885) Litigation and conduct (237) (108) (29) (374) Total operating expenses (7,406) (2,424) (429) (10,259) Other net (expenses)/income a (8) 1 (1) (8) Profit/(loss) before tax 5,528 729 (839) 5,418 Total assets (£bn) 986.2 64.4 11.2 1,061.8 Number of employees (full time equivalent) 7,800 2,600 9,800 20,200 Average number of employees (full time equivalent) 20,300 Corporate and Investment Bank Consumer, Cards Head Barclays Bank £m £m £m £m For the year ended 31 December 2020 Total income 12,607 3,490 (319) 15,778 Credit impairment charges (1,565) (1,720) (92) (3,377) Net operating income/(expenses) 11,042 1,770 (411) 12,401 Operating expenses (7,125) (2,132) (126) (9,383) Litigation and conduct (4) (44) (28) (76) Total operating expenses (7,129) (2,176) (154) (9,459) Other net income a 16 114 3 133 Profit/(loss) before tax 3,929 (292) (562) 3,075 Total assets (£bn) 990.9 57.8 11.0 1,059.7 Number of employees (full time equivalent) 7,800 3,000 10,100 20,900 Average number of employees (full time equivalent) 20,145 Note a Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. b 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. Corporate and Consumer, Cards Head Barclays Bank Group £m £m £m £m For the year ended 31 December 2019 Total income 10,009 4,462 (320) 14,151 Credit impairment charges (157) (1,016) (29) (1,202) Net operating income/(expenses) 9,852 3,446 (349) 12,949 Operating expenses (7,267) (2,359) (92) (9,718) Litigation and conduct (108) (7) (149) (264) Total operating expenses (7,375) (2,366) (241) (9,982) Other net income/(expenses) a 113 40 (8) 145 Profit/(loss) before tax 2,590 1,120 (598) 3,112 Total assets (£bn) 799.6 65.7 11.4 876.7 Number of employees (full time equivalent) 8,100 3,100 9,300 20,500 Average number of employees (full time equivalent) 21,700 Note a Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures, and gains on acquisitions. |
Income by geographic region | Income by geographic region a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 4,585 4,954 4,084 Europe 2,358 2,119 1,752 Americas 7,326 7,590 7,251 Africa and Middle East 45 37 62 Asia 1,094 1,078 1,002 Total 15,408 15,778 14,151 Income from individual countries which represent more than 5% of total income a 2021 2020 2019 For the year ended 31 December £m £m £m United Kingdom 4,585 4,954 4,084 United States 7,162 7,471 7,121 Note a The geographical analysis is based on the location of the office where the transactions are recorded. |
Net interest income (Table)
Net interest income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Analysis of income and expense [abstract] | |
Net interest income | 2021 2020 2019 £m £m £m Cash and balances at central banks 128 226 919 Loans and advances at amortised cost 4,265 4,510 5,514 Fair value through other comprehensive income 380 604 831 Negative interest on liabilities 248 68 13 Other 651 598 808 Interest and similar income 5,672 6,006 8,085 Deposits at amortised cost (331) (644) (1,778) Debt securities in issue a (413) (424) (873) Subordinated liabilities (934) (1,112) (1,096) Negative interest on assets (374) (325) (250) Other (547) (341) (181) Interest and similar expense (2,599) (2,846) (4,178) Net interest income 3,073 3,160 3,907 Notes a Barclays Bank Group has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest and similar expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparative of £25m in 2019 has not been restated. |
Net fee and commission income (
Net fee and commission income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Fee and commission income (expense) [abstract] | |
Total fees in scope of IFRS 15 Revenues from Contracts with Customers | Fee and commission income is disaggregated below by fee types that reflect the nature of the services offered across the Barclays Bank Group and operating segments, in accordance with IFRS 15. The below table includes a total for fees in scope of IFRS 15. Refer to Note 2 for more detailed information about operating segments. 2021 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total £m £m £m £m Fee type Transactional 390 2,158 — 2,548 Advisory 968 128 — 1,096 Brokerage and execution 1,082 53 — 1,135 Underwriting and syndication 3,425 — — 3,425 Other 80 155 21 256 Total revenue from contracts with customers 5,945 2,494 21 8,460 Other non-contract fee income 116 5 — 121 Fee and commission income 6,061 2,499 21 8,581 Fee and commission expense (781) (1,207) (6) (1,994) Net fee and commission income 5,280 1,292 15 6,587 2020 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total £m £m £m £m Fee type Transactional 357 1,973 — 2,330 Advisory 593 100 — 693 Brokerage and execution 1,116 57 — 1,173 Underwriting and syndication 2,867 — — 2,867 Other 54 152 29 235 Total revenue from contracts with customers 4,987 2,282 29 7,298 Other non-contract fee income 114 5 — 119 Fee and commission income 5,101 2,287 29 7,417 Fee and commission expense (768) (988) (2) (1,758) Net fee and commission income 4,333 1,299 27 5,659 2019 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total £m £m £m £m Fee type Transactional 391 2,418 — 2,809 Advisory 821 83 — 904 Brokerage and execution 1,082 49 — 1,131 Underwriting and syndication 2,358 — — 2,358 Other 90 227 30 347 Total revenue from contracts with customers 4,742 2,777 30 7,549 Other non-contract fee income 110 5 — 115 Fee and commission income 4,852 2,782 30 7,664 Fee and commission expense (743) (1,249) — (1,992) Net fee and commission income 4,109 1,533 30 5,672 |
Net trading income (Table)
Net trading income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Trading income (expense) [abstract] | |
Net trading income | 2021 2020 2019 £m £m £m Net gains on financial instruments held for trading 3,999 5,392 2,795 Net gains on financial instruments designated at fair value 682 695 240 Net gains on financial instruments mandatorily at fair value 1,107 989 1,038 Net trading income 5,788 7,076 4,073 |
Net investment (expense) inco_2
Net investment (expense) income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Gains (losses) on financial instruments [abstract] | |
Net investment (expense)/income | 2021 2020 2019 £m £m £m Net (losses)/gains from financial assets mandatorily at fair value (116) (39) 218 Net gains from disposal of debt instruments at fair value through other comprehensive income 248 251 454 Net gains/(losses) from disposal of financial assets and liabilities measured at amortised cost a 22 (128) (38) Dividend income — — — Net losses on other investments b (234) (205) (214) Net investment (expense)/income (80) (121) 420 Notes a Included within the 2021 balance are gains of £25m relating to the sale of municipal bonds . Included within the 2020 balance are losses of £115m relating to partial redemption of contingent capital note. b Barclays has amended the presentation of the premium paid for purchased financial guarantees which are embedded in notes it issues directly to the market. From 2020 onwards, the full note coupon is presented as interest expense within net interest income. The financial guarantee element of the coupon had previously been recognised in net investment income. The comparative of £25m in 2019 has not been restated. |
Credit impairment (release)_c_2
Credit impairment (release)/charge (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of impairment loss and reversal of impairment loss [abstract] | |
Credit impairment (release)/charge | 2021 2020 2019 Impairment Charges Recoveries and Reimbursements a Total Impairment Charges Recoveries and Reimbursements Total Impairment Charges Recoveries and Reimbursements Total £m £m £m £m £m £m £m £m £m Loans and advances (264) 259 (5) 3,060 (368) 2,692 1,214 (73) 1,141 Provision for undrawn contractually committed facilities and guarantees provided (257) — (257) 547 — 547 55 — 55 Loans impairment (521) 259 (262) 3,607 (368) 3,239 1,269 (73) 1,196 Cash collateral and settlement balances (4) — (4) 2 — 2 1 — 1 Financial instruments at fair value through OCI (6) — (6) — — — — — — Other financial assets measured at cost (5) — (5) 136 — 136 5 — 5 Credit impairment (release)/charge (536) 259 (277) 3,745 (368) 3,377 1,275 (73) 1,202 Notes a. Recoveries and reimbursements include a net reduction in amounts recoverable from financial guarantee contracts held with third parties of £290m (2020: £364m) and cash recoveries of previously written off amounts of £31m (2020: £4m). |
Operating expenses (Table)
Operating expenses (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Expenses by nature [abstract] | |
Operating expenses | Restated c 2021 2020 2019 £m £m £m Infrastructure costs Property and equipment 367 373 368 Depreciation and amortisation 403 421 457 Lease payments 4 1 7 Impairment of property, equipment and intangible assets a 280 21 3 Total infrastructure costs 1,054 816 835 Administration and general expenses Consultancy, legal and professional fees 390 345 362 Marketing and advertising 235 176 258 UK bank levy 134 249 185 Other administration and general expenses 3,616 3,432 3,513 Total administration and general expenses 4,375 4,202 4,318 Staff costs b 4,456 4,365 4,565 Litigation and conduct 374 76 264 Operating expenses 10,259 9,459 9,982 Note a Impairment of property, equipment and intangible assets includes £266m relating to structural cost actions taken as part of the real estate review conducted in 2021 (see Note 19). b For further details on staff costs including accounting policies, refer to Note 29. |
Tax (Tables)
Tax (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Major components of tax expense (income) [abstract] | |
Components of income tax | Restated a 2021 2020 2019 £m £m £m Current tax charge/(credit) Current year 904 993 327 Adjustments in respect of prior years 393 3 (50) 1,297 996 277 Deferred tax (credit)/charge Current year (179) (563) 157 Adjustments in respect of prior years (288) 191 (102) (467) (372) 55 Tax charge 830 624 332 a. 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Reconciliation between the actual tax charge and the corporate tax rate | The table below shows the reconciliation between the actual tax charge and the tax charge that would result from applying the standard UK corporation tax rate to the Barclays Bank Group’s profit before tax. Restated a Restated a 2021 2021 2020 2020 2019 2019 £m % £m % £m % Profit before tax from continuing operations 5,418 3,075 3,112 Tax charge based on the standard UK corporation tax rate of 19% (2020: 19%, 2019: 19%) 1,029 19.0 % 584 19.0 % 593 19.0 % Impact of profits/losses earned in territories with different statutory rates to the UK (weighted average tax rate is 24.0% (2020: 25.0% , 2019: 26.0%)) 273 5.0 % 183 6.0 % 217 7.0 % Recurring items: Non-creditable taxes including withholding taxes 124 2.3 % 107 3.4 % 146 4.7 % Adjustments in respect of prior years 105 1.9 % 194 6.3 % (152) (4.9 %) Non-deductible expenses 61 1.1 % 28 0.9 % 34 1.1 % Impact of UK bank levy being non-deductible 25 0.5 % 48 1.6 % 35 1.1 % Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK 25 0.5 % 25 0.8 % 15 0.5 % Tax adjustments in respect of share-based payments (5) (0.1 %) 14 0.5 % (7) (0.2 %) Banking surcharge and other items (48) (0.9 %) (70) (2.3 %) (103) (3.3 %) Tax relief on payments made under AT1 instruments (113) (2.1 %) (124) (4.0 %) (121) (3.9 %) Changes in recognition of deferred tax and effect of unrecognised tax losses (140) (2.6 %) (123) (4.0 %) (85) (2.7 %) Non-taxable gains and income (309) (5.7 %) (200) (6.5 %) (240) (7.7 %) Non-recurring items: Remeasurement of UK deferred tax assets due to tax rate changes (218) (4.0 %) (43) (1.4 %) — — Non-deductible provisions for UK customer redress 21 0.4 % 7 0.2 % — — Non-deductible provisions for investigations and litigation — — (6) (0.2 %) — — Total tax charge 830 15.3 % 624 20.3 % 332 10.7 % a. 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Deferred tax assets and liabilities | The deferred tax amounts on the balance sheet were as follows: Barclays Bank Group 2021 2020 £m £m US Intermediate Holding Company Tax Group ("IHC Tax Group") 1,004 1,001 US Branch Tax Group 1,002 1,048 UK Tax Group 576 — Other (outside the UK and US tax groups) 399 503 Deferred tax asset 2,981 2,552 Deferred tax liability (6) (225) Net deferred tax 2,975 2,327 |
Movements on deferred tax assets and liabilities during the year before offsetting | The table below shows movements on deferred tax assets and liabilities during the year. The amounts are different from those disclosed on the balance sheet and in the preceding table as they are presented before offsetting asset and liability balances where there is a legal right to set-off and an intention to settle on a net basis. Barclays Bank Group Fixed asset timing differences Fair value through other comprehensive income Cash flow hedges Retirement benefit obligations Loan impairment allowance Other provisions Share based payments and deferred compensation Other temporary differences Tax losses carried forward Total £m £m £m £m £m £m £m £m £m £m Assets 659 — — 30 455 139 317 1,377 711 3,688 Liabilities (33) (21) (441) (826) — — — (40) — (1,361) As at 1 January 2021 626 (21) (441) (796) 455 139 317 1,337 711 2,327 Income statement 14 (6) — 1 38 3 (13) (55) 485 467 Other comprehensive income and reserves — 170 750 (855) — — 20 97 — 182 Other movements 8 1 — — (12) — 3 (1) — (1) 648 144 309 (1,650) 481 142 327 1,378 1,196 2,975 Assets 678 144 309 24 481 142 327 1,418 1,196 4,719 Liabilities (30) — — (1,674) — — — (40) — (1,744) As at 31 December 2021 648 144 309 (1,650) 481 142 327 1,378 1,196 2,975 Assets 719 110 — 31 284 127 305 1,329 523 3,428 Liabilities (29) (18) (139) (640) — — — (222) — (1,048) As at 1 January 2020 690 92 (139) (609) 284 127 305 1,107 523 2,380 Income statement (39) — — — 164 18 15 23 191 372 Other comprehensive income and reserves — (112) (291) (191) — — 3 238 — (353) Other movements (25) (1) (11) 4 7 (6) (6) (31) (3) (72) 626 (21) (441) (796) 455 139 317 1,337 711 2,327 Assets 659 — — 30 455 139 317 1,377 711 3,688 Liabilities (33) (21) (441) (826) — — — (40) — (1,361) As at 31 December 2020 626 (21) (441) (796) 455 139 317 1,337 711 2,327 |
Trading portfolio (Table)
Trading portfolio (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Net assets (liabilities) [abstract] | |
Trading portfolio assets | Barclays Bank Group 2021 2020 £m £m Debt securities and other eligible bills 50,700 56,196 Equity securities 83,113 62,192 Traded loans 12,525 8,348 Commodities 533 928 Trading Portfolio Assets 146,871 127,664 Debt securities and other eligible bills (34,079) (28,836) Equity securities (19,212) (17,303) Trading Portfolio Liabilities (53,291) (46,139) |
Trading portfolio liabilities | Barclays Bank Group 2021 2020 £m £m Debt securities and other eligible bills 50,700 56,196 Equity securities 83,113 62,192 Traded loans 12,525 8,348 Commodities 533 928 Trading Portfolio Assets 146,871 127,664 Debt securities and other eligible bills (34,079) (28,836) Equity securities (19,212) (17,303) Trading Portfolio Liabilities (53,291) (46,139) |
Financial assets at fair valu_3
Financial assets at fair value through the income statement (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through profit or loss [abstract] | |
Financial assets designated at fair value | Barclays Bank Group 2021 2020 £m £m Loans and advances 2,813 2,170 Debt securities 318 291 Reverse repurchase agreements and other similar secured lending — 19 Financial assets designated at fair value 3,131 2,480 Loans and advances 33,089 25,279 Debt securities 1,937 1,406 Equity securities 4,798 3,742 Reverse repurchase agreements and other similar secured lending 145,186 138,539 Other financial assets 85 315 Financial assets mandatorily at fair value 185,095 169,281 Total 188,226 171,761 Barclays Bank Group 2021 2020 Fair value Contractual Fair value Contractual £m £m £m £m Debt securities 53,164 61,333 50,216 57,650 Deposits 29,409 29,836 21,718 22,120 Repurchase agreements and other similar secured borrowing 168,075 168,144 177,455 177,513 Subordinated debt a 483 613 — — Other financial liabilities — — 237 237 Financial liabilities designated at fair value 251,131 259,926 249,626 257,520 Note a. Subordinated debt measured at fair value (2020: £221m) was previously disclosed in Note 26 Subordinated Liabilities. For the current year, it is disclosed within Financial Liabilities designated at fair value to better reflect that it is accounted for at fair value. |
Credit risk of loans and advances designated at fair value and related credit derivatives | The following table shows the maximum exposure to credit risk, the changes in fair value attributable to changes in credit risk, and the cumulative changes in fair value since initial recognition for loans and advances. The table does not include debt securities and reverse repurchase agreements and other similar secured lending designated at fair value as they have minimal exposure to credit risk. Reverse repurchase agreements are collateralised and debt securities are primarily relating to high quality sovereigns. Barclays Bank Group Maximum exposure as at 31 December Changes in fair value during the year ended Cumulative changes in fair value from inception 2021 2020 2021 2020 2021 2020 £m £m £m £m £m £m Loans and advances designated at fair value, attributable to credit risk 2,813 2,170 1 (46) (3) (51) Value mitigated by related credit derivatives 1,617 795 (3) 3 (3) 3 |
Derivative financial instrume_2
Derivative financial instruments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of nature and extent of risks arising from financial instruments [abstract] | |
Total derivatives | Barclays Bank Group 2021 2020 Notional contract amount Fair value Notional contract amount Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Total derivative assets/(liabilities) held for trading 47,286,623 262,046 (255,471) 42,515,577 302,429 (299,637) Total derivative assets/(liabilities) held for risk management 126,292 245 (1,052) 110,028 264 (943) Derivative assets/(liabilities) 47,412,915 262,291 (256,523) 42,625,605 302,693 (300,580) |
Derivatives held for trading and risk management | The fair values and notional amounts of derivatives held for trading are set out in the following table: Derivatives held for trading and risk management 2021 2020 Barclays Bank Group Notional contract amount Fair value Notional contract amount Fair value Assets Liabilities Assets Liabilities £m £m £m £m £m £m Derivatives held for trading Foreign exchange derivatives OTC derivatives 5,700,055 76,055 (74,014) 5,463,632 84,518 (83,912) Derivatives cleared by central counterparty 99,664 171 (208) 78,946 335 (335) Exchange traded derivatives 20,084 10 (3) 14,034 3 (3) Foreign exchange derivatives 5,819,803 76,236 (74,225) 5,556,612 84,856 (84,250) Interest rate derivatives OTC derivatives 14,229,139 124,187 (113,098) 13,551,506 171,244 (161,223) Derivatives cleared by central counterparty 18,865,670 1,055 (762) 18,330,003 965 (795) Exchange traded derivatives 5,200,838 905 (907) 2,971,966 371 (360) Interest rate derivatives 38,295,647 126,147 (114,767) 34,853,475 172,580 (162,378) Credit derivatives OTC derivatives 606,504 4,007 (4,752) 384,900 3,674 (3,909) Derivatives cleared by central counterparty 665,600 1,675 (1,809) 462,945 931 (1,095) Credit derivatives 1,272,104 5,682 (6,561) 847,845 4,605 (5,004) Equity and stock index derivatives OTC derivatives 278,370 18,793 (24,440) 213,078 18,803 (26,091) Exchange traded derivatives 1,469,078 32,901 (33,174) 927,114 20,165 (20,521) Equity and stock index derivatives 1,747,448 51,694 (57,614) 1,140,192 38,968 (46,612) Commodity derivatives OTC derivatives 4,670 56 (107) 4,244 89 (110) Exchange traded derivatives 146,951 2,231 (2,197) 113,209 1,331 (1,283) Commodity derivatives 151,621 2,287 (2,304) 117,453 1,420 (1,393) Derivative assets/(liabilities) held for trading 47,286,623 262,046 (255,471) 42,515,577 302,429 (299,637) Total OTC derivatives 20,818,738 223,098 (216,411) 19,617,360 278,328 (275,245) Total derivatives cleared by central counterparty 19,630,934 2,901 (2,779) 18,871,894 2,231 (2,225) Total exchange traded derivatives 6,836,951 36,047 (36,281) 4,026,323 21,870 (22,167) Derivative assets/(liabilities) held for trading 47,286,623 262,046 (255,471) 42,515,577 302,429 (299,637) Derivatives held for risk management Derivatives designated as cash flow hedges Currency Swaps 1,000 155 — 1,000 67 — Interest rate swaps 465 — (3) 1,819 49 — Interest rate derivatives cleared by central counterparty 63,584 — — 43,499 — — Derivatives designated as cash flow hedges 65,049 155 (3) 46,318 116 — Derivatives designated as fair value hedges Interest rate swaps 5,856 53 (1,045) 7,986 123 (943) Forward foreign exchange — — — — — — Interest rate derivatives cleared by central counterparty 52,964 — — 54,933 — — Derivatives designated as fair value hedges 58,820 53 (1,045) 62,919 123 (943) Derivatives designated as hedges of net investments Forward foreign exchange 2,423 37 (4) 791 25 — Derivatives designated as hedges of net investments 2,423 37 (4) 791 25 — Derivative assets/(liabilities) held for risk management 126,292 245 (1,052) 110,028 264 (943) Total OTC derivatives 9,744 245 (1,052) 11,596 264 (943) Total derivatives cleared by central counterparty 116,548 — — 98,432 — — Derivative assets/(liabilities) held for risk management 126,292 245 (1,052) 110,028 264 (943) |
Significant hedge accounting exposures impacted by the IBOR reform | The following table summarises the significant hedge accounting exposures impacted by the IBOR reform as at 31 December 2021: Barclays Bank Group Nominal amount of hedged items directly impacted by IBOR reform Nominal amount of hedging instruments directly impacted by IBOR reform Current benchmark rate Expected convergence to RFR £m £m GBP London Interbank Offered rate (LIBOR) Reformed Sterling Overnight Index Average (SONIA) 9,718 200 USD LIBOR Secured Overnight Financing Rate (SOFR) 19,945 20,013 JPY LIBOR Tokyo Overnight Average (TONA) — 52 Singapore Swap Offered Rate (SOR) Singapore Overnight Rate Average (SORA) 110 110 Total IBOR Notionals 29,773 20,375 |
Hedged items in fair value hedge accounting relationships and Hedged items in cash flow hedge accounting and hedges of net investments in foreign operations | Hedged items in fair value hedges Barclays Bank Group Accumulated fair value adjustment included in carrying amount Carrying amount Total Of which: Accumulated fair value adjustment on items no longer in a hedge relationship Change in fair value used as a basis to determine ineffectiveness Hedge ineffectiveness recognised in the income statement a Hedged item statement of financial position classification and risk category £m £m £m £m £m 2021 Assets Loans and advances at amortised cost - Interest rate risk 1,257 24 6 (77) (1) - Inflation risk 556 354 — 9 — Debt securities classified as amortised cost - Interest rate risk 1,378 (39) — (75) (18) - Inflation risk 4,087 400 — (16) (1) Financial assets at fair value through other comprehensive income b - Interest rate risk 22,895 (293) 28 (1,122) 35 - Inflation risk 6,271 386 (32) 81 10 Total Assets 36,444 832 2 (1,200) 25 Liabilities Debt securities in issue - Interest rate risk (26,691) (622) (320) 769 6 Total Liabilities (26,691) (622) (320) 769 6 Total Hedged Items 9,753 210 (318) (431) 31 2020 Assets Loans and advances at amortised cost - Interest rate risk 835 99 2 55 — - Inflation risk 545 345 — 25 3 Debt securities classified as amortised cost - Interest rate risk 1,440 23 — 17 (7) - Inflation risk 4,071 (43) — 453 3 Financial assets at fair value through other comprehensive income b - Interest rate risk 27,959 964 322 864 (33) - Inflation risk 7,782 319 (9) 249 (9) Total Assets 42,632 1,707 315 1,663 (43) Liabilities Debt securities in issue - Interest rate risk (26,978) (1,477) (414) (797) (6) Total Liabilities (26,978) (1,477) (414) (797) (6) Total Hedged Items 15,654 230 (99) 866 (49) Note a Hedge ineffectiveness is recognised in net interest income. b For items classified as fair value through other comprehensive income, the hedge accounting adjustment is not included in the carrying amount, but rather adjusts other comprehensive income. Hedged items in cash flow hedges and hedges of net investments in foreign operations Barclays Bank Group Change in value of hedged item used as the basis for recognising ineffectiveness Balance in cash flow hedging reserve for continuing hedges Balance in currency translation reserve for continuing hedges Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied Balances remaining in currency translation reserve for which hedge accounting is no longer applied Hedging gains or losses recognised in other comprehensive income Hedge ineffectiveness recognised in the income statement a Description of hedge relationship and hedged risk £m £m £m £m £m £m £m 2021 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost 2,042 935 — (192) — 2,042 (211) Foreign exchange risk Loans and advances at amortised cost (88) (16) — — — (88) 1 Inflation risk Debt securities classified at amortised cost 252 204 — (12) — 252 (22) Total cash flow hedges 2,206 1,123 — (204) — 2,206 (232) Hedge of net investment in foreign operations USD foreign operations 143 — 1,184 — — 143 — EUR foreign operations (49) — (39) — — (49) — Other foreign operations (3) — 44 — 186 (3) — Total foreign operations 91 — 1,189 — 186 91 — 2020 Cash flow hedge of: Interest rate risk Loans and advances at amortised cost (1,260) (758) — (780) — (1,260) 40 Foreign exchange risk Loans and advances at amortised cost (70) (15) — — — (70) — Inflation risk Debt securities classified at amortised cost (41) (65) — — — (41) 1 Total cash flow hedges (1,371) (838) — (780) — (1,371) 41 Hedge of net investment in foreign operations USD foreign operations (83) — 1,097 — — (83) — EUR foreign operations (2) — 16 — — (2) — Other foreign operations (9) — 55 — 162 (9) — Total foreign operations (94) — 1,168 — 162 (94) — Note a Hedge ineffectiveness is recognised in net interest income |
Hedging instruments which are carried on the Barclays Bank Group's balance sheet | The following table shows the fair value hedging instruments which are carried on the Barclays Bank Group’s balance sheet: Barclays Bank Group Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Fair value Interest rate risk 53 — — 51,219 527 8,855 Inflation risk — (1,045) — 7,601 (65) 1,624 Total 53 (1,045) — 58,820 462 10,479 As at 31 December 2020 Fair value Interest rate risk 117 (164) — 55,093 (185) 17,697 Inflation risk 6 (779) — 7,826 (730) 1,487 Total 123 (943) — 62,919 (915) 19,184 Barclays Bank Group Carrying value Nominal amount Change in fair value used as a basis to determine ineffectiveness Nominal amount directly impacted by IBOR reform Derivative assets Derivative liabilities Loan liabilities Hedge type Risk category £m £m £m £m £m £m As at 31 December 2021 Cash flow Interest rate risk — — — 59,957 (2,253) 9,896 Foreign exchange risk 155 — — 1,000 89 — Inflation risk — (3) — 4,092 (274) — Total 155 (3) — 65,049 (2,438) 9,896 Net investment Foreign exchange risk 37 (4) (6,933) 9,356 (91) — As at 31 December 2020 Cash flow Interest rate risk 47 — — 42,520 1,300 27,160 Foreign exchange risk 67 — — 1,000 70 — Inflation risk 2 — — 2,798 42 0 Total 116 — — 46,318 1,412 27,160 Net investment Foreign exchange risk 25 — (4,832) 5,623 94 — |
The Expected notional values of current hedging instruments in future years | The following table profiles the expected notional values of current hedging instruments for fair value hedging in future years: 2021 2022 2023 2024 2025 2026 2027 and later As at 31 December 2021 £m £m £m £m £m £m £m Barclays Bank Group Fair value hedges of: Interest rate risk (outstanding notional amount) 51,219 49,156 43,857 37,590 31,635 27,011 22,555 Inflation risk (outstanding notional amount) 7,601 7,435 6,603 5,341 4,283 3,131 818 |
Effect on the income statement and OCI of recycling amounts in respect of Cash flow hedges and Net investment hedges of foreign operations | The effect on the income statement and other comprehensive income of recycling amounts in respect of cash flow hedges and net investment hedges of foreign operations is set out in the following table: Barclays Bank Group 2021 2020 Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Amount recycled from other comprehensive income due to hedged item affecting income statement Amount recycled from other comprehensive income due to sale of investment, or cash flows no longer expected to occur Description of hedge relationship and hedged risk £m £m £m £m Cash flow hedge of interest rate risk Recycled to net interest income 228 13 239 37 Cash flow hedge of foreign exchange risk Recycled to net interest income 87 — 55 — Hedge of net investment in foreign operations Recycled to other income — (28) — (4) A detailed reconciliation of the movements of the cash flow hedging reserve and the currency translation reserve is as follows: Barclays Bank Group 2021 2020 Cash flow hedging reserve Currency translation reserve Cash flow hedging reserve Currency translation reserve £m £m £m £m Balance on 1 January 1,181 2,736 388 3,383 Currency translation movements (6) (92) 50 (745) Hedging (losses)/gains for the year (2,206) (91) 1,316 94 Amounts reclassified in relation to cash flows affecting profit or loss (327) 28 (282) 4 Tax 740 — (291) — Balance on 31 December (618) 2,581 1,181 2,736 |
Financial assets at fair valu_4
Financial assets at fair value through other comprehensive income (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Financial assets at fair value through other comprehensive income [abstract] | |
Financial assets at fair value through other comprehensive income | Barclays Bank Group 2021 2020 £m £m Debt securities and other eligible bills 45,854 51,710 Equity securities 1 1 Loans and advances 53 191 Financial assets at fair value through other comprehensive income 45,908 51,902 |
Financial liabilities designa_2
Financial liabilities designated at fair value (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Designated financial liabilities at fair value through profit or loss [abstract] | |
Financial liabilities designated at fair value | Barclays Bank Group 2021 2020 £m £m Loans and advances 2,813 2,170 Debt securities 318 291 Reverse repurchase agreements and other similar secured lending — 19 Financial assets designated at fair value 3,131 2,480 Loans and advances 33,089 25,279 Debt securities 1,937 1,406 Equity securities 4,798 3,742 Reverse repurchase agreements and other similar secured lending 145,186 138,539 Other financial assets 85 315 Financial assets mandatorily at fair value 185,095 169,281 Total 188,226 171,761 Barclays Bank Group 2021 2020 Fair value Contractual Fair value Contractual £m £m £m £m Debt securities 53,164 61,333 50,216 57,650 Deposits 29,409 29,836 21,718 22,120 Repurchase agreements and other similar secured borrowing 168,075 168,144 177,455 177,513 Subordinated debt a 483 613 — — Other financial liabilities — — 237 237 Financial liabilities designated at fair value 251,131 259,926 249,626 257,520 Note a. Subordinated debt measured at fair value (2020: £221m) was previously disclosed in Note 26 Subordinated Liabilities. For the current year, it is disclosed within Financial Liabilities designated at fair value to better reflect that it is accounted for at fair value. |
Fair value of financial instr_2
Fair value of financial instruments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [abstract] | |
Assets and liabilities held at fair value, disaggregated by valuation technique and by product type | The following table shows Barclays Bank Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Assets and liabilities held at fair value 2021 2020 Valuation technique using Valuation technique using Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Barclays Bank Group £m £m £m £m £m £m £m £m Trading portfolio assets 80,836 63,754 2,281 146,871 60,619 65,182 1,863 127,664 Financial assets at fair value through the income statement 4,953 177,194 6,079 188,226 4,439 162,930 4,392 171,761 Derivative financial assets 6,150 252,131 4,010 262,291 9,154 289,071 4,468 302,693 Financial assets at fair value through other comprehensive income 16,070 29,800 38 45,908 12,150 39,599 153 51,902 Investment property — — 7 7 — — 10 10 Total assets 108,009 522,879 12,415 643,303 86,362 556,782 10,886 654,030 Trading portfolio liabilities (26,701) (26,563) (27) (53,291) (23,331) (22,780) (28) (46,139) Financial liabilities designated at fair value (174) (250,553) (404) (251,131) (159) (249,126) (341) (249,626) Derivative financial liabilities (6,571) (243,893) (6,059) (256,523) (8,762) (285,579) (6,239) (300,580) Total liabilities (33,446) (521,009) (6,490) (560,945) (32,252) (557,485) (6,608) (596,345) |
Analysis of movements in Level 3 assets | The following table shows Barclays Bank Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: Level 3 Assets and liabilities held at fair value by product type 2021 2020 Assets Liabilities Assets Liabilities Barclays Bank Group £m £m £m £m Interest rate derivatives 1,091 (1,351) 1,613 (1,615) Foreign exchange derivatives 376 (374) 144 (143) Credit derivatives 323 (709) 196 (351) Equity derivatives 2,220 (3,625) 2,497 (4,112) Corporate debt 1,205 (21) 698 (3) Reverse repurchase and repurchase agreements 13 (172) — (174) Non-asset backed loans 3,743 — 3,093 — Asset backed securities 558 — 767 (24) Equity cash products 393 — 542 — Private equity investments 148 — 84 — Other a 2,345 (238) 1,252 (186) Total 12,415 (6,490) 10,886 (6,608) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. The following table summarises the movements in the Level 3 balances during the year. Transfers have been reflected as if they had taken place at the beginning of the year. Assets and liabilities included in disposal groups classified as held for sale and measured at fair value less cost to sell are not included as these are measured at fair value on a non-recurring basis. Asset and liability transfers between Level 2 and Level 3 are primarily due to 1) an increase or decrease in observable market activity related to an input or 2) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Analysis of movements in Level 3 assets and liabilities As at 1 January 2021 Total gains and (losses) in the period recognised in the income statement Total gains or losses recognised in OCI Transfers As at 31 December 2021 Purchases Sales Issues Settlements Trading income Other income In Out Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 310 (123) — (12) 38 — — 41 (16) 389 Non-asset backed loans 709 1,580 (1,409) — (85) (1) — — 45 (81) 758 Asset backed securities 686 209 (370) — — (69) — — 114 (116) 454 Equity cash products 214 45 (53) — 4 23 — — 80 (10) 303 Other 103 117 (2) — (61) (3) — — 248 (25) 377 Trading portfolio assets 1,863 2,261 (1,957) — (154) (12) — — 528 (248) 2,281 Non-asset backed loans 2,280 1,379 (306) — (248) (59) (174) — 113 — 2,985 Equity cash products 320 3 (247) — — — 7 — 1 — 84 Private equity investments 88 68 (7) — (8) — 10 — 35 (38) 148 Other 1,704 11,253 (9,981) — (184) 2 21 — 48 (1) 2,862 Financial assets at fair value through the income statement 4,392 12,703 (10,541) — (440) (57) (136) — 197 (39) 6,079 Non-asset backed loans 106 — — — — — — — — (106) — Asset backed securities 47 — — — (7) — — (2) — — 38 Financial assets at fair value through other comprehensive income 153 — — — (7) — — (2) — (106) 38 Investment property 10 — (2) — — — (1) — — — 7 Trading portfolio liabilities (28) (5) 23 — — (6) — — (12) 1 (27) Financial liabilities designated at fair value (341) (4) — (101) 66 21 — — (68) 23 (404) Interest rate derivatives (2) 20 — — 105 (255) — — 90 (218) (260) Foreign exchange derivatives 1 — — — 40 (2) — — 10 (47) 2 Credit derivatives (155) (239) 9 — (45) 34 — — 10 — (386) Equity derivatives (1,615) 90 (1) — (15) (3) — — (3) 142 (1,405) Net derivative financial instruments a (1,771) (129) 8 — 85 (226) — — 107 (123) (2,049) Total 4,278 14,826 (12,469) (101) (450) (280) (137) (2) 752 (492) 5,925 Analysis of movements in Level 3 assets and liabilities As at 1 January 2020 Total gains and losses in the period recognised in the income statement Total gains or losses recognised in OCI Transfers As at 31 December 2020 Purchases Sales Issues Settlements Trading income Other income In Out Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m Corporate debt 120 77 (6) — — (35) — — 12 (17) 151 Non-asset backed loans 974 1,955 (2,182) — (12) (10) — — 39 (55) 709 Asset backed securities 656 458 (428) — (40) (25) — — 99 (34) 686 Equity cash products 392 5 (149) — — (41) — — 11 (4) 214 Other 122 — — — — (21) — — 2 — 103 Trading portfolio assets 2,264 2,495 (2,765) — (52) (132) — — 163 (110) 1,863 Non-asset backed loans 1,964 1,102 (283) — (293) 142 — — — (352) 2,280 Equity cash products 835 9 (404) — — (93) (36) — 9 — 320 Private equity investments 113 2 (20) — (1) — (9) — 15 (12) 88 Other 1,250 3,716 (3,606) — (26) 32 (48) — 386 — 1,704 Financial assets at fair value through the income statement 4,162 4,829 (4,313) — (320) 81 (93) — 410 (364) 4,392 Non-asset backed loans 343 — — — (237) — — — — — 106 Asset backed securities 86 — (35) — — — — (4) — — 47 Financial assets at fair value through other comprehensive income 429 — (35) — (237) — — (4) — — 153 Investment property 13 — (2) — — — (1) — — — 10 Trading portfolio liabilities — (27) — — — (1) — — — — (28) Financial liabilities designated at fair value (343) — 1 (21) 1 21 — — (38) 38 (341) Interest rate derivatives (206) 17 (12) — 85 109 — — (18) 23 (2) Foreign exchange derivatives (7) — — — 21 (16) — — (19) 22 1 Credit derivatives 198 (125) 24 — (371) 24 — — (21) 116 (155) Equity derivatives (820) (699) (43) — 105 (101) — — (13) (44) (1,615) Net derivative financial instruments a (835) (807) (31) — (160) 16 — — (71) 117 (1,771) Total 5,690 6,490 (7,145) (21) (768) (15) (94) (4) 464 (319) 4,278 Note a The derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets are £4,010m (2020: £4,468m) and derivative financial liabilities are £6,059m (2020: £6,239m). |
Analysis of movements in Level 3 liabilities | The following table shows Barclays Bank Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: Level 3 Assets and liabilities held at fair value by product type 2021 2020 Assets Liabilities Assets Liabilities Barclays Bank Group £m £m £m £m Interest rate derivatives 1,091 (1,351) 1,613 (1,615) Foreign exchange derivatives 376 (374) 144 (143) Credit derivatives 323 (709) 196 (351) Equity derivatives 2,220 (3,625) 2,497 (4,112) Corporate debt 1,205 (21) 698 (3) Reverse repurchase and repurchase agreements 13 (172) — (174) Non-asset backed loans 3,743 — 3,093 — Asset backed securities 558 — 767 (24) Equity cash products 393 — 542 — Private equity investments 148 — 84 — Other a 2,345 (238) 1,252 (186) Total 12,415 (6,490) 10,886 (6,608) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. The following table summarises the movements in the Level 3 balances during the year. Transfers have been reflected as if they had taken place at the beginning of the year. Assets and liabilities included in disposal groups classified as held for sale and measured at fair value less cost to sell are not included as these are measured at fair value on a non-recurring basis. Asset and liability transfers between Level 2 and Level 3 are primarily due to 1) an increase or decrease in observable market activity related to an input or 2) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Analysis of movements in Level 3 assets and liabilities As at 1 January 2021 Total gains and (losses) in the period recognised in the income statement Total gains or losses recognised in OCI Transfers As at 31 December 2021 Purchases Sales Issues Settlements Trading income Other income In Out Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 310 (123) — (12) 38 — — 41 (16) 389 Non-asset backed loans 709 1,580 (1,409) — (85) (1) — — 45 (81) 758 Asset backed securities 686 209 (370) — — (69) — — 114 (116) 454 Equity cash products 214 45 (53) — 4 23 — — 80 (10) 303 Other 103 117 (2) — (61) (3) — — 248 (25) 377 Trading portfolio assets 1,863 2,261 (1,957) — (154) (12) — — 528 (248) 2,281 Non-asset backed loans 2,280 1,379 (306) — (248) (59) (174) — 113 — 2,985 Equity cash products 320 3 (247) — — — 7 — 1 — 84 Private equity investments 88 68 (7) — (8) — 10 — 35 (38) 148 Other 1,704 11,253 (9,981) — (184) 2 21 — 48 (1) 2,862 Financial assets at fair value through the income statement 4,392 12,703 (10,541) — (440) (57) (136) — 197 (39) 6,079 Non-asset backed loans 106 — — — — — — — — (106) — Asset backed securities 47 — — — (7) — — (2) — — 38 Financial assets at fair value through other comprehensive income 153 — — — (7) — — (2) — (106) 38 Investment property 10 — (2) — — — (1) — — — 7 Trading portfolio liabilities (28) (5) 23 — — (6) — — (12) 1 (27) Financial liabilities designated at fair value (341) (4) — (101) 66 21 — — (68) 23 (404) Interest rate derivatives (2) 20 — — 105 (255) — — 90 (218) (260) Foreign exchange derivatives 1 — — — 40 (2) — — 10 (47) 2 Credit derivatives (155) (239) 9 — (45) 34 — — 10 — (386) Equity derivatives (1,615) 90 (1) — (15) (3) — — (3) 142 (1,405) Net derivative financial instruments a (1,771) (129) 8 — 85 (226) — — 107 (123) (2,049) Total 4,278 14,826 (12,469) (101) (450) (280) (137) (2) 752 (492) 5,925 Analysis of movements in Level 3 assets and liabilities As at 1 January 2020 Total gains and losses in the period recognised in the income statement Total gains or losses recognised in OCI Transfers As at 31 December 2020 Purchases Sales Issues Settlements Trading income Other income In Out Barclays Bank Group £m £m £m £m £m £m £m £m £m £m £m Corporate debt 120 77 (6) — — (35) — — 12 (17) 151 Non-asset backed loans 974 1,955 (2,182) — (12) (10) — — 39 (55) 709 Asset backed securities 656 458 (428) — (40) (25) — — 99 (34) 686 Equity cash products 392 5 (149) — — (41) — — 11 (4) 214 Other 122 — — — — (21) — — 2 — 103 Trading portfolio assets 2,264 2,495 (2,765) — (52) (132) — — 163 (110) 1,863 Non-asset backed loans 1,964 1,102 (283) — (293) 142 — — — (352) 2,280 Equity cash products 835 9 (404) — — (93) (36) — 9 — 320 Private equity investments 113 2 (20) — (1) — (9) — 15 (12) 88 Other 1,250 3,716 (3,606) — (26) 32 (48) — 386 — 1,704 Financial assets at fair value through the income statement 4,162 4,829 (4,313) — (320) 81 (93) — 410 (364) 4,392 Non-asset backed loans 343 — — — (237) — — — — — 106 Asset backed securities 86 — (35) — — — — (4) — — 47 Financial assets at fair value through other comprehensive income 429 — (35) — (237) — — (4) — — 153 Investment property 13 — (2) — — — (1) — — — 10 Trading portfolio liabilities — (27) — — — (1) — — — — (28) Financial liabilities designated at fair value (343) — 1 (21) 1 21 — — (38) 38 (341) Interest rate derivatives (206) 17 (12) — 85 109 — — (18) 23 (2) Foreign exchange derivatives (7) — — — 21 (16) — — (19) 22 1 Credit derivatives 198 (125) 24 — (371) 24 — — (21) 116 (155) Equity derivatives (820) (699) (43) — 105 (101) — — (13) (44) (1,615) Net derivative financial instruments a (835) (807) (31) — (160) 16 — — (71) 117 (1,771) Total 5,690 6,490 (7,145) (21) (768) (15) (94) (4) 464 (319) 4,278 Note a The derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets are £4,010m (2020: £4,468m) and derivative financial liabilities are £6,059m (2020: £6,239m). |
Unrealised gains and losses on Level 3 financial assets and liabilities | The following tables disclose the unrealised gains and losses recognised in the year arising on Level 3 financial assets and liabilities held at year end. Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at year end 2021 2020 Income statement Other compre- Income statement Other Barclays Bank Group Trading income Other income Total Trading income Other income Total As at 31 December £m £m £m £m £m £m £m £m Trading portfolio assets (67) — — (67) (114) — — (114) Financial assets at fair value through the income statement (53) 22 — (31) 115 (89) — 26 Fair value through other comprehensive income — — — — — — (1) (1) Investment property — — — — — (1) — (1) Trading portfolio liabilities (5) — — (5) — — — — Financial liabilities designated at fair value 16 (1) — 15 20 (1) — 19 Net derivative financial instruments (196) — — (196) (91) — — (91) Total (305) 21 — (284) (70) (91) (1) (162) |
Significant unobservable inputs, assets | The following table discloses the valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 along with the range of values used for those significant unobservable inputs: Valuation technique(s) a Significant unobservable inputs 2021 2020 Range Range Barclays Bank Group Min Max Min Max Units b Derivative financial instruments c Interest rate derivatives Discounted cash flows Inflation forwards — 3 1 3 % Credit spread 9 1,848 17 1,831 bps Correlation Model Inflation forwards (20) (13) (20) (13) % Comparable pricing Price — 38 — 84 points Option model Inflation volatility 31 130 31 227 bps vol Interest rate volatility 5 600 6 489 bps vol FX - IR correlation (20) 78 (30) 78 % IR - IR correlation (100) 99 (20) 99 % Credit derivatives Discounted cash flows Credit spread 2 2,925 5 480 bps Comparable pricing Price — — — 100 points Equity derivatives Option model Equity volatility 2 108 1 110 % Equity - equity correlation 10 100 (45) 100 % Discounted cash flow Discounted margin (129) 93 (225) 3,000 bps Foreign exchange derivatives Option Model Option Volatility — 100 — 30 points Non-derivative financial instruments Non-asset backed loans Discounted cash flows Loan spread 31 811 32 477 bps Credit spread 200 300 200 300 bps Price — 112 — 104 points Yield 3 10 5 8 % Comparable pricing Price — 145 — 137 points Asset backed securities Comparable pricing Price — 120 — 112 points Corporate debt Comparable pricing Price — 284 — 127 points Discounted cash flows Loan spread 229 854 — — bps Price — 100 — 104 points Commercial Real Estate loans Discounted cash flows Credit spread 68 543 146 483 bps Equity cash products Discounted cash flows Discount margin 26 34 49 49 bps Notes a A range has not been provided for Net Asset Value as there would be a wide range reflecting the diverse nature of the positions. b The units used to disclose ranges for significant unobservable inputs are percentages, points and basis points. Points are a percentage of par; for example, 100 points equals 100% of par. A basis point equals 1/100th of 1%; for example, 150 basis points equals 1.5%. c Certain derivative instruments are classified as Level 3 due to a significant unobservable credit spread input into the calculation of the Credit Valuation Adjustment for the instruments. The range of significant unobservable credit spreads is between 32bps- 1,848bps (2020: 17bps-1,831bps). |
Significant unobservable inputs, liabilities | The following table discloses the valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 along with the range of values used for those significant unobservable inputs: Valuation technique(s) a Significant unobservable inputs 2021 2020 Range Range Barclays Bank Group Min Max Min Max Units b Derivative financial instruments c Interest rate derivatives Discounted cash flows Inflation forwards — 3 1 3 % Credit spread 9 1,848 17 1,831 bps Correlation Model Inflation forwards (20) (13) (20) (13) % Comparable pricing Price — 38 — 84 points Option model Inflation volatility 31 130 31 227 bps vol Interest rate volatility 5 600 6 489 bps vol FX - IR correlation (20) 78 (30) 78 % IR - IR correlation (100) 99 (20) 99 % Credit derivatives Discounted cash flows Credit spread 2 2,925 5 480 bps Comparable pricing Price — — — 100 points Equity derivatives Option model Equity volatility 2 108 1 110 % Equity - equity correlation 10 100 (45) 100 % Discounted cash flow Discounted margin (129) 93 (225) 3,000 bps Foreign exchange derivatives Option Model Option Volatility — 100 — 30 points Non-derivative financial instruments Non-asset backed loans Discounted cash flows Loan spread 31 811 32 477 bps Credit spread 200 300 200 300 bps Price — 112 — 104 points Yield 3 10 5 8 % Comparable pricing Price — 145 — 137 points Asset backed securities Comparable pricing Price — 120 — 112 points Corporate debt Comparable pricing Price — 284 — 127 points Discounted cash flows Loan spread 229 854 — — bps Price — 100 — 104 points Commercial Real Estate loans Discounted cash flows Credit spread 68 543 146 483 bps Equity cash products Discounted cash flows Discount margin 26 34 49 49 bps Notes a A range has not been provided for Net Asset Value as there would be a wide range reflecting the diverse nature of the positions. b The units used to disclose ranges for significant unobservable inputs are percentages, points and basis points. Points are a percentage of par; for example, 100 points equals 100% of par. A basis point equals 1/100th of 1%; for example, 150 basis points equals 1.5%. c Certain derivative instruments are classified as Level 3 due to a significant unobservable credit spread input into the calculation of the Credit Valuation Adjustment for the instruments. The range of significant unobservable credit spreads is between 32bps- 1,848bps (2020: 17bps-1,831bps). |
Sensitivity analysis of valuations using unobservable inputs, assets | In general, a significant increase in loan spreads in isolation will result in a fair value decrease for a loan. Sensitivity analysis of valuations using unobservable inputs 2021 2020 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity Barclays Bank Group £m £m £m £m £m £m £m £m Interest rate derivatives 51 — (79) — 82 — (123) — Foreign exchange derivatives 20 — (28) — 6 — (11) — Credit derivatives 112 — (103) — 55 — (44) — Equity derivatives 181 — (190) — 174 — (179) — Corporate debt 38 — (28) — 16 — (14) — Non asset backed loans 99 — (150) — 104 3 (190) (3) Equity cash products 25 — (42) — 158 — (141) — Private equity investments 10 — (11) — 15 — (15) — Other a 19 — (20) — 23 — (23) — Total 555 — (651) — 633 3 (740) (3) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. |
Sensitivity analysis of valuations using unobservable inputs, liabilities | In general, a significant increase in loan spreads in isolation will result in a fair value decrease for a loan. Sensitivity analysis of valuations using unobservable inputs 2021 2020 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity Barclays Bank Group £m £m £m £m £m £m £m £m Interest rate derivatives 51 — (79) — 82 — (123) — Foreign exchange derivatives 20 — (28) — 6 — (11) — Credit derivatives 112 — (103) — 55 — (44) — Equity derivatives 181 — (190) — 174 — (179) — Corporate debt 38 — (28) — 16 — (14) — Non asset backed loans 99 — (150) — 104 3 (190) (3) Equity cash products 25 — (42) — 158 — (141) — Private equity investments 10 — (11) — 15 — (15) — Other a 19 — (20) — 23 — (23) — Total 555 — (651) — 633 3 (740) (3) Note a Other includes commercial real estate loans, asset backed loans, funds and fund-linked products, issued debt, government sponsored debt, commodity derivatives and investment property. |
Fair value adjustments | Key balance sheet valuation adjustments are quantified below: 2021 2020 Barclays Bank Group £m £m Exit price adjustments derived from market bid-offer spreads (498) (483) Uncollateralised derivative funding (127) (115) Derivative credit valuation adjustments (212) (268) Derivative debit valuation adjustments 91 113 |
Comparison of carrying amounts and fair values for assets and liabilities not held at fair value | The following tables summarises the fair value of financial assets and liabilities measured at amortised cost on Barclays Bank Group’s and Barclays Bank PLC's balance sheet: Barclays Bank Group 2021 2020 Carrying amount Fair value Level 1 Level 2 Level 3 Carrying amount Fair value Level 1 Level 2 Level 3 As at 31 December £m £m £m £m £m £m £m £m £m £m Financial assets Loans and advances at amortised cost 145,259 145,665 15,406 63,948 66,311 134,267 134,537 8,824 65,267 60,446 Reverse repurchase agreements and other similar secured lending 3,177 3,177 — 3,177 — 8,981 8,981 — 8,981 — Financial liabilities Deposits at amortised cost (262,828) (262,843) (180,829) (82,014) — (244,696) (244,738) (165,909) (78,769) (60) Repurchase agreements and other similar secured borrowing (12,769) (12,776) — (12,776) — (10,443) (10,443) — (10,443) — Debt securities in issue (48,388) (48,350) — (46,201) (2,149) (29,423) (29,486) — (27,630) (1,856) Subordinated liabilities (32,185) (33,598) — (33,598) — (32,005) (33,356) — (33,356) — |
Offsetting financial assets a_2
Offsetting financial assets and financial liabilities (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Offsetting financial assets and financial liabilities | |
Offsetting of financial assets | Barclays Bank Group Amounts subject to enforceable netting arrangements Amounts not subject to enforceable netting arrangements c Balance sheet total d Effects of offsetting on-balance sheet Related amounts not offset Gross amounts Amounts offset a Net amounts reported on the balance sheet Financial instruments Financial collateral b Net amount As at 31 December 2021 £m £m £m £m £m £m £m £m Derivative financial assets 279,286 (24,137) 255,149 (202,347) (39,953) 12,849 7,142 262,291 Reverse repurchase agreements and other similar secured lending e 519,855 (375,376) 144,479 — (143,976) 503 3,884 148,363 Total assets 799,141 (399,513) 399,628 (202,347) (183,929) 13,352 11,026 410,654 Derivative financial liabilities (273,996) 23,606 (250,390) 202,347 34,151 (13,892) (6,133) (256,523) Repurchase agreements and other similar secured borrowing e (540,462) 375,376 (165,086) — 165,086 — (15,758) (180,844) Total liabilities (814,458) 398,982 (415,476) 202,347 199,237 (13,892) (21,891) (437,367) As at 31 December 2020 Derivative financial assets 342,896 (44,305) 298,591 (233,088) (47,820) 17,683 4,102 302,693 Reverse repurchase agreements and other similar secured lending e 448,377 (305,749) 142,628 — (142,244) 384 4,911 147,539 Total assets 791,273 (350,054) 441,219 (233,088) (190,064) 18,067 9,013 450,232 Derivative financial liabilities (333,748) 41,982 (291,766) 233,088 46,592 (12,086) (8,814) (300,580) Repurchase agreements and other similar secured borrowing e (475,616) 305,749 (169,867) — 169,867 — (18,031) (187,898) Total liabilities (809,364) 347,731 (461,633) 233,088 216,459 (12,086) (26,845) (488,478) Notes a Amounts offset for derivative financial assets additionally includes cash collateral netted of £3,815m (2020: £4,990m). Amounts offset for derivative financial liabilities additionally includes cash collateral netted of £4,346m (2020: £7,313m). Settlements assets and liabilities have been offset amounting to £22,837m (2020: £18,143m). b Financial collateral of £39,953m (2020: £47,820m) was received in respect of derivative assets, including £34,149m (2020: £43,164m) of cash collateral and £5,804m (2020: £4,656m) of non-cash collateral. Financial collateral of £34,151m (2020: £46,592m) was placed in respect of derivative liabilities, including £31,861m (2020: £42,518m) of cash collateral and £2,290m (2020: £4,074m) of non-cash collateral. The collateral amounts are limited to net balance sheet exposure so as to not include over-collateralisation. c This column includes contractual rights of set-off that are subject to uncertainty under the laws of the relevant jurisdiction. d The balance sheet total is the sum of ‘Net amounts reported on the balance sheet’ that are subject to enforceable netting arrangements and ‘Amounts not subject to enforceable netting arrangements’. e Reverse Repurchase agreements and other similar secured lending of £148,363m (2020: £147,539m) is split by fair value £145,186m (2020: £138,558m) and amortised cost £3,177m (2020: £8,981m). Repurchase agreements and other similar secured borrowing of £180,844m (2020: £187,898m) is split by fair value £168,075m (2020: £177,455m) and amortised cost £12,769m (2020: £10,443m). |
Offsetting of financial liabilities | Barclays Bank Group Amounts subject to enforceable netting arrangements Amounts not subject to enforceable netting arrangements c Balance sheet total d Effects of offsetting on-balance sheet Related amounts not offset Gross amounts Amounts offset a Net amounts reported on the balance sheet Financial instruments Financial collateral b Net amount As at 31 December 2021 £m £m £m £m £m £m £m £m Derivative financial assets 279,286 (24,137) 255,149 (202,347) (39,953) 12,849 7,142 262,291 Reverse repurchase agreements and other similar secured lending e 519,855 (375,376) 144,479 — (143,976) 503 3,884 148,363 Total assets 799,141 (399,513) 399,628 (202,347) (183,929) 13,352 11,026 410,654 Derivative financial liabilities (273,996) 23,606 (250,390) 202,347 34,151 (13,892) (6,133) (256,523) Repurchase agreements and other similar secured borrowing e (540,462) 375,376 (165,086) — 165,086 — (15,758) (180,844) Total liabilities (814,458) 398,982 (415,476) 202,347 199,237 (13,892) (21,891) (437,367) As at 31 December 2020 Derivative financial assets 342,896 (44,305) 298,591 (233,088) (47,820) 17,683 4,102 302,693 Reverse repurchase agreements and other similar secured lending e 448,377 (305,749) 142,628 — (142,244) 384 4,911 147,539 Total assets 791,273 (350,054) 441,219 (233,088) (190,064) 18,067 9,013 450,232 Derivative financial liabilities (333,748) 41,982 (291,766) 233,088 46,592 (12,086) (8,814) (300,580) Repurchase agreements and other similar secured borrowing e (475,616) 305,749 (169,867) — 169,867 — (18,031) (187,898) Total liabilities (809,364) 347,731 (461,633) 233,088 216,459 (12,086) (26,845) (488,478) Notes a Amounts offset for derivative financial assets additionally includes cash collateral netted of £3,815m (2020: £4,990m). Amounts offset for derivative financial liabilities additionally includes cash collateral netted of £4,346m (2020: £7,313m). Settlements assets and liabilities have been offset amounting to £22,837m (2020: £18,143m). b Financial collateral of £39,953m (2020: £47,820m) was received in respect of derivative assets, including £34,149m (2020: £43,164m) of cash collateral and £5,804m (2020: £4,656m) of non-cash collateral. Financial collateral of £34,151m (2020: £46,592m) was placed in respect of derivative liabilities, including £31,861m (2020: £42,518m) of cash collateral and £2,290m (2020: £4,074m) of non-cash collateral. The collateral amounts are limited to net balance sheet exposure so as to not include over-collateralisation. c This column includes contractual rights of set-off that are subject to uncertainty under the laws of the relevant jurisdiction. d The balance sheet total is the sum of ‘Net amounts reported on the balance sheet’ that are subject to enforceable netting arrangements and ‘Amounts not subject to enforceable netting arrangements’. e Reverse Repurchase agreements and other similar secured lending of £148,363m (2020: £147,539m) is split by fair value £145,186m (2020: £138,558m) and amortised cost £3,177m (2020: £8,981m). Repurchase agreements and other similar secured borrowing of £180,844m (2020: £187,898m) is split by fair value £168,075m (2020: £177,455m) and amortised cost £12,769m (2020: £10,443m). |
Loans and advances and deposi_2
Loans and advances and deposits at amortised cost (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Loans and advances and deposits at amortised cost | |
Loans and advances at amortised cost | Financial assets at fair value through other comprehensive income Accounting for financial assets at fair value through other comprehensive income (FVOCI) Financial assets that are debt instruments held in a business model that is achieved by both collecting contractual cash flows and selling and that contain contractual terms that give rise on specified dates to cash flows that are SPPI are measured at FVOCI. They are subsequently re-measured at fair value and changes therein (except for those relating to impairment, interest income and foreign currency exchange gains and losses) are recognised in other comprehensive income until the assets are sold. Interest (calculated using the effective interest method) is recognised in the income statement in net interest income (Note 3). Upon disposal, the cumulative gain or loss recognised in other comprehensive income is included in net investment income (Note 6). In determining whether the business model is achieved by both collecting contractual cash flows and selling financial assets, it is determined that both collecting contractual cash flows and selling financial assets are integral to achieving the objective of the business model. The Barclays Bank Group will consider past sales and expectations about future sales to establish if the business model is achieved. For equity securities that are not held for trading, the Barclays Bank Group may make an irrevocable election on initial recognition to present subsequent changes in the fair value of the instrument in other comprehensive income (except for dividend income which is recognised in profit or loss). Gains or losses on the de-recognition of these equity securities are not transferred to profit or loss. These assets are also not subject to the impairment requirements and therefore no amounts are recycled to the income statement. Where the Barclays Bank Group has not made the irrevocable election to present subsequent changes in the fair value of the instrument in other comprehensive income, equity securities are measured at fair value through profit or loss. Barclays Bank Group 2021 2020 £m £m Debt securities and other eligible bills 45,854 51,710 Equity securities 1 1 Loans and advances 53 191 Financial assets at fair value through other comprehensive income 45,908 51,902 Loans and advances and deposits at amortised cost Barclays Bank Group 2021 2020 As at 31 December £m £m Loans and advances at amortised cost to banks 8,750 9,003 Loans and advances at amortised cost to customers 117,014 110,101 Debt securities at amortised cost 19,495 15,163 Total loans and advances at amortised cost 145,259 134,267 Deposits at amortised cost from banks 17,911 17,348 Deposits at amortised cost from customers 244,917 227,348 Total deposits at amortised cost 262,828 244,696 |
Deposits at amortised cost | Financial liabilities designated at fair value Accounting for liabilities designated at fair value through profit and loss In accordance with IFRS 9, financial liabilities may be designated at fair value, with gains and losses taken to the income statement within net trading income (Note 5) and net investment income (Note 6). Movements in own credit are reported through other comprehensive income, unless the effects of changes in the liability's credit risk would create or enlarge an accounting mismatch in profit and loss. In these scenarios, all gains and losses on that liability (including the effects of changes in the credit risk of the liability) are presented in profit and loss. On derecognition of the financial liability no amount relating to own credit risk are recycled to the income statement. The Barclays Bank Group has the ability to make the fair value designation when holding the instruments at fair value reduces an accounting mismatch (caused by an offsetting liability or asset being held at fair value), or is managed by the Barclays Bank Group on the basis of its fair value, or includes terms that have substantive derivative characteristics (Note 13). The details on how the fair value amounts are arrived at for financial liabilities designated at fair value are described in Note 16. Barclays Bank Group 2021 2020 Fair value Contractual Fair value Contractual £m £m £m £m Debt securities 53,164 61,333 50,216 57,650 Deposits 29,409 29,836 21,718 22,120 Repurchase agreements and other similar secured borrowing 168,075 168,144 177,455 177,513 Subordinated debt a 483 613 — — Other financial liabilities — — 237 237 Financial liabilities designated at fair value 251,131 259,926 249,626 257,520 The cumulative own credit net loss recognised for Barclays Bank Group is £960m (2020: £954m). Note a. Subordinated debt measured at fair value (2020: £221m) was previously disclosed in Note 26 Subordinated Liabilities. For the current year, it is disclosed within Financial Liabilities designated at fair value to better reflect that it is accounted for at fair value. Loans and advances and deposits at amortised cost Barclays Bank Group 2021 2020 As at 31 December £m £m Loans and advances at amortised cost to banks 8,750 9,003 Loans and advances at amortised cost to customers 117,014 110,101 Debt securities at amortised cost 19,495 15,163 Total loans and advances at amortised cost 145,259 134,267 Deposits at amortised cost from banks 17,911 17,348 Deposits at amortised cost from customers 244,917 227,348 Total deposits at amortised cost 262,828 244,696 |
Property, plant and equipment (
Property, plant and equipment (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about property, plant and equipment [abstract] | |
Detailed disclosure of property, plant and equipment | The Barclays Bank Group uses the following annual rates in calculating depreciation: Annual rates in calculating depreciation Depreciation rate Freehold land Not depreciated Freehold buildings and long-leasehold property (more than 50 years to run) 2%-3.3% Leasehold property over the remaining life of the lease (less than 50 years to run) Over the remaining life of the lease Costs of adaptation of freehold and leasehold property 6%-10% Equipment installed in freehold and leasehold property 6%-10% Computers and similar equipment 17%-33% Fixtures and fittings and other equipment 9%-20% Barclays Bank Group Investment property Property Equipment Right of use assets a Total £m £m £m £m £m Cost As at 1 January 2021 10 1,619 987 688 3,304 Additions — 85 70 27 182 Disposals (2) (32) (12) (58) (104) Exchange and other movements (1) 30 13 58 100 As at 31 December 2021 7 1,702 1,058 715 3,482 Accumulated depreciation and impairment As at 1 January 2021 — (730) (821) (216) (1,767) Depreciation charge — (70) (55) (68) (193) Impairment charge b — (108) — (160) (268) Disposals — 27 10 9 46 Exchange and other movements — (39) (11) (2) (52) As at 31 December 2021 — (920) (877) (437) (2,234) Net book value 7 782 181 278 1,248 Cost As at 1 January 2020 13 1,635 1,080 621 3,349 Additions — 39 35 28 102 Disposals (1) (25) (97) (6) (129) Exchange and other movements (2) (30) (31) 45 (18) As at 31 December 2020 10 1,619 987 688 3,304 Accumulated depreciation and impairment As at 1 January 2020 — (697) (875) (146) (1,718) Depreciation charge — (72) (61) (77) (210) Impairment charge — — — (2) (2) Disposals — 22 93 1 116 Exchange and other movements — 17 22 8 47 As at 31 December 2020 — (730) (821) (216) (1,767) Net book value 10 889 166 472 1,537 Notes a Right of use (ROU) asset balances relate to Property Leases under IFRS 16. Refer to Note 20 for further details. b Impairment charge includes £266m related to structural cost action in relation to the real estate review. |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Leases | |
Finance lease income | Finance lease income is included within interest income. The following table shows amounts recognised in the income statement during the year. Barclays Bank Group 2021 2020 £m £m Finance income from net investment in lease — 10 Loss on sales — (27) |
Lease liabilities and Lease liabilities maturity analysis | Lease liabilities Barclays Bank Group 2021 2020 £m £m As at 1 January 515 529 Interest expense 20 23 New leases 38 27 Disposals (45) (5) Cash payments (92) (114) Exchange and other movements 59 55 As at 31 December (see Note 22) 495 515 The below table sets out a maturity analysis of undiscounted lease liabilities, showing the lease payments to be paid after the reporting date. Undiscounted lease liabilities maturity analysis Barclays Bank Group 2021 2020 £m £m Not more than one year 81 91 One to two years 77 70 Two to three years 74 60 Three to four years 66 58 Four to five years 60 55 Five to ten years 210 227 Greater than ten years 30 68 Total undiscounted lease liabilities as at 31 December 598 629 |
Goodwill and intangible assets
Goodwill and intangible assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Intangible assets and goodwill [abstract] | |
Goodwill and intangible assets, amortisation periods | Intangible assets are stated at cost (which is, in the case of assets acquired in a business combination, the acquisition date fair value) less accumulated amortisation and provisions for impairment, if any, and are amortised over their useful lives in a manner that reflects the pattern to which they contribute to future cash flows, generally using the amortisation periods set out below: Annual rates in calculating amortisation Amortisation period Goodwill Not amortised Internally generated software a 12 months to 6 years Other software 12 months to 6 years Customer lists 12 months to 25 years Licences and other 12 months to 25 years Note a Exceptions to the above period relate to useful lives of certain core banking platforms that are assessed individually and, if appropriate, amortised over longer periods ranging from 10 years to 15 years. |
Intangible assets | Intangible assets Goodwill Internally generated software Other software Customer lists Licences and other Total £m £m £m £m £m £m Barclays Bank Group Cost As at 1 January 2021 324 1,539 106 1,325 457 3,751 Additions a — 195 1 — 405 601 Disposals — (148) (12) (5) (2) (167) Exchange and other movements 2 (78) — 19 16 (41) As at 31 December 2021 326 1,508 95 1,339 876 4,144 Accumulated amortisation and impairment As at 1 January 2021 (68) (964) (55) (1,158) (352) (2,597) Disposals — 148 12 5 2 167 Amortisation charge — (126) (6) (36) (42) (210) Impairment charge — (12) — — — (12) Exchange and other movements — (12) (3) (18) (10) (43) As at 31 December 2021 (68) (966) (52) (1,207) (402) (2,695) Net book value 258 542 43 132 474 1,449 Note a. Additions in 'Licences and others' primarily relate to new and renewed long-term partnership agreements. Goodwill Internally generated software Other software Customer lists Licences and other Total £m £m £m £m £m £m Barclays Bank Group Cost As at 1 January 2020 406 1,430 81 1,371 458 3,746 Additions and disposals (77) 169 21 — 20 133 Exchange and other movements (5) (60) 4 (46) (21) (128) As at 31 December 2020 324 1,539 106 1,325 457 3,751 Accumulated amortisation and impairment As at 1 January 2020 (111) (870) (54) (1,159) (340) (2,534) Disposals 43 22 9 — 4 78 Amortisation charge — (132) (8) (40) (31) (211) Impairment charge — (18) — — — (18) Exchange and other movements — 34 (2) 41 15 88 As at 31 December 2020 (68) (964) (55) (1,158) (352) (2,597) Net book value 256 575 51 167 105 1,154 |
Goodwill | Goodwill Goodwill is allocated to business operations according to business segments as follows: Barclays Bank Group 2021 2020 £m £m Consumer, Cards and Payments 258 256 Total net book value of goodwill 258 256 |
Other liabilities (Table)
Other liabilities (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Accruals and deferred income including contract liabilities [abstract] | |
Other liabilities | Barclays Bank Group 2021 2020 £m £m Accruals and deferred income 2,657 2,428 Other creditors 4,030 2,250 Items in the course of collection due to other banks 67 58 Lease liabilities (refer to Note 20) 495 515 Other liabilities 7,249 5,251 |
Provisions (Table)
Provisions (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Provisions [abstract] | |
Provisions | Restated b Restated b Onerous contracts Redundancy and restructuring Undrawn contractually committed facilities and guarantees provided a Customer redress Legal, competition and regulatory matters Sundry provisions Total £m £m £m £m £m £m £m Barclays Bank Group As at 1 January 2021 6 44 769 44 222 123 1,208 Additions 1 55 129 235 54 28 502 Amounts utilised (2) (39) — (4) (45) (29) (119) Unused amounts reversed (3) (11) (386) (7) (18) (26) (451) Exchange and other movements — (3) (13) (2) (2) (10) (30) As at 31 December 2021 2 46 499 266 211 86 1,110 Note a Undrawn contractually committed facilities and guarantees provisions are accounted for under IFRS 9 |
Contingent liabilities and co_2
Contingent liabilities and commitments (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | The following table summarises the nominal principal amount of contingent liabilities and commitments which are not recorded on-balance sheet: Barclays Bank Group 2021 2020 £m £m Guarantees and letters of credit pledged as collateral security 15,759 15,138 Performance guarantees, acceptances and endorsements 7,987 5,794 Total contingent liabilities and financial guarantees a 23,746 20,932 Of which: Financial guarantees carried at fair value 231 229 Documentary credits and other short-term trade related transactions 1,584 1,086 Standby facilities, credit lines and other commitments 282,867 263,936 Total commitments 284,451 265,022 Of which: Loan commitments carried at fair value 18,571 9,248 |
Subordinated Liabilities (Table
Subordinated Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Barclays Bank Group 2021 2020 £m £m At amortised cost As at 1 January 32,005 33,425 Issuances 9,099 3,856 Redemptions (7,241) (5,954) Other (1,678) 678 As at 31 December 32,185 32,005 Designated at fair value (Note 15) 483 — Total subordinated liabilities 32,668 32,005 Subordinated liabilities include accrued interest and comprise undated and dated subordinated liabilities as follows: Barclays Bank Group 2021 2020 £m £m Undated subordinated liabilities 795 905 Dated subordinated liabilities 31,873 31,100 Total subordinated liabilities 32,668 32,005 Undated subordinated liabilities a Barclays Bank Group 2021 2020 Initial call date £m £m Barclays Bank PLC externally issued subordinated liabilities Tier One Notes (TONs) 6% Callable Perpetual Core Tier One Notes 2032 15 17 6.86% Callable Perpetual Core Tier One Notes (USD 179m) 2032 194 205 Reserve Capital Instruments (RCIs) 5.3304% Step-up Callable Perpetual Reserve Capital Instruments 2036 51 56 Undated Notes 6.125% Undated Subordinated Notes 2027 39 43 Junior Undated Floating Rate Notes (USD 38m) Any interest payment date 28 28 Undated Floating Rate Primary Capital Notes Series 1 (USD 167m) Any interest payment date 90 89 Undated Floating Rate Primary Capital Notes Series 2 (USD 295m) Any interest payment date 189 186 Undated Floating Rate Primary Capital Notes Series 3 Any interest payment date 21 21 Bonds 9.25% Perpetual Subordinated Bonds (ex-Woolwich Plc) 2021 — 78 9% Permanent Interest Bearing Capital Bonds (GBP 40m) At any time 42 44 Loans 5.03% Reverse Dual Currency Undated Subordinated Loan (JPY 8,000m) 2028 51 57 5% Reverse Dual Currency Undated Subordinated Loan (JPY 12,000m) 2028 75 83 Total undated subordinated liabilities 795 905 Note a Instrument values are disclosed to the nearest million. Dated subordinated liabilities a Barclays Bank Group 2021 2020 Initial call date Maturity date £m £m Barclays Bank PLC externally issued subordinated liabilities 10% Fixed Rate Subordinated Notes 2021 — 2,108 6% Fixed Rate Subordinated Notes (EUR 1,500m) 2021 — 1,427 10.179% Fixed Rate Subordinated Notes (USD 1,521m) 2021 — 1,101 9.5% Subordinated Bonds (ex-Woolwich Plc) 2021 — 221 Subordinated Floating Rate Notes (EUR 100m) 2021 — 90 7.625% Contingent Capital Notes (USD 3,000m) 2022 1,159 1,189 6.625% Fixed Rate Subordinated Notes (EUR 1,000m) 2022 889 982 Subordinated Floating Rate Notes (EUR 50m) 2022 42 45 Subordinated Floating Rate Notes (EUR 50m) 2023 42 45 5.75% Fixed Rate Subordinated Notes 2026 322 351 5.4% Reverse Dual Currency Subordinated Loan (JPY 15,000m) 2027 97 108 6.33% Subordinated Notes (GBP 50m) 2032 59 64 Subordinated Floating Rate Notes (EUR 68m) 2040 57 61 External issuances by other subsidiaries 2026 311 146 Barclays Bank PLC notes issued intra-group to Barclays PLC 2% Fixed Rate Subordinated Callable Notes (EUR 1,500) 2023 2028 1,288 1,388 3.75% Fixed Rate Resetting Subordinated Callable Notes (SGD 200m) 2025 2030 113 119 5.20% Fixed Rate Subordinated Notes (USD 1,367m) 2026 1,037 1,069 1.125% Fixed Rate Resetting Subordinated Callable Notes (EUR 1,000m) 2026 2031 831 — 4.836% Fixed Rate Subordinated Callable Notes (USD 1,200m) 2027 2028 937 973 5.088% Fixed-to-Floating Rate Subordinated Callable Notes (USD 1,300m) 2029 2030 1,005 1,049 3.811% Fixed Rate Resetting Subordinated Callable Notes (USD 1,000m) 2041 2042 778 — 5.25% Fixed Rate Subordinated Notes (USD 827m) 2045 618 660 4.95% Fixed Rate Subordinated Notes (USD 1,250m) 2047 896 960 Floating Rate Subordinated Notes (USD 456m) 2047 341 337 Barclays Bank PLC intra-group loans from Barclays PLC Various Fixed Rate Subordinated Loans 7,184 9,563 Various Subordinated Floating Rate Loans 646 489 Various Fixed Rate Subordinated Callable Loans 11,016 5,838 Various Subordinated Floating Rate Callable Loans 1,725 500 Zero Coupon Callable Loans 2051 483 221 Total dated subordinated liabilities 31,873 31,100 Notes a Instrument values are disclosed to the nearest million |
Ordinary shares, preference s_2
Ordinary shares, preference shares and other equity (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [abstract] | |
Called up share capital | Called up share capital, allotted and fully paid and other equity instruments Barclays Bank Group Barclays Bank Group Ordinary share capital Preference share capital Total share capital Other equity instruments £m £m £m £m As at 1 January 2021 2,342 6 2,348 8,621 AT1 securities issuance — — — 1,072 As at 31 December 2021 2,342 6 2,348 9,693 As at 1 January 2020 2,342 6 2,348 8,323 AT1 securities issuance — — — 1,134 Increase in borrowings from subsidiary — — — — AT1 securities redemption — — — (836) As at 31 December 2020 2,342 6 2,348 8,621 |
AT1 equity instruments | AT1 equity instruments 2021 2020 Initial call date £m £m AT1 equity instruments - Barclays Bank Group 7.875% Perpetual Subordinated Contingent Convertible Securities 2022 1,000 1,000 7.875% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2022 1,136 1,136 7.25% Perpetual Subordinated Contingent Convertible Securities 2023 500 500 7.75% Perpetual Subordinated Contingent Convertible Securities (USD 2,500m) 2023 1,925 1,925 5.875% Perpetual Subordinated Contingent Convertible Securities 2024 623 623 8% Perpetual Subordinated Contingent Convertible Securities (USD 2,000m) 2024 1,509 1,509 7.125% Perpetual Subordinated Contingent Convertible Securities 2025 299 299 6.375% Perpetual Subordinated Contingent Convertible Securities 2025 495 495 6.125% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2025 1,134 1,134 4.375% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) 2028 1,072 — 9,693 8,621 |
Reserves (Table)
Reserves (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | Barclays Bank Group 2021 2020 £m £m Currency translation reserve 2,581 2,736 Fair value through other comprehensive income reserve (118) 244 Cash flow hedging reserve (618) 1,181 Own credit reserve (960) (954) Other reserves (24) (24) Total 861 3,183 |
Staff costs (Table)
Staff costs (Table) | 12 Months Ended |
Dec. 31, 2021 | |
Classes of employee benefits expense [abstract] | |
Staff costs | 2021 2020 2019 £m £m £m Performance costs 1,308 1,145 1,104 Salaries a 2,245 2,285 2,373 Social security costs 297 295 269 Post-retirement benefits b 181 176 184 Other compensation costs 172 208 237 Total compensation costs 4,203 4,109 4,167 Other resourcing costs Outsourcing 136 142 211 Redundancy and restructuring 49 47 69 Temporary staff costs 17 14 48 Other 51 53 70 Total other resourcing costs 253 256 398 Total staff costs 4,456 4,365 4,565 Notes a £152m (2020: £156m; 2019: £123m) of compensation was capitalised as internally generated software. b Post-retirement benefits charge includes £121m (2020: £127m; 2019: £126m) in respect of defined contribution schemes and £60m (2020: £49m; 2019: £58m) in respect of defined benefit schemes. |
Share-based payments (Tables)
Share-based payments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Share-based payment schemes | The charge for the year arising from share based payment schemes was as follows: Charge for the year 2021 2020 2019 £m £m £m Deferred Share Value Plan / Share Value Plan 235 220 244 Others 159 129 148 Total equity settled 394 349 392 Cash settled 4 2 3 Total share based payments 398 351 395 |
Share option and award plans | The weighted average fair value per award granted, weighted average share price at the date of exercise/release of shares during the year, weighted average contractual remaining life and number of options and awards outstanding (including those exercisable) at the balance sheet date were as follows: 2021 2020 Weighted average fair value per award granted in year Weighted average share price at exercise/ release during year Weighted Number of Weighted average fair value per award granted in year Weighted average share price at exercise/ release during year Weighted Number of £ £ £ £ DSVP / SVP a.b 1.63 1.76 1.15 370,505 1.04 1.24 1 370,006 Others a 0.64-1.81 1.76-1.92 0-3 47,480 0.24-1.24 1.19-1.67 0-4 53,767 |
Movements in options and awards | The movement in the number of options and awards for the major schemes and the weighted average exercise price of options was: DSVP / SVP a,b Others a,c Number (000s) Number (000s) Weighted average 2021 2020 2021 2020 2021 2020 Outstanding at beginning of year/acquisition date 370,006 297,149 53,767 37,481 0.95 1.27 Transfers in the year d (2,214) 953 (2,697) 140 — — Granted in the year 174,338 203,157 79,050 136,227 1.43 0.84 Exercised/released in the year (144,943) (117,355) (78,273) (99,465) 1.36 1.21 Less: forfeited in the year (26,682) (13,898) (3,395) (18,285) 0.95 1.23 Less: expired in the year — — (972) (2,331) 1.69 1.33 Outstanding at end of year 370,505 370,006 47,480 53,767 0.95 0.95 Of which exercisable: — — 4,428 4,746 1.16 1.64 Notes a Options/award granted over Barclays PLC shares. b Weighted average exercise price is not applicable for SVP and DSVP awards as these are not share option schemes. c The number of awards within Others at the end of the year principally relates to Sharesave (number of awards exercisable at end of year was 1,499,920). The weighted average exercise price relates to Sharesave. d Awards of employees transferred between the Barclays Bank Group and the rest of the Barclays PLC Group. |
Pension and post-retirement ben
Pension and post-retirement benefits (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of defined benefit plans [abstract] | |
Income statement charge | The following tables include amounts recognised in the income statement and an analysis of benefit obligations and scheme assets for all Barclays Bank Group defined benefit schemes. The net position is reconciled to the assets and liabilities recognised on the balance sheet. The tables include funded and unfunded post-retirement benefits. Income statement charge 2021 2020 £m £m Current service cost 58 53 Net finance cost (26) (40) Past service cost — (4) Other movements 2 — Total 34 9 |
Balance sheet reconciliation | Balance sheet reconciliation 2021 2020 Barclays Bank Group Total Of which relates to UKRF Barclays Bank Group Total Of which relates to UKRF £m £m £m £m Benefit obligation at beginning of the year (33,131) (32,108) (30,298) (29,304) Current service cost (240) (225) (232) (217) Interest costs on scheme liabilities (422) (405) (573) (549) Past service cost — — 4 — Remeasurement gain/(loss) - financial 849 820 (3,439) (3,358) Remeasurement gain/(loss) - demographic 53 50 (281) (286) Remeasurement gain/(loss) - experience (249) (259) 243 237 Employee contributions (4) — (5) (1) Benefits paid 1,309 1,268 1,406 1,370 Exchange and other movements 1 — 44 — Benefit obligation at end of the year (31,834) (30,859) (33,131) (32,108) Fair value of scheme assets at beginning of the year 34,713 33,915 32,093 31,362 Interest income on scheme assets 448 434 613 595 Employer contribution 971 955 265 248 Settlements — — — — Remeasurement - return on plan assets greater than discount rate 653 642 3,411 3,328 Employee contributions 4 — 5 1 Benefits paid (1,309) (1,268) (1,406) (1,370) Exchange and other movements (13) — (268) (249) Fair value of scheme assets at the end of the year 35,467 34,678 34,713 33,915 Net surplus 3,633 3,819 1,582 1,807 Retirement benefit assets 3,879 3,819 1,814 1,807 Retirement benefit liabilities (246) — (232) — Net retirement benefit assets 3,633 3,819 1,582 1,807 |
Actuarial valuation of the schemes' obligation based on assumptions | Actuarial valuation of the schemes’ obligations is dependent upon a series of assumptions. Below is a summary of the main financial and demographic assumptions adopted for the UKRF. Key UKRF financial assumptions 2021 2020 % p.a. % p.a. Discount rate 1.84 1.29 Inflation rate (RPI) 3.56 2.99 Assumed life expectancy 2021 2020 2019 Life expectancy at 60 for current pensioners (years) – Males 27.3 27.2 27.1 – Females 29.6 29.4 29.3 Life expectancy at 60 for future pensioners currently aged 40 (years) – Males 29.1 29.0 28.9 – Females 31.4 31.2 31.1 The UKRF entered into a £5bn longevity swap in 2020 covering around a quarter of the pensioner liabilities. The swap is part of the UKRF’s investment portfolio and provides income in the event that pensions are paid out for longer than expected. The swap is not included directly within the balance sheet of Barclays PLC as it is an asset of the UKRF. At 31 December 2021, the swap is valued at nil (2020: nil) as experience since the swap was effected has been neutral. Sensitivity analysis on actuarial assumptions The sensitivity analysis has been calculated by valuing the UKRF liabilities using the amended assumptions shown in the table below and keeping the remaining assumptions the same as disclosed in the table above, except in the case of the inflation sensitivity where other assumptions that depend on assumed inflation have also been amended correspondingly. The difference between the recalculated liability figure and that stated in the balance sheet reconciliation table above is the figure shown. The selection of these movements to illustrate the sensitivity of the defined benefit obligation to key assumptions should not be interpreted as Barclays Bank Group expressing any specific view of the probability of such movements happening. Change in key assumptions 2021 2020 (Decrease)/Increase in UKRF defined benefit obligation (Decrease)/Increase in UKRF defined benefit obligation £bn £bn Discount rate 0.50% p.a. increase (2.3) (2.5) 0.25% p.a. increase (1.2) (1.3) 0.25% p.a. decrease 1.3 1.4 0.50% p.a. decrease 2.6 2.9 Assumed RPI 0.50% p.a. increase 1.6 1.8 0.25% p.a. increase 0.8 0.9 0.25% p.a. decrease (0.8) (0.9) 0.50% p.a. decrease (1.6) (1.8) Life expectancy at 60 One year increase 1.2 1.2 One year decrease (1.2) (1.2) |
Analysis of scheme assets | The value of the assets of the schemes and their percentage in relation to total scheme assets were as follows: Analysis of scheme assets Barclays Bank Group Total Of which relates to UKRF Quoted Unquoted a Value % of total Quoted Unquoted a Value % of total £m £m £m % £m £m £m % As at 31 December 2021 Equities 214 1,377 1,591 4.5 86 1,377 1,463 4.2 Private equities — 2,991 2,991 8.4 0 2,991 2,991 8.6 Bonds - fixed government 2,387 95 2,482 7.0 2,083 95 2,178 6.3 Bonds - index-linked government 13,478 679 14,157 39.9 13,455 679 14,134 40.8 Bonds - corporate and other 6,223 2,854 9,077 25.6 5,986 2,854 8,840 25.5 Property 14 1,490 1,504 4.3 0 1,490 1,490 4.3 Infrastructure — 1,815 1,815 5.1 0 1,815 1,815 5.2 Cash and liquid assets 189 1,577 1,766 5.0 176 1,577 1,753 5.1 Mixed investment funds 9 — 9 — — — — — Other 19 56 75 0.2 — 14 14 — Fair value of scheme assets 22,533 12,934 35,467 100.0 21,786 12,892 34,678 100.0 As at 31 December 2020 Equities 567 1,498 2,065 5.9 378 1,498 1,876 5.5 Private equities — 2,233 2,233 6.4 — 2,233 2,233 6.6 Bonds - fixed government 4,205 110 4,315 12.4 3,932 110 4,042 11.9 Bonds - index-linked government 10,706 1,014 11,720 33.8 10,697 1,014 11,711 34.5 Bonds - corporate and other 7,439 1,678 9,117 26.3 7,214 1,678 8,892 26.2 Property 10 1,416 1,426 4.1 — 1,416 1,416 4.2 Infrastructure — 1,812 1,812 5.2 — 1,812 1,812 5.3 Cash and liquid assets 64 1,830 1,894 5.5 46 1,830 1,876 5.5 Mixed Investment funds 9 — 9 — — — — — Other 14 108 122 0.4 — 57 57 0.2 Fair value of scheme assets 23,014 11,699 34,713 100.0 22,267 11,648 33,915 100.0 Notes a Valuations of unquoted assets are provided by the underlying managers or qualified independent valuers. Valuations of complex instruments are based on UKRF custodian valuations. All valuations are determined in accordance with relevant industry guidance. |
Deficit reduction contributions | The deficit reduction contributions agreed with the UKRF Trustee as part of the 30 September 2019 triennial valuation recovery plan are shown in the table below. Deficit reduction contributions under the 30 September 2019 valuation Year £m Cash paid: 2019 500 2020 500 2021 700 Future commitments: 2022 294 2023 286 2024 and beyond — |
Defined benefit contributions paid | Defined benefit contributions paid with respect to the UKRF were as follows: Contributions paid £m 2021 955 2020 748 2019 1,231 |
Principal subsidiaries (Tables)
Principal subsidiaries (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of subsidiaries [abstract] | |
Principal subsidiaries details | Principal subsidiaries of the Barclays Bank Group are set out below. This includes those subsidiaries that are most significant in the context of the Barclays Bank Group’s business, results or financial position. Company Name Principal place of business or incorporation Nature of business Percentage of voting rights held Non-controlling interests - proportion of ownership interests Non-controlling interests - proportion of voting interests % % % Barclays Bank Ireland PLC Ireland Banking 100 — — Barclays Capital Inc. United States Securities dealing 100 — — Barclays Capital Securities Limited United Kingdom Securities dealing 100 — — Barclays Securities Japan Limited Japan Securities dealing 100 — — Barclays US LLC United States Holding company 100 — — Barclays Bank Delaware United States Credit card issuer 100 — — |
Entities excluded from consolidation | However, the entity set out below is excluded from consolidation because the Barclays Bank Group does not have exposure to its variable returns. Company name Country of registration or incorporation Percentage of voting rights held (%) Equity shareholders' funds (£m) Retained profit for the year (£m) Palomino Limited Cayman Islands 100 — — |
Structured entities (Tables)
Structured entities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of information about consolidated structured entities [abstract] | |
Summary of interests in unconsolidated structured entities | The nature and extent of the Barclays Bank Group’s interests in structured entities is summarised below: Summary of interests in unconsolidated structured entities Secured financing Short-term traded interests Traded derivatives Other interests Total £m £m £m £m £m As at 31 December 2021 Assets Trading portfolio assets — 7,170 — — 7,170 Financial assets at fair value through the income statement 61,816 — — 3,417 65,233 Derivative financial instruments — — 5,160 — 5,160 Financial assets at fair value through other comprehensive income — — — 91 91 Loans and advances at amortised cost — — — 22,741 22,741 Reverse repurchase agreements and other similar secured lending 104 — — — 104 Other assets — — — 12 12 Total assets 61,920 7,170 5,160 26,261 100,511 Liabilities Derivative financial instruments — — 9,543 — 9,543 As at 31 December 2020 Assets Trading portfolio assets — 11,361 — — 11,361 Financial assets at fair value through the income statement 56,265 — — 2,780 59,045 Derivative financial instruments — — 2,968 — 2,968 Financial assets at fair value through other comprehensive income — — — 153 153 Loans and advances at amortised cost — — — 18,418 18,418 Reverse repurchase agreements and other similar secured lending 10 — — — 10 Other assets — — — 11 11 Total assets 56,275 11,361 2,968 21,362 91,966 Liabilities Derivative financial instruments — — 7,075 — 7,075 The Barclays Bank Group’s interests in structured entities not held for the purposes of short-term trading activities are set out below, summarised by the nature of the interest and limited to significant categories, based on maximum exposure to loss. Nature of interest Multi-seller conduit programme Lending Other Total Of which: Barclays Bank Group owned, not consolidated entities 1 £m £m £m £m £m As at 31 December 2021 Financial assets at fair value through the income statement — 2 3,415 3,417 3,335 Financial assets at fair value through other comprehensive income — 53 38 91 — Loans and advances at amortised cost 5,184 14,294 3,263 22,741 — Other assets 8 4 — 12 — Total on-balance sheet exposures 5,192 14,353 6,716 26,261 3,335 Total off-balance sheet notional amounts 11,015 9,394 — 20,409 — Maximum exposure to loss 16,207 23,747 6,716 46,670 3,335 Total assets of the entity 65,441 160,611 28,582 254,634 11,513 As at 31 December 2020 Financial assets at fair value through the income statement — 15 2,765 2,780 2,698 Financial assets at fair value through other comprehensive income — 106 47 153 — Loans and advances at amortised cost 5,146 12,475 797 18,418 — Other assets 8 3 — 11 — Total on-balance sheet exposures 5,154 12,599 3,609 21,362 2,698 Total off-balance sheet notional amounts 11,750 7,531 — 19,281 — Maximum exposure to loss 16,904 20,130 3,609 40,643 2,698 Total assets of the entity 87,004 153,990 22,389 263,383 11,008 |
Investments in associates and_2
Investments in associates and joint ventures (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Investments in subsidiaries, joint ventures and associates reported in separate financial statements [abstract] | |
Investments in associates and joint ventures | 2021 2020 Associates Joint ventures Total Associates Joint ventures Total £m £m £m £m £m £m Equity accounted (Group) 24 — 24 24 — 24 |
Summarised financial information, equity accounted associates and joint ventures | Summarised financial information for the Barclays Bank Group’s equity accounted associates and joint ventures is set out below. The amounts shown are the Barclays Bank Group’s share of the comprehensive income of the investees for the year ended 31 December 2021, with the exception of certain undertakings for which the amounts are based on accounts made up to dates not earlier than three months before the balance sheet date. Associates Joint ventures 2021 2020 2021 2020 £m £m £m £m (Loss)/profit from continuing operations — (1) — 2 Other comprehensive income / (loss) 1 (3) — — Total comprehensive income/(loss) from continuing operations 1 (4) — 2 |
Securitisations (Tables)
Securitisations (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transferred financial assets that are not derecognised in their entirety [abstract] | |
Transfers of financial assets that do not result in derecognition | The following table shows the carrying amount of securitised assets that have not resulted in full derecognition, together with the associated liabilities, for each category of asset on the balance sheet: 2021 2020 Assets Liabilities Assets Liabilities Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value £m £m £m £m £m £m £m £m Barclays Bank Group Loans and advances at amortised cost Credit cards, unsecured loans and other retail lending 1,303 1,423 (1,225) (1,219) 963 1,051 (952) (966) |
Continuing involvement in financial assets that have been derecognised | The table below shows the potential financial implications of such continuing involvement: Continuing involvement a Gain/(loss) from continuing involvement Carrying amount Fair value Maximum exposure to loss For the year ended Cumulative to 31 December Type of transfer £m £m £m £m £m 2021 Asset backed securities 25 25 25 1 2 Residential mortgage backed securities 78 78 78 3 4 Commercial mortgage backed securities 311 307 311 5 11 Total 414 410 414 9 17 2020 Asset backed securities 56 56 56 1 1 Residential mortgage backed securities 49 49 49 1 1 Commercial mortgage backed securities 243 237 243 2 6 Total 348 342 348 4 8 Note a Assets which represent the Barclays Bank Group’s continuing involvement in derecognised assets are recorded in Loans and advances at amortised cost and Debt Securities at FVTP&L. |
Assets pledged, collateral re_2
Assets pledged, collateral received and assets transferred (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Assets pledged, collateral received and assets transferred | |
Assets pledged and assets transferred as security against liabilities | The following table summarises the nature and carrying amount of the assets pledged as security against these liabilities: Barclays Bank Group 2021 2020 £m £m Cash collateral and settlement balances 63,080 69,271 Loans and advances at amortised cost 29,962 25,437 Trading portfolio assets 71,201 76,750 Financial assets at fair value through the income statement 5,595 5,584 Financial assets at fair value through other comprehensive income 14,699 15,303 Assets pledged 184,537 192,345 The following table summarises the transferred financial assets and the associated liabilities: Barclays Bank Group Transferred assets Associated liabilities £m £m At 31 December 2021 Derivatives 64,826 (64,826) Repurchase agreements 48,504 (28,494) Securities lending arrangements 66,703 — Other 4,504 (4,174) 184,537 (97,494) At 31 December 2020 Derivatives 72,732 (72,732) Repurchase agreements 58,398 (39,044) Securities lending arrangements 59,824 — Other 1,391 (1,134) 192,345 (112,910) Carrying value Fair value Transferred assets Associated liabilities Transferred assets Associated liabilities Net position £m £m £m £m £m Barclays Bank Group 2021 Recourse to transferred assets only 1,303 (1,225) 1,423 (1,219) 204 2020 Recourse to transferred assets only 963 (952) 1,051 (966) 85 |
Collateral held as security for assets | Under certain transactions, including reverse repurchase agreements and stock borrowing transactions, the Barclays Bank Group is allowed to resell or re-pledge the collateral held. The fair value at the balance sheet date of collateral accepted and re-pledged to others was as follows: Barclays Bank Group 2021 2020 £m £m Fair value of securities accepted as collateral 934,363 792,317 Of which fair value of securities re-pledged/transferred to others 819,169 684,389 |
Related party transactions an_2
Related party transactions and Directors remuneration (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transactions between related parties [abstract] | |
Amounts included in the Group and Bank financial statements, by category | Amounts included in the Barclays Bank Group’s financial statements, in aggregate, by category of related party entity are as follows: Parent Fellow subsidiaries Associates Pension funds £m £m £m £m For the year ended and as at 31 December 2021 Total income (611) 20 — 3 Operating expenses (64) (3,195) — (1) Total assets 6,491 909 — 3 Total liabilities 32,141 3,962 177 81 For the year ended and as at 31 December 2020 Total income (606) 41 — 3 Operating expenses (62) (2,937) — (1) Total assets 6,803 1,917 — 4 Total liabilities 25,819 3,954 66 69 |
Related party transactions Loans and deposits outstanding | Transactions during the year and the balances outstanding were as follows: Loans outstanding 2021 2020 £m £m As at 1 January — — Loans issued during the year a — — Loan repayments during the year b — — As at 31 December — — Notes a Includes loans issued to existing Key Management Personnel and new or existing loans issued to newly appointed Key Management Personnel. b Includes loan repayments by existing Key Management Personnel and loans to former Key Management Personnel. Deposits outstanding 2021 2020 £m £m As at 1 January 3.4 4.2 Deposits received during the year a 9.0 13.3 Deposits repaid during the year b (10.3) (14.1) As at 31 December 2.1 3.4 Notes a Includes deposits received from existing Key Management Personnel and new or existing deposits received from newly appointed Key Management Personnel. b Includes deposits repaid by existing Key Management Personnel and deposits of former Key Management Personnel. |
Remuneration of Directors and other Key Management Personnel | Figures are provided for the period that individuals met the definition of Key Management Personnel. 2021 2020 £m £m Salaries and other short-term benefits 35.2 37.5 Pension costs 0.2 0.1 Other long-term benefits 8.5 7.2 Share-based payments 13.2 12.4 Employer social security charges on emoluments 6.0 6.0 Costs recognised for accounting purposes 63.1 63.2 Employer social security charges on emoluments (6.0) (6.0) Other long-term benefits – difference between awards granted and costs recognised 3.3 0.4 Share-based payments – difference between awards granted and costs recognised 6.1 1.3 Total remuneration awarded 66.5 58.9 |
Disclosure required by the Companies Act 2006 | The following information regarding the Barclays Bank PLC Board of Directors is presented in accordance with the Companies Act 2006: 2021 2020 £m £m Aggregate emoluments a 6.3 6.4 Amounts paid under LTIPs b 1.2 — 7.5 6.4 Notes a The aggregate emoluments include amounts paid for the 2021 year. In addition, deferred share awards for 2021 with a total value at grant of £1.4m (2020: £0.6m) will be made to Directors which will only vest subject to meeting certain conditions. b The figure above for "Amounts paid under LTIPs" for 2021 relates to LTIP awards that were released to Directors in 2021. This includes the first tranche of the 2017 LTIP, the release of which was delayed from June 2020 to March 2021. Dividend shares released on the awards are excluded (where applicable). Of the figures in the table above, the amounts attributable to the highest paid Director in respect of qualifying services are as follows: 2021 2020 £m £m Aggregate emoluments a 2.1 3.0 Amounts paid under LTIPs 0.7 — 2.8 3.0 Note a The aggregate emoluments include amounts paid for the 2021 year. |
Auditor's remuneration (Tables)
Auditor's remuneration (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Auditor's remuneration [abstract] | |
Auditor's remuneration | Auditor’s remuneration is included within consultancy, legal and professional fees in administration and general expenses and comprises: 2021 2020 2019 £m £m £m Audit of the Barclays Bank Group's annual accounts 19 17 16 Other services: Audit of the Barclays Bank PLC subsidiaries a 14 13 12 Other audit related fees b 7 7 6 Other services 1 1 1 Total Auditor's remuneration 41 38 35 Notes a Comprises the fees for the statutory audit of the subsidiaries both inside and outside UK and fees for the work performed by associates of KPMG in respect of the consolidated financial statements of the Company. b Comprises services in relation to statutory and regulatory filings. These include audit services for the review of the interim financial information under the Listing Rules of the UK listing authority. |
Interest rate benchmark reform
Interest rate benchmark reform (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial instruments by type of interest rate [abstract] | |
Significant hedge accounting exposures impacted by the interest rate benchmark reform | The following table summarises the significant exposures impacted by interest rate benchmark reform: As at 31 December 2021 GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 11,761 15,801 24 222 442 28,250 Reverse repurchase agreements and other similar secured lending — 186 — — — 186 Financial assets at fair value through the income statement 101 8,538 5 327 194 9,165 Financial assets at fair value through other comprehensive income — — — — — — Non-derivative financial assets 11,862 24,525 29 549 636 37,601 Non-derivative financial liabilities Debt securities in issue — — — — — — Subordinated liabilities (36) (3,774) (1,213) — (113) (5,136) Financial liabilities designated at fair value (708) (212) — — — (920) Non-derivative financial liabilities (744) (3,986) (1,213) — (113) (6,056) Equity Other equity instruments — (3,062) — — — (3,062) Standby facilities, credit lines and other commitments a 58,094 42,767 1,284 375 12,973 115,493 As at 31 December 2020 GBP LIBOR USD LIBOR JPY LIBOR CHF LIBOR Others b Total £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 19,317 17,990 173 11 1,725 39,216 Reverse repurchase agreements and other similar secured lending — 334 — — — 334 Financial assets at fair value through the income statement 1,190 6,373 — 283 209 8,055 Financial assets at fair value through other comprehensive income 186 106 — — 8 300 Non-derivative financial assets 20,693 24,803 173 294 1,942 47,905 Non-derivative financial liabilities Debt securities in issue — (1,430) (22) — — (1,452) Subordinated liabilities (21) (876) — — — (897) Financial liabilities designated at fair value (149) (1,273) (759) — (139) (2,320) Non-derivative financial liabilities (170) (3,579) (781) — (139) (4,669) Equity Other equity instruments (2,122) (3,062) — — — (5,184) Standby facilities, credit lines and other commitments a 18,169 74,008 — 74 15,951 108,202 Notes a There has been a change on how exposures for multi currency loan facilities are reported in 2021, from base currency to the currency which needs to be remediated first. This has resulted in an increase in GBP LIBOR and a corresponding reduction in USD LIBOR exposure of £34bn. 2020 comparatives have not been restated to reflect this change. b Includes EUR LIBOR and SOR The following table represents the derivative exposures to interest rate benchmark reform, which have yet to transition: As at 31 December 2021 GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 245,604 2,283,077 7,811 140,357 4,396 61,937 2,743,182 OTC interest rate derivatives - cleared by central counterparty — 2,211,729 — — — 168,649 2,380,378 Exchange traded interest rate derivatives — 466,339 — — — — 466,339 OTC foreign exchange derivatives 183,477 461,680 — 122,823 32,900 1,419 802,299 OTC equity and stock index derivatives — 9,949 — — — — 9,949 Derivative notional contract amount 429,081 5,432,774 7,811 263,180 37,296 232,005 6,402,147 As at 31 December 2020 GBP LIBOR USD LIBOR EONIA JPY LIBOR CHF LIBOR Others a Total £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 596,564 2,832,339 457,844 754,206 25,681 41,782 4,708,416 OTC interest rate derivatives - cleared by central counterparty 1,552,637 2,872,962 623,802 1,091,479 119,382 198,113 6,458,375 Exchange traded interest rate derivatives 300,182 333,705 — — 2,494 — 636,381 OTC foreign exchange derivatives 155,285 589,332 — 93,108 31,257 1,921 870,903 OTC equity and stock index derivatives 1,845 7,946 544 1,929 491 2,141 14,896 Derivative notional contract amount 2,606,513 6,636,284 1,082,190 1,940,722 179,305 243,957 12,688,971 Note a Includes EUR LIBOR, SOR and STIBOR With appropriate fallback clause Without appropriate fallback clause GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m Non-derivative financial assets Loans and advances at amortised cost 7,389 — 210 413 8,012 4,372 24 12 29 4,437 Financial assets at fair value through the income statement 84 5 327 8 424 17 — — 186 203 Non-derivative financial assets 7,473 5 537 421 8,436 4,389 24 12 215 4,640 Non-derivative financial liabilities Subordinated liabilities (36) (1,213) — — (1,249) — — — — — Financial liabilities designated at fair value (708) — — — (708) — — — — — Non-derivative financial liabilities (744) (1,213) — — (1,957) — — — — — Standby facilities, credit lines and other commitments 36,087 657 375 9,436 46,555 22,007 627 — 3,538 26,172 The majority of the remaining exposures without fallbacks in place are either undrawn facilities or syndicated facilities where the transition is led by a third party agent. Work is ongoing with clients and agents to transition facilities or insert fallbacks prior to the next rate reset. There may be some scenarios where synthetic LIBOR is temporarily used whilst Barclays continues to work with the client to remediate their exposures, with little expectation of longer term usage. With appropriate fallback clause Without appropriate fallback clause GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total GBP LIBOR EONIA JPY LIBOR CHF LIBOR EUR LIBOR Total As at 31 December 2021 £m £m £m £m £m £m £m £m £m £m £m £m Derivative notional contract amount OTC interest rate derivatives 234,813 7,568 135,720 4,362 3,626 386,089 10,791 244 4,638 35 403 16,111 OTC foreign exchange derivatives 183,203 — 122,822 32,900 — 338,925 274 — 1 — — 275 Derivative notional contract amount 418,016 7,568 258,542 37,262 3,626 725,014 11,065 244 4,639 35 403 16,386 |
Other disclosures - Risk Mana_3
Other disclosures - Risk Management and Principal Risks - Maximum exposure and effects of collateral and other credit enhancements (audited) (Details) £ in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2021USD ($) | |
Disclosure of detailed information about financial instruments [line items] | |||
Total financial assets | £ 1,049,896 | £ 1,051,400 | $ 132 |
Notional contract amount | 47,412,915 | 42,625,605 | |
Other (outside the UK and US tax groups) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Guarantees, pledges or commitments | 1,700 | 2,600 | |
ECL | |||
Disclosure of detailed information about financial instruments [line items] | |||
Total financial assets | (3,998) | (5,835) | |
Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 1,269,648 | 1,270,491 | |
Netting and set-off | (207,348) | (240,076) | |
Cash collateral | (38,006) | (46,169) | |
Non-cash collateral | (269,266) | (250,759) | |
Risk transfer | (13,973) | (13,934) | |
Net exposure | 741,055 | 719,553 | |
On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 961,451 | 984,537 | |
Netting and set-off | (207,348) | (240,076) | |
Cash collateral | (37,001) | (45,018) | |
Non-cash collateral | (227,795) | (212,654) | |
Risk transfer | (12,090) | (12,173) | |
Net exposure | 477,217 | 474,616 | |
Cash and balances at central banks | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 169,085 | 155,902 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | 0 | 0 | |
Risk transfer | 0 | 0 | |
Net exposure | 169,085 | 155,902 | |
Cash collateral and settlement balances | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 88,085 | 97,616 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | 0 | 0 | |
Risk transfer | 0 | 0 | |
Net exposure | 88,085 | 97,616 | |
Reverse repurchase agreements and other similar secured lending | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 3,177 | 8,981 | |
Netting and set-off | 0 | ||
Cash collateral | 0 | ||
Non-cash collateral | (3,177) | (8,981) | |
Risk transfer | 0 | ||
Net exposure | 0 | 0 | |
Other assets | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 994 | 614 | |
Netting and set-off | 0 | ||
Cash collateral | 0 | ||
Non-cash collateral | 0 | 0 | |
Risk transfer | 0 | ||
Net exposure | 994 | 614 | |
Total off-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 308,197 | 285,954 | |
Netting and set-off | 0 | ||
Cash collateral | (1,005) | (1,151) | |
Non-cash collateral | (41,471) | (38,105) | |
Risk transfer | (1,883) | (1,761) | |
Net exposure | 263,838 | 244,937 | |
Notional contract amount | 39,300 | 30,800 | |
Total off-balance sheet | Contingent liabilities | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 23,746 | 20,932 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (906) | (1,095) | |
Non-cash collateral | (1,367) | (2,135) | |
Risk transfer | (256) | (282) | |
Net exposure | 21,217 | 17,420 | |
Trading portfolio assets | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 63,225 | 64,544 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | (729) | (765) | |
Risk transfer | 0 | 0 | |
Net exposure | 62,496 | 63,779 | |
Financial assets at fair value through the income statement | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 183,428 | 168,019 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (1,428) | (694) | |
Non-cash collateral | (173,033) | (159,577) | |
Risk transfer | 0 | 0 | |
Net exposure | 8,967 | 7,748 | |
Fair value through other comprehensive income | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 45,907 | 51,901 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | (53) | (106) | |
Risk transfer | (931) | (1,065) | |
Net exposure | 44,923 | 50,730 | |
Loans and advances | Financial assets at amortised cost | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 145,259 | 134,267 | |
Netting and set-off | (5,001) | (6,988) | |
Cash collateral | (1,424) | (1,160) | |
Non-cash collateral | (44,999) | (38,569) | |
Risk transfer | (5,421) | (4,699) | |
Net exposure | 88,414 | 82,851 | |
Loans and advances | Financial assets at amortised cost | On-balance sheet | Credit derivatives | Credit-impaired | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 1,664 | 2,650 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (40) | (27) | |
Non-cash collateral | (897) | (1,093) | |
Risk transfer | (25) | (87) | |
Net exposure | 702 | 1,443 | |
Loans and advances | Financial assets at fair value through the income statement | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 35,901 | 27,449 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | (9) | |
Non-cash collateral | (29,485) | (21,819) | |
Risk transfer | 0 | 0 | |
Net exposure | 6,416 | 5,621 | |
Home loans | Financial assets at amortised cost | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 10,985 | 11,193 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (338) | (283) | |
Non-cash collateral | (10,483) | (10,782) | |
Risk transfer | (89) | (85) | |
Net exposure | 75 | 43 | |
Home loans | Financial assets at amortised cost | On-balance sheet | Credit derivatives | Credit-impaired | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 615 | 723 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (11) | (13) | |
Non-cash collateral | (604) | (708) | |
Risk transfer | 0 | 0 | |
Net exposure | 0 | 2 | |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 25,960 | 23,368 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (968) | (827) | |
Non-cash collateral | (4,229) | (3,459) | |
Risk transfer | (252) | (195) | |
Net exposure | 20,511 | 18,887 | |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | On-balance sheet | Credit derivatives | Credit-impaired | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 563 | 600 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (29) | (10) | |
Non-cash collateral | (217) | (218) | |
Risk transfer | (3) | (2) | |
Net exposure | 314 | 370 | |
Wholesale loans | Financial assets at amortised cost | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 108,314 | 99,706 | |
Netting and set-off | (5,001) | (6,988) | |
Cash collateral | (118) | (50) | |
Non-cash collateral | (30,287) | (24,328) | |
Risk transfer | (5,080) | (4,419) | |
Net exposure | 67,828 | 63,921 | |
Wholesale loans | Financial assets at amortised cost | On-balance sheet | Credit derivatives | Credit-impaired | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 486 | 1,327 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | (4) | |
Non-cash collateral | (76) | (167) | |
Risk transfer | (22) | (85) | |
Net exposure | 388 | 1,071 | |
Traded loans | Trading portfolio assets | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 12,525 | 8,348 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | (268) | (374) | |
Risk transfer | 0 | 0 | |
Net exposure | 12,257 | 7,974 | |
Reverse repurchase agreements | Financial assets at fair value through the income statement | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 145,186 | 138,558 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (1,428) | (685) | |
Non-cash collateral | (143,229) | (137,466) | |
Risk transfer | 0 | 0 | |
Net exposure | 529 | 407 | |
Other financial assets measured at cost | Financial assets at fair value through the income statement | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 85 | 315 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | 0 | 0 | |
Risk transfer | 0 | 0 | |
Net exposure | 85 | 315 | |
Derivative financial instruments | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 262,291 | 302,693 | |
Netting and set-off | (202,347) | (233,088) | |
Cash collateral | (34,149) | (43,164) | |
Non-cash collateral | (5,804) | (4,656) | |
Risk transfer | (5,738) | (6,409) | |
Net exposure | 14,253 | 15,376 | |
Financial assets at amortised cost | Total off-balance sheet | ECL | |||
Disclosure of detailed information about financial instruments [line items] | |||
Total financial assets | (499) | (769) | |
Goverment bonds | Financial assets at amortised cost | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Risk transfer | (800) | (900) | |
Total financial assets | 1,000 | 1,200 | |
Debt securities classified as amortised cost | Trading portfolio assets | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 50,700 | 56,196 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | (461) | (391) | |
Risk transfer | 0 | 0 | |
Net exposure | 50,239 | 55,805 | |
Debt securities classified as amortised cost | Financial assets at fair value through the income statement | On-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 2,256 | 1,697 | |
Netting and set-off | 0 | 0 | |
Cash collateral | 0 | 0 | |
Non-cash collateral | (319) | (292) | |
Risk transfer | 0 | 0 | |
Net exposure | 1,937 | 1,405 | |
Total commitments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Notional contract amount | 284,451 | 265,022 | |
Total commitments | Total off-balance sheet | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Maximum exposure | 284,451 | 265,022 | |
Netting and set-off | 0 | 0 | |
Cash collateral | (99) | (56) | |
Non-cash collateral | (40,104) | (35,970) | |
Risk transfer | (1,627) | (1,479) | |
Net exposure | £ 242,621 | £ 227,517 |
Other disclosures - Risk Mana_4
Other disclosures - Risk Management and Principal Risks - Loans and advances at amortised cost by product (audited) (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2020USD ($) | Dec. 31, 2019GBP (£) | |
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 1,049,896 | $ 132 | £ 1,051,400 | |||
Provisions | 1,110 | [1] | 1,208 | |||
Expected credit losses held against contingent liabilities and commitments | ||||||
Disclosure of financial assets [line items] | ||||||
Provisions | 499 | 769 | ||||
ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (3,998) | (5,835) | ||||
Other financial assets subject to impairment | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | 135,500 | 150,300 | £ 125,500 | |||
Other financial assets subject to impairment | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (104) | (145) | (22) | |||
Other financial assets subject to impairment | Stage 1 | Expected credit losses held against contingent liabilities and commitments | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | 4 | 7 | 10 | |||
Other financial assets subject to impairment | Stage 1 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | 135,300 | 146,300 | 124,700 | |||
Other financial assets subject to impairment | Stage 1 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (4) | (7) | ||||
Other financial assets subject to impairment | Stage 1 | ECL | Expected credit losses held against contingent liabilities and commitments | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (7) | (10) | ||||
Other financial assets subject to impairment | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | 65 | 3,800 | 800 | |||
Other financial assets subject to impairment | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | 0 | (6) | ||||
Other assets | Lifetime expected credit losses | Stage 3 | Expected credit losses held against contingent liabilities and commitments | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | 100 | 132 | ||||
Other assets | Lifetime expected credit losses | Stage 3 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | 100 | $ 100 | 132 | $ 132 | 10 | |
Other assets | Lifetime expected credit losses | Stage 3 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (100) | (132) | £ (10) | |||
Financial assets at amortised cost | Loans and advances at amortised cost | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 145,259 | £ 134,267 | ||||
Coverage ratio | 2.40% | 2.40% | 3.60% | 3.60% | ||
Financial assets at amortised cost | Loans and advances at amortised cost | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 148,758 | £ 139,333 | ||||
Financial assets at amortised cost | Loans and advances at amortised cost | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (3,499) | (5,066) | ||||
Financial assets at amortised cost | Loans and advances at amortised cost | Stage 1 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 128,217 | £ 111,119 | ||||
Coverage ratio | 0.60% | 0.60% | 0.60% | 0.60% | ||
Financial assets at amortised cost | Loans and advances at amortised cost | Stage 1 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 129,013 | £ 111,804 | ||||
Financial assets at amortised cost | Loans and advances at amortised cost | Stage 1 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (796) | (685) | ||||
Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 15,378 | £ 20,498 | ||||
Coverage ratio | 6.20% | 6.20% | 8.50% | 8.50% | ||
Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 16,397 | £ 22,410 | ||||
Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (1,019) | (1,912) | ||||
Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 1,664 | £ 2,650 | ||||
Coverage ratio | 50.30% | 50.30% | 48.20% | 48.20% | ||
Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 3,348 | £ 5,119 | ||||
Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (1,684) | (2,469) | ||||
Financial assets at amortised cost | Home loans | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 10,985 | £ 11,193 | ||||
Coverage ratio | 3.40% | 3.40% | 3.70% | 3.70% | ||
Financial assets at amortised cost | Home loans | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 11,371 | £ 11,627 | ||||
Financial assets at amortised cost | Home loans | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (386) | (434) | ||||
Financial assets at amortised cost | Home loans | Stage 1 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 9,752 | £ 9,621 | ||||
Coverage ratio | 0.10% | 0.10% | 0.10% | 0.10% | ||
Financial assets at amortised cost | Home loans | Stage 1 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 9,760 | £ 9,627 | ||||
Financial assets at amortised cost | Home loans | Stage 1 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (8) | (6) | ||||
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 618 | £ 849 | ||||
Coverage ratio | 5.40% | 5.40% | 5.80% | 5.80% | ||
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 653 | £ 901 | ||||
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (35) | (52) | ||||
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 3 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 615 | £ 723 | ||||
Coverage ratio | 35.80% | 35.80% | 34.20% | 34.20% | ||
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 3 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 958 | £ 1,099 | ||||
Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 3 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (343) | (376) | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 25,960 | £ 23,368 | ||||
Coverage ratio | 8.10% | 8.10% | 11.30% | 11.30% | ||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 28,262 | £ 26,347 | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (2,302) | (2,979) | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Stage 1 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 23,406 | £ 18,524 | ||||
Coverage ratio | 2.50% | 2.50% | 2.10% | 2.10% | ||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 24,011 | £ 18,923 | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (605) | (399) | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 1,991 | £ 4,244 | ||||
Coverage ratio | 28.40% | 28.40% | 23.80% | 23.80% | ||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 2,782 | £ 5,571 | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (791) | (1,327) | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 563 | £ 600 | ||||
Coverage ratio | 61.70% | 61.70% | 67.60% | 67.60% | ||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 1,469 | £ 1,853 | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (906) | (1,253) | ||||
Financial assets at amortised cost | Wholesale loans | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 108,314 | £ 99,706 | ||||
Coverage ratio | 0.70% | 0.70% | 1.60% | 1.60% | ||
Financial assets at amortised cost | Wholesale loans | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 109,125 | £ 101,359 | ||||
Financial assets at amortised cost | Wholesale loans | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (811) | (1,653) | ||||
Financial assets at amortised cost | Wholesale loans | Stage 1 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 95,059 | £ 82,974 | ||||
Coverage ratio | 0.20% | 0.20% | 0.30% | 0.30% | ||
Financial assets at amortised cost | Wholesale loans | Stage 1 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 95,242 | £ 83,254 | ||||
Financial assets at amortised cost | Wholesale loans | Stage 1 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (183) | (280) | ||||
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 12,769 | £ 15,405 | ||||
Coverage ratio | 1.50% | 1.50% | 3.30% | 3.30% | ||
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 12,962 | £ 15,938 | ||||
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (193) | (533) | ||||
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 3 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 486 | £ 1,327 | ||||
Coverage ratio | 47.20% | 47.20% | 38.80% | 38.80% | ||
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 3 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 921 | £ 2,167 | ||||
Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 3 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (435) | (840) | ||||
Not past due | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 14,327 | £ 18,325 | ||||
Coverage ratio | 5.90% | 5.90% | 8.10% | 8.10% | ||
Not past due | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 15,225 | £ 19,932 | ||||
Not past due | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (898) | (1,607) | ||||
Not past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 515 | £ 721 | ||||
Coverage ratio | 6.00% | 6.00% | 5.30% | 5.30% | ||
Not past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 548 | £ 761 | ||||
Not past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (33) | (40) | ||||
Not past due | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 1,725 | £ 3,895 | ||||
Coverage ratio | 28.20% | 28.20% | 21.90% | 21.90% | ||
Not past due | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 2,402 | £ 4,987 | ||||
Not past due | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (677) | (1,092) | ||||
Not past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 12,087 | £ 13,709 | ||||
Coverage ratio | 1.50% | 1.50% | 3.30% | 3.30% | ||
Not past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 12,275 | £ 14,184 | ||||
Not past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (188) | (475) | ||||
Not later than one month | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 478 | £ 1,346 | ||||
Coverage ratio | 8.30% | 8.30% | 11.00% | 11.00% | ||
Not later than one month | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 521 | £ 1,512 | ||||
Not later than one month | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (43) | (166) | ||||
Not later than one month | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 21 | £ 47 | ||||
Coverage ratio | 4.50% | 4.50% | 11.30% | 11.30% | ||
Not later than one month | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 22 | £ 53 | ||||
Not later than one month | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (1) | (6) | ||||
Not later than one month | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 159 | £ 282 | ||||
Coverage ratio | 19.70% | 19.70% | 28.20% | 28.20% | ||
Not later than one month | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 198 | £ 393 | ||||
Not later than one month | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (39) | (111) | ||||
Not later than one month | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 298 | £ 1,017 | ||||
Coverage ratio | 1.00% | 1.00% | 4.60% | 4.60% | ||
Not later than one month | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 301 | £ 1,066 | ||||
Not later than one month | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (3) | (49) | ||||
Greater than 30 days past due | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 573 | £ 827 | ||||
Coverage ratio | 12.00% | 12.00% | 14.40% | 14.40% | ||
Greater than 30 days past due | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 651 | £ 966 | ||||
Greater than 30 days past due | Financial assets at amortised cost | Loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (78) | (139) | ||||
Greater than 30 days past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 82 | £ 81 | ||||
Coverage ratio | 1.20% | 1.20% | 6.90% | 6.90% | ||
Greater than 30 days past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 83 | £ 87 | ||||
Greater than 30 days past due | Financial assets at amortised cost | Home loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (1) | (6) | ||||
Greater than 30 days past due | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 107 | £ 67 | ||||
Coverage ratio | 41.20% | 41.20% | 64.90% | 64.90% | ||
Greater than 30 days past due | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 182 | £ 191 | ||||
Greater than 30 days past due | Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | (75) | (124) | ||||
Greater than 30 days past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 384 | £ 679 | ||||
Coverage ratio | 0.50% | 0.50% | 1.30% | 1.30% | ||
Greater than 30 days past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | Gross | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ 386 | £ 688 | ||||
Greater than 30 days past due | Financial assets at amortised cost | Wholesale loans | Lifetime expected credit losses | Stage 2 | ECL | ||||||
Disclosure of financial assets [line items] | ||||||
Total financial assets | £ (2) | £ (9) | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Other disclosures - Risk Mana_5
Other disclosures - Risk Management and Principal Risks -Movement in gross exposures and impairment allowance including reconciliation of ECL (audited) (Details) £ in Millions, $ in Millions | 12 Months Ended | |||||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | ||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Recoveries and reimbursements | £ 259 | £ (368) | £ (73) | |||
Exchange and other adjustments | 70 | 267 | ||||
Income statement charge for the year | (277) | [1] | 3,377 | 1,202 | ||
Total financial assets | 1,049,896 | 1,051,400 | $ 132 | |||
Gain on recovery of loans and advances previously written off | 31 | 4 | ||||
Provision for undrawn contractually committed facilities and guarantees provided | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Income statement charge for the year | (257) | 547 | 55 | |||
Financial guarantee contracts | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Recoveries and reimbursements | (364) | |||||
Gain on recovery of loans and advances previously written off | 4 | |||||
Financial guarantee contracts | Third parties | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Income statement charge for the year | 290 | 364 | ||||
Loans and advances at amortised cost | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 5,835 | |||||
Closing/Ending balance | 3,998 | 5,835 | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
ECL movement excluding assets derecognised due to disposals and write-offs | (334) | 2,793 | ||||
Income statement charge for the year | (262) | 3,239 | 1,196 | |||
Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 434 | |||||
Closing/Ending balance | 386 | 434 | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
ECL movement excluding assets derecognised due to disposals and write-offs | (30) | 103 | ||||
Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 3,069 | |||||
Closing/Ending balance | 2,391 | 3,069 | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
ECL movement excluding assets derecognised due to disposals and write-offs | 171 | 1,484 | ||||
Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 2,332 | |||||
Closing/Ending balance | 1,221 | 2,332 | ||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
ECL movement excluding assets derecognised due to disposals and write-offs | (475) | 1,206 | ||||
Provision for undrawn contractually committed facilities and guarantees provided | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Income statement charge for the year | (257) | 547 | ||||
Other financial assets subject to impairment | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Income statement charge for the year | (15) | 138 | ||||
Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 11,627 | 11,334 | ||||
Business activity in the year | 1,745 | 1,194 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (837) | 103 | ||||
Final repayments | (1,146) | (987) | ||||
Disposals | 0 | |||||
Write-offs | (18) | (17) | ||||
Closing/Ending balance | 11,371 | 11,627 | 11,334 | |||
Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 26,347 | 36,120 | ||||
Business activity in the year | 4,853 | 3,626 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (101) | (5,806) | ||||
Final repayments | (1,974) | (2,468) | ||||
Disposals | (37) | 1,768 | ||||
Write-offs | (826) | (1,036) | ||||
Closing/Ending balance | 28,262 | 26,347 | 36,120 | |||
Gross | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (2,321) | |||||
Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 101,359 | 97,878 | ||||
Business activity in the year | 29,657 | 22,120 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 3,438 | 10,007 | ||||
Final repayments | (24,307) | (27,225) | ||||
Disposals | (708) | (10) | ||||
Write-offs | (314) | (284) | ||||
Closing/Ending balance | 109,125 | 101,359 | 97,878 | |||
Gross | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (1,127) | |||||
Gross | Other financial assets subject to impairment | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 135,500 | 150,300 | 125,500 | |||
ECL | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (3,998) | (5,835) | ||||
ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 434 | 348 | ||||
Business activity in the year | 2 | 1 | ||||
Changes to models used for calculation | 34 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (61) | 104 | ||||
Final repayments | 5 | 2 | ||||
Disposals | 0 | |||||
Write-offs | 18 | 17 | ||||
Closing/Ending balance | 386 | 434 | 348 | |||
ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 2,979 | 2,617 | ||||
Business activity in the year | 112 | 74 | ||||
Changes to models used for calculation | (30) | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 124 | 1,552 | ||||
Final repayments | 35 | 60 | ||||
Disposals | 22 | 86 | ||||
Write-offs | 826 | 1,036 | ||||
Closing/Ending balance | 2,302 | 2,979 | 2,617 | |||
ECL | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (82) | |||||
ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,653 | 731 | ||||
Business activity in the year | 112 | 255 | ||||
Changes to models used for calculation | 3 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (268) | 1,089 | ||||
Final repayments | 322 | 109 | ||||
Disposals | 53 | 0 | ||||
Write-offs | 314 | 284 | ||||
Closing/Ending balance | 811 | 1,653 | 731 | |||
ECL | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (29) | |||||
ECL | Other financial assets subject to impairment | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (104) | (145) | (22) | |||
Stage 1 | Other financial assets subject to impairment | Expected credit losses held against contingent liabilities and commitments | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 4 | 7 | 10 | |||
Stage 1 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 9,627 | 9,604 | ||||
Business activity in the year | 1,745 | 1,193 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (742) | 133 | ||||
Final repayments | (890) | (842) | ||||
Disposals | 0 | |||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 9,760 | 9,627 | 9,604 | |||
Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 18,923 | 29,541 | ||||
Business activity in the year | 4,731 | 3,467 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 509 | (4,613) | ||||
Final repayments | (1,489) | (2,232) | ||||
Disposals | 0 | 1,493 | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 24,011 | 18,923 | 29,541 | |||
Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (2,182) | |||||
Stage 1 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 83,254 | 89,200 | ||||
Business activity in the year | 27,946 | 19,773 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 2,448 | 7,033 | ||||
Final repayments | (19,481) | (24,098) | ||||
Disposals | (588) | 0 | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 95,242 | 83,254 | 89,200 | |||
Stage 1 | Gross | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (509) | |||||
Stage 1 | Gross | Other financial assets subject to impairment | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 135,300 | 146,300 | 124,700 | |||
Stage 1 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 6 | 16 | ||||
Business activity in the year | 2 | 1 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (22) | (17) | ||||
Final repayments | 0 | 0 | ||||
Disposals | 0 | |||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 8 | 6 | 16 | |||
Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 399 | 362 | ||||
Business activity in the year | 84 | 35 | ||||
Changes to models used for calculation | (3) | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (360) | 15 | ||||
Final repayments | 14 | 29 | ||||
Disposals | 0 | 8 | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 605 | 399 | 362 | |||
Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (16) | |||||
Stage 1 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 280 | 114 | ||||
Business activity in the year | 74 | 44 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (301) | 154 | ||||
Final repayments | 29 | 22 | ||||
Disposals | 8 | 0 | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 183 | 280 | 114 | |||
Stage 1 | ECL | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (1) | |||||
Stage 1 | ECL | Other financial assets subject to impairment | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (4) | (7) | ||||
Stage 1 | ECL | Other financial assets subject to impairment | Expected credit losses held against contingent liabilities and commitments | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (7) | (10) | ||||
Lifetime expected credit losses | Stage 2 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 901 | 674 | ||||
Business activity in the year | 0 | 0 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (25) | (62) | ||||
Final repayments | (142) | (47) | ||||
Disposals | 0 | |||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 653 | 901 | 674 | |||
Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 5,571 | 4,450 | ||||
Business activity in the year | 106 | 130 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (514) | (1,231) | ||||
Final repayments | (409) | (168) | ||||
Disposals | 0 | 183 | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 2,782 | 5,571 | 4,450 | |||
Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (92) | |||||
Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 15,938 | 7,515 | ||||
Business activity in the year | 1,674 | 1,954 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 1,072 | 2,969 | ||||
Final repayments | (4,322) | (2,844) | ||||
Disposals | (49) | (10) | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 12,962 | 15,938 | 7,515 | |||
Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (600) | |||||
Lifetime expected credit losses | Stage 2 | Gross | Other financial assets subject to impairment | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 65 | 3,800 | 800 | |||
Lifetime expected credit losses | Stage 2 | Gross | Fair value through other comprehensive income | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 100 | 132 | ||||
Lifetime expected credit losses | Stage 2 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 52 | 40 | ||||
Business activity in the year | 0 | 0 | ||||
Changes to models used for calculation | (4) | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 11 | 25 | ||||
Final repayments | 1 | 1 | ||||
Disposals | 0 | |||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 35 | 52 | 40 | |||
Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,327 | 784 | ||||
Business activity in the year | 23 | 32 | ||||
Changes to models used for calculation | (27) | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 147 | 806 | ||||
Final repayments | 16 | 23 | ||||
Disposals | 0 | 20 | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 791 | 1,327 | 784 | |||
Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (25) | |||||
Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 533 | 234 | ||||
Business activity in the year | 15 | 144 | ||||
Changes to models used for calculation | 3 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (14) | 248 | ||||
Final repayments | 168 | 28 | ||||
Disposals | 4 | 0 | ||||
Write-offs | 0 | 0 | ||||
Closing/Ending balance | 193 | 533 | 234 | |||
Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (22) | |||||
Lifetime expected credit losses | Stage 2 | ECL | Other financial assets subject to impairment | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 0 | (6) | ||||
Lifetime expected credit losses | Stage 2 | ECL | Fair value through other comprehensive income | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (6) | (2) | ||||
Lifetime expected credit losses | Stage 3 | Other assets | Expected credit losses held against contingent liabilities and commitments | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 100 | 132 | ||||
Lifetime expected credit losses | Stage 3 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,099 | 1,056 | ||||
Business activity in the year | 0 | 1 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (70) | 32 | ||||
Final repayments | (114) | (98) | ||||
Disposals | 0 | |||||
Write-offs | (18) | (17) | ||||
Closing/Ending balance | 958 | 1,099 | 1,056 | |||
Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,853 | 2,129 | ||||
Business activity in the year | 16 | 29 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (96) | 38 | ||||
Final repayments | (76) | (68) | ||||
Disposals | (37) | 92 | ||||
Write-offs | (826) | (1,036) | ||||
Closing/Ending balance | 1,469 | 1,853 | 2,129 | |||
Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (47) | |||||
Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 2,167 | 1,163 | ||||
Business activity in the year | 37 | 393 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (82) | 5 | ||||
Final repayments | (504) | (283) | ||||
Disposals | (71) | 0 | ||||
Write-offs | (314) | (284) | ||||
Closing/Ending balance | 921 | 2,167 | 1,163 | |||
Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (18) | |||||
Lifetime expected credit losses | Stage 3 | Gross | Other assets | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 100 | 132 | 10 | $ 100 | $ 132 | |
Lifetime expected credit losses | Stage 3 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 376 | 292 | ||||
Business activity in the year | 0 | 0 | ||||
Changes to models used for calculation | 38 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | (50) | 96 | ||||
Final repayments | 4 | 1 | ||||
Disposals | 0 | |||||
Write-offs | 18 | 17 | ||||
Closing/Ending balance | 343 | 376 | 292 | |||
Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,253 | 1,471 | ||||
Business activity in the year | 5 | 7 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 337 | 731 | ||||
Final repayments | 5 | 8 | ||||
Disposals | 22 | 58 | ||||
Write-offs | 826 | 1,036 | ||||
Closing/Ending balance | 906 | 1,253 | 1,471 | |||
Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (41) | |||||
Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 840 | 383 | ||||
Business activity in the year | 23 | 67 | ||||
Changes to models used for calculation | 0 | 0 | ||||
Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes | 47 | 687 | ||||
Final repayments | 125 | 59 | ||||
Disposals | 41 | 0 | ||||
Write-offs | 314 | 284 | ||||
Closing/Ending balance | 435 | 840 | 383 | |||
Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | Fellow subsidiaries | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (6) | |||||
Lifetime expected credit losses | Stage 3 | ECL | Other assets | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (100) | (132) | (10) | |||
Financial assets at amortised cost | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 145,259 | 134,267 | ||||
Financial assets at amortised cost | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 10,985 | 11,193 | ||||
Financial assets at amortised cost | Credit cards, unsecured loans and other retail lending | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 25,960 | 23,368 | ||||
Financial assets at amortised cost | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 108,314 | 99,706 | ||||
Financial assets at amortised cost | Gross | Loans and advances at amortised cost | ||||||
Loans and advances at amortised cost | ||||||
Write-offs | (1,158) | (1,337) | (1,293) | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 148,758 | 139,333 | ||||
Gain on recovery of loans and advances previously written off | 31 | 4 | 73 | |||
Net write-offs | 1,127 | 1,333 | £ 1,220 | |||
Financial assets at amortised cost | Gross | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 11,371 | 11,627 | ||||
Financial assets at amortised cost | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 26,347 | |||||
Final repayments | (37) | |||||
Disposals | (708) | |||||
Closing/Ending balance | 26,347 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 28,262 | 26,347 | ||||
Financial assets at amortised cost | Gross | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 109,125 | 101,359 | ||||
Financial assets at amortised cost | ECL | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (3,499) | (5,066) | ||||
Financial assets at amortised cost | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Changes to models used for calculation | 34 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (386) | (434) | ||||
Financial assets at amortised cost | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 2,979 | |||||
Changes to models used for calculation | (30) | |||||
Closing/Ending balance | 2,979 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (2,302) | (2,979) | ||||
Financial assets at amortised cost | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Changes to models used for calculation | (3) | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (811) | (1,653) | ||||
Financial assets at amortised cost | ECL | Provision for undrawn contractually committed facilities and guarantees provided | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (499) | (769) | ||||
Financial assets at amortised cost | Stage 1 | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 128,217 | 111,119 | ||||
Financial assets at amortised cost | Stage 1 | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 9,752 | 9,621 | ||||
Financial assets at amortised cost | Stage 1 | Credit cards, unsecured loans and other retail lending | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 23,406 | 18,524 | ||||
Financial assets at amortised cost | Stage 1 | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 95,059 | 82,974 | ||||
Financial assets at amortised cost | Stage 1 | Gross | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 129,013 | 111,804 | ||||
Financial assets at amortised cost | Stage 1 | Gross | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 9,760 | 9,627 | ||||
Financial assets at amortised cost | Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 18,923 | |||||
Closing/Ending balance | 18,923 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 24,011 | 18,923 | ||||
Financial assets at amortised cost | Stage 1 | Gross | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 95,242 | 83,254 | ||||
Financial assets at amortised cost | Stage 1 | ECL | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (796) | (685) | ||||
Financial assets at amortised cost | Stage 1 | ECL | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (8) | (6) | ||||
Financial assets at amortised cost | Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 399 | |||||
Closing/Ending balance | 399 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (605) | (399) | ||||
Financial assets at amortised cost | Stage 1 | ECL | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (183) | (280) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 15,378 | 20,498 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 618 | 849 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Credit cards, unsecured loans and other retail lending | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 1,991 | 4,244 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 12,769 | 15,405 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 16,397 | 22,410 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 653 | 901 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 5,571 | |||||
Closing/Ending balance | 5,571 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 2,782 | 5,571 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 12,962 | 15,938 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (1,019) | (1,912) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (35) | (52) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,327 | |||||
Closing/Ending balance | 1,327 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (791) | (1,327) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (193) | (533) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 1,664 | 2,650 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 615 | 723 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Credit cards, unsecured loans and other retail lending | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 563 | 600 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 486 | 1,327 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Gross | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 3,348 | 5,119 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Gross | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 958 | 1,099 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,853 | |||||
Closing/Ending balance | 1,853 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 1,469 | 1,853 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | 921 | 2,167 | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Loans and advances at amortised cost | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (1,684) | (2,469) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Home loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (343) | (376) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Opening/Beginning balance | 1,253 | |||||
Closing/Ending balance | 1,253 | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (906) | (1,253) | ||||
Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | ||||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | ||||||
Total financial assets | (435) | (840) | ||||
Transfers from Stage 1 to Stage 2 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Stage 1 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (253) | (537) | ||||
Transfers from Stage 1 to Stage 2 | Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (897) | (4,116) | ||||
Transfers from Stage 1 to Stage 2 | Stage 1 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (4,122) | (10,213) | ||||
Transfers from Stage 1 to Stage 2 | Stage 1 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | (1) | ||||
Transfers from Stage 1 to Stage 2 | Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (41) | (92) | ||||
Transfers from Stage 1 to Stage 2 | Stage 1 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (14) | (31) | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 253 | 537 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 897 | 4,116 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 4,122 | 10,213 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 1 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 41 | 92 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 14 | 31 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 1 to Stage 2 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Stage 1 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 331 | 204 | ||||
Transfers from Stage 2 to Stage 1 | Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 2,520 | 994 | ||||
Transfers from Stage 2 to Stage 1 | Stage 1 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 5,454 | 2,651 | ||||
Transfers from Stage 2 to Stage 1 | Stage 1 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 22 | 7 | ||||
Transfers from Stage 2 to Stage 1 | Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 548 | 139 | ||||
Transfers from Stage 2 to Stage 1 | Stage 1 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 179 | 25 | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (331) | (204) | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (2,520) | (994) | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (5,454) | (2,651) | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (22) | (7) | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (548) | (139) | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (179) | (25) | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 2 to Stage 1 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | Stage 1 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (80) | (157) | ||||
Transfers to Stage 3 | Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (307) | (464) | ||||
Transfers to Stage 3 | Stage 1 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (32) | (772) | ||||
Transfers to Stage 3 | Stage 1 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers to Stage 3 | Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (13) | (19) | ||||
Transfers to Stage 3 | Stage 1 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (1) | (3) | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (52) | (52) | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (362) | (516) | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (164) | (642) | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (5) | (7) | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (165) | (188) | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (12) | (50) | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 132 | 209 | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 669 | 980 | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 196 | 1,414 | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 5 | 7 | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 178 | 207 | ||||
Transfers to Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 13 | 53 | ||||
Transfers from Stage 3 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 3 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 3 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 3 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 3 | Stage 1 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 22 | 29 | ||||
Transfers from Stage 3 | Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 21 | 21 | ||||
Transfers from Stage 3 | Stage 1 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 363 | 189 | ||||
Transfers from Stage 3 | Stage 1 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 0 | 0 | ||||
Transfers from Stage 3 | Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 5 | 12 | ||||
Transfers from Stage 3 | Stage 1 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 3 | 0 | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 49 | 55 | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 13 | 59 | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 145 | 34 | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 4 | 1 | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 9 | 8 | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | 5 | 1 | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | Gross | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (71) | (84) | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (34) | (80) | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (508) | (223) | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Home loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (4) | (1) | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | ||||||
Loans and advances at amortised cost | ||||||
Transfers | (14) | (20) | ||||
Transfers from Stage 3 | Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | ||||||
Loans and advances at amortised cost | ||||||
Transfers | £ (8) | £ (1) | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Other disclosures - Risk Mana_6
Other disclosures - Risk Management and Principal Risks - Gross exposure and impairment allowance for loan commitment and financial guarantees (audited) (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Other (outside the UK and US tax groups) | |||
Loan commitments and financial guarantee contracts | |||
Guarantees, pledges or commitments | £ 1,700 | £ 2,600 | |
Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Limit management and final repayments | 0 | 0 | £ 0 |
Gross | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Net transfers between stages | 0 | 0 | |
Gross | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 131 | 34 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 19 | 113 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) | 5 | |
Limit management and final repayments | (92) | (21) | |
Closing/Ending balance | 54 | 131 | 34 |
Gross | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 74,485 | 80,377 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 11,040 | 4,720 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 3,860 | 1,994 | |
Limit management and final repayments | (7,484) | (12,606) | |
Closing/Ending balance | 81,901 | 74,485 | 80,377 |
Gross | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 201,861 | 195,690 | |
Business activity in the year | 50,062 | 48,383 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 11,092 | 12,457 | |
Limit management and final repayments | (55,575) | (54,669) | |
Closing/Ending balance | 207,440 | 201,861 | 195,690 |
ECL | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Net transfers between stages | 0 | 0 | |
ECL | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
ECL | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 90 | 51 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 4 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) | 40 | |
Limit management and final repayments | 0 | 5 | |
Closing/Ending balance | 89 | 90 | 51 |
ECL | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 679 | 201 | |
Business activity in the year | 116 | 136 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (233) | 365 | |
Limit management and final repayments | 152 | 23 | |
Closing/Ending balance | 410 | 679 | 201 |
Stage 1 | Gross | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 125 | 34 | |
Net transfers between stages | 0 | (4) | |
Business activity in the year | 19 | 113 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) | 1 | |
Limit management and final repayments | (87) | (19) | |
Closing/Ending balance | 53 | 125 | 34 |
Stage 1 | Gross | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 68,211 | 78,257 | |
Net transfers between stages | 2,992 | (4,124) | |
Business activity in the year | 10,628 | 4,591 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 3,712 | 1,471 | |
Limit management and final repayments | (6,888) | (11,984) | |
Closing/Ending balance | 78,655 | 68,211 | 78,257 |
Stage 1 | Gross | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 160,404 | 183,001 | |
Net transfers between stages | 7,801 | (28,048) | |
Business activity in the year | 45,395 | 42,904 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 10,551 | 12,755 | |
Limit management and final repayments | (46,145) | (50,208) | |
Closing/Ending balance | 178,006 | 160,404 | 183,001 |
Stage 1 | ECL | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
Stage 1 | ECL | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 34 | 22 | |
Net transfers between stages | (4) | 6 | |
Business activity in the year | 0 | 2 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 6 | 5 | |
Limit management and final repayments | 0 | 1 | |
Closing/Ending balance | 36 | 34 | 22 |
Stage 1 | ECL | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 205 | 63 | |
Net transfers between stages | 220 | 67 | |
Business activity in the year | 14 | 32 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (232) | 50 | |
Limit management and final repayments | 40 | 7 | |
Closing/Ending balance | 167 | 205 | 63 |
Lifetime expected credit losses | Stage 2 | Gross | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 2 | 0 | |
Net transfers between stages | 0 | 4 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | (2) | (2) | |
Closing/Ending balance | 0 | 2 | 0 |
Lifetime expected credit losses | Stage 2 | Gross | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 6,244 | 2,053 | |
Net transfers between stages | (3,431) | 3,603 | |
Business activity in the year | 410 | 128 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 585 | 1,076 | |
Limit management and final repayments | (594) | (616) | |
Closing/Ending balance | 3,214 | 6,244 | 2,053 |
Lifetime expected credit losses | Stage 2 | Gross | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 39,426 | 12,053 | |
Net transfers between stages | (6,730) | 27,052 | |
Business activity in the year | 4,658 | 4,705 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | (219) | |
Limit management and final repayments | (8,939) | (4,165) | |
Closing/Ending balance | 28,417 | 39,426 | 12,053 |
Lifetime expected credit losses | Stage 2 | ECL | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
Lifetime expected credit losses | Stage 2 | ECL | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 33 | 15 | |
Net transfers between stages | (2) | (2) | |
Business activity in the year | 0 | 1 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | 20 | |
Limit management and final repayments | 0 | 1 | |
Closing/Ending balance | 33 | 33 | 15 |
Lifetime expected credit losses | Stage 2 | ECL | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 446 | 97 | |
Net transfers between stages | (214) | (72) | |
Business activity in the year | 102 | 102 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 12 | 334 | |
Limit management and final repayments | 105 | 15 | |
Closing/Ending balance | 241 | 446 | 97 |
Lifetime expected credit losses | Stage 3 | Gross | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 4 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 4 | |
Limit management and final repayments | (3) | 0 | |
Closing/Ending balance | 1 | 4 | 0 |
Lifetime expected credit losses | Stage 3 | Gross | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 30 | 67 | |
Net transfers between stages | 439 | 521 | |
Business activity in the year | 2 | 1 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (437) | (553) | |
Limit management and final repayments | (2) | (6) | |
Closing/Ending balance | 32 | 30 | 67 |
Lifetime expected credit losses | Stage 3 | Gross | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 2,031 | 636 | |
Net transfers between stages | (1,071) | 996 | |
Business activity in the year | 9 | 774 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 539 | (79) | |
Limit management and final repayments | (491) | (296) | |
Closing/Ending balance | 1,017 | 2,031 | 636 |
Lifetime expected credit losses | Stage 3 | ECL | Home loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 0 | 0 | |
Net transfers between stages | 0 | 0 | |
Business activity in the year | 0 | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | 0 | |
Limit management and final repayments | 0 | 0 | |
Closing/Ending balance | 0 | 0 | 0 |
Lifetime expected credit losses | Stage 3 | ECL | Credit cards, unsecured loans and other retail lending | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 23 | 14 | |
Net transfers between stages | 6 | (4) | |
Business activity in the year | 0 | 1 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (9) | 15 | |
Limit management and final repayments | 0 | 3 | |
Closing/Ending balance | 20 | 23 | 14 |
Lifetime expected credit losses | Stage 3 | ECL | Wholesale loans | Provision for undrawn contractually committed facilities and guarantees provided | |||
Loan commitments and financial guarantee contracts | |||
Opening/Beginning balance | 28 | 41 | |
Net transfers between stages | (6) | 5 | |
Business activity in the year | 0 | 2 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (13) | (19) | |
Limit management and final repayments | 7 | 1 | |
Closing/Ending balance | £ 2 | £ 28 | £ 41 |
Other disclosures - Risk Mana_7
Other disclosures - Risk Management and Principal Risks - Management adjustments to models for impairment (audited) (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,049,896 | $ 132 | £ 1,051,400 | |
ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (3,998) | (5,835) | ||
Total model ECL | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,318) | (3,875) | ||
ECL from individually assessed impairments | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (463) | (835) | ||
ECL from non-modelled exposures | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (200) | (200) | ||
Loans and advances at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ 1,142 | £ 936 | ||
Proportion of total impairment allowances | 28.60% | 28.60% | 16.00% | |
Impairment allowance pre management adjustments | £ 2,856 | £ 4,899 | ||
Impairment allowance | 3,998 | 5,835 | ||
Loans and advances at amortised cost | Economic uncertainty adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | 1,049 | 1,386 | ||
Loans and advances at amortised cost | Other adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | 93 | (450) | ||
Loans and advances at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | (2,200) | (3,900) | ||
Impairment allowance | 100 | |||
Loans and advances at amortised cost | ECL from individually assessed impairments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | (500) | (800) | ||
Home loans | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ 34 | £ 54 | ||
Proportion of total impairment allowances | 8.80% | 8.80% | 12.40% | |
Impairment allowance pre management adjustments | £ 352 | £ 380 | ||
Impairment allowance | 386 | 434 | ||
Home loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Impairment allowance | 386 | 434 | £ 348 | |
Home loans | Economic uncertainty adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | 34 | 21 | ||
Home loans | Other adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | 0 | 33 | ||
Credit cards, unsecured loans and other retail lending | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ 966 | £ 960 | ||
Proportion of total impairment allowances | 40.40% | 40.40% | 31.30% | |
Impairment allowance pre management adjustments | £ 1,425 | £ 2,109 | ||
Impairment allowance | 2,391 | 3,069 | ||
Credit cards, unsecured loans and other retail lending | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Impairment allowance | 2,302 | 2,979 | 2,617 | |
Credit cards, unsecured loans and other retail lending | Economic uncertainty adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | 771 | 986 | ||
Credit cards, unsecured loans and other retail lending | Other adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | 195 | (26) | ||
Wholesale loans | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ 142 | £ (78) | ||
Proportion of total impairment allowances | 11.60% | 11.60% | (3.30%) | |
Impairment allowance pre management adjustments | £ 1,079 | £ 2,410 | ||
Impairment allowance | 1,221 | 2,332 | ||
Wholesale loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Impairment allowance | 811 | 1,653 | £ 731 | |
Wholesale loans | Economic uncertainty adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | 244 | 379 | ||
Wholesale loans | Other adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ (102) | £ (457) |
Other disclosures - Risk Mana_8
Other disclosures - Risk Management and Principal Risks - Economic uncertainty adjustments (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)method | Dec. 31, 2020GBP (£) | |
Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 3,998 | £ 5,835 |
ECL movement excluding assets derecognised due to disposals and write-offs | (334) | 2,793 |
Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 2,391 | 3,069 |
ECL movement excluding assets derecognised due to disposals and write-offs | 171 | 1,484 |
Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 1,221 | 2,332 |
ECL movement excluding assets derecognised due to disposals and write-offs | £ (475) | 1,206 |
Covid-19 related adjustments | ||
Disclosure of financial assets [line items] | ||
Number of uncertainty adjustment methods | method | 2 | |
Allowance account for credit losses of financial assets | £ 1,000 | 1,400 |
Covid-19 related adjustments | Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 800 | 1,000 |
Covid-19 related adjustments | Credit cards, unsecured loans and other retail lending | United States | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 600 | 800 |
Covid-19 related adjustments | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 200 | 200 |
Covid-19 related adjustments | Model uncertainty risk | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 100 | 300 |
ECL movement excluding assets derecognised due to disposals and write-offs | 200 | |
Covid-19 related adjustments | Customers | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 900 | 1,100 |
Covid-19 related adjustments | Customers | Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 100 | £ 100 |
Other disclosures - Risk Mana_9
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty, narrative (Details) £ in Billions | 12 Months Ended | |
Dec. 31, 2021GBP (£)economic_scenarioeconomicVariable | Dec. 31, 2020GBP (£) | |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios, percentage | 100.00% | |
Covid-19 related adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 1 | £ 1.4 |
Covid-19 related adjustments | Customers | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 0.9 | 1.1 |
Credit derivatives | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 5 | |
Number of economic variables | economicVariable | 8 | |
Stress horizon period, ECL | 5 years | |
Term at which scenario converges to steady state | 8 years | |
Credit derivatives | Downside scenario | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 2 | |
Credit derivatives | Upside scenario | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 2 | |
Baseline | UNITED KINGDOM | Later than one month and not later than three months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 5.00% | |
Downside 2 | UNITED KINGDOM | Not more than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Bank rate | 4.00% | |
Downside 2 | UNITED KINGDOM | Over six months but not more than nine months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.20% | |
Downside 2 | United States | Not more than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Average rate paid for federal funds | 3.50% | |
Downside 2 | United States | Over six months but not more than nine months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.50% | |
Model uncertainty risk | Covid-19 related adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 0.1 | £ 0.3 |
Other disclosures - Risk Man_10
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty and sensitivity analysis - Scenario probability weighting and Macroeconomic variables used in calculation of ECL (audited) (Details) | Dec. 31, 2021 | Dec. 31, 2020 |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 30.10% | 24.70% |
Baseline | GDP | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Baseline | GDP | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 6.30% |
Baseline | GDP | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 3.30% |
Baseline | GDP | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.60% |
Baseline | GDP | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 2.00% |
Baseline | GDP | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Baseline | GDP | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.90% |
Baseline | GDP | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 3.10% |
Baseline | GDP | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.90% |
Baseline | GDP | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.90% |
Baseline | GDP | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 0.70% |
Baseline | GDP | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 1.60% |
Baseline | GDP | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 0.70% |
Baseline | GDP | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 1.60% |
Baseline | Unemployment | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Baseline | Unemployment | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.70% |
Baseline | Unemployment | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.40% |
Baseline | Unemployment | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 5.80% |
Baseline | Unemployment | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 5.10% |
Baseline | Unemployment | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Baseline | Unemployment | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 6.90% |
Baseline | Unemployment | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.70% |
Baseline | Unemployment | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.60% |
Baseline | Unemployment | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.60% |
Baseline | Unemployment | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 5.70% |
Baseline | Unemployment | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 6.40% |
Baseline | Unemployment | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 5.70% |
Baseline | Unemployment | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 6.40% |
Baseline | HPI | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Baseline | HPI | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 2.40% |
Baseline | HPI | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.30% |
Baseline | HPI | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 5.00% |
Baseline | HPI | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 2.40% |
Baseline | HPI | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Baseline | HPI | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 2.80% |
Baseline | HPI | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 4.70% |
Baseline | HPI | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 4.70% |
Baseline | HPI | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.00% | 4.70% |
Baseline | HPI | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.60% |
Baseline | HPI | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 3.80% |
Baseline | HPI | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.60% |
Baseline | HPI | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 3.80% |
Baseline | UK bank rate | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Baseline | UK bank rate | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.00% |
Baseline | UK bank rate | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | (0.10%) |
Baseline | UK bank rate | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 0.00% |
Baseline | UK bank rate | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Baseline | UK bank rate | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.70% | 0.00% |
Baseline | UK bank rate | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.70% | 0.00% |
Baseline | US federal funds rate | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Baseline | US federal funds rate | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Baseline | US federal funds rate | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.90% | 0.30% |
Baseline | US federal funds rate | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.20% | 0.30% |
Baseline | US federal funds rate | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.40% |
Baseline | US federal funds rate | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.30% |
Baseline | US federal funds rate | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.30% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 15.40% |
Downside 2 | GDP | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Downside 2 | GDP | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | (3.90%) |
Downside 2 | GDP | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.00%) | 6.50% |
Downside 2 | GDP | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2.60% |
Downside 2 | GDP | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 1.40% |
Downside 2 | GDP | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Downside 2 | GDP | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.80%) | (2.40%) |
Downside 2 | GDP | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (3.50%) | 3.60% |
Downside 2 | GDP | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.10% |
Downside 2 | GDP | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 2.00% |
Downside 2 | GDP | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.60%) | (22.10%) |
Downside 2 | GDP | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.30%) | (10.60%) |
Downside 2 | GDP | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | (0.90%) |
Downside 2 | GDP | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.10% |
Downside 2 | Unemployment | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Downside 2 | Unemployment | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.20% | 8.00% |
Downside 2 | Unemployment | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.00% | 9.30% |
Downside 2 | Unemployment | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.60% | 7.80% |
Downside 2 | Unemployment | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.30% | 6.30% |
Downside 2 | Unemployment | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Downside 2 | Unemployment | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.40% | 13.40% |
Downside 2 | Unemployment | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.10% | 11.90% |
Downside 2 | Unemployment | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.10% | 10.10% |
Downside 2 | Unemployment | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.40% | 8.20% |
Downside 2 | Unemployment | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.20% | 10.10% |
Downside 2 | Unemployment | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.50% | 13.70% |
Downside 2 | Unemployment | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 7.20% |
Downside 2 | Unemployment | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.10% | 10.40% |
Downside 2 | HPI | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Downside 2 | HPI | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (14.30%) | (13.60%) |
Downside 2 | HPI | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (21.80%) | (10.80%) |
Downside 2 | HPI | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.90% | 0.50% |
Downside 2 | HPI | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 15.20% | 1.50% |
Downside 2 | HPI | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Downside 2 | HPI | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (6.60%) | (17.20%) |
Downside 2 | HPI | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (9.00%) | (0.70%) |
Downside 2 | HPI | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.90% | 0.60% |
Downside 2 | HPI | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.70% | 1.30% |
Downside 2 | HPI | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (29.90%) | (18.30%) |
Downside 2 | HPI | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (5.00%) | (15.90%) |
Downside 2 | HPI | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.00%) | (3.60%) |
Downside 2 | HPI | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.40% | (3.00%) |
Downside 2 | UK bank rate | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Downside 2 | UK bank rate | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | (0.20%) |
Downside 2 | UK bank rate | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | (0.20%) |
Downside 2 | UK bank rate | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | (0.10%) |
Downside 2 | UK bank rate | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | (0.10%) |
Downside 2 | UK bank rate | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 0.60% |
Downside 2 | UK bank rate | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | (0.10%) |
Downside 2 | US federal funds rate | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Downside 2 | US federal funds rate | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.30% |
Downside 2 | US federal funds rate | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 0.30% |
Downside 2 | US federal funds rate | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 0.30% |
Downside 2 | US federal funds rate | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.00% | 0.30% |
Downside 2 | US federal funds rate | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 1.30% |
Downside 2 | US federal funds rate | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.30% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 14.80% | 15.50% |
Downside 1 | GDP | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Downside 1 | GDP | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | (3.90%) |
Downside 1 | GDP | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.70%) | 6.50% |
Downside 1 | GDP | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 2.60% |
Downside 1 | GDP | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 1.40% |
Downside 1 | GDP | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Downside 1 | GDP | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | (2.40%) |
Downside 1 | GDP | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.40%) | 3.60% |
Downside 1 | GDP | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.10% |
Downside 1 | GDP | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 2.00% |
Downside 1 | GDP | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.60%) | (22.10%) |
Downside 1 | GDP | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | (10.60%) |
Downside 1 | GDP | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 0.10% |
Downside 1 | GDP | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 0.80% |
Downside 1 | Unemployment | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Downside 1 | Unemployment | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 8.00% |
Downside 1 | Unemployment | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.80% | 9.30% |
Downside 1 | Unemployment | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.00% | 7.80% |
Downside 1 | Unemployment | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 6.30% |
Downside 1 | Unemployment | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Downside 1 | Unemployment | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.40% | 13.40% |
Downside 1 | Unemployment | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.60% | 11.90% |
Downside 1 | Unemployment | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.10% | 10.10% |
Downside 1 | Unemployment | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 8.20% |
Downside 1 | Unemployment | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 8.40% |
Downside 1 | Unemployment | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.80% | 13.00% |
Downside 1 | Unemployment | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.80% | 6.50% |
Downside 1 | Unemployment | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 8.30% |
Downside 1 | HPI | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Downside 1 | HPI | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (6.80%) | (13.60%) |
Downside 1 | HPI | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (10.50%) | (10.80%) |
Downside 1 | HPI | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.90% | 0.50% |
Downside 1 | HPI | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.60% | 1.50% |
Downside 1 | HPI | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Downside 1 | HPI | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.20%) | (17.20%) |
Downside 1 | HPI | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.10%) | (0.70%) |
Downside 1 | HPI | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 0.60% |
Downside 1 | HPI | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 1.30% |
Downside 1 | HPI | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (12.70%) | (4.50%) |
Downside 1 | HPI | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | (3.70%) |
Downside 1 | HPI | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | (0.20%) |
Downside 1 | HPI | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 0.80% |
Downside 1 | UK bank rate | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Downside 1 | UK bank rate | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | (0.20%) |
Downside 1 | UK bank rate | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | (0.20%) |
Downside 1 | UK bank rate | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | (0.10%) |
Downside 1 | UK bank rate | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | (0.10%) |
Downside 1 | UK bank rate | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 0.60% |
Downside 1 | UK bank rate | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.00% |
Downside 1 | US federal funds rate | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Downside 1 | US federal funds rate | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.30% |
Downside 1 | US federal funds rate | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 0.30% |
Downside 1 | US federal funds rate | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.30% |
Downside 1 | US federal funds rate | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 0.30% |
Downside 1 | US federal funds rate | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 1.30% |
Downside 1 | US federal funds rate | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.30% |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 20.90% | 20.20% |
Upside 2 | GDP | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Upside 2 | GDP | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.20% | 12.20% |
Upside 2 | GDP | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 5.30% |
Upside 2 | GDP | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 3.90% |
Upside 2 | GDP | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.90% |
Upside 2 | GDP | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Upside 2 | GDP | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 7.10% |
Upside 2 | GDP | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.60% |
Upside 2 | GDP | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.00% |
Upside 2 | GDP | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.50% |
Upside 2 | GDP | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 21.40% | 14.20% |
Upside 2 | GDP | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 22.80% | 15.70% |
Upside 2 | GDP | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 2.50% |
Upside 2 | GDP | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 2.90% |
Upside 2 | Unemployment | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Upside 2 | Unemployment | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.20% |
Upside 2 | Unemployment | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 5.50% |
Upside 2 | Unemployment | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 4.80% |
Upside 2 | Unemployment | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 4.40% |
Upside 2 | Unemployment | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Upside 2 | Unemployment | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 5.50% |
Upside 2 | Unemployment | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.30% |
Upside 2 | Unemployment | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4.10% |
Upside 2 | Unemployment | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4.10% |
Upside 2 | Unemployment | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 4.00% |
Upside 2 | Unemployment | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.80% |
Upside 2 | Unemployment | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 5.00% |
Upside 2 | Unemployment | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 5.30% |
Upside 2 | HPI | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Upside 2 | HPI | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.50% | 6.60% |
Upside 2 | HPI | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.00% | 10.40% |
Upside 2 | HPI | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 10.80% |
Upside 2 | HPI | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 7.30% |
Upside 2 | HPI | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Upside 2 | HPI | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 10.60% | 8.80% |
Upside 2 | HPI | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.50% | 9.10% |
Upside 2 | HPI | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.20% | 8.90% |
Upside 2 | HPI | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.60% | 7.50% |
Upside 2 | HPI | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 35.70% | 48.20% |
Upside 2 | HPI | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 53.30% | 42.20% |
Upside 2 | HPI | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.30% | 8.20% |
Upside 2 | HPI | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.90% | 7.30% |
Upside 2 | UK bank rate | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Upside 2 | UK bank rate | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.10% |
Upside 2 | UK bank rate | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.30% |
Upside 2 | UK bank rate | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.30% |
Upside 2 | UK bank rate | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.50% |
Upside 2 | UK bank rate | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 2 | UK bank rate | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Upside 2 | US federal funds rate | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Upside 2 | US federal funds rate | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Upside 2 | US federal funds rate | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.40% | 0.40% |
Upside 2 | US federal funds rate | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.70% | 0.60% |
Upside 2 | US federal funds rate | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 0.90% |
Upside 2 | US federal funds rate | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 2 | US federal funds rate | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.50% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 27.20% | 24.20% |
Upside 1 | GDP | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | (10.10%) |
Upside 1 | GDP | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.00% | 9.30% |
Upside 1 | GDP | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.90% |
Upside 1 | GDP | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 3.40% |
Upside 1 | GDP | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.50% |
Upside 1 | GDP | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | (4.40%) |
Upside 1 | GDP | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 5.50% |
Upside 1 | GDP | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.00% |
Upside 1 | GDP | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 3.70% |
Upside 1 | GDP | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 3.30% |
Upside 1 | GDP | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 18.30% | 8.80% |
Upside 1 | GDP | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 19.60% | 12.80% |
Upside 1 | GDP | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 1.60% |
Upside 1 | GDP | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 2.40% |
Upside 1 | Unemployment | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.50% |
Upside 1 | Unemployment | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 6.40% |
Upside 1 | Unemployment | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 6.00% |
Upside 1 | Unemployment | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 5.20% |
Upside 1 | Unemployment | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.70% |
Upside 1 | Unemployment | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 8.40% |
Upside 1 | Unemployment | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 6.00% |
Upside 1 | Unemployment | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.80% |
Upside 1 | Unemployment | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.60% |
Upside 1 | Unemployment | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.60% |
Upside 1 | Unemployment | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.00% |
Upside 1 | Unemployment | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.80% |
Upside 1 | Unemployment | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 5.30% |
Upside 1 | Unemployment | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.00% | 5.70% |
Upside 1 | HPI | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.10% |
Upside 1 | HPI | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.00% | 4.60% |
Upside 1 | HPI | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.00% | 6.10% |
Upside 1 | HPI | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 6.10% |
Upside 1 | HPI | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4.70% |
Upside 1 | HPI | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.80% | 2.30% |
Upside 1 | HPI | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.30% | 6.80% |
Upside 1 | HPI | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.00% | 6.70% |
Upside 1 | HPI | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.00% | 6.30% |
Upside 1 | HPI | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 5.60% |
Upside 1 | HPI | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 23.80% | 30.80% |
Upside 1 | HPI | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 45.20% | 30.90% |
Upside 1 | HPI | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 5.50% |
Upside 1 | HPI | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.70% | 5.50% |
Upside 1 | UK bank rate | UK | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.20% |
Upside 1 | UK bank rate | UK | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.10% |
Upside 1 | UK bank rate | UK | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Upside 1 | UK bank rate | UK | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.30% |
Upside 1 | UK bank rate | UK | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.30% |
Upside 1 | UK bank rate | Specific bases | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 1 | UK bank rate | 5-year averages | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.20% |
Upside 1 | US federal funds rate | United States | Not more than one year | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 0.50% |
Upside 1 | US federal funds rate | United States | One to two years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.30% |
Upside 1 | US federal funds rate | United States | Two to three years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.30% |
Upside 1 | US federal funds rate | United States | Three to four years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.00% | 0.50% |
Upside 1 | US federal funds rate | United States | Four to five years | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | 0.80% |
Upside 1 | US federal funds rate | Specific bases | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.10% | 0.10% |
Upside 1 | US federal funds rate | 5-year averages | United States | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.50% |
Other disclosures - Risk Man_11
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty - ECL under 100% weighted scenarios for modelled portfolios, narrative (Details) £ in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2021USD ($) | |
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 100.00% | 100.00% | |
Average EAD period | 12 months | ||
Total financial assets | £ 1,049,896 | £ 1,051,400 | $ 132 |
Loans and advances at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
ECL movement excluding assets derecognised due to disposals and write-offs | £ (334) | £ 2,793 | |
Loans and advances at amortised cost | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 2.40% | 3.60% | 2.40% |
Total financial assets | £ 145,259 | £ 134,267 | |
Coverage ratio | 2.40% | 3.60% | 2.40% |
Home loans | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
ECL movement excluding assets derecognised due to disposals and write-offs | £ (30) | £ 103 | |
Home loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ 10,985 | £ 11,193 | |
Coverage ratio | 3.40% | 3.70% | 3.40% |
Credit cards, unsecured loans and other retail lending | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
ECL movement excluding assets derecognised due to disposals and write-offs | £ 171 | £ 1,484 | |
Credit cards, unsecured loans and other retail lending | Downside 2 | Stage 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 31.10% | 31.10% | |
Credit cards, unsecured loans and other retail lending | Credit derivatives | Stage 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 18.30% | 18.30% | |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ 25,960 | £ 23,368 | |
Coverage ratio | 8.10% | 11.30% | 8.10% |
Wholesale loans | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
ECL movement excluding assets derecognised due to disposals and write-offs | £ (475) | £ 1,206 | |
Wholesale loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ 108,314 | £ 99,706 | |
Coverage ratio | 0.70% | 1.60% | 0.70% |
ECL | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Treasury assets ECL | £ 3 | ||
Total financial assets | £ (3,998) | £ (5,835) | |
ECL | Baseline | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Weighted expected credit loss, uplift percentage | 5.90% | ||
ECL | Loans and advances at amortised cost | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ (3,499) | (5,066) | |
ECL | Home loans | Baseline | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ (309) | ||
Increase (decrease) in coverage rates | 0.60% | ||
ECL | Home loans | Credit derivatives | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ (311) | ||
ECL | Home loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | (386) | (434) | |
ECL | Credit cards, unsecured loans and other retail lending | Downside 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | (3,332) | ||
ECL | Credit cards, unsecured loans and other retail lending | Baseline | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ (1,202) | ||
Increase (decrease) in coverage rates | 6.70% | ||
ECL | Credit cards, unsecured loans and other retail lending | Credit derivatives | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ (1,282) | ||
ECL | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | (2,302) | (2,979) | |
ECL | Wholesale loans | Baseline | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ (678) | ||
Increase (decrease) in coverage rates | 6.90% | ||
ECL | Wholesale loans | Credit derivatives | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ (725) | ||
ECL | Wholesale loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | (811) | (1,653) | |
Gross | Loans and advances at amortised cost | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | 148,758 | 139,333 | |
Gross | Loans and advances at amortised cost | Financial assets at amortised cost | Downside 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Transfers into Stage 2 | 12,400 | ||
Gross | Home loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | 11,371 | 11,627 | |
Gross | Credit cards, unsecured loans and other retail lending | Baseline | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
ECL movement excluding assets derecognised due to disposals and write-offs | 5,300 | ||
Gross | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | 28,262 | 26,347 | |
Gross | Wholesale loans | Financial assets at amortised cost | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Total financial assets | £ 109,125 | £ 101,359 | |
Gross | UNITED KINGDOM | Loans and advances at amortised cost | Financial assets at amortised cost | Downside 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 9.20% | 9.20% | |
Gross | United States | Loans and advances at amortised cost | Financial assets at amortised cost | Downside 2 | |||
Disclosure of nature and extent of risks arising from financial instruments [line items] | |||
Coverage ratio | 9.50% | 9.50% |
Other disclosures - Risk Man_12
Other disclosures - Risk Management and Principal Risks - Measurement uncertainty and sensitivity analysis - ECL under 100% weighted scenarios for modelled portfolios (audited) (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,049,896 | $ 132 | £ 1,051,400 | |
ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (3,998) | (5,835) | ||
ECL | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,318) | (3,875) | ||
ECL | ECL from individually assessed impairments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (463) | (835) | ||
ECL | ECL from non-modelled and other management adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (1,217) | (1,125) | ||
Loans and advances | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (3,998) | (5,835) | ||
Loans and advances | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (100) | |||
Loans and advances | ECL from post-model adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | 1,100 | 900 | ||
Loans and advances | ECL from non-modelled and other management adjustments | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | 200 | 200 | ||
Loans and advances | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 145,259 | £ 134,267 | ||
Coverage ratio | 2.40% | 2.40% | 3.60% | |
Loans and advances | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 148,758 | £ 139,333 | ||
Loans and advances | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (3,499) | (5,066) | ||
Loans and advances | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 128,217 | £ 111,119 | ||
Coverage ratio | 0.60% | 0.60% | 0.60% | |
Loans and advances | Stage 1 | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 129,013 | £ 111,804 | ||
Loans and advances | Stage 1 | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (796) | (685) | ||
Loans and advances | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 15,378 | £ 20,498 | ||
Coverage ratio | 6.20% | 6.20% | 8.50% | |
Loans and advances | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,664 | £ 2,650 | ||
Coverage ratio | 50.30% | 50.30% | 48.20% | |
Loans and advances | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 16,397 | £ 22,410 | ||
Loans and advances | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 3,348 | 5,119 | ||
Loans and advances | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (1,019) | (1,912) | ||
Loans and advances | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (1,684) | (2,469) | ||
Home loans | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (386) | (434) | ||
Home loans | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 10,985 | £ 11,193 | ||
Coverage ratio | 3.40% | 3.40% | 3.70% | |
Home loans | Gross | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (11,371) | £ (11,627) | £ (11,334) | |
Home loans | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 11,371 | 11,627 | ||
Home loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (386) | (434) | (348) | |
Home loans | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (386) | (434) | ||
Home loans | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 9,752 | £ 9,621 | ||
Coverage ratio | 0.10% | 0.10% | 0.10% | |
Home loans | Stage 1 | Gross | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (9,760) | £ (9,627) | (9,604) | |
Home loans | Stage 1 | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 9,760 | 9,627 | ||
Home loans | Stage 1 | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (8) | (6) | (16) | |
Home loans | Stage 1 | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (8) | (6) | ||
Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 618 | £ 849 | ||
Coverage ratio | 5.40% | 5.40% | 5.80% | |
Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 615 | £ 723 | ||
Coverage ratio | 35.80% | 35.80% | 34.20% | |
Home loans | Lifetime expected credit losses | Gross | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (653) | £ (901) | (674) | |
Home loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 653 | 901 | ||
Home loans | Lifetime expected credit losses | Gross | Stage 3 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (958) | (1,099) | (1,056) | |
Home loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 958 | 1,099 | ||
Home loans | Lifetime expected credit losses | ECL | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (35) | (52) | (40) | |
Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (35) | (52) | ||
Home loans | Lifetime expected credit losses | ECL | Stage 3 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (343) | (376) | (292) | |
Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (343) | (376) | ||
Credit cards, unsecured loans and other retail lending | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (2,391) | (3,069) | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 25,960 | £ 23,368 | ||
Coverage ratio | 8.10% | 8.10% | 11.30% | |
Credit cards, unsecured loans and other retail lending | Gross | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (28,262) | £ (26,347) | (36,120) | |
Credit cards, unsecured loans and other retail lending | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 28,262 | 26,347 | ||
Allowance account for credit losses of financial assets | (26,347) | |||
Credit cards, unsecured loans and other retail lending | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (2,302) | (2,979) | (2,617) | |
Credit cards, unsecured loans and other retail lending | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,302) | (2,979) | ||
Allowance account for credit losses of financial assets | (2,979) | |||
Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 23,406 | £ 18,524 | ||
Coverage ratio | 2.50% | 2.50% | 2.10% | |
Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (24,011) | £ (18,923) | (29,541) | |
Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 24,011 | 18,923 | ||
Allowance account for credit losses of financial assets | (18,923) | |||
Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (605) | (399) | (362) | |
Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (605) | (399) | ||
Allowance account for credit losses of financial assets | (399) | |||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,991 | £ 4,244 | ||
Coverage ratio | 28.40% | 28.40% | 23.80% | |
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 563 | £ 600 | ||
Coverage ratio | 61.70% | 61.70% | 67.60% | |
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (2,782) | £ (5,571) | (4,450) | |
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 2,782 | 5,571 | ||
Allowance account for credit losses of financial assets | (5,571) | |||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (1,469) | (1,853) | (2,129) | |
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 1,469 | 1,853 | ||
Allowance account for credit losses of financial assets | (1,853) | |||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (791) | (1,327) | (784) | |
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (791) | (1,327) | ||
Allowance account for credit losses of financial assets | (1,327) | |||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (906) | (1,253) | (1,471) | |
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (906) | (1,253) | ||
Allowance account for credit losses of financial assets | (1,253) | |||
Wholesale loans | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (1,221) | (2,332) | ||
Wholesale loans | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 108,314 | £ 99,706 | ||
Coverage ratio | 0.70% | 0.70% | 1.60% | |
Wholesale loans | Gross | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (109,125) | £ (101,359) | (97,878) | |
Wholesale loans | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 109,125 | 101,359 | ||
Wholesale loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (811) | (1,653) | (731) | |
Wholesale loans | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (811) | (1,653) | ||
Wholesale loans | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 95,059 | £ 82,974 | ||
Coverage ratio | 0.20% | 0.20% | 0.30% | |
Wholesale loans | Stage 1 | Gross | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (95,242) | £ (83,254) | (89,200) | |
Wholesale loans | Stage 1 | Gross | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 95,242 | 83,254 | ||
Wholesale loans | Stage 1 | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (183) | (280) | (114) | |
Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (183) | (280) | ||
Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 12,769 | £ 15,405 | ||
Coverage ratio | 1.50% | 1.50% | 3.30% | |
Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 486 | £ 1,327 | ||
Coverage ratio | 47.20% | 47.20% | 38.80% | |
Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | £ (12,962) | £ (15,938) | (7,515) | |
Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 12,962 | 15,938 | ||
Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (921) | (2,167) | (1,163) | |
Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 921 | 2,167 | ||
Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (193) | (533) | (234) | |
Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (193) | (533) | ||
Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Allowance account for credit losses of financial assets | (435) | (840) | £ (383) | |
Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (435) | (840) | ||
Credit derivatives | Loans and advances | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,318) | (3,875) | ||
Credit derivatives | Home loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (311) | |||
Credit derivatives | Home loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (311) | £ (335) | ||
Credit derivatives | Home loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.10% | |
Credit derivatives | Home loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 3,905 | £ 4,404 | ||
Credit derivatives | Home loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (2) | £ (4) | ||
Credit derivatives | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 5.30% | 5.30% | 5.90% | |
Credit derivatives | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 48.70% | 48.70% | 40.90% | |
Credit derivatives | Home loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 228 | £ 557 | ||
Credit derivatives | Home loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 610 | 728 | ||
Credit derivatives | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (12) | (33) | ||
Credit derivatives | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (297) | (298) | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 18.30% | 18.30% | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (1,282) | |||
Credit derivatives | Credit cards, unsecured loans and other retail lending | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (1,282) | £ (1,938) | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 1.20% | 1.20% | 0.90% | |
Credit derivatives | Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 19,001 | £ 24,980 | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (221) | £ (236) | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 18.30% | 18.30% | 16.10% | |
Credit derivatives | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 67.70% | 67.70% | 93.00% | |
Credit derivatives | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,991 | £ 3,171 | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 1,028 | 1,279 | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (365) | (512) | ||
Credit derivatives | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (696) | (1,190) | ||
Credit derivatives | Wholesale loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (725) | |||
Credit derivatives | Wholesale loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (725) | £ (1,602) | ||
Credit derivatives | Wholesale loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.20% | 0.20% | 0.20% | |
Credit derivatives | Wholesale loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 142,804 | £ 115,949 | ||
Credit derivatives | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (219) | £ (219) | ||
Credit derivatives | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 1.70% | 1.70% | 4.60% | |
Credit derivatives | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | 2.90% | |
Credit derivatives | Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 29,124 | £ 29,834 | ||
Credit derivatives | Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | 863 | ||
Credit derivatives | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (506) | (1,358) | ||
Credit derivatives | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | (25) | ||
Upside 2 | Loans and advances | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (1,992) | (3,178) | ||
Upside 2 | Home loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (302) | £ (313) | ||
Upside 2 | Home loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.10% | |
Upside 2 | Home loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 3,915 | £ 4,422 | ||
Upside 2 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (2) | £ (4) | ||
Upside 2 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 4.60% | 4.60% | 5.80% | |
Upside 2 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 47.50% | 47.50% | 38.20% | |
Upside 2 | Home loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 219 | £ 539 | ||
Upside 2 | Home loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 610 | 728 | ||
Upside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (10) | (31) | ||
Upside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (290) | (278) | ||
Upside 2 | Credit cards, unsecured loans and other retail lending | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (1,106) | £ (1,684) | ||
Upside 2 | Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.80% | 0.80% | 0.80% | |
Upside 2 | Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 19,357 | £ 24,929 | ||
Upside 2 | Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (157) | £ (187) | ||
Upside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 16.70% | 16.70% | 15.50% | |
Upside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 66.60% | 66.60% | 91.50% | |
Upside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,584 | £ 2,111 | ||
Upside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 1,028 | 1,279 | ||
Upside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (264) | (327) | ||
Upside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (685) | (1,170) | ||
Upside 2 | Wholesale loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (584) | £ (1,181) | ||
Upside 2 | Wholesale loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.20% | |
Upside 2 | Wholesale loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 145,097 | £ 121,769 | ||
Upside 2 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (189) | £ (239) | ||
Upside 2 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 1.50% | 1.50% | 3.80% | |
Upside 2 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | 2.30% | |
Upside 2 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 26,831 | £ 24,015 | ||
Upside 2 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | 863 | ||
Upside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (395) | (922) | ||
Upside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | (20) | ||
Upside 1 | Loans and advances | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,073) | (3,344) | ||
Upside 1 | Home loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (304) | £ (316) | ||
Upside 1 | Home loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.10% | |
Upside 1 | Home loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 3,911 | £ 4,416 | ||
Upside 1 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (2) | £ (4) | ||
Upside 1 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 4.50% | 4.50% | 5.70% | |
Upside 1 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 47.90% | 47.90% | 38.60% | |
Upside 1 | Home loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 222 | £ 545 | ||
Upside 1 | Home loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 610 | 728 | ||
Upside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (10) | (31) | ||
Upside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (292) | (281) | ||
Upside 1 | Credit cards, unsecured loans and other retail lending | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (1,149) | £ (1,766) | ||
Upside 1 | Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.90% | 0.90% | 0.80% | |
Upside 1 | Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 19,284 | £ 25,097 | ||
Upside 1 | Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (164) | £ (204) | ||
Upside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 17.50% | 17.50% | 15.50% | |
Upside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 67.10% | 67.10% | 92.30% | |
Upside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,683 | £ 2,462 | ||
Upside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 1,028 | 1,279 | ||
Upside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (295) | (382) | ||
Upside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (690) | (1,180) | ||
Upside 1 | Wholesale loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (620) | £ (1,262) | ||
Upside 1 | Wholesale loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.20% | |
Upside 1 | Wholesale loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 144,688 | £ 120,741 | ||
Upside 1 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (200) | £ (231) | ||
Upside 1 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 1.50% | 1.50% | 4.00% | |
Upside 1 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | 2.40% | |
Upside 1 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 27,240 | £ 25,043 | ||
Upside 1 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | 863 | ||
Upside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (420) | (1,010) | ||
Upside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | (21) | ||
Baseline | Loans and advances | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,189) | (3,624) | ||
Baseline | Home loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (309) | |||
Baseline | Home loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (309) | £ (320) | ||
Baseline | Home loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.10% | |
Baseline | Home loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 3,906 | £ 4,407 | ||
Baseline | Home loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (2) | £ (4) | ||
Baseline | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 4.80% | 4.80% | 5.80% | |
Baseline | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 48.50% | 48.50% | 39.00% | |
Baseline | Home loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 227 | £ 554 | ||
Baseline | Home loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 610 | 728 | ||
Baseline | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (11) | (32) | ||
Baseline | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (296) | (284) | ||
Baseline | Credit cards, unsecured loans and other retail lending | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (1,202) | |||
Baseline | Credit cards, unsecured loans and other retail lending | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (1,202) | £ (1,902) | ||
Baseline | Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.90% | 0.90% | 0.90% | |
Baseline | Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 19,201 | £ 24,820 | ||
Baseline | Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (173) | £ (230) | ||
Baseline | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 18.60% | 18.60% | 15.00% | |
Baseline | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 67.70% | 67.70% | 93.10% | |
Baseline | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 1,793 | £ 3,215 | ||
Baseline | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 1,028 | 1,279 | ||
Baseline | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (333) | (481) | ||
Baseline | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (696) | (1,191) | ||
Baseline | Wholesale loans | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (678) | |||
Baseline | Wholesale loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (678) | £ (1,402) | ||
Baseline | Wholesale loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.20% | 0.20% | 0.20% | |
Baseline | Wholesale loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 143,967 | £ 118,930 | ||
Baseline | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (216) | £ (205) | ||
Baseline | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 1.70% | 1.70% | 4.40% | |
Baseline | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | 2.70% | |
Baseline | Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 27,961 | £ 26,853 | ||
Baseline | Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | 863 | ||
Baseline | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (462) | (1,174) | ||
Baseline | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | (23) | ||
Downside 1 | Loans and advances | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,856) | (4,542) | ||
Downside 1 | Home loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (331) | £ (347) | ||
Downside 1 | Home loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.10% | |
Downside 1 | Home loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 3,885 | £ 4,387 | ||
Downside 1 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (3) | £ (5) | ||
Downside 1 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 7.20% | 7.20% | 6.30% | |
Downside 1 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 50.80% | 50.80% | 42.00% | |
Downside 1 | Home loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 249 | £ 575 | ||
Downside 1 | Home loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 610 | 728 | ||
Downside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (18) | (36) | ||
Downside 1 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (310) | (306) | ||
Downside 1 | Credit cards, unsecured loans and other retail lending | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (1,563) | £ (2,265) | ||
Downside 1 | Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 1.50% | 1.50% | 1.10% | |
Downside 1 | Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 17,445 | £ 24,411 | ||
Downside 1 | Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (254) | £ (258) | ||
Downside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 16.60% | 16.60% | 16.90% | |
Downside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 69.10% | 69.10% | 94.70% | |
Downside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 3,605 | £ 4,721 | ||
Downside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 1,028 | 1,279 | ||
Downside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (599) | (796) | ||
Downside 1 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (710) | (1,211) | ||
Downside 1 | Wholesale loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (962) | £ (1,930) | ||
Downside 1 | Wholesale loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.20% | 0.20% | 0.20% | |
Downside 1 | Wholesale loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 140,402 | £ 113,027 | ||
Downside 1 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (250) | £ (218) | ||
Downside 1 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 2.30% | 2.30% | 5.10% | |
Downside 1 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | 3.40% | |
Downside 1 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 31,525 | £ 32,757 | ||
Downside 1 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | 863 | ||
Downside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (712) | (1,683) | ||
Downside 1 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | (29) | ||
Downside 2 | Loans and advances | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (5,190) | (5,938) | ||
Downside 2 | Home loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (347) | £ (408) | ||
Downside 2 | Home loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.10% | 0.10% | 0.10% | |
Downside 2 | Home loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 3,868 | £ 4,365 | ||
Downside 2 | Home loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (3) | £ (5) | ||
Downside 2 | Home loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 9.00% | 9.00% | 6.70% | |
Downside 2 | Home loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 52.50% | 52.50% | 49.90% | |
Downside 2 | Home loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 266 | £ 597 | ||
Downside 2 | Home loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 610 | 728 | ||
Downside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (24) | (40) | ||
Downside 2 | Home loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (320) | (363) | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | Stage 2 | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 31.10% | 31.10% | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (3,332) | |||
Downside 2 | Credit cards, unsecured loans and other retail lending | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (3,332) | £ (2,518) | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 2.40% | 2.40% | 1.10% | |
Downside 2 | Credit cards, unsecured loans and other retail lending | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 13,785 | £ 24,247 | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (332) | £ (263) | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 31.10% | 31.10% | 18.00% | |
Downside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 70.20% | 70.20% | 94.60% | |
Downside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 7,331 | £ 5,796 | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 1,028 | 1,279 | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (2,278) | (1,045) | ||
Downside 2 | Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (722) | (1,210) | ||
Downside 2 | Wholesale loans | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (1,511) | £ (3,012) | ||
Downside 2 | Wholesale loans | Stage 1 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.20% | 0.20% | 0.20% | |
Downside 2 | Wholesale loans | Stage 1 | Gross | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 135,764 | £ 101,759 | ||
Downside 2 | Wholesale loans | Stage 1 | ECL | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ (282) | £ (221) | ||
Downside 2 | Wholesale loans | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 3.40% | 3.40% | 6.20% | |
Downside 2 | Wholesale loans | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Coverage ratio | 0.00% | 0.00% | 4.60% | |
Downside 2 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 36,163 | £ 44,024 | ||
Downside 2 | Wholesale loans | Lifetime expected credit losses | Gross | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | 0 | 863 | ||
Downside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 2 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | (1,229) | (2,751) | ||
Downside 2 | Wholesale loans | Lifetime expected credit losses | ECL | Stage 3 | Financial assets at amortised cost | Total model ECL | ||||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||||
Total financial assets | £ 0 | £ (40) |
Other disclosures - Risk Man_13
Other disclosures - Risk Management and Principal Risks - Credit risk concentrations by geography and industry (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
On-balance sheet: | ||||
Cash and balances at central banks | £ 169,085 | [1] | £ 155,902 | £ 125,940 |
Cash collateral and settlement balances | 88,085 | [2] | 97,616 | |
Loans and advances at amortised cost | 145,259 | [2] | 134,267 | |
Reverse repurchase agreements and other similar secured lending | 3,177 | [2] | 8,981 | |
Trading portfolio assets | 146,871 | [2] | 127,664 | |
Financial assets at fair value through the income statement | 188,226 | [2] | 171,761 | |
Derivative financial instruments | 262,291 | [2] | 302,693 | |
Financial assets at fair value through other comprehensive income | 45,908 | [2] | 51,902 | |
Other assets | 994 | 614 | ||
Total assets | 1,061,778 | [2] | 1,059,731 | £ 876,700 |
Off-balance sheet: | ||||
Contingent liabilities | 23,746 | 20,932 | ||
Total off-balance sheet | 308,197 | 285,954 | ||
Credit risk | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 169,085 | 155,902 | ||
Cash collateral and settlement balances | 88,085 | 97,616 | ||
Loans and advances at amortised cost | 145,259 | 134,267 | ||
Reverse repurchase agreements and other similar secured lending | 3,177 | 8,981 | ||
Trading portfolio assets | 63,225 | 64,544 | ||
Financial assets at fair value through the income statement | 183,428 | 168,019 | ||
Derivative financial instruments | 262,291 | 302,693 | ||
Financial assets at fair value through other comprehensive income | 45,907 | 51,901 | ||
Other assets | 994 | 614 | ||
Total assets | 961,451 | 984,537 | ||
Off-balance sheet: | ||||
Contingent liabilities | 23,746 | 20,932 | ||
Loan commitments | 284,451 | 265,022 | ||
Total off-balance sheet | 308,197 | 285,954 | ||
Total | 1,269,648 | 1,270,491 | ||
Credit risk | Banks | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 28 | 3 | ||
Cash collateral and settlement balances | 14,605 | 17,961 | ||
Loans and advances at amortised cost | 7,955 | 8,649 | ||
Reverse repurchase agreements and other similar secured lending | 595 | 656 | ||
Trading portfolio assets | 2,560 | 2,752 | ||
Financial assets at fair value through the income statement | 26,239 | 22,766 | ||
Derivative financial instruments | 120,607 | 155,986 | ||
Financial assets at fair value through other comprehensive income | 9,942 | 13,003 | ||
Other assets | 401 | 303 | ||
Total assets | 182,932 | 222,079 | ||
Off-balance sheet: | ||||
Contingent liabilities | 1,005 | 1,150 | ||
Loan commitments | 1,340 | 1,773 | ||
Total off-balance sheet | 2,345 | 2,923 | ||
Total | 185,277 | 225,002 | ||
Credit risk | Other financial insti-tutions | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 61,252 | 66,696 | ||
Loans and advances at amortised cost | 33,563 | 24,766 | ||
Reverse repurchase agreements and other similar secured lending | 2,049 | 7,964 | ||
Trading portfolio assets | 8,818 | 11,464 | ||
Financial assets at fair value through the income statement | 131,232 | 131,929 | ||
Derivative financial instruments | 117,050 | 116,421 | ||
Financial assets at fair value through other comprehensive income | 2,972 | 4,258 | ||
Other assets | 474 | 193 | ||
Total assets | 357,410 | 363,691 | ||
Off-balance sheet: | ||||
Contingent liabilities | 7,772 | 5,501 | ||
Loan commitments | 53,212 | 51,900 | ||
Total off-balance sheet | 60,984 | 57,401 | ||
Total | 418,394 | 421,092 | ||
Credit risk | Manu- facturing | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 320 | 375 | ||
Loans and advances at amortised cost | 5,821 | 7,122 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 4,881 | 4,104 | ||
Financial assets at fair value through the income statement | 763 | 603 | ||
Derivative financial instruments | 4,168 | 4,126 | ||
Financial assets at fair value through other comprehensive income | 0 | 1 | ||
Other assets | 1 | 5 | ||
Total assets | 15,954 | 16,336 | ||
Off-balance sheet: | ||||
Contingent liabilities | 3,080 | 3,187 | ||
Loan commitments | 42,434 | 39,447 | ||
Total off-balance sheet | 45,514 | 42,634 | ||
Total | 61,468 | 58,970 | ||
Credit risk | Const- ruction and property | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 79 | 35 | ||
Loans and advances at amortised cost | 13,714 | 12,889 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 1,048 | 516 | ||
Financial assets at fair value through the income statement | 5,444 | 2,481 | ||
Derivative financial instruments | 1,898 | 2,725 | ||
Financial assets at fair value through other comprehensive income | 514 | 333 | ||
Other assets | 0 | 3 | ||
Total assets | 22,697 | 18,982 | ||
Off-balance sheet: | ||||
Contingent liabilities | 1,342 | 1,260 | ||
Loan commitments | 15,752 | 12,843 | ||
Total off-balance sheet | 17,094 | 14,103 | ||
Total | 39,791 | 33,085 | ||
Credit risk | Govern- ment and central bank | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 169,057 | 155,899 | ||
Cash collateral and settlement balances | 10,684 | 10,828 | ||
Loans and advances at amortised cost | 15,462 | 13,759 | ||
Reverse repurchase agreements and other similar secured lending | 533 | 361 | ||
Trading portfolio assets | 32,483 | 35,607 | ||
Financial assets at fair value through the income statement | 13,935 | 5,519 | ||
Derivative financial instruments | 7,233 | 11,649 | ||
Financial assets at fair value through other comprehensive income | 31,975 | 33,774 | ||
Other assets | 8 | 1 | ||
Total assets | 281,370 | 267,397 | ||
Off-balance sheet: | ||||
Contingent liabilities | 1,092 | 1,028 | ||
Loan commitments | 1,360 | 1,398 | ||
Total off-balance sheet | 2,452 | 2,426 | ||
Total | 283,822 | 269,823 | ||
Credit risk | Energy and water | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 390 | 871 | ||
Loans and advances at amortised cost | 4,244 | 4,554 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 4,043 | 3,052 | ||
Financial assets at fair value through the income statement | 76 | 13 | ||
Derivative financial instruments | 3,544 | 3,288 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Other assets | 0 | 10 | ||
Total assets | 12,297 | 11,788 | ||
Off-balance sheet: | ||||
Contingent liabilities | 3,284 | 3,223 | ||
Loan commitments | 26,447 | 25,766 | ||
Total off-balance sheet | 29,731 | 28,989 | ||
Total | 42,028 | 40,777 | ||
Credit risk | Wholesale and retail distribution and leisure | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 60 | 30 | ||
Loans and advances at amortised cost | 7,266 | 7,814 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 1,734 | 1,883 | ||
Financial assets at fair value through the income statement | 181 | 64 | ||
Derivative financial instruments | 1,172 | 1,235 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Other assets | 0 | 1 | ||
Total assets | 10,413 | 11,027 | ||
Off-balance sheet: | ||||
Contingent liabilities | 1,182 | 978 | ||
Loan commitments | 15,811 | 16,626 | ||
Total off-balance sheet | 16,993 | 17,604 | ||
Total | 27,406 | 28,631 | ||
Credit risk | Business and other services | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 354 | 576 | ||
Loans and advances at amortised cost | 13,881 | 13,528 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 4,716 | 2,625 | ||
Financial assets at fair value through the income statement | 3,547 | 3,479 | ||
Derivative financial instruments | 2,825 | 2,496 | ||
Financial assets at fair value through other comprehensive income | 444 | 527 | ||
Other assets | 105 | 95 | ||
Total assets | 25,872 | 23,326 | ||
Off-balance sheet: | ||||
Contingent liabilities | 3,118 | 2,283 | ||
Loan commitments | 25,201 | 24,001 | ||
Total off-balance sheet | 28,319 | 26,284 | ||
Total | 54,191 | 49,610 | ||
Credit risk | Home loans | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 0 | 0 | ||
Loans and advances at amortised cost | 10,985 | 11,193 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 0 | 0 | ||
Financial assets at fair value through the income statement | 1,595 | 971 | ||
Derivative financial instruments | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Other assets | 0 | 0 | ||
Total assets | 12,580 | 12,164 | ||
Off-balance sheet: | ||||
Contingent liabilities | 0 | 0 | ||
Loan commitments | 341 | 134 | ||
Total off-balance sheet | 341 | 134 | ||
Total | 12,921 | 12,298 | ||
Credit risk | Cards, unsecured loans and other personal lending | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 0 | 0 | ||
Loans and advances at amortised cost | 26,477 | 23,955 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 0 | 0 | ||
Financial assets at fair value through the income statement | 0 | 0 | ||
Derivative financial instruments | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Other assets | 0 | 0 | ||
Total assets | 26,477 | 23,955 | ||
Off-balance sheet: | ||||
Contingent liabilities | 73 | 155 | ||
Loan commitments | 76,759 | 69,646 | ||
Total off-balance sheet | 76,832 | 69,801 | ||
Total | 103,309 | 93,756 | ||
Credit risk | Other | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 0 | 0 | ||
Cash collateral and settlement balances | 341 | 244 | ||
Loans and advances at amortised cost | 5,891 | 6,038 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 2,942 | 2,541 | ||
Financial assets at fair value through the income statement | 416 | 194 | ||
Derivative financial instruments | 3,794 | 4,767 | ||
Financial assets at fair value through other comprehensive income | 60 | 5 | ||
Other assets | 5 | 3 | ||
Total assets | 13,449 | 13,792 | ||
Off-balance sheet: | ||||
Contingent liabilities | 1,798 | 2,167 | ||
Loan commitments | 25,794 | 21,488 | ||
Total off-balance sheet | 27,592 | 23,655 | ||
Total | 41,041 | 37,447 | ||
United Kingdom | Credit risk | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 45,470 | 31,235 | ||
Cash collateral and settlement balances | 30,107 | 30,261 | ||
Loans and advances at amortised cost | 62,269 | 61,754 | ||
Reverse repurchase agreements and other similar secured lending | 9 | 10 | ||
Trading portfolio assets | 12,852 | 9,787 | ||
Financial assets at fair value through the income statement | 26,096 | 31,745 | ||
Derivative financial instruments | 78,449 | 93,685 | ||
Financial assets at fair value through other comprehensive income | 4,525 | 6,921 | ||
Other assets | 747 | 392 | ||
Total assets | 260,524 | 265,790 | ||
Off-balance sheet: | ||||
Contingent liabilities | 7,926 | 5,200 | ||
Loan commitments | 46,616 | 46,746 | ||
Total off-balance sheet | 54,542 | 51,946 | ||
Total | 315,066 | 317,736 | ||
Americas | Credit risk | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 38,735 | 36,063 | ||
Cash collateral and settlement balances | 28,272 | 27,255 | ||
Loans and advances at amortised cost | 50,718 | 40,403 | ||
Reverse repurchase agreements and other similar secured lending | 123 | 152 | ||
Trading portfolio assets | 29,478 | 31,003 | ||
Financial assets at fair value through the income statement | 95,456 | 88,302 | ||
Derivative financial instruments | 91,992 | 90,796 | ||
Financial assets at fair value through other comprehensive income | 20,750 | 19,451 | ||
Other assets | 224 | 185 | ||
Total assets | 355,748 | 333,610 | ||
Off-balance sheet: | ||||
Contingent liabilities | 10,329 | 10,121 | ||
Loan commitments | 192,270 | 175,893 | ||
Total off-balance sheet | 202,599 | 186,014 | ||
Total | 558,347 | 519,624 | ||
Europe | Credit risk | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 76,846 | 69,962 | ||
Cash collateral and settlement balances | 21,754 | 30,105 | ||
Loans and advances at amortised cost | 23,576 | 23,931 | ||
Reverse repurchase agreements and other similar secured lending | 351 | 323 | ||
Trading portfolio assets | 15,062 | 16,861 | ||
Financial assets at fair value through the income statement | 30,080 | 25,706 | ||
Derivative financial instruments | 75,245 | 101,099 | ||
Financial assets at fair value through other comprehensive income | 15,603 | 22,138 | ||
Other assets | 17 | 37 | ||
Total assets | 258,534 | 290,162 | ||
Off-balance sheet: | ||||
Contingent liabilities | 3,957 | 3,809 | ||
Loan commitments | 38,567 | 36,713 | ||
Total off-balance sheet | 42,524 | 40,522 | ||
Total | 301,058 | 330,684 | ||
Asia | Credit risk | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 7,789 | 17,987 | ||
Cash collateral and settlement balances | 7,210 | 9,487 | ||
Loans and advances at amortised cost | 4,775 | 4,859 | ||
Reverse repurchase agreements and other similar secured lending | 2,508 | 8,285 | ||
Trading portfolio assets | 4,943 | 5,947 | ||
Financial assets at fair value through the income statement | 21,798 | 14,742 | ||
Derivative financial instruments | 14,709 | 14,532 | ||
Financial assets at fair value through other comprehensive income | 4,666 | 3,276 | ||
Other assets | 6 | 0 | ||
Total assets | 68,404 | 79,115 | ||
Off-balance sheet: | ||||
Contingent liabilities | 1,131 | 1,222 | ||
Loan commitments | 5,079 | 4,132 | ||
Total off-balance sheet | 6,210 | 5,354 | ||
Total | 74,614 | 84,469 | ||
Africa and Middle East | Credit risk | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 245 | 655 | ||
Cash collateral and settlement balances | 742 | 508 | ||
Loans and advances at amortised cost | 3,921 | 3,320 | ||
Reverse repurchase agreements and other similar secured lending | 186 | 211 | ||
Trading portfolio assets | 890 | 946 | ||
Financial assets at fair value through the income statement | 9,998 | 7,524 | ||
Derivative financial instruments | 1,896 | 2,581 | ||
Financial assets at fair value through other comprehensive income | 363 | 115 | ||
Other assets | 0 | 0 | ||
Total assets | 18,241 | 15,860 | ||
Off-balance sheet: | ||||
Contingent liabilities | 403 | 580 | ||
Loan commitments | 1,919 | 1,538 | ||
Total off-balance sheet | 2,322 | 2,118 | ||
Total | £ 20,563 | £ 17,978 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Other disclosures - Risk Man_14
Other disclosures - Risk Management and Principal Risks - Balance sheet credit quality (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
On-balance sheet: | ||||
Cash and balances at central banks | £ 169,085 | [1] | £ 155,902 | £ 125,940 |
Cash collateral and settlement balances | 88,085 | [2] | 97,616 | |
Loans and advances at amortised cost | 145,259 | [2] | 134,267 | |
Reverse repurchase agreements and other similar secured lending | 3,177 | [2] | 8,981 | |
Trading portfolio assets | 146,871 | [2] | 127,664 | |
Financial assets at fair value through the income statement | 188,226 | [2] | 171,761 | |
Derivative financial instruments | 262,291 | [2] | 302,693 | |
Other assets | 994 | 614 | ||
Total assets | 1,061,778 | [2] | 1,059,731 | £ 876,700 |
Debt securities classified as amortised cost | ||||
On-balance sheet: | ||||
Trading portfolio assets | 50,700 | 56,196 | ||
Traded loans | ||||
On-balance sheet: | ||||
Trading portfolio assets | 12,525 | 8,348 | ||
Internal credit grades | ||||
On-balance sheet: | ||||
Cash and balances at central banks | 169,085 | 155,902 | ||
Cash collateral and settlement balances | 88,085 | 97,616 | ||
Reverse repurchase agreements and other similar secured lending | 3,177 | 8,981 | ||
Trading portfolio assets | 63,225 | 64,544 | ||
Financial assets at fair value through the income statement | 183,428 | 168,019 | ||
Derivative financial instruments | 262,291 | 302,693 | ||
Financial assets at fair value through other comprehensive income | 45,907 | 51,901 | ||
Other assets | 994 | 614 | ||
Total assets | £ 961,451 | £ 984,537 | ||
On-balance sheet, percentage | ||||
Cash and balances at central banks, percentage | 100.00% | 100.00% | ||
Cash collateral and settlement balance, percentage | 100.00% | 100.00% | ||
Reverse repurchase agreements and other similar secured lending, percentage | 100.00% | 100.00% | ||
Trading portfolio assets, percentage | 100.00% | 100.00% | ||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | ||
Derivative financial instruments, percentage | 100.00% | 100.00% | ||
Financial assets measured at fair value through other comprehensive income, percentage | 100.00% | 100.00% | ||
Other assets, percentage | 100.00% | 100.00% | ||
Total assets, percentage | 100.00% | 100.00% | ||
Internal credit grades | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Cash and balances at central banks | £ 169,085 | £ 155,902 | ||
Cash collateral and settlement balances | 78,881 | 86,882 | ||
Reverse repurchase agreements and other similar secured lending | 3,091 | 8,969 | ||
Trading portfolio assets | 46,660 | 51,813 | ||
Financial assets at fair value through the income statement | 126,999 | 110,930 | ||
Derivative financial instruments | 246,347 | 282,864 | ||
Financial assets at fair value through other comprehensive income | 45,901 | 51,893 | ||
Other assets | 948 | 572 | ||
Total assets | £ 824,130 | £ 843,821 | ||
On-balance sheet, percentage | ||||
Cash and balances at central banks, percentage | 100.00% | 100.00% | ||
Cash collateral and settlement balance, percentage | 90.00% | 89.00% | ||
Reverse repurchase agreements and other similar secured lending, percentage | 97.00% | 100.00% | ||
Trading portfolio assets, percentage | 74.00% | 80.00% | ||
Financial assets at fair value through the income statement, percentage | 70.00% | 66.00% | ||
Derivative financial instruments, percentage | 94.00% | 94.00% | ||
Financial assets measured at fair value through other comprehensive income, percentage | 100.00% | 100.00% | ||
Other assets, percentage | 95.00% | 93.00% | ||
Total assets, percentage | 86.00% | 86.00% | ||
Internal credit grades | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Cash and balances at central banks | £ 0 | £ 0 | ||
Cash collateral and settlement balances | 9,194 | 10,725 | ||
Reverse repurchase agreements and other similar secured lending | 86 | 12 | ||
Trading portfolio assets | 15,879 | 9,978 | ||
Financial assets at fair value through the income statement | 55,819 | 56,326 | ||
Derivative financial instruments | 15,678 | 19,352 | ||
Financial assets at fair value through other comprehensive income | 6 | 8 | ||
Other assets | 46 | 42 | ||
Total assets | £ 130,687 | £ 131,370 | ||
On-balance sheet, percentage | ||||
Cash and balances at central banks, percentage | 0.00% | 0.00% | ||
Cash collateral and settlement balance, percentage | 10.00% | 11.00% | ||
Reverse repurchase agreements and other similar secured lending, percentage | 3.00% | 0.00% | ||
Trading portfolio assets, percentage | 25.00% | 16.00% | ||
Financial assets at fair value through the income statement, percentage | 30.00% | 34.00% | ||
Derivative financial instruments, percentage | 6.00% | 6.00% | ||
Financial assets measured at fair value through other comprehensive income, percentage | 0.00% | 0.00% | ||
Other assets, percentage | 5.00% | 7.00% | ||
Total assets, percentage | 13.00% | 13.00% | ||
Internal credit grades | 11.35% to 100% | ||||
On-balance sheet: | ||||
Cash and balances at central banks | £ 0 | £ 0 | ||
Cash collateral and settlement balances | 10 | 9 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Trading portfolio assets | 686 | 2,753 | ||
Financial assets at fair value through the income statement | 610 | 763 | ||
Derivative financial instruments | 266 | 477 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Other assets | 0 | 0 | ||
Total assets | £ 6,634 | £ 9,346 | ||
On-balance sheet, percentage | ||||
Cash and balances at central banks, percentage | 0.00% | 0.00% | ||
Cash collateral and settlement balance, percentage | 0.00% | 0.00% | ||
Reverse repurchase agreements and other similar secured lending, percentage | 0.00% | 0.00% | ||
Trading portfolio assets, percentage | 1.00% | 4.00% | ||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | ||
Derivative financial instruments, percentage | 0.00% | 0.00% | ||
Financial assets measured at fair value through other comprehensive income, percentage | 0.00% | 0.00% | ||
Other assets, percentage | 0.00% | 0.00% | ||
Total assets, percentage | 1.00% | 1.00% | ||
Internal credit grades | Total loans and advances at amortised cost | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 145,259 | £ 134,267 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | ||
Internal credit grades | Total loans and advances at amortised cost | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 106,218 | £ 93,996 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 73.00% | 70.00% | ||
Internal credit grades | Total loans and advances at amortised cost | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 33,979 | £ 34,927 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 23.00% | 26.00% | ||
Internal credit grades | Total loans and advances at amortised cost | 11.35% to 100% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 5,062 | £ 5,344 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 4.00% | 4.00% | ||
Internal credit grades | Home loans | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 10,985 | £ 11,193 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | ||
Internal credit grades | Home loans | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 9,519 | £ 7,582 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 87.00% | 68.00% | ||
Internal credit grades | Home loans | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 809 | £ 2,840 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 7.00% | 25.00% | ||
Internal credit grades | Home loans | 11.35% to 100% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 657 | £ 771 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 6.00% | 7.00% | ||
Internal credit grades | Credit cards, unsecured loans and other retail lending | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 25,960 | £ 23,368 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | ||
Internal credit grades | Credit cards, unsecured loans and other retail lending | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 18,460 | £ 10,742 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 71.00% | 46.00% | ||
Internal credit grades | Credit cards, unsecured loans and other retail lending | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 6,178 | £ 11,259 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 24.00% | 48.00% | ||
Internal credit grades | Credit cards, unsecured loans and other retail lending | 11.35% to 100% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 1,322 | £ 1,367 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 5.00% | 6.00% | ||
Internal credit grades | Wholesale loans | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 108,314 | £ 99,706 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 100.00% | 100.00% | ||
Internal credit grades | Wholesale loans | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 78,239 | £ 75,672 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 72.00% | 76.00% | ||
Internal credit grades | Wholesale loans | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 26,992 | £ 20,828 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 25.00% | 21.00% | ||
Internal credit grades | Wholesale loans | 11.35% to 100% | ||||
On-balance sheet: | ||||
Loans and advances at amortised cost | £ 3,083 | £ 3,206 | ||
On-balance sheet, percentage | ||||
Loans and advances at amortised cost, percentage | 3.00% | 3.00% | ||
Internal credit grades | Loans and advances | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 35,901 | £ 27,449 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | ||
Internal credit grades | Loans and advances | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 16,977 | £ 13,174 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 47.00% | 48.00% | ||
Internal credit grades | Loans and advances | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 18,896 | £ 14,232 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 53.00% | 52.00% | ||
Internal credit grades | Loans and advances | 11.35% to 100% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 28 | £ 43 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | ||
Internal credit grades | Reverse repurchase agreements | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 145,186 | £ 138,558 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | ||
Internal credit grades | Reverse repurchase agreements | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 108,609 | £ 96,318 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 75.00% | 70.00% | ||
Internal credit grades | Reverse repurchase agreements | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 36,047 | £ 41,566 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 25.00% | 30.00% | ||
Internal credit grades | Reverse repurchase agreements | 11.35% to 100% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 530 | £ 674 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | ||
Internal credit grades | Other financial assets measured at cost | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 85 | £ 315 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | ||
Internal credit grades | Other financial assets measured at cost | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 67 | £ 302 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 79.00% | 96.00% | ||
Internal credit grades | Other financial assets measured at cost | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 18 | £ 13 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 21.00% | 4.00% | ||
Internal credit grades | Other financial assets measured at cost | 11.35% to 100% | ||||
On-balance sheet: | ||||
Financial assets at fair value through the income statement | £ 0 | £ 0 | ||
On-balance sheet, percentage | ||||
Financial assets at fair value through the income statement, percentage | 0.00% | 0.00% | ||
Internal credit grades | Debt securities classified as amortised cost | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 50,700 | £ 56,196 | ||
Financial assets at fair value through the income statement | £ 2,256 | £ 1,697 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 100.00% | 100.00% | ||
Financial assets at fair value through the income statement, percentage | 100.00% | 100.00% | ||
Internal credit grades | Debt securities classified as amortised cost | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 44,488 | £ 51,109 | ||
Financial assets at fair value through the income statement | £ 1,346 | £ 1,136 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 88.00% | 91.00% | ||
Financial assets at fair value through the income statement, percentage | 60.00% | 67.00% | ||
Internal credit grades | Debt securities classified as amortised cost | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 5,735 | £ 4,871 | ||
Financial assets at fair value through the income statement | £ 858 | £ 515 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 11.00% | 9.00% | ||
Financial assets at fair value through the income statement, percentage | 38.00% | 30.00% | ||
Internal credit grades | Debt securities classified as amortised cost | 11.35% to 100% | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 477 | £ 216 | ||
Financial assets at fair value through the income statement | £ 52 | £ 46 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 1.00% | 0.00% | ||
Financial assets at fair value through the income statement, percentage | 2.00% | 3.00% | ||
Internal credit grades | Traded loans | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 12,525 | £ 8,348 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 100.00% | 100.00% | ||
Internal credit grades | Traded loans | 0.0 to 0.60% | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 2,172 | £ 704 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 17.00% | 9.00% | ||
Internal credit grades | Traded loans | 0.60 to 11.35% | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 10,144 | £ 5,107 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 81.00% | 61.00% | ||
Internal credit grades | Traded loans | 11.35% to 100% | ||||
On-balance sheet: | ||||
Trading portfolio assets | £ 209 | £ 2,537 | ||
On-balance sheet, percentage | ||||
Trading portfolio assets, percentage | 2.00% | 30.00% | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Other disclosures - Risk Man_15
Other disclosures - Risk Management and Principal Risks - Credit exposures by internal PD grade (audited) (Details) - GBP (£) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of internal credit grades [line items] | ||
Coverage ratio | 100.00% | |
Other (outside the UK and US tax groups) | ||
Disclosure of internal credit grades [line items] | ||
Guarantees, pledges or commitments | £ 1,700,000,000 | £ 2,600,000,000 |
Financial assets at fair value, class | ||
Disclosure of internal credit grades [line items] | ||
Exposure to credit risk on loan commitments and financial guarantee contracts | 18,800,000,000 | 9,500,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 145,259,000,000 | £ 134,267,000,000 |
Coverage ratio | 2.40% | 3.60% |
Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 148,758,000,000 | £ 139,333,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 129,013,000,000 | 111,804,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 16,397,000,000 | 22,410,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,348,000,000 | 5,119,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,499,000,000 | 5,066,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 796,000,000 | 685,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,019,000,000 | 1,912,000,000 |
Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,684,000,000 | 2,469,000,000 |
Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 23,313,000,000 | £ 20,420,000,000 |
Coverage ratio | 0.90% | 1.40% |
Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 23,515,000,000 | £ 20,703,000,000 |
Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 20,064,000,000 | 16,580,000,000 |
Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,271,000,000 | 3,469,000,000 |
Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 180,000,000 | 654,000,000 |
Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 202,000,000 | 283,000,000 |
Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 58,000,000 | 44,000,000 |
Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 143,000,000 | 229,000,000 |
Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,000,000 | 10,000,000 |
Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 265,583,000,000 | £ 255,288,000,000 |
Coverage ratio | 0.10% | 0.20% |
Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 265,880,000,000 | £ 255,774,000,000 |
Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 236,650,000,000 | 212,160,000,000 |
Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 28,360,000,000 | 42,203,000,000 |
Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 870,000,000 | 1,411,000,000 |
Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 297,000,000 | 486,000,000 |
Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 145,000,000 | 195,000,000 |
Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 131,000,000 | 250,000,000 |
Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21,000,000 | 41,000,000 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,664,000,000 | £ 2,650,000,000 |
Coverage ratio | 50.30% | 48.20% |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,348,000,000 | £ 5,119,000,000 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,348,000,000 | 5,119,000,000 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,684,000,000 | 2,469,000,000 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,684,000,000 | 2,469,000,000 |
100% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 179,000,000 | £ 644,000,000 |
Coverage ratio | 0.60% | 1.50% |
100% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 180,000,000 | £ 654,000,000 |
100% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 180,000,000 | 654,000,000 |
100% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,000,000 | 10,000,000 |
100% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,000,000 | 10,000,000 |
100% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 849,000,000 | £ 1,370,000,000 |
Coverage ratio | 2.40% | 2.90% |
100% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 870,000,000 | £ 1,411,000,000 |
100% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 870,000,000 | 1,411,000,000 |
100% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21,000,000 | 41,000,000 |
100% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
100% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21,000,000 | 41,000,000 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 53,325,000,000 | £ 37,072,000,000 |
Coverage ratio | 0.50% | 0.00% |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 53,611,000,000 | £ 37,077,000,000 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 52,756,000,000 | 36,388,000,000 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 855,000,000 | 689,000,000 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 286,000,000 | 5,000,000 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 280,000,000 | 2,000,000 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,000,000 | 3,000,000 |
Strong | 0.0 to 0.05% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 8,409,000,000 | £ 5,689,000,000 |
Coverage ratio | 0.00% | 0.00% |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 8,412,000,000 | £ 5,690,000,000 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8,240,000,000 | 5,502,000,000 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 172,000,000 | 188,000,000 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,000,000 | 1,000,000 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,000,000 | 1,000,000 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,000,000 | 0 |
Strong | 0.0 to 0.05% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 95,858,000,000 | £ 57,829,000,000 |
Coverage ratio | 0.00% | 0.00% |
Strong | 0.0 to 0.05% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 95,866,000,000 | £ 57,833,000,000 |
Strong | 0.0 to 0.05% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 92,864,000,000 | 52,522,000,000 |
Strong | 0.0 to 0.05% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,002,000,000 | 5,311,000,000 |
Strong | 0.0 to 0.05% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.0 to 0.05% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8,000,000 | 4,000,000 |
Strong | 0.0 to 0.05% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,000,000 | 3,000,000 |
Strong | 0.0 to 0.05% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,000,000 | 1,000,000 |
Strong | 0.0 to 0.05% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 18,000,000,000 | £ 17,614,000,000 |
Coverage ratio | 0.00% | 0.10% |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 18,008,000,000 | £ 17,635,000,000 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 17,797,000,000 | 17,008,000,000 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 211,000,000 | 627,000,000 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8,000,000 | 21,000,000 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,000,000 | 17,000,000 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,000,000 | 4,000,000 |
Strong | 0.05 to 0.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,978,000,000 | £ 3,188,000,000 |
Coverage ratio | 0.10% | 0.20% |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,982,000,000 | £ 3,193,000,000 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,479,000,000 | 2,765,000,000 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 503,000,000 | 428,000,000 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4,000,000 | 5,000,000 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,000,000 | 3,000,000 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,000,000 | 2,000,000 |
Strong | 0.05 to 0.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 61,309,000,000 | £ 68,388,000,000 |
Coverage ratio | 0.00% | 0.00% |
Strong | 0.05 to 0.15% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 61,324,000,000 | £ 68,407,000,000 |
Strong | 0.05 to 0.15% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 55,979,000,000 | 62,677,000,000 |
Strong | 0.05 to 0.15% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,345,000,000 | 5,730,000,000 |
Strong | 0.05 to 0.15% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.05 to 0.15% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 15,000,000 | 19,000,000 |
Strong | 0.05 to 0.15% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10,000,000 | 11,000,000 |
Strong | 0.05 to 0.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,000,000 | 8,000,000 |
Strong | 0.05 to 0.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 11,962,000,000 | £ 16,044,000,000 |
Coverage ratio | 0.20% | 0.50% |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 11,984,000,000 | £ 16,130,000,000 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10,764,000,000 | 13,667,000,000 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,220,000,000 | 2,463,000,000 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 22,000,000 | 86,000,000 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 15,000,000 | 34,000,000 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 7,000,000 | 52,000,000 |
Strong | 0.15 to 0.30% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,191,000,000 | £ 1,626,000,000 |
Coverage ratio | 0.20% | 0.40% |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,195,000,000 | £ 1,633,000,000 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,996,000,000 | 1,468,000,000 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 199,000,000 | 165,000,000 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4,000,000 | 7,000,000 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,000,000 | 3,000,000 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,000,000 | 4,000,000 |
Strong | 0.15 to 0.30% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 24,411,000,000 | £ 47,846,000,000 |
Coverage ratio | 0.10% | 0.10% |
Strong | 0.15 to 0.30% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 24,424,000,000 | £ 47,881,000,000 |
Strong | 0.15 to 0.30% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 22,345,000,000 | 41,621,000,000 |
Strong | 0.15 to 0.30% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,079,000,000 | 6,260,000,000 |
Strong | 0.15 to 0.30% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.15 to 0.30% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 13,000,000 | 35,000,000 |
Strong | 0.15 to 0.30% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 7,000,000 | 15,000,000 |
Strong | 0.15 to 0.30% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,000,000 | 20,000,000 |
Strong | 0.15 to 0.30% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 22,931,000,000 | £ 23,266,000,000 |
Coverage ratio | 0.30% | 0.90% |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 23,001,000,000 | £ 23,481,000,000 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21,865,000,000 | 21,049,000,000 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,136,000,000 | 2,432,000,000 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 70,000,000 | 215,000,000 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 55,000,000 | 88,000,000 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 15,000,000 | 127,000,000 |
Strong | 0.30 to 0.60% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,005,000,000 | £ 4,038,000,000 |
Coverage ratio | 0.20% | 0.90% |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,010,000,000 | £ 4,076,000,000 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,794,000,000 | 3,524,000,000 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 216,000,000 | 552,000,000 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,000,000 | 38,000,000 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4,000,000 | 5,000,000 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,000,000 | 33,000,000 |
Strong | 0.30 to 0.60% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 25,747,000,000 | £ 31,615,000,000 |
Coverage ratio | 0.00% | 0.10% |
Strong | 0.30 to 0.60% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 25,757,000,000 | £ 31,648,000,000 |
Strong | 0.30 to 0.60% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 23,445,000,000 | 25,461,000,000 |
Strong | 0.30 to 0.60% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,312,000,000 | 6,187,000,000 |
Strong | 0.30 to 0.60% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Strong | 0.30 to 0.60% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10,000,000 | 33,000,000 |
Strong | 0.30 to 0.60% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,000,000 | 14,000,000 |
Strong | 0.30 to 0.60% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,000,000 | 19,000,000 |
Strong | 0.30 to 0.60% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 19,661,000,000 | £ 21,220,000,000 |
Coverage ratio | 1.40% | 2.90% |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 19,937,000,000 | £ 21,864,000,000 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 16,429,000,000 | 16,951,000,000 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,508,000,000 | 4,913,000,000 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 276,000,000 | 644,000,000 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 160,000,000 | 293,000,000 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 116,000,000 | 351,000,000 |
Satisfactory | 0.60 to 2.15% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,249,000,000 | £ 3,225,000,000 |
Coverage ratio | 1.20% | 1.00% |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 2,276,000,000 | £ 3,258,000,000 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,990,000,000 | 2,712,000,000 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 286,000,000 | 546,000,000 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 27,000,000 | 33,000,000 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 19,000,000 | 8,000,000 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8,000,000 | 25,000,000 |
Satisfactory | 0.60 to 2.15% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 26,327,000,000 | £ 27,577,000,000 |
Coverage ratio | 0.40% | 0.50% |
Satisfactory | 0.60 to 2.15% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 26,429,000,000 | £ 27,708,000,000 |
Satisfactory | 0.60 to 2.15% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 23,189,000,000 | 20,730,000,000 |
Satisfactory | 0.60 to 2.15% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,240,000,000 | 6,978,000,000 |
Satisfactory | 0.60 to 2.15% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 102,000,000 | 131,000,000 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 79,000,000 | 113,000,000 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 23,000,000 | 18,000,000 |
Satisfactory | 0.60 to 2.15% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 11,177,000,000 | £ 11,091,000,000 |
Coverage ratio | 4.00% | 7.00% |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 11,648,000,000 | £ 11,925,000,000 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,653,000,000 | 5,264,000,000 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 4,995,000,000 | 6,661,000,000 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 471,000,000 | 834,000,000 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 169,000,000 | 183,000,000 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 302,000,000 | 651,000,000 |
Satisfactory | 2.15 to 10% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,281,000,000 | £ 675,000,000 |
Coverage ratio | 1.20% | 4.00% |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,296,000,000 | £ 703,000,000 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 817,000,000 | 305,000,000 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 479,000,000 | 398,000,000 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 15,000,000 | 28,000,000 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 5,000,000 | 7,000,000 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10,000,000 | 21,000,000 |
Satisfactory | 2.15 to 10% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 9,070,000,000 | £ 6,545,000,000 |
Coverage ratio | 0.50% | 1.00% |
Satisfactory | 2.15 to 10% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 9,111,000,000 | £ 6,612,000,000 |
Satisfactory | 2.15 to 10% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,362,000,000 | 3,621,000,000 |
Satisfactory | 2.15 to 10% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,749,000,000 | 2,991,000,000 |
Satisfactory | 2.15 to 10% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 41,000,000 | 67,000,000 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 20,000,000 | 23,000,000 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21,000,000 | 44,000,000 |
Satisfactory | 2.15 to 10% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,141,000,000 | £ 2,616,000,000 |
Coverage ratio | 8.50% | 4.50% |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,432,000,000 | £ 2,740,000,000 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,156,000,000 | 1,042,000,000 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,276,000,000 | 1,698,000,000 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 291,000,000 | 124,000,000 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 39,000,000 | 25,000,000 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 252,000,000 | 99,000,000 |
Satisfactory | 10 to 11.35% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 798,000,000 | £ 587,000,000 |
Coverage ratio | 7.30% | 14.60% |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 861,000,000 | £ 687,000,000 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 607,000,000 | 264,000,000 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 254,000,000 | 423,000,000 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 63,000,000 | 100,000,000 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21,000,000 | 17,000,000 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 42,000,000 | 83,000,000 |
Satisfactory | 10 to 11.35% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 13,213,000,000 | £ 9,713,000,000 |
Coverage ratio | 0.20% | 0.40% |
Satisfactory | 10 to 11.35% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 13,234,000,000 | £ 9,749,000,000 |
Satisfactory | 10 to 11.35% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 10,270,000,000 | 4,778,000,000 |
Satisfactory | 10 to 11.35% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,964,000,000 | 4,971,000,000 |
Satisfactory | 10 to 11.35% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 21,000,000 | 36,000,000 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 8,000,000 | 11,000,000 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 13,000,000 | 25,000,000 |
Satisfactory | 10 to 11.35% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,398,000,000 | £ 2,694,000,000 |
Coverage ratio | 10.30% | 19.90% |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 3,789,000,000 | £ 3,362,000,000 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 593,000,000 | 435,000,000 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,196,000,000 | 2,927,000,000 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 391,000,000 | 668,000,000 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 72,000,000 | 43,000,000 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 319,000,000 | 625,000,000 |
Higher Risk | 11.35% to 100% | Loans and advances at amortised cost | Financial assets at amortised cost | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,223,000,000 | £ 748,000,000 |
Coverage ratio | 6.10% | 7.50% |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 1,303,000,000 | £ 809,000,000 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 141,000,000 | 40,000,000 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 1,162,000,000 | 769,000,000 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 80,000,000 | 61,000,000 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 3,000,000 | 0 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 77,000,000 | 61,000,000 |
Higher Risk | 11.35% to 100% | Contingent liabilities [member] | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35% to 100% | Total commitments | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 8,799,000,000 | £ 4,405,000,000 |
Coverage ratio | 0.70% | 2.70% |
Higher Risk | 11.35% to 100% | Total commitments | Gross | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 8,865,000,000 | £ 4,525,000,000 |
Higher Risk | 11.35% to 100% | Total commitments | Gross | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 2,196,000,000 | 750,000,000 |
Higher Risk | 11.35% to 100% | Total commitments | Gross | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 6,669,000,000 | 3,775,000,000 |
Higher Risk | 11.35% to 100% | Total commitments | Gross | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 0 | 0 |
Higher Risk | 11.35% to 100% | Total commitments | ECL | ECL | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 66,000,000 | 120,000,000 |
Higher Risk | 11.35% to 100% | Total commitments | ECL | Stage 1 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 11,000,000 | 5,000,000 |
Higher Risk | 11.35% to 100% | Total commitments | ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | 55,000,000 | 115,000,000 |
Higher Risk | 11.35% to 100% | Total commitments | ECL | Lifetime expected credit losses | Stage 3 | ||
Disclosure of internal credit grades [line items] | ||
Credit exposure | £ 0 | £ 0 |
Other disclosures - Risk Man_16
Other disclosures - Risk Management and Principal Risks - Management VaR (95%, one day) (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | £ 19 | £ 31 |
Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 36 | 57 |
Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 6 | 17 |
Credit risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 14 | 20 |
Credit risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 30 | 38 |
Credit risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 7 | 10 |
Interest rate risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 7 | 10 |
Interest rate risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 14 | 17 |
Interest rate risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 6 |
Equity risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 9 | 13 |
Equity risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 29 | 35 |
Equity risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 6 |
Basis risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 5 | 9 |
Basis risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 10 | 14 |
Basis risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 3 | 7 |
Spread risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 5 |
Spread risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 6 | 9 |
Spread risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 3 | 3 |
Foreign exchange risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 4 | 4 |
Foreign exchange risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 16 | 7 |
Foreign exchange risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 1 | 2 |
Commodity risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 0 | 1 |
Commodity risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 1 | 1 |
Commodity risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 0 | 0 |
Inflation risk | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 3 | 2 |
Inflation risk | Top of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 5 | 3 |
Inflation risk | Bottom of range | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | 2 | 1 |
Diversification effect | Average | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Value at risk | £ (27) | £ (33) |
Other disclosures - Risk Man_17
Other disclosures - Risk Management and Principal Risks - Contractural maturity of financial assets and liabilities (audited) (Details) £ in Millions, $ in Millions | 12 Months Ended | |||||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |||
Assets | ||||||
Cash and balances at central banks | £ 169,085 | [1] | £ 155,902 | £ 125,940 | ||
Cash collateral and settlement balances | 88,085 | [2] | 97,616 | |||
Loans and advances at amortised cost | 145,259 | [2] | 134,267 | |||
Reverse repurchase agreements and other similar secured lending | 3,177 | [2] | 8,981 | |||
Trading portfolio assets | 146,871 | [2] | 127,664 | |||
Financial assets at fair value through the income statement | 188,226 | [2] | 171,761 | |||
Derivative financial instruments | 262,291 | [2] | 302,693 | |||
Financial assets at fair value through other comprehensive income | 45,908 | [2] | 51,902 | |||
Other financial assets | 994 | 614 | ||||
Non-derivative financial assets | 1,049,896 | $ 132 | 1,051,400 | |||
Other assets | 11,882 | 8,331 | ||||
Total assets | 1,061,778 | [2] | 1,059,731 | 876,700 | ||
Liabilities | ||||||
Deposits at amortised cost | 262,828 | [2] | 244,696 | |||
Cash collateral and settlement balances | 79,047 | [2] | 85,549 | |||
Repurchase agreements and other similar secured borrowing | 12,769 | [2] | 10,443 | |||
Debt securities in issue | 48,388 | [2] | 29,423 | |||
Subordinated liabilities | 32,185 | [2] | 32,005 | 33,425 | ||
Trading portfolio liabilities | 53,291 | 46,139 | ||||
Financial liabilities designated at fair value | 251,131 | [2] | 249,626 | |||
Derivative financial instruments | 256,523 | [2] | 300,580 | |||
Other financial liabilities | 4,592 | 2,810 | ||||
Total financial liabilities | 1,000,754 | 1,001,271 | ||||
Other liabilities | 4,707 | 4,750 | ||||
Total liabilities | 1,005,461 | [2] | 1,006,021 | |||
Cumulative liquidity gap | 56,317 | [3] | 53,710 | [3] | £ 50,615 | |
On demand | ||||||
Assets | ||||||
Cash and balances at central banks | 168,881 | 155,122 | ||||
Cash collateral and settlement balances | 2,743 | 1,281 | ||||
Loans and advances at amortised cost | 17,470 | 12,854 | ||||
Reverse repurchase agreements and other similar secured lending | 58 | 150 | ||||
Trading portfolio assets | 146,871 | 127,664 | ||||
Financial assets at fair value through the income statement | 24,174 | 17,377 | ||||
Derivative financial instruments | 262,046 | 302,429 | ||||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||||
Other financial assets | 607 | 213 | ||||
Non-derivative financial assets | 622,850 | 617,090 | ||||
Liabilities | ||||||
Deposits at amortised cost | 201,501 | 181,455 | ||||
Cash collateral and settlement balances | 2,951 | 1,944 | ||||
Repurchase agreements and other similar secured borrowing | 20 | 4 | ||||
Debt securities in issue | 0 | 0 | ||||
Subordinated liabilities | 0 | 0 | ||||
Trading portfolio liabilities | 53,291 | 46,139 | ||||
Financial liabilities designated at fair value | 21,339 | 15,555 | ||||
Derivative financial instruments | 255,471 | 299,637 | ||||
Other financial liabilities | 87 | 70 | ||||
Total financial liabilities | 534,660 | 544,804 | ||||
Cumulative liquidity gap | 88,190 | 72,286 | ||||
On demand | Over issuance of securities | ||||||
Liabilities | ||||||
Securities issued in excess of limit | 6,997 | |||||
Not more than three months | ||||||
Assets | ||||||
Cash and balances at central banks | 204 | 182 | ||||
Cash collateral and settlement balances | 85,342 | 96,335 | ||||
Loans and advances at amortised cost | 7,855 | 11,149 | ||||
Reverse repurchase agreements and other similar secured lending | 2,934 | 8,648 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 127,244 | 123,948 | ||||
Derivative financial instruments | 36 | 24 | ||||
Financial assets at fair value through other comprehensive income | 3,194 | 3,086 | ||||
Other financial assets | 255 | 286 | ||||
Non-derivative financial assets | 227,064 | 243,658 | ||||
Liabilities | ||||||
Deposits at amortised cost | 41,632 | 39,409 | ||||
Cash collateral and settlement balances | 76,096 | 83,605 | ||||
Repurchase agreements and other similar secured borrowing | 5,022 | 2,545 | ||||
Debt securities in issue | 18,274 | 12,207 | ||||
Subordinated liabilities | 1,005 | 3,708 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 158,078 | 172,250 | ||||
Derivative financial instruments | 4 | 0 | ||||
Other financial liabilities | 3,656 | 2,072 | ||||
Total financial liabilities | 303,767 | 315,796 | ||||
Cumulative liquidity gap | 11,487 | 148 | ||||
Over three months but not more than six months | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 598 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 6,745 | 6,291 | ||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 9,280 | 7,547 | ||||
Derivative financial instruments | 1 | 0 | ||||
Financial assets at fair value through other comprehensive income | 1,080 | 1,627 | ||||
Other financial assets | 130 | 107 | ||||
Non-derivative financial assets | 17,236 | 16,170 | ||||
Liabilities | ||||||
Deposits at amortised cost | 12,380 | 13,975 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||
Debt securities in issue | 12,150 | 3,808 | ||||
Subordinated liabilities | 0 | 3,222 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 16,857 | 8,677 | ||||
Derivative financial instruments | 22 | 50 | ||||
Other financial liabilities | 15 | 15 | ||||
Total financial liabilities | 41,424 | 29,747 | ||||
Cumulative liquidity gap | (12,701) | (13,429) | ||||
Over six months but not more than nine months | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 0 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 4,238 | 3,770 | ||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 7,036 | 6,959 | ||||
Derivative financial instruments | 0 | 0 | ||||
Financial assets at fair value through other comprehensive income | 449 | 151 | ||||
Other financial assets | 2 | 5 | ||||
Non-derivative financial assets | 11,725 | 10,885 | ||||
Liabilities | ||||||
Deposits at amortised cost | 1,920 | 3,665 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||
Debt securities in issue | 5,845 | 3,833 | ||||
Subordinated liabilities | 74 | 459 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 10,267 | 5,067 | ||||
Derivative financial instruments | 0 | 0 | ||||
Other financial liabilities | 15 | 15 | ||||
Total financial liabilities | 18,121 | 13,039 | ||||
Cumulative liquidity gap | (19,097) | (15,583) | ||||
Over nine months but not more than one year | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 0 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 9,611 | 4,314 | ||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 3,336 | 4,027 | ||||
Derivative financial instruments | 0 | 0 | ||||
Financial assets at fair value through other comprehensive income | 547 | 95 | ||||
Other financial assets | 0 | 0 | ||||
Non-derivative financial assets | 13,494 | 8,436 | ||||
Liabilities | ||||||
Deposits at amortised cost | 2,898 | 2,283 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||
Debt securities in issue | 3,254 | 1,791 | ||||
Subordinated liabilities | 1,243 | 143 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 3,588 | 2,928 | ||||
Derivative financial instruments | 2 | 0 | ||||
Other financial liabilities | 12 | 16 | ||||
Total financial liabilities | 10,997 | 7,161 | ||||
Cumulative liquidity gap | (16,600) | (14,308) | ||||
Over one year but not more than two years | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 0 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 19,162 | 21,271 | ||||
Reverse repurchase agreements and other similar secured lending | 184 | 0 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 5,351 | 4,294 | ||||
Derivative financial instruments | 0 | 15 | ||||
Financial assets at fair value through other comprehensive income | 2,656 | 3,059 | ||||
Other financial assets | 0 | 3 | ||||
Non-derivative financial assets | 27,353 | 28,642 | ||||
Liabilities | ||||||
Deposits at amortised cost | 558 | 1,144 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 3,216 | 1,400 | ||||
Debt securities in issue | 463 | 2,124 | ||||
Subordinated liabilities | 7,030 | 3,545 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 6,534 | 8,593 | ||||
Derivative financial instruments | 121 | 66 | ||||
Other financial liabilities | 443 | 233 | ||||
Total financial liabilities | 18,365 | 17,105 | ||||
Cumulative liquidity gap | (7,612) | (2,771) | ||||
Over two years but not more than three years | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 0 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 20,813 | 16,663 | ||||
Reverse repurchase agreements and other similar secured lending | 0 | 183 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 5,376 | 1,216 | ||||
Derivative financial instruments | 0 | 15 | ||||
Financial assets at fair value through other comprehensive income | 5,389 | 3,770 | ||||
Other financial assets | 0 | 0 | ||||
Non-derivative financial assets | 31,578 | 21,847 | ||||
Liabilities | ||||||
Deposits at amortised cost | 435 | 532 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 4,424 | 2,329 | ||||
Debt securities in issue | 3,319 | 640 | ||||
Subordinated liabilities | 2,251 | 4,811 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 6,114 | 6,939 | ||||
Derivative financial instruments | 151 | 67 | ||||
Other financial liabilities | 52 | 50 | ||||
Total financial liabilities | 16,746 | 15,368 | ||||
Cumulative liquidity gap | 7,220 | 3,708 | ||||
Over three years but not more than five years | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 0 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 27,416 | 22,387 | ||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 2,062 | 2,284 | ||||
Derivative financial instruments | 184 | 112 | ||||
Financial assets at fair value through other comprehensive income | 10,093 | 12,741 | ||||
Other financial assets | 0 | 0 | ||||
Non-derivative financial assets | 39,755 | 37,524 | ||||
Liabilities | ||||||
Deposits at amortised cost | 242 | 602 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 0 | 4,073 | ||||
Debt securities in issue | 1,792 | 2,815 | ||||
Subordinated liabilities | 5,714 | 6,241 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 7,734 | 8,576 | ||||
Derivative financial instruments | 279 | 174 | ||||
Other financial liabilities | 102 | 90 | ||||
Total financial liabilities | 15,863 | 22,571 | ||||
Cumulative liquidity gap | 31,112 | 18,661 | ||||
Over five years but not more than ten years | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 0 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 14,420 | 14,127 | ||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 1,996 | 1,853 | ||||
Derivative financial instruments | 15 | 77 | ||||
Financial assets at fair value through other comprehensive income | 13,823 | 19,236 | ||||
Other financial assets | 0 | 0 | ||||
Non-derivative financial assets | 30,254 | 35,293 | ||||
Liabilities | ||||||
Deposits at amortised cost | 1,031 | 1,252 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||||
Debt securities in issue | 2,654 | 1,995 | ||||
Subordinated liabilities | 8,490 | 5,629 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 7,366 | 8,344 | ||||
Derivative financial instruments | 111 | 183 | ||||
Other financial liabilities | 183 | 187 | ||||
Total financial liabilities | 19,835 | 17,590 | ||||
Cumulative liquidity gap | 41,531 | 36,364 | ||||
Over ten years | ||||||
Assets | ||||||
Cash and balances at central banks | 0 | 0 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Loans and advances at amortised cost | 17,529 | 21,441 | ||||
Reverse repurchase agreements and other similar secured lending | 1 | 0 | ||||
Trading portfolio assets | 0 | 0 | ||||
Financial assets at fair value through the income statement | 2,371 | 2,256 | ||||
Derivative financial instruments | 9 | 21 | ||||
Financial assets at fair value through other comprehensive income | 8,677 | 8,137 | ||||
Other financial assets | 0 | 0 | ||||
Non-derivative financial assets | 28,587 | 31,855 | ||||
Liabilities | ||||||
Deposits at amortised cost | 231 | 379 | ||||
Cash collateral and settlement balances | 0 | 0 | ||||
Repurchase agreements and other similar secured borrowing | 87 | 92 | ||||
Debt securities in issue | 637 | 210 | ||||
Subordinated liabilities | 6,378 | 4,247 | ||||
Trading portfolio liabilities | 0 | 0 | ||||
Financial liabilities designated at fair value | 13,254 | 12,697 | ||||
Derivative financial instruments | 362 | 403 | ||||
Other financial liabilities | 27 | 62 | ||||
Total financial liabilities | 20,976 | 18,090 | ||||
Cumulative liquidity gap | £ 49,142 | £ 50,129 | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Other disclosures - Risk Man_18
Other disclosures - Risk Management and Principal Risks - Contractural maturity of financial liabilities - undiscounted (audited) (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | £ 262,876 | £ 244,717 |
Cash collateral and settlement balances, undiscounted | 79,047 | 85,549 |
Repurchase agreements and other similar secured lending, undiscounted | 12,986 | 10,519 |
Debt securities in issue, undiscounted | 48,929 | 29,770 |
Subordinated liabilities, undiscounted | 35,380 | 36,583 |
Trading portfolio liabilities, undiscounted | 53,291 | 46,139 |
Financial liabilities designated at fair value, undiscounted | 260,044 | 257,471 |
Derivative financial instruments, undiscounted | 256,637 | 300,631 |
Other financial liabilities, undiscounted | 4,687 | 2,943 |
Total financial liabilities, undiscounted cash flows | 1,013,877 | 1,014,322 |
On demand | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 201,501 | 181,455 |
Cash collateral and settlement balances, undiscounted | 2,951 | 1,944 |
Repurchase agreements and other similar secured lending, undiscounted | 20 | 4 |
Debt securities in issue, undiscounted | 0 | 0 |
Subordinated liabilities, undiscounted | 0 | 0 |
Trading portfolio liabilities, undiscounted | 53,291 | 46,139 |
Financial liabilities designated at fair value, undiscounted | 21,339 | 15,555 |
Derivative financial instruments, undiscounted | 255,471 | 299,637 |
Other financial liabilities, undiscounted | 87 | 70 |
Total financial liabilities, undiscounted cash flows | 534,660 | 544,804 |
On demand | Over issuance of securities | ||
Disclosure of financial liabilities [line items] | ||
Securities issued in excess of limit, undiscounted | 6,997 | |
Not more than three months | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 41,632 | 39,409 |
Cash collateral and settlement balances, undiscounted | 76,096 | 83,605 |
Repurchase agreements and other similar secured lending, undiscounted | 5,022 | 2,545 |
Debt securities in issue, undiscounted | 18,293 | 12,226 |
Subordinated liabilities, undiscounted | 1,061 | 3,716 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 158,249 | 172,282 |
Derivative financial instruments, undiscounted | 4 | 4 |
Other financial liabilities, undiscounted | 3,658 | 2,076 |
Total financial liabilities, undiscounted cash flows | 304,015 | 315,863 |
Over three months but not more than six months | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 12,380 | 13,975 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 0 | 0 |
Debt securities in issue, undiscounted | 12,168 | 3,818 |
Subordinated liabilities, undiscounted | 0 | 3,342 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 16,887 | 8,684 |
Derivative financial instruments, undiscounted | 22 | 50 |
Other financial liabilities, undiscounted | 19 | 19 |
Total financial liabilities, undiscounted cash flows | 41,476 | 29,888 |
Over six months but not more than one year | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 4,818 | 5,949 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 0 | 0 |
Debt securities in issue, undiscounted | 9,075 | 5,629 |
Subordinated liabilities, undiscounted | 1,404 | 703 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 13,945 | 7,998 |
Derivative financial instruments, undiscounted | 2 | 0 |
Other financial liabilities, undiscounted | 38 | 39 |
Total financial liabilities, undiscounted cash flows | 29,282 | 20,318 |
Over one year but not more than three years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 996 | 1,686 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 7,798 | 3,729 |
Debt securities in issue, undiscounted | 3,879 | 2,799 |
Subordinated liabilities, undiscounted | 9,328 | 8,845 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 12,939 | 15,599 |
Derivative financial instruments, undiscounted | 276 | 133 |
Other financial liabilities, undiscounted | 526 | 313 |
Total financial liabilities, undiscounted cash flows | 35,742 | 33,104 |
Over three years but not more than five years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 240 | 600 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 0 | 4,087 |
Debt securities in issue, undiscounted | 1,832 | 2,923 |
Subordinated liabilities, undiscounted | 5,917 | 6,555 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 8,043 | 8,586 |
Derivative financial instruments, undiscounted | 291 | 175 |
Other financial liabilities, undiscounted | 122 | 113 |
Total financial liabilities, undiscounted cash flows | 16,445 | 23,039 |
Over five years but not more than ten years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 1,048 | 1,258 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 0 | 0 |
Debt securities in issue, undiscounted | 2,938 | 2,098 |
Subordinated liabilities, undiscounted | 8,918 | 6,922 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 7,544 | 8,369 |
Derivative financial instruments, undiscounted | 122 | 190 |
Other financial liabilities, undiscounted | 208 | 227 |
Total financial liabilities, undiscounted cash flows | 20,778 | 19,064 |
Over ten years | ||
Disclosure of financial liabilities [line items] | ||
Deposits at amortised cost, undiscounted | 261 | 385 |
Cash collateral and settlement balances, undiscounted | 0 | 0 |
Repurchase agreements and other similar secured lending, undiscounted | 146 | 154 |
Debt securities in issue, undiscounted | 744 | 277 |
Subordinated liabilities, undiscounted | 8,752 | 6,500 |
Trading portfolio liabilities, undiscounted | 0 | 0 |
Financial liabilities designated at fair value, undiscounted | 21,098 | 20,398 |
Derivative financial instruments, undiscounted | 449 | 442 |
Other financial liabilities, undiscounted | 29 | 86 |
Total financial liabilities, undiscounted cash flows | £ 31,479 | £ 28,242 |
Other disclosures - Risk Man_19
Other disclosures - Risk Management and Principal Risks - Maturity analysis of off-balance sheet commitments received/given (audited) (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | £ 7,515 | £ 6,805 |
Other commitments received | 455 | 92 |
Total off-balance sheet commitments received | 7,970 | 6,897 |
Contingent liabilities | 23,746 | 20,932 |
Documentary credits and other short-term trade related transactions | 1,584 | 1,086 |
Standby facilities, credit lines and other commitments | 282,867 | 263,936 |
Total off-balance sheet | 308,197 | 285,954 |
Other (outside the UK and US tax groups) | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, pledges or commitments | 1,700 | 2,600 |
On demand | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 7,258 | 6,462 |
Other commitments received | 455 | 92 |
Total off-balance sheet commitments received | 7,713 | 6,554 |
Contingent liabilities | 23,607 | 20,630 |
Documentary credits and other short-term trade related transactions | 1,582 | 1,084 |
Standby facilities, credit lines and other commitments | 282,867 | 262,586 |
Total off-balance sheet | 308,056 | 284,300 |
Not more than three months | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 31 | 86 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 31 | 86 |
Contingent liabilities | 135 | 213 |
Documentary credits and other short-term trade related transactions | 2 | 1 |
Standby facilities, credit lines and other commitments | 0 | 564 |
Total off-balance sheet | 137 | 778 |
Over three months but not more than six months | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 21 | 37 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 21 | 37 |
Contingent liabilities | 4 | 57 |
Documentary credits and other short-term trade related transactions | 0 | 1 |
Standby facilities, credit lines and other commitments | 0 | 93 |
Total off-balance sheet | 4 | 151 |
Over six months but not more than nine months | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 10 | 68 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 10 | 68 |
Contingent liabilities | 0 | 6 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 123 |
Total off-balance sheet | 0 | 129 |
Over nine months but not more than one year | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 12 | 8 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 12 | 8 |
Contingent liabilities | 0 | 1 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 95 |
Total off-balance sheet | 0 | 96 |
Over one year but not more than two years | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 4 | 18 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 4 | 18 |
Contingent liabilities | 0 | 25 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 49 |
Total off-balance sheet | 0 | 74 |
Over two years but not more than three years | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 12 | 14 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 12 | 14 |
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 196 |
Total off-balance sheet | 0 | 196 |
Over three years but not more than five years | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 83 | 47 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 83 | 47 |
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 202 |
Total off-balance sheet | 0 | 202 |
Over five years but not more than ten years | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 65 | 40 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 65 | 40 |
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 21 |
Total off-balance sheet | 0 | 21 |
Over ten years | ||
Disclosure of contingent liabilities [line items] | ||
Guarantees, letters of credit and credit insurance | 19 | 25 |
Other commitments received | 0 | 0 |
Total off-balance sheet commitments received | 19 | 25 |
Contingent liabilities | 0 | 0 |
Documentary credits and other short-term trade related transactions | 0 | 0 |
Standby facilities, credit lines and other commitments | 0 | 7 |
Total off-balance sheet | £ 0 | £ 7 |
Other disclosures - Risk Man_20
Other disclosures - Risk Management and Principal Risks - Capital resources (audited) (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of objectives, policies and processes for managing capital [line items] | ||
Risk weighted assets | £ 185,467 | £ 178,156 |
CET1 capital | ||
Disclosure of objectives, policies and processes for managing capital [line items] | ||
PRA transitional regulatory capital | 23,928 | 25,227 |
T1 capital | ||
Disclosure of objectives, policies and processes for managing capital [line items] | ||
PRA transitional regulatory capital | 32,395 | 32,172 |
Total regulatory capital | ||
Disclosure of objectives, policies and processes for managing capital [line items] | ||
PRA transitional regulatory capital | £ 37,954 | £ 37,493 |
Other disclosures - Risk Man_21
Other disclosures - Risk Management and Principal Risks - Functional currency of operations (audited) (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | £ 37,064 | £ 31,614 |
Borrowings which hedge the net investments | (6,933) | (4,832) |
Derivatives which hedge the net investments | (2,423) | (791) |
Structural currency exposures pre- economic hedges | 27,708 | 25,991 |
Economic hedges | (7,378) | (6,204) |
Remaining structural currency exposures | 20,330 | 19,787 |
Financial instrument which hedge net investments | 9,400 | 5,600 |
USD LIBOR | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 26,023 | 24,262 |
Borrowings which hedge the net investments | (5,512) | (4,512) |
Derivatives which hedge the net investments | (2,356) | (764) |
Structural currency exposures pre- economic hedges | 18,155 | 18,986 |
Economic hedges | (7,111) | (5,918) |
Remaining structural currency exposures | 11,044 | 13,068 |
Increase in financial instruments which hedge net investments | (500) | |
EUR LIBOR | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 8,342 | 5,174 |
Borrowings which hedge the net investments | (1,324) | (278) |
Derivatives which hedge the net investments | (3) | (3) |
Structural currency exposures pre- economic hedges | 7,015 | 4,893 |
Economic hedges | (267) | (286) |
Remaining structural currency exposures | 6,748 | 4,607 |
Increase in financial instruments which hedge net investments | 3,200 | |
JPY LIBOR | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 614 | 582 |
Borrowings which hedge the net investments | (97) | 0 |
Derivatives which hedge the net investments | 0 | 0 |
Structural currency exposures pre- economic hedges | 517 | 582 |
Economic hedges | 0 | 0 |
Remaining structural currency exposures | 517 | 582 |
Other Currencies [Member] | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 2,085 | 1,596 |
Borrowings which hedge the net investments | 0 | (42) |
Derivatives which hedge the net investments | (64) | (24) |
Structural currency exposures pre- economic hedges | 2,021 | 1,530 |
Economic hedges | 0 | 0 |
Remaining structural currency exposures | 2,021 | 1,530 |
Increase in financial instruments which hedge net investments | 1,800 | |
Foreign exchange risk | ||
Disclosure of risk management strategy related to hedge accounting [line items] | ||
Foreign currency net investments | 37,100 | 31,600 |
Remaining structural currency exposures | 20,300 | £ 19,800 |
Increase in structural currency exposures, net of hedging instruments | 500 | |
Increase in foreign currency net investments | 5,500 | |
Increase in financial instruments which hedge net investments | £ (3,800) |
Other disclosures - Risk Man_22
Other disclosures - Risk Management and Principal Risks - Interest Income sensitivity (AEaR) by currency (audited) (Details) - +/- 25bps - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Interest rate risk | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | £ 68 | £ 86 |
Net interest income sensitivity (AEaR), decrease | (99) | (263) |
Interest rate risk | Pro Forma | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 67 | |
GBP LIBOR | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 21 | 32 |
Net interest income sensitivity (AEaR), decrease | (37) | (169) |
USD LIBOR | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | 55 | 47 |
Net interest income sensitivity (AEaR), decrease | (59) | (61) |
EUR LIBOR | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | (5) | 9 |
Net interest income sensitivity (AEaR), decrease | (4) | (32) |
Other currencies | ||
Disclosure of operating segments [line items] | ||
Net interest income sensitivity (AEaR), increase | (3) | (2) |
Net interest income sensitivity (AEaR), decrease | £ 1 | £ (1) |
Other disclosures - Risk Man_23
Other disclosures - Risk Management and Principal Risks - Analysis of equity sensitivity (audited) (Details) - Interest rate risk - +/- 25bps - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | £ 68 | £ 86 |
Effect on profit for the year, decrease | (99) | (263) |
Effect on equity, increase | (729) | (644) |
Effect on equity, decrease | 653 | 521 |
Pro Forma | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | 67 | |
Effect on equity, increase | (617) | |
Retained earnings | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | 56 | 65 |
Effect on profit for the year, decrease | £ (81) | £ (200) |
As percentage, increase | 1.20% | 2.70% |
Percentage of reasonably possible decrease in risk exposure that arises from contracts within scope of IFRS 17 | (1.80%) | (8.20%) |
Effect on equity, increase | £ 56 | £ 65 |
Effect on equity, decrease | (81) | (200) |
Taxation effects on the above | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on profit for the year, increase | (12) | (21) |
Effect on profit for the year, decrease | 18 | 63 |
Effect on equity, increase | 290 | 262 |
Effect on equity, decrease | (272) | (266) |
Fair value through other comprehensive income reserve | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on equity, increase | (449) | (417) |
Effect on equity, decrease | 380 | 433 |
Cash flow hedge reserve | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
Effect on equity, increase | (626) | (554) |
Effect on equity, decrease | £ 626 | £ 554 |
Equity attributable to owners of parent | ||
Disclosure of sensitivity analysis to changes in risk exposures that arise from contracts within scope of IFRS 17 [line items] | ||
As percentage, increase | (1.30%) | (1.20%) |
Percentage of reasonably possible decrease in risk exposure that arises from contracts within scope of IFRS 17 | 1.20% | 1.00% |
Significant accounting polici_4
Significant accounting policies - Narrative (Details) £ in Millions, $ in Billions | Sep. 30, 2022 | Apr. 29, 2022GBP (£) | Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Mar. 10, 2022USD ($) | Mar. 31, 2022GBP (£) | Sep. 30, 2021GBP (£) | |
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | £ (374) | [1] | £ (76) | £ (264) | |||||
Total operating expenses | (10,259) | [1] | (9,459) | (9,982) | |||||
Provisions | 1,110 | [2] | 1,208 | ||||||
Taxation | (830) | [1] | (624) | (332) | |||||
Current tax liabilities | 688 | [2] | 644 | ||||||
Profit after tax | £ 4,588 | [1] | £ 2,451 | 2,780 | |||||
CET1 ratio | 12.90% | 14.20% | |||||||
T1 capital ratio | 17.50% | 18.10% | |||||||
Total regulatory capital ratio | 20.50% | 21.00% | |||||||
Other provisions | £ 1,110 | £ 1,208 | |||||||
Notional contract amount | 47,412,915 | 42,625,605 | |||||||
Net surplus | 3,633 | 1,582 | |||||||
Capital contribution from Barclays Plc | 0 | [3] | 1,500 | ||||||
Forecast | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Reasonably possible decrease in capital ratio | 0.65% | ||||||||
UK | Pension defined benefit plans | UKRF | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Net surplus | 3,819 | 1,807 | £ 600 | ||||||
Total loans and advances at amortised cost | The senior notes | UK | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Notional contract amount | 1,250 | 1,250 | |||||||
Disclosure of post year end balances | Forecast | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Reasonably possible decrease in capital ratio | 0.65% | ||||||||
Disclosure of post year end balances | UK | Pension defined benefit plans | UKRF | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Net surplus | £ 4,400 | £ 600 | |||||||
Capital contribution from parent | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Capital contribution from Barclays Plc | £ 750 | ||||||||
Customer Remediation Provision | Disclosure of post year end balances | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Other provisions | £ 181 | ||||||||
CET1 capital | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
PRA transitional regulatory capital | (23,928) | (25,227) | |||||||
Barclays Bank PLC | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | (360) | [4] | (60) | (154) | |||||
Total operating expenses | (5,525) | [4] | (4,991) | (5,160) | |||||
Provisions | 919 | [5] | 984 | ||||||
Taxation | 113 | [4] | (21) | 391 | |||||
Current tax liabilities | 342 | [5] | 336 | ||||||
Profit after tax | 3,436 | [4],[6] | 2,134 | £ 2,409 | |||||
Capital contribution from Barclays Plc | £ 1,500 | ||||||||
Barclays Bank PLC | Capital contribution from parent | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Capital contribution from Barclays Plc | £ 750 | ||||||||
As reported £m | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | (154) | ||||||||
Total operating expenses | (10,039) | ||||||||
Provisions | 890 | ||||||||
Taxation | (880) | ||||||||
Current tax liabilities | 738 | ||||||||
Profit after tax | 4,758 | ||||||||
As reported £m | Barclays Bank PLC | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | (140) | ||||||||
Total operating expenses | (5,305) | ||||||||
Provisions | 699 | ||||||||
Taxation | 63 | ||||||||
Current tax liabilities | 392 | ||||||||
Profit after tax | 3,606 | ||||||||
Restatement £m | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | (220) | ||||||||
Total operating expenses | (220) | ||||||||
Provisions | 220 | ||||||||
Taxation | 50 | ||||||||
Current tax liabilities | (50) | ||||||||
Profit after tax | (170) | ||||||||
Restatement £m | Barclays Bank PLC | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | (220) | ||||||||
Total operating expenses | (220) | ||||||||
Provisions | 220 | ||||||||
Taxation | 50 | ||||||||
Current tax liabilities | (50) | ||||||||
Profit after tax | £ (170) | ||||||||
United States | Over issuance of securities | Disclosure of post year end balances | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Securities issued in excess of limit | $ | $ 15 | ||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[6] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details.The Parent company financials on pages 111 to 114 form part of this note. |
Significant accounting polici_5
Significant accounting policies (Details) - GBP (£) £ in Millions | 12 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |||
Disclosure of retrospective restatement [Line Items] | |||||
Litigation and conduct | £ 374 | [1] | £ 76 | £ 264 | |
Operating expenses | 10,259 | [1] | 9,459 | 9,982 | |
Profit/(loss) before tax | 5,418 | [2] | 3,075 | 3,112 | |
Taxation | 830 | [1] | 624 | 332 | |
Profit after tax | 4,588 | [1] | 2,451 | 2,780 | |
Total comprehensive income for the year | 2,903 | [3] | 2,294 | 2,476 | |
Current tax liabilities | 688 | [4] | 644 | ||
Provisions | 1,110 | [4] | 1,208 | ||
Total liabilities | 1,005,461 | [4] | 1,006,021 | ||
Retained earnings | 43,415 | [4] | 39,558 | ||
Total equity | 56,317 | [5] | 53,710 | [5] | 50,615 |
Adjustment for non-cash items | |||||
Other provisions, including pensions | 85 | [2] | 634 | 417 | |
Equity holders of the parent | 3,957 | [1] | 1,774 | 2,120 | |
Barclays Bank PLC | |||||
Disclosure of retrospective restatement [Line Items] | |||||
Litigation and conduct | 360 | [6] | 60 | 154 | |
Operating expenses | 5,525 | [6] | 4,991 | 5,160 | |
Profit/(loss) before tax | 3,323 | [6] | 2,155 | 2,018 | |
Taxation | (113) | [6] | 21 | (391) | |
Profit after tax | 3,436 | [6],[7] | 2,134 | 2,409 | |
Total comprehensive income for the year | 2,029 | [7],[8] | 2,121 | 2,510 | |
Current tax liabilities | 342 | [9] | 336 | ||
Provisions | 919 | [9] | 984 | ||
Total liabilities | 1,011,979 | [9] | 1,030,409 | ||
Retained earnings | 37,180 | [9] | 34,691 | ||
Total equity | 52,692 | [8] | 51,143 | [8] | 46,425 |
Adjustment for non-cash items | |||||
Other provisions, including pensions | 75 | [10] | 505 | 268 | |
Equity holders of the parent | 2,641 | [6] | £ 1,305 | £ 1,570 | |
As reported £m | |||||
Disclosure of retrospective restatement [Line Items] | |||||
Litigation and conduct | 154 | ||||
Operating expenses | 10,039 | ||||
Profit/(loss) before tax | 5,638 | ||||
Taxation | 880 | ||||
Profit after tax | 4,758 | ||||
Total comprehensive income for the year | 3,073 | ||||
Current tax liabilities | 738 | ||||
Provisions | 890 | ||||
Total liabilities | 1,005,291 | ||||
Retained earnings | 43,585 | ||||
Total equity | 56,487 | ||||
Adjustment for non-cash items | |||||
Other provisions, including pensions | (135) | ||||
As reported £m | Barclays Bank PLC | |||||
Disclosure of retrospective restatement [Line Items] | |||||
Litigation and conduct | 140 | ||||
Operating expenses | 5,305 | ||||
Profit/(loss) before tax | 3,543 | ||||
Taxation | (63) | ||||
Profit after tax | 3,606 | ||||
Total comprehensive income for the year | 2,199 | ||||
Current tax liabilities | 392 | ||||
Provisions | 699 | ||||
Total liabilities | 1,011,809 | ||||
Retained earnings | 37,350 | ||||
Total equity | 52,862 | ||||
Adjustment for non-cash items | |||||
Other provisions, including pensions | (145) | ||||
Equity holders of the parent | 2,811 | ||||
Restatement £m | |||||
Disclosure of retrospective restatement [Line Items] | |||||
Litigation and conduct | 220 | ||||
Operating expenses | 220 | ||||
Profit/(loss) before tax | (220) | ||||
Taxation | (50) | ||||
Profit after tax | (170) | ||||
Total comprehensive income for the year | (170) | ||||
Current tax liabilities | (50) | ||||
Provisions | 220 | ||||
Total liabilities | 170 | ||||
Retained earnings | (170) | ||||
Total equity | (170) | ||||
Adjustment for non-cash items | |||||
Other provisions, including pensions | 220 | ||||
Restatement £m | Barclays Bank PLC | |||||
Disclosure of retrospective restatement [Line Items] | |||||
Litigation and conduct | 220 | ||||
Operating expenses | 220 | ||||
Profit/(loss) before tax | (220) | ||||
Taxation | (50) | ||||
Profit after tax | (170) | ||||
Total comprehensive income for the year | (170) | ||||
Current tax liabilities | (50) | ||||
Provisions | 220 | ||||
Total liabilities | 170 | ||||
Retained earnings | (170) | ||||
Total equity | (170) | ||||
Adjustment for non-cash items | |||||
Other provisions, including pensions | 220 | ||||
Equity holders of the parent | £ (170) | ||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[6] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[7] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details.The Parent company financials on pages 111 to 114 form part of this note. | ||||
[8] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[9] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||
[10] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Segmental reporting - Analysis
Segmental reporting - Analysis of results by business (Details) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021GBP (£)Employees | Dec. 31, 2020GBP (£)Employees | Dec. 31, 2019GBP (£)Employees | ||
Disclosure of operating segments [line items] | ||||
Total income | £ 15,408 | [1] | £ 15,778 | £ 14,151 |
Credit impairment charges | 277 | [1] | (3,377) | (1,202) |
Net operating income | 15,685 | [1] | 12,401 | 12,949 |
Operating expenses | (9,885) | (9,383) | (9,718) | |
Litigation and conduct | (374) | (76) | (264) | |
Total operating expenses | (10,259) | [1] | (9,459) | (9,982) |
Other net income/(expenses) | (8) | 133 | 145 | |
Profit before tax | 5,418 | [2] | 3,075 | 3,112 |
Total assets (£bn) | £ 1,061,778 | [3] | £ 1,059,731 | £ 876,700 |
Number of employees (full time equivalent) | Employees | 20,200 | 20,900 | 20,500 | |
Average number of employees (full time equivalent) | Employees | 20,300 | 20,145 | 21,700 | |
Operating segments | Corporate and Investment Bank | ||||
Disclosure of operating segments [line items] | ||||
Total income | £ 12,481 | £ 12,607 | £ 10,009 | |
Credit impairment charges | 461 | (1,565) | (157) | |
Net operating income | 12,942 | 11,042 | 9,852 | |
Operating expenses | (7,169) | (7,125) | (7,267) | |
Litigation and conduct | (237) | (4) | (108) | |
Total operating expenses | (7,406) | (7,129) | (7,375) | |
Other net income/(expenses) | (8) | 16 | 113 | |
Profit before tax | 5,528 | 3,929 | 2,590 | |
Total assets (£bn) | £ 986,200 | £ 990,900 | £ 799,600 | |
Number of employees (full time equivalent) | Employees | 7,800 | 7,800 | 8,100 | |
Operating segments | Consumer, Cards and Payments | ||||
Disclosure of operating segments [line items] | ||||
Total income | £ 3,337 | £ 3,490 | £ 4,462 | |
Credit impairment charges | (185) | (1,720) | (1,016) | |
Net operating income | 3,152 | 1,770 | 3,446 | |
Operating expenses | (2,316) | (2,132) | (2,359) | |
Litigation and conduct | (108) | (44) | (7) | |
Total operating expenses | (2,424) | (2,176) | (2,366) | |
Other net income/(expenses) | 1 | 114 | 40 | |
Profit before tax | 729 | (292) | 1,120 | |
Total assets (£bn) | £ 64,400 | £ 57,800 | £ 65,700 | |
Number of employees (full time equivalent) | Employees | 2,600 | 3,000 | 3,100 | |
Head Office | ||||
Disclosure of operating segments [line items] | ||||
Total income | £ (410) | £ (319) | £ (320) | |
Credit impairment charges | 1 | (92) | (29) | |
Net operating income | (409) | (411) | (349) | |
Operating expenses | (400) | (126) | (92) | |
Litigation and conduct | (29) | (28) | (149) | |
Total operating expenses | (429) | (154) | (241) | |
Other net income/(expenses) | (1) | 3 | (8) | |
Profit before tax | (839) | (562) | (598) | |
Total assets (£bn) | £ 11,200 | £ 11,000 | £ 11,400 | |
Number of employees (full time equivalent) | Employees | 9,800 | 10,100 | 9,300 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Segmental reporting - Income by
Segmental reporting - Income by geographic region (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of operating segments [line items] | ||||
Total income | £ 15,408 | [1] | £ 15,778 | £ 14,151 |
United Kingdom | ||||
Disclosure of operating segments [line items] | ||||
Total income | 4,585 | 4,954 | 4,084 | |
United Kingdom | Income from individual countries which represent more than 5% of total income | ||||
Disclosure of operating segments [line items] | ||||
Total income | 4,585 | 4,954 | 4,084 | |
Europe | ||||
Disclosure of operating segments [line items] | ||||
Total income | 2,358 | 2,119 | 1,752 | |
Americas | ||||
Disclosure of operating segments [line items] | ||||
Total income | 7,326 | 7,590 | 7,251 | |
Africa and Middle East | ||||
Disclosure of operating segments [line items] | ||||
Total income | 45 | 37 | 62 | |
Asia | ||||
Disclosure of operating segments [line items] | ||||
Total income | 1,094 | 1,078 | 1,002 | |
United States | Income from individual countries which represent more than 5% of total income | ||||
Disclosure of operating segments [line items] | ||||
Total income | £ 7,162 | £ 7,471 | £ 7,121 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Net interest income - Summary (
Net interest income - Summary (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Analysis of income and expense [abstract] | ||||
Cash and balances at central banks | £ 128 | £ 226 | £ 919 | |
Loans and advances at amortised cost | 4,265 | 4,510 | 5,514 | |
Fair value through other comprehensive income | 380 | 604 | 831 | |
Negative interest on liabilities | 248 | 68 | 13 | |
Other | 651 | 598 | 808 | |
Interest and similar income | 5,672 | [1] | 6,006 | 8,085 |
Deposits at amortised cost | (331) | (644) | (1,778) | |
Debt securities in issue | (413) | (424) | (873) | |
Subordinated liabilities | (934) | (1,112) | (1,096) | |
Negative interest on assets | (374) | (325) | (250) | |
Other | (547) | (341) | (181) | |
Interest and similar expense | (2,599) | [1] | (2,846) | (4,178) |
Net interest income | 3,073 | [1] | 3,160 | 3,907 |
Disclosure of detailed information about financial instruments [line items] | ||||
Net investment income | £ (80) | [1] | £ (121) | 420 |
Financial guarantee contracts | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net investment income | £ 25 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Net interest income - Narrative
Net interest income - Narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Analysis of income and expense [abstract] | |||
Costs to originate credit card balances | £ 623 | £ 687 | £ 684 |
Interest income on impaired financial assets accrued | 7 | 9 | 9 |
Interest expense on lease liabilities | £ 20 | £ 23 | £ 25 |
Net fee and commission income -
Net fee and commission income - Summary (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Fee type | ||||
Total revenue from contracts with customers | £ 8,460 | £ 7,298 | £ 7,549 | |
Other non-contract fee income | 121 | 119 | 115 | |
Fee and commission income | 8,581 | [1] | 7,417 | 7,664 |
Fee and commission expense | (1,994) | [1] | (1,758) | (1,992) |
Net fee and commission income | 6,587 | [1] | 5,659 | 5,672 |
Transactional | ||||
Fee type | ||||
Total revenue from contracts with customers | 2,548 | 2,330 | 2,809 | |
Advisory | ||||
Fee type | ||||
Total revenue from contracts with customers | 1,096 | 693 | 904 | |
Brokerage and execution | ||||
Fee type | ||||
Total revenue from contracts with customers | 1,135 | 1,173 | 1,131 | |
Underwriting and syndication | ||||
Fee type | ||||
Total revenue from contracts with customers | 3,425 | 2,867 | 2,358 | |
Other | ||||
Fee type | ||||
Total revenue from contracts with customers | 256 | 235 | 347 | |
Operating segments | Corporate and Investment Bank | ||||
Fee type | ||||
Total revenue from contracts with customers | 5,945 | 4,987 | 4,742 | |
Other non-contract fee income | 116 | 114 | 110 | |
Fee and commission income | 6,061 | 5,101 | 4,852 | |
Fee and commission expense | (781) | (768) | (743) | |
Net fee and commission income | 5,280 | 4,333 | 4,109 | |
Operating segments | Corporate and Investment Bank | Transactional | ||||
Fee type | ||||
Total revenue from contracts with customers | 390 | 357 | 391 | |
Operating segments | Corporate and Investment Bank | Advisory | ||||
Fee type | ||||
Total revenue from contracts with customers | 968 | 593 | 821 | |
Operating segments | Corporate and Investment Bank | Brokerage and execution | ||||
Fee type | ||||
Total revenue from contracts with customers | 1,082 | 1,116 | 1,082 | |
Operating segments | Corporate and Investment Bank | Underwriting and syndication | ||||
Fee type | ||||
Total revenue from contracts with customers | 3,425 | 2,867 | 2,358 | |
Operating segments | Corporate and Investment Bank | Other | ||||
Fee type | ||||
Total revenue from contracts with customers | 80 | 54 | 90 | |
Operating segments | Consumer, Cards and Payments | ||||
Fee type | ||||
Total revenue from contracts with customers | 2,494 | 2,282 | 2,777 | |
Other non-contract fee income | 5 | 5 | 5 | |
Fee and commission income | 2,499 | 2,287 | 2,782 | |
Fee and commission expense | (1,207) | (988) | (1,249) | |
Net fee and commission income | 1,292 | 1,299 | 1,533 | |
Operating segments | Consumer, Cards and Payments | Transactional | ||||
Fee type | ||||
Total revenue from contracts with customers | 2,158 | 1,973 | 2,418 | |
Operating segments | Consumer, Cards and Payments | Advisory | ||||
Fee type | ||||
Total revenue from contracts with customers | 128 | 100 | 83 | |
Operating segments | Consumer, Cards and Payments | Brokerage and execution | ||||
Fee type | ||||
Total revenue from contracts with customers | 53 | 57 | 49 | |
Operating segments | Consumer, Cards and Payments | Underwriting and syndication | ||||
Fee type | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Operating segments | Consumer, Cards and Payments | Other | ||||
Fee type | ||||
Total revenue from contracts with customers | 155 | 152 | 227 | |
Head Office | ||||
Fee type | ||||
Total revenue from contracts with customers | 21 | 29 | 30 | |
Other non-contract fee income | 0 | 0 | 0 | |
Fee and commission income | 21 | 29 | 30 | |
Fee and commission expense | (6) | (2) | 0 | |
Net fee and commission income | 15 | 27 | 30 | |
Head Office | Transactional | ||||
Fee type | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Head Office | Advisory | ||||
Fee type | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Head Office | Brokerage and execution | ||||
Fee type | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Head Office | Underwriting and syndication | ||||
Fee type | ||||
Total revenue from contracts with customers | 0 | 0 | 0 | |
Head Office | Other | ||||
Fee type | ||||
Total revenue from contracts with customers | £ 21 | £ 29 | £ 30 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Net fee and commission income_2
Net fee and commission income - Narrative (Details) - GBP (£) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Fee and commission income (expense) [abstract] | |||
Contract assets | £ 0 | £ 0 | £ 0 |
Impairment loss, assets recognised from costs incurred to obtain or fulfil contracts with customers | 0 | 0 | 0 |
Capitalised contract costs | 148,000,000 | 135,000,000 | 153,000,000 |
Amortisation, assets recognised from costs incurred to obtain or fulfil contracts with customers | 35,000,000 | 35,000,000 | 29,000,000 |
Impairment loss on receivables or contract assets arising from contracts with customers | £ 0 | £ 0 | £ 0 |
Net trading income (Details)
Net trading income (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | £ 5,788 | [1] | £ 7,076 | £ 4,073 |
Net gains on financial instruments held for trading | Liabilities held for trading | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | 3,999 | 5,392 | 2,795 | |
Net gains on financial instruments designated at fair value | Financial liabilities designated at fair value | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | 682 | 695 | 240 | |
Net gains on financial instruments mandatorily at fair value | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net trading income | £ 1,107 | £ 989 | £ 1,038 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Net investment (expense) inco_3
Net investment (expense) income (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of detailed information about financial instruments [line items] | ||||
Net (losses)/gains from financial assets mandatorily at fair value | £ (116) | £ (39) | £ 218 | |
Net gains from disposal of debt instruments at fair value through other comprehensive income | 248 | 251 | 454 | |
Net gains/(losses) from disposal of financial assets and liabilities measured at amortised costa | 22 | (128) | (38) | |
Dividend income | 0 | 0 | 0 | |
Net (losses)/gains on other investments | (234) | (205) | (214) | |
Net investment (expense)/income | (80) | [1] | (121) | 420 |
Municipal Bond | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net gains/(losses) from disposal of financial assets and liabilities measured at amortised costa | £ 25 | |||
Capital Notes | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net gains/(losses) from disposal of financial assets and liabilities measured at amortised costa | £ (115) | |||
Financial guarantee contracts | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Net (losses)/gains on other investments | 25 | |||
Net investment (expense)/income | £ 25 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Credit impairment (release)_c_3
Credit impairment (release)/charge - Narrative (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)economic_scenarioeconomicVariable | Dec. 31, 2020GBP (£) | |
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Number of economic scenarios, percentage | 100.00% | |
Financial assets written and subject to enforcement activity, contractual amount outstanding | £ 752 | £ 816 |
Amortised cost before modification | 3,260 | 3,781 |
Financial assets with contractual cash flows modified during reporting period while loss allowance measured at lifetime expected credit losses, modification gain (loss) | 2 | (21) |
Carrying amount of financial assets for which loss allowance has changed to 12-month measurement | £ 419 | £ 1,194 |
Credit derivatives | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Number of economic scenarios | economic_scenario | 5 | |
Number of economic variables | economicVariable | 8 | |
Stress horizon period, ECL | 5 years | |
Term at which scenario converges to steady state | 8 years | |
Downside scenario | Credit derivatives | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Number of economic scenarios | economic_scenario | 2 | |
Upside scenario | Credit derivatives | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Number of economic scenarios | economic_scenario | 2 | |
Wholesale portfolios | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Changes in inputs, assumptions and estimation techniques used for ECL, probability | 100.00% | |
Wholesale portfolios | Bottom of range | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Inputs, assumptions and estimation techniques used for ECL, probability | 0.20% | |
Retail portfolios | Bottom of range | Minimum | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Inputs, assumptions and estimation techniques used for ECL, probability | 50.00% | |
Retail portfolios | Bottom of range | Maximum | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Inputs, assumptions and estimation techniques used for ECL, probability | 100.00% | |
Retail portfolios | Top of range | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||
Inputs, assumptions and estimation techniques used for ECL, probability | 400.00% |
Credit impairment (release)_c_4
Credit impairment (release)/charge - Charges, recoveries and reimbursements (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment Charges | £ (536) | £ 3,745 | £ 1,275 | |
Recoveries and reimbursements | 259 | (368) | (73) | |
Income statement charge for the year | (277) | [1] | 3,377 | 1,202 |
Gain on recovery of loans and advances previously written off | 31 | 4 | ||
Provision for undrawn contractually committed facilities and guarantees provided | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Provision for undrawn contractually committed facilities and guarantees provided, recoveries and reimbursements, impairment charges | (257) | 547 | 55 | |
Provision for undrawn contractually committed facilities and guarantees provided, recoveries and reimbursements | 0 | 0 | 0 | |
Income statement charge for the year | (257) | 547 | 55 | |
Financial guarantee contracts | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Recoveries and reimbursements | (364) | |||
Gain on recovery of loans and advances previously written off | 4 | |||
Financial guarantee contracts | Third parties | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Income statement charge for the year | 290 | 364 | ||
Loans and advances at amortised cost | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Loan impairment, impairment charges | (521) | 3,607 | 1,269 | |
Loans impairment, recoveries and reimbursements | 259 | (368) | (73) | |
Income statement charge for the year | (262) | 3,239 | 1,196 | |
Financial instruments at fair value through OCI | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment Charges | (6) | 0 | 0 | |
Recoveries and reimbursements | 0 | 0 | 0 | |
Income statement charge for the year | (6) | 0 | 0 | |
Financial assets at amortised cost | Loans and advances at amortised cost | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Loans and advances, impairment charges | 264 | (3,060) | (1,214) | |
Loans and advances, recoveries and reimbursements | 259 | (368) | (73) | |
Income statement charge for the year | (5) | 2,692 | 1,141 | |
Cash collateral and settlement balances | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment Charges | (4) | 2 | 1 | |
Recoveries and reimbursements | 0 | 0 | 0 | |
Income statement charge for the year | (4) | 2 | 1 | |
Other financial assets measured at cost | Financial assets at amortised cost | ||||
Disclosure of impairment loss and reversal of impairment loss [line items] | ||||
Impairment Charges | (5) | 136 | 5 | |
Recoveries and reimbursements | 0 | 0 | 0 | |
Income statement charge for the year | £ (5) | £ 136 | £ 5 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Credit impairment (release)_c_5
Credit impairment (release)/charge - Modification of financial assets (Narrative) (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of impairment loss and reversal of impairment loss [abstract] | ||
Financial assets written and subject to enforcement activity, contractual amount outstanding | £ 752 | £ 816 |
Amortised cost before modification | 3,260 | 3,781 |
Net modification loss | 2 | (21) |
Carrying amount of financial assets for which loss allowance has changed to 12-month measurement | £ 419 | £ 1,194 |
Operating expenses (Details)
Operating expenses (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Infrastructure costs | ||||
Property and equipment | £ 367 | £ 373 | £ 368 | |
Depreciation and amortisation | 403 | 421 | 457 | |
Lease payments | 4 | 1 | 7 | |
Impairment of property, equipment and intangible assets | 280 | 21 | 3 | |
Total infrastructure costs | 1,054 | [1] | 816 | 835 |
Administration and general expenses | ||||
Consultancy, legal and professional fees | 390 | 345 | 362 | |
Marketing and advertising | 235 | 176 | 258 | |
UK bank levy | 134 | 249 | 185 | |
Other administration and general expenses | 3,616 | 3,432 | 3,513 | |
Total administration and general expenses | 4,375 | [1] | 4,202 | 4,318 |
Staff costs | 4,456 | [1] | 4,365 | 4,565 |
Litigation and conduct | 374 | [1] | 76 | 264 |
Operating expense | 10,259 | [1] | £ 9,459 | £ 9,982 |
Impairment loss - structural costs | £ 266 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Tax - Tax Charge (Details)
Tax - Tax Charge (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Current tax charge/(credit) | ||||
Current year | £ 904 | £ 993 | £ 327 | |
Adjustments in respect of prior years | 393 | 3 | (50) | |
Total | 1,297 | 996 | 277 | |
Deferred tax (credit)/charge | ||||
Current year | (179) | (563) | 157 | |
Adjustments in respect of prior years | (288) | 191 | (102) | |
Total | (467) | (372) | 55 | |
Tax charge | £ 830 | [1] | £ 624 | £ 332 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Tax - Reconciliation between th
Tax - Reconciliation between the actual tax charge and the corporate tax rate (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Profit before tax | £ 5,418 | [1] | £ 3,075 | £ 3,112 |
Tax charge based on the standard UK corporation tax rate of 19% (2020: 19%, 2019: 19%) | 1,029 | 584 | 593 | |
Impact of profits/losses earned in territories with different statutory rates to the UK (weighted average tax rate is 24.0% (2020: 25.0% , 2019: 26.0%)) | £ 273 | £ 183 | £ 217 | |
Tax, percentage [abstract] | ||||
Applicable tax rate | 19.00% | 19.00% | 19.00% | |
Tax rate impact of profits/losses earned in territories with different statutory rates to the UK | 5.00% | 6.00% | 7.00% | |
Recurring items: | ||||
Non-creditable taxes including withholding taxes | £ 124 | £ 107 | £ 146 | |
Adjustments in respect of prior years | 105 | 194 | (152) | |
Non-deductible expenses | 61 | 28 | 34 | |
Impact of UK bank levy being non-deductible | 25 | 48 | 35 | |
Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK | 25 | 25 | 15 | |
Tax adjustments in respect of share-based payments | (5) | 14 | (7) | |
Banking surcharge and other items | (48) | (70) | (103) | |
Tax relief on payments made under AT1 instruments | (113) | (124) | (121) | |
Changes in recognition of deferred tax and effect of unrecognised tax losses | (140) | (123) | (85) | |
Non-taxable gains and income | £ (309) | £ (200) | £ (240) | |
Recurring items, percentages [abstract] | ||||
Non-creditable taxes including withholding taxes, percentage | 2.30% | 3.40% | 4.70% | |
Adjustments in respect of prior years, percentage | 1.90% | 6.30% | (4.90%) | |
Non-deductible expenses, percentage | 1.10% | 0.90% | 1.10% | |
Impact of UK bank levy being non-deductible, percentage | 0.50% | 1.60% | 1.10% | |
Impact of Barclays Bank PLC's overseas branches being taxed both locally and in the UK, percentage | 0.50% | 0.80% | 0.50% | |
Tax adjustments in respect of share-based payments, percentage | (0.10%) | 0.50% | (0.20%) | |
Banking surcharge and other items, percentage | (0.90%) | (2.30%) | (3.30%) | |
Tax relief on payments made under AT1 instruments, percentage | (2.10%) | (4.00%) | (3.90%) | |
Changes in recognition of deferred tax and effect of unrecognised tax losses, percentage | (2.60%) | (4.00%) | (2.70%) | |
Non-taxable gains and income, percentage | (5.70%) | (6.50%) | (7.70%) | |
Non-recurring items: | ||||
Remeasurement of UK deferred tax assets due to tax rate changes | £ (218) | £ (43) | £ 0 | |
Non-deductible provisions for UK customer redress | 21 | 7 | 0 | |
Non-deductible provisions for investigations and litigation | £ 0 | £ (6) | £ 0 | |
Non-recurring items, percentages [abstract] | ||||
Remeasurement of UK deferred tax assets due to tax rate changes, percentage | (4.00%) | (1.40%) | 0.00% | |
Non-deductible provisions for UK customer redress, percentage | 0.40% | 0.20% | 0.00% | |
Non-deductible provisions for investigations and litigation, percentage | 0.00% | (0.20%) | 0.00% | |
Tax charge | £ 830 | [2] | £ 624 | £ 332 |
Total tax charge, percentage | 15.30% | 20.30% | 10.70% | |
Weighted average | ||||
Tax, percentage [abstract] | ||||
Tax rate impact of profits/losses earned in territories with different statutory rates to the UK | 24.00% | 25.00% | 26.00% | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Tax - Narrative (Details)
Tax - Narrative (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Average effective tax rate | 15.30% | 20.30% | 10.70% | |
Income tax credit relating to other comprehensive income | £ 0 | £ 3 | ||
Current tax relating to items credited directly to equity | 38 | 14 | ||
Deferred tax assets | 2,981 | [1] | 2,552 | |
Deferred tax liabilities | 6 | [1] | 225 | |
Unused tax credits for which no deferred tax asset recognised | 283 | 236 | ||
Temporary differences associated with investments in related entities for which deferred tax liabilities have not been recognised | 900 | 800 | ||
Other (outside the UK and US tax groups) | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 399 | 503 | ||
US Intermediate Holding Company Tax Group ("IHC Tax Group") | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,004 | 1,001 | ||
US Branch Tax Group | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,002 | 1,048 | ||
After more than 12 months | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 4,328 | 3,356 | ||
Deferred tax liabilities | 1,740 | 1,359 | ||
Within five years | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 63 | 139 | ||
Within six to ten years | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 370 | 236 | ||
Within eleven to twenty years | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 10,529 | 7,271 | ||
Indefinitely | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax credits for which no deferred tax asset recognised | 11,534 | 12,307 | ||
Unused tax losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deductible temporary differences for which no deferred tax asset is recognised | 22,496 | 19,953 | ||
Unused tax losses | Other (outside the UK and US tax groups) | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 121 | 170 | ||
Unused tax losses | US Intermediate Holding Company Tax Group ("IHC Tax Group") | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1 | 0 | ||
Loss in current or prior year | Other (outside the UK and US tax groups) | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 9 | 8 | ||
Loss in current or prior year | US Intermediate Holding Company Tax Group ("IHC Tax Group") | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 301 | 330 | ||
Temporary differences | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deductible temporary differences for which no deferred tax asset is recognised | 110 | 123 | ||
Capital losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Unused tax losses for which no deferred tax asset recognised | 3,642 | 2,987 | ||
US Intermediate Holding Company Tax Group ("IHC Tax Group") | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,004 | 1,001 | ||
UK Tax Group | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,679 | [2] | 1,171 | |
Deferred tax liabilities | 6 | [2] | 225 | |
UK Tax Group | UNITED KINGDOM | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 576 | 0 | ||
UK Tax Group | Unused tax losses | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 1,074 | 541 | ||
UK Tax Group | Temporary differences | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax liabilities | 498 | 766 | ||
Other (outside the UK and US tax groups) | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax assets | 399 | 503 | ||
UNITED KINGDOM | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes, other comprehensive income | 148 | £ 49 | ||
UNITED KINGDOM | Pro Forma | Changes in tax rates or tax laws enacted or announced | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes | 183 | |||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes, other comprehensive income | £ (122) | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Tax - Deferred tax assets and l
Tax - Deferred tax assets and liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | £ 2,981 | [1] | £ 2,552 |
Deferred tax liability | (6) | [1] | (225) |
Net deferred tax | 2,975 | 2,327 | |
US Intermediate Holding Company Tax Group ("IHC Tax Group") | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 1,004 | 1,001 | |
US Branch Tax Group | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 1,002 | 1,048 | |
UK Tax Group | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 1,679 | [2] | 1,171 |
Deferred tax liability | (6) | [2] | (225) |
UK Tax Group | UNITED KINGDOM | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 576 | 0 | |
Other (outside the UK and US tax groups) | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | £ 399 | £ 503 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Tax - Movements on deferred tax
Tax - Movements on deferred tax assets and liabilities during the year before offsetting (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | £ 3,688 | £ 3,428 | |
Deferred tax liabilities, before offsetting | (1,361) | (1,048) | |
Net deferred tax (liability) asset | 2,975 | 2,327 | £ 2,380 |
Deferred tax liability (asset), before offsetting | 2,327 | 2,380 | |
Income statement | 467 | 372 | (55) |
Other comprehensive income and reserves | 182 | (353) | |
Other movements | (1) | (72) | |
Assets | 4,719 | 3,688 | 3,428 |
Deferred tax liabilities, before offsetting | (1,744) | (1,361) | (1,048) |
Deferred tax liability (asset), before offsetting | 2,975 | 2,327 | 2,380 |
Share based payments and deferred compensation | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 317 | 305 | |
Deferred tax liabilities, before offsetting | 0 | 0 | |
Net deferred tax (liability) asset | 327 | 317 | 305 |
Deferred tax liability (asset), before offsetting | 317 | 305 | |
Income statement | (13) | 15 | |
Other comprehensive income and reserves | 20 | 3 | |
Other movements | 3 | (6) | |
Assets | 327 | 317 | 305 |
Deferred tax liabilities, before offsetting | 0 | 0 | 0 |
Deferred tax liability (asset), before offsetting | 327 | 317 | 305 |
Other provisions | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 139 | 127 | |
Deferred tax liabilities, before offsetting | 0 | 0 | |
Net deferred tax (liability) asset | 142 | 139 | 127 |
Deferred tax liability (asset), before offsetting | 139 | 127 | |
Income statement | 3 | 18 | |
Other comprehensive income and reserves | 0 | 0 | |
Other movements | 0 | (6) | |
Assets | 142 | 139 | 127 |
Deferred tax liabilities, before offsetting | 0 | 0 | 0 |
Deferred tax liability (asset), before offsetting | 142 | 139 | 127 |
Retirement benefit obligations | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 30 | 31 | |
Deferred tax liabilities, before offsetting | (826) | (640) | |
Net deferred tax (liability) asset | (1,650) | (796) | (609) |
Deferred tax liability (asset), before offsetting | (796) | (609) | |
Income statement | (1) | 0 | |
Other comprehensive income and reserves | (855) | (191) | |
Other movements | 0 | 4 | |
Assets | 24 | 30 | 31 |
Deferred tax liabilities, before offsetting | (1,674) | (826) | (640) |
Deferred tax liability (asset), before offsetting | (1,650) | (796) | (609) |
Cash flow hedges | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 0 | 0 | |
Deferred tax liabilities, before offsetting | (441) | (139) | |
Net deferred tax (liability) asset | 309 | (441) | (139) |
Deferred tax liability (asset), before offsetting | (441) | (139) | |
Income statement | 0 | 0 | |
Other comprehensive income and reserves | 750 | (291) | |
Other movements | 0 | (11) | |
Assets | 309 | 0 | 0 |
Deferred tax liabilities, before offsetting | 0 | (441) | (139) |
Deferred tax liability (asset), before offsetting | 309 | (441) | (139) |
Fair value through other comprehensive income | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 0 | 110 | |
Deferred tax liabilities, before offsetting | (21) | (18) | |
Net deferred tax (liability) asset | 144 | (21) | 92 |
Deferred tax liability (asset), before offsetting | (21) | 92 | |
Income statement | 6 | 0 | |
Other comprehensive income and reserves | 170 | (112) | |
Other movements | 1 | (1) | |
Assets | 144 | 0 | 110 |
Deferred tax liabilities, before offsetting | 0 | (21) | (18) |
Deferred tax liability (asset), before offsetting | 144 | (21) | 92 |
Fixed asset timing differences | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 659 | 719 | |
Deferred tax liabilities, before offsetting | (33) | (29) | |
Net deferred tax (liability) asset | 648 | 626 | 690 |
Deferred tax liability (asset), before offsetting | 626 | 690 | |
Income statement | 14 | (39) | |
Other comprehensive income and reserves | 0 | 0 | |
Other movements | 8 | (25) | |
Assets | 678 | 659 | 719 |
Deferred tax liabilities, before offsetting | (30) | (33) | (29) |
Deferred tax liability (asset), before offsetting | 648 | 626 | 690 |
Loan impairment allowance | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 455 | 284 | |
Deferred tax liabilities, before offsetting | 0 | 0 | |
Net deferred tax (liability) asset | 481 | 455 | 284 |
Deferred tax liability (asset), before offsetting | 455 | 284 | |
Income statement | 38 | 164 | |
Other comprehensive income and reserves | 0 | 0 | |
Other movements | (12) | 7 | |
Assets | 481 | 455 | 284 |
Deferred tax liabilities, before offsetting | 0 | 0 | 0 |
Deferred tax liability (asset), before offsetting | 481 | 455 | 284 |
Other temporary differences | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 1,377 | 1,329 | |
Deferred tax liabilities, before offsetting | (40) | (222) | |
Net deferred tax (liability) asset | 1,378 | 1,337 | 1,107 |
Deferred tax liability (asset), before offsetting | 1,337 | 1,107 | |
Income statement | (55) | 23 | |
Other comprehensive income and reserves | 97 | 238 | |
Other movements | (1) | (31) | |
Assets | 1,418 | 1,377 | 1,329 |
Deferred tax liabilities, before offsetting | (40) | (40) | (222) |
Deferred tax liability (asset), before offsetting | 1,378 | 1,337 | 1,107 |
Tax losses carried forward | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Assets | 711 | 523 | |
Deferred tax liabilities, before offsetting | 0 | 0 | |
Net deferred tax (liability) asset | 1,196 | 711 | 523 |
Deferred tax liability (asset), before offsetting | 711 | 523 | |
Income statement | 485 | 191 | |
Other comprehensive income and reserves | 0 | 0 | |
Other movements | 0 | (3) | |
Assets | 1,196 | 711 | 523 |
Deferred tax liabilities, before offsetting | 0 | 0 | 0 |
Deferred tax liability (asset), before offsetting | £ 1,196 | £ 711 | £ 523 |
Dividends on ordinary shares _2
Dividends on ordinary shares and preference shares (Narrative) (Details) | 1 Months Ended | 5 Months Ended | 12 Months Ended | ||||||
Jul. 31, 2021GBP (£) | Feb. 28, 2021GBP (£) | Dec. 31, 2021GBP (£) | Dec. 31, 2021GBP (£)£ / shares | Dec. 31, 2020GBP (£)£ / shares | Dec. 31, 2021$ / shares | Jun. 08, 2005$ / shares | Mar. 15, 2005€ / shares | ||
Dividends paid, ordinary shares | £ 794,000,000 | [1] | £ 263,000,000 | ||||||
Dividends on preference shares and other shareholders equity | 27,000,000 | [1] | 42,000,000 | ||||||
Other equity instruments coupons paid | 631,000,000 | [1] | 677,000,000 | ||||||
Ordinary share capital | |||||||||
Dividends paid, ordinary shares | 794,000,000 | 263,000,000 | |||||||
Dividends paid, relating to prior years | £ 174,000,000 | 263,000,000 | |||||||
Dividends, interim | £ 100,000,000 | £ 520,000,000 | £ 200,000,000 | £ 0 | |||||
Dividends paid on ordinary shares (in GBP per share) | £ / shares | £ 0.34 | £ 0.11 | |||||||
Preference share capital | |||||||||
Dividends on preference shares and other shareholders equity | £ 27,000,000 | £ 42,000,000 | |||||||
4.75% Euro preference shares | |||||||||
Dividends paid on preference shares (in GBP per share) | £ / shares | £ 14.37 | £ 439.21 | |||||||
Par value (in USD per share) | € / shares | € 100 | ||||||||
6.278% US$100 preference shares | |||||||||
Dividends paid on preference shares (in GBP per share) | £ / shares | £ 459.69 | £ 485.75 | |||||||
Other equity instruments coupons paid | £ (0.06278) | ||||||||
Par value (in USD per share) | $ / shares | $ 100 | $ 100,000,000 | |||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Trading portfolio (Details)
Trading portfolio (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | £ 146,871 | [1] | £ 127,664 |
Trading Portfolio Liabilities | (53,291) | [1] | (46,139) |
Debt securities and other eligible bills | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 50,700 | 56,196 | |
Trading Portfolio Liabilities | (34,079) | (28,836) | |
Equity securities | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 83,113 | 62,192 | |
Trading Portfolio Liabilities | (19,212) | (17,303) | |
Traded loans | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 12,525 | 8,348 | |
Commodities | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | £ 533 | £ 928 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Financial assets at fair valu_5
Financial assets at fair value through the income statement (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial assets [line items] | |||
Loans and advances | £ 145,259 | [1] | £ 134,267 |
Reverse repurchase agreements and other similar secured lending | 3,177 | [1] | 8,981 |
Other financial assets | 994 | 614 | |
Financial assets at fair value through profit or loss | 188,226 | [1] | 171,761 |
Net gains on financial instruments designated at fair value | |||
Disclosure of financial assets [line items] | |||
Loans and advances | 2,813 | 2,170 | |
Debt securities | 318 | 291 | |
Reverse repurchase agreements and other similar secured lending | 0 | 19 | |
Financial assets at fair value through profit or loss | 3,131 | 2,480 | |
Net gains on financial instruments mandatorily at fair value | |||
Disclosure of financial assets [line items] | |||
Loans and advances | 33,089 | 25,279 | |
Debt securities | 1,937 | 1,406 | |
Equity securities | 4,798 | 3,742 | |
Reverse repurchase agreements and other similar secured lending | 145,186 | 138,539 | |
Other financial assets | 85 | 315 | |
Financial assets at fair value through profit or loss | £ 185,095 | £ 169,281 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Financial assets at fair valu_6
Financial assets at fair value through the income statement - Credit risk of loans and advances designated at fair value and related credit derivatives (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Credit derivatives | Derivatives | ||
Disclosure of financial assets [line items] | ||
Value mitigated by related credit derivatives | £ 1,617 | £ 795 |
Changes in fair value during the year ended | (3) | 3 |
Cumulative changes in fair value from inception | (3) | 3 |
Loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Loans and advances designated at fair value, attributable to credit risk | 2,813 | 2,170 |
Changes in fair value during the year ended | 1 | (46) |
Cumulative changes in fair value from inception | £ (3) | £ (51) |
Derivative financial instrume_3
Derivative financial instruments - Narrative (Details) £ in Billions | 12 Months Ended | |
Dec. 31, 2021GBP (£)Hedges | Dec. 31, 2020Hedges | |
Derivatives | Central Counterparty Clearing House (CCP) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Increase nominal amount | £ | £ 1,717 | |
Derivatives designated as fair value hedges | Fixed interest rate | Interest rate derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Number of hedges | 618 | 586 |
Average rate of hedging instrument | 1.10% | 1.20% |
Derivatives designated as fair value hedges | Fixed interest rate | - Inflation risk | ||
Disclosure of detailed information about financial instruments [line items] | ||
Number of hedges | 60 | 70 |
Average rate of hedging instrument | 0.59% | 0.52% |
Bottom of range | ||
Disclosure of detailed information about financial instruments [line items] | ||
Hedging effectiveness | 80.00% | |
Top of range | ||
Disclosure of detailed information about financial instruments [line items] | ||
Hedging effectiveness | 125.00% |
Derivative financial instrume_4
Derivative financial instruments - Total Derivatives (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 26, 2019 | |
Disclosure of risk management strategy related to hedge accounting [line items] | ||||
Notional contract amount | £ 47,412,915 | £ 42,625,605 | ||
Derivative assets | 262,291 | [1] | 302,693 | |
Derivative liabilities | (256,523) | [1] | (300,580) | |
Fair value | ||||
Disclosure of risk management strategy related to hedge accounting [line items] | ||||
Derivative assets held for trading | 262,046 | 302,429 | ||
Derivative assets held for held for risk management | 245 | 264 | ||
Derivative assets | 262,291 | 302,693 | £ 302,693 | |
Derivative liabilities held for trading | (255,471) | (299,637) | ||
Derivative liabilities held for risk management | (1,052) | (943) | ||
Derivative liabilities | (256,523) | (300,580) | £ (300,580) | |
Held for risk management | ||||
Disclosure of risk management strategy related to hedge accounting [line items] | ||||
Notional contract amount | 126,292 | 110,028 | ||
Held for risk management | Fair value | ||||
Disclosure of risk management strategy related to hedge accounting [line items] | ||||
Derivative assets held for held for risk management | 245 | 264 | ||
Derivative liabilities held for risk management | (1,052) | (943) | ||
Held for trading | ||||
Disclosure of risk management strategy related to hedge accounting [line items] | ||||
Notional contract amount | 47,286,623 | 42,515,577 | ||
Held for trading | Fair value | ||||
Disclosure of risk management strategy related to hedge accounting [line items] | ||||
Derivative assets held for trading | 262,046 | 302,429 | ||
Derivative liabilities held for trading | £ (255,471) | £ (299,637) | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Derivative financial instrume_5
Derivative financial instruments - Derivatives held for trading and risk management (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | £ 47,412,915 | £ 42,625,605 |
Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 262,046 | 302,429 |
Derivative liabilities held for trading | (255,471) | (299,637) |
Derivative financial assets held for hedging | 245 | 264 |
Derivative liabilities held for risk management | (1,052) | (943) |
Held for risk management | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 126,292 | 110,028 |
Held for risk management | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 245 | 264 |
Derivative liabilities held for risk management | (1,052) | (943) |
Held for risk management | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 245 | 264 |
Derivative liabilities held for risk management | (1,052) | (943) |
Held for risk management | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 0 | 0 |
Derivative liabilities held for risk management | 0 | 0 |
Held for risk management | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 126,292 | 110,028 |
Held for risk management | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 9,744 | 11,596 |
Held for risk management | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 116,548 | 98,432 |
Held for risk management | Cash flow hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 155 | 116 |
Derivative liabilities held for risk management | (3) | 0 |
Held for risk management | Cash flow hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 65,049 | 46,318 |
Held for risk management | Derivatives designated as fair value hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 53 | 123 |
Derivative liabilities held for risk management | (1,045) | (943) |
Held for risk management | Derivatives designated as fair value hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 58,820 | 62,919 |
Held for risk management | Derivatives designated as hedges of net investments | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 37 | 25 |
Derivative liabilities held for risk management | (4) | 0 |
Held for risk management | Derivatives designated as hedges of net investments | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 2,423 | 791 |
Held for risk management | Foreign exchange derivatives | Cash flow hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 155 | 67 |
Derivative liabilities held for risk management | 0 | 0 |
Held for risk management | Foreign exchange derivatives | Cash flow hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 1,000 | 1,000 |
Held for risk management | Foreign exchange derivatives | Derivatives designated as fair value hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 0 | 0 |
Derivative liabilities held for risk management | 0 | 0 |
Held for risk management | Foreign exchange derivatives | Derivatives designated as fair value hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 0 | 0 |
Held for risk management | Foreign exchange derivatives | Derivatives designated as hedges of net investments | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 37 | 25 |
Derivative liabilities held for risk management | (4) | 0 |
Held for risk management | Foreign exchange derivatives | Derivatives designated as hedges of net investments | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 2,423 | 791 |
Held for risk management | Interest rate derivatives | Cash flow hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 0 | 49 |
Derivative liabilities held for risk management | (3) | 0 |
Held for risk management | Interest rate derivatives | Cash flow hedges | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 0 | 0 |
Derivative liabilities held for risk management | 0 | 0 |
Held for risk management | Interest rate derivatives | Cash flow hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 465 | 1,819 |
Held for risk management | Interest rate derivatives | Cash flow hedges | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 63,584 | 43,499 |
Held for risk management | Interest rate derivatives | Derivatives designated as fair value hedges | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 53 | 123 |
Derivative liabilities held for risk management | (1,045) | (943) |
Held for risk management | Interest rate derivatives | Derivatives designated as fair value hedges | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative financial assets held for hedging | 0 | 0 |
Derivative liabilities held for risk management | 0 | 0 |
Held for risk management | Interest rate derivatives | Derivatives designated as fair value hedges | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 5,856 | 7,986 |
Held for risk management | Interest rate derivatives | Derivatives designated as fair value hedges | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 52,964 | 54,933 |
Held for trading | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 47,286,623 | 42,515,577 |
Held for trading | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 262,046 | 302,429 |
Derivative liabilities held for trading | (255,471) | (299,637) |
Held for trading | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 223,098 | 278,328 |
Derivative liabilities held for trading | (216,411) | (275,245) |
Held for trading | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 2,901 | 2,231 |
Derivative liabilities held for trading | (2,779) | (2,225) |
Held for trading | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 36,047 | 21,870 |
Derivative liabilities held for trading | (36,281) | (22,167) |
Held for trading | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 47,286,623 | 42,515,577 |
Held for trading | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 20,818,738 | 19,617,360 |
Held for trading | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 19,630,934 | 18,871,894 |
Held for trading | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 6,836,951 | 4,026,323 |
Held for trading | Foreign exchange derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 76,236 | 84,856 |
Derivative liabilities held for trading | (74,225) | (84,250) |
Held for trading | Foreign exchange derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 76,055 | 84,518 |
Derivative liabilities held for trading | (74,014) | (83,912) |
Held for trading | Foreign exchange derivatives | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 171 | 335 |
Derivative liabilities held for trading | (208) | (335) |
Held for trading | Foreign exchange derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 10 | 3 |
Derivative liabilities held for trading | (3) | (3) |
Held for trading | Foreign exchange derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 5,819,803 | 5,556,612 |
Held for trading | Foreign exchange derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 5,700,055 | 5,463,632 |
Held for trading | Foreign exchange derivatives | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 99,664 | 78,946 |
Held for trading | Foreign exchange derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 20,084 | 14,034 |
Held for trading | Interest rate derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 126,147 | 172,580 |
Derivative liabilities held for trading | (114,767) | (162,378) |
Held for trading | Interest rate derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 124,187 | 171,244 |
Derivative liabilities held for trading | (113,098) | (161,223) |
Held for trading | Interest rate derivatives | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 1,055 | 965 |
Derivative liabilities held for trading | (762) | (795) |
Held for trading | Interest rate derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 905 | 371 |
Derivative liabilities held for trading | (907) | (360) |
Held for trading | Interest rate derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 38,295,647 | 34,853,475 |
Held for trading | Interest rate derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 14,229,139 | 13,551,506 |
Held for trading | Interest rate derivatives | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 18,865,670 | 18,330,003 |
Held for trading | Interest rate derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 5,200,838 | 2,971,966 |
Held for trading | Credit derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 5,682 | 4,605 |
Derivative liabilities held for trading | (6,561) | (5,004) |
Held for trading | Credit derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 4,007 | 3,674 |
Derivative liabilities held for trading | (4,752) | (3,909) |
Held for trading | Credit derivatives | Fair value | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 1,675 | 931 |
Derivative liabilities held for trading | (1,809) | (1,095) |
Held for trading | Credit derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 1,272,104 | 847,845 |
Held for trading | Credit derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 606,504 | 384,900 |
Held for trading | Credit derivatives | Derivatives | Derivatives cleared by central counterparty | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 665,600 | 462,945 |
Held for trading | Equity and stock index derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 51,694 | 38,968 |
Derivative liabilities held for trading | (57,614) | (46,612) |
Held for trading | Equity and stock index derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 18,793 | 18,803 |
Derivative liabilities held for trading | (24,440) | (26,091) |
Held for trading | Equity and stock index derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 32,901 | 20,165 |
Derivative liabilities held for trading | (33,174) | (20,521) |
Held for trading | Equity and stock index derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 1,747,448 | 1,140,192 |
Held for trading | Equity and stock index derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 278,370 | 213,078 |
Held for trading | Equity and stock index derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 1,469,078 | 927,114 |
Held for trading | Commodity derivatives | Fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 2,287 | 1,420 |
Derivative liabilities held for trading | (2,304) | (1,393) |
Held for trading | Commodity derivatives | Fair value | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 56 | 89 |
Derivative liabilities held for trading | (107) | (110) |
Held for trading | Commodity derivatives | Fair value | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Derivative assets held for trading | 2,231 | 1,331 |
Derivative liabilities held for trading | (2,197) | (1,283) |
Held for trading | Commodity derivatives | Derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 151,621 | 117,453 |
Held for trading | Commodity derivatives | Derivatives | OTC derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | 4,670 | 4,244 |
Held for trading | Commodity derivatives | Derivatives | Exchange traded derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Notional contract amount | £ 146,951 | £ 113,209 |
Derivative financial instrume_6
Derivative financial instruments - The significant hedge accounting exposures impacted by the IBOR reform (Details) - IBOR Reform £ / shares in Millions, £ in Millions | Dec. 31, 2021GBP (£)£ / shares |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ | £ 29,773 |
Nominal amount of hedging instruments directly impacted by IBOR reform | £ / shares | 20,375 |
GBP London Interbank Offered rate (LIBOR) | |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ | £ 9,718 |
Nominal amount of hedging instruments directly impacted by IBOR reform | £ / shares | 200 |
USD LIBOR | |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ | £ 19,945 |
Nominal amount of hedging instruments directly impacted by IBOR reform | £ / shares | 20,013 |
JPY LIBOR | |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ | £ 0 |
Nominal amount of hedging instruments directly impacted by IBOR reform | £ / shares | 52 |
Singapore Swap Offered Rate (SOR) | |
Disclosure of risk management strategy related to hedge accounting [line items] | |
Nominal amount of hedged items directly impacted by IBOR reform | £ | £ 110 |
Nominal amount of hedging instruments directly impacted by IBOR reform | £ / shares | 110 |
Derivative financial instrume_7
Derivative financial instruments - Hedged items in fair value hedges (Details) - Derivatives designated as fair value hedges - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Assets | ||
Carrying amount, hedged assets | £ 36,444 | £ 42,632 |
Accumulated fair value hedge adjustment included in carrying amount | 832 | 1,707 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | 2 | 315 |
Liabilities | ||
Carrying amount, hedged liabilities | (26,691) | (26,978) |
Accumulated fair value hedge adjustment included in carrying amount | (622) | (1,477) |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | (320) | (414) |
Total Hedged Items | 9,753 | 15,654 |
Accumulated fair value hedge adjustment included in carrying amount, total | 210 | 230 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship, total | (318) | (99) |
Change in fair value used as a basis to determine ineffectiveness | (431) | 866 |
Hedge ineffectiveness recognised in the income statement | 31 | (49) |
Hedged assets | ||
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (1,200) | 1,663 |
Hedge ineffectiveness recognised in the income statement | 25 | (43) |
Hedged assets | Interest rate risk | Debt securities classified as amortised cost | ||
Assets | ||
Carrying amount, hedged assets | 1,378 | 1,440 |
Accumulated fair value hedge adjustment included in carrying amount | (39) | 23 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | 0 | 0 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (75) | 17 |
Hedge ineffectiveness recognised in the income statement | (18) | (7) |
Hedged assets | Interest rate risk | Fair value through other comprehensive income | ||
Assets | ||
Carrying amount, hedged assets | 22,895 | 27,959 |
Accumulated fair value hedge adjustment included in carrying amount | (293) | 964 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | 28 | 322 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (1,122) | 864 |
Hedge ineffectiveness recognised in the income statement | 35 | (33) |
Hedged assets | - Inflation risk | Debt securities classified as amortised cost | ||
Assets | ||
Carrying amount, hedged assets | 4,087 | 4,071 |
Accumulated fair value hedge adjustment included in carrying amount | 400 | (43) |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | 0 | 0 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (16) | 453 |
Hedge ineffectiveness recognised in the income statement | (1) | 3 |
Hedged assets | - Inflation risk | Fair value through other comprehensive income | ||
Assets | ||
Carrying amount, hedged assets | 6,271 | 7,782 |
Accumulated fair value hedge adjustment included in carrying amount | 386 | 319 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | (32) | (9) |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | 81 | 249 |
Hedge ineffectiveness recognised in the income statement | 10 | (9) |
Loans and advances at amortised cost | Interest rate risk | Financial assets at amortised cost | ||
Assets | ||
Carrying amount, hedged assets | 1,257 | 835 |
Accumulated fair value hedge adjustment included in carrying amount | 24 | 99 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | 6 | 2 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | (77) | 55 |
Hedge ineffectiveness recognised in the income statement | (1) | 0 |
Loans and advances at amortised cost | - Inflation risk | Financial assets at amortised cost | ||
Assets | ||
Carrying amount, hedged assets | 556 | 545 |
Accumulated fair value hedge adjustment included in carrying amount | 354 | 345 |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | 0 | 0 |
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | 9 | 25 |
Hedge ineffectiveness recognised in the income statement | 0 | 3 |
Hedged liabilities | ||
Liabilities | ||
Change in fair value used as a basis to determine ineffectiveness | 769 | (797) |
Hedge ineffectiveness recognised in the income statement | 6 | (6) |
Debt securities classified as amortised cost | Interest rate risk | ||
Liabilities | ||
Carrying amount, hedged liabilities | (26,691) | (26,978) |
Accumulated fair value hedge adjustment included in carrying amount | (622) | (1,477) |
Of which: Accumulated fair value adjustment on items no longer in a hedge relationship | (320) | (414) |
Change in fair value used as a basis to determine ineffectiveness | 769 | (797) |
Hedge ineffectiveness recognised in the income statement | £ 6 | £ (6) |
Derivative financial instrume_8
Derivative financial instruments - Hedging instruments which are carried on the Barclays Bank's balance sheet (Fair value hedges) (Details) £ / shares in Millions, £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)£ / shares | Dec. 31, 2020GBP (£)£ / shares | |
Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 20,375 | |
Nominal amount directly impacted by IBOR reform | JPY LIBOR | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 52 | |
Derivatives designated as fair value hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 58,820 | 62,919 |
Change in fair value used as a basis to determine ineffectiveness | £ 462 | £ (915) |
Derivatives designated as fair value hedges | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 10,479 | 19,184 |
Derivatives designated as fair value hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 51,219 | 55,093 |
Change in fair value used as a basis to determine ineffectiveness | £ 527 | £ (185) |
Derivatives designated as fair value hedges | Interest rate risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 8,855 | 17,697 |
Derivatives designated as fair value hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 7,601 | 7,826 |
Change in fair value used as a basis to determine ineffectiveness | £ (65) | £ (730) |
Derivatives designated as fair value hedges | - Inflation risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 1,624 | 1,487 |
Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 65,049 | 46,318 |
Change in fair value used as a basis to determine ineffectiveness | £ (2,438) | £ 1,412 |
Cash flow hedges | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 9,896 | 27,160 |
Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 59,957 | 42,520 |
Change in fair value used as a basis to determine ineffectiveness | £ (2,253) | £ 1,300 |
Cash flow hedges | Interest rate risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 9,896 | 27,160 |
Cash flow hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 4,092 | 2,798 |
Change in fair value used as a basis to determine ineffectiveness | £ (274) | £ 42 |
Cash flow hedges | - Inflation risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Cash flow hedges | Foreign exchange derivatives | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 1,000 | 1,000 |
Change in fair value used as a basis to determine ineffectiveness | £ 89 | £ 70 |
Cash flow hedges | Foreign exchange derivatives | JPY LIBOR | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Average rate of hedging instrument | 133.03% | 133.03% |
Cash flow hedges | Foreign exchange derivatives | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Derivatives | Derivatives designated as fair value hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | £ 53 | £ 123 |
Hedging instrument, liabilities | (1,045) | (943) |
Derivatives | Derivatives designated as fair value hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 53 | 117 |
Hedging instrument, liabilities | 0 | (164) |
Derivatives | Derivatives designated as fair value hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 0 | 6 |
Hedging instrument, liabilities | (1,045) | (779) |
Derivatives | Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 155 | 116 |
Hedging instrument, liabilities | (3) | 0 |
Derivatives | Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 0 | 47 |
Hedging instrument, liabilities | 0 | 0 |
Derivatives | Cash flow hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 0 | 2 |
Hedging instrument, liabilities | (3) | 0 |
Derivatives | Cash flow hedges | Foreign exchange derivatives | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 155 | 67 |
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Derivatives designated as fair value hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Derivatives designated as fair value hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Derivatives designated as fair value hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | Foreign exchange derivatives | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | £ 0 | £ 0 |
Derivative financial instrume_9
Derivative financial instruments - The expected notional values of current hedging instruments in future years (Details) - Derivatives designated as fair value hedges - £ / shares £ / shares in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 58,820 | 62,919 |
Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 51,219 | 55,093 |
- Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 7,601 | 7,826 |
2021 | Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 51,219 | |
2021 | - Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 7,601 | |
2022 | Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 49,156 | |
2022 | - Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 7,435 | |
2023 | Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 43,857 | |
2023 | - Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 6,603 | |
2024 | Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 37,590 | |
2024 | - Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 5,341 | |
2025 | Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 31,635 | |
2025 | - Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 4,283 | |
2026 | Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 27,011 | |
2026 | - Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 3,131 | |
2027 | Interest rate risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 22,555 | |
2027 | - Inflation risk | ||
Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items] | ||
Nominal amount | 818 |
Derivative financial instrum_10
Derivative financial instruments - Hedged items in cash flow hedges and hedges of net investments in foreign operations (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of detailed information about hedged items [line items] | |||
Balance in currency translation reserve for continuing hedges | £ 2,581 | £ 2,736 | £ 3,383 |
Cash flow hedges | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | 2,206 | (1,371) | |
Balance in cash flow hedging reserve for continuing hedges | 1,123 | (838) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | (204) | (780) | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 2,206 | (1,371) | |
Hedge ineffectiveness recognised in the income statement | (232) | 41 | |
Hedge of net investment in foreign operations | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | 91 | (94) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | 1,189 | 1,168 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 186 | 162 | |
Hedging gains or losses recognised in other comprehensive income | 91 | (94) | |
Hedge ineffectiveness recognised in the income statement | 0 | 0 | |
Hedge of net investment in foreign operations | USD LIBOR | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | 143 | (83) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | 1,184 | 1,097 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 143 | (83) | |
Hedge ineffectiveness recognised in the income statement | 0 | 0 | |
Hedge of net investment in foreign operations | EUR LIBOR | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | (49) | (2) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | (39) | 16 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | (49) | (2) | |
Hedge ineffectiveness recognised in the income statement | 0 | 0 | |
Hedge of net investment in foreign operations | Other Currencies [Member] | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | (3) | (9) | |
Balance in cash flow hedging reserve for continuing hedges | 0 | 0 | |
Balance in currency translation reserve for continuing hedges | 44 | 55 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 186 | 162 | |
Hedging gains or losses recognised in other comprehensive income | (3) | (9) | |
Hedge ineffectiveness recognised in the income statement | 0 | 0 | |
Financial assets at amortised cost | Cash flow hedges | Loans and advances at amortised cost | Interest rate derivatives | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | 2,042 | (1,260) | |
Balance in cash flow hedging reserve for continuing hedges | 935 | (758) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | (192) | (780) | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 2,042 | (1,260) | |
Hedge ineffectiveness recognised in the income statement | (211) | 40 | |
Financial assets at amortised cost | Cash flow hedges | Loans and advances at amortised cost | Foreign exchange derivatives | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | (88) | (70) | |
Balance in cash flow hedging reserve for continuing hedges | (16) | (15) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | 0 | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | (88) | (70) | |
Hedge ineffectiveness recognised in the income statement | 1 | 0 | |
Financial assets at amortised cost | Cash flow hedges | Debt securities classified as amortised cost | - Inflation risk | |||
Disclosure of detailed information about hedged items [line items] | |||
Change in fair value used as a basis to determine ineffectiveness | 252 | (41) | |
Balance in cash flow hedging reserve for continuing hedges | 204 | (65) | |
Balance in currency translation reserve for continuing hedges | 0 | 0 | |
Balances remaining in cash flow hedging reserve for which hedge accounting is no longer applied | (12) | 0 | |
Balances remaining in currency translation reserve for which hedge accounting is no longer applied | 0 | 0 | |
Hedging gains or losses recognised in other comprehensive income | 252 | (41) | |
Hedge ineffectiveness recognised in the income statement | £ (22) | £ 1 |
Derivative financial instrum_11
Derivative financial instruments - Cash flow and net investment hedging instruments which are carried on the balance sheet (Details) £ / shares in Millions, £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)£ / shares | Dec. 31, 2020GBP (£)£ / shares | |
Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 20,375 | |
Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Change in fair value used as a basis to determine ineffectiveness | £ (2,438) | £ 1,412 |
Nominal amount | £ / shares | 65,049 | 46,318 |
Cash flow hedges | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 9,896 | 27,160 |
Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Change in fair value used as a basis to determine ineffectiveness | £ (2,253) | £ 1,300 |
Nominal amount | £ / shares | 59,957 | 42,520 |
Cash flow hedges | Interest rate risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 9,896 | 27,160 |
Cash flow hedges | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Change in fair value used as a basis to determine ineffectiveness | £ 89 | £ 70 |
Nominal amount | £ / shares | 1,000 | 1,000 |
Cash flow hedges | Foreign exchange risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Cash flow hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Change in fair value used as a basis to determine ineffectiveness | £ (274) | £ 42 |
Nominal amount | £ / shares | 4,092 | 2,798 |
Cash flow hedges | - Inflation risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Hedge of net investment in foreign operations | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Change in fair value used as a basis to determine ineffectiveness | £ (91) | £ 94 |
Nominal amount | £ / shares | 9,356 | 5,623 |
Hedge of net investment in foreign operations | Foreign exchange risk | Nominal amount directly impacted by IBOR reform | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Nominal amount | £ / shares | 0 | 0 |
Derivatives | Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | £ 155 | £ 116 |
Hedging instrument, liabilities | (3) | 0 |
Derivatives | Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 0 | 47 |
Hedging instrument, liabilities | 0 | 0 |
Derivatives | Cash flow hedges | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 155 | 67 |
Hedging instrument, liabilities | 0 | 0 |
Derivatives | Cash flow hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 0 | 2 |
Hedging instrument, liabilities | (3) | 0 |
Derivatives | Hedge of net investment in foreign operations | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Derivative assets | 37 | 25 |
Hedging instrument, liabilities | (4) | 0 |
Loan liabilities | Cash flow hedges | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | Interest rate risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Cash flow hedges | - Inflation risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | 0 | 0 |
Loan liabilities | Hedge of net investment in foreign operations | Foreign exchange risk | ||
Disclosure of detailed information about hedging instruments [line items] | ||
Hedging instrument, liabilities | £ (6,933) | £ (4,832) |
Derivative financial instrum_12
Derivative financial instruments - Effect on the income statement and OCI of recycling amounts in respect of Cash flow hedges and Net investment hedges of foreign operations (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Recycled to other income | ||
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items] | ||
Amount recycled from OCI due to hedged item affecting income statement, hedges of net investments in foreign operations | £ 0 | £ 0 |
Amount recycled from OCI due to sale of investment, or cash flows no longer expected to occur, hedges of net investments in foreign operations | (28) | (4) |
Interest rate risk | Recycled to net interest income | ||
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items] | ||
Amount recycled from OCI due to hedged item affecting income statement, cash flow hedges | 228 | 239 |
Amount recycled from OCI due to sale of investment, or cash flows no longer expected to occur, cash flow hedges | 13 | 37 |
Foreign exchange risk | Recycled to net interest income | ||
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items] | ||
Amount recycled from OCI due to hedged item affecting income statement, hedges of net investments in foreign operations | 87 | 55 |
Amount recycled from OCI due to sale of investment, or cash flows no longer expected to occur, hedges of net investments in foreign operations | £ 0 | £ 0 |
Derivative financial instrum_13
Derivative financial instruments - Reconciliation of movement of reserves (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Reconciliation of hedging reserve | ||||
Reserve of cash flow hedges, beginning of period | £ 1,181 | £ 388 | ||
Currency translation movements | (6) | 50 | ||
Hedging (losses)/gains for the year | (2,206) | 1,316 | ||
Amounts reclassified in relation to cash flows affecting profit or loss | 327 | [1] | 282 | £ 141 |
Tax | 740 | [1] | (291) | (171) |
Reserve of cash flow hedges, end of period | (618) | 1,181 | 388 | |
Reconciliation of currency translation reserve [Roll Forward] | ||||
Currency translation reserve, beginning of period | 2,736 | 3,383 | ||
Currency translation movements | (92) | (745) | ||
Hedging (losses)/gains for the year | (91) | 94 | ||
Amounts reclassified in relation to cash flows affecting profit or loss | (28) | (4) | ||
Tax | 0 | 0 | ||
Currency translation reserve, end of period | £ 2,581 | £ 2,736 | £ 3,383 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Financial assets at fair valu_7
Financial assets at fair value through other comprehensive income (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | £ 45,908 | [1] | £ 51,902 |
Loans and advances | |||
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | 53 | 191 | |
Debt securities and other eligible bills | |||
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | 45,854 | 51,710 | |
Equity securities | |||
Disclosure of financial assets [line items] | |||
Financial assets at fair value through other comprehensive income | £ 1 | £ 1 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Financial liabilities designa_3
Financial liabilities designated at fair value (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of financial liabilities [line items] | ||||
Debt securities | £ 48,388 | [1] | £ 29,423 | |
Repurchase agreements and other similar secured borrowing | 12,769 | [1] | 10,443 | |
Subordinated debt | 32,185 | [1] | 32,005 | £ 33,425 |
Other financial liabilities | 4,592 | 2,810 | ||
Financial liabilities designated at fair value | 251,131 | [1] | 249,626 | |
Cumulative own credit net loss recognised | 960 | 954 | ||
Contractual amount due on maturity | ||||
Disclosure of financial liabilities [line items] | ||||
Debt securities | 61,333 | 57,650 | ||
Deposits | 29,836 | 22,120 | ||
Repurchase agreements and other similar secured borrowing | 168,144 | 177,513 | ||
Subordinated debt | 613 | 0 | ||
Other financial liabilities | 0 | 237 | ||
Financial liabilities designated at fair value | 259,926 | 257,520 | ||
Fair value | ||||
Disclosure of financial liabilities [line items] | ||||
Debt securities | 53,164 | 50,216 | ||
Deposits | 29,409 | 21,718 | ||
Repurchase agreements and other similar secured borrowing | 168,075 | 177,455 | ||
Subordinated debt | 483 | 0 | ||
Other financial liabilities | 0 | 237 | ||
Financial liabilities designated at fair value | £ 251,131 | 249,626 | ||
Fair value | As reported £m | ||||
Disclosure of financial liabilities [line items] | ||||
Subordinated debt | £ 221 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Fair value of financial instr_3
Fair value of financial instruments - Assets and liabilities held at fair value disaggregated by valuation technique (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 26, 2019 | |
Assets | ||||
Trading portfolio assets | £ 146,871 | [1] | £ 127,664 | |
Financial assets at fair value through the income statement | 188,226 | [1] | 171,761 | |
Derivative financial assets | 262,291 | [1] | 302,693 | |
Financial assets at fair value through other comprehensive income | 45,908 | [1] | 51,902 | |
Liabilities | ||||
Trading Portfolio Liabilities | (53,291) | [1] | (46,139) | |
Financial liabilities designated at fair value | (251,131) | [1] | (249,626) | |
Derivative financial liabilities | (256,523) | [1] | (300,580) | |
Fair value | ||||
Assets | ||||
Trading portfolio assets | 146,871 | 127,664 | ||
Financial assets at fair value through the income statement | 188,226 | 171,761 | ||
Derivative financial assets | 262,291 | 302,693 | £ 302,693 | |
Financial assets at fair value through other comprehensive income | 45,908 | 51,902 | ||
Investment property | 7 | 10 | ||
Total assets | 643,303 | 654,030 | ||
Liabilities | ||||
Trading Portfolio Liabilities | (53,291) | (46,139) | ||
Financial liabilities designated at fair value | (251,131) | (249,626) | ||
Derivative financial liabilities | (256,523) | (300,580) | £ (300,580) | |
Total liabilities | (560,945) | (596,345) | ||
Level 1 | Fair value | ||||
Assets | ||||
Trading portfolio assets | 80,836 | 60,619 | ||
Financial assets at fair value through the income statement | 4,953 | 4,439 | ||
Derivative financial assets | 6,150 | 9,154 | ||
Financial assets at fair value through other comprehensive income | 16,070 | 12,150 | ||
Investment property | 0 | 0 | ||
Total assets | 108,009 | 86,362 | ||
Liabilities | ||||
Trading Portfolio Liabilities | (26,701) | (23,331) | ||
Financial liabilities designated at fair value | (174) | (159) | ||
Derivative financial liabilities | (6,571) | (8,762) | ||
Total liabilities | (33,446) | (32,252) | ||
Level 2 | Fair value | ||||
Assets | ||||
Trading portfolio assets | 63,754 | 65,182 | ||
Financial assets at fair value through the income statement | 177,194 | 162,930 | ||
Derivative financial assets | 252,131 | 289,071 | ||
Financial assets at fair value through other comprehensive income | 29,800 | 39,599 | ||
Investment property | 0 | 0 | ||
Total assets | 522,879 | 556,782 | ||
Liabilities | ||||
Trading Portfolio Liabilities | (26,563) | (22,780) | ||
Financial liabilities designated at fair value | (250,553) | (249,126) | ||
Derivative financial liabilities | (243,893) | (285,579) | ||
Total liabilities | (521,009) | (557,485) | ||
Level 3 | ||||
Assets | ||||
Total assets | 12,415 | 10,886 | ||
Liabilities | ||||
Total liabilities | (6,490) | (6,608) | ||
Level 3 | Fair value | ||||
Assets | ||||
Trading portfolio assets | 2,281 | 1,863 | ||
Financial assets at fair value through the income statement | 6,079 | 4,392 | ||
Derivative financial assets | 4,010 | 4,468 | ||
Financial assets at fair value through other comprehensive income | 38 | 153 | ||
Investment property | 7 | 10 | ||
Total assets | 12,415 | 10,886 | ||
Liabilities | ||||
Trading Portfolio Liabilities | (27) | (28) | ||
Financial liabilities designated at fair value | (404) | (341) | ||
Derivative financial liabilities | (6,059) | (6,239) | ||
Total liabilities | £ (6,490) | £ (6,608) | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Fair value of financial instr_4
Fair value of financial instruments - Assets and liabilities held at fair value by product type (Details) - Level 3 - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of detailed information about financial instruments [line items] | ||
Assets | £ 12,415 | £ 10,886 |
Liabilities | (6,490) | (6,608) |
Asset backed securities | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 558 | 767 |
Liabilities | 0 | (24) |
Corporate debt | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,205 | 698 |
Liabilities | (21) | (3) |
Reverse repurchase and repurchase agreements | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 13 | 0 |
Liabilities | (172) | (174) |
Non-asset backed loans | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 3,743 | 3,093 |
Liabilities | 0 | 0 |
Equity cash products | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 393 | 542 |
Liabilities | 0 | 0 |
Private equity investments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 148 | 84 |
Liabilities | 0 | 0 |
Other | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 2,345 | 1,252 |
Liabilities | (238) | (186) |
Interest rate derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,091 | 1,613 |
Liabilities | (1,351) | (1,615) |
Foreign exchange derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 376 | 144 |
Liabilities | (374) | (143) |
Credit derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 323 | 196 |
Liabilities | (709) | (351) |
Equity derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 2,220 | 2,497 |
Liabilities | £ (3,625) | £ (4,112) |
Fair value of financial instr_5
Fair value of financial instruments - Analysis of movements in Level 3 assets and liabilities (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Derivative financial assets | £ 262,291 | [1] | £ 302,693 |
Derivative financial instruments | 256,523 | [1] | 300,580 |
Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 10,886 | ||
Ending balance, financial assets | 12,415 | 10,886 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (6,608) | ||
Ending balance, financial liabilities | (6,490) | (6,608) | |
Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | 4,278 | 5,690 | |
Purchases, fair value measurement, assets (liabilities) net | (14,826) | (6,490) | |
Sales, fair value measurement, assets (liabilities) net | (12,469) | (7,145) | |
Issues, fair value measurement, assets (liabilities) net | (101) | (21) | |
Settlements, fair value measurement, assets (liabilities) net | (450) | (768) | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | (2) | (4) | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 752 | 464 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (492) | (319) | |
Ending balance, Assets (liabilities) net | 5,925 | 4,278 | |
Derivative financial assets | 4,010 | 4,468 | |
Derivative financial instruments | 6,059 | 6,239 | |
Recurring fair value measurement | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (280) | (15) | |
Recurring fair value measurement | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (137) | (94) | |
Recurring fair value measurement | Investment property | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 10 | 13 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | (2) | (2) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | 0 | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 7 | 10 | |
Recurring fair value measurement | Investment property | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Recurring fair value measurement | Investment property | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (1) | (1) | |
Recurring fair value measurement | Derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (1,771) | (835) | |
Purchases, fair value measurement, assets (liabilities) net | 129 | 807 | |
Sales, fair value measurement, assets (liabilities) net | 8 | (31) | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | 85 | (160) | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 107 | (71) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (123) | 117 | |
Ending balance, Assets (liabilities) net | (2,049) | (1,771) | |
Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (226) | 16 | |
Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Trading portfolio liabilities | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (28) | 0 | |
Purchases, fair value measurement, liabilities | (5) | (27) | |
Sales, fair value measurement, liabilities | 23 | 0 | |
Issues, fair value measurement, liabilities | 0 | 0 | |
Settlements, fair value measurement, liabilities | 0 | 0 | |
Total gains or losses recognised in OCI, liabilities | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, liabilities | (12) | 0 | |
Transfers out of Level 3 of fair value hierarchy, liabilities | 1 | 0 | |
Ending balance, financial liabilities | (27) | (28) | |
Trading portfolio liabilities | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and losses in the period recognised in the income statement, liabilities | (6) | (1) | |
Trading portfolio liabilities | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and losses in the period recognised in the income statement, liabilities | 0 | 0 | |
Financial liabilities designated at fair value | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (341) | (343) | |
Purchases, fair value measurement, liabilities | (4) | 0 | |
Sales, fair value measurement, liabilities | 0 | 1 | |
Issues, fair value measurement, liabilities | (101) | (21) | |
Settlements, fair value measurement, liabilities | 66 | 1 | |
Total gains or losses recognised in OCI, liabilities | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, liabilities | (68) | (38) | |
Transfers out of Level 3 of fair value hierarchy, liabilities | 23 | 38 | |
Ending balance, financial liabilities | (404) | (341) | |
Financial liabilities designated at fair value | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and losses in the period recognised in the income statement, liabilities | 21 | 21 | |
Financial liabilities designated at fair value | Recurring fair value measurement | Level 3 | Financial liabilities at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Total gains and losses in the period recognised in the income statement, liabilities | 0 | 0 | |
Asset backed securities | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Derivative financial assets | 0 | 0 | |
Derivative financial instruments | 0 | 0 | |
Asset backed securities | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 767 | ||
Ending balance, financial assets | 558 | 767 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (24) | ||
Ending balance, financial liabilities | 0 | (24) | |
Interest rate derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,613 | ||
Ending balance, financial assets | 1,091 | 1,613 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (1,615) | ||
Ending balance, financial liabilities | (1,351) | (1,615) | |
Interest rate derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (2) | (206) | |
Purchases, fair value measurement, assets (liabilities) net | (20) | (17) | |
Sales, fair value measurement, assets (liabilities) net | 0 | (12) | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | 105 | 85 | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 90 | (18) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (218) | 23 | |
Ending balance, Assets (liabilities) net | (260) | (2) | |
Interest rate derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (255) | 109 | |
Interest rate derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Foreign exchange derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 144 | ||
Ending balance, financial assets | 376 | 144 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (143) | ||
Ending balance, financial liabilities | (374) | (143) | |
Foreign exchange derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | 1 | (7) | |
Purchases, fair value measurement, assets (liabilities) net | 0 | 0 | |
Sales, fair value measurement, assets (liabilities) net | 0 | 0 | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | 40 | 21 | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 10 | (19) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | (47) | 22 | |
Ending balance, Assets (liabilities) net | 2 | 1 | |
Foreign exchange derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (2) | (16) | |
Foreign exchange derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Credit derivatives | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Derivative financial assets | 262,291 | 302,693 | |
Credit derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 196 | ||
Ending balance, financial assets | 323 | 196 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (351) | ||
Ending balance, financial liabilities | (709) | (351) | |
Credit derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (155) | 198 | |
Purchases, fair value measurement, assets (liabilities) net | 239 | 125 | |
Sales, fair value measurement, assets (liabilities) net | 9 | 24 | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | (45) | (371) | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 10 | (21) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 0 | 116 | |
Ending balance, Assets (liabilities) net | (386) | (155) | |
Credit derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 34 | 24 | |
Credit derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Equity derivatives | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 2,497 | ||
Ending balance, financial assets | 2,220 | 2,497 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (4,112) | ||
Ending balance, financial liabilities | (3,625) | (4,112) | |
Equity derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Beginning balance, Assets (liabilities) net | (1,615) | (820) | |
Purchases, fair value measurement, assets (liabilities) net | (90) | 699 | |
Sales, fair value measurement, assets (liabilities) net | (1) | (43) | |
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities) net | (15) | 105 | |
Gains (losses) recognised in other comprehensive income, fair value measurement, assets (liabilities) net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (3) | (13) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 142 | (44) | |
Ending balance, Assets (liabilities) net | (1,405) | (1,615) | |
Equity derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (3) | (101) | |
Equity derivatives | Recurring fair value measurement | Derivative financial instruments | Level 3 | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets (liabilities) | |||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | |
Corporate debt | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 698 | ||
Ending balance, financial assets | 1,205 | 698 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (3) | ||
Ending balance, financial liabilities | (21) | (3) | |
Non-asset backed loans | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 3,093 | ||
Ending balance, financial assets | 3,743 | 3,093 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | 0 | ||
Ending balance, financial liabilities | 0 | 0 | |
Equity cash products | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 542 | ||
Ending balance, financial assets | 393 | 542 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | 0 | ||
Ending balance, financial liabilities | 0 | 0 | |
Private equity investments | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 84 | ||
Ending balance, financial assets | 148 | 84 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | 0 | ||
Ending balance, financial liabilities | 0 | 0 | |
Other | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,252 | ||
Ending balance, financial assets | 2,345 | 1,252 | |
Reconciliation of changes in fair value measurement, liabilities [abstract] | |||
Beginning balance, financial liabilities | (186) | ||
Ending balance, financial liabilities | (238) | (186) | |
Trading portfolio assets | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,863 | 2,264 | |
Purchases, fair value measurement, assets | 2,261 | 2,495 | |
Sales, fair value measurement, assets | (1,957) | (2,765) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (154) | (52) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 528 | 163 | |
Transfers out of Level 3 of fair value hierarchy, assets | (248) | (110) | |
Ending balance, financial assets | 2,281 | 1,863 | |
Trading portfolio assets | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (12) | (132) | |
Trading portfolio assets | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 686 | 656 | |
Purchases, fair value measurement, assets | 209 | 458 | |
Sales, fair value measurement, assets | (370) | (428) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | (40) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 114 | 99 | |
Transfers out of Level 3 of fair value hierarchy, assets | (116) | (34) | |
Ending balance, financial assets | 454 | 686 | |
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (69) | (25) | |
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 151 | 120 | |
Purchases, fair value measurement, assets | 310 | 77 | |
Sales, fair value measurement, assets | (123) | (6) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (12) | 0 | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 41 | 12 | |
Transfers out of Level 3 of fair value hierarchy, assets | (16) | (17) | |
Ending balance, financial assets | 389 | 151 | |
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 38 | (35) | |
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 709 | 974 | |
Purchases, fair value measurement, assets | 1,580 | 1,955 | |
Sales, fair value measurement, assets | (1,409) | (2,182) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (85) | (12) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 45 | 39 | |
Transfers out of Level 3 of fair value hierarchy, assets | (81) | (55) | |
Ending balance, financial assets | 758 | 709 | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (1) | (10) | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 214 | 392 | |
Purchases, fair value measurement, assets | 45 | 5 | |
Sales, fair value measurement, assets | (53) | (149) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 4 | 0 | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 80 | 11 | |
Transfers out of Level 3 of fair value hierarchy, assets | (10) | (4) | |
Ending balance, financial assets | 303 | 214 | |
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 23 | (41) | |
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Other | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 103 | 122 | |
Purchases, fair value measurement, assets | 117 | 0 | |
Sales, fair value measurement, assets | (2) | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (61) | 0 | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 248 | 2 | |
Transfers out of Level 3 of fair value hierarchy, assets | (25) | 0 | |
Ending balance, financial assets | 377 | 103 | |
Trading portfolio assets | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (3) | (21) | |
Trading portfolio assets | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 4,392 | 4,162 | |
Purchases, fair value measurement, assets | 12,703 | 4,829 | |
Sales, fair value measurement, assets | (10,541) | (4,313) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (440) | (320) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 197 | 410 | |
Transfers out of Level 3 of fair value hierarchy, assets | (39) | (364) | |
Ending balance, financial assets | 6,079 | 4,392 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (57) | 81 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (136) | (93) | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 2,280 | 1,964 | |
Purchases, fair value measurement, assets | 1,379 | 1,102 | |
Sales, fair value measurement, assets | (306) | (283) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (248) | (293) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 113 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | (352) | |
Ending balance, financial assets | 2,985 | 2,280 | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (59) | 142 | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | (174) | 0 | |
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 320 | 835 | |
Purchases, fair value measurement, assets | 3 | 9 | |
Sales, fair value measurement, assets | (247) | (404) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | 0 | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 1 | 9 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 84 | 320 | |
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | (93) | |
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 7 | (36) | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 88 | 113 | |
Purchases, fair value measurement, assets | 68 | 2 | |
Sales, fair value measurement, assets | (7) | (20) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (8) | (1) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 35 | 15 | |
Transfers out of Level 3 of fair value hierarchy, assets | (38) | (12) | |
Ending balance, financial assets | 148 | 88 | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 10 | (9) | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 1,704 | 1,250 | |
Purchases, fair value measurement, assets | 11,253 | 3,716 | |
Sales, fair value measurement, assets | (9,981) | (3,606) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (184) | (26) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 48 | 386 | |
Transfers out of Level 3 of fair value hierarchy, assets | (1) | 0 | |
Ending balance, financial assets | 2,862 | 1,704 | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 2 | 32 | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 21 | (48) | |
Fair value through other comprehensive income | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 153 | 429 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | (35) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (7) | (237) | |
Total gains or losses recognised in OCI, assets | (2) | (4) | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | (106) | 0 | |
Ending balance, financial assets | 38 | 153 | |
Fair value through other comprehensive income | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 47 | 86 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | (35) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (7) | 0 | |
Total gains or losses recognised in OCI, assets | (2) | (4) | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 38 | 47 | |
Fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Level 3 | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Beginning balance, financial assets | 106 | 343 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | (237) | |
Total gains or losses recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | (106) | 0 | |
Ending balance, financial assets | 0 | 106 | |
Fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category trading | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | |
Fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Level 3 | Financial assets at fair value through profit or loss, category other income | |||
Reconciliation of changes in fair value measurement, assets [abstract] | |||
Total gains and losses in the period recognised in the income statement, assets | £ 0 | £ 0 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Fair value of financial instr_6
Fair value of financial instruments - Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at year end (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | £ 5,788 | [1] | £ 7,076 | £ 4,073 |
Other income | 40 | [1] | 4 | 79 |
Other compre- hensive income | (1,685) | [2] | (157) | (304) |
Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (305) | (70) | ||
Other income | 21 | (91) | ||
Other compre- hensive income | 0 | (1) | ||
Total | (284) | (162) | ||
Level 3 | Investment property | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 0 | 0 | ||
Other income | 0 | (1) | ||
Other compre- hensive income | 0 | 0 | ||
Total | 0 | (1) | ||
Level 3 | Net derivative financial instruments | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (196) | (91) | ||
Other income | 0 | 0 | ||
Other compre- hensive income | 0 | 0 | ||
Total | (196) | (91) | ||
Trading portfolio liabilities | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (5) | 0 | ||
Other income | 0 | 0 | ||
Other compre- hensive income | 0 | 0 | ||
Total | (5) | 0 | ||
Financial liabilities designated at fair value | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 16 | 20 | ||
Other income | (1) | (1) | ||
Other compre- hensive income | 0 | 0 | ||
Total | 15 | 19 | ||
Trading portfolio assets | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (67) | (114) | ||
Other income | 0 | 0 | ||
Other compre- hensive income | 0 | 0 | ||
Total | (67) | (114) | ||
Trading portfolio assets | Trading portfolio liabilities | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 3,999 | 5,392 | £ 2,795 | |
Financial assets at fair value through the income statement | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | (53) | 115 | ||
Other income | 22 | (89) | ||
Other compre- hensive income | 0 | 0 | ||
Total | (31) | 26 | ||
Fair value through other comprehensive income | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Trading income | 0 | 0 | ||
Other income | 0 | 0 | ||
Other compre- hensive income | 0 | (1) | ||
Total | £ 0 | £ (1) | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Fair value of financial instr_7
Fair value of financial instruments - Significant unobservable inputs (Details) - Level 3 | Dec. 31, 2021 | Dec. 31, 2020 |
Min | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0032 | 0.0017 |
Max | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.1848 | 0.1831 |
Asset backed securities | Min | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Asset backed securities | Max | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 1.20 | 112 |
Non-asset backed loans | Min | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0200 | 0.0200 |
Non-asset backed loans | Min | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Non-asset backed loans | Min | Discounted cash flows | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.03 | 0.05 |
Non-asset backed loans | Min | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0031 | 0.0032 |
Non-asset backed loans | Min | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Non-asset backed loans | Max | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0300 | 0.0300 |
Non-asset backed loans | Max | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 1.12 | 104 |
Non-asset backed loans | Max | Discounted cash flows | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.10 | 0.08 |
Non-asset backed loans | Max | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0811 | 0.0477 |
Non-asset backed loans | Max | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 1.45 | 137 |
Corporate debt | Min | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Corporate debt | Min | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0229 | 0 |
Corporate debt | Min | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Corporate debt | Max | Discounted cash flows | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 1 | 104 |
Corporate debt | Max | Discounted cash flows | Loan spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0854 | 0 |
Corporate debt | Max | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 2.84 | 127 |
Commercial Real Estate loans | Min | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0068 | 0.0146 |
Commercial Real Estate loans | Max | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0543 | 0.0483 |
Equity cash products | Min | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0026 | 0.0049 |
Equity cash products | Max | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0034 | 0.0049 |
Interest rate derivatives | Min | Discounted cash flows | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0.01 |
Interest rate derivatives | Min | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0009 | 0.0017 |
Interest rate derivatives | Min | Correlation Model | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (0.20) | (0.20) |
Interest rate derivatives | Min | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Interest rate derivatives | Min | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0031 | 0.0031 |
Interest rate derivatives | Min | Option model | Interest rate volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0005 | 0.0006 |
Interest rate derivatives | Min | Option model | FX - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (0.20) | (0.30) |
Interest rate derivatives | Min | Option model | IR - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (1) | (0.20) |
Interest rate derivatives | Max | Discounted cash flows | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.03 | 0.03 |
Interest rate derivatives | Max | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.1848 | 0.1831 |
Interest rate derivatives | Max | Correlation Model | Inflation forwards | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (0.13) | (0.13) |
Interest rate derivatives | Max | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.38 | 84 |
Interest rate derivatives | Max | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0130 | 0.0227 |
Interest rate derivatives | Max | Option model | Interest rate volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0600 | 0.0489 |
Interest rate derivatives | Max | Option model | FX - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.78 | 0.78 |
Interest rate derivatives | Max | Option model | IR - IR correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.99 | 0.99 |
Credit derivatives | Min | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0002 | 0.0005 |
Credit derivatives | Min | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Credit derivatives | Max | Discounted cash flows | Credit spread | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.2925 | 0.0480 |
Credit derivatives | Max | Comparable pricing | Price | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 100 |
Equity derivatives | Min | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | (0.0129) | (0.0225) |
Equity derivatives | Min | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.02 | 0.01 |
Equity derivatives | Min | Option model | Equity - equity correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.10 | (0.45) |
Equity derivatives | Max | Discounted cash flows | Discounted margin | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0.0093 | 0.3000 |
Equity derivatives | Max | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 1.08 | 1.10 |
Equity derivatives | Max | Option model | Equity - equity correlation | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 1 | 1 |
Foreign exchange derivatives | Min | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 0 | 0 |
Foreign exchange derivatives | Max | Option model | Volatility | ||
Disclosure of detailed information about financial instruments [line items] | ||
Significant unobservable inputs, assets and liabilities | 1 | 30 |
Fair value of financial instr_8
Fair value of financial instruments - Narrative (Details) £ in Millions, $ in Millions | 12 Months Ended | |||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2021USD ($) | ||
Disclosure of detailed information about financial instruments [line items] | ||||
Deposits at amortised cost | £ 262,828 | [1] | £ 244,696 | |
Brokered certificates of deposit | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Deposits at amortised cost | 790 | 1,494 | ||
Derivative credit valuation adjustments | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Increase (decrease) In Derivative Fair Value Adjustments | (56) | |||
Fair value adjustments | 212 | |||
Level 3 | Exit price adjustments derived from market bid-offer spreads | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Increase (decrease) In Derivative Fair Value Adjustments | 15 | |||
Fair value adjustments | 498 | 483 | $ 498 | |
Level 3 | Uncollateralised derivative funding | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Increase (decrease) In Derivative Fair Value Adjustments | 12 | |||
Fair value adjustments | 127 | 115 | ||
Level 3 | Derivative credit valuation adjustments | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Fair value adjustments | 212 | 268 | ||
Level 3 | Derivative debit valuation adjustments | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Increase (decrease) In Derivative Fair Value Adjustments | (22) | |||
Fair value adjustments | (91) | (113) | ||
Top of range | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Favorable changes | 555 | 636 | ||
Unfavorable changes | £ 651 | £ 743 | ||
Education, social housing, and local authority portfolio | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Percentage of fixed rate loan notional amount concentrated towards bottom of range | 99.00% | 98.00% | ||
Education, social housing, and local authority portfolio | Level 3 | Loan spread | Maximum | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Significant unobservable input, assets | 0.0200 | 0.0200 | ||
Education, social housing, and local authority portfolio | Bottom of range | Level 3 | Loan spread | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Significant unobservable input, assets | 0.0031 | 0.0032 | 0.0031 | |
Education, social housing, and local authority portfolio | Top of range | Level 3 | Loan spread | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Significant unobservable input, assets | 0.0601 | 0.0477 | 0.0601 | |
Financial instruments at fair value | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | £ 122 | £ 103 | ||
Increase (decrease) in aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 19 | 3 | ||
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 59 | 26 | ||
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 40 | 23 | ||
Financial instruments at amortised cost | Level 3 | ||||
Disclosure of detailed information about financial instruments [line items] | ||||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 28 | 30 | ||
Increase (decrease) in aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | (2) | 1 | ||
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 0 | 1 | ||
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | £ 2 | £ 2 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Fair value of financial instr_9
Fair value of financial instruments - Sensitivity analysis of valuations using unobservable inputs (Details) - Level 3 - Derivatives - Recurring fair value measurement - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | £ 555 | £ 633 |
Favourable changes, Equity | 0 | 3 |
Unfavourable changes, Income Statement | (651) | (740) |
Unfavourable changes, Equity | 0 | (3) |
Corporate debt | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 38 | 16 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (28) | (14) |
Unfavourable changes, Equity | 0 | 0 |
Non-asset backed loans | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 99 | 104 |
Favourable changes, Equity | 0 | 3 |
Unfavourable changes, Income Statement | (150) | (190) |
Unfavourable changes, Equity | 0 | (3) |
Equity cash products | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 25 | 158 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (42) | (141) |
Unfavourable changes, Equity | 0 | 0 |
Private equity investments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 10 | 15 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (11) | (15) |
Unfavourable changes, Equity | 0 | 0 |
Other | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 19 | 23 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (20) | (23) |
Unfavourable changes, Equity | 0 | 0 |
Interest rate derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 51 | 82 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (79) | (123) |
Unfavourable changes, Equity | 0 | 0 |
Foreign exchange derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 20 | 6 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (28) | (11) |
Unfavourable changes, Equity | 0 | 0 |
Credit derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 112 | 55 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (103) | (44) |
Unfavourable changes, Equity | 0 | 0 |
Equity derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Favorable changes, Income statement | 181 | 174 |
Favourable changes, Equity | 0 | 0 |
Unfavourable changes, Income Statement | (190) | (179) |
Unfavourable changes, Equity | £ 0 | £ 0 |
Fair value of financial inst_10
Fair value of financial instruments - Fair value adjustments (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) |
Exit price adjustments derived from market bid-offer spreads | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Fair value adjustments | £ (498) | $ (498) | £ (483) |
Uncollateralised derivative funding | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Fair value adjustments | (127) | (115) | |
Derivative credit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Fair value adjustments | (212) | ||
Derivative credit valuation adjustments | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Fair value adjustments | (212) | (268) | |
Derivative debit valuation adjustments | Level 3 | |||
Disclosure of detailed information about financial instruments [line items] | |||
Fair value adjustments | £ 91 | £ 113 |
Fair value of financial inst_11
Fair value of financial instruments - Comparison of carrying amounts and fair values for assets and liabilities not held at fair value (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Financial assets | ||||
Loans and advances at amortised cost | £ 145,259 | [1] | £ 134,267 | |
Reverse repurchase agreements and other similar secured lending | 3,177 | [1] | 8,981 | |
Financial liabilities | ||||
Repurchase agreements and other similar secured borrowing | (12,769) | [1] | (10,443) | |
Debt securities in issue | (48,388) | [1] | (29,423) | |
Subordinated liabilities | (32,185) | [1] | (32,005) | £ (33,425) |
Not held at fair value | ||||
Financial assets | ||||
Loans and advances at amortised cost | 145,665 | 134,537 | ||
Reverse repurchase agreements and other similar secured lending | 3,177 | 8,981 | ||
Financial liabilities | ||||
Deposits at amortised cost | (262,843) | (244,738) | ||
Repurchase agreements and other similar secured borrowing | (12,776) | (10,443) | ||
Debt securities in issue | (48,350) | (29,486) | ||
Subordinated liabilities | (33,598) | (33,356) | ||
Not held at fair value | Level 1 | ||||
Financial assets | ||||
Loans and advances at amortised cost | 15,406 | 8,824 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Financial liabilities | ||||
Deposits at amortised cost | (180,829) | (165,909) | ||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||
Debt securities in issue | 0 | 0 | ||
Subordinated liabilities | 0 | 0 | ||
Not held at fair value | Level 2 | ||||
Financial assets | ||||
Loans and advances at amortised cost | 63,948 | 65,267 | ||
Reverse repurchase agreements and other similar secured lending | 3,177 | 8,981 | ||
Financial liabilities | ||||
Deposits at amortised cost | (82,014) | (78,769) | ||
Repurchase agreements and other similar secured borrowing | (12,776) | (10,443) | ||
Debt securities in issue | (46,201) | (27,630) | ||
Subordinated liabilities | (33,598) | (33,356) | ||
Not held at fair value | Level 3 | ||||
Financial assets | ||||
Loans and advances at amortised cost | 66,311 | 60,446 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Financial liabilities | ||||
Deposits at amortised cost | 0 | (60) | ||
Repurchase agreements and other similar secured borrowing | 0 | 0 | ||
Debt securities in issue | (2,149) | (1,856) | ||
Subordinated liabilities | 0 | 0 | ||
Carrying amount | ||||
Financial assets | ||||
Loans and advances at amortised cost | 145,259 | 134,267 | ||
Reverse repurchase agreements and other similar secured lending | 3,177 | 8,981 | ||
Financial liabilities | ||||
Deposits at amortised cost | (262,828) | (244,696) | ||
Repurchase agreements and other similar secured borrowing | (12,769) | (10,443) | ||
Debt securities in issue | (48,388) | (29,423) | ||
Subordinated liabilities | £ (32,185) | £ (32,005) | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Offsetting financial assets a_3
Offsetting financial assets and financial liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Derivative assets | £ 262,291 | [1] | £ 302,693 |
Reverse repurchase agreements and other similar secured lending | 3,177 | [1] | 8,981 |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Derivative liabilities | (256,523) | [1] | (300,580) |
Repurchase agreements and other similar secured borrowing | 12,769 | [1] | 10,443 |
Settlements assets liabilities offset amounts | 22,837 | 18,143 | |
Derivatives | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Gross amounts | (273,996) | (333,748) | |
Amounts offset | 23,606 | 41,982 | |
Net amounts reported on the balance sheet | (250,390) | (291,766) | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial instruments | 202,347 | 233,088 | |
Derivative liability expsoure | (13,892) | (12,086) | |
Amounts not subject to enforceable netting arrangements | (6,133) | (8,814) | |
Financial collateral pledged subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities | 34,151 | 46,592 | |
Cash collateral pledged | 31,861 | 42,518 | |
Non-cash assets pledged as collateral | 2,290 | 4,074 | |
Repurchase agreements and other similar secured borrowing | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Gross amounts | (540,462) | (475,616) | |
Amounts offset | 375,376 | 305,749 | |
Net amounts reported on the balance sheet | (165,086) | (169,867) | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial instruments | 0 | 0 | |
Derivative liability expsoure | 0 | 0 | |
Amounts not subject to enforceable netting arrangements | (15,758) | (18,031) | |
Repurchase agreements and other similar secured borrowing | 180,844 | 187,898 | |
Financial collateral pledged subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities | 165,086 | 169,867 | |
Repurchase agreements and other similar secured borrowing | Financial liabilities at fair value | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Derivative liability expsoure | (168,075) | (177,455) | |
Repurchase agreements and other similar secured borrowing | Financial liabilities at amortised cost | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Derivative liability expsoure | (12,769) | (10,443) | |
Financial liabilities subject to offsetting | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Gross amounts | (814,458) | (809,364) | |
Amounts offset | 398,982 | 347,731 | |
Net amounts reported on the balance sheet | (415,476) | (461,633) | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial instruments | 202,347 | 233,088 | |
Derivative liability expsoure | (13,892) | (12,086) | |
Amounts not subject to enforceable netting arrangements | (21,891) | (26,845) | |
Total liabilities | (437,367) | (488,478) | |
Financial collateral pledged subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities | 199,237 | 216,459 | |
Cash collateral netted | Derivatives | |||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Amounts offset | 4,346 | 7,313 | |
Derivatives | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Gross amounts | 279,286 | 342,896 | |
Amounts offset | (24,137) | (44,305) | |
Net amounts reported on the balance sheet | 255,149 | 298,591 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Netting and set-off | (202,347) | (233,088) | |
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements | 12,849 | 17,683 | |
Amounts not subject to enforceable netting arrangements | 7,142 | 4,102 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial collateral received subject to enforceable master netting arrangement or similar agreement not set off against financial assets | (39,953) | (47,820) | |
Non-cash collateral received subject to enforceable master netting arrangements or similar agreement not set off against financial assets | 5,804 | 4,656 | |
Cash collateral received subject to enforceable master netting arrangement or similar agreement not set off against financial assets | 34,149 | 43,164 | |
Derivatives | Cash collateral netted | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Amounts offset | (4,990) | ||
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position [abstract] | |||
Amounts offset | 3,815 | ||
Reverse repurchase agreements and other similar secured lending | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Gross amounts | 519,855 | 448,377 | |
Amounts offset | (375,376) | (305,749) | |
Net amounts reported on the balance sheet | 144,479 | 142,628 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Netting and set-off | 0 | 0 | |
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements | 503 | 384 | |
Amounts not subject to enforceable netting arrangements | 3,884 | 4,911 | |
Reverse repurchase agreements and other similar secured lending | 148,363 | 147,539 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial collateral received subject to enforceable master netting arrangement or similar agreement not set off against financial assets | (143,976) | (142,244) | |
Reverse repurchase agreements and other similar secured lending | Net gains on financial instruments designated at fair value | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements | 145,186 | 138,558 | |
Reverse repurchase agreements and other similar secured lending | Financial assets at amortised cost | |||
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements | 3,177 | 8,981 | |
Financial Assets Subject To Offsetting | |||
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [abstract] | |||
Gross amounts | 799,141 | 791,273 | |
Amounts offset | (399,513) | (350,054) | |
Net amounts reported on the balance sheet | 399,628 | 441,219 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial assets [abstract] | |||
Netting and set-off | (202,347) | (233,088) | |
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements | 13,352 | 18,067 | |
Amounts not subject to enforceable netting arrangements | 11,026 | 9,013 | |
Total assets | 410,654 | 450,232 | |
Amounts subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities [abstract] | |||
Financial collateral received subject to enforceable master netting arrangement or similar agreement not set off against financial assets | £ (183,929) | £ (190,064) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Loans and advances and deposi_3
Loans and advances and deposits held at amortised cost (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | £ 145,259 | £ 134,267 |
Deposits | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | 262,828 | 244,696 |
Banks | Deposits | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | 17,911 | 17,348 |
Customers | Deposits | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | 244,917 | 227,348 |
Loans and advances | Banks | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 8,750 | 9,003 |
Loans and advances | Customers | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 117,014 | 110,101 |
Debt securities classified as amortised cost | Banks | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | £ 19,495 | £ 15,163 |
Property, plant and equipment -
Property, plant and equipment - Depreciation rates (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Freehold buildings and long-leasehold property (more than 50 years to run) | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 2.00% |
Freehold buildings and long-leasehold property (more than 50 years to run) | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 3.30% |
Costs of adaptation of freehold and leasehold property | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 6.00% |
Costs of adaptation of freehold and leasehold property | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 10.00% |
Equipment installed in freehold and leasehold property | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 6.00% |
Equipment installed in freehold and leasehold property | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 10.00% |
Computers and similar equipment | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 17.00% |
Computers and similar equipment | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 33.00% |
Fixtures and fittings and other equipment | Bottom of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 9.00% |
Fixtures and fittings and other equipment | Top of range | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate | 20.00% |
Property, plant and equipment_2
Property, plant and equipment (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | £ 1,537 | |||
Ending balance, Property, plant and equipment | 1,248 | [1] | £ 1,537 | |
Impairment loss - structural costs | 266 | |||
Other income | 40 | [2] | 4 | £ 79 |
Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 3,304 | 3,349 | ||
Additions | 182 | 102 | ||
Disposals | (104) | (129) | ||
Exchange and other movements | 100 | (18) | ||
Ending balance, Property, plant and equipment | 3,482 | 3,304 | 3,349 | |
Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (1,767) | (1,718) | ||
Depreciation charge | (193) | (210) | ||
Impairment charge | (268) | (2) | ||
Disposals | 46 | 116 | ||
Exchange and other movements | (52) | 47 | ||
Ending balance, Property, plant and equipment | (2,234) | (1,767) | (1,718) | |
Property | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 889 | |||
Ending balance, Property, plant and equipment | 782 | 889 | ||
Property | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 1,619 | 1,635 | ||
Additions | 85 | 39 | ||
Disposals | (32) | (25) | ||
Exchange and other movements | 30 | (30) | ||
Ending balance, Property, plant and equipment | 1,702 | 1,619 | 1,635 | |
Property | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (730) | (697) | ||
Depreciation charge | (70) | (72) | ||
Impairment charge | (108) | 0 | ||
Disposals | 27 | 22 | ||
Exchange and other movements | (39) | 17 | ||
Ending balance, Property, plant and equipment | (920) | (730) | (697) | |
Equipment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 166 | |||
Ending balance, Property, plant and equipment | 181 | 166 | ||
Equipment | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 987 | 1,080 | ||
Additions | 70 | 35 | ||
Disposals | (12) | (97) | ||
Exchange and other movements | 13 | (31) | ||
Ending balance, Property, plant and equipment | 1,058 | 987 | 1,080 | |
Equipment | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (821) | (875) | ||
Depreciation charge | (55) | (61) | ||
Impairment charge | 0 | 0 | ||
Disposals | 10 | 93 | ||
Exchange and other movements | (11) | 22 | ||
Ending balance, Property, plant and equipment | (877) | (821) | (875) | |
Investment property | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 10 | |||
Ending balance, Property, plant and equipment | 7 | 10 | ||
Other income | 6 | 8 | ||
Investment property | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 10 | 13 | ||
Additions | 0 | 0 | ||
Disposals | (2) | (1) | ||
Exchange and other movements | (1) | (2) | ||
Ending balance, Property, plant and equipment | 7 | 10 | 13 | |
Investment property | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 0 | 0 | ||
Depreciation charge | 0 | 0 | ||
Impairment charge | 0 | 0 | ||
Disposals | 0 | 0 | ||
Exchange and other movements | 0 | 0 | ||
Ending balance, Property, plant and equipment | 0 | 0 | 0 | |
Right of use assets | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 472 | |||
Ending balance, Property, plant and equipment | 278 | 472 | ||
Right of use assets | Cost | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | 688 | 621 | ||
Additions | 27 | 28 | ||
Disposals | (58) | (6) | ||
Exchange and other movements | 58 | 45 | ||
Ending balance, Property, plant and equipment | 715 | 688 | 621 | |
Right of use assets | Accumulated depreciation and impairment | ||||
Reconciliation of changes in property, plant and equipment [abstract] | ||||
Beginning balance, Property, plant and equipment | (216) | (146) | ||
Depreciation charge | (68) | (77) | ||
Impairment charge | (160) | (2) | ||
Disposals | 9 | 1 | ||
Exchange and other movements | (2) | 8 | ||
Ending balance, Property, plant and equipment | £ (437) | £ (216) | £ (146) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Leases - Finance lease income (
Leases - Finance lease income (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Finance leases | ||
Finance income from net investment in lease | £ 0 | £ 10 |
Loss on sales | £ 0 | £ (27) |
Leases - Lease liabilities (Det
Leases - Lease liabilities (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation Of Lease Liabilities [Roll Forward] | |||
Lease liabilities, Beginning Balance | £ 515 | £ 529 | |
Interest expense | 20 | 23 | £ 25 |
New leases | 38 | 27 | |
Disposals | (45) | (5) | |
Cash payments | (92) | (114) | |
Exchange and other movements | 59 | 55 | |
Lease liabilities, Ending Balance | £ 495 | £ 515 | £ 529 |
Leases - Lease liability maturi
Leases - Lease liability maturity analysis (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | £ 598 | £ 629 |
Not more than one year | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 81 | 91 |
One to two years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 77 | 70 |
Two to three years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 74 | 60 |
Three to four years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 66 | 58 |
Four to five years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 60 | 55 |
Five to ten years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | 210 | 227 |
Greater than ten years | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Total undiscounted lease liabilities | £ 30 | £ 68 |
Leases - Narrative (Details)
Leases - Narrative (Details) £ in Millions | 12 Months Ended | |
Dec. 31, 2021GBP (£)leases | Dec. 31, 2020GBP (£)leases | |
Leases | ||
Number of leases with variable lease payment terms | leases | 47 | 59 |
Number of leases | leases | 110 | 121 |
Expense relating to variable lease payments not included in measurement of lease liabilities | £ 362 | £ 121 |
Extension and termination options reasonably certain to be exercised | 408 | £ 395 |
Gains (losses) arising from sale and leaseback transactions | £ 33 |
Goodwill and intangible asset_2
Goodwill and intangible assets - Annual rates in calculating amortisation (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Software | Bottom of range | Internally generated | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 12 months |
Software | Bottom of range | Other | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 12 months |
Software | Top of range | Internally generated | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 6 years |
Software | Top of range | Other | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 6 years |
Customer lists | Bottom of range | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 12 months |
Customer lists | Top of range | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 25 years |
Licences and other | Bottom of range | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 12 months |
Licences and other | Top of range | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 25 years |
Certain core banking platforms | Bottom of range | Internally generated | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 10 years |
Certain core banking platforms | Top of range | Internally generated | |
Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | |
Amortisation period | 15 years |
Goodwill and intangible asset_3
Goodwill and intangible assets - Goodwill and Intangible assets (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | £ 1,154 | ||
Intangible assets and goodwill, end of period | 1,449 | [1] | £ 1,154 |
Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 3,751 | 3,746 | |
Additions | 601 | ||
Disposals | (167) | ||
Additions and disposals | 133 | ||
Exchange and other movements | (41) | (128) | |
Intangible assets and goodwill, end of period | 4,144 | 3,751 | |
Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | (2,597) | (2,534) | |
Disposals | 167 | 78 | |
Amortisation charge | (210) | (211) | |
Impairment charge | (12) | (18) | |
Exchange and other movements | (43) | 88 | |
Intangible assets and goodwill, end of period | (2,695) | (2,597) | |
Goodwill | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 256 | ||
Intangible assets and goodwill, end of period | 258 | 256 | |
Goodwill | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 324 | 406 | |
Additions | 0 | ||
Disposals | 0 | ||
Additions and disposals | (77) | ||
Exchange and other movements | 2 | (5) | |
Intangible assets and goodwill, end of period | 326 | 324 | |
Goodwill | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | (68) | (111) | |
Disposals | 0 | 43 | |
Amortisation charge | 0 | 0 | |
Impairment charge | 0 | 0 | |
Exchange and other movements | 0 | 0 | |
Intangible assets and goodwill, end of period | (68) | (68) | |
Software | Internally generated | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 575 | ||
Intangible assets and goodwill, end of period | 542 | 575 | |
Software | Internally generated | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 1,539 | 1,430 | |
Additions | 195 | ||
Disposals | (148) | ||
Additions and disposals | 169 | ||
Exchange and other movements | (78) | (60) | |
Intangible assets and goodwill, end of period | 1,508 | 1,539 | |
Software | Internally generated | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | (964) | (870) | |
Disposals | 148 | 22 | |
Amortisation charge | (126) | (132) | |
Impairment charge | (12) | (18) | |
Exchange and other movements | (12) | 34 | |
Intangible assets and goodwill, end of period | (966) | (964) | |
Software | Other | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 51 | ||
Intangible assets and goodwill, end of period | 43 | 51 | |
Software | Other | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 106 | 81 | |
Additions | 1 | ||
Disposals | (12) | ||
Additions and disposals | 21 | ||
Exchange and other movements | 0 | 4 | |
Intangible assets and goodwill, end of period | 95 | 106 | |
Software | Other | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | (55) | (54) | |
Disposals | 12 | 9 | |
Amortisation charge | (6) | (8) | |
Impairment charge | 0 | 0 | |
Exchange and other movements | (3) | (2) | |
Intangible assets and goodwill, end of period | (52) | (55) | |
Customer lists | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 167 | ||
Intangible assets and goodwill, end of period | 132 | 167 | |
Customer lists | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 1,325 | 1,371 | |
Additions | 0 | ||
Disposals | (5) | ||
Additions and disposals | 0 | ||
Exchange and other movements | 19 | (46) | |
Intangible assets and goodwill, end of period | 1,339 | 1,325 | |
Customer lists | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | (1,158) | (1,159) | |
Disposals | 5 | 0 | |
Amortisation charge | (36) | (40) | |
Impairment charge | 0 | 0 | |
Exchange and other movements | (18) | 41 | |
Intangible assets and goodwill, end of period | (1,207) | (1,158) | |
Licences and other | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 105 | ||
Intangible assets and goodwill, end of period | 474 | 105 | |
Licences and other | Cost | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | 457 | 458 | |
Additions | 405 | ||
Disposals | (2) | ||
Additions and disposals | 20 | ||
Exchange and other movements | 16 | (21) | |
Intangible assets and goodwill, end of period | 876 | 457 | |
Licences and other | Accumulated amortisation and impairment | |||
Reconciliation of changes in intangible assets and goodwill [abstract] | |||
Intangible assets and goodwill, beginning of period | (352) | (340) | |
Disposals | 2 | 4 | |
Amortisation charge | (42) | (31) | |
Impairment charge | 0 | 0 | |
Exchange and other movements | (10) | 15 | |
Intangible assets and goodwill, end of period | £ (402) | £ (352) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Goodwill and intangible asset_4
Goodwill and intangible assets - Goodwill allocated to business operations according to business segments (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Goodwill | £ 258 | £ 256 |
Consumer, Cards and Payments | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Goodwill | £ 258 | £ 256 |
Goodwill and intangible asset_5
Goodwill and intangible assets (Narrative) (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
VIU forecast period | 5 years | |
Cash-generating units | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Growth rate used to extrapolate cash flow projections | 2.00% | 2.00% |
Cash-generating units | Bottom of range | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Discount rate | 12.50% | 12.00% |
Cash-generating units | Top of range | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Discount rate | 14.70% | 16.30% |
Other liabilities (Details)
Other liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Accruals and deferred income including contract liabilities [abstract] | |||
Accruals and deferred income | £ 2,657 | £ 2,428 | |
Other creditors | 4,030 | 2,250 | |
Items in the course of collection due to other banks | 67 | 58 | |
Lease liabilities (refer to Note 20) | 495 | 515 | |
Other liabilities | £ 7,249 | [1] | £ 5,251 |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Provisions (Details)
Provisions (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | £ 1,208 | |
Additions | 502 | |
Amounts utilised | (119) | |
Unused amounts reversed | (451) | |
Exchange and other movements | (30) | |
Provisions, Ending balance | 1,110 | |
Not more than one year | ||
Reconciliation of changes in other provisions [abstract] | ||
Expected reimbursement, other provisions | 1,023 | £ 787 |
Onerous contracts | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 6 | |
Additions | 1 | |
Amounts utilised | (2) | |
Unused amounts reversed | (3) | |
Exchange and other movements | 0 | |
Provisions, Ending balance | 2 | |
Redundancy and restructuring | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 44 | |
Additions | 55 | |
Amounts utilised | (39) | |
Unused amounts reversed | (11) | |
Exchange and other movements | (3) | |
Provisions, Ending balance | 46 | |
Undrawn contractually committed facilities and guarantees provided | IFRSs 9 | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 769 | |
Additions | 129 | |
Amounts utilised | 0 | |
Unused amounts reversed | (386) | |
Exchange and other movements | (13) | |
Provisions, Ending balance | 499 | |
Customer redress | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 44 | |
Additions | 235 | |
Amounts utilised | (4) | |
Unused amounts reversed | (7) | |
Exchange and other movements | (2) | |
Provisions, Ending balance | 266 | |
Legal, competition and regulatory matters | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 222 | |
Additions | 54 | |
Amounts utilised | (45) | |
Unused amounts reversed | (18) | |
Exchange and other movements | (2) | |
Provisions, Ending balance | 211 | |
Sundry provisions | ||
Reconciliation of changes in other provisions [abstract] | ||
Provisions, Beginning balance | 123 | |
Additions | 28 | |
Amounts utilised | (29) | |
Unused amounts reversed | (26) | |
Exchange and other movements | (10) | |
Provisions, Ending balance | £ 86 |
Contingent liabilities and co_3
Contingent liabilities and commitments (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | £ 47,412,915 | £ 42,625,605 | |
Provisions | 1,110 | [1] | 1,208 |
Expected credit losses held against contingent liabilities and commitments | |||
Disclosure of contingent liabilities [line items] | |||
Provisions | 499 | 769 | |
Other (outside the UK and US tax groups) | |||
Disclosure of contingent liabilities [line items] | |||
Guarantees, pledges or commitments | 1,700 | 2,600 | |
Financial guarantee contracts | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | 23,746 | 20,932 | |
Total commitments | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | 284,451 | 265,022 | |
of which: Carried at fair value | Financial guarantee contracts | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | 231 | 229 | |
of which: Carried at fair value | Total commitments | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | 18,571 | 9,248 | |
Guarantees and letters of credit pledged as collateral security | Financial guarantee contracts | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | 15,759 | 15,138 | |
Performance guarantees, acceptances and endorsements | Financial guarantee contracts | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | 7,987 | 5,794 | |
Documentary credits and other short-term trade related transactions | Total commitments | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | 1,584 | 1,086 | |
Standby facilities, credit lines and other commitments | Total commitments | |||
Disclosure of contingent liabilities [line items] | |||
Notional contract amount | £ 282,867 | £ 263,936 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Legal, competition and regula_2
Legal, competition and regulatory matters (Narrative) (Details) € in Millions, £ in Millions, SFr in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Aug. 01, 2019 | Dec. 31, 2021EUR (€) | Jun. 30, 2021USD ($) | Apr. 30, 2021USD ($) | Dec. 31, 2020USD ($)defendantpensionFund | Jun. 30, 2019CHF (SFr) | May 31, 2019EUR (€)settlement | Sep. 30, 2013GBP (£) | May 31, 2021USD ($) | Jul. 01, 2007lawsuits | Dec. 31, 2021GBP (£)lawsuitssettlementplaintiff | Dec. 31, 2021USD ($)lawsuitssettlementplaintiff | Dec. 31, 2021EUR (€)lawsuitssettlementplaintiff | Dec. 31, 2020GBP (£) | Dec. 31, 2020USD ($) | Dec. 31, 2019GBP (£) | Dec. 31, 2018GBP (£) | Dec. 31, 2018USD ($) | Dec. 31, 2016lawsuits | Dec. 31, 2015USD ($) | Dec. 31, 2012USD ($)lawsuits | Dec. 31, 2008USD ($)agreement | Mar. 10, 2022USD ($) | Mar. 31, 2022GBP (£) | Dec. 31, 2020USD ($) | Aug. 31, 2020GBP (£) | |
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | £ | £ 374 | [1] | £ 76 | £ 264 | ||||||||||||||||||||||||
Other provisions | £ | £ 1,110 | 1,110 | 1,208 | |||||||||||||||||||||||||
Contingent liabilities | £ | 23,746 | £ 23,746 | 20,932 | |||||||||||||||||||||||||
Over issuance of securities | United States | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Validity term | 3 years | |||||||||||||||||||||||||||
Increase (decrease) in other provisions | £ | £ 220 | £ 0 | ||||||||||||||||||||||||||
Over issuance of securities | United States | Disclosure of post year end balances | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Securities issued in excess of limit | $ 13,000 | |||||||||||||||||||||||||||
Customer Remediation Provision | Disclosure of post year end balances | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Other provisions | £ | £ 181 | |||||||||||||||||||||||||||
FCA Proceedings and other investigations | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of advisory service agreements | agreement | 2 | |||||||||||||||||||||||||||
Financial penalty warning | £ | £ 50 | |||||||||||||||||||||||||||
USD LIBOR cases in MDL court | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of settlements with court approval | settlement | 2 | 2 | 2 | |||||||||||||||||||||||||
USD LIBOR cases in MDL court | Lawsuits with specified damages sought | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | lawsuits | 3 | |||||||||||||||||||||||||||
Damages sought | $ 100 | |||||||||||||||||||||||||||
USD LIBOR cases in MDL court | Exchange-based class claims | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | $ 7.5 | $ 7.1 | $ 20 | |||||||||||||||||||||||||
Sterling LIBOR case in SDNY | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | lawsuits | 2 | |||||||||||||||||||||||||||
Forex investigations | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | $ 2,380 | |||||||||||||||||||||||||||
Forex investigations | SEC | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | SFr 27 | € 210 | ||||||||||||||||||||||||||
Forex investigations | Fines settlement | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | € | € 54 | |||||||||||||||||||||||||||
Number of settlements with court approval | settlement | 2 | |||||||||||||||||||||||||||
Consolidated FX action | SEC | Barclays Capital Inc. | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | $ 384 | |||||||||||||||||||||||||||
Non-US forex civil actions | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | lawsuits | 2 | 2 | 2 | |||||||||||||||||||||||||
Metals related civil actions | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | € | € 50 | |||||||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | RMBS repurchase requests | Originated and sold to third parties by acquired subsidiary | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | 4 | 2 | 2 | 2 | ||||||||||||||||||||||||
Number of settlements with court approval | settlement | 1 | 1 | 1 | |||||||||||||||||||||||||
Revenue | $ 2,100 | |||||||||||||||||||||||||||
Number of lawsuits dismissed | settlement | 1 | 1 | 1 | |||||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | $ 32.5 | |||||||||||||||||||||||||||
Number of defendants | defendant | 6 | |||||||||||||||||||||||||||
Asset-backed debt instruments held | $ 22 | |||||||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | NEW MEXICO | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of retirement benefit funds | pensionFund | 2 | |||||||||||||||||||||||||||
Supranational, Sovereign and Agency Bonds civil actions | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits dismissed | lawsuits | 1 | 1 | 1 | |||||||||||||||||||||||||
Civil actions in respect of VRDO - private plaintiffs | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | lawsuits | 2 | 2 | 2 | |||||||||||||||||||||||||
Civil actions in respect of VRDO - SNDY | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | lawsuits | 3 | 3 | 3 | |||||||||||||||||||||||||
Government and agency securities civil actions and related matters | Barclays Bank PLC | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | $ 5.7 | |||||||||||||||||||||||||||
Government and agency securities civil actions and related matters | Barclays Capital Inc. | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation and conduct | $ 87 | |||||||||||||||||||||||||||
BDC Finance LLC | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Litigation settlements approved | $ 3.3 | $ 298 | ||||||||||||||||||||||||||
Civil actions in respect of the US Anti-Terrorism Act - EDNY | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | lawsuits | 6 | 6 | 6 | |||||||||||||||||||||||||
Number of lawsuits dismissed | lawsuits | 3 | 3 | 3 | |||||||||||||||||||||||||
Number of plaintiffs | plaintiff | 4,000 | 4,000 | 4,000 | |||||||||||||||||||||||||
Number of lawsuits subject to appeal | lawsuits | 1 | 1 | 1 | |||||||||||||||||||||||||
Civil actions in respect of the US Anti-Terrorism Act - SDNY | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Number of lawsuits with specified damages sought | lawsuits | 2 | 2 | 2 | |||||||||||||||||||||||||
Derivative transactions civil action | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Damages sought | £ | £ 329 | |||||||||||||||||||||||||||
CFS remediation of ASL loans | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Expected reimbursement, other provisions | £ | £ 37 | |||||||||||||||||||||||||||
Over issuance of securities | United States | Disclosure of post year end balances | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Securities issue limit | 20,800 | |||||||||||||||||||||||||||
Securities issued in excess of limit | $ 15,000 | |||||||||||||||||||||||||||
HMRC assessments concerning UK VAT | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Damages sought | £ | £ 181 | |||||||||||||||||||||||||||
HMRC assessments concerning UK VAT | Barclays Bank PLC | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Damages sought | £ | 53 | |||||||||||||||||||||||||||
HMRC assessments concerning UK VAT | UK Banking Business | ||||||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||||||
Damages sought | £ | £ 128 | |||||||||||||||||||||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Subordinated liabilities - Acco
Subordinated liabilities - Accounting for subordinated liabilities (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Subordinated liabilities [abstract] | ||||
Opening balance as at 1 January | £ 32,005 | £ 33,425 | ||
Issuance of subordinated liabilities | 9,099 | [1] | 3,856 | £ 6,785 |
Redemptions | (7,241) | (5,954) | ||
Other | (1,678) | 678 | ||
Closing balance as at 31 December | 32,185 | [2] | 32,005 | £ 33,425 |
Subordinated Liabilities, Including Those Designated At Fair Value | £ 32,668 | £ 32,005 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Subordinated liabilities - Narr
Subordinated liabilities - Narrative (Details) € in Millions, ¥ in Millions, kr in Millions, kr in Millions, SFr in Millions, $ in Millions, $ in Millions, $ in Millions | 12 Months Ended | |||||||||||
Dec. 31, 2021GBP (£) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2021JPY (¥) | Dec. 31, 2021EUR (€) | Dec. 31, 2021AUD ($) | Dec. 31, 2021SEK (kr) | Dec. 31, 2021NOK (kr) | Dec. 31, 2021CAD ($) | Dec. 31, 2021CHF (SFr) | ||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Issuance of subordinated liabilities | £ 9,099,000,000 | [1] | £ 3,856,000,000 | £ 6,785,000,000 | ||||||||
Redemption of subordinated debt | 7,241,000,000 | [1] | 4,746,000,000 | £ 6,574,000,000 | ||||||||
Dated subordinated liabilities | 31,873,000,000 | 31,100,000,000 | ||||||||||
Notional contract amount | 47,412,915,000,000 | 42,625,605,000,000 | ||||||||||
Other (outside the UK and US tax groups) | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Dated subordinated liabilities | 311,000,000 | 146,000,000 | ||||||||||
Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | 4,736,000,000 | |||||||||||
Dated subordinated liabilities | 31,873,000,000 | 31,100,000,000 | ||||||||||
Barclays Bank PLC loans issued intra-group to Barclays PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Issuance of subordinated liabilities | 8,788,000,000 | |||||||||||
Redemption of subordinated debt | 2,359,000,000 | |||||||||||
Reclassification From Intra-Group Loans | 221,000,000 | |||||||||||
USD Notes | Floating interest rate | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Issuance of subordinated liabilities | 229,000,000 | |||||||||||
USD Notes | Floating interest rate | Other (outside the UK and US tax groups) | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | 146,000,000 | |||||||||||
South African Rand notes | Floating interest rate | Other (outside the UK and US tax groups) | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Issuance of subordinated liabilities | 82,000,000 | |||||||||||
GBP 10% fixed rate notes | Fixed interest rate | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | £ 1,961,000,000 | |||||||||||
Interest rate | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | |||
EUR 6% fixed rate notes | Fixed interest rate | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | £ 1,339,000,000 | |||||||||||
Interest rate | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | |||
USD 10.179% fixed rate notes | Fixed interest rate | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | £ 1,075,000,000 | |||||||||||
Interest rate | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | 10.179% | |||
GBP 9.5% subordinated bonds | Fixed interest rate | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | £ 200,000,000 | |||||||||||
Interest rate | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | 9.50% | |||
EUR floating rate notes | Floating interest rate | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | £ 86,000,000 | |||||||||||
GBP 9.25% perpetual subordinated bonds | Fixed interest rate | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Redemption of subordinated debt | £ 75,000,000 | |||||||||||
Interest rate | 9.25% | 9.25% | 9.25% | 9.25% | 9.25% | 9.25% | 9.25% | 9.25% | 9.25% | |||
6.125% Undated Subordinated Notes (GBP 550m) | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Interest rate | 6.125% | 6.125% | 6.125% | 6.125% | 6.125% | 6.125% | 6.125% | 6.125% | 6.125% | |||
Maturity period | 5 years | |||||||||||
Various subordinated loans | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Dated subordinated liabilities | £ 21,052,000,000 | 16,607,000,000 | ||||||||||
Various subordinated loans | USD LIBOR | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | $ | $ 14,809 | |||||||||||
Various subordinated loans | EUR LIBOR | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | € | € 5,937 | |||||||||||
Various subordinated loans | GBP LIBOR | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | 1,250,000,000 | |||||||||||
Various subordinated loans | JPY LIBOR | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | ¥ | ¥ 252,600 | |||||||||||
Various subordinated loans | Australia, Dollars | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | $ | $ 2,315 | |||||||||||
Various subordinated loans | Sweden, Kronor | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | kr | kr 500 | |||||||||||
Various subordinated loans | Norway, Krone | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | kr 970 | $ 450 | ||||||||||
Various subordinated loans | CHF LIBOR | Dated subordinated liabilities | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Notional contract amount | SFr | SFr 435 | |||||||||||
Various subordinated loans | Floating interest rate | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Dated subordinated liabilities | 646,000,000 | 489,000,000 | ||||||||||
Various subordinated loans | Fixed interest rate | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Dated subordinated liabilities | £ 7,184,000,000 | £ 9,563,000,000 | ||||||||||
7.625% Contingent Capital Notes (USD 3,000m) | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Interest rate | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | |||
Consideration If CET1 Ratio Falls Below The Threshold | £ 0 | |||||||||||
7.625% Contingent Capital Notes (USD 3,000m) | Barclays Bank PLC | Minimum | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
CET1 ratio for automatic transfer | 7.00% | 7.00% | 7.00% | 7.00% | 7.00% | 7.00% | 7.00% | 7.00% | 7.00% | |||
9% Permanent Interest Bearing Capital Bonds (GBP 40m) | Barclays Bank PLC | ||||||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||||||
Interest rate | 9.00% | 9.00% | 9.00% | 9.00% | 9.00% | 9.00% | 9.00% | 9.00% | 9.00% | |||
Notional contract amount | £ 40,000,000 | |||||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Subordinated liabilities - Summ
Subordinated liabilities - Summary (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Subclassifications of assets, liabilities and equities [abstract] | ||
Undated subordinated liabilities | £ 795 | £ 905 |
Dated subordinated liabilities | 31,873 | 31,100 |
Subordinated Liabilities, Including Those Designated At Fair Value | £ 32,668 | £ 32,005 |
Subordinated liabilities - Unda
Subordinated liabilities - Undated (Details) | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2021JPY (¥) | Dec. 31, 2020GBP (£) |
Disclosure of detailed information about borrowings [line items] | ||||
Notional contract amount | £ 47,412,915,000,000 | £ 42,625,605,000,000 | ||
Undated subordinated liabilities | £ 795,000,000 | 905,000,000 | ||
6% Callable Perpetual Core Tier One Notes | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 6.00% | 6.00% | 6.00% | |
Undated subordinated liabilities | £ 15,000,000 | 17,000,000 | ||
6.86% Callable Perpetual Core Tier One Notes (USD 179m) | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 6.86% | 6.86% | 6.86% | |
Notional contract amount | $ | $ 179,000,000 | |||
Undated subordinated liabilities | £ 194,000,000 | 205,000,000 | ||
5.3304% Step-up Callable Perpetual Reserve Capital Instruments | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 5.3304% | 5.3304% | 5.3304% | |
Undated subordinated liabilities | £ 51,000,000 | 56,000,000 | ||
6.125% Undated Subordinated Notes (GBP 550m) | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 6.125% | 6.125% | 6.125% | |
Undated subordinated liabilities | £ 39,000,000 | 43,000,000 | ||
Junior Undated Floating Rate Notes (USD 38m) | Barclays Bank PLC | Floating interest rate | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Notional contract amount | $ | $ 38,000,000 | |||
Undated subordinated liabilities | 28,000,000 | 28,000,000 | ||
Undated Floating Rate Primary Capital Notes Series 1 (USD 167m) | Barclays Bank PLC | Floating interest rate | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Notional contract amount | $ | 167,000,000 | |||
Undated subordinated liabilities | 90,000,000 | 89,000,000 | ||
Undated Floating Rate Primary Capital Notes Series 2 (USD 295m) | Barclays Bank PLC | Floating interest rate | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Notional contract amount | $ | $ 295,000,000 | |||
Undated subordinated liabilities | 189,000,000 | 186,000,000 | ||
Undated Floating Rate Primary Capital Notes Series 3 (GBP 145m) | Barclays Bank PLC | Floating interest rate | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Undated subordinated liabilities | £ 21,000,000 | 21,000,000 | ||
9.25% Perpetual Sub Notes (ex Woolwich) (GBP 150m) | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 9.25% | 9.25% | 9.25% | |
Undated subordinated liabilities | £ 0 | 78,000,000 | ||
9% Permanent Interest Bearing Capital Bonds (GBP 40m) | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 9.00% | 9.00% | 9.00% | |
Notional contract amount | £ 40,000,000 | |||
Undated subordinated liabilities | £ 42,000,000 | 44,000,000 | ||
5.03% Reverse Dual Currency Undated Subordinated Loan (JPY 8,000m) | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 5.03% | 5.03% | 5.03% | |
Notional contract amount | ¥ | ¥ 8,000,000,000 | |||
Undated subordinated liabilities | £ 51,000,000 | 57,000,000 | ||
5.0% Reverse Dual Currency Subordinated (JPY12bn) | Barclays Bank PLC | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Interest rate | 5.00% | 5.00% | 5.00% | |
Notional contract amount | ¥ | ¥ 12,000,000,000 | |||
Undated subordinated liabilities | £ 75,000,000 | £ 83,000,000 |
Subordinated liabilities - Date
Subordinated liabilities - Dated (Details) | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2021JPY (¥) | Dec. 31, 2021EUR (€) | Dec. 31, 2021SGD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2020USD ($) | Dec. 31, 2020EUR (€) |
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional contract amount | £ 47,412,915,000,000 | £ 42,625,605,000,000 | ||||||
Dated subordinated liabilities | 31,873,000,000 | 31,100,000,000 | ||||||
Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 31,873,000,000 | 31,100,000,000 | ||||||
Other (outside the UK and US tax groups) | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 311,000,000 | £ 146,000,000 | ||||||
10% Fixed Rate Subordinated Notes | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 10.00% | 10.00% | 10.00% | |||||
Dated subordinated liabilities | 0 | £ 2,108,000,000 | ||||||
6% Fixed Rate Subordinated Notes (EUR 1,500m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 6.00% | 6.00% | 6.00% | |||||
Notional contract amount | € | € 1,500,000,000 | |||||||
Dated subordinated liabilities | 0 | £ 1,427,000,000 | ||||||
10.179% Fixed Rate Subordinated Notes (USD 1,521m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 10.179% | 10.179% | 10.179% | |||||
Notional contract amount | $ | $ 1,521,000,000 | |||||||
Dated subordinated liabilities | 0 | £ 1,101,000,000 | ||||||
9.5% Subordinated Bonds (ex-Woolwich Plc) | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 9.50% | 9.50% | 9.50% | |||||
Dated subordinated liabilities | 0 | £ 221,000,000 | ||||||
Subordinated Floating Rate Notes (EUR 100m) | Floating interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional contract amount | € | € 100,000,000 | |||||||
Dated subordinated liabilities | £ 0 | 90,000,000 | ||||||
7.625% Contingent Capital Notes (USD 3,000m) | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | |||
7.625% Contingent Capital Notes (USD 3,000m) | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 7.625% | 7.625% | 7.625% | 7.625% | 7.625% | |||
Notional contract amount | $ | $ 3,000,000,000 | |||||||
Dated subordinated liabilities | £ 1,159,000,000 | 1,189,000,000 | ||||||
6.625% Fixed Rate Subordinated Notes (EUR 1,000m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 6.625% | 6.625% | 6.625% | 6.625% | 6.625% | |||
Notional contract amount | € | € 1,000,000,000 | |||||||
Dated subordinated liabilities | £ 889,000,000 | 982,000,000 | ||||||
Subordinated Floating Rate Notes (EUR 50m) | Floating interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional contract amount | € | 50,000,000 | |||||||
Dated subordinated liabilities | 42,000,000 | 45,000,000 | ||||||
Subordinated Floating Rate Notes (EUR 50m) | Floating interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional contract amount | € | € 50,000,000 | |||||||
Dated subordinated liabilities | £ 42,000,000 | 45,000,000 | ||||||
5.75% Fixed Rate Subordinated Notes | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | |||
Dated subordinated liabilities | £ 322,000,000 | 351,000,000 | ||||||
5.4% Reverse Dual Currency Subordinated Loan (JPY 15,000m) | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 5.40% | 5.40% | 5.40% | 5.40% | 5.40% | |||
Notional contract amount | ¥ | ¥ 15,000,000,000 | |||||||
Dated subordinated liabilities | £ 97,000,000 | 108,000,000 | ||||||
6.33% Subordinated Notes (GBP 50m) | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 6.33% | 6.33% | 6.33% | 6.33% | 6.33% | |||
Notional contract amount | £ 50,000,000 | |||||||
Dated subordinated liabilities | 59,000,000 | 64,000,000 | ||||||
Subordinated Floating Rate Notes (EUR 68m) | Floating interest rate | Barclays Bank PLC | Barclays Bank PLC externally issued | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional contract amount | € | € 68,000,000 | |||||||
Dated subordinated liabilities | £ 57,000,000 | 61,000,000 | ||||||
2% Fixed Rate Subordinated Callable Notes (EUR 1,500) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 2.00% | 2.00% | 2.00% | 2.00% | 2.00% | |||
Notional contract amount | € | € 1,500,000,000 | |||||||
Dated subordinated liabilities | £ 1,288,000,000 | 1,388,000,000 | ||||||
3.75% Fixed Rate Resetting Subordinated Callable Notes (SGD 200m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | |||
Notional contract amount | $ | $ 200,000,000 | |||||||
Dated subordinated liabilities | £ 113,000,000 | 119,000,000 | ||||||
5.20% Fixed Rate Subordinated Notes (USD 1,367m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 5.20% | 5.20% | 5.20% | 5.20% | 5.20% | |||
Notional contract amount | $ | $ 1,367,000,000 | |||||||
Dated subordinated liabilities | £ 1,037,000,000 | 1,069,000,000 | ||||||
1.125% Fixed Rate Resetting Subordinated Callable Notes (EUR 1,000m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 1.125% | 1.125% | 1.125% | 1.125% | 1.125% | |||
Notional contract amount | € | € 1,000,000,000 | |||||||
Dated subordinated liabilities | £ 831,000,000 | 0 | ||||||
4.836% Fixed Rate Subordinated Callable Notes (USD 1,200m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 4.836% | 4.836% | 4.836% | 4.836% | 4.836% | |||
Notional contract amount | $ | $ 1,200,000,000 | |||||||
Dated subordinated liabilities | £ 937,000,000 | 973,000,000 | ||||||
5.088% Fixed-to-Floating Rate Subordinated Callable Notes (USD 1,300m) | Fixed-to-Floating Interest Rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 5.088% | 5.088% | 5.088% | 5.088% | 5.088% | |||
Notional contract amount | $ | $ 1,300,000,000 | |||||||
Dated subordinated liabilities | £ 1,005,000,000 | 1,049,000,000 | ||||||
3.811% Fixed Rate Resetting Subordinated Callable Notes (USD 1,000m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 3.811% | 3.811% | 3.811% | 3.811% | 3.811% | |||
Notional contract amount | $ | $ 1,000,000,000 | |||||||
Dated subordinated liabilities | £ 778,000,000 | 0 | ||||||
5.25% Fixed Rate Subordinated Notes (USD 827m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | |||
Notional contract amount | $ | $ 827,000,000 | |||||||
Dated subordinated liabilities | £ 618,000,000 | 660,000,000 | ||||||
4.95% Fixed Rate Subordinated Notes (USD 1,250m) | Fixed interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest rate | 4.95% | 4.95% | 4.95% | 4.95% | 4.95% | |||
Notional contract amount | $ | $ 1,250,000,000 | |||||||
Dated subordinated liabilities | £ 896,000,000 | 960,000,000 | ||||||
Floating Rate Subordinated Notes (USD 456m) | Floating interest rate | Barclays Bank PLC | Barclays Bank PLC | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Notional contract amount | $ | $ 456,000,000 | |||||||
Dated subordinated liabilities | 341,000,000 | 337,000,000 | ||||||
Various subordinated loans | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 21,052,000,000 | 16,607,000,000 | ||||||
Various subordinated loans | Fixed interest rate | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 7,184,000,000 | 9,563,000,000 | ||||||
Various subordinated loans | Fixed interest rate | Callable | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 11,016,000,000 | 5,838,000,000 | ||||||
Various subordinated loans | Floating interest rate | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 646,000,000 | 489,000,000 | ||||||
Various subordinated loans | Floating interest rate | Callable | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | 1,725,000,000 | 500,000,000 | ||||||
Zero Coupon Callable Loans | Callable | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Dated subordinated liabilities | £ 483,000,000 | £ 221,000,000 |
Ordinary shares, preference s_3
Ordinary shares, preference shares and other equity - Called up share capital, allotted and fully paid and other equity instruments (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | |||
Reconciliation of equity instruments [Roll Forward] | ||||
Beginning balance, equity | £ 53,710 | [1] | £ 50,615 | |
Ending balance, equity | [1] | 56,317 | 53,710 | |
Total share capital | ||||
Reconciliation of equity instruments [Roll Forward] | ||||
Beginning balance, equity | 2,348 | 2,348 | ||
AT1 securities issuance | 0 | 0 | ||
AT1 securities redemption | 0 | |||
Ending balance, equity | 2,348 | 2,348 | ||
Total share capital | Ordinary share capital | ||||
Reconciliation of equity instruments [Roll Forward] | ||||
Beginning balance, equity | 2,342 | 2,342 | ||
AT1 securities issuance | 0 | 0 | ||
AT1 securities redemption | 0 | |||
Ending balance, equity | 2,342 | 2,342 | ||
Total share capital | Preference share capital | ||||
Reconciliation of equity instruments [Roll Forward] | ||||
Beginning balance, equity | 6 | 6 | ||
AT1 securities issuance | 0 | 0 | ||
AT1 securities redemption | 0 | |||
Ending balance, equity | 6 | 6 | ||
Other equity instruments | ||||
Reconciliation of equity instruments [Roll Forward] | ||||
Beginning balance, equity | [2] | 8,621 | 8,323 | |
AT1 securities issuance | 1,072 | 1,134 | ||
AT1 securities redemption | (836) | |||
Ending balance, equity | [2] | £ 9,693 | £ 8,621 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | For further details refer to Note 27. |
Ordinary shares, preference s_4
Ordinary shares, preference shares and other equity - Narrative (Details) € / shares in Units, £ / shares in Units, $ / shares in Units, € in Millions, £ in Millions | Jun. 08, 2005GBP (£) | Jun. 08, 2005USD ($)$ / sharesshares | Mar. 15, 2005GBP (£) | Mar. 15, 2005EUR (€)€ / sharesshares | Dec. 31, 2021GBP (£)dummyRedemptions£ / sharesshares | Dec. 31, 2021USD ($)dummyRedemptions | Dec. 31, 2020GBP (£)Redemptions£ / sharesshares | Dec. 31, 2019GBP (£) | Dec. 31, 2021USD ($)$ / sharesshares | Dec. 31, 2021€ / shares | Dec. 31, 2020$ / shares | |||
Issue of shares and other equity instruments | £ 1,072 | [1] | £ 1,134 | £ 2,292 | ||||||||||
Notional contract amount | 47,412,915 | 42,625,605 | ||||||||||||
Total equity | £ 56,317 | [2] | 53,710 | [2] | 50,615 | |||||||||
4.75% Euro preference shares | ||||||||||||||
Number of shares issued and fully paid | shares | 140,000 | |||||||||||||
Par value (in USD per share) | € / shares | € 100 | |||||||||||||
Issue of shares and other equity instruments | £ 966.7 | € 1,383.3 | ||||||||||||
Notional contract amount | € | € 14 | |||||||||||||
Liquidating distributions subject to the ranking of reserve capital instruments | (per share) | $ 10,000 | € 10,000 | ||||||||||||
4.75% Euro preference shares | 3-Month Euribor | ||||||||||||||
Adjustment to interest rate basis | 0.71% | 0.71% | ||||||||||||
4.75% Euro preference shares | 2020 | ||||||||||||||
Adjustment to interest rate basis | 4.75% | 4.75% | ||||||||||||
6.278% US$100 preference shares | ||||||||||||||
Number of shares issued and fully paid | shares | 100,000 | |||||||||||||
Par value (in USD per share) | $ / shares | $ 100,000,000 | $ 100 | ||||||||||||
Issue of shares and other equity instruments | £ 548.1 | $ 995,400,000 | ||||||||||||
Notional contract amount | $ | $ 10,000,000 | |||||||||||||
Liquidating distributions subject to the ranking of reserve capital instruments | $ / shares | $ 10,000 | |||||||||||||
6.278% US$100 preference shares | Later than 1 year but not later than 18 years | ||||||||||||||
Preference shares interest rate | 6.278% | 6.278% | ||||||||||||
6.278% US$100 preference shares | Later than 18 years | 3-Month LIBOR | ||||||||||||||
Adjustment to interest rate basis | 1.55% | 1.55% | ||||||||||||
Fixed rate resetting contingent convertible securities | ||||||||||||||
AT1 securities issuance | £ 1,072 | 1,134 | ||||||||||||
Retained earnings | ||||||||||||||
Total equity | 43,415 | [2] | 39,558 | [2] | 36,709 | |||||||||
Total share capital | ||||||||||||||
AT1 securities issuance | 0 | 0 | ||||||||||||
Total equity | 2,348 | 2,348 | 2,348 | |||||||||||
Total share capital | Ordinary share capital | ||||||||||||||
AT1 securities issuance | 0 | 0 | ||||||||||||
Total equity | 2,342 | 2,342 | 2,342 | |||||||||||
Called up share capital and share premium | ||||||||||||||
Total equity | [3] | £ 2,348 | 2,348 | 2,348 | ||||||||||
Issuances of AT1 equity instruments | Fixed rate resetting contingent convertible securities | ||||||||||||||
Number of convertible instruments issued | dummy | 1 | 1 | ||||||||||||
Redemptions of AT1 equity instruments | Fixed rate resetting contingent convertible securities | ||||||||||||||
Number of convertible instruments redeemed | dummy | 1 | 1 | ||||||||||||
Other equity instruments | ||||||||||||||
AT1 securities issuance | £ 1,072 | 1,134 | ||||||||||||
Total equity | [3] | £ 9,693 | £ 8,621 | 8,323 | ||||||||||
AT1 Securities | Fixed rate resetting contingent convertible securities | ||||||||||||||
Number of convertible instruments issued | dummy | 1 | 1 | ||||||||||||
Number of convertible instruments redeemed | Redemptions | 0 | 0 | 1 | |||||||||||
Notional contract amount | £ 836 | |||||||||||||
Barclays Bank PLC | ||||||||||||||
Issue of shares and other equity instruments | £ 1,072 | [4] | 3,075 | 2,292 | ||||||||||
Total equity | 52,692 | [5] | 51,143 | [5] | 46,425 | |||||||||
Amounts payable, related party transactions | 6,000 | 6,000 | ||||||||||||
Interest paid, classified as financing activities | 164 | £ 152 | ||||||||||||
Barclays Bank PLC | 6% Callable Perpetual Core Tier One Notes | ||||||||||||||
Notional contract amount | £ 13 | |||||||||||||
Interest rate | 6.00% | 6.00% | ||||||||||||
Barclays Bank PLC | 6.86% Callable Perpetual Core Tier One Notes (USD 179m) | ||||||||||||||
Notional contract amount | $ | $ 179,000,000 | |||||||||||||
Interest rate | 6.86% | 6.86% | ||||||||||||
Barclays Bank PLC | 5.3304% Step-up Callable Perpetual Reserve Capital Instruments | ||||||||||||||
Notional contract amount | £ 35 | |||||||||||||
Interest rate | 5.3304% | 5.3304% | ||||||||||||
Barclays Bank PLC | Ordinary share capital | ||||||||||||||
Number of shares issued and fully paid | shares | 2,342,000,000 | 2,342,000,000 | 2,342,000,000 | |||||||||||
Par value (in USD per share) | £ / shares | £ 1 | |||||||||||||
Barclays Bank PLC | GBP1 preference shares | ||||||||||||||
Number of shares issued and fully paid | shares | 1,000 | 1,000 | 1,000 | |||||||||||
Par value (in USD per share) | £ / shares | £ 1 | |||||||||||||
Barclays Bank PLC | Retained earnings | ||||||||||||||
Total equity | £ 37,180 | [5] | £ 34,691 | [5] | 32,310 | |||||||||
Barclays Bank PLC | Total share capital | GBP1 preference shares | ||||||||||||||
Number of shares issued and fully paid | shares | 1,000 | 1,000 | ||||||||||||
Par value (in USD per share) | £ / shares | £ 1 | |||||||||||||
Pay-out upon winding up | £ / shares | £ 1 | |||||||||||||
Barclays Bank PLC | Total share capital | GBP1 preference shares | Minimum | ||||||||||||||
Dividend default period | 7 days | 7 days | ||||||||||||
Barclays Bank PLC | Total share capital | 4.75% Euro preference shares | ||||||||||||||
Number of shares issued and fully paid | shares | 31,856 | 31,856 | 31,856 | |||||||||||
Par value (in USD per share) | € / shares | € 100 | |||||||||||||
Barclays Bank PLC | Total share capital | 6.278% US$100 preference shares | ||||||||||||||
Number of shares issued and fully paid | shares | 58,133 | 58,133 | 58,133 | |||||||||||
Par value (in USD per share) | $ / shares | $ 100 | |||||||||||||
Barclays Bank PLC | Called up share capital and share premium | ||||||||||||||
AT1 securities issuance | $ | $ 0 | |||||||||||||
Total equity | [6] | £ 2,348 | £ 2,348 | 2,348 | ||||||||||
Barclays Bank PLC | Called up share capital and share premium | GBP1 preference shares | ||||||||||||||
Percentage of issued share capital | 100.00% | 100.00% | 100.00% | |||||||||||
Barclays Bank PLC | Other equity instruments | ||||||||||||||
Total equity | [6] | £ 14,400 | [7] | £ 13,328 | [7] | £ 11,089 | ||||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||||||||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||||||||||||
[3] | For further details refer to Note 27. | |||||||||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||||||||||||
[5] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||||||||||||
[6] | For further details refer to Note 27 in the Barclays Bank PLC Annual Report 2021. | |||||||||||||
[7] | Other equity instruments includes AT1 securities issued by Barclays Bank PLC and borrowings of $6bn from a wholly-owned, indirect subsidiary of Barclays Bank PLC. The borrowings have been recorded as equity since, under their terms, interest payments are non cumulative and discretionary whilst repayment of principal is perpetually deferrable by Barclays Bank PLC. Should Barclays Bank PLC make a discretionary dividend payment on its ordinary shares in the six months preceding the date of an interest payment, it will be obliged to make that interest payment. In 2021, interest paid on these borrowings was £164m. |
Ordinary shares, preference s_5
Ordinary shares, preference shares and other equity - AT1 Equity instruments (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | |
Total AT1 equity instruments | £ 9,693 | [1] | £ 8,621 | |
Notional contract amount | 47,412,915 | 42,625,605 | ||
Barclays Bank PLC | ||||
Total AT1 equity instruments | 14,400 | [2] | 13,328 | |
AT1 equity instruments | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | 9,693 | 8,621 | ||
AT1 equity instruments | 7.875% Perpetual Subordinated Contingent Convertible Securities | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 1,000 | 1,000 | ||
Interest rate | 7.875% | 7.875% | ||
AT1 equity instruments | 7.875% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 1,136 | 1,136 | ||
Interest rate | 7.875% | 7.875% | ||
Notional contract amount | $ | $ 1,500 | |||
AT1 equity instruments | 7.25% Perpetual Subordinated Contingent Convertible Securities | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 500 | 500 | ||
Interest rate | 7.25% | 7.25% | ||
AT1 equity instruments | 7.75% Perpetual Subordinated Contingent Convertible Securities (USD 2,500m) | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 1,925 | 1,925 | ||
Interest rate | 7.75% | 7.75% | ||
Notional contract amount | $ | $ 2,500 | |||
AT1 equity instruments | 5.875% Perpetual Subordinated Contingent Convertible Securities | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 623 | 623 | ||
Interest rate | 5.875% | 5.875% | ||
AT1 equity instruments | 8% Perpetual Subordinated Contingent Convertible Securities (USD 2,000m) | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 1,509 | 1,509 | ||
Interest rate | 8.00% | 8.00% | ||
Notional contract amount | $ | $ 2,000 | |||
AT1 equity instruments | 7.125% Perpetual Subordinated Contingent Convertible Securities | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 299 | 299 | ||
Interest rate | 7.125% | 7.125% | ||
AT1 equity instruments | 6.375% Perpetual Subordinated Contingent Convertible Securities | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 495 | 495 | ||
Interest rate | 6.375% | 6.375% | ||
AT1 equity instruments | 6.125% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 1,134 | 1,134 | ||
Interest rate | 6.125% | 6.125% | ||
Notional contract amount | $ | $ 1,500 | |||
AT1 equity instruments | 4.375% Perpetual Subordinated Contingent Convertible Securities (USD 1,500m) | Fixed interest rate | Barclays Bank PLC | ||||
Total AT1 equity instruments | £ 1,072 | £ 0 | ||
Interest rate | 4.375% | 4.375% | ||
Notional contract amount | $ | $ 1,500 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Reserves (Details)
Reserves (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of reserves within equity [line items] | |||
Total Reserves | £ 861 | [1] | £ 3,183 |
Currency translation reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | 2,581 | 2,736 | |
Fair value through other comprehensive income reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | (118) | 244 | |
Cash flow hedging reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | (618) | 1,181 | |
Own credit reserve | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | (960) | (954) | |
Other reserves | |||
Disclosure of reserves within equity [line items] | |||
Total Reserves | £ (24) | £ (24) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Staff costs (Details)
Staff costs (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Compensation costs | ||||
Performance costs | £ 1,308 | £ 1,145 | £ 1,104 | |
Salaries | 2,245 | 2,285 | 2,373 | |
Social security costs | 297 | 295 | 269 | |
Post-retirement benefits | 181 | 176 | 184 | |
Other compensation costs | 172 | 208 | 237 | |
Total compensation costs | 4,203 | 4,109 | 4,167 | |
Other resourcing costs | ||||
Outsourcing | 136 | 142 | 211 | |
Redundancy and restructuring | 49 | 47 | 69 | |
Temporary staff costs | 17 | 14 | 48 | |
Other | 51 | 53 | 70 | |
Total other resourcing costs | 253 | 256 | 398 | |
Total staff costs | 4,456 | [1] | 4,365 | 4,565 |
Defined contribution schemes | ||||
Compensation costs | ||||
Post-retirement benefits | 121 | 127 | 126 | |
Pension defined benefit plans | ||||
Compensation costs | ||||
Post-retirement benefits | 60 | 49 | 58 | |
Software | Internally generated | ||||
Compensation costs | ||||
Salaries | £ 152 | £ 156 | £ 123 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Share-based payments - Share ba
Share-based payments - Share based payments (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Total equity settled | £ 394 | £ 349 | £ 392 |
Cash settled | 4 | 2 | 3 |
Total share based payments | 398 | 351 | 395 |
Deferred Share Value Plan / Share Value Plan | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Total equity settled | 235 | 220 | 244 |
Others | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Total equity settled | £ 159 | £ 129 | £ 148 |
Share-based payments - Share op
Share-based payments - Share options and awards (Details) £ / shares in Units, shares in Thousands | 12 Months Ended | ||
Dec. 31, 2021GBP (£)shares£ / shares | Dec. 31, 2020GBP (£)shares£ / shares | Dec. 31, 2019shares | |
Deferred Share Value Plan / Share Value Plan | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average fair value per award granted in year | £ | £ 1.63 | £ 1.04 | |
Weighted average share price at exercise/ release during year | £ / shares | £ 1.76 | £ 1.24 | |
Weighted average remaining contractual life in years | 1 year 1 month 24 days | 1 year | |
Number of options/ awards outstanding (000s) | 370,505 | 370,006 | 297,149 |
Others | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Number of options/ awards outstanding (000s) | 47,480 | 53,767 | 37,481 |
Others | Bottom of range | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average fair value per award granted in year | £ | £ 0.64 | £ 0.24 | |
Weighted average share price at exercise/ release during year | £ / shares | £ 1.76 | £ 1.19 | |
Weighted average remaining contractual life in years | 0 years | 0 years | |
Others | Top of range | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average fair value per award granted in year | £ | £ 1.81 | £ 1.24 | |
Weighted average share price at exercise/ release during year | £ / shares | £ 1.92 | £ 1.67 | |
Weighted average remaining contractual life in years | 3 years | 4 years |
Share-based payments - Movement
Share-based payments - Movements in option and award plans (Details) | 12 Months Ended | |
Dec. 31, 2021shares£ / shares | Dec. 31, 2020shares£ / shares | |
Deferred Share Value Plan / Share Value Plan | ||
Reconciliation of options and award plans [Roll Forward] | ||
Outstanding at beginning of year/acquisition date, Number of options | 370,006,000 | 297,149,000 |
Transfers in the year, number of options | (2,214,000) | 953,000 |
Granted in the year, number of options | 174,338,000 | 203,157,000 |
Exercised/released in the year, number of options | (144,943,000) | (117,355,000) |
Less: forfeited in the year, number of options | (26,682,000) | (13,898,000) |
Less: expired in the year, number of options | 0 | 0 |
Outstanding at end of year, Number of options | 370,505,000 | 370,006,000 |
Of which exercisable, number of options | 0 | 0 |
Reconciliation of share price of options and award plans [Roll Forward] | ||
Outstanding at beginning of year/acquisition date, Weighted average | £ / shares | £ 1.24 | |
Outstanding at end of year, Weighted average exercise price | £ / shares | £ 1.76 | £ 1.24 |
Others | ||
Reconciliation of options and award plans [Roll Forward] | ||
Outstanding at beginning of year/acquisition date, Number of options | 53,767,000 | 37,481,000 |
Transfers in the year, number of options | (2,697,000) | 140,000 |
Granted in the year, number of options | 79,050,000 | 136,227,000 |
Exercised/released in the year, number of options | (78,273,000) | (99,465,000) |
Less: forfeited in the year, number of options | (3,395,000) | (18,285,000) |
Less: expired in the year, number of options | (972,000) | (2,331,000) |
Outstanding at end of year, Number of options | 47,480,000 | 53,767,000 |
Of which exercisable, number of options | 4,428,000 | 4,746,000 |
Sharesave | ||
Reconciliation of options and award plans [Roll Forward] | ||
Transfers in the year, number of options | 0 | 0 |
Of which exercisable, number of options | 1,499,920 | |
Reconciliation of share price of options and award plans [Roll Forward] | ||
Outstanding at beginning of year/acquisition date, Weighted average | £ / shares | £ 0.95 | £ 1.27 |
Granted in the year, weighted average exercise price | £ / shares | 1.43 | 0.84 |
Exercised/released in the year, weighted average exercise price | £ / shares | 1.36 | 1.21 |
Less: forfeited in the year, weighted average exercise price | £ / shares | 0.95 | 1.23 |
Less: expired in the year, weighted average exercise price | £ / shares | 1.69 | 1.33 |
Outstanding at end of year, Weighted average exercise price | £ / shares | 0.95 | 0.95 |
Of which exercisable, weighted average exercise price | £ / shares | £ 1.16 | £ 1.64 |
Share-based payments (Narrative
Share-based payments (Narrative) (Details) shares in Thousands | Dec. 31, 2021GBP (£)shares | Dec. 31, 2020GBP (£)shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Total liability arising from cash-settled share-based payments transactions | £ | £ 4,000,000 | £ 2,000,000 |
Deferred Share Value Plan / Share Value Plan | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Number of options exercisable | shares | 0 | 0 |
Pensions and post-retirement _2
Pensions and post-retirement benefits - Narrative (Details) £ in Millions | Sep. 30, 2022 | Jun. 12, 2020GBP (£) | Dec. 31, 2021GBP (£)tranchedirector | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | Mar. 31, 2022GBP (£) | Sep. 30, 2021GBP (£) | Sep. 30, 2020GBP (£) | |
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Current service cost | £ 58 | £ 53 | |||||||
Retirement benefit assets | 3,879 | [1] | 1,814 | ||||||
Surplus (deficit) in plan | (3,633) | (1,582) | |||||||
Notional contract amount | 47,412,915 | 42,625,605 | |||||||
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 47,601 | [2] | 53,367 | £ 67,743 | |||||
Past service cost | 0 | (4) | |||||||
Forecast | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Reasonably possible decrease in capital ratio | 0.65% | ||||||||
Forecast | Disclosure of post year end balances | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Reasonably possible decrease in capital ratio | 0.65% | ||||||||
Retirement benefit obligations | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Current service cost | 240 | 232 | |||||||
Past service cost | £ 0 | £ (4) | |||||||
Fair value of plan assets | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
% of total fair value of scheme assets | 100.00% | 100.00% | |||||||
Fair value of plan assets | Investment funds and trusts | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
% of total fair value of scheme assets | 0.00% | 0.00% | |||||||
Fair value of plan assets | Other | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
% of total fair value of scheme assets | 0.20% | 0.40% | |||||||
Barclays Bank PLC | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Retirement benefit assets | £ 3,825 | [3] | £ 1,812 | ||||||
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 41,544 | [4] | 47,254 | £ 62,915 | |||||
Barclays Bank PLC | Fair value of plan assets | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Equity instruments, amount contributed to fair value of plan assets | 0 | 0 | |||||||
Bonds | £ 0 | 0 | |||||||
Director | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Number of directors on trustee board | director | 6 | ||||||||
Independent director | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Number of directors on trustee board | director | 3 | ||||||||
Member nominated director | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Number of directors on trustee board | director | 3 | ||||||||
UK | The senior notes | Total loans and advances at amortised cost | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Notional contract amount | £ 1,250 | 1,250 | |||||||
Maturity period | 5 years | ||||||||
Number of Tranches | tranche | 3 | ||||||||
UK | The senior notes | Total loans and advances at amortised cost | Heron Issuer Limited | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Notional contract amount | £ 500 | ||||||||
UK | The senior notes | Total loans and advances at amortised cost | Heron Issuer Number 2 Limited | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Notional contract amount | 750 | ||||||||
UK | Over one year but not more than two years | The senior notes | Total loans and advances at amortised cost | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 250 | ||||||||
UK | Two to three years | The senior notes | Total loans and advances at amortised cost | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 750 | ||||||||
UK | Three to four years | The senior notes | Total loans and advances at amortised cost | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Proceeds from sale or redemption of financial assets at fair value through other comprehensive income | 250 | ||||||||
UKRF | UK | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Current service cost | 240 | ||||||||
UKRF | UK | Barclays Bank UK PLC | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Current service cost | 90 | ||||||||
UKRF | UK | Barclays Execution Services | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Current service cost | 92 | ||||||||
Pension defined benefit plans | Foreign countries | Retirement benefit obligations | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Defined benefit obligation, at present value | £ 821 | 866 | |||||||
Pension defined benefit plans | UKRF | UK | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Scheme as a percentage of total retirement benefit obligations | 97.00% | ||||||||
Retirement benefit assets | £ 3,819 | 1,807 | |||||||
Benefits paid | 1,268 | 1,370 | |||||||
Transfers out of the fund and contribution refunds | £ 419 | £ 520 | |||||||
% of total fair value of scheme assets | 100.00% | 100.00% | |||||||
Surplus (deficit) in plan | £ (3,819) | £ (1,807) | £ (600) | ||||||
Deficit reduction contribution | 700 | ||||||||
Estimate of contributions expected to be paid to plan for next annual reporting period | £ 352 | £ 783 | |||||||
Pension defined benefit plans | UKRF | UK | Disclosure of post year end balances | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Surplus (deficit) in plan | £ (4,400) | (600) | |||||||
Pension defined benefit plans | UKRF | UK | 30 September 2020 valuation | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Surplus (deficit) in plan | £ (600) | ||||||||
Pension defined benefit plans | UKRF | UK | 30 September 2019 valuation | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Surplus (deficit) in plan | £ 900 | ||||||||
Pension defined benefit plans | UKRF | UK | Investment funds and trusts | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
% of total fair value of scheme assets | 0.00% | 0.00% | |||||||
Pension defined benefit plans | UKRF | UK | Other | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
% of total fair value of scheme assets | 0.00% | 0.20% | |||||||
Pension defined benefit plans | UKRF | UK | Swaps | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Retirement benefit assets | £ 5,000 | ||||||||
Pension defined benefit plans | UKRF | UK | Key UKRF financial assumptions | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Assumption For Future Inflation Increase (Decrease) | 0.20% | ||||||||
Future mortality improvement percentage | 1.50% | ||||||||
Pension defined benefit plans | UKRF | UK | Over one year but not more than two years | 30 September 2019 valuation | Forecast | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Deficit reduction contribution | £ 294 | ||||||||
Pension defined benefit plans | UKRF | UK | Two to three years | 30 September 2019 valuation | Forecast | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Deficit reduction contribution | 286 | ||||||||
Pension defined benefit plans | UKRF | UK | Retirement benefit obligations | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Current service cost | £ 225 | £ 217 | |||||||
Weighted average duration of the benefit payments reflected in defined benefit obligation, UKRF | 16 years | 17 years | |||||||
Past service cost | £ 0 | £ 0 | |||||||
Pension defined benefit plans | UKRF | UK | Retirement benefit obligations | Within 10 years | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Percentage of benefits are expected to be paid | 25.00% | ||||||||
Pension defined benefit plans | UKRF | UK | Retirement benefit obligations | In years 11 to 20 | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Percentage of benefits are expected to be paid | 30.00% | ||||||||
Pension defined benefit plans | UKRF | UK | Retirement benefit obligations | In years 20 to 30 | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Percentage of benefits are expected to be paid | 25.00% | ||||||||
Pension defined benefit plans | UKRF | UK | Retirement benefit obligations | Bottom of range | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Duration of expected benefits are projected to be paid out | 50 years | ||||||||
Pension defined benefit plans | UKRF | UK | Fair value of plan assets | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
% fair value of scheme assets invested in liability driven investment strategies | 45.00% | ||||||||
Pension defined benefit plans | UKRF | UK | Barclays Bank PLC | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Maximum funding deficit secured by collateral pool | £ 9,000 | ||||||||
Pension defined benefit plans | UKRF | UK | Barclays Bank PLC | Bottom of range | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Percentage of funding deficit secured by collateral pool | 100.00% | ||||||||
Pension defined benefit plans | UKRF | UK | Barclays Bank PLC | The senior notes | Heron Issuer Limited | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Regulatory capital impact | £ 700 | ||||||||
Post-employment medical defined benefit plans | Other | Retirement benefit obligations | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Defined benefit obligation, at present value | £ 154 | 157 | |||||||
Defined contribution schemes | UKRF | UK | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Estimate of contributions expected to be paid to plan for next annual reporting period | 6 | 9 | |||||||
Defined contribution schemes | BPSP | UK | |||||||||
Disclosure of net defined benefit liability (asset) [line items] | |||||||||
Estimate of contributions expected to be paid to plan for next annual reporting period | £ 42 | £ 47 | |||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[3] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||||
[4] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Pensions and post-retirement _3
Pensions and post-retirement benefits - Income statement charge (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of defined benefit plans [abstract] | ||
Current service cost | £ 58 | £ 53 |
Net finance cost | (26) | (40) |
Past service cost | 0 | (4) |
Other movements | 2 | 0 |
Total | £ 34 | £ 9 |
Pensions and post-retirement _4
Pensions and post-retirement benefits - Balance sheet reconciliation (Details) £ in Millions, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Sep. 30, 2021GBP (£) | ||
Reconciliation of changes in net assets available for benefits [abstract] | |||||
Net defined benefit liability (asset), beginning of period | £ 1,582 | ||||
Current service cost | (58) | £ (53) | |||
Interest costs or income on scheme liabilities or assets | 26 | 40 | |||
Past service cost | 0 | 4 | |||
Net defined benefit liability (asset), end of period | 3,633 | 1,582 | |||
Net surplus | 3,633 | 1,582 | |||
Retirement benefit assets | 3,879 | [1] | 1,814 | ||
Retirement benefit liabilities | (246) | [1] | (232) | ||
UKRF | UK | |||||
Reconciliation of changes in net assets available for benefits [abstract] | |||||
Current service cost | (240) | ||||
UKRF | UK | Pension defined benefit plans | |||||
Reconciliation of changes in net assets available for benefits [abstract] | |||||
Net defined benefit liability (asset), beginning of period | 1,807 | ||||
Net defined benefit liability (asset), end of period | 3,819 | 1,807 | |||
Net surplus | 3,819 | 1,807 | £ 600 | ||
Retirement benefit assets | 3,819 | 1,807 | |||
Retirement benefit liabilities | 0 | 0 | |||
Defined benefit obligations | |||||
Reconciliation of changes in net assets available for benefits [abstract] | |||||
Net defined benefit liability (asset), beginning of period | (33,131) | $ (33,131) | (30,298) | ||
Current service cost | (240) | (232) | |||
Interest costs or income on scheme liabilities or assets | (422) | (573) | |||
Past service cost | 0 | 4 | |||
Remeasurement gain/(loss) - financial | 849 | (3,439) | |||
Remeasurement gain/(loss) - demographic | 53 | (281) | |||
Remeasurement gain/(loss) - experience | (249) | 243 | |||
Employee contributions | (4) | (5) | |||
Benefits paid | 1,309 | 1,406 | |||
Exchange and other movements | 1 | 44 | |||
Net defined benefit liability (asset), end of period | (31,834) | (33,131) | |||
Defined benefit obligations | UKRF | UK | Pension defined benefit plans | |||||
Reconciliation of changes in net assets available for benefits [abstract] | |||||
Net defined benefit liability (asset), beginning of period | (32,108) | (29,304) | |||
Current service cost | (225) | (217) | |||
Interest costs or income on scheme liabilities or assets | (405) | (549) | |||
Past service cost | 0 | 0 | |||
Remeasurement gain/(loss) - financial | 820 | (3,358) | |||
Remeasurement gain/(loss) - demographic | 50 | (286) | |||
Remeasurement gain/(loss) - experience | (259) | 237 | |||
Employee contributions | 0 | (1) | |||
Benefits paid | 1,268 | 1,370 | |||
Exchange and other movements | 0 | 0 | |||
Net defined benefit liability (asset), end of period | (30,859) | (32,108) | |||
Fair value of plan assets | |||||
Reconciliation of changes in net assets available for benefits [abstract] | |||||
Net defined benefit liability (asset), beginning of period | 34,713 | 32,093 | |||
Interest costs or income on scheme liabilities or assets | 448 | 613 | |||
Remeasurement - return on plan assets greater than discount rate | 653 | 3,411 | |||
Employer contribution | 971 | 265 | |||
Settlements | 0 | 0 | |||
Employee contributions | 4 | 5 | |||
Benefits paid | (1,309) | (1,406) | |||
Exchange and other movements | (13) | (268) | |||
Net defined benefit liability (asset), end of period | 35,467 | 34,713 | |||
Fair value of plan assets | UKRF | UK | Pension defined benefit plans | |||||
Reconciliation of changes in net assets available for benefits [abstract] | |||||
Net defined benefit liability (asset), beginning of period | 33,915 | 31,362 | |||
Interest costs or income on scheme liabilities or assets | 434 | 595 | |||
Remeasurement - return on plan assets greater than discount rate | 642 | 3,328 | |||
Employer contribution | 955 | 248 | |||
Settlements | 0 | 0 | |||
Employee contributions | 0 | 1 | |||
Benefits paid | (1,268) | (1,370) | |||
Exchange and other movements | 0 | (249) | |||
Net defined benefit liability (asset), end of period | £ 34,678 | £ 33,915 | |||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Pensions and post-retirement _5
Pensions and post-retirement benefits - Actuarial valuation of schemes (Details) - UKRF - UK - Pension defined benefit plans - GBP (£) £ in Billions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Key UKRF financial assumptions | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Discount rate | 1.84% | 1.29% | |
Inflation rate (RPI) | 3.56% | 2.99% | |
Life expectancy at 60 for current pensioners, males | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 27 years 3 months 18 days | 27 years 2 months 12 days | 27 years 1 month 6 days |
Life expectancy at 60 for current pensioners, females | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 29 years 7 months 6 days | 29 years 4 months 24 days | 29 years 3 months 18 days |
Life expectancy at 60 for future pensioners at 40 years, males | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 29 years 1 month 6 days | 29 years | 28 years 10 months 24 days |
Life expectancy at 60 for future pensioners at 40 years, females | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
Assumed life expectancy at 60 | 31 years 4 months 24 days | 31 years 2 months 12 days | 31 years 1 month 6 days |
0.5% change in discount rate per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | £ (2.3) | £ (2.5) | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | 2.6 | 2.9 | |
0.25% change in discount rate per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | (1.2) | (1.3) | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | 1.3 | 1.4 | |
0.5% change in RPI per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | 1.6 | 1.8 | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | (1.6) | (1.8) | |
0.25% change in RPI per annum | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | 0.8 | 0.9 | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | (0.8) | (0.9) | |
Change in life expectancy by one year | |||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | |||
(Decrease)/Increase in UKRF defined benefit obligations, due to increase in actuarial assumption | 1.2 | 1.2 | |
(Decrease)/Increase in UKRF defined benefit obligations, due to decrease in actuarial assumption | £ (1.2) | £ (1.2) |
Pensions and post-retirement _6
Pensions and post-retirement benefits - Analysis of scheme assets (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Fair value of scheme assets | £ 35,467 | £ 34,713 |
% of total fair value of scheme assets | 100.00% | 100.00% |
Equities | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | £ 1,591 | £ 2,065 |
% of total fair value of scheme assets | 4.50% | 5.90% |
Private equities | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | £ 2,991 | £ 2,233 |
% of total fair value of scheme assets | 8.40% | 6.40% |
Bonds - fixed government | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | £ 2,482 | £ 4,315 |
% of total fair value of scheme assets | 7.00% | 12.40% |
Bonds - index-linked government | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | £ 14,157 | £ 11,720 |
% of total fair value of scheme assets | 39.90% | 33.80% |
Bonds - corporate and other | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | £ 9,077 | £ 9,117 |
% of total fair value of scheme assets | 25.60% | 26.30% |
Property | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Property | £ 1,504 | £ 1,426 |
% of total fair value of scheme assets | 4.30% | 4.10% |
Infrastructure | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Infrastructure | £ 1,815 | £ 1,812 |
% of total fair value of scheme assets | 5.10% | 5.20% |
Cash and liquid assets | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Cash and liquid assets | £ 1,766 | £ 1,894 |
% of total fair value of scheme assets | 5.00% | 5.50% |
Mixed investment funds | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Mixed investment funds | £ 9 | £ 9 |
% of total fair value of scheme assets | 0.00% | 0.00% |
Other | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Other | £ 75 | £ 122 |
% of total fair value of scheme assets | 0.20% | 0.40% |
Quoted | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Fair value of scheme assets | £ 22,533 | £ 23,014 |
Quoted | Equities | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 214 | 567 |
Quoted | Private equities | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 0 | 0 |
Quoted | Bonds - fixed government | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 2,387 | 4,205 |
Quoted | Bonds - index-linked government | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 13,478 | 10,706 |
Quoted | Bonds - corporate and other | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 6,223 | 7,439 |
Quoted | Property | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Property | 14 | 10 |
Quoted | Infrastructure | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Infrastructure | 0 | 0 |
Quoted | Cash and liquid assets | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Cash and liquid assets | 189 | 64 |
Quoted | Mixed investment funds | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Mixed investment funds | 9 | 9 |
Quoted | Other | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Other | 19 | 14 |
Unquoted | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Fair value of scheme assets | 12,934 | 11,699 |
Unquoted | Equities | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 1,377 | 1,498 |
Unquoted | Private equities | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 2,991 | 2,233 |
Unquoted | Bonds - fixed government | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 95 | 110 |
Unquoted | Bonds - index-linked government | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 679 | 1,014 |
Unquoted | Bonds - corporate and other | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 2,854 | 1,678 |
Unquoted | Property | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Property | 1,490 | 1,416 |
Unquoted | Infrastructure | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Infrastructure | 1,815 | 1,812 |
Unquoted | Cash and liquid assets | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Cash and liquid assets | 1,577 | 1,830 |
Unquoted | Mixed investment funds | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Mixed investment funds | 0 | 0 |
Unquoted | Other | Fair value of plan assets | ||
Disclosure of fair value of plan assets [line items] | ||
Other | 56 | 108 |
UKRF | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Fair value of scheme assets | £ 34,678 | £ 33,915 |
% of total fair value of scheme assets | 100.00% | 100.00% |
UKRF | Equities | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | £ 1,463 | £ 1,876 |
% of total fair value of scheme assets | 4.20% | 5.50% |
UKRF | Private equities | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | £ 2,991 | £ 2,233 |
% of total fair value of scheme assets | 8.60% | 6.60% |
UKRF | Bonds - fixed government | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | £ 2,178 | £ 4,042 |
% of total fair value of scheme assets | 6.30% | 11.90% |
UKRF | Bonds - index-linked government | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | £ 14,134 | £ 11,711 |
% of total fair value of scheme assets | 40.80% | 34.50% |
UKRF | Bonds - corporate and other | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | £ 8,840 | £ 8,892 |
% of total fair value of scheme assets | 25.50% | 26.20% |
UKRF | Property | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Property | £ 1,490 | £ 1,416 |
% of total fair value of scheme assets | 4.30% | 4.20% |
UKRF | Infrastructure | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Infrastructure | £ 1,815 | £ 1,812 |
% of total fair value of scheme assets | 5.20% | 5.30% |
UKRF | Cash and liquid assets | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Cash and liquid assets | £ 1,753 | £ 1,876 |
% of total fair value of scheme assets | 5.10% | 5.50% |
UKRF | Mixed investment funds | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Mixed investment funds | £ 0 | £ 0 |
% of total fair value of scheme assets | 0.00% | 0.00% |
UKRF | Other | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Other | £ 14 | £ 57 |
% of total fair value of scheme assets | 0.00% | 0.20% |
UKRF | Quoted | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Fair value of scheme assets | £ 21,786 | £ 22,267 |
UKRF | Quoted | Equities | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 86 | 378 |
UKRF | Quoted | Private equities | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 0 | 0 |
UKRF | Quoted | Bonds - fixed government | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 2,083 | 3,932 |
UKRF | Quoted | Bonds - index-linked government | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 13,455 | 10,697 |
UKRF | Quoted | Bonds - corporate and other | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 5,986 | 7,214 |
UKRF | Quoted | Property | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Property | 0 | 0 |
UKRF | Quoted | Infrastructure | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Infrastructure | 0 | 0 |
UKRF | Quoted | Cash and liquid assets | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Cash and liquid assets | 176 | 46 |
UKRF | Quoted | Mixed investment funds | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Mixed investment funds | 0 | 0 |
UKRF | Quoted | Other | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Other | 0 | 0 |
UKRF | Unquoted | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Fair value of scheme assets | 12,892 | 11,648 |
UKRF | Unquoted | Equities | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 1,377 | 1,498 |
UKRF | Unquoted | Private equities | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Equities | 2,991 | 2,233 |
UKRF | Unquoted | Bonds - fixed government | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 95 | 110 |
UKRF | Unquoted | Bonds - index-linked government | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 679 | 1,014 |
UKRF | Unquoted | Bonds - corporate and other | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Bonds | 2,854 | 1,678 |
UKRF | Unquoted | Property | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Property | 1,490 | 1,416 |
UKRF | Unquoted | Infrastructure | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Infrastructure | 1,815 | 1,812 |
UKRF | Unquoted | Cash and liquid assets | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Cash and liquid assets | 1,577 | 1,830 |
UKRF | Unquoted | Mixed investment funds | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Mixed investment funds | 0 | 0 |
UKRF | Unquoted | Other | UK | Pension defined benefit plans | ||
Disclosure of fair value of plan assets [line items] | ||
Other | £ 14 | £ 57 |
Pensions and post-retirement _7
Pensions and post-retirement benefits - Deficit reduction contributions (Details) - UKRF - Pension defined benefit plans - United Kingdom £ in Millions | 12 Months Ended |
Dec. 31, 2021GBP (£) | |
Disclosure of fair value of plan assets [line items] | |
Deficit reduction contribution | £ 700 |
2019 | 30 September 2019 valuation | |
Disclosure of fair value of plan assets [line items] | |
Deficit reduction contribution | 500 |
2020 | 30 September 2019 valuation | |
Disclosure of fair value of plan assets [line items] | |
Deficit reduction contribution | 500 |
2021 | 30 September 2019 valuation | |
Disclosure of fair value of plan assets [line items] | |
Deficit reduction contribution | 700 |
2022 | 30 September 2019 valuation | Forecast | |
Disclosure of fair value of plan assets [line items] | |
Deficit reduction contribution | 294 |
2023 | 30 September 2019 valuation | Forecast | |
Disclosure of fair value of plan assets [line items] | |
Deficit reduction contribution | 286 |
2024 and beyond | 30 September 2019 valuation | Forecast | |
Disclosure of fair value of plan assets [line items] | |
Deficit reduction contribution | £ 0 |
Pensions and post-retirement _8
Pensions and post-retirement benefits - Contributions paid (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
UKRF | UK | Pension defined benefit plans | |||
Disclosure of fair value of plan assets [line items] | |||
Defined benefit contributions paid | £ 955 | £ 748 | £ 1,231 |
Principal subsidiaries - Narrat
Principal subsidiaries - Narrative (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of subsidiaries [line items] | ||||
Total assets | £ 1,061,778 | [1] | £ 1,059,731 | £ 876,700 |
Total liabilities | 1,005,461 | [1] | 1,006,021 | |
Balances with banks and other regulatory authorities | 4,260 | £ 3,119 | ||
Subsidiaries | ||||
Disclosure of subsidiaries [line items] | ||||
Total assets | 439,000 | 417,000 | ||
Total liabilities | £ 414,000 | £ 393,000 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Principal subsidiaries - Signif
Principal subsidiaries - Significant subsidiaries (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Barclays Bank Ireland PLC | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Capital Inc. | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Capital Securities Limited | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Securities Japan Limited | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays US LLC | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Barclays Bank Delaware | |
Disclosure of subsidiaries [line items] | |
Percentage of voting rights held | 100.00% |
Non-controlling interests - proportion of ownership interests | 0.00% |
Non-controlling interests - proportion of voting interests | 0.00% |
Principal subsidiaries - Exclud
Principal subsidiaries - Excluded from consolidation because the Group does not have exposure to its variable returns (Details) - Unconsolidated structured entities £ in Millions | 12 Months Ended |
Dec. 31, 2021GBP (£) | |
Disclosure of unconsolidated structured entities [line items] | |
Percentage of voting rights held | 100.00% |
Equity shareholders' funds (£m) | £ 0 |
Retained profit for the year (£m) | £ 0 |
Structured entities - Narrative
Structured entities - Narrative (Details) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021GBP (£)entity | Dec. 31, 2020GBP (£)entity | Dec. 31, 2019GBP (£) | |
Disclosure of unconsolidated structured entities [line items] | |||
Number of structured entities | entity | 5,696 | 3,162 | |
Notional contract amount | £ 47,412,915 | £ 42,625,605 | |
Impairment cost of loan facilities | (536) | 3,745 | £ 1,275 |
Assets transferred to sponsored unconsolidated structured entities | 1,662 | 730 | |
Employee benefit and other trusts | |||
Disclosure of unconsolidated structured entities [line items] | |||
Standby facilities, credit lines and other commitments | £ 3,300 | 2,900 | |
Securitisation vehicles | Debt securities classified as amortised cost | Not more than three months | |||
Disclosure of unconsolidated structured entities [line items] | |||
Maturity period | 90 days | ||
Structured entities | Derivatives | |||
Disclosure of unconsolidated structured entities [line items] | |||
Notional contract amount | £ 217,055 | 153,894 | |
Lending | Debt securities classified as amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Impairment cost of loan facilities | 25 | 22 | |
Contractual backstop liquidity facilities | CP's and medium-term note conduits | |||
Disclosure of unconsolidated structured entities [line items] | |||
Standby facilities, credit lines and other commitments | £ 17,200 | £ 16,900 |
Structured entities - Summary o
Structured entities - Summary of interests in unconsolidated structured entities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of unconsolidated structured entities [line items] | ||||
Trading portfolio assets | £ 146,871 | [1] | £ 127,664 | |
Financial assets at fair value through the income statement | 188,226 | [1] | 171,761 | |
Derivative financial instruments | 262,291 | [1] | 302,693 | |
Financial assets at fair value through other comprehensive income | 45,908 | [1] | 51,902 | |
Loans and advances at amortised cost | 145,259 | [1] | 134,267 | |
Reverse repurchase agreements and other similar secured lending | 3,177 | [1] | 8,981 | |
Other assets | 2,706 | [1] | 1,440 | |
Total assets | 1,061,778 | [1] | 1,059,731 | £ 876,700 |
Derivative financial instruments | 256,523 | [1] | 300,580 | |
Structured entities | ||||
Disclosure of unconsolidated structured entities [line items] | ||||
Trading portfolio assets | 7,170 | 11,361 | ||
Financial assets at fair value through the income statement | 65,233 | 59,045 | ||
Derivative financial instruments | 5,160 | 2,968 | ||
Financial assets at fair value through other comprehensive income | 91 | 153 | ||
Loans and advances at amortised cost | 22,741 | 18,418 | ||
Reverse repurchase agreements and other similar secured lending | 104 | 10 | ||
Other assets | 12 | 11 | ||
Total assets | 100,511 | 91,966 | ||
Derivative financial instruments | 9,543 | 7,075 | ||
Secured financing | ||||
Disclosure of unconsolidated structured entities [line items] | ||||
Trading portfolio assets | 0 | 0 | ||
Financial assets at fair value through the income statement | 61,816 | 56,265 | ||
Derivative financial instruments | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Loans and advances at amortised cost | 0 | 0 | ||
Reverse repurchase agreements and other similar secured lending | 104 | 10 | ||
Other assets | 0 | 0 | ||
Total assets | 61,920 | 56,275 | ||
Derivative financial instruments | 0 | 0 | ||
Short-term traded interests | ||||
Disclosure of unconsolidated structured entities [line items] | ||||
Trading portfolio assets | 7,170 | 11,361 | ||
Financial assets at fair value through the income statement | 0 | 0 | ||
Derivative financial instruments | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Loans and advances at amortised cost | 0 | 0 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Other assets | 0 | 0 | ||
Total assets | 7,170 | 11,361 | ||
Derivative financial instruments | 0 | 0 | ||
Traded derivatives | ||||
Disclosure of unconsolidated structured entities [line items] | ||||
Trading portfolio assets | 0 | 0 | ||
Financial assets at fair value through the income statement | 0 | 0 | ||
Derivative financial instruments | 5,160 | 2,968 | ||
Financial assets at fair value through other comprehensive income | 0 | 0 | ||
Loans and advances at amortised cost | 0 | 0 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Other assets | 0 | 0 | ||
Total assets | 5,160 | 2,968 | ||
Derivative financial instruments | 9,543 | 7,075 | ||
Other interests | ||||
Disclosure of unconsolidated structured entities [line items] | ||||
Trading portfolio assets | 0 | 0 | ||
Financial assets at fair value through the income statement | 3,417 | 2,780 | ||
Derivative financial instruments | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | 91 | 153 | ||
Loans and advances at amortised cost | 22,741 | 18,418 | ||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | ||
Other assets | 12 | 11 | ||
Total assets | 26,261 | 21,362 | ||
Derivative financial instruments | £ 0 | £ 0 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Structured entities - Nature of
Structured entities - Nature of interests (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | £ 188,226 | [1] | £ 171,761 |
Financial assets at fair value through other comprehensive income | 45,908 | [1] | 51,902 |
Loans and advances at amortised cost | 145,259 | [1] | 134,267 |
Other assets | 2,706 | [1] | 1,440 |
Other interests | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 3,417 | 2,780 | |
Financial assets at fair value through other comprehensive income | 91 | 153 | |
Loans and advances at amortised cost | 22,741 | 18,418 | |
Other assets | 12 | 11 | |
Total on balance sheet exposures | 26,261 | 21,362 | |
Total off balance sheet notional amounts | 20,409 | 19,281 | |
Maximum exposure to loss | 46,670 | 40,643 | |
Total assets of the entity | 254,634 | 263,383 | |
Other interests | Of which: Barclays owned, not consolidated entities | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 3,335 | 2,698 | |
Financial assets at fair value through other comprehensive income | 0 | 0 | |
Other assets | 0 | 0 | |
Total on balance sheet exposures | 3,335 | 2,698 | |
Total off balance sheet notional amounts | 0 | 0 | |
Maximum exposure to loss | 3,335 | 2,698 | |
Total assets of the entity | 11,513 | 11,008 | |
Other interests | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 22,741 | 18,418 | |
Other interests | Financial assets at amortised cost | Of which: Barclays owned, not consolidated entities | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 0 | 0 | |
Multi-seller conduit programme | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 0 | 0 | |
Financial assets at fair value through other comprehensive income | 0 | 0 | |
Other assets | 8 | 8 | |
Total on balance sheet exposures | 5,192 | 5,154 | |
Total off balance sheet notional amounts | 11,015 | 11,750 | |
Maximum exposure to loss | 16,207 | 16,904 | |
Total assets of the entity | 65,441 | 87,004 | |
Multi-seller conduit programme | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 5,184 | 5,146 | |
Lending | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 2 | 15 | |
Financial assets at fair value through other comprehensive income | 53 | 106 | |
Other assets | 4 | 3 | |
Total on balance sheet exposures | 14,353 | 12,599 | |
Total off balance sheet notional amounts | 9,394 | 7,531 | |
Maximum exposure to loss | 23,747 | 20,130 | |
Total assets of the entity | 160,611 | 153,990 | |
Lending | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | 14,294 | 12,475 | |
Other | |||
Disclosure of unconsolidated structured entities [line items] | |||
Financial assets at fair value through the income statement | 3,415 | 2,765 | |
Financial assets at fair value through other comprehensive income | 38 | 47 | |
Other assets | 0 | 0 | |
Total on balance sheet exposures | 6,716 | 3,609 | |
Total off balance sheet notional amounts | 0 | 0 | |
Maximum exposure to loss | 6,716 | 3,609 | |
Total assets of the entity | 28,582 | 22,389 | |
Other | Financial assets at amortised cost | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances at amortised cost | £ 3,263 | £ 797 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Investments in associates and_3
Investments in associates and joint ventures (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Min | |
Disclosure of associates [line items] | |
Voting rights in associates | 20.00% |
Max | |
Disclosure of associates [line items] | |
Voting rights in associates | 50.00% |
Investments in associates and_4
Investments in associates and joint ventures (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Disclosure of associates [line items] | |||
Associates | £ 24 | £ 24 | |
Joint ventures | 0 | 0 | |
Total | 24 | [1] | 24 |
Joint ventures | |||
Disclosure of associates [line items] | |||
(Loss)/profit from continuing operations | 0 | 2 | |
Other comprehensive income / (loss) | 0 | 0 | |
Total comprehensive income/(loss) from continuing operations | 0 | 2 | |
Associates | |||
Disclosure of associates [line items] | |||
(Loss)/profit from continuing operations | 0 | (1) | |
Other comprehensive income / (loss) | 1 | (3) | |
Total comprehensive income/(loss) from continuing operations | £ 1 | £ (4) | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Securitisations - Transfers of
Securitisations - Transfers of financial assets that do not result in derecognition (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Assets carrying amount | £ 184,537 | £ 192,345 |
Liabilities carrying amount | (97,494) | (112,910) |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Assets carrying amount | 1,303 | 963 |
Assets fair value | 1,423 | 1,051 |
Liabilities carrying amount | (1,225) | (952) |
Liabilities fair value | (1,219) | (966) |
Assets that entity continues to recognise to extent of continuing involvement | £ 249 | £ 0 |
Securitisations - Continuing in
Securitisations - Continuing involvement in financial assets that have been derecognised (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | £ 414 | £ 348 |
Fair value | 410 | 342 |
Maximum exposure to loss | 414 | 348 |
Gain (loss) from continuing involvement for the year ended | 9 | 4 |
Gain (loss) from continuing involvement, cumulative | 17 | 8 |
Asset backed securities | ||
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | 25 | 56 |
Fair value | 25 | 56 |
Maximum exposure to loss | 25 | 56 |
Gain (loss) from continuing involvement for the year ended | 1 | 1 |
Gain (loss) from continuing involvement, cumulative | 2 | 1 |
Residential mortgage backed securities | ||
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | 78 | 49 |
Fair value | 78 | 49 |
Maximum exposure to loss | 78 | 49 |
Gain (loss) from continuing involvement for the year ended | 3 | 1 |
Gain (loss) from continuing involvement, cumulative | 4 | 1 |
Commercial mortgage backed securities | ||
Disclosure of continuing involvement in derecognised financial assets [line items] | ||
Carrying amount | 311 | 243 |
Fair value | 307 | 237 |
Maximum exposure to loss | 311 | 243 |
Gain (loss) from continuing involvement for the year ended | 5 | 2 |
Gain (loss) from continuing involvement, cumulative | £ 11 | £ 6 |
Assets pledged, collateral re_3
Assets pledged, collateral received and assets transferred - Carrying amount of the assets pledged as security against liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | £ 184,537 | £ 192,345 |
Cash collateral and settlement balances | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 63,080 | 69,271 |
Loans and advances at amortised cost | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 29,962 | 25,437 |
Trading portfolio assets | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 71,201 | 76,750 |
Financial assets at fair value through the income statement | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | 5,595 | 5,584 |
Fair value through other comprehensive income | ||
Disclosure of offsetting of financial liabilities [line items] | ||
Assets pledged | £ 14,699 | £ 15,303 |
Assets pledged, collateral re_4
Assets pledged, collateral received and assets transferred - Transferred financial assets and the associated liabilities (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | £ 184,537 | £ 192,345 |
Associated liabilities | (97,494) | (112,910) |
Derivatives | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 64,826 | 72,732 |
Associated liabilities | (64,826) | (72,732) |
Repurchase agreements | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 48,504 | 58,398 |
Associated liabilities | (28,494) | (39,044) |
Securities lending arrangements | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 66,703 | 59,824 |
Associated liabilities | 0 | 0 |
Other | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 4,504 | 1,391 |
Associated liabilities | £ (4,174) | £ (1,134) |
Assets pledged, collateral re_5
Assets pledged, collateral received and assets transferred - Recourse to transferred assets (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | £ 184,537 | £ 192,345 |
Associated liabilities | (97,494) | (112,910) |
Other | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 4,504 | 1,391 |
Associated liabilities | (4,174) | (1,134) |
Other | Securitisation vehicles | ||
Disclosure of transferred financial assets that are not derecognised in their entirety [line items] | ||
Transferred assets | 1,303 | 963 |
Associated liabilities | (1,225) | (952) |
Transferred assets, fair value | 1,423 | 1,051 |
Associated liabilities, fair value | (1,219) | (966) |
Net position | £ 204 | £ 85 |
Assets pledged, collateral re_6
Assets pledged, collateral received and assets transferred - Narrative (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances | £ 145,259 | [1] | £ 134,267 |
Asset backed funding programmes | |||
Disclosure of unconsolidated structured entities [line items] | |||
Loans and advances | £ 3,500 | £ 3,100 | |
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Assets pledged, collateral re_7
Assets pledged, collateral received and assets transferred - Fair value at the balance sheet date of collateral accepted and re-pledged to others (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Assets pledged, collateral received and assets transferred | ||
Fair value of securities accepted as collateral | £ 934,363 | £ 792,317 |
Of which fair value of securities re-pledged/transferred to others | £ 819,169 | £ 684,389 |
Related party transactions an_3
Related party transactions and Directors' remuneration - Group's financial statements (Details) - GBP (£) £ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Disclosure of transactions between related parties [line items] | ||||
Total income | £ 15,408 | [1] | £ 15,778 | £ 14,151 |
Operating expenses | (10,259) | [1] | (9,459) | (9,982) |
Total assets | 1,061,778 | [2] | 1,059,731 | £ 876,700 |
Total liabilities | 1,005,461 | [2] | 1,006,021 | |
Parent | ||||
Disclosure of transactions between related parties [line items] | ||||
Total income | (611) | (606) | ||
Operating expenses | (64) | (62) | ||
Total assets | 6,491 | 6,803 | ||
Total liabilities | 32,141 | 25,819 | ||
Fellow subsidiaries | ||||
Disclosure of transactions between related parties [line items] | ||||
Total income | 20 | 41 | ||
Operating expenses | (3,195) | (2,937) | ||
Total assets | 909 | 1,917 | ||
Total liabilities | 3,962 | 3,954 | ||
Associates | ||||
Disclosure of transactions between related parties [line items] | ||||
Total income | 0 | 0 | ||
Operating expenses | 0 | 0 | ||
Total assets | 0 | 0 | ||
Total liabilities | 177 | 66 | ||
Pension funds | ||||
Disclosure of transactions between related parties [line items] | ||||
Total income | 3 | 3 | ||
Operating expenses | (1) | (1) | ||
Total assets | 3 | 4 | ||
Total liabilities | £ 81 | £ 69 | ||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | |||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. |
Related party transactions an_4
Related party transactions and Directors' remuneration - Narrative (Details) - GBP (£) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of transactions between related parties [line items] | |||
Accruing benefits under defined benefit scheme | £ 181,000,000 | £ 176,000,000 | £ 184,000,000 |
Notional contract amount | 47,412,915,000,000 | 42,625,605,000,000 | |
Defined contribution schemes | |||
Disclosure of transactions between related parties [line items] | |||
Accruing benefits under defined benefit scheme | 121,000,000 | 127,000,000 | 126,000,000 |
Key Management Personnel and persons connected to them | |||
Disclosure of transactions between related parties [line items] | |||
Total commitments outstanding | 100,000 | 200,000 | |
Amounts payable, related party transactions | 2,100,000 | 3,400,000 | £ 4,200,000 |
Directors | |||
Disclosure of transactions between related parties [line items] | |||
Accruing benefits under defined benefit scheme | 0 | ||
Loans issued during the year | 0 | 0 | |
Total value of guarantees entered into on behalf of Directors | 0 | 0 | |
Directors | Redundancy and restructuring | |||
Disclosure of transactions between related parties [line items] | |||
Amounts payable, related party transactions | 426,139 | 1,850,713 | |
Directors | Defined contribution schemes | |||
Disclosure of transactions between related parties [line items] | |||
Defined benefit contributions paid | 0 | 0 | |
Notional contract amount | 0 | 0 | |
Highest paid director | |||
Disclosure of transactions between related parties [line items] | |||
Accruing benefits under defined benefit scheme | 0 | 0 | |
Commitments made by entity, related party transactions | 0 | 0 | |
Pension funds | |||
Disclosure of transactions between related parties [line items] | |||
Derivatives transacted | £ 18,000,000 | £ 13,000,000 |
Related party transactions an_5
Related party transactions and Directors' remuneration - Loans and deposits outstanding (Details) - Key Management Personnel and persons connected to them £ in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | |
Reconciliation of receivables from related parties [Roll Forward] | |||
Loans outstanding beginning balance | £ 0 | $ 0 | £ 0 |
Loans issued during the year | 0 | 0 | |
Loan repayments during the year | 0 | 0 | |
Loan outstanding ending balance | $ 0 | 0 | |
Deposits outstanding beginning balance | 3.4 | 4.2 | |
Deposits received during the year | 9 | 13.3 | |
Deposits repaid during the year | (10.3) | (14.1) | |
Deposits oustanding ending balance | £ 2.1 | £ 3.4 |
Related party transactions an_6
Related party transactions and Directors' remuneration - Remuneration of Directors and other Key Management Personnel (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of transactions between related parties [abstract] | ||
Salaries and other short-term benefits | £ 35.2 | £ 37.5 |
Pension costs | 0.2 | 0.1 |
Other long-term benefits | 8.5 | 7.2 |
Share-based payments | 13.2 | 12.4 |
Employer social security charges on emoluments | 6 | 6 |
Costs recognised for accounting purposes | 63.1 | 63.2 |
Employer social security charges on emoluments | (6) | (6) |
Other long-term benefits – difference between awards granted and costs recognised | 3.3 | 0.4 |
Share-based payments – difference between awards granted and costs recognised | 6.1 | 1.3 |
Total remuneration awarded | £ 66.5 | £ 58.9 |
Related party transactions an_7
Related party transactions and Directors' remuneration - Disclosure required by the Companies Act 2006 (Details) - GBP (£) £ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Directors | ||
Disclosure of transactions between related parties [line items] | ||
Aggregate emoluments | £ 6.3 | £ 6.4 |
Amounts paid under LTIPs | 1.2 | 0 |
Total directors expense in accordance with companies act 2006 | 7.5 | 6.4 |
Directors | Deferred Share Value Plan / Share Value Plan | ||
Disclosure of transactions between related parties [line items] | ||
Aggregate emoluments | 1.4 | 0.6 |
Highest paid director | ||
Disclosure of transactions between related parties [line items] | ||
Aggregate emoluments | 2.1 | 3 |
Amounts paid under LTIPs | 0.7 | 0 |
Total directors expense in accordance with companies act 2006 | £ 2.8 | £ 3 |
Disposal of business (Narrative
Disposal of business (Narrative) (Details) - Barclays Insurance Guernsey PCC £ in Millions | 12 Months Ended |
Dec. 31, 2021GBP (£) | |
Disclosure of operating segments [line items] | |
Consideration received | £ 65 |
Profit (loss) on disposal of investments and changes in value of investments | £ (10) |
Auditor's remuneration (Details
Auditor's remuneration (Details) - GBP (£) £ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of products and services [line items] | |||
Audit fees | £ 19 | £ 17 | £ 16 |
Total Auditor's remuneration | 41 | 38 | 35 |
KPMG | |||
Disclosure of products and services [line items] | |||
Audit fees | 36 | 33 | 31 |
All other fees | 0 | 0 | 1 |
Tax fees | 0 | 0 | 0 |
Subsidiaries | |||
Disclosure of products and services [line items] | |||
Audit fees | 14 | 13 | 12 |
Other audit related fees | |||
Disclosure of products and services [line items] | |||
Audit fees | 7 | 7 | 6 |
Other audit related fees | KPMG | |||
Disclosure of products and services [line items] | |||
Audit fees | 5 | 5 | 3 |
Other services | |||
Disclosure of products and services [line items] | |||
All other fees | £ 1 | £ 1 | £ 1 |
Interest rate benchmark refor_2
Interest rate benchmark reform - Significant exposures impacted by the interest rate benchmark reform (Details) £ in Millions, $ in Millions | 12 Months Ended | ||||||
Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | ||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | £ 145,259 | [1] | £ 134,267 | ||||
Reverse repurchase agreements and other similar secured lending | 3,177 | [1] | 8,981 | ||||
Financial assets at fair value through the income statement | 188,226 | [1] | 171,761 | ||||
Financial assets at fair value through other comprehensive income | 45,908 | [1] | 51,902 | ||||
Non-derivative financial assets | 1,049,896 | $ 132 | 1,051,400 | ||||
Debt securities in issue | (48,388) | [1] | (29,423) | ||||
Subordinated liabilities | (32,185) | [1] | (32,005) | £ (33,425) | |||
Financial liabilities designated at fair value | (251,131) | [1] | (249,626) | ||||
Non-derivative financial liabilities | (1,000,754) | (1,001,271) | |||||
Other equity instruments | (56,317) | [2] | (53,710) | [2] | (50,615) | ||
Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | [3] | (9,693) | (8,621) | £ (8,323) | |||
IBOR Reform | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 28,250 | 39,216 | |||||
Reverse repurchase agreements and other similar secured lending | 186 | 334 | |||||
Financial assets at fair value through the income statement | 9,165 | 8,055 | |||||
Financial assets at fair value through other comprehensive income | 0 | 300 | |||||
Non-derivative financial assets | 37,601 | 47,905 | |||||
Debt securities in issue | 0 | (1,452) | |||||
Subordinated liabilities | (5,136) | (897) | |||||
Financial liabilities designated at fair value | (920) | (2,320) | |||||
Non-derivative financial liabilities | (6,056) | (4,669) | |||||
Standby facilities, credit lines and other commitments | 115,493 | 108,202 | |||||
IBOR Reform | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | (3,062) | (5,184) | |||||
IBOR Reform | GBP LIBOR | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 11,761 | 19,317 | |||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||||
Financial assets at fair value through the income statement | 101 | 1,190 | |||||
Financial assets at fair value through other comprehensive income | 0 | 186 | |||||
Non-derivative financial assets | 11,862 | 20,693 | |||||
Debt securities in issue | 0 | 0 | |||||
Subordinated liabilities | (36) | (21) | |||||
Financial liabilities designated at fair value | (708) | (149) | |||||
Non-derivative financial liabilities | (744) | (170) | |||||
Standby facilities, credit lines and other commitments | 58,094 | 18,169 | |||||
Increase (decrease) in standby facilities, credit lines and other commitments | (34,000) | ||||||
IBOR Reform | GBP LIBOR | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | 0 | (2,122) | |||||
IBOR Reform | USD LIBOR | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 15,801 | 17,990 | |||||
Reverse repurchase agreements and other similar secured lending | 186 | 334 | |||||
Financial assets at fair value through the income statement | 8,538 | 6,373 | |||||
Financial assets at fair value through other comprehensive income | 0 | 106 | |||||
Non-derivative financial assets | 24,525 | 24,803 | |||||
Debt securities in issue | 0 | (1,430) | |||||
Subordinated liabilities | (3,774) | (876) | |||||
Financial liabilities designated at fair value | (212) | (1,273) | |||||
Non-derivative financial liabilities | (3,986) | (3,579) | |||||
Standby facilities, credit lines and other commitments | 42,767 | 74,008 | |||||
Increase (decrease) in standby facilities, credit lines and other commitments | 34,000 | ||||||
IBOR Reform | USD LIBOR | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | (3,062) | (3,062) | |||||
IBOR Reform | JPY LIBOR | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 24 | 173 | |||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||||
Financial assets at fair value through the income statement | 5 | 0 | |||||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||||
Non-derivative financial assets | 29 | 173 | |||||
Debt securities in issue | 0 | (22) | |||||
Subordinated liabilities | (1,213) | 0 | |||||
Financial liabilities designated at fair value | 0 | (759) | |||||
Non-derivative financial liabilities | (1,213) | (781) | |||||
Standby facilities, credit lines and other commitments | 1,284 | 0 | |||||
IBOR Reform | JPY LIBOR | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | 0 | 0 | |||||
IBOR Reform | CHF LIBOR | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 222 | 11 | |||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||||
Financial assets at fair value through the income statement | 327 | 283 | |||||
Financial assets at fair value through other comprehensive income | 0 | 0 | |||||
Non-derivative financial assets | 549 | 294 | |||||
Debt securities in issue | 0 | 0 | |||||
Subordinated liabilities | 0 | 0 | |||||
Financial liabilities designated at fair value | 0 | 0 | |||||
Non-derivative financial liabilities | 0 | 0 | |||||
Standby facilities, credit lines and other commitments | 375 | 74 | |||||
IBOR Reform | CHF LIBOR | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | 0 | 0 | |||||
IBOR Reform | Other | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 442 | 1,725 | |||||
Reverse repurchase agreements and other similar secured lending | 0 | 0 | |||||
Financial assets at fair value through the income statement | 194 | 209 | |||||
Financial assets at fair value through other comprehensive income | 0 | 8 | |||||
Non-derivative financial assets | 636 | 1,942 | |||||
Debt securities in issue | 0 | 0 | |||||
Subordinated liabilities | (113) | 0 | |||||
Financial liabilities designated at fair value | 0 | (139) | |||||
Non-derivative financial liabilities | (113) | (139) | |||||
Standby facilities, credit lines and other commitments | 12,973 | 15,951 | |||||
IBOR Reform | Other | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | £ 0 | £ 0 | |||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||
[3] | For further details refer to Note 27. |
Interest rate benchmark refor_3
Interest rate benchmark reform - Significant exposures impacted by the interest rate benchmark reform - Derivative notional contract amount (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | £ 47,412,915 | £ 42,625,605 |
IBOR Reform | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 6,402,147 | 12,688,971 |
IBOR Reform | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 429,081 | 2,606,513 |
IBOR Reform | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 5,432,774 | 6,636,284 |
IBOR Reform | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 7,811 | 1,082,190 |
IBOR Reform | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 263,180 | 1,940,722 |
IBOR Reform | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 37,296 | 179,305 |
IBOR Reform | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 232,005 | 243,957 |
IBOR Reform | OTC | Interest rate derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,743,182 | 4,708,416 |
IBOR Reform | OTC | Interest rate derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 245,604 | 596,564 |
IBOR Reform | OTC | Interest rate derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,283,077 | 2,832,339 |
IBOR Reform | OTC | Interest rate derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 7,811 | 457,844 |
IBOR Reform | OTC | Interest rate derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 140,357 | 754,206 |
IBOR Reform | OTC | Interest rate derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 4,396 | 25,681 |
IBOR Reform | OTC | Interest rate derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 61,937 | 41,782 |
IBOR Reform | OTC | Foreign exchange derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 802,299 | 870,903 |
IBOR Reform | OTC | Foreign exchange derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 183,477 | 155,285 |
IBOR Reform | OTC | Foreign exchange derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 461,680 | 589,332 |
IBOR Reform | OTC | Foreign exchange derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 0 |
IBOR Reform | OTC | Foreign exchange derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 122,823 | 93,108 |
IBOR Reform | OTC | Foreign exchange derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 32,900 | 31,257 |
IBOR Reform | OTC | Foreign exchange derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 1,419 | 1,921 |
IBOR Reform | OTC | Equity and stock index derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 9,949 | 14,896 |
IBOR Reform | OTC | Equity and stock index derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,845 |
IBOR Reform | OTC | Equity and stock index derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 9,949 | 7,946 |
IBOR Reform | OTC | Equity and stock index derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 544 |
IBOR Reform | OTC | Equity and stock index derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,929 |
IBOR Reform | OTC | Equity and stock index derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 491 |
IBOR Reform | OTC | Equity and stock index derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 2,141 |
IBOR Reform | Cleared by central counterparty | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,380,378 | 6,458,375 |
IBOR Reform | Cleared by central counterparty | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,552,637 |
IBOR Reform | Cleared by central counterparty | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 2,211,729 | 2,872,962 |
IBOR Reform | Cleared by central counterparty | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 623,802 |
IBOR Reform | Cleared by central counterparty | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 1,091,479 |
IBOR Reform | Cleared by central counterparty | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 119,382 |
IBOR Reform | Cleared by central counterparty | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 168,649 | 198,113 |
IBOR Reform | Exchange traded derivatives | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 466,339 | 636,381 |
IBOR Reform | Exchange traded derivatives | GBP LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 300,182 |
IBOR Reform | Exchange traded derivatives | USD LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 466,339 | 333,705 |
IBOR Reform | Exchange traded derivatives | EUR LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 0 |
IBOR Reform | Exchange traded derivatives | JPY LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 0 |
IBOR Reform | Exchange traded derivatives | CHF LIBOR | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 0 | 2,494 |
IBOR Reform | Exchange traded derivatives | Others | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | £ 0 | £ 0 |
Interest rate benchmark refor_4
Interest rate benchmark reform - Narrative (Details) - GBP (£) £ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | £ 47,412,915 | £ 42,625,605 |
IBOR Reform | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 6,402,147 | 12,688,971 |
Currency Swaps | IBOR Reform | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Notional contract amount | 256,000 | 264,000 |
Currency Swaps | IBOR Reform | Expected credit losses held against contingent liabilities and commitments | ||
Disclosure of financial instruments by type of interest rate [line items] | ||
Retained debt issuance | £ 9,000 | £ 23,000 |
Interest rate benchmark refor_5
Interest rate benchmark reform - Exposures with or without fallback clauses (Details) £ in Millions, $ in Millions | Dec. 31, 2021GBP (£) | Dec. 31, 2021USD ($) | Dec. 31, 2020GBP (£) | Dec. 31, 2019GBP (£) | |||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | £ 145,259 | [1] | £ 134,267 | ||||
Financial assets at fair value through the income statement | 188,226 | [1] | 171,761 | ||||
Non-derivative financial assets | 1,049,896 | $ 132 | 1,051,400 | ||||
Subordinated liabilities | (32,185) | [1] | (32,005) | £ (33,425) | |||
Financial liabilities designated at fair value | (251,131) | [1] | (249,626) | ||||
Non-derivative financial liabilities | (1,000,754) | (1,001,271) | |||||
Other equity instruments | (56,317) | [2] | (53,710) | [2] | (50,615) | ||
Notional contract amount | 47,412,915 | 42,625,605 | |||||
Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | [3] | (9,693) | (8,621) | £ (8,323) | |||
IBOR Reform | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 28,250 | 39,216 | |||||
Financial assets at fair value through the income statement | 9,165 | 8,055 | |||||
Non-derivative financial assets | 37,601 | 47,905 | |||||
Subordinated liabilities | (5,136) | (897) | |||||
Financial liabilities designated at fair value | (920) | (2,320) | |||||
Non-derivative financial liabilities | (6,056) | (4,669) | |||||
Standby facilities, credit lines and other commitments | 115,493 | 108,202 | |||||
Notional contract amount | 6,402,147 | 12,688,971 | |||||
IBOR Reform | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 2,743,182 | 4,708,416 | |||||
IBOR Reform | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 802,299 | 870,903 | |||||
IBOR Reform | OTC derivatives | Equity and stock index derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 9,949 | 14,896 | |||||
IBOR Reform | Derivatives cleared by central counterparty | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 2,380,378 | 6,458,375 | |||||
IBOR Reform | Exchange traded derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 466,339 | 636,381 | |||||
IBOR Reform | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | (3,062) | (5,184) | |||||
IBOR Reform | With appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 8,012 | ||||||
Financial assets at fair value through the income statement | 424 | ||||||
Non-derivative financial assets | 8,436 | ||||||
Subordinated liabilities | (1,249) | ||||||
Financial liabilities designated at fair value | (708) | ||||||
Non-derivative financial liabilities | (1,957) | ||||||
Standby facilities, credit lines and other commitments | 46,555 | ||||||
Notional contract amount | 725,014 | ||||||
IBOR Reform | With appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 386,089 | ||||||
IBOR Reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 338,925 | ||||||
IBOR Reform | Without appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 4,437 | ||||||
Financial assets at fair value through the income statement | 203 | ||||||
Non-derivative financial assets | 4,640 | ||||||
Subordinated liabilities | 0 | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | 0 | ||||||
Standby facilities, credit lines and other commitments | 26,172 | ||||||
Notional contract amount | 16,386 | ||||||
IBOR Reform | Without appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 16,111 | ||||||
IBOR Reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 275 | ||||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 11,761 | 19,317 | |||||
Financial assets at fair value through the income statement | 101 | 1,190 | |||||
Non-derivative financial assets | 11,862 | 20,693 | |||||
Subordinated liabilities | (36) | (21) | |||||
Financial liabilities designated at fair value | (708) | (149) | |||||
Non-derivative financial liabilities | (744) | (170) | |||||
Standby facilities, credit lines and other commitments | 58,094 | 18,169 | |||||
Notional contract amount | 429,081 | 2,606,513 | |||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 245,604 | 596,564 | |||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 183,477 | 155,285 | |||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | OTC derivatives | Equity and stock index derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 1,845 | |||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | Derivatives cleared by central counterparty | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 1,552,637 | |||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | Exchange traded derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 300,182 | |||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | 0 | (2,122) | |||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | With appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 7,389 | ||||||
Financial assets at fair value through the income statement | 84 | ||||||
Non-derivative financial assets | 7,473 | ||||||
Subordinated liabilities | (36) | ||||||
Financial liabilities designated at fair value | (708) | ||||||
Non-derivative financial liabilities | (744) | ||||||
Standby facilities, credit lines and other commitments | 36,087 | ||||||
Notional contract amount | 418,016 | ||||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | With appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 234,813 | ||||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 183,203 | ||||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | Without appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 4,372 | ||||||
Financial assets at fair value through the income statement | 17 | ||||||
Non-derivative financial assets | 4,389 | ||||||
Subordinated liabilities | 0 | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | 0 | ||||||
Standby facilities, credit lines and other commitments | 22,007 | ||||||
Notional contract amount | 11,065 | ||||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 10,791 | ||||||
GBP London Interbank Offered rate (LIBOR) | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 274 | ||||||
EONIA | IBOR Reform | With appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 7,568 | ||||||
EONIA | IBOR Reform | With appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 7,568 | ||||||
EONIA | IBOR Reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | ||||||
EONIA | IBOR Reform | Without appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 244 | ||||||
EONIA | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 244 | ||||||
EONIA | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | ||||||
JPY LIBOR | IBOR Reform | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 24 | 173 | |||||
Financial assets at fair value through the income statement | 5 | 0 | |||||
Non-derivative financial assets | 29 | 173 | |||||
Subordinated liabilities | (1,213) | 0 | |||||
Financial liabilities designated at fair value | 0 | (759) | |||||
Non-derivative financial liabilities | (1,213) | (781) | |||||
Standby facilities, credit lines and other commitments | 1,284 | 0 | |||||
Notional contract amount | 263,180 | 1,940,722 | |||||
JPY LIBOR | IBOR Reform | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 140,357 | 754,206 | |||||
JPY LIBOR | IBOR Reform | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 122,823 | 93,108 | |||||
JPY LIBOR | IBOR Reform | OTC derivatives | Equity and stock index derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 1,929 | |||||
JPY LIBOR | IBOR Reform | Derivatives cleared by central counterparty | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 1,091,479 | |||||
JPY LIBOR | IBOR Reform | Exchange traded derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 0 | |||||
JPY LIBOR | IBOR Reform | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | 0 | 0 | |||||
JPY LIBOR | IBOR Reform | With appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 0 | ||||||
Financial assets at fair value through the income statement | 5 | ||||||
Non-derivative financial assets | 5 | ||||||
Subordinated liabilities | (1,213) | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | (1,213) | ||||||
Standby facilities, credit lines and other commitments | 657 | ||||||
Notional contract amount | 258,542 | ||||||
JPY LIBOR | IBOR Reform | With appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 135,720 | ||||||
JPY LIBOR | IBOR Reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 122,822 | ||||||
JPY LIBOR | IBOR Reform | Without appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 24 | ||||||
Financial assets at fair value through the income statement | 0 | ||||||
Non-derivative financial assets | 24 | ||||||
Subordinated liabilities | 0 | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | 0 | ||||||
Standby facilities, credit lines and other commitments | 627 | ||||||
Notional contract amount | 4,639 | ||||||
JPY LIBOR | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 4,638 | ||||||
JPY LIBOR | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 1 | ||||||
CHF LIBOR | IBOR Reform | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 222 | 11 | |||||
Financial assets at fair value through the income statement | 327 | 283 | |||||
Non-derivative financial assets | 549 | 294 | |||||
Subordinated liabilities | 0 | 0 | |||||
Financial liabilities designated at fair value | 0 | 0 | |||||
Non-derivative financial liabilities | 0 | 0 | |||||
Standby facilities, credit lines and other commitments | 375 | 74 | |||||
Notional contract amount | 37,296 | 179,305 | |||||
CHF LIBOR | IBOR Reform | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 4,396 | 25,681 | |||||
CHF LIBOR | IBOR Reform | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 32,900 | 31,257 | |||||
CHF LIBOR | IBOR Reform | OTC derivatives | Equity and stock index derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 491 | |||||
CHF LIBOR | IBOR Reform | Derivatives cleared by central counterparty | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 119,382 | |||||
CHF LIBOR | IBOR Reform | Exchange traded derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 2,494 | |||||
CHF LIBOR | IBOR Reform | Other equity instruments | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Other equity instruments | 0 | 0 | |||||
CHF LIBOR | IBOR Reform | With appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 210 | ||||||
Financial assets at fair value through the income statement | 327 | ||||||
Non-derivative financial assets | 537 | ||||||
Subordinated liabilities | 0 | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | 0 | ||||||
Standby facilities, credit lines and other commitments | 375 | ||||||
Notional contract amount | 37,262 | ||||||
CHF LIBOR | IBOR Reform | With appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 4,362 | ||||||
CHF LIBOR | IBOR Reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 32,900 | ||||||
CHF LIBOR | IBOR Reform | Without appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 12 | ||||||
Financial assets at fair value through the income statement | 0 | ||||||
Non-derivative financial assets | 12 | ||||||
Subordinated liabilities | 0 | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | 0 | ||||||
Standby facilities, credit lines and other commitments | 0 | ||||||
Notional contract amount | 35 | ||||||
CHF LIBOR | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 35 | ||||||
CHF LIBOR | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | ||||||
EUR LIBOR | IBOR Reform | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 7,811 | 1,082,190 | |||||
EUR LIBOR | IBOR Reform | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 7,811 | 457,844 | |||||
EUR LIBOR | IBOR Reform | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 0 | |||||
EUR LIBOR | IBOR Reform | OTC derivatives | Equity and stock index derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 544 | |||||
EUR LIBOR | IBOR Reform | Derivatives cleared by central counterparty | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | 623,802 | |||||
EUR LIBOR | IBOR Reform | Exchange traded derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | £ 0 | |||||
EUR LIBOR | IBOR Reform | With appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 413 | ||||||
Financial assets at fair value through the income statement | 8 | ||||||
Non-derivative financial assets | 421 | ||||||
Subordinated liabilities | 0 | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | 0 | ||||||
Standby facilities, credit lines and other commitments | 9,436 | ||||||
Notional contract amount | 3,626 | ||||||
EUR LIBOR | IBOR Reform | With appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 3,626 | ||||||
EUR LIBOR | IBOR Reform | With appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 0 | ||||||
EUR LIBOR | IBOR Reform | Without appropriate fallback clause | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Loans and advances at amortised cost | 29 | ||||||
Financial assets at fair value through the income statement | 186 | ||||||
Non-derivative financial assets | 215 | ||||||
Subordinated liabilities | 0 | ||||||
Financial liabilities designated at fair value | 0 | ||||||
Non-derivative financial liabilities | 0 | ||||||
Standby facilities, credit lines and other commitments | 3,538 | ||||||
Notional contract amount | 403 | ||||||
EUR LIBOR | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Interest rate derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | 403 | ||||||
EUR LIBOR | IBOR Reform | Without appropriate fallback clause | OTC derivatives | Foreign exchange derivatives | |||||||
Disclosure of financial instruments by type of interest rate [line items] | |||||||
Notional contract amount | £ 0 | ||||||
[1] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||
[2] | 2021 financial metrics have been restated to reflect the over-issuance of securities under the Company's 2019 F-3. See Restatement of financial statements (Note 1a) on page 118 for further details. | ||||||
[3] | For further details refer to Note 27. |